FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Du, XL Qian, XL Papageorge, A Vass, WC Braverman, R Lowy, DR AF Du, Xiaoli Qian, Xiaolan Papageorge, Alex Vass, William C. Braverman, Richard Lowy, Douglas R. TI Complex formation between the DLC1 START domain and Cav1 contributes to the tumor suppressor function of DLC1 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Du, Xiaoli; Qian, Xiaolan; Papageorge, Alex; Vass, William C.; Braverman, Richard; Lowy, Douglas R.] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2184 DI 10.1158/1538-7445.AM2011-2184 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402278 ER PT J AU Edelman, DC Stevenson, H Suuriniemi, M Singh, P Rodriguez-Canales, J Hanson, JC Walker, R Emmert-Buck, MR Meltzer, P AF Edelman, Daniel C. Stevenson, Holly Suuriniemi, Miiia Singh, Parvati Rodriguez-Canales, Jamie Hanson, Jeffery C. Walker, Robert Emmert-Buck, Michael R. Meltzer, Paul TI Whole genome amplification allows for testing of valuable specimens by array comparative genomic hybridization SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Edelman, Daniel C.; Stevenson, Holly] NCI, NIH, Gaithersburg, MD USA. [Suuriniemi, Miiia; Singh, Parvati; Rodriguez-Canales, Jamie; Hanson, Jeffery C.; Walker, Robert; Emmert-Buck, Michael R.; Meltzer, Paul] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4862 DI 10.1158/1538-7445.AM2011-4862 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701403442 ER PT J AU El Meskini, R Lacovelli, A Kulaga, A Gumprecht, M Martin, P Baran, M Song, YR Ohler, ZW Van Dyke, T AF El Meskini, Rajaa Lacovelli, Anthony Kulaga, Alan Gumprecht, Michelle Martin, Philip Baran, Maureen Song, Yurong Ohler, Zoe Weaver Van Dyke, Terry TI A preclinical orthotopic mouse model for human GBM: Recapitulation of features of GEM model of origin and potency of PI3K inhibitors SO CANCER RESEARCH LA English DT Meeting Abstract C1 [El Meskini, Rajaa; Lacovelli, Anthony; Kulaga, Alan; Gumprecht, Michelle; Martin, Philip; Baran, Maureen; Ohler, Zoe Weaver] SAIC NCI Frederick, Frederick, MD USA. [Song, Yurong; Van Dyke, Terry] NCI, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4322 DI 10.1158/1538-7445.AM2011-4322 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301332 ER PT J AU Emre, NCT Shaffer, AL Wright, GW Kohlhammer, H Staudt, LM AF Emre, N. C. Tolga Shaffer, Arthur L. Wright, George W. Kohlhammer, Holger Staudt, Louis M. TI IRF4 as a critical regulator and potential therapeutic target in ABC type diffuse large B-cell lymphoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Emre, N. C. Tolga] Bogazici Univ, Istanbul, Turkey. [Shaffer, Arthur L.; Wright, George W.; Staudt, Louis M.] NIH, Bethesda, MD 20892 USA. [Kohlhammer, Holger] Univ Ulm Klinikum, Ulm, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA LB-248 DI 10.1158/1538-7445.AM2011-LB-248 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303051 ER PT J AU Ericson, ME Nye, S Bode, A Grubbs, C Lubet, R AF Ericson, Marna E. Nye, Steffan Bode, Ann Grubbs, Clinton Lubet, Ron TI Degree or extent of radially-aligned collagen fibrils in the tumor-stromal interface of rodent mammary tumor tissue is an indicator of chemotherapeutic potential of the EGFr inhibitor, Gefitinib SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Ericson, Marna E.; Nye, Steffan] Univ Minnesota, Minneapolis, MN USA. [Bode, Ann] Univ Minnesota, Austin, MN USA. [Grubbs, Clinton] Univ Alabama Birmingham, Birmingham, AL USA. [Lubet, Ron] NCI, Bethesda, MD 20892 USA. RI ericson, marna/C-9591-2017 OI ericson, marna/0000-0003-1862-4957 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 441 DI 10.1158/1538-7445.AM2011-441 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301026 ER PT J AU Eyans, LM Woditschka, S Fitzgerald, DP Palmieri, D Badve, S Sledge, GW Steeg, PS AF Eyans, Lynda M. Woditschka, Stephan Fitzgerald, Daniel P. Palmieri, Diane Badve, Sunil Sledge, George W. Steeg, Patricia S. TI L1CAM neural adhesion molecule is overexpressed in human brain metastases of breast cancer and contributes to colony formation efficiency SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Eyans, Lynda M.; Woditschka, Stephan; Fitzgerald, Daniel P.; Palmieri, Diane; Steeg, Patricia S.] NCI, NIH, Bethesda, MD 20892 USA. [Badve, Sunil; Sledge, George W.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2667 DI 10.1158/1538-7445.AM2011-2667 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300302 ER PT J AU Fitzgerald, DP Palmieri, D Qian, YZ Deshpande, M Subramanian, P Graves, C Davis, S Meltzer, P Camphausen, K Becerra, PS Steeg, PS AF Fitzgerald, Daniel P. Palmieri, Diane Qian, Yongzhen Deshpande, Monika Subramanian, Pretti Graves, Christian Davis, Sean Meltzer, Paul Camphausen, Kevin Becerra, Patricia S. Steeg, Patricia S. TI Pigment epithelium-derived factor (PEDF) functions as a brain metastasis suppressor of breast cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Fitzgerald, Daniel P.; Palmieri, Diane; Graves, Christian; Davis, Sean; Meltzer, Paul; Camphausen, Kevin; Steeg, Patricia S.] NCI, Bethesda, MD 20892 USA. [Qian, Yongzhen] NCI, Lab Sci Anim Program, Frederick, MD 21701 USA. [Deshpande, Monika; Subramanian, Pretti; Becerra, Patricia S.] NEI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2846 DI 10.1158/1538-7445.AM2011-2846 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303321 ER PT J AU Flavell, DJ Holmes, SE Gibbs, EL Adcott, JE Flavell, SU Bachran, C Fuchs, H Weng, A Bachran, D Melzig, MF AF Flavell, David J. Holmes, Suzanne E. Gibbs, Emily L. Adcott, Jennifer E. Flavell, Sopsamorn U. Bachran, Christopher Fuchs, Hendrik Weng, Alexander Bachran, Diana Melzig, Matthias F. TI Gypsophila saponins significantly augment the cytotoxicity of saporin-based anti-CD19,-CD22,-CD38 and-CD71 immunotoxins in human leukemia and lymphoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Flavell, David J.; Flavell, Sopsamorn U.] Univ Southampton, Southampton, Hants, England. [Holmes, Suzanne E.; Gibbs, Emily L.; Adcott, Jennifer E.] Leukaemia Busters, Southampton, Hants, England. [Bachran, Christopher] NIAID, NIH, Bethesda, MD 20892 USA. [Fuchs, Hendrik; Weng, Alexander; Bachran, Diana] Charite, Zent Inst Lab Med & Pathobiochem, D-13353 Berlin, Germany. [Melzig, Matthias F.] Free Univ Berlin, Inst Pharm, Berlin, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 767 DI 10.1158/1538-7445.AM2011-767 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303163 ER PT J AU Fortner, RT Eliassen, AH Xu, X Schairer, C Veenstra, TD Ziegler, RG Hankinson, SE AF Fortner, Renee Turzanski Eliassen, A. Heather Xu, Xia Schairer, Catherine Veenstra, Timothy D. Ziegler, Regina G. Hankinson, Susan E. TI Association between reproductive factors and urinary estrogen metabolites in premenopausal women SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Fortner, Renee Turzanski; Eliassen, A. Heather; Hankinson, Susan E.] Harvard Univ, Boston, MA 02115 USA. [Xu, Xia; Veenstra, Timothy D.] SAIC Frederick Inc, Frederick, MD USA. [Schairer, Catherine; Ziegler, Regina G.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4634 DI 10.1158/1538-7445.AM2011-4634 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701406052 ER PT J AU Gan, ZY Kodela, R Goswami, S Chattopadhyay, M Boring, D Crowell, JA Kashfi, K AF Gan, Zong Yuan Kodela, Ravinder Goswami, Satindra Chattopadhyay, Mitali Boring, Daniel Crowell, James A. Kashfi, Khosrow TI All three positional isomers of acetyl salicylic acids are equally potent in inhibiting colon cancer cell growth: Differences in mode of COX inhibition SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Gan, Zong Yuan; Kodela, Ravinder; Goswami, Satindra; Chattopadhyay, Mitali; Kashfi, Khosrow] CUNY, Sch Med, New York, NY 10031 USA. [Boring, Daniel; Crowell, James A.] NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5560 DI 10.1158/1538-7445.AM2011-5560 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305317 ER PT J AU Gan, ZY Chattopadhyay, M Kodela, R Boring, D Crowell, JA Kashfi, K AF Gan, Zong Yuan Chattopadhyay, Mitali Kodela, Ravinder Boring, Daniel Crowell, James A. Kashfi, Khosrow TI Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Gan, Zong Yuan; Chattopadhyay, Mitali; Kodela, Ravinder; Kashfi, Khosrow] CUNY, Sch Med, New York, NY 10031 USA. [Boring, Daniel; Crowell, James A.] NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4608 DI 10.1158/1538-7445.AM2011-4608 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303030 ER PT J AU Gandini, S di Pietro, A Maisonneuve, P Autier, P Fargnoli, MC Garcia-Borron, JC Han, JL Kanetsky, PA Landi, MT Little, J Newton-Bishop, J Sera, F Raimondi, S AF Gandini, Sara di Pietro, Alessandra Maisonneuve, Patrick Autier, Philippe Fargnoli, Maria Concetta Garcia-Borron, Jose C. Han, Jiali Kanetsky, Peter A. Landi, Maria Teresa Little, Julian Newton-Bishop, Julia Sera, Francesco Raimondi, Sara TI The M-SKIP Project: an international pooled-analysis on melanocortin-1 receptor (MC1 R) variants and skin carcinogenesis SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Gandini, Sara; di Pietro, Alessandra; Maisonneuve, Patrick; Raimondi, Sara] IEO European Inst Oncol, Milan, Italy. [Autier, Philippe] Int Prevent Res Inst, Lyon, France. [Fargnoli, Maria Concetta] Univ Aquila, IEO European Inst Oncol, Dept Dermatol, I-67100 Laquila, Italy. [Garcia-Borron, Jose C.] Univ Murcia, Dept Biochem & Mol Biol, Murcia, Spain. [Han, Jiali] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA. [Han, Jiali] Harvard Univ, Sch Med, Boston, MA USA. [Kanetsky, Peter A.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Landi, Maria Teresa] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Little, Julian] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. [Newton-Bishop, Julia] Univ Leeds, Epidemiol & Biostat Sect, Leeds Inst Mol Med, Leeds, W Yorkshire, England. [Sera, Francesco] UCL Inst Child Hlth, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2244 DI 10.1158/1538-7445.AM2011-2244 PG 2 WC Oncology SC Oncology GA V43SP UT WOS:000209701405217 ER PT J AU Gao, Y Chow, WH AF Gao, Ying Chow, Wong-Ho TI Leukocyte LINE1 and Alu DNA methylation and gastric cancer risk in the Shanghai Women's Health Study cohort SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Gao, Ying; Chow, Wong-Ho] NCI, DCEG, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3747 DI 10.1158/1538-7445.AM2011-3747 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305064 ER PT J AU Garimella, SV Gehlhaus, K Grandin, M Caplen, N Lipkowitz, S AF Garimella, Sireesha V. Gehlhaus, Kristie Grandin, Magda Caplen, Natasha Lipkowitz, Stanley TI A functional genomic approach to identify novel molecular regulators of the TRAIL pathway in breast cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Garimella, Sireesha V.; Lipkowitz, Stanley] NCI, LCMB, CCR, NIH, Bethesda, MD 20892 USA. [Gehlhaus, Kristie; Grandin, Magda; Caplen, Natasha] NCI, Genet Branch, CCR, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4106 DI 10.1158/1538-7445.AM2011-4106 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402080 ER PT J AU Gaudet, MM Falk, R Stevens, RD Pfeiffer, R Potischman, N Brinton, LA Garcia-Closas, M Sherman, ME Bain, JR Muehlbauer, MJ Newgard, CB Gunter, MJ Lissowska, J Peplonska, B AF Gaudet, Mia M. Falk, Roni Stevens, Robert D. Pfeiffer, Ruth Potischman, Nancy Brinton, Louise A. Garcia-Closas, Montserrat Sherman, Mark E. Bain, James R. Muehlbauer, Michael J. Newgard, Christopher B. Gunter, Marc J. Lissowska, Jolanta Peplonska, Beata TI Serum metabolic profiles and endometrial cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Gaudet, Mia M.] Amer Canc Soc, Atlanta, GA 30329 USA. [Falk, Roni; Pfeiffer, Ruth; Potischman, Nancy; Brinton, Louise A.; Garcia-Closas, Montserrat; Sherman, Mark E.] NCI, Bethesda, MD 20892 USA. [Stevens, Robert D.; Bain, James R.; Muehlbauer, Michael J.; Newgard, Christopher B.] Duke Univ, Durham, NC USA. [Gunter, Marc J.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Lissowska, Jolanta] Ctr Canc, Warsaw, Poland. [Lissowska, Jolanta] M Sklodowska Curie Inst Oncol, Warsaw, Poland. [Peplonska, Beata] Nofer Inst Occupat Med, Lodz, Poland. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA LB-454 DI 10.1158/1538-7445.AM2011-LB-454 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701406036 ER PT J AU Geczy, T Valle, CJ Selezneva, JS Kedei, N Lewin, NE Lim, L Mannam, P Garfield, SH Peach, ML Blumberg, PM AF Geczy, Tamas Valle, Christopher J. Selezneva, Julia S. Kedei, Noemi Lewin, Nancy E. Lim, Langston Mannam, Poonam Garfield, Susan H. Peach, Megan L. Blumberg, Peter M. TI Identification of crucial residues at the rim of the binding cleft of the C1 domain of Vav1 that determine its ligand sensitivity SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Geczy, Tamas; Valle, Christopher J.; Selezneva, Julia S.; Kedei, Noemi; Lewin, Nancy E.; Lim, Langston; Mannam, Poonam; Garfield, Susan H.; Blumberg, Peter M.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Peach, Megan L.] NCI, Ctr Canc Res, NIH, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3854 DI 10.1158/1538-7445.AM2011-3854 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401464 ER PT J AU Geiger, TR Mattaini, K Williams, M Walker, R Alsarraj, J Borges, RN Hunters, K AF Geiger, Thomas R. Mattaini, Katie Williams, Mia Walker, Renard Alsarraj, Jude Borges, Rosan Nieves Hunters, Kent TI Mechanistic insights into regulation of metastasis by Sipal SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Geiger, Thomas R.; Walker, Renard; Alsarraj, Jude; Borges, Rosan Nieves; Hunters, Kent] NCI, CCR, Bethesda, MD 20892 USA. [Mattaini, Katie] MIT, Cambridge, MA 02139 USA. [Williams, Mia] Cleveland Clin, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5269 DI 10.1158/1538-7445.AM2011-5269 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301059 ER PT J AU Gijsen, M Kramer-Marek, G Bennett, R Harris, A Capala, J Kong, A AF Gijsen, Mere Kramer-Marek, Gabriela Bennett, Ruth Harris, Adrian Capala, Jacek Kong, Anthony TI Trastuzumab treatment induces ADAM17 and HER ligands in vivo SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Gijsen, Mere; Bennett, Ruth; Harris, Adrian; Kong, Anthony] Univ Oxford, Oxford, England. [Kramer-Marek, Gabriela; Capala, Jacek] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1530 DI 10.1158/1538-7445.AM2011-1530 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302158 ER PT J AU Gills, JJ Zhang, CY Abu-Asab, MS Castillo, SS Marceau, C Kozikowski, A Tsokos, M Goldkorn, T Dennis, PA AF Gills, Joel J. Zhang, Chunyu Abu-Asab, Mones S. Castillo, S. Sianna Marceau, Caleb Kozikowski, Alan Tsokos, Maria Goldkorn, Tzipora Dennis, Phillip A. TI Ceramide-dependent release of nanovesicles is a class effect oflipid-based Akt inhibitors SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Gills, Joel J.; Zhang, Chunyu; Abu-Asab, Mones S.; Marceau, Caleb; Tsokos, Maria; Dennis, Phillip A.] NCI, Bethesda, MD 20892 USA. [Castillo, S. Sianna; Goldkorn, Tzipora] Univ Calif Davis, Sacramento, CA 95817 USA. [Kozikowski, Alan] Univ Illinois, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 960 DI 10.1158/1538-7445.AM2011-960 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701400277 ER PT J AU Glinskii, OV Li, F Rittenhouse-Olson, K Barchi, J Glinsky, VV AF Glinskii, Olga V. Li, Feng Rittenhouse-Olson, Kate Barchi, Joseph Glinsky, Vladislav V. TI Endothelial integrin alpha 3 beta 1 stabilizes TF antigen/Galectin-3 mediated metastatic cell adhesion to the endothelium SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Glinskii, Olga V.; Li, Feng; Glinsky, Vladislav V.] Univ Missouri, Columbia, MO USA. [Glinskii, Olga V.; Li, Feng; Glinsky, Vladislav V.] Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA. [Rittenhouse-Olson, Kate] Univ Buffalo, Buffalo, NY USA. [Barchi, Joseph] NCI, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2436 DI 10.1158/1538-7445.AM2011-2436 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301079 ER PT J AU Goldberger, NE Kim, CH Walker, R Hunter, K AF Goldberger, Natalie E. Kim, Chang Hee Walker, Renard Hunter, Kent TI Identification of miR-132 and miR-290-3p as putative tumor and metastasis suppressor microRNAs in breast cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Goldberger, Natalie E.; Walker, Renard; Hunter, Kent] NCI, Bethesda, MD 20892 USA. [Kim, Chang Hee] NCI, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3988 DI 10.1158/1538-7445.AM2011-3988 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404026 ER PT J AU Grade, M Spitzner, M Emons, G Kramer, F Gaedcke, J Rave-Frank, M Scharf, JG Burfeind, P Becker, H Beissbarth, T Ghadimi, BM Ried, T AF Grade, Marian Spitzner, Melanie Emons, Georg Kramer, Frank Gaedcke, Jochen Rave-Fraenk, Margret Scharf, Jens-Gerd Burfeind, Peter Becker, Heinz Beissbarth, Tim Ghadimi, B. Michael Ried, Thomas TI Identification of potential relevant pathways and genes for resistance to chemoradiotherapy in colorectal cancer cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Grade, Marian; Spitzner, Melanie; Emons, Georg; Kramer, Frank; Gaedcke, Jochen; Rave-Fraenk, Margret; Burfeind, Peter; Becker, Heinz; Beissbarth, Tim; Ghadimi, B. Michael] Univ Gottingen, D-37073 Gottingen, Germany. [Scharf, Jens-Gerd] HELIOS Klinikum Erfurt, Erfurt, Germany. [Ried, Thomas] NCI, Genet Branch, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2508 DI 10.1158/1538-7445.AM2011-2508 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302047 ER PT J AU Gril, B Vidal-Vanaclocha, F Qian, Y Liewehr, DJ Steinberg, SM Palmieri, D Steeg, PS AF Gril, Brunilde Vidal-Vanaclocha, Fernando Qian, Yong Liewehr, David J. Steinberg, Seth M. Palmieri, Diane Steeg, Patricia S. TI Pazopanib inhibits a subpopulation of PDGFR plus astrocytes in the neuro-inflammatory microenvironment of breast cancer brain metastases SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Gril, Brunilde; Qian, Yong; Liewehr, David J.; Steinberg, Seth M.; Palmieri, Diane; Steeg, Patricia S.] NCI, Bethesda, MD 20892 USA. [Vidal-Vanaclocha, Fernando] CEU San Pablo Univ, Sch Med Urb Monteprincipe, Madrid, Spain. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3561 DI 10.1158/1538-7445.AM2011-3561 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401127 ER PT J AU Grubbs, CJ Boring, D Steele, VE Verney, ZM Lu, Y You, M Lubet, RA AF Grubbs, Clinton J. Boring, Daniel Steele, Vernon E. Verney, Zoe M. Lu, Yian You, Ming Lubet, Ronald A. TI Chemopreventive efficacy of naproxen, sulindac, and their nitric oxide derivatives in the hydroxylbutyl(butyl)nitrosamine induced model of urinary bladder cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Grubbs, Clinton J.; Verney, Zoe M.] Univ Alabama Birmingham, Birmingham, AL USA. [Boring, Daniel; Steele, Vernon E.; Lubet, Ronald A.] NCI, Bethesda, MD 20892 USA. [Lu, Yian; You, Ming] Washington Sch Med, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1849 DI 10.1158/1538-7445.AM2011-1849 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303161 ER PT J AU Gu, FY Caporaso, NE Eliassen, AH Xu, X Hankinson, SE Ziegler, RG AF Gu, Fangyi Caporaso, Neil E. Eliassen, A. Heather Xu, Xia Hankinson, Susan E. Ziegler, Regina G. TI Associations between cigarette smoking and urinary estrogens/estrogen metabolites (EM) in premenopausal women SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Gu, Fangyi; Caporaso, Neil E.; Ziegler, Regina G.] NCI, Rockville, MD USA. [Eliassen, A. Heather; Hankinson, Susan E.] Harvard Univ, Sch Med, Boston, MA USA. [Xu, Xia] SAIC Inc, Frederick, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3738 DI 10.1158/1538-7445.AM2011-3738 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701405446 ER PT J AU Gupta, GN Lin, KY Sourbier, C Baba, M Guichard, S Linehan, WM Srinivasan, R AF Gupta, Gopal N. Lin, Kelly Y. Sourbier, Carole Baba, Masaya Guichard, Sylvie Linehan, W. Marston Srinivasan, Ramaprasad TI Preclinical efficacy of AZD8055, an ATP-competitive mammalian target of rapamycin (mTOR) kinase inhibitor, in vitro in clear cell renal cell carcinoma (RCC) SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Gupta, Gopal N.; Lin, Kelly Y.; Sourbier, Carole; Baba, Masaya; Linehan, W. Marston; Srinivasan, Ramaprasad] NCI, NIH, Bethesda, MD 20892 USA. [Guichard, Sylvie] AstraZeneca, Chester, Cheshire, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 645 DI 10.1158/1538-7445.AM2011-645 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401335 ER PT J AU Gurpinar, E Sun, Y Keeton, A Tinsley, H Gary, B Butler, BL Binkowski, BF Kopelovich, L Athar, M Piazza, GA AF Gurpinar, Evrim Sun, Yanjie Keeton, Adam Tinsley, Heather Gary, Bernard Butler, Braeden L. Binkowski, Brock F. Kopelovich, Levy Athar, Mohammad Piazza, Gary A. TI NO-NSAIDs inhibit colon tumor cell growth by a cGMP-independent mechanism SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Gurpinar, Evrim; Tinsley, Heather; Athar, Mohammad; Piazza, Gary A.] Univ Alabama Birmingham, Birmingham, AL USA. [Sun, Yanjie; Keeton, Adam; Gary, Bernard] So Res Inst, Birmingham, AL 35255 USA. [Butler, Braeden L.; Binkowski, Brock F.] Promega Corp, Birmingham, AL USA. [Kopelovich, Levy] NCI, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4610 DI 10.1158/1538-7445.AM2011-4610 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303032 ER PT J AU Harada, T Wang, YS Yatabe, Y Takeshita, M Koga, T Yano, T Giaccone, G AF Harada, Taishi Wang, Yisong Yatabe, Yasushi Takeshita, Masafumi Koga, Takaomi Yano, Tokujiro Giaccone, Giuseppe TI Role and relevance of TrkB mutations and expression in non-small cell lung cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Harada, Taishi; Wang, Yisong; Giaccone, Giuseppe] NCI, Bethesda, MD 20892 USA. [Yatabe, Yasushi] Aichi Canc Ctr, Nagoya, Aichi 464, Japan. [Takeshita, Masafumi; Koga, Takaomi; Yano, Tokujiro] Kyushu Univ, Fukuoka 812, Japan. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1120 DI 10.1158/1538-7445.AM2011-1120 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701403342 ER PT J AU Hayman, TJ Williams, ES Camphausen, K Tofilon, PJ AF Hayman, Thomas J. Williams, Eli S. Camphausen, Kevin Tofilon, Philip J. TI eIF4E is a potential tumor specific target for radiosensitization SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Hayman, Thomas J.] Univ S Florida, Tampa, FL USA. [Williams, Eli S.] Emory Univ, Sch Med, Decatur, GA 30033 USA. [Camphausen, Kevin] NCI, Radiat Oncol Branch, Bethesda, MD 20892 USA. [Tofilon, Philip J.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2510 DI 10.1158/1538-7445.AM2011-2510 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302050 ER PT J AU Held, N Rangel, C Castro, N Gonzales, M Nagaoka, T Karasawa, H Salomon, DS Bianco, C AF Held, Natalie Rangel, Cristina Castro, Nadia Gonzales, Monica Nagaoka, Tadahiro Karasawa, Hideaki Salomon, David S. Bianco, Caterina TI Role of p38 MAPK in regulating Cripto-1 expression and signaling in human embryonal carcinoma cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Held, Natalie; Rangel, Cristina; Castro, Nadia; Gonzales, Monica; Nagaoka, Tadahiro; Karasawa, Hideaki; Salomon, David S.; Bianco, Caterina] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2175 DI 10.1158/1538-7445.AM2011-2175 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402184 ER PT J AU Hirsch, D Stapleton, M Ried, T Camps, J Gaiser, T AF Hirsch, Daniela Stapleton, Mark Ried, Thomas Camps, Jordi Gaiser, Timo TI Isothermal whole genome amplification of FFPE samples to detect copy number changes in the progression from colonic adenoma to carcinoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Hirsch, Daniela; Ried, Thomas; Camps, Jordi; Gaiser, Timo] NCI, NIH, Washington, DC USA. [Stapleton, Mark] NuGEN Technol, San Carlos, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3073 DI 10.1158/1538-7445.AM2011-3073 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402033 ER PT J AU Holbeck, SL Collins, JM Doroshow, JH AF Holbeck, Susan L. Collins, Jerry M. Doroshow, James H. TI NCI-60 combination screening matrix of approved anticancer drugs SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Holbeck, Susan L.; Collins, Jerry M.; Doroshow, James H.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2547 DI 10.1158/1538-7445.AM2011-2547 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401226 ER PT J AU Holczbauer, A Factor, VM Marguardt, JU Kleiner, D Seo, D Raggi, C Kitade, M Andersen, JB Durkin, M Thorgeirsson, SS AF Holczbauer, Agnes Factor, Valentina M. Marguardt, Jens U. Kleiner, David Seo, Daekwan Raggi, Chiara Kitade, Mitsuteru Andersen, Jesper B. Durkin, Marian Thorgeirsson, Snorri S. TI Generation of hepatocellular carcinomas with cancer stem cell properties from primary mouse hepatocytes SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Holczbauer, Agnes; Factor, Valentina M.; Marguardt, Jens U.; Kleiner, David; Seo, Daekwan; Raggi, Chiara; Kitade, Mitsuteru; Andersen, Jesper B.; Durkin, Marian; Thorgeirsson, Snorri S.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2452 DI 10.1158/1538-7445.AM2011-2452 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301352 ER PT J AU Hosgood, HD Zhang, LP Tang, XJ Vermeulen, R Shen, M Smith, M Qiu, CY Ge, YC Ji, ZY Xiong, J Reiss, B Hao, ZY Liu, SW Xie, YX Guo, WH Galvan, N Li, LY Rothman, N Huang, HL Lan, Q AF Hosgood, H. Dean Zhang, Luoping Tang, Xiaojiang Vermeulen, Roel Shen, Min Smith, Martyn Qiu, Chuangyi Ge, Yichen Ji, Zhiying Xiong, Jun Reiss, Boris Hao, Zhenyue Liu, Songwang Xie, Yuxuan Guo, Weihong Galvan, Noe Li, Laiyu Rothman, Nat Huang, Hanlin Lan, Qing TI Decreased CD4+naive and effector memory T cell counts, and CD8+naive T cell counts, are associated with trichloroethylene exposure SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Hosgood, H. Dean; Shen, Min; Rothman, Nat; Lan, Qing] NCI, Bethesda, MD 20892 USA. [Zhang, Luoping; Tang, Xiaojiang; Smith, Martyn; Ji, Zhiying; Guo, Weihong; Galvan, Noe] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Vermeulen, Roel; Reiss, Boris] Univ Utrecht, Utrecht, Netherlands. [Qiu, Chuangyi; Ge, Yichen; Xie, Yuxuan; Li, Laiyu; Huang, Hanlin] Guangdong Poison Control Ctr, Guangzhou, Guangdong, Peoples R China. [Xiong, Jun] Dongguan Ctr Dis Control & Prevent, Dongguan, Guangdong, Peoples R China. [Hao, Zhenyue] Inst Breast Canc Res, Toronto, ON, Canada. [Hao, Zhenyue] Univ Hlth Network, Toronto, ON, Canada. [Liu, Songwang] Qiaotou Hosp, Dongguan, Guangdong, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4645 DI 10.1158/1538-7445.AM2011-4645 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701406063 ER PT J AU Houghton, PJ Lock, RB Carol, H Morton, CL Gorlick, R Kolb, EA Kier, ST Reynolds, CP Kang, MH Maris, JM Billups, CA Smiths, MA AF Houghton, Peter J. Lock, Richard B. Carol, Hernan Morton, Christopher L. Gorlick, Richard Kolb, E. Anders Kier, Stephen T. Reynolds, C. Patrick Kang, Min H. Maris, John M. Billups, Catherine A. Smiths, Malcolm A. TI Pediatric preclinical testing program (PPTP) evaluation of the non-camptothecin topoisomerase 1 targeted agent Genz644282 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Houghton, Peter J.] Nationwide Childrens Hosp, Columbus, OH USA. [Lock, Richard B.; Carol, Hernan] Childrens Canc Inst Australia Med Res, Randwick, NSW, Australia. [Morton, Christopher L.; Billups, Catherine A.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Gorlick, Richard] Childrens Hosp Montefiore, Bronx, NY USA. [Kolb, E. Anders] Alfred I DuPont Hosp Children, Wilmington, DE USA. [Kier, Stephen T.] Duke Univ, Med Ctr, Durham, NC USA. [Reynolds, C. Patrick; Kang, Min H.] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA. [Maris, John M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Smiths, Malcolm A.] NCI, Canc Therapy Evaluat Program, Bethesda, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5358 DI 10.1158/1538-7445.AM2011-5358 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701301420 ER PT J AU House, CD Samaan, M Irby, RB Lee, NH AF House, Carrie D. Samaan, May Irby, Rosalyn B. Lee, Norman H. TI Voltage-gated Na+ channel activation leads to increased invasion potential through persistent MAPK signaling involving PKA, Src, and Rap1 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [House, Carrie D.; Lee, Norman H.] George Washington Univ, Washington, DC USA. [Samaan, May] Natl Inst Dent & Craniofacial Res, Bethesda, MD USA. [Irby, Rosalyn B.] Penn State Hershey Canc Inst, Hershey, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1418 DI 10.1158/1538-7445.AM2011-1418 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304146 ER PT J AU Huang, WY Su, JL Hayes, RB Moore, LE Katki, HA Berndt, SI Weissfeld, JL Yegnasubramanian, S Purdue, MP AF Huang, Wen-Yi Su, Joseph L. Hayes, Richard B. Moore, Lee E. Katki, Hormuzd A. Berndt, Sonja I. Weissfeld, Joel L. Yegnasubramanian, Srinivasan Purdue, Mark P. TI Prospective study of genomic hypomethylation of leukocyte DNA and colorectal cancer risk SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Huang, Wen-Yi; Su, Joseph L.; Moore, Lee E.; Katki, Hormuzd A.; Berndt, Sonja I.; Purdue, Mark P.] NCI, Bethesda, MD 20892 USA. [Hayes, Richard B.] NYU, Sch Med, New York, NY USA. [Weissfeld, Joel L.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Yegnasubramanian, Srinivasan] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3755 DI 10.1158/1538-7445.AM2011-3755 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305072 ER PT J AU Hudson, RS Yi, M Esposito, D Stephens, RM Croce, CM Ambs, S AF Hudson, Robert S. Yi, Ming Esposito, Dominic Stephens, Robert M. Croce, Carlo M. Ambs, Stefan TI Tumor suppressor role of microRNA-1 in prostate cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Hudson, Robert S.; Ambs, Stefan] NCI, Human Carcinogenesis Lab, Bethesda, MD 20892 USA. [Yi, Ming; Stephens, Robert M.] NCI, Adv Biomed Comp Ctr, SAIC Frederick Inc, Frederick, MD 21701 USA. [Esposito, Dominic] NCI, Prot Express Lab, SAIC Frederick Inc, Frederick, MD 21701 USA. [Croce, Carlo M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 140 DI 10.1158/1538-7445.AM2011-140 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404065 ER PT J AU Huppi, K Pitt, J Wahlberg, B Jones, TL Mushinski, JF Janz, S Caplen, NJ AF Huppi, Konrad Pitt, Jason Wahlberg, Brady Jones, Tamara L. Mushinski, J. Frederic Janz, Siegfried Caplen, Natasha J. TI Expression studies from the PVT1 region of 8q24 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Huppi, Konrad; Pitt, Jason; Wahlberg, Brady; Jones, Tamara L.; Mushinski, J. Frederic; Caplen, Natasha J.] NCI, Bethesda, MD 20892 USA. [Janz, Siegfried] Univ Iowa, Iowa City, IA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1181 DI 10.1158/1538-7445.AM2011-1181 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404218 ER PT J AU Ibarrondo, J Comin-Anduix, B Lee, Y Chodon, T Sazegar, H Jalil, J Chmielowski, B Koya, RC Gomez-Navarro, J Jamieson, BD Ribas, A AF Ibarrondo, Javier Comin-Anduix, Begona Lee, Yohan Chodon, Thinle Sazegar, Hooman Jalil, Jason Chmielowski, Bartosz Koya, Richard C. Gomez-Navarro, Jesus Jamieson, Beth D. Ribas, Antoni TI Characterization of invariant natural killer T cells in patients with advanced melanoma treated with CTLA4 blockade and dendritic cell vaccination SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Ibarrondo, Javier; Comin-Anduix, Begona; Chodon, Thinle; Sazegar, Hooman; Jalil, Jason; Chmielowski, Bartosz; Koya, Richard C.; Jamieson, Beth D.; Ribas, Antoni] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Lee, Yohan] NIMH, NIH, Bethesda, WA USA. [Gomez-Navarro, Jesus] Pfiser Global Res & Dev, New London, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5518 DI 10.1158/1538-7445.AM2011-5518 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301103 ER PT J AU Ierano, C To, KW Robey, RW Bates, SE Scala, S AF Ierano, Caterina To, Kin Wah Robey, Robert W. Bates, Susan E. Scala, Stefania TI Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Ierano, Caterina; Robey, Robert W.; Bates, Susan E.] NCI, Bethesda, MD 20892 USA. [To, Kin Wah] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Scala, Stefania] Natl Canc Inst G Pascale, Naples, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2633 DI 10.1158/1538-7445.AM2011-2633 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401118 ER PT J AU Issa, S Braggio, E Molnar, S Jimenez-Zepeda, VH Van Wier, S Keats, JJ Kuehl, MW Ahmann, GJ Carpten, J Stewart, K Bergsagel, L Chng, WJ Fonseca, R AF Issa, Samar Braggio, Esteban Molnar, Soledad Jimenez-Zepeda, Victor Hugo Van Wier, Scott Keats, Jonathan J. Kuehl, Michael W. Ahmann, Gregory J. Carpten, John Stewart, Keith Bergsagel, Leif Chng, Wee Joo Fonseca, Rafael TI TP53 loss: An overriding marker of disease progression in Multiple Myeloma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Issa, Samar; Braggio, Esteban; Molnar, Soledad; Jimenez-Zepeda, Victor Hugo; Van Wier, Scott; Ahmann, Gregory J.; Stewart, Keith; Bergsagel, Leif; Fonseca, Rafael] Mayo Clin Arizona, Scottsdale, AZ USA. [Keats, Jonathan J.; Carpten, John] TGEN, Phoenix, AZ USA. [Kuehl, Michael W.] NCI, Genet Branch, Bethesda, MD 20892 USA. [Chng, Wee Joo] Natl Univ Singapore, Singapore 117548, Singapore. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 219 DI 10.1158/1538-7445.AM2011-219 PG 2 WC Oncology SC Oncology GA V43SP UT WOS:000209701402371 ER PT J AU Iyer, S Perera, F Zhang, BZ Chanock, S Wang, S Tang, DL AF Iyer, Shoba Perera, Frederica Zhang, Bingzhi Chanock, Stephen Wang, Shuang Tang, Deliang TI Interactions between PAH exposure and genetic polymorphisms on BaP-DNA adducts in a NYC cohort of African American and Dominican mothers and newborns SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Iyer, Shoba; Perera, Frederica; Zhang, Bingzhi; Wang, Shuang; Tang, Deliang] Columbia Mailman Sch Publ Hlth, New York, NY USA. [Chanock, Stephen] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2753 DI 10.1158/1538-7445.AM2011-2753 PG 2 WC Oncology SC Oncology GA V43SP UT WOS:000209701406101 ER PT J AU Janakiram, NB Mohammed, A Qian, L Venkateshwar, M Reddy, MP Steele, VE Rao, CV AF Janakiram, Naveena B. Mohammed, Altaf Qian, Li Venkateshwar, Madka Reddy, Manasa P. Steele, Vernon E. Rao, Chinthalapally V. TI Chemopreventive effects of selective estrogen receptor modulator (SERM) raloxifene on intestinal neoplasia of APC(Min/+) mice SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Janakiram, Naveena B.; Mohammed, Altaf; Qian, Li; Venkateshwar, Madka; Reddy, Manasa P.; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Ctr Canc, Ctr Chemoprevent & Drug Dev,Hem Onc Sect, Oklahoma City, OK USA. [Steele, Vernon E.] NCI, Chemoprevent Agent Dev Res Grp, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 831 DI 10.1158/1538-7445.AM2011-831 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303082 ER PT J AU Janakiram, NB Mohammed, A Qian, L Steele, VE Rao, CV AF Janakiram, Naveena B. Mohammed, Altaf Qian, Li Steele, Vernon E. Rao, Chinthalapally V. TI miRNA profiling and target identification during normal pancreata transformation to PanINs to pancreatic ductal cancer progression in p48(Cre/+)-LSL-KrasG(12D/+) mice: Implication for human pancreatic cancer chemoprevention and treatment SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Janakiram, Naveena B.; Mohammed, Altaf; Qian, Li; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Ctr Chemoprevent & Drug Dev, Canc Ctr,Dept Med Hem Onc Sect, Oklahoma City, OK USA. [Steele, Vernon E.] NCI, Chemoprevent Agent Dev Res Grp, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 821 DI 10.1158/1538-7445.AM2011-821 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303071 ER PT J AU Jansen, R Robinson, D Stolzenberg-Solomon, R Bamlet, W Cunningham, J Rider, D Oberg, A Hammer, T Rabi, K Anderson, K Olson, J Sinha, R Petersen, G AF Jansen, Rick Robinson, Dennis Stolzenberg-Solomon, Rachael Bamlet, William Cunningham, Julie Rider, David Oberg, Ann Hammer, Traci Rabi, Kari Anderson, Kristin Olson, Janet Sinha, Rashmi Petersen, Gloria TI Polymorphisms in metabolism genes may mediate the effect of dietary intake on pancreatic cancer risk SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Jansen, Rick; Robinson, Dennis; Bamlet, William; Cunningham, Julie; Rider, David; Oberg, Ann; Hammer, Traci; Rabi, Kari; Olson, Janet; Petersen, Gloria] Mayo Clin, Rochester, MN USA. [Stolzenberg-Solomon, Rachael; Sinha, Rashmi] NCI, Bethesda, MD 20892 USA. [Anderson, Kristin] Univ Minnesota, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3749 DI 10.1158/1538-7445.AM2011-3749 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305066 ER PT J AU Ji, JP Lee, MP Kadota, M Zhang, YP Parchment, RE Tomaszewski, JE Doroshow, JH AF Ji, Jiuping Lee, Maxwell P. Kadota, Mitsutaka Zhang, Yiping Parchment, Ralph E. Tomaszewski, Joseph E. Doroshow, James H. TI Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Ji, Jiuping; Zhang, Yiping; Parchment, Ralph E.] NCI Frederick, SAIC Frederick Inc, Appl Dev Res Directorate, Frederick, MD USA. [Lee, Maxwell P.; Kadota, Mitsutaka; Doroshow, James H.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. [Tomaszewski, Joseph E.; Doroshow, James H.] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4527 DI 10.1158/1538-7445.AM2011-4527 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300151 ER PT J AU Jia, JP Frank, N Parikh, H Flandez, M Collins, I Hussain, P Lo, K Petersen, GM Real, F Ammundadottir, L AF Jia, Jinping Frank, Naomi Parikh, Hemang Flandez, Marta Collins, Irene Hussain, Perwez Lo, Ken Petersen, Gloria M. Real, Francisco Ammundadottir, Laufey TI Genome analysis of a pancreatic cancer susceptibility locus in the NR5A2 gene on chromosome 1q32.1 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Jia, Jinping; Frank, Naomi; Parikh, Hemang; Collins, Irene; Ammundadottir, Laufey] NCI, Lab Translat Genom, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Flandez, Marta; Real, Francisco] Ctr Nacl Invest Oncol, Mol Pathyol Programme, Madrid, Spain. [Hussain, Perwez] NCI, Lab Human Carcinogenesis, CCR, NIH, Bethesda, MD 20892 USA. [Lo, Ken] Roche Nimblegen, Madison, WI USA. [Petersen, Gloria M.] Mayo Clin, Ctr Canc, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4965 DI 10.1158/1538-7445.AM2011-4965 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404186 ER PT J AU Jin, GX Zhao, H Cong, Y Fu, CH Chang, J Lewis, M Wong, S AF Jin, Guangxu Zhao, Hong Cong, Yang Fu, Changhe Chang, Jenny Lewis, Michael Wong, Stephen TI Network-based signatures for drug repositioning and combination for the breast tumor initiating cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Jin, Guangxu; Zhao, Hong; Cong, Yang; Fu, Changhe; Wong, Stephen] Methodist Hosp, NCI Ctr Modeling Canc Dev, Bioengn & Bioinformat Program, Res Inst, Houston, TX 77030 USA. [Chang, Jenny] Methodist Hosp, Methodist Canc Ctr, Houston, TX 77030 USA. [Lewis, Michael] Baylor Coll Med, Sue Smith Breast Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4370 DI 10.1158/1538-7445.AM2011-4370 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302105 ER PT J AU Jochems, C Poole, DJ Vergati, M Gulley, JL Schlom, J Tsang, KY AF Jochems, Caroline Poole, Diane J. Vergati, Matteo Gulley, James L. Schlom, Jeffrey Tsang, Kwong Yok TI Generation of cellular immune responses to MUC1-C to target the portion of MUC1 that is most biologically relevant to the transformation process SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Jochems, Caroline; Poole, Diane J.; Vergati, Matteo; Gulley, James L.; Schlom, Jeffrey; Tsang, Kwong Yok] NCI, Bethesda, MD 20892 USA. RI Gulley, James/K-4139-2016 OI Gulley, James/0000-0002-6569-2912 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5524 DI 10.1158/1538-7445.AM2011-5524 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301158 ER PT J AU Johansson, P Wei, JS Chen, QR Bowden, N Badgett, TC Song, YK Wen, XY Holman, C Yeh, S Khan, J AF Johansson, Peter Wei, Jun S. Chen, Qingrong Bowden, Nikola Badgett, Tom C. Song, Young K. Wen, Xinyu Holman, Catherine Yeh, Susan Khan, Javed TI A genomic portrait of tumor progression using next-generation sequencing SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Johansson, Peter; Wei, Jun S.; Chen, Qingrong; Badgett, Tom C.; Song, Young K.; Holman, Catherine; Yeh, Susan; Khan, Javed] NCI, Gaithersburg, MD USA. [Bowden, Nikola] Univ Newcastle, Sch Biomed Sci & Pharm, Newcastle, NSW 2300, Australia. [Wen, Xinyu] NCI, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4833 DI 10.1158/1538-7445.AM2011-4833 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701403278 ER PT J AU Jong, L Chao, WR Green, C Kapetanovic, I Sambucetti, L Collins, N AF Jong, Ling Chao, Wan-Ru Green, Carol Kapetanovic, Izet Sambucetti, Lidia Collins, Nathan TI SR13668, a selective 12-lipoxygenase inhibitor, suppresses tumor growth by modulating the Akt signaling pathway SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Jong, Ling; Chao, Wan-Ru; Green, Carol; Sambucetti, Lidia; Collins, Nathan] SRI Int, Menlo Pk, CA 94025 USA. [Kapetanovic, Izet] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4483 DI 10.1158/1538-7445.AM2011-4483 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404267 ER PT J AU Kaira, N Zhang, JL Yu, YK Ho, M Cao, L Hassan, R AF Kaira, Neetu Zhang, Jingli Yu, Yunkai Ho, Mitchell Cao, Liang Hassan, Raffit TI Anti-tumor efficacy of IMC-A12, a fully human anti-insulin like growth factor 1 receptor (IGF-1R) antibody, against malignant mesothelioma (MM) SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kaira, Neetu; Zhang, Jingli; Yu, Yunkai; Ho, Mitchell; Cao, Liang; Hassan, Raffit] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 646 DI 10.1158/1538-7445.AM2011-646 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401340 ER PT J AU Kales, SC Lipkowitz, S AF Kales, Stephen C. Lipkowitz, Stanley TI Enigma blocks Cbl-c-mediated RET ubiquitination and degradation SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kales, Stephen C.; Lipkowitz, Stanley] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1220 DI 10.1158/1538-7445.AM2011-1220 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401466 ER PT J AU Kang, ZG Chen, JJ Yu, YK Zhang, BL Cao, L AF Kang, Zhigang Chen, Junjie Yu, Yunkai Zhang, Baolin Cao, Liang TI A human antibody to death receptor 5 has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kang, Zhigang; Yu, Yunkai; Cao, Liang] NCI, Bethesda, MD 20892 USA. [Chen, Junjie; Zhang, Baolin] US FDA, Bethesda, MD 20014 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4094 DI 10.1158/1538-7445.AM2011-4094 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402066 ER PT J AU Karasawa, H Nagaoka, T Rangel, MC Castro, NP Held, N Gonzales, M Bianco, C Salomon, DS AF Karasawa, Hideaki Nagaoka, Tadahiro Rangel, Maria Cristina Castro, Nadia P. Held, Natalie Gonzales, Monica Bianco, Caterina Salomon, David S. TI Phospholipid scramblase 1 and 3 as novel effectors of cripto-1 signaling SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Karasawa, Hideaki; Nagaoka, Tadahiro; Rangel, Maria Cristina; Castro, Nadia P.; Held, Natalie; Gonzales, Monica; Bianco, Caterina; Salomon, David S.] NCI, MBTL, CCR, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1944 DI 10.1158/1538-7445.AM2011-1944 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401439 ER PT J AU Katiyar, S Casimiro, M Dettin, L Ju, XM Wagner, E Tanaka, H Pestell, R AF Katiyar, Sanjay Casimiro, Mathew Dettin, Luis Ju, Xiaoming Wagner, Erwin Tanaka, Hirokazu Pestell, Richard TI Endogenous c-jun inhibits mammary epithelial cellular apoptosis in vivo SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Katiyar, Sanjay] Univ Delhi, Delhi 110007, India. [Casimiro, Mathew; Ju, Xiaoming; Pestell, Richard] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Dettin, Luis] NIH, Ctr Sci Review, Bethesda, MD 20892 USA. [Wagner, Erwin] CNIO Canc Cell Biol Programme, Madrid, Spain. [Tanaka, Hirokazu] Inst Biomed Res & Innovat, Kobe, Hyogo, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 202 DI 10.1158/1538-7445.AM2011-202 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402356 ER PT J AU Kaur, I Kosak, KM Sweeley, JC Terrazas, M Saavedra, JE Keefer, LK Herron, JN Shami, PJ AF Kaur, Imit Kosak, Ken M. Sweeley, John C. Terrazas, Moises Saavedra, Joseph E. Keefer, Larry K. Herron, James N. Shami, Paul J. TI Protein Interaction and Binding Studies of the Nitric Oxide-Generating Antineoplastic Agent JS-K SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kaur, Imit; Herron, James N.] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT USA. [Kosak, Ken M.; Terrazas, Moises; Shami, Paul J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Sweeley, John C.] Univ Utah, Dept Pediat, Salt Lake City, UT USA. [Saavedra, Joseph E.] SAIC Frederick, Frederick, MD USA. [Keefer, Larry K.] NCI, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4392 DI 10.1158/1538-7445.AM2011-4392 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401361 ER PT J AU Kawabata, S Mercado, J Hollander, MC Wilson, W Regales, L Pao, W Janne, PA Wong, KK Dennis, PA AF Kawabata, Shigeru Mercado, Jose Hollander, M. Christine Wilson, Willie Regales, Lucia Pao, William Janne, Pasi A. Wong, Kwok-Kin Dennis, Phillip A. TI Rapamycin prolongs overall survival and progression-free survival in a mouse model of lung cancer in never smokers resistant to erlotinib SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kawabata, Shigeru; Mercado, Jose; Hollander, M. Christine; Wilson, Willie; Dennis, Phillip A.] NCI, Med Oncol Branch, CCR, Bethesda, MD 20892 USA. [Regales, Lucia] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Pao, William] Vanderbilt Univ, Nashville, TN 37235 USA. [Janne, Pasi A.; Wong, Kwok-Kin] Dana Farber Canc Inst, Boston, MA 02115 USA. OI wong, kwok kin/0000-0001-6323-235X NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2836 DI 10.1158/1538-7445.AM2011-2836 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302368 ER PT J AU Kawabata, S Hollander, MC Munasinghe, JP Mercado, J Brinster, LR Butman, JA Lonser, RR Regales, L Pao, W Janne, PA Wong, KK Dennis, PA AF Kawabata, Shigeru Hollander, M. Christine Munasinghe, Jeeva P. Mercado, Jose Brinster, Lauren R. Butman, John A. Lonser, Russell R. Regales, Lucia Pao, William Janne, Pasi A. Wong, Kwok-Kin Dennis, Phillip A. TI A new mouse model for epithelial ear neoplasms based upon expression of mutant EGFRL858R/T790M SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kawabata, Shigeru; Hollander, M. Christine; Mercado, Jose; Dennis, Phillip A.] NCI, Med Oncol Branch, CCR, Bethesda, MD 20892 USA. [Munasinghe, Jeeva P.] NINDS, MRI Res Facil, Bethesda, MD 20892 USA. [Brinster, Lauren R.] Div Vet Resources, Bethesda, MD USA. [Butman, John A.] Ctr Clin, Radiol & Imaging Sci, Bethesda, MD USA. [Lonser, Russell R.] NINDS, Surg Neurol Branch, Bethesda, MD 20892 USA. [Regales, Lucia] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Pao, William] Vanderbilt Univ, Nashville, TN 37235 USA. [Janne, Pasi A.; Wong, Kwok-Kin] Dana Farber Canc Inst, Boston, MA 02115 USA. OI wong, kwok kin/0000-0001-6323-235X NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2417 DI 10.1158/1538-7445.AM2011-2417 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300458 ER PT J AU Kayode, O Reid, JM Satele, DV Tang, H Haluska, P Peethambaram, PP Ames, MM Chen, A Kaufmann, SH Northfelt, DW Erlichman, C Menefee, ME AF Kayode, Olumide Reid, Joel M. Satele, Danel V. Tang, Hui Haluska, Paul Peethambaram, Prema P. Ames, Matthew M. Chen, Alice Kaufmann, Scott H. Northfelt, Donald W. Erlichman, Charles Menefee, Michael E. TI Investigation of a potential pharmacokinetic interaction between ABT-888 and topotecan in a phase I trial SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kayode, Olumide; Reid, Joel M.; Satele, Danel V.; Tang, Hui; Haluska, Paul; Peethambaram, Prema P.; Ames, Matthew M.; Kaufmann, Scott H.; Erlichman, Charles] Mayo Clin, Rochester, MN USA. [Chen, Alice] NCI, Rockville, MD USA. [Northfelt, Donald W.] Mayo Clin Arizona, Scottsdale, AZ USA. [Menefee, Michael E.] Mayo Clin Florida, Jacksonville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1301 DI 10.1158/1538-7445.AM2011-1301 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701405294 ER PT J AU Kedei, N Telek, A Lubart, ES Lewin, NE Yang, DZ Chen, JQ Herrmann, MA Goldsmith, PK Lim, L Mannam, P Garfield, SH Blumberg, PM AF Kedei, Noemi Telek, Andrea Lubart, Emanuel S. Lewin, Nancy E. Yang, Dazhi Chen, Jinqiu Herrmann, Michelle A. Goldsmith, Paul K. Lim, Langston Mannam, Poonam Garfield, Susan H. Blumberg, Peter M. TI Diverse patterns of biological response to phorbol esters and related protein kinaseC activators in LNCaP human prostate cancer cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kedei, Noemi; Telek, Andrea; Lubart, Emanuel S.; Lewin, Nancy E.; Yang, Dazhi; Chen, Jinqiu; Herrmann, Michelle A.; Goldsmith, Paul K.; Lim, Langston; Mannam, Poonam; Garfield, Susan H.; Blumberg, Peter M.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4058 DI 10.1158/1538-7445.AM2011-4058 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404309 ER PT J AU Keir, ST Morton, CL Kolb, EA Gorlick, R Caroi, H Lock, R Kang, MH Reynolds, CP Maris, JM Wu, JR Smith, MA Houghton, PJ AF Keir, Stephen T. Morton, Christopher L. Kolb, E. Anders Gorlick, Richard Caroi, Hernan Lock, Richard Kang, Min H. Reynolds, C. Patrick Maris, John M. Wu, Jianrong Smith, Malcolm A. Houghton, Peter J. TI Pediatric preclinical testing program (PPTP) evaluation of the DNA methylating agent temozolomide SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Keir, Stephen T.] Duke Univ, Med Ctr, Durham, NC USA. [Morton, Christopher L.; Wu, Jianrong] St Jude Childrens Res Hosp, Memphis, TN USA. [Kolb, E. Anders] Alfred I DuPont Hosp Children, Wilmington, DE USA. [Gorlick, Richard] Montefiore Med Ctr, Bronx, NY 10467 USA. [Caroi, Hernan; Lock, Richard] Childrens Canc Inst Australia, Randwick, NSW, Australia. [Kang, Min H.; Reynolds, C. Patrick] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA. [Maris, John M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Smith, Malcolm A.] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Houghton, Peter J.] Nationwide Childrens Hosp, Columbus, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5356 DI 10.1158/1538-7445.AM2011-5356 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701301418 ER PT J AU Kelly, L Bryan, K Kim, SY Debiec-Rychter, M O'Sulliyan, MJ AF Kelly, Lorna Bryan, Kenneth Kim, Su Young Debiec-Rychter, Maria O'Sulliyan, Maureen J. TI An investigation into the role of miRNAs in the pathogenesis of pediatric gastrointestinal stromal tumor SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kelly, Lorna; O'Sulliyan, Maureen J.] Univ Dublin Trinity Coll, Dublin 2, Ireland. [Bryan, Kenneth] Royal Coll Surgeons Ireland, Dublin 2, Ireland. [Kim, Su Young] NCI, Bethesda, MD 20892 USA. [Debiec-Rychter, Maria] Katholieke Univ Leuven, Leuven, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 169 DI 10.1158/1538-7445.AM2011-169 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404094 ER PT J AU Kendziorra, E Ahlborn, K Spitzner, M Rave-Frank, M Gaedcke, J Emons, G Kramer, F Beissbarth, T Ebner, R Becker, H Ghadimi, BM Pukrop, T Ried, T Grade, M AF Kendziorra, Emil Ahlborn, Kerstin Spitzner, Melanie Rave-Fraenk, Margret Gaedcke, Jochen Emons, Georg Kramer, Frank Beissbarth, Tim Ebner, Reinhard Becker, Heinz Ghadimi, B. Michael Pukrop, Tobias Ried, Thomas Grade, Marian TI Silencing of TCF7L2 sensitizes Wnt/beta-catenin signaling-dependent colorectal cancer cells to radiation SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kendziorra, Emil; Ahlborn, Kerstin; Spitzner, Melanie; Gaedcke, Jochen; Emons, Georg; Becker, Heinz; Ghadimi, B. Michael; Grade, Marian] Univ Med Ctr Gottingen, Dept Gen & Visceral Surg, Gottingen, Germany. [Rave-Fraenk, Margret] Univ Med Ctr Gottingen, Dept Radiotherapy & Radiooncol, Gottingen, Germany. [Kramer, Frank; Beissbarth, Tim] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany. [Ebner, Reinhard; Ried, Thomas] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Pukrop, Tobias] Univ Med Ctr Gottingen, Dept Hematol Oncol, Gottingen, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2490 DI 10.1158/1538-7445.AM2011-2490 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302028 ER PT J AU Khan, MH deGraffenried, LA Sanders, BG Ciolino, HP AF Khan, Maruf H. deGraffenried, Linda A. Sanders, Bob G. Ciolino, Henry P. TI Induction of apoptosis and cell cycle arrest in renal cancer cells by phenethyl isothiocyanate (PEITC) and the mechanisms involved SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Khan, Maruf H.; deGraffenried, Linda A.; Sanders, Bob G.] Univ Texas Austin, Austin, TX 78712 USA. [Ciolino, Henry P.] NCI, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4222 DI 10.1158/1538-7445.AM2011-4222 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305105 ER PT J AU Kim, HK Chanock, SJ Fang, J Collins, I Amundadottir, L AF Kim, Hye Kyung Chanock, Stephen J. Fang, Jun Collins, Irene Amundadottir, Laufey TI MicroRNA gene polymorphisms in cancer susceptibility loci 5p12, 8q24 and 11q13 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kim, Hye Kyung; Chanock, Stephen J.; Fang, Jun; Collins, Irene; Amundadottir, Laufey] NIH, Gaithersburg, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1170 DI 10.1158/1538-7445.AM2011-1170 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404130 ER PT J AU Kim, JS Chrysovergis, K Kosak, J Kissling, G Eling, T AF Kim, Jong-Sik Chrysovergis, Kaliopi Kosak, Justin Kissling, Grace Eling, Thomas TI Transgenic expression of NSAID-activated gene-1 (NAG-1) protects mice from high fat diet-induced obesity SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kim, Jong-Sik] Andong Natl Univ, Dept Biol Sci, Andong, Gyeongbuk, South Korea. [Chrysovergis, Kaliopi; Kosak, Justin; Kissling, Grace; Eling, Thomas] NIEHS, Res Triangle Pk, NC 27709 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 982 DI 10.1158/1538-7445.AM2011-982 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305354 ER PT J AU Kohaar, I Fu, YP Tang, W Tarway, M Muchmore, B Porter-Gill, P Prokunina-Olsson, L AF Kohaar, Indu Fu, Yi-Ping Tang, Wei Tarway, McAnthony Muchmore, Brian Porter-Gill, Patricia Prokunina-Olsson, Ludmila TI Allele-specific mRNA and protein expression on genetic variants of CCNE1 associated with risk of bladder cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kohaar, Indu; Fu, Yi-Ping; Tang, Wei; Tarway, McAnthony; Muchmore, Brian; Porter-Gill, Patricia; Prokunina-Olsson, Ludmila] NCI, NIH, Gaithersburg, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4974 DI 10.1158/1538-7445.AM2011-4974 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404195 ER PT J AU Kramer-Marek, G Shenoy, N Seidel, J Griffiths, G Choyke, P Capala, J AF Kramer-Marek, Gabriela Shenoy, Nalini Seidel, Jurgen Griffiths, Gary Choyke, Peter Capala, Jacek TI Ga-68-radiolabeled DOTA-affibody molecule for in vivo assessment of HER2 expression with PET SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kramer-Marek, Gabriela; Seidel, Jurgen; Choyke, Peter; Capala, Jacek] NCI, NIH, Bethesda, MD 20892 USA. [Shenoy, Nalini; Griffiths, Gary] NHLBI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5284 DI 10.1158/1538-7445.AM2011-5284 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301149 ER PT J AU Kratz, CP Greene, MH Shi, JX AF Kratz, Christian P. Greene, Mark H. Shi, Jianxin TI A stratified genetic risk assessment for testicular cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kratz, Christian P.; Greene, Mark H.; Shi, Jianxin] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 871 DI 10.1158/1538-7445.AM2011-871 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701405454 ER PT J AU Krueger, A Dehdashti, S Southhall, N Patnaik, S Marugan, J Zheng, W Ford, H Zhao, R AF Krueger, Aaron Dehdashti, Seameen Southhall, Noel Patnaik, Samarjit Marugan, Juan Zheng, Wei Ford, Heide Zhao, Rui TI Identification and characterization of small molecule inhibitors targeting Eya phosphatase activity for anti-breast cancer therapy SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Krueger, Aaron; Zhao, Rui] Univ Colorado, Dept Biochem & Mol Genet, Aurora, CO USA. [Dehdashti, Seameen; Southhall, Noel; Patnaik, Samarjit; Marugan, Juan; Zheng, Wei] NIH, Chem Genom Ctr, Rockville, MD USA. [Ford, Heide] Univ Colorado, Dept Obstet & Gynecol, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1378 DI 10.1158/1538-7445.AM2011-1378 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304223 ER PT J AU Kunnumakkara, AB Memmott, RM Maier, CR Kawabata, S Quinn, B Gills, J Dallos, M Hollander, CM Dennis, PA AF Kunnumakkara, Ajaikumar B. Memmott, Regan M. Maier, Colleen R. Kawabata, Shigeru Quinn, Brendan Gills, Joell Dallos, Matthew Hollander, Christine M. Dennis, Phillip A. TI Efficacy of metformin in two mouse models of Li-Fraumeni syndrome SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Kunnumakkara, Ajaikumar B.; Memmott, Regan M.; Maier, Colleen R.; Kawabata, Shigeru; Quinn, Brendan; Gills, Joell; Dallos, Matthew; Hollander, Christine M.; Dennis, Phillip A.] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 614 DI 10.1158/1538-7445.AM2011-614 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401011 ER PT J AU Lai, G Park, Y Hartge, P Hollenbeck, A Schatzkin, A Freedman, N AF Lai, Gabriel Park, Yikyung Hartge, Patricia Hollenbeck, Albert Schatzkin, Arthur Freedman, Neal TI The association between diabetes and cancer incidence and mortality in the NIH-AARP study SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Lai, Gabriel; Park, Yikyung; Hartge, Patricia; Schatzkin, Arthur; Freedman, Neal] NCI, Rockville, MD USA. [Hollenbeck, Albert] AARP, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 947 DI 10.1158/1538-7445.AM2011-947 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701406031 ER PT J AU Lee, MP Kadota, M AF Lee, Maxwell P. Kadota, Mitsutaka TI Transcriptome analysis and the identification of novel somatic mutations in breast cancer by the next-generation sequencing SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Lee, Maxwell P.; Kadota, Mitsutaka] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4971 DI 10.1158/1538-7445.AM2011-4971 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404191 ER PT J AU Lee, S Zhu, L Mansfield, JR Chen, XY AF Lee, Seulki Zhu, Lei Mansfield, James R. Chen, Xiaoyuan TI Real-time video imaging of protease expression in vivo SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Lee, Seulki; Zhu, Lei; Chen, Xiaoyuan] NIH, Bethesda, MD 20892 USA. [Mansfield, James R.] CRi, Woburn, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5313 DI 10.1158/1538-7445.AM2011-5313 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301178 ER PT J AU Lee, YH Andersen, JB Judge, AD Seo, D Raggi, C Jens, MU Conner, EA MacLachlan, I Factor, VM Thorgeirsson, SS AF Lee, Yun-Han Andersen, Jesper B. Judge, Adam D. Seo, Daekwan Raggi, Chiara Jens, Marquardt U. Conner, Elizabeth A. MacLachlan, Ian Factor, Valentina M. Thorgeirsson, Snorri S. TI siRNA targeting of cell cycle kinase Wee1 inhibits hepatocullar carconima growth in vitro and in vivo SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Lee, Yun-Han; Andersen, Jesper B.; Seo, Daekwan; Raggi, Chiara; Jens, Marquardt U.; Conner, Elizabeth A.; Factor, Valentina M.; Thorgeirsson, Snorri S.] NCI, Bethesda, MD 20892 USA. [Judge, Adam D.; MacLachlan, Ian] Tekmira Pharmaceut, Burnaby, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1644 DI 10.1158/1538-7445.AM2011-1644 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401057 ER PT J AU Li, HZ Liu, WL Zhu, JQ Rodriguez-Canales, J Hanson, JC Emmert-Buck, MR Rodgers, GP AF Li, Hongzhen Liu, Wenli Zhu, Jianqiong Rodriguez-Canales, Jaime Hanson, Jeffrey C. Emmert-Buck, Michael R. Rodgers, Griffin P. TI Detections of olfactomedin 4 gene expression by qRT-PCR in human prostatic samples and cell lines SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Li, Hongzhen; Liu, Wenli; Zhu, Jianqiong; Rodgers, Griffin P.] NHLBI, NIH, Bethesda, MD 20892 USA. [Rodriguez-Canales, Jaime; Hanson, Jeffrey C.; Emmert-Buck, Michael R.] NIH, CCR, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2168 DI 10.1158/1538-7445.AM2011-2168 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402177 ER PT J AU Li, JX Cho, YY Ericson, M Lubet, R Grubbs, CJ Bode, AM AF Li, Jixia Cho, Yeon-Yong Ericson, Marna Lubet, Ronald Grubbs, Clinton J. Bode, Ann M. TI Lapatinib suppresses RTK-mediated signaling through multiple signaling pathways in the chemically-induced ER plus model of mammary cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Li, Jixia; Cho, Yeon-Yong; Grubbs, Clinton J.; Bode, Ann M.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA. [Ericson, Marna] Univ Minnesota, Minneapolis, MN USA. [Lubet, Ronald] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1050 DI 10.1158/1538-7445.AM2011-1050 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701400094 ER PT J AU Li, ZJ Ramalingam, S Yan, S Thiele, CJ AF Li, Zhijie Ramalingam, Sridevi Yan, Shuang Thiele, Carol J. TI The allosteric Akt inhibitor MK-2206 inhibits neuroblastoma tumor cell growth in vitro and in vivo SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Li, Zhijie; Ramalingam, Sridevi; Yan, Shuang; Thiele, Carol J.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4342 DI 10.1158/1538-7445.AM2011-4342 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701405255 ER PT J AU Lin, KY Gupta, GN Sourbier, C Williams, H Guichard, S Linehan, WM Srinivasan, R AF Lin, Kelly Y. Gupta, Gopal N. Sourbier, Carole Williams, Heinric Guichard, Sylvie Linehan, W. Marston Srinivasan, Ramaprasad TI Preclinical efficacy of AZD8055, an ATP-competitive mammalian target of rapamycin (mTOR) kinase inhibitor, in vitro in urothelial carcinoma of the bladder SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Lin, Kelly Y.; Gupta, Gopal N.; Sourbier, Carole; Williams, Heinric; Linehan, W. Marston; Srinivasan, Ramaprasad] NCI, NIH, Bethesda, MD 20892 USA. [Guichard, Sylvie] AstraZeneca, Chester, Cheshire, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4493 DI 10.1158/1538-7445.AM2011-4493 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404278 ER PT J AU Liu, W Sharma, A Phang, JM AF Liu, Wei Sharma, Anit Phang, James M. TI Tumor cell survival under microenvironmental stress: Hypoxia and/or low glucose upregulate poline oxidase SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Liu, Wei; Sharma, Anit; Phang, James M.] NCI, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2067 DI 10.1158/1538-7445.AM2011-2067 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701403425 ER PT J AU Liu, Y Chen, KG Yao, XH Gong, WH Yoshimura, T Ford, J McVicar, D Wang, JM AF Liu, Ying Chen, Kegiang Yao, Xiaohong Gong, Wanghua Yoshimura, Teizo Ford, Jill McVicar, Daniel Wang, Ji Ming TI The G protein-coupled receptor mFPR2 promotes antitumor host defense SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Liu, Ying; Chen, Kegiang; Yao, Xiaohong; Gong, Wanghua; Yoshimura, Teizo; Ford, Jill; McVicar, Daniel; Wang, Ji Ming] NCI, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1562 DI 10.1158/1538-7445.AM2011-1562 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302268 ER PT J AU Liu, ZH Rader, J Thiele, C AF Liu, Zhihui Rader, JulieAnn Thiele, Carol TI CASZ1 suppresses neuroblastoma cell growth by restoring Rb activity in G1 and regulating kinases involved in G2/M progression SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Liu, Zhihui; Rader, JulieAnn; Thiele, Carol] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2115 DI 10.1158/1538-7445.AM2011-2115 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402007 ER PT J AU Lu, AJ Yu, YL Merlino, G AF Lu, Andrew J. Yu, Yanlin Merlino, Glenn TI Role of Fc gamma RIIB in metastatic melanoma and rhabdomyosarcoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Lu, Andrew J.; Yu, Yanlin; Merlino, Glenn] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1475 DI 10.1158/1538-7445.AM2011-1475 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301454 ER PT J AU Lu, H Si, H Yang, XP Burnett, J Davis, S Sun, HW Xiao, WM Wei, L Meltzer, P Van Waes, C Chen, Z AF Lu, Hai Si, Han Yang, Xinping Burnett, Jeffery Davis, Sean Sun, Hongwei Xiao, Wenming Wei, Lai Meltzer, Paul Van Waes, Carter Chen, Zhong TI TNF-alpha promotes genome-wide replacement of TAp73 chromatin occupancy by cREL and DeltaNp63 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Lu, Hai; Si, Han; Yang, Xinping; Burnett, Jeffery; Van Waes, Carter; Chen, Zhong] NIDCD, NIH, Bethesda, MD USA. [Davis, Sean; Meltzer, Paul] NCI, NIH, Bethesda, MD 20892 USA. [Sun, Hongwei] NIAMS, NIH, Bethesda, MD USA. [Xiao, Wenming] CIT, NIH, Bethesda, MD USA. [Wei, Lai] NEI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4968 DI 10.1158/1538-7445.AM2011-4968 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404188 ER PT J AU Lu, H Brown, M Hu, M Unger, G Van Waes, C Chen, Z AF Lu, Hai Brown, Matthew Hu, Michael Unger, Gretchen Van Waes, Carter Chen, Zhong TI Protein kinase CK2 modulates TAp73 phosphorylation and suppresses apoptosis in head and neck cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Lu, Hai; Brown, Matthew; Hu, Michael; Unger, Gretchen; Van Waes, Carter; Chen, Zhong] NIDCD, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4788 DI 10.1158/1538-7445.AM2011-4788 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402480 ER PT J AU Lu, J Ikejiri, B Yang, CZ Thompson, E Mushlin, H Kovach, JS Lonser, R Zhuang, ZP AF Lu, Jie Ikejiri, Barbara Yang, Chunzhang Thompson, Eli Mushlin, Harry Kovach, John S. Lonser, Russell Zhuang, Zhengping TI An inhibitor of phosphatase PP2A enhances in vivo anticancer activity of a phospho (ADP-ribosyl) polymerase inhibitor (PARPi) combined with temozolomide (TMZ) SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Lu, Jie; Ikejiri, Barbara; Yang, Chunzhang; Thompson, Eli; Mushlin, Harry; Lonser, Russell; Zhuang, Zhengping] NINDS, Bethesda, MD 20892 USA. [Kovach, John S.] Lixte Biotechnol Holdings Inc, East Setauket, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5497 DI 10.1158/1538-7445.AM2012-5497 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300208 ER PT J AU Lu, Y Liu, PY Grubbs, C Lubet, R You, M AF Lu, Yan Liu, Pengyuan Grubbs, Clinton Lubet, Ronald You, Ming TI Modulation of gene expression and cell cycle signaling pathways in Iressa-treated urinary bladder cancer in rats SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Lu, Yan; Liu, Pengyuan; You, Ming] Med Coll Wisconsin, Miwaukee, WI USA. [Grubbs, Clinton] Univ Alabama Birmingham, Birmingham, AL USA. [Lubet, Ronald] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 818 DI 10.1158/1538-7445.AM2011-818 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303068 ER PT J AU Lu, YN Ma, HY Malone, KE Norman, SA Sullivan-Halley, J Strom, BL Marchbanks, PA Spirtas, R Burkman, RT Deapen, D Folger, SG Simon, MS Press, MF McDonald, JA Bernstein, L AF Lu, Yani Ma, Huiyan Malone, Kathleen E. Norman, Sandra A. Sullivan-Halley, Jane Strom, Brian L. Marchbanks, Polly A. Spirtas, Robert Burkman, Ronald T. Deapen, Dennis Folger, Suzanne G. Simon, Michael S. Press, Michael F. McDonald, Jill A. Bernstein, Leslie TI Obesity and mortality among black women and white women with invasive breast cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Lu, Yani; Ma, Huiyan; Sullivan-Halley, Jane; Bernstein, Leslie] City Hope Natl Med Ctr, Duarte, CA USA. [Malone, Kathleen E.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Norman, Sandra A.; Strom, Brian L.] Univ Penn, Philadelphia, PA 19104 USA. [Marchbanks, Polly A.; Folger, Suzanne G.; McDonald, Jill A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Spirtas, Robert] NICHD, Bethesda, MD USA. [Burkman, Ronald T.] Tufts Univ, Sch Med, Springfield, MA 01199 USA. [Burkman, Ronald T.] Baystate Med Ctr, Springfield, MA USA. [Deapen, Dennis; Press, Michael F.] Univ So Calif, Los Angeles, CA USA. [Simon, Michael S.] Wayne State Univ, Detroit, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3720 DI 10.1158/1538-7445.AM2011-3720 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701406086 ER PT J AU Lubet, RA Bode, A Szabo, E Grubbs, CJ AF Lubet, Ronald A. Bode, Ann Szabo, Eva Grubbs, Clinton J. TI Alternative dosing regimens with the EGFr inhibitors (Gefitinib and Lapatinib) in a mammary cancer model: Prevention efficacy SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Lubet, Ronald A.; Szabo, Eva] NCI, Bethesda, MD 20892 USA. [Bode, Ann] Hormel Inst, Minnesota, MO USA. [Grubbs, Clinton J.] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 854 DI 10.1158/1538-7445.AM2011-854 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303106 ER PT J AU Luchenko, VL Litman, T Devor, C Heffner, A Robey, RW Wilkerson, J Chakraborty, AR Bangiolo, L Levens, D Bates, SE AF Luchenko, Victoria L. Litman, Thomas Devor, Christopher Heffner, Aaron Robey, Robert W. Wilkerson, Julia Chakraborty, Arup R. Bangiolo, Lois Levens, David Bates, Susan E. TI Identification of cell context specific and pleiotropic effects of the histone deacetylase inhibitors romidepsin (depsipeptide) and vorinostat (SAHA) SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Luchenko, Victoria L.; Litman, Thomas; Devor, Christopher; Heffner, Aaron; Robey, Robert W.; Wilkerson, Julia; Bangiolo, Lois; Levens, David; Bates, Susan E.] NCI, NIH, Bethesda, MD 20892 USA. [Chakraborty, Arup R.] Texas Tech Univ, Lubbock, TX 79409 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2620 DI 10.1158/1538-7445.AM2011-2620 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401104 ER PT J AU Maier, C Hollander, MC Dennis, P AF Maier, Colleen Hollander, M. Christine Dennis, Phillip TI Nicotine does not promote tumor growth in preclinical mouse models of lung cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Maier, Colleen; Hollander, M. Christine; Dennis, Phillip] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1336 DI 10.1158/1538-7445.AM2011-1336 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304250 ER PT J AU Marchio, S Di Paolo, D Loi, M Soster, M Bartolini, A Cilli, M Sun, J Gambini, C Longhi, R Curnis, F Corti, A Arap, W Pasqualini, R Ponzoni, M Pastorino, F AF Marchio, Serena Di Paolo, Daniela Loi, Monica Soster, Marco Bartolini, Alice Cilli, Michele Sun, Jessica Gambini, Claudio Longhi, Renato Curnis, Flavio Corti, Angelo Arap, Wadih Pasqualini, Renata Ponzoni, Mirco Pastorino, Fabio TI Novel phage-display derived peptides for tumor- and vasculature-targeted therapies in neuroblastoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Marchio, Serena; Soster, Marco; Bartolini, Alice] Univ Turin, IRCC, Dept Oncol Sci, Turin, Italy. [Di Paolo, Daniela; Loi, Monica; Ponzoni, Mirco; Pastorino, Fabio] G Gaslini Childrens Hosp, Lab Oncol, Genoa, Italy. [Cilli, Michele] Natl Canc Inst, Anim Res Facil, Genoa, Italy. [Sun, Jessica; Arap, Wadih; Pasqualini, Renata] Univ Texas MD Anderson Canc Ctr, GU Med Oncol, Houston, TX 77030 USA. [Gambini, Claudio] G Gaslini Childrens Hosp, Pathol Lab, Genoa, Italy. [Longhi, Renato] CNR, Ist Chim Riconoscimento Mol, I-20133 Milan, Italy. [Curnis, Flavio; Corti, Angelo] San Raffaele Inst, Dept Mol Oncol, Milan, Italy. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3625 DI 10.1158/1538-7445.AM2011-3625 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401262 ER PT J AU Marino, N Marshall, JCA Collins, J Zhou, M Veenstra, T Steeg, PS AF Marino, Natascia Marshall, Jean-Claude A. Collins, Joshua Zhou, Ming Veenstra, Timothy Steeg, Patricia S. TI The interaction of two metastasis suppressor genes, Nm23-H1 and Gelsolin, results in synergistic phenotypes SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Marino, Natascia; Marshall, Jean-Claude A.; Collins, Joshua; Steeg, Patricia S.] NCI, Bethesda, MD 20892 USA. [Zhou, Ming; Veenstra, Timothy] NCI, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4753 DI 10.1158/1538-7445.AM2011-4753 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303290 ER PT J AU Marsh, CA Patel, V El Dinali, M Seiwert, T Molinolo, AA Gutkind, JS AF Marsh, Christina A. Patel, Vyomesh El Dinali, Mohamed Seiwert, Tanguy Molinolo, Alfredo A. Gutkind, J. Silvio TI HPV-associated HNSCC: Widespread mTOR pathway activity and preclinical evaluation of mTOR inhibitors rapamycin and RAD-001 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Marsh, Christina A.; Patel, Vyomesh; Molinolo, Alfredo A.; Gutkind, J. Silvio] NIDCR, Bethesda, MD USA. [El Dinali, Mohamed; Seiwert, Tanguy] Univ Chicago, Dept Med, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA LB-7 DI 10.1158/1538-7445.AM2011-LB-7 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305413 ER PT J AU Marshall, JCA Collins, J Zhou, M Veenstra, T Khanna, C Steeg, P AF Marshall, Jean-Claude A. Collins, Joshua Zhou, Ming Veenstra, Timothy Khanna, Chand Steeg, Patricia TI An unbiased screen for Nm23-H1 interacting proteins identifies the cytoskeletal crosslinking protein Ezrin SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Marshall, Jean-Claude A.; Collins, Joshua; Zhou, Ming; Veenstra, Timothy; Khanna, Chand; Steeg, Patricia] NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1447 DI 10.1158/1538-7445.AM2011-1447 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301263 ER PT J AU Mayeenuddin, L Yu, YK Kang, ZG Helman, L Cao, L AF Mayeenuddin, Linnia Yu, Yunkai Kang, Zhigang Helman, Lee Cao, Liang TI Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-xL SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Mayeenuddin, Linnia; Yu, Yunkai; Kang, Zhigang] NCI, Frederick SAIC Inc, Bethesda, MD 20892 USA. [Helman, Lee; Cao, Liang] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 651 DI 10.1158/1538-7445.AM2011-651 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401346 ER PT J AU McCormick, DL Horn, TL Johnson, WD Lubet, RA Steele, VE AF McCormick, David L. Horn, Thomas L. Johnson, William D. Lubet, Ronald A. Steele, Vernon E. TI Inhibition of oral carcinogenesis in rats by the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA) SO CANCER RESEARCH LA English DT Meeting Abstract C1 [McCormick, David L.; Horn, Thomas L.; Johnson, William D.] IIT, Res Inst, Chicago, IL 60616 USA. [Lubet, Ronald A.; Steele, Vernon E.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1858 DI 10.1158/1538-7445.AM2011-1858 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303172 ER PT J AU Miller, NR Huang, RL Xia, MH AF Miller, Nicole R. Huang, Ruili Xia, Menghang TI Identification and characterization of small molecule inhibitors of the activator protein-1 pathway SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Miller, Nicole R.; Huang, Ruili; Xia, Menghang] NIH, Chem Genom Ctr, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1377 DI 10.1158/1538-7445.AM2011-1377 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304222 ER PT J AU Mineo, M Garfield, SH Alessandro, R Kohn, EC AF Mineo, Marco Garfield, Susan H. Alessandro, Riccardo Kohn, Elise C. TI Exosomes released by K562 chronic myeloid leukemia cells promote endothelial cell tubular differentiation through uptake and cell-to-cell transfer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Mineo, Marco; Kohn, Elise C.] NCI, Mol Signaling Sect, Med Oncol Branch, CCR, Bethesda, MD 20892 USA. [Garfield, Susan H.] NCI, Confocal Microscopy Core Facil, Expt Carcinogenesis Lab, CCR, Bethesda, MD 20892 USA. [Alessandro, Riccardo] Univ Palermo, Dipartimento Biopatol & Biotecnol Med & Forensi, Sez Biol & Genet, Palermo, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5135 DI 10.1158/1538-7445.AM2011-5135 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303494 ER PT J AU Mirabello, L Sun, C Ghosh, A Rodriguez, AC Schiffman, M Wentzensen, N Wacholder, S Lorincz, A Burk, RD AF Mirabello, Lisa Sun, Chang Ghosh, Arpita Rodriguez, Ana C. Schiffman, Mark Wentzensen, Nicolas Wacholder, Sholom Lorincz, Attila Burk, Robert D. TI Methylation of the HPV16 L1 gene is associated with disease progression in a prospective population-based cohort SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Mirabello, Lisa; Ghosh, Arpita; Schiffman, Mark; Wentzensen, Nicolas; Wacholder, Sholom] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA. [Sun, Chang; Burk, Robert D.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Rodriguez, Ana C.] Fdn INCIENSA, Epidemiol Guanacaste, San Jose, Costa Rica. [Lorincz, Attila] Univ London, Wolfson Inst Prevent Med, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1991 DI 10.1158/1538-7445.AM2011-1991 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402481 ER PT J AU Mitsunaga, M Ogawa, M Kosaka, N Choyke, PL Kobayashi, H AF Mitsunaga, Makoto Ogawa, Mikako Kosaka, Nobuyuki Choyke, Peter L. Kobayashi, Hisataka TI Target-specific photo-activatable immunotherapy (PIT) for cancer based on a monoclonal antibody-photosensitizer conjugate SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Mitsunaga, Makoto; Ogawa, Mikako; Kosaka, Nobuyuki; Choyke, Peter L.; Kobayashi, Hisataka] NCI, CCR, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3618 DI 10.1158/1538-7445.AM2011-3618 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401254 ER PT J AU Mohammed, A Janakiram, NB Ely, M Lightfoot, S Steele, VE Rao, CV AF Mohammed, Altaf Janakiram, Naveena B. Ely, Misty Lightfoot, Stan Steele, Vernon E. Rao, Chinthalapally V. TI Licofelone, a novel dual COX-LOX inhibitor prevents progression of PanIN lesions to pancreatic carcinoma by targeting miRNAs and cancer stem cells in p48(Cre/+)-LSL-Kras(G12D/+) transgenic mice SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Mohammed, Altaf; Janakiram, Naveena B.; Ely, Misty; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Ctr Chemoprevent & Canc Drug Dev, Dept Med,Hemonc Sect,Canc Inst, Oklahoma City, OK USA. [Lightfoot, Stan] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA. [Steele, Vernon E.] NCI, Canc Prevent Div, Chemoprevent Agent Dev Res Grp, Bethesda, MD 20892 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2839 DI 10.1158/1538-7445.AM2011-2839 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302371 ER PT J AU Mondul, AM Yu, K Weinstein, SJ Virtamo, J Jacobs, KB Kraft, P Chanock, SJ Albanes, D AF Mondul, Alison M. Yu, Kai Weinstein, Stephanie J. Virtamo, Jarmo Jacobs, Kevin B. Kraft, Peter Chanock, Stephen J. Albanes, Demetrius TI Genetic determinants of serum retinol: A genome-wide association study SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Mondul, Alison M.; Yu, Kai; Weinstein, Stephanie J.; Jacobs, Kevin B.; Chanock, Stephen J.; Albanes, Demetrius] NCI, DCEG, Rockville, MD USA. [Virtamo, Jarmo] Natl Inst Hlth & Welf, Helsinki, Finland. [Kraft, Peter] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4726 DI 10.1158/1538-7445.AM2011-4726 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701400244 ER PT J AU Monks, A Hose, CD Doroshow, JH AF Monks, Anne Hose, Curtis D. Doroshow, James H. TI Sunitinib induces anti-angiogenic splice-variant VEGF165b through induction of CLK1 and CLK4 kinases in prostate cell line DU-145 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Monks, Anne; Hose, Curtis D.] SAIC Frederick Inc, Frederick, MD USA. [Doroshow, James H.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2853 DI 10.1158/1538-7445.AM2011-2853 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303266 ER PT J AU Moody, TW Osefo, N Sancho, V DiFlorio, A Mantey, S Jensen, RT AF Moody, Terry W. Osefo, Nauramy Sancho, Veronica DiFlorio, Alessia Mantey, Samuel Jensen, Robert T. TI Lung cancer epidermal growth factor receptors are transactivated by neurotensin SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Moody, Terry W.; Osefo, Nauramy] NCI, CCR, Bethesda, MD 20892 USA. [Sancho, Veronica; DiFlorio, Alessia; Mantey, Samuel; Jensen, Robert T.] NIDDK, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4534 DI 10.1158/1538-7445.AM2011-4534 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701400224 ER PT J AU Morozova, O Birol, I Corbett, R Mungall, K Attiyeh, EF Asgharzadeh, S Zhao, YJ Moore, RA Hirst, M Jones, S Hogarty, MD Diskin, S Mosse, YP Diamond, M Sposto, R Ji, LY Gerhard, DS Smith, MA Khan, J Seeger, RC Marra, MA Maris, JM AF Morozova, Olena Birol, Inanc Corbett, Richard Mungall, Karen Attiyeh, Edward F. Asgharzadeh, Shahab Zhao, Yongjun Moore, Richard A. Hirst, Martin Jones, Steven Hogarty, Michael D. Diskin, Sharon Mosse, Yael P. Diamond, Maura Sposto, Richard Ji, Lingyun Gerhard, Daniela S. Smith, Malcolm A. Khan, Javed Seeger, Robert C. Marra, Marco A. Maris, John M. CA NCI TARGET Initiative TI Whole genome and transcriptome sequencing defines the spectrum of somatic changes in high-risk neuroblastoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Morozova, Olena; Birol, Inanc; Corbett, Richard; Mungall, Karen; Zhao, Yongjun; Moore, Richard A.; Hirst, Martin; Jones, Steven; Marra, Marco A.] BC Canc Agcy, Genome Sci Ctr, Vancouver, BC, Canada. [Attiyeh, Edward F.; Hogarty, Michael D.; Diskin, Sharon; Mosse, Yael P.; Diamond, Maura; Maris, John M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Attiyeh, Edward F.; Hogarty, Michael D.; Diskin, Sharon; Mosse, Yael P.; Diamond, Maura; Maris, John M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Asgharzadeh, Shahab; Sposto, Richard; Ji, Lingyun; Seeger, Robert C.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Asgharzadeh, Shahab; Sposto, Richard; Ji, Lingyun; Seeger, Robert C.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Gerhard, Daniela S.; Smith, Malcolm A.; Khan, Javed] NCI, Bethesda, MD 20892 USA. [Marra, Marco A.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. RI Birol, Inanc/G-5440-2011 OI Birol, Inanc/0000-0003-0950-7839 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 926 DI 10.1158/1538-7445.AM2011-926 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305334 ER PT J AU Muchmore, B Park, H Dickensheets, H O'Brien, T Rehermann, B Donnelly, R Prokunina-Olsson, L AF Muchmore, Brian Park, Heiyoung Dickensheets, Harold O'Brien, Thomas Rehermann, Barbara Donnelly, Raymond Prokunina-Olsson, Ludmila TI Expression analysis of the IL28A, IL28B, IL29 and IL28L genes in primary human peripheral blood mononuclear cells and hepatocytes: Effects of activation mode, time-course and genotypes SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Muchmore, Brian; Prokunina-Olsson, Ludmila] NCI, Lab Translat Genom, DCEG, NIH, Gaithersburg, MD USA. [Park, Heiyoung; Rehermann, Barbara] NIDDK, Immunol Sect, Liver Dis Branch, NIH, Bethesda, MD 20892 USA. [Dickensheets, Harold; Donnelly, Raymond] US FDA, Div Therapeut Prot, CDER, Bethesda, MD 20014 USA. [O'Brien, Thomas] NCI, Infect & Immunoepidemiol Branch, DCEG, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3751 DI 10.1158/1538-7445.AM2011-3751 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305068 ER PT J AU Murthy, SRK Lee, TK Cawley, NX Pacak, K Loh, P AF Murthy, Saravana R. K. Lee, Terence K. Cawley, Niamh X. Pacak, Karel Loh, Peng TI Carboxypeptidase E splice isoform is a novel tumor inducer and biomarker for predicting future metastasis in human cancers SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Murthy, Saravana R. K.; Cawley, Niamh X.; Pacak, Karel; Loh, Peng] NICHD, NIH, Bethesda, MD USA. [Lee, Terence K.] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5162 DI 10.1158/1538-7445.AM2011-5162 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304021 ER PT J AU Nakayama, J Marshall, JCA Murone, M Steeg, PS AF Nakayama, Joji Marshall, Jean-Claude A. Murone, Maximilien Steeg, Patricia S. TI LPA1 regulated pathways that mediate breast cancer dormancy in the liver and lung SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Nakayama, Joji; Marshall, Jean-Claude A.; Steeg, Patricia S.] NCI, Bethesda, MD 20892 USA. [Murone, Maximilien] Debiopharm, Lausanne, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1454 DI 10.1158/1538-7445.AM2011-1454 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301270 ER PT J AU Nasser, MW Qamri, Z Deol, YS Leone, G Zou, XH Wolf, R Yuspa, SH Ganju, RK AF Nasser, Mohd W. Qamri, Zahida Deol, Yadwinder S. Leone, Gustavo Zou, Xianghong Wolf, Ronald Yuspa, Stuart H. Ganju, Ramesh K. TI Overexpression of S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Nasser, Mohd W.; Qamri, Zahida; Deol, Yadwinder S.; Leone, Gustavo; Zou, Xianghong; Ganju, Ramesh K.] Ohio State Univ, Columbus, OH 43210 USA. [Wolf, Ronald] Univ Munich, Munich, Germany. [Yuspa, Stuart H.] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 403 DI 10.1158/1538-7445.AM2011-403 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300347 ER PT J AU Nesbitt, DE Chattopadhyay, M Kodela, R Boring, D Crowell, JA Kashfi, K AF Nesbitt, Diandra E. Chattopadhyay, Mitali Kodela, Ravinder Boring, Daniel Crowell, James A. Kashfi, Khosrow TI Hydrogen sulfide-releasing naproxen inhibits HT-29 human colon cancer cell growth: Modulation of NF-kappa B SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Nesbitt, Diandra E.; Chattopadhyay, Mitali; Kodela, Ravinder; Kashfi, Khosrow] CUNY, Sch Med, New York, NY 10031 USA. [Boring, Daniel; Crowell, James A.] NCI, Canc Prevent Div, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1353 DI 10.1158/1538-7445.AM2011-1353 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304267 ER PT J AU Newman, EM Morgan, RJ Beumer, JH Blanchard, SM EI-Khoueiry, AB Kummar, S Carroll, MI Synold, TW Lenz, HJ Doroshow, JH AF Newman, Edward M. Morgan, Robert J. Beumer, Jan H. Blanchard, Suzette M. EI-Khoueiry, Anthony B. Kummar, Shivaani Carroll, Mary I. Synold, Timothy W. Lenz, Heinz J. Doroshow, James H. TI Phase I and pharmacokinetic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2 '-deoxycytidine: A California Cancer Consortium study SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Newman, Edward M.; Morgan, Robert J.; Blanchard, Suzette M.; Carroll, Mary I.; Synold, Timothy W.] City Hope Natl Med Ctr, Duarte, CA USA. [Beumer, Jan H.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [EI-Khoueiry, Anthony B.; Lenz, Heinz J.] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA. [Kummar, Shivaani; Doroshow, James H.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1283 DI 10.1158/1538-7445.AM2011-1283 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701405275 ER PT J AU Niedan, S Kauer, M Jug, G Walker, RL Meltzer, PS Kovar, H AF Niedan, Stephan Kauer, Maximilian Jug, Gunhild Walker, Robert L. Meltzer, Paul S. Kovar, Heinrich TI A repressive EWS-FLI1 subsignature is the result of FOXO1 suppression and nuclear exclusion SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Niedan, Stephan; Kauer, Maximilian; Jug, Gunhild; Kovar, Heinrich] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria. [Walker, Robert L.; Meltzer, Paul S.] NCI, Genet Branch, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5338 DI 10.1158/1538-7445.AM2011-5338 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301399 ER PT J AU Nishizuka, SS Ishida, K Uesugi, N Chiba, T Matsuo, T Yamada, N Otsuka, K Koeda, K Sugai, T Wakabayashi, G AF Nishizuka, Satoshi Stephen Ishida, Kazushige Uesugi, Noriyuki Chiba, Takehiro Matsuo, Teppei Yamada, Noriyuki Otsuka, Koki Koeda, Keisuke Sugai, Tamotsu Wakabayashi, Go TI An isolation strategy for biomarkers that predict cancer relapse after 5-FU based adjuvant chemotherapy SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Nishizuka, Satoshi Stephen; Uesugi, Noriyuki; Chiba, Takehiro; Matsuo, Teppei; Yamada, Noriyuki; Otsuka, Koki; Koeda, Keisuke; Sugai, Tamotsu; Wakabayashi, Go] Iwate Med Univ, Sch Med, Morioka, Iwate 020, Japan. [Ishida, Kazushige] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4129 DI 10.1158/1538-7445.AM2011-4129 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701405395 ER PT J AU O'Connell, MP Nelson, JL Fiori, JL Subaran, SS Indig, FE Weeraratna, AT AF O'Connell, Michael P. Nelson, Janelle L. Fiori, Jennifer L. Subaran, Sarah S. Indig, Fred E. Weeraratna, Ashani T. TI Switching from an ROR1-positive phenotype to an ROR2-positive phenotype promotes melanoma progression SO CANCER RESEARCH LA English DT Meeting Abstract C1 [O'Connell, Michael P.; Nelson, Janelle L.; Fiori, Jennifer L.; Subaran, Sarah S.; Indig, Fred E.; Weeraratna, Ashani T.] NIA, NIH, Baltimore, MD 21224 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2346 DI 10.1158/1538-7445.AM2011-2346 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304181 ER PT J AU O'Konek, JJ Illarinov, P Khursigara, DS Ambrosino, E Izhak, L Castillo, BF Raju, R Khalili, M Kim, HY Howell, A Besra, GS Porcelli, SA Berzofsky, JA Terabe, M AF O'Konek, Jessica J. Illarinov, Petr Khursigara, Deborah Stewart Ambrosino, Elena Izhak, Liat Castillo, Bernard F. Raju, Ravinder Khalili, Maryam Kim, Hee-Yong Howell, Amy Besra, Gurdyal S. Porcelli, Steven A. Berzofsky, Jay A. Terabe, Masaki TI Type I NKT cells mediate anti-tumor immunity through a TNF-a- and NOS-dependent pathway when stimulated with p-M an Ce SO CANCER RESEARCH LA English DT Meeting Abstract C1 [O'Konek, Jessica J.; Khursigara, Deborah Stewart; Ambrosino, Elena; Izhak, Liat; Berzofsky, Jay A.; Terabe, Masaki] NCI, Bethesda, MD 20892 USA. [Illarinov, Petr; Besra, Gurdyal S.] Univ Birmingham, Birmingham, W Midlands, England. [Castillo, Bernard F.; Raju, Ravinder; Khalili, Maryam; Howell, Amy] Univ Connecticut, Storrs, CT USA. [Kim, Hee-Yong] NIAAA, Rockville, MD 20852 USA. [Porcelli, Steven A.] Albert Einstein Coll Med, Bronx, NY 10467 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4746 DI 10.1158/1538-7445.AM2011-4746 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301291 ER PT J AU Olivo-Marston, SE Hursting, S Schetter, A Khan, M Harris, C Lavigne, J AF Olivo-Marston, Susan E. Hursting, Stephen Schetter, Aaron Khan, Mohammed Harris, Curtis Lavigne, Jackie TI Genetic reduction of circulating insulin-like growth factor (IGF)-1 inhibits obesity-promoted colon tumorigenesis in mice and alters microRNA expression SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Olivo-Marston, Susan E.] Ohio State Univ, Columbus, OH 43210 USA. [Hursting, Stephen] Univ Texas Austin, Austin, TX 78712 USA. [Schetter, Aaron; Khan, Mohammed; Harris, Curtis; Lavigne, Jackie] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 823 DI 10.1158/1538-7445.AM2011-823 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303073 ER PT J AU Ou, LH Huppi, K Gehlhaus, K Jones, T Caplen, N AF Ou, Lihui Huppi, Konrad Gehlhaus, Kristen Jones, Tamara Caplen, Natasha TI Large-scale RNAi screening identifies PCTK3/CDK18 as a putative cancer related molecular target SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Ou, Lihui; Huppi, Konrad; Gehlhaus, Kristen; Jones, Tamara; Caplen, Natasha] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2041 DI 10.1158/1538-7445.AM2011-2041 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701403170 ER PT J AU Paes, MF Cerri, MF Daltoe, RD Dias, LCR Herlinger, AL Madeira, KP Silva, D Bacchi, CE Duarte, IX Morin, PJ Silva, IV Rangel, LB AF Paes, Marcela F. Cerri, Murilo F. Daltoe, Renata D. Dias, Lucas C. R. Herlinger, Alice L. Madeira, Klesia P. Silva, Debora Bacchi, Carlos E. Duarte, Ivison X. Morin, Patrice J. Silva, Ian V. Rangel, Leticia B. TI Retrospective analysis of Claudin-16 (CLDN16) overexpression in ovarian cancer (OVCA): Evaluation of a biomarker candidate and a novel potential therapeutic target SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Paes, Marcela F.; Cerri, Murilo F.; Daltoe, Renata D.; Dias, Lucas C. R.; Herlinger, Alice L.; Madeira, Klesia P.; Silva, Debora; Silva, Ian V.; Rangel, Leticia B.] Univ Fed Espirito Santo, Vitoria, ES, Brazil. [Bacchi, Carlos E.; Duarte, Ivison X.] Consultoria Patol, Botucatu, SP, Brazil. [Morin, Patrice J.] NIH, Es, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3812 DI 10.1158/1538-7445.AM2011-3812 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701400043 ER PT J AU Parikh, HM Wang, ZM Pettigrew, K Jia, JP Daugherty, S Yeager, M Jacobs, K Hutchinson, A Burdett, L Cullen, M Qi, LQ Boland, J Collins, I Albert, T Vatten, L Hveem, K Njolstad, I Cancel-Tassin, G Cussenot, O Valeri, A Virtamo, J Thun, M Feigelson, HS Diver, WR Chatterjee, N Thomas, G Albanes, D Chanock, S Hunter, D Hoover, R Hayes, R Berndt, S Sampson, J Amundadottir, L AF Parikh, Hemang M. Wang, Zhaoming Pettigrew, Kerry Jia, Jinping Daugherty, Sarah Yeager, Meredith Jacobs, Kevin Hutchinson, Amy Burdett, Laura Cullen, Michael Qi, Liqun Boland, Joseph Collins, Irene Albert, Thomas Vatten, Lars Hveem, Kristian Njolstad, Inger Cancel-Tassin, Geraldine Cussenot, Olivier Valeri, Antoine Virtamo, Jarmo Thun, Michael Feigelson, Heather Spencer Diver, W. Ryan Chatterjee, Nilanjan Thomas, Gilles Albanes, Demetrius Chanock, Stephen Hunter, David Hoover, Robert Hayes, Richard Berndt, Sonja Sampson, Joshua Amundadottir, Laufey TI Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Parikh, Hemang M.; Wang, Zhaoming; Pettigrew, Kerry; Jia, Jinping; Daugherty, Sarah; Yeager, Meredith; Jacobs, Kevin; Hutchinson, Amy; Burdett, Laura; Cullen, Michael; Qi, Liqun; Boland, Joseph; Collins, Irene; Chatterjee, Nilanjan; Thomas, Gilles; Albanes, Demetrius; Chanock, Stephen; Hoover, Robert; Berndt, Sonja; Sampson, Joshua; Amundadottir, Laufey] NCI, DCEG, Bethesda, MD 20892 USA. [Albert, Thomas] Roche NimbleGen, Madison, WI USA. [Vatten, Lars; Hveem, Kristian] Norwegian Univ Sci & Technol, N-7034 Trondheim, Norway. [Njolstad, Inger] Univ Tromso, Tromso, Norway. [Cancel-Tassin, Geraldine; Cussenot, Olivier; Valeri, Antoine] AP HP, Paris, France. [Virtamo, Jarmo] Natl Inst Hlth & Welf, Helsinki, Finland. [Thun, Michael; Feigelson, Heather Spencer; Diver, W. Ryan] Amer Canc Soc, Atlanta, GA 30329 USA. [Hunter, David] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Hayes, Richard] NYU, Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2778 DI 10.1158/1538-7445.AM2011-2778 PG 2 WC Oncology SC Oncology GA V43SP UT WOS:000209701400193 ER PT J AU Parise, RA Beumer, J Clausen, D Egorin, M Covey, J Eiseman, J AF Parise, Robert A. Beumer, Jan Clausen, Dana Egorin, Merrill Covey, Joseph Eiseman, Julie TI Modulation of DMS612 (BEN) pharmacokinetics and metabolism in mice by disulfiram, and aldehyde dehydrogenase inhibitor SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Parise, Robert A.; Beumer, Jan; Clausen, Dana; Egorin, Merrill; Eiseman, Julie] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Covey, Joseph] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5465 DI 10.1158/1538-7445.AM2011-5465 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300090 ER PT J AU Park, Y Hollenbeck, A Schatzkin, A AF Park, Yikyung Hollenbeck, Albert Schatzkin, Arthur TI Prediagnosis body mass index and smoking in relation to colon cancer survival: The NIH-AARP Diet and Health Study SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Park, Yikyung; Schatzkin, Arthur] NCI, DCEG, Rockville, MD USA. [Hollenbeck, Albert] AARP, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4667 DI 10.1158/1538-7445.AM2011-4667 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401207 ER PT J AU Pastorino, F Dewilde, S Loi, M Tosti, S Ricci, L Cilli, M Ribatti, D Sapio, R Bucci, E Barone, D Ponzoni, M AF Pastorino, Fabio Dewilde, Sarah Loi, Monica Tosti, Sara Ricci, Laura Cilli, Michele Ribatti, Domenico Sapio, Roberto Bucci, Enrico Barone, Domenico Ponzoni, Mirco TI Oligonucleotide-based inhibition of the pro-angiogenic activity of Hepatoma-derived growth factor related protein 3 in neuroblastoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Pastorino, Fabio; Loi, Monica; Ponzoni, Mirco] G Gaslini Childrens Hosp, Genoa, Italy. [Dewilde, Sarah; Sapio, Roberto; Bucci, Enrico; Barone, Domenico] BioNucleon Srl, Naples, Italy. [Tosti, Sara; Ricci, Laura] Bioind Pk Canavese, Colleretto Giacosa, TO, Italy. [Cilli, Michele] Natl Canc Inst, Anim Res Facil, Genoa, Italy. [Ribatti, Domenico] Univ Bari, Dept Human Anat & Histol, Bari, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5144 DI 10.1158/1538-7445.AM2011-5144 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304005 ER PT J AU Patel, JP Kuang, YH Sodani, K Wu, CP Liao, LQ Tiwari, AK Dai, CL Chen, X Fu, LW Ambudkar, SV Korlipara, VL Chen, ZS AF Patel, Jay P. Kuang, Ye-Hong Sodani, Kamlesh Wu, Chun-Pu Liao, Li-Qiu Tiwari, Amit K. Dai, Chun-ling Chen, Xiang Fu, Li-Wu Ambudkar, Suresh V. Korlipara, Vijaya L. Chen, Zhe-Sheng TI Analogs of OSI-930 as potent ABCG2-mediated multidrug resistance reversal agents SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Patel, Jay P.; Kuang, Ye-Hong; Sodani, Kamlesh; Tiwari, Amit K.; Dai, Chun-ling; Korlipara, Vijaya L.; Chen, Zhe-Sheng] St Johns Univ, Coll Pharm & Allied Hlth Profess, Queens, NY USA. [Wu, Chun-Pu; Ambudkar, Suresh V.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Liao, Li-Qiu; Chen, Xiang] Cent S Univ, Xiang Ya Hosp, Chanhsha, Peoples R China. [Fu, Li-Wu] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1740 DI 10.1158/1538-7445.AM2011-1740 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300088 ER PT J AU Patiolla, JMR Lubet, R Ely, M Zhang, YT Janakiram, NB Madka, V Mohammed, A Steele, VE Rao, CV AF Patiolla, Jagan Mohan Reddy Lubet, Ronald Ely, Misty Zhang, Yuting Janakiram, Naveena B. Madka, Venkateshwar Mohammed, Altaf Steele, Vernon E. Rao, Chinthalapally V. TI Chemoprevention of colon cancer by DFMO, sulindac and NO-sulindac administered individually or in combinations in male F344 rats SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Patiolla, Jagan Mohan Reddy; Ely, Misty; Zhang, Yuting; Janakiram, Naveena B.; Madka, Venkateshwar; Mohammed, Altaf; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Lubet, Ronald; Steele, Vernon E.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 808 DI 10.1158/1538-7445.AM2011-808 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303058 ER PT J AU Peng, HZ Hou, ZY He, M Kebebew, E Orntoft, TF Herlyn, M Caton, AJ Fredericks, WJ Malkowicz, B Rauscher, FJ AF Peng, Hongzhuang Hou, Zhaoyuan He, Mei Kebebew, Electron Orntoft, Torben F. Herlyn, Meenhard Caton, Andrew J. Fredericks, William J. Malkowicz, Bruce Rauscher, Frank J. TI The LIM protein LIMD2 functions as an effector and biomarker for metastasis in multiple tumor types SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Peng, Hongzhuang; Hou, Zhaoyuan; Herlyn, Meenhard; Caton, Andrew J.; Rauscher, Frank J.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA. [He, Mei; Kebebew, Electron] NCI, Bethesda, MD 20892 USA. [Orntoft, Torben F.] Skejby Sygehus, Aarhus Univ Hosp, Aarhus, Denmark. [Fredericks, William J.; Malkowicz, Bruce] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5219 DI 10.1158/1538-7445.AM2011-5219 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300393 ER PT J AU Persson, EC Shiels, MS Bhatia, K Dawsey, SM Engels, EA AF Persson, E. Christina Shiels, Meredith S. Bhatia, Kishor Dawsey, Sanford M. Engels, Eric A. TI Risk of esophageal and stomach malignancies in people with AIDS SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Persson, E. Christina; Shiels, Meredith S.; Bhatia, Kishor; Dawsey, Sanford M.; Engels, Eric A.] NIH, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3744 DI 10.1158/1538-7445.AM2011-3744 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305061 ER PT J AU Petrini, L Zucali, PA Lee, HS Luo, J Killian, KJ Melzer, PS Wang, YH Wang, YS Giaccone, G AF Petrini, Lacopo Zucali, Paolo A. Lee, Hye Seung Luo, Ji Killian, Keith J. Melzer, Paul S. Wang, Yonghong Wang, Yisong Giaccone, Giuseppe TI Array comparative genomic hybridization of thymic epithelial tumors identifies loss of CDKN2A as a prognostic factor and BCL2 family members as targets for therapy SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Petrini, Lacopo; Lee, Hye Seung; Luo, Ji; Killian, Keith J.; Melzer, Paul S.; Wang, Yonghong; Wang, Yisong; Giaccone, Giuseppe] NCI, Bethesda, MD 20892 USA. [Zucali, Paolo A.] IRCCS, Humanitas Clin Inst, Dept Oncol, Milan, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA LB-314 DI 10.1158/1538-7445.AM2011-LB-314 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701405405 ER PT J AU Plyler, RJ Wang, WX Ghobrial, IM Roccaro, AM Korde, N Zingone, A Landgren, O Calvo, KR AF Plyler, Ryan J. Wang, Weixin Ghobrial, Irene M. Roccaro, Aldo M. Korde, Neha Zingone, Adriana Landgren, Ola Calvo, Katherine R. TI Cytokine profiles in bone marrow supernatant and peripheral blood of patients with multiple myeloma and Waldenstrom's macroglobulinemia SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Plyler, Ryan J.] Georgetown Sch Med, Georgetown, DC USA. [Wang, Weixin; Calvo, Katherine R.] NIH, Bethesda, MD 20892 USA. [Ghobrial, Irene M.; Roccaro, Aldo M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Korde, Neha; Zingone, Adriana; Landgren, Ola] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 802 DI 10.1158/1538-7445.AM2011-802 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302342 ER PT J AU Porter-Gill, PA Fu, YP Kaushiva, A Price, D Dahut, W Figg, W Prokunina-Olsson, L AF Porter-Gill, Patricia A. Fu, Yi-Ping Kaushiva, Alpana Price, Douglas Dahut, William Figg, William Prokunina-Olsson, Ludmila TI Tissue and serum miRNA profiling for detection of bladder, breast and prostate cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Porter-Gill, Patricia A.; Fu, Yi-Ping; Kaushiva, Alpana; Prokunina-Olsson, Ludmila] NCI, DCEG, Gaithersburg, MD USA. [Price, Douglas; Dahut, William; Figg, William] NCI, MOB, Bethesda, MD 20892 USA. RI Figg Sr, William/M-2411-2016 NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA LB-350 DI 10.1158/1538-7445.AM2011-LB-350 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701306042 ER PT J AU Poruchynsky, MS Gramza, AW Wells, SA Fojo, T AF Poruchynsky, Marianne S. Gramza, Ann W. Wells, Samuel A. Fojo, Tito TI Treatment of human medullary thyroid carcinoma (MTC) with either proteasome (Pr) or histone deacetylase (HDAC) inhibitors leads to a fall in RET mRNA levels and, in turn, a decrease in RET protein expression providing alternate strategies to reduce RET expression in a tyrosine-kinase driven disease SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Poruchynsky, Marianne S.; Gramza, Ann W.; Wells, Samuel A.; Fojo, Tito] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4547 DI 10.1158/1538-7445.AM2011-4547 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701400209 ER PT J AU Prickett, TD Wei, XM Viloria, CG Molinolo, A Lin, JC Cruz, P Rosenberg, SA Davies, MA Gershenwald, JE Lopez-Otin, C Samuels, Y AF Prickett, Todd D. Wei, Xiaomu Viloria, Cristina G. Molinolo, Alfredo Lin, Jimmy C. Cruz, Pedro Rosenberg, Steven A. Davies, Michael A. Gershenwald, Jeffrey E. Lopez-Otin, Carlos Samuels, Yardena TI Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Prickett, Todd D.; Wei, Xiaomu; Cruz, Pedro; Samuels, Yardena] NHGRI, NIH, Bethesda, MD 20892 USA. [Viloria, Cristina G.; Lopez-Otin, Carlos] Univ Oviedo, Oviedo, Spain. [Molinolo, Alfredo] NIDCR, NIH, Bethesda, MD USA. [Lin, Jimmy C.] Johns Hopkins Kimmel Canc Ctr, Baltimiore, MD USA. [Rosenberg, Steven A.] NCI, NIH, Bethesda, MD 20892 USA. [Davies, Michael A.; Gershenwald, Jeffrey E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4970 DI 10.1158/1538-7445.AM2011-4970 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404190 ER PT J AU Pugh, TJ Lawrence, M Sougnez, C Getz, G Attiyeh, E Hogarty, M Diskin, S Yaei, M Diamond, M Asgharzadeh, S Sposto, R Wei, JS Badgett, T London, WB Gastier-Foster, J Smith, MA Gerhard, DS Seeger, R Khan, J Meyerson, ML Maris, JM AF Pugh, Trevor J. Lawrence, Michael Sougnez, Carrie Getz, Gad Attiyeh, Edward Hogarty, Michael Diskin, Sharon Yaei, Mosse Diamond, Maura Asgharzadeh, Shahab Sposto, Richard Wei, Jun S. Badgett, Thomas London, Wendy B. Gastier-Foster, Julie Smith, Malcolm A. Gerhard, Daniela S. Seeger, Robert Khan, Javed Meyerson, Matthew L. Maris, John M. CA NCI Therapeutically Applicable Res TI Exome sequencing of 81 neuroblastomas identifies a wide diversity of somatic mutation SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Pugh, Trevor J.; Lawrence, Michael; Sougnez, Carrie; Getz, Gad; Meyerson, Matthew L.; NCI Therapeutically Applicable Res] Broad Inst MIT & Harvard, Cambridge, MA USA. [Attiyeh, Edward; Hogarty, Michael; Diskin, Sharon; Yaei, Mosse; Diamond, Maura; Maris, John M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Asgharzadeh, Shahab; Sposto, Richard; Seeger, Robert] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Wei, Jun S.; Badgett, Thomas; Smith, Malcolm A.; Gerhard, Daniela S.; Khan, Javed] NCI, Bethesda, MD 20892 USA. [London, Wendy B.] Dana Farber Canc Inst, Boston, MA 02115 USA. [London, Wendy B.] Childrens Oncol Grp, Stat & Data Ctr, Boston, MA USA. [Gastier-Foster, Julie] Nationwide Childrens Hosp, Columbus, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4756 DI 10.1158/1538-7445.AM2011-4756 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303278 ER PT J AU Puntervoll, HE Yang, R Vetti, HH Bachmann, IM Avrii, MF Ghiorzo, P Grammatico, P Harland, M Hayward, N Pjanova, D Soufir, N Newton-Bishop, J Goldstein, A Akslen, LA Molven, A AF Puntervoll, Hanne E. Yang, R. Vetti, Hildegunn H. Bachmann, Ingeborg M. Avrii, Marie-Francoise Ghiorzo, Paola Grammatico, Paola Harland, Mark Hayward, Nick Pjanova, Daze Soufir, Nadem Newton-Bishop, Julia Goldstein, Alisa Akslen, Lars A. Molven, Anders TI Characterization of malignant melanoma families with CDK4 germ-line mutation SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Puntervoll, Hanne E.; Akslen, Lars A.; Molven, Anders] Univ Bergen, Gade Inst, Sect Pathol, Bergen, Norway. [Yang, R.; Goldstein, Alisa] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Vetti, Hildegunn H.] Haukeland Hosp, Dept Med Gentet & Mol Med, N-5021 Bergen, Norway. [Bachmann, Ingeborg M.] Haukeland Hosp, Dept Dermatol, N-5021 Bergen, Norway. [Avrii, Marie-Francoise] Univ Paris, Hop Cochin, F-75252 Paris, France. [Ghiorzo, Paola] UoGenova, Dept Oncol Biol & Genet, Genoa, Italy. [Grammatico, Paola] Univ Roma La Sapienza, Rome, Italy. [Harland, Mark; Newton-Bishop, Julia] UoLeeds, Leeds Inst Mol Med & GenoMEL, Leeds, W Yorkshire, England. [Hayward, Nick] Queensland Inst Med Res, Brisbane, Qld 4006, Australia. [Pjanova, Daze] Latvian Biomed Res & Study Ctr, Riga, Latvia. [Soufir, Nadem] Hop Bichat Claude Bernard, F-75877 Paris 18, France. RI Akslen, Lars /C-1202-2017 OI Akslen, Lars /0000-0003-2710-9543 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 869 DI 10.1158/1538-7445.AM2011-869 PG 2 WC Oncology SC Oncology GA V43SP UT WOS:000209701405452 ER PT J AU Qin, J Calado, R AF Qin, James Calado, Rodrigo TI Development of a quick sensitive real-time PCR assay for measuring telomere length SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Qin, James] QIAGEN Inc, Germantown, MD USA. [Calado, Rodrigo] NHLBI, Nihon Univ, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1234 DI 10.1158/1538-7445.AM2011-1234 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401477 ER PT J AU Raggi, C Marguardt, JU Andersen, JB Factor, VM Thorgeirsson, SS AF Raggi, Chiara Marguardt, Jens U. Andersen, Jesper B. Factor, Valentina M. Thorgeirsson, Snorri S. TI Tumorigenic potential is independent of sphere phenotype in liver cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Raggi, Chiara; Marguardt, Jens U.; Andersen, Jesper B.; Factor, Valentina M.; Thorgeirsson, Snorri S.] NCI, LEC, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2460 DI 10.1158/1538-7445.AM2011-2460 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301360 ER PT J AU Rath, BH Camphausen, K Tofilon, PJ AF Rath, Barbara H. Camphausen, Kevin Tofilon, Philip J. TI Astrocytes enhance the migration potential of glioblastoma stem-like cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Rath, Barbara H.; Tofilon, Philip J.] H Lee Moffitt Canc & Res Ctr, Tampa, FL USA. [Camphausen, Kevin] NCI, Radiat Oncol Branch, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 533 DI 10.1158/1538-7445.AM2011-533 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302150 ER PT J AU Reece, KM Pisle, ST Richardson, ED Cook, KM Price, DK Figg, WD AF Reece, Kelie M. Pisle, Stephen T. Richardson, Emily D. Cook, Kristina M. Price, Douglas K. Figg, William D. TI The molecular, cellular, and physiological consequences of disrupting the HIF-1 alpha interaction SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Reece, Kelie M.; Richardson, Emily D.; Cook, Kristina M.; Price, Douglas K.; Figg, William D.] NCI, NIH, Bethesda, MD 20892 USA. [Pisle, Stephen T.] NCI, Clin Pharmacol Program, SAIC Frederick, Frederick, MD 21701 USA. RI Figg Sr, William/M-2411-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3095 DI 10.1158/1538-7445.AM2011-3095 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402239 ER PT J AU Reinhold, WC Erliandri, I Liu, HF Zoppoli, G Pommier, Y Larionov, V AF Reinhold, William C. Erliandri, Indri Liu, Hongfang Zoppoli, Gabriele Pommier, Yves Larionov, Vladimir TI Identification of a predominant pattern of co-regulation among kinetochore genes; prospective regulatory elements, and association with genomic instability SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Reinhold, William C.; Erliandri, Indri; Zoppoli, Gabriele; Pommier, Yves; Larionov, Vladimir] NCI, Bethesda, MD 20892 USA. [Liu, Hongfang] Georgetown Univ, Med Ctr, Washington, DC 20007 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3074 DI 10.1158/1538-7445.AM2011-3074 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402217 ER PT J AU Rossi, GR Vahanian, NN Morris, JC Ramsey, JW Tennant, L Link, CJ AF Rossi, Gabriela R. Vahanian, Nicholas N. Morris, John C. Ramsey, Jay W. Tennant, Lucinda Link, Charles J. TI Immunological findings in a phase II immunotherapy study using allogeneic lung cancer cells modified to express alpha(1,3)galactosyltransferase in advanced non-small cell lung cancer (NSCLC) SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Rossi, Gabriela R.; Vahanian, Nicholas N.; Ramsey, Jay W.; Tennant, Lucinda; Link, Charles J.] NewLink Genet, Ames, IA USA. [Morris, John C.] NCI, Metab Branch, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5507 DI 10.1158/1538-7445.AM2011-5507 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300472 ER PT J AU Rotunno, M Lam, TK Caporaso, NE Landi, MT AF Rotunno, Melissa Lam, Tram K. Caporaso, Neil E. Landi, Maria Teresa TI Gene expression signatures of meat intake in lung cancer tissues SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Rotunno, Melissa; Lam, Tram K.; Caporaso, Neil E.; Landi, Maria Teresa] NIH, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2748 DI 10.1158/1538-7445.AM2011-2748 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701406097 ER PT J AU Ryan, BM Robles, AI Bowman, E McClary, AC Harris, CC AF Ryan, Brid M. Robles, Ana I. Bowman, Elise McClary, Andrew C. Harris, Curtis C. TI From genotypes to phenotypes: genetic variation in microRNA-related genes and lung cancer risk SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Ryan, Brid M.; Robles, Ana I.; Bowman, Elise; McClary, Andrew C.; Harris, Curtis C.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1171 DI 10.1158/1538-7445.AM2011-1171 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404131 ER PT J AU Saber, B Zhang, CY Wilson, W Gills, J Dennis, P AF Saber, Barbara Zhang, Chunyu Wilson, Willie Gills, Joell Dennis, Phillip TI Application of a novel cell-based dual luciferase assay to identify inducers of the tumor suppressor RhoB SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Saber, Barbara; Zhang, Chunyu; Wilson, Willie; Gills, Joell; Dennis, Phillip] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2193 DI 10.1158/1538-7445.AM2011-2193 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402288 ER PT J AU Saleh, A Savage, JE Harris, CC Mitchell, JB Simone, NL AF Saleh, Anthony Savage, Jason E. Harris, Curtis C. Mitchell, James B. Simone, Nicole L. TI miRs are altered by caloric restriction: Therapeutic implications SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Saleh, Anthony; Savage, Jason E.; Harris, Curtis C.; Mitchell, James B.; Simone, Nicole L.] NCI, CCR, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2075 DI 10.1158/1538-7445.AM2011-2075 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404238 ER PT J AU Salvucci, O Maric, D Zhang, F Li, XR Basik, M Buchanan, M Tosato, G AF Salvucci, Ombretta Maric, Dragan Zhang, Fan Li, Xuri Basik, Mark Buchanan, Marguerite Tosato, Giovanna TI EphrinB2 promotes endothelial cell survival and vascular integrity SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Salvucci, Ombretta; Tosato, Giovanna] NCI, NIH, Bethesda, MD 20892 USA. [Maric, Dragan] NINDS, NIH, Bethesda, MD 20892 USA. [Zhang, Fan] NEI, NIH, Rockville, MD USA. [Li, Xuri] NEI, NIH, Bethesda, MD 20892 USA. [Basik, Mark; Buchanan, Marguerite] McGill Univ, Montreal, PQ, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3469 DI 10.1158/1538-7445.AM2011-3469 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302231 ER PT J AU Samimi, G Wong, C Spong, SM Birrer, MJ AF Samimi, Goli Wong, Carol Spong, Suzanne M. Birrer, Michael J. TI The CTGF antibody FG-3019 blocks CTGF-stimulated migration in ovarian cancer cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Samimi, Goli] NCI, Bethesda, MD 20892 USA. [Wong, Carol; Spong, Suzanne M.] FibroGen Inc, San Francisco, CA USA. [Birrer, Michael J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 509 DI 10.1158/1538-7445.AM2011-509 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302124 ER PT J AU Sanda, T Tyner, JW Gutierrez, A Ngo, VN Moriggl, R Ahn, Y Glover, J Chang, BH Willis, SG Zhou, WJ Gray, NS Staudt, LM Druker, BJ Look, AT AF Sanda, Takaomi Tyner, Jeffrey W. Gutierrez, Alejandro Ngo, Vu N. Moriggl, Richard Ahn, Yebin Glover, Jason Chang, Bill H. Willis, Stephanie G. Zhou, Wenjun Gray, Nathanael S. Staudt, Louis M. Druker, Brian J. Look, A. Thomas TI Pathway dependence on the tyrosine kinase TYK2 in T-cell acute lymphoblastic leukemia SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Sanda, Takaomi; Gutierrez, Alejandro; Ahn, Yebin; Zhou, Wenjun; Gray, Nathanael S.; Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tyner, Jeffrey W.; Glover, Jason; Chang, Bill H.; Willis, Stephanie G.; Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Ngo, Vu N.] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Moriggl, Richard] Ludwig Boltzmann Inst Canc Res, Vienna, Austria. [Staudt, Louis M.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2809 DI 10.1158/1538-7445.AM2011-2809 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304483 ER PT J AU Satpathy, M Qian, WP Capala, J Yang, L AF Satpathy, Minati Qian, Weiping Capala, Jacek Yang, Lily TI Development of theranostic nanoparticles for targeted tumor imaging and treatment of HER-2/neu positive cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Satpathy, Minati; Qian, Weiping; Yang, Lily] Emory Univ, Atlanta, GA 30322 USA. [Capala, Jacek] NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5314 DI 10.1158/1538-7445.AM2011-5314 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301179 ER PT J AU Sawyer, SJ Myers, K Anthony, D Benkesser, R Fombonne, B Litwack, D Thomas, M Lockhart, N Rogers, J Vaught, J Compton, C AF Sawyer, Sherilyn J. Myers, Kimberly Anthony, Dickherber Benkesser, Rachel Fombonne, Benjamin Litwack, David Thomas, Mary Lockhart, Nicole Rogers, Joyce Vaught, Jim Compton, Carolyn TI The National Cancer Human Biobank: CaHUB SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Sawyer, Sherilyn J.; Myers, Kimberly; Anthony, Dickherber; Benkesser, Rachel; Fombonne, Benjamin; Litwack, David; Thomas, Mary; Lockhart, Nicole; Rogers, Joyce; Vaught, Jim; Compton, Carolyn] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4660 DI 10.1158/1538-7445.AM2011-4660 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701406077 ER PT J AU Scheel, C NgEaton, E Li, SHJ Chaffer, CL Reinhardt, F Kah, KJ Bell, G Guo, WJ Rubin, J Richardson, A Weinberg, RA AF Scheel, Christina NgEaton, Elinor Li, Sophia Hsin-Jung Chaffer, Christine L. Reinhardt, Ferenc Kah, Kong-Jie Bell, George Guo, Wenjun Rubin, Jeffrey Richardson, Andrea Weinberg, Robert A. TI Formation and maintenance of mesenchymal and stem-cell states in the breast by paracrine and autocrine signals SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Scheel, Christina; NgEaton, Elinor; Li, Sophia Hsin-Jung; Chaffer, Christine L.; Reinhardt, Ferenc; Kah, Kong-Jie; Bell, George; Guo, Wenjun; Weinberg, Robert A.] MIT, Whitehead Inst Biomed Res, Cambridge, MA USA. [Rubin, Jeffrey] NCI, Bethesda, MD 20892 USA. [Richardson, Andrea] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA LB-108 DI 10.1158/1538-7445.AM2011-LB-108 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303343 ER PT J AU Schetter, AJ Welsh, JA Bowman, ED Harris, CC AF Schetter, Aaron J. Welsh, Judith A. Bowman, Elise D. Harris, Curtis C. TI Association of inflammation related microRNA gene expression in inflammatory bowel disease and IBD-associated colon cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Schetter, Aaron J.; Welsh, Judith A.; Bowman, Elise D.; Harris, Curtis C.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3945 DI 10.1158/1538-7445.AM2011-3945 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701403378 ER PT J AU Schlom, J Gulley, JL Madan, RA Tsang, KY Greiner, JW Palena, C Hodge, JW AF Schlom, Jeffrey Gulley, James L. Madan, Ravi A. Tsang, Kwong-Yok Greiner, John W. Palena, Claudia Hodge, James W. TI Development of recombinant vaccines for the prevention and therapy of human carcinomas SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Schlom, Jeffrey; Gulley, James L.; Madan, Ravi A.; Tsang, Kwong-Yok; Greiner, John W.; Palena, Claudia; Hodge, James W.] NCI, Bethesda, MD 20892 USA. RI Gulley, James/K-4139-2016 OI Gulley, James/0000-0002-6569-2912 NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA SY24-02 DI 10.1158/1538-7445.AM2011-SY24-02 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701300262 ER PT J AU Schumacher, FR Berndt, SI Siddig, A Jacobs, K Wang, ZM Lindstrom, S Stevens, VL Chen, C Mondul, AM Travis, RC Straml, DO Eeles, RA Easton, DF Giles, G Severi, G Gronberg, H Wiklund, F Allen, NE Andriolell, GL Barricarte, A Boeing, H de Mesquita, HBB Crawford, ED Divers, WR Gonzalez, CA Garziano, JM Giovannucci, EL Johansson, M Le Marchand, L Ma, J Sier, S Stattin, P Stampfer, MJ Tjonneland, A Vineis, P Virtamo, J Voge, U Weinstein, SJ Yeager, M Thun, MJ Kolonel, LN Henderson, BE Albanes, D Hayes, RB Feigelson, HS Riboli, E Hunter, DJ Chanock, SJ Haimanl, CA Kraft, P AF Schumacher, Fredrick R. Berndt, Sonja I. Siddig, Afshan Jacobs, Kevin Wang, Zhaoming Lindstrom, Sara Stevens, Victoria L. Chen, Constance Mondul, Alison M. Travis, Ruth C. Straml, Daniel O. Eeles, Rosalind A. Easton, Douglas F. Giles, Graham Severi, Gianluca Gronberg, Henrik Wiklund, Fredrik Allen, Naomi E. Andriolell, Gerald L. Barricarte, Aurelio Boeing, Heiner de Mesquita, H. Bas Bueno Crawford, E. David Divers, W. Ryan Gonzalez, Carlos A. Garziano, J. Michael Giovannucci, Edward L. Johansson, Mattias Le Marchand, Loic Ma, Jing Sier, Sabina Stattin, Par Stampfer, Meir J. Tjonneland, Anne Vineis, Paolo Virtamo, Jarmo Voge, Ulla Weinstein, Stephanie J. Yeager, Meredith Thun, Michael J. Kolonel, Laurence N. Henderson, Brian E. Albanes, Demetrius Hayes, Richard B. Feigelson, Heather Spencer Riboli, Elio Hunter, David J. Chanock, Stephen J. Haimanl, Christopher A. Kraft, Peter TI Genome-wide association study identifies new prostate cancer susceptibility loci SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Schumacher, Fredrick R.; Straml, Daniel O.; Henderson, Brian E.; Haimanl, Christopher A.] Univ So Calif, Los Angeles, CA USA. [Berndt, Sonja I.; Jacobs, Kevin; Wang, Zhaoming; Mondul, Alison M.; Weinstein, Stephanie J.; Yeager, Meredith; Albanes, Demetrius; Chanock, Stephen J.] NCI, Bethesda, MD 20892 USA. [Siddig, Afshan; Vineis, Paolo; Riboli, Elio] Univ London Imperial Coll Sci Technol & Med, London, England. [Lindstrom, Sara; Chen, Constance; Giovannucci, Edward L.; Hunter, David J.; Kraft, Peter] Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA. [Stevens, Victoria L.; Divers, W. Ryan; Thun, Michael J.] Amer Canc Soc, Atlanta, GA 30329 USA. [Travis, Ruth C.; Allen, Naomi E.] Univ Oxford, Oxford, England. [Eeles, Rosalind A.] Inst Canc Res, Sutton, Surrey, England. [Easton, Douglas F.] Univ Cambridge, Cambridge, England. [Giles, Graham; Severi, Gianluca] Canc Council Victoria, Melbourne, Vic, Australia. [Gronberg, Henrik; Wiklund, Fredrik] Karolinska Inst, Stockholm, Sweden. [Andriolell, Gerald L.] Washington Univ, Sch Med, St Louis, MO USA. [Barricarte, Aurelio] Navarre Publ Hlth Inst, Pamplona, Spain. [Boeing, Heiner] Deutsch Inst Ernahrungsforsch, Potsdam, Germany. [de Mesquita, H. Bas Bueno] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [Crawford, E. David] Univ Colorado, Aurora, CO USA. [Gonzalez, Carlos A.] Hosp Llobregat, Barcelona, Spain. [Garziano, J. Michael; Ma, Jing; Stampfer, Meir J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Johansson, Mattias] Int Agcy Res Canc, F-69372 Lyon, France. [Le Marchand, Loic; Kolonel, Laurence N.] Canc Res Ctr Hawaii, Honolulu, HI USA. [Sier, Sabina] IRCCS Ist Nazl Tumori, Milan, Italy. [Stattin, Par] Umea Univ, Umea, Sweden. [Tjonneland, Anne] Danish Canc Soc, Copenhagen, Denmark. [Virtamo, Jarmo] Natl Inst Hlth & Welf, Helsinki, Finland. [Voge, Ulla] Natl Res Ctr Working Environm, Copenhagen, Denmark. [Hayes, Richard B.] NYU, Inst Canc, New York, NY USA. [Feigelson, Heather Spencer] Kaiser Permanente, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA LB-448 DI 10.1158/1538-7445.AM2011-LB-448 PG 2 WC Oncology SC Oncology GA V43SP UT WOS:000209701406047 ER PT J AU Schwentner, R Kauer, M Bilke, S Jug, G Meltzer, PS Kovar, H AF Schwentner, Raphaela Kauer, Maximilian Bilke, Sven Jug, Gunhild Meltzer, Paul S. Kovar, Heinrich TI Combinatorial regulation of E2F target genes by the oncogenic ETS transcription factor EWS-FLI1 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Schwentner, Raphaela; Kauer, Maximilian; Jug, Gunhild; Kovar, Heinrich] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria. [Bilke, Sven; Meltzer, Paul S.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5341 DI 10.1158/1538-7445.AM2011-5341 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301401 ER PT J AU Shah, GV Tamrakar, P Thomas, S Lakshmikanthan, V Parajuli, P Sathyanarayanajois, S Bahouth, S Fanning, A Anderson, J AF Shah, Girish V. Tamrakar, Pratistha Thomas, Shibu Lakshmikanthan, Vijaybasker Parajuli, Parash Sathyanarayanajois, Seetharama Bahouth, Suleiman Fanning, Alan Anderson, James TI Calcitonin receptor-zonnula occludens-1 interaction is critical for calcitonin-induced destabilization of tight junctions and s prostate cancer metastasis SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Shah, Girish V.; Tamrakar, Pratistha; Thomas, Shibu; Lakshmikanthan, Vijaybasker; Parajuli, Parash; Sathyanarayanajois, Seetharama] Univ Louisiana, Sch Pharm, Monroe, LA USA. [Bahouth, Suleiman] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA. [Fanning, Alan] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Anderson, James] NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA LB-13 DI 10.1158/1538-7445.AM2011-LB-13 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305419 ER PT J AU Shah, P Katuri, V Awad, O Gul, N Metzer, PS Loeb, D AF Shah, Preeti Katuri, Varalakshmi Awad, Ola Gul, Naheed Metzer, Paul S. Loeb, David TI Establishment and characterization of a primary chordoma xenograft SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Shah, Preeti; Katuri, Varalakshmi; Awad, Ola; Gul, Naheed; Loeb, David] Johns Hopkins Univ, Baltimore, MD USA. [Metzer, Paul S.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2418 DI 10.1158/1538-7445.AM2011-2418 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300459 ER PT J AU Sharma, S Zou, MX Lee, J Steele, VE AF Sharma, Sheela Zou, Minxu Lee, Jin Steele, Vernon E. TI Chemopreventive efficacy of vandetanib, a multikinase inhibitor, in a primary respiratory tract epithelial cell transformation assay SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Sharma, Sheela; Zou, Minxu; Lee, Jin] Hamner Inst Hlth Sci, Res Triangle Pk, NC USA. [Steele, Vernon E.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3703 DI 10.1158/1538-7445.AM2011-3703 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303144 ER PT J AU Shi, KR Parekh, V Roy, S Agarwal, SK AF Shi, Kerong Parekh, Vaishali Roy, Swarnava Agarwal, Sunita K. TI Menin-mediated regulation of pancreatic beta-cell differentiation factors SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Shi, Kerong; Parekh, Vaishali; Roy, Swarnava; Agarwal, Sunita K.] NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA LB-140 DI 10.1158/1538-7445.AM2011-LB-140 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305488 ER PT J AU Shilkaitis, A Green, A Bratescu, L Peng, XJ Steele, V Christov, KT AF Shilkaitis, Anne Green, Albert Bratescu, Laura Peng, Xinjian Steele, Vernon Christov, Konstantin T. TI Rexinoids induce cellular senescence in ER-negative breast cancer cells and in MMTV-Neu mammary tumors SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Shilkaitis, Anne; Green, Albert; Bratescu, Laura; Christov, Konstantin T.] Univ Illinois, Chicago, IL USA. [Peng, Xinjian] IIT, Res Inst, Chicago, IL 60616 USA. [Steele, Vernon] NCI, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 836 DI 10.1158/1538-7445.AM2011-836 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303087 ER PT J AU Shirota, H Klinman, DM AF Shirota, Hidekazu Klinman, Dennis M. TI Role of Interferon Regulatory Factor (IRF)-3 in lung tumor microenvironment SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Shirota, Hidekazu; Klinman, Dennis M.] NCI, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 412 DI 10.1158/1538-7445.AM2011-412 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300357 ER PT J AU Sholler, GLS Kahn, J Ferguson, W Bergendahl, G Currier, E Lenox, S Bond, J Roberts, W Mitchell, D Eslin, D Kraveka, J Kaplan, J Parikh, N Malempati, S Hanna, G Kamen, B Webb, C AF Sholler, Giselle L. Saulnier Kahn, Javed Ferguson, William Bergendahl, Genvieve Currier, Erika Lenox, Shannon Bond, Jeffrey Roberts, William Mitchell, Deanna Eslin, Don Kraveka, Jacqueline Kaplan, Joel Parikh, Nehal Malempati, Suman Hanna, Gina Kamen, Barton Webb, Craig TI A pilot trial testing the feasibility of using molecular-guided therapy in patients with refractory or recurrent neuroblastoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Sholler, Giselle L. Saulnier; Bergendahl, Genvieve; Currier, Erika; Lenox, Shannon; Bond, Jeffrey] Univ Vermont, Burlington, VT USA. [Kahn, Javed] NIH, Bethesda, MD 20892 USA. [Ferguson, William] St Louis Univ, Sch Med, St Louis, MO USA. [Roberts, William] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Mitchell, Deanna] Michigan State Univ, Grand Rapids, MI USA. [Eslin, Don] MD Anderson Canc Ctr Orlando, Orlando, FL USA. [Kraveka, Jacqueline] Med Univ S Carolina, Charleston, SC 29425 USA. [Kaplan, Joel] Levine Childrens Hosp, Charlotte, NC USA. [Parikh, Nehal] Connecticut Childrens Med Ctr, Hartford, CT USA. [Malempati, Suman] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Hanna, Gina] Inova Fairfax Hosp Children & Women, Falls Church, VA USA. [Kamen, Barton] Canc Inst New Jersey, New Brunswick, NJ USA. [Webb, Craig] Van Andel Res Inst, Grand Rapids, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3942 DI 10.1158/1538-7445.AM2011-3942 PG 2 WC Oncology SC Oncology GA V43SP UT WOS:000209701403265 ER PT J AU Sissung, TM Kirkland, CT Reece, K Arnold, JT Figg, WD AF Sissung, Tristan M. Kirkland, C. Tyler Reece, Kelie Arnold, Julia Tyler Figg, William D. TI Thalidomide inhibits the TGF beta-mediated synthesis of testosterone from DHEA in prostate cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Sissung, Tristan M.; Kirkland, C. Tyler; Reece, Kelie; Figg, William D.] NCI, Bethesda, MD 20892 USA. [Arnold, Julia Tyler] Natl Ctr Complementary & Alternat Med, Bethesda, MD USA. RI Figg Sr, William/M-2411-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4535 DI 10.1158/1538-7445.AM2011-4535 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701400235 ER PT J AU Smith, SM Chiao, LJ Nogueria, L Usary, J Perou, CM Varticovski, L Hursting, SD AF Smith, Sarah M. Chiao, Lucia J. Nogueria, Leticia Usary, Jerry Perou, Charles M. Varticovski, Lyuba Hursting, Stephen D. TI Obesity drives epithelial/mesenchymal transition and tumor progression in a novel Wnt-1 mammary cancer model SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Smith, Sarah M.; Chiao, Lucia J.; Nogueria, Leticia; Hursting, Stephen D.] UT Austin, Austin, TX USA. [Usary, Jerry; Perou, Charles M.] Univ N Carolina, Chapel Hill, NC USA. [Varticovski, Lyuba] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3332 DI 10.1158/1538-7445.AM2011-3332 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304081 ER PT J AU Song, YR Zhang, Q Bash, R Yin, CY Yang, CY Gilbert, D Wang, S Bullitt, E Kafri, T McCarthy, KD Louis, DN Miller, CR Van Dyke, T AF Song, Yurong Zhang, Qian Bash, Ryan Yin, Chaoying Yang, Chunyu Gilbert, Debra Wang, Sophie Bullitt, Elizabeth Kafri, Tal McCarthy, Ken D. Louis, David N. Miller, C. Ryan Van Dyke, Terry TI Delineation of grade-specific molecular drivers in inducible preclinical mouse models of astrocytoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Song, Yurong; Zhang, Qian; Gilbert, Debra; Wang, Sophie; Van Dyke, Terry] Natl Canc Inst Frederick, Frederick, MD USA. [Bash, Ryan; Yin, Chaoying; Yang, Chunyu; Bullitt, Elizabeth; Kafri, Tal; McCarthy, Ken D.; Miller, C. Ryan] Univ N Carolina, Chapel Hill, NC USA. [Louis, David N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Louis, David N.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2854 DI 10.1158/1538-7445.AM2011-2854 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303267 ER PT J AU Sourbier, C Ratnayake, R Scroggins, B Lee, MJ Lee, S Trepel, J Beutler, J Neckers, L Linehan, WM AF Sourbier, Carole Ratnayake, Ranjala Scroggins, Brad Lee, Min-Jung Lee, Sunmin Trepel, Jane Beutler, John Neckers, Len Linehan, W. Marston TI Targeting renal cell carcinoma with englerin A SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Sourbier, Carole; Scroggins, Brad; Lee, Min-Jung; Lee, Sunmin; Trepel, Jane; Beutler, John; Neckers, Len; Linehan, W. Marston] NCI, Bethesda, MD 20892 USA. [Ratnayake, Ranjala] NCI, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 959 DI 10.1158/1538-7445.AM2011-959 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701400276 ER PT J AU Street, CR Chattopadhyay, M Kodela, R Boring, D Crowell, JA Kashfi, K AF Street, Cherease R. Chattopadhyay, Mitali Kodela, Ravinder Boring, Daniel Crowell, James A. Kashfi, Khosrow TI Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Street, Cherease R.; Chattopadhyay, Mitali; Kodela, Ravinder; Kashfi, Khosrow] CUNY, Sch Med, New York, NY 10031 USA. [Boring, Daniel; Crowell, James A.] NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 807 DI 10.1158/1538-7445.AM2011-807 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303057 ER PT J AU Sturgeon, SR Balasubramanian, R Schairer, C Ziegler, R Muss, H Arcaro, K AF Sturgeon, Susan R. Balasubramanian, Raji Schairer, Catherine Ziegler, Regina Muss, Hyman Arcaro, Kathleen TI Detection of promoter methylation of tumor supressor genes in serum DNA of breast cancer patients and controls SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Sturgeon, Susan R.; Balasubramanian, Raji; Arcaro, Kathleen] Univ Massachusetts, Amherst, MA 01003 USA. [Schairer, Catherine; Ziegler, Regina] NCI, Bethesda, MD 20892 USA. [Muss, Hyman] UNC Lineberger Canc Ctr, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 85 DI 10.1158/1538-7445.AM2011-85 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701403066 ER PT J AU Su, WH Tse, KP Yang, ML Shugart, YY Chang, YS AF Su, Wen-Hui Tse, Ka-Po Yang, Min-Lee Shugart, Yin Yao Chang, Yu-Sun TI Copy number variation analysis identified multiple genetic variants related to nasopharyngeal carcinoma predisposition SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Su, Wen-Hui; Tse, Ka-Po; Yang, Min-Lee; Chang, Yu-Sun] Chang Gung Univ, Tao Yuan, Taiwan. [Shugart, Yin Yao] NIMH, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 882 DI 10.1158/1538-7445.AM2011-882 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701405466 ER PT J AU Suh, N Reddy, BS Paul, S DeCastro, A Lee, HJ Smolarek, AK So, JY Simi, B Wang, CX Janakiram, NB Steele, VE Rao, CV AF Suh, Nanjoo Reddy, Bandaru S. Paul, Shiby DeCastro, Andrew Lee, Hong Jin Smolarek, Amanda K. So, Jae Young Simi, Barbara Wang, Chung Xiou Janakiram, Naveena B. Steele, Vernon E. Rao, Chinthalapally V. TI Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/beta-catenin/cyclin D1 signaling pathway in rats SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Suh, Nanjoo; Reddy, Bandaru S.; Paul, Shiby; DeCastro, Andrew; Lee, Hong Jin; Smolarek, Amanda K.; So, Jae Young; Simi, Barbara; Wang, Chung Xiou] Rutgers State Univ, Piscataway, NJ USA. [Janakiram, Naveena B.; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Steele, Vernon E.] NCI, Chemoprevent Agent Dev Res Grp, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 833 DI 10.1158/1538-7445.AM2011-833 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303084 ER PT J AU Suzuki, T Kosaka-Suzuki, N Morse, HC Loukinov, D Lobanenkov, V AF Suzuki, Teruhiko Kosaka-Suzuki, Natsuki Morse, Herbert C. Loukinov, Dmitri Lobanenkov, Victor TI BORIS directly regulates in vivo expression of the cancer testis antigen, testes-specific protease 50 (TSP50) SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Suzuki, Teruhiko; Kosaka-Suzuki, Natsuki; Morse, Herbert C.; Loukinov, Dmitri; Lobanenkov, Victor] NIH, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2043 DI 10.1158/1538-7445.AM2011-2043 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701403174 ER PT J AU Takai, S Schlom, J Greiner, JW AF Takai, Shinji Schlom, Jeffrey Greiner, John W. TI Distinctive effects of the Src-inhibitor, saracatinib (AZD0530), on T-cell activation and differentiation: A basic study to combine Src-inhibitor and vaccine based cancer immunotherapy SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Takai, Shinji; Schlom, Jeffrey; Greiner, John W.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1783 DI 10.1158/1538-7445.AM2011-1783 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302048 ER PT J AU Tang, LY Yamashita, M Tang, Y Zhang, YE AF Tang, Liu-Ya Yamashita, Motozo Tang, Yi Zhang, Ying E. TI Mono-ubiquitination of Smad2/3 by Smurf2 regulates TGF-beta transcriptional response SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Tang, Liu-Ya; Yamashita, Motozo; Tang, Yi; Zhang, Ying E.] NCI, CCR, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4057 DI 10.1158/1538-7445.AM2011-4057 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404308 ER PT J AU Tang, W Fu, YP Liu, LY Orduz, N Kaushiva, A Mumy, A Porter-Gill, P Meyers, T Garcia-Closas, M Malats, N Chanock, S Real, FX Kogevinas, M Rothman, N Silverman, D Prokunina-Olsson, L AF Tang, Wei Fu, Yi-Ping Liu, Luyang Orduz, Natalia Kaushiva, Alpana Mumy, Adam Porter-Gill, Patricia Meyers, Timothy Garcia-Closas, Montserrat Malats, Nuria Chanock, Stephen Real, Francisco X. Kogevinas, Manolis Rothman, Nathaniel Silverman, Debra Prokunina-Olsson, Ludmila TI Exploring the relationships between genetic variants within the UGT1A locus, cellular detoxification and risk of bladder cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Tang, Wei; Fu, Yi-Ping; Liu, Luyang; Orduz, Natalia; Kaushiva, Alpana; Mumy, Adam; Porter-Gill, Patricia; Meyers, Timothy; Garcia-Closas, Montserrat; Chanock, Stephen; Rothman, Nathaniel; Silverman, Debra; Prokunina-Olsson, Ludmila] NCI, Gaithersburg, MD USA. [Malats, Nuria; Real, Francisco X.] CNIO, Madrid, Spain. [Kogevinas, Manolis] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain. RI Kogevinas, Manolis/C-3918-2017 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4680 DI 10.1158/1538-7445.AM2011-4680 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401220 ER PT J AU Tarim, J Sowers, RS Piperdi, S Khanna, C Gorlick, RG AF Tarim, John Sowers, Rebecca S. Piperdi, Sajida Khanna, Chand Gorlick, Richard G. TI Evaluation of GD2 expression in patients with osteosarcoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Tarim, John; Sowers, Rebecca S.; Piperdi, Sajida; Gorlick, Richard G.] Childrens Hosp Montefiore, Bronx, NY USA. [Khanna, Chand] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5332 DI 10.1158/1538-7445.AM2011-5332 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301393 ER PT J AU Tarway, MD Tang, W Fu, YP Liu, LY Porter-Gill, P Hall, J Ambs, S Prokunina-Olsson, L AF Tarway, McAnthony D. Tang, Wei Fu, Yi-Ping Liu, Luyang Porter-Gill, Patricia Hall, Jennifer Ambs, Stefan Prokunina-Olsson, Ludmila TI Genetic variants within JAZF1 are associated with differential binding of androgen receptor, altered mRNA expression and risk of prostate cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Tarway, McAnthony D.; Tang, Wei; Fu, Yi-Ping; Liu, Luyang; Porter-Gill, Patricia; Ambs, Stefan; Prokunina-Olsson, Ludmila] NIH, Bethesda, MD 20892 USA. [Hall, Jennifer] Lillehei Heart Inst, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3816 DI 10.1158/1538-7445.AM2011-3816 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701400048 ER PT J AU Thyparambil, S Hembrough, T Cao, L Krizman, D Darfler, M Burrows, J Helman, L AF Thyparambil, Sheeno Hembrough, Todd Cao, Liang Krizman, David Darfler, Marlene Burrows, Jon Helman, Lee TI Quantitative analysis of IGF-1R expression and signaling pathway activation in FFPE xenograft and human tumor tissues SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Thyparambil, Sheeno; Hembrough, Todd; Krizman, David; Darfler, Marlene; Burrows, Jon] Express Pathol Inc, Rockville, MD USA. [Cao, Liang; Helman, Lee] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2211 DI 10.1158/1538-7445.AM2011-2211 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701405163 ER PT J AU Tiwari, AK Shi, Z Shukla, S Robey, RW Singh, S Kim, IW Bates, SE Peng, XX Abraham, I Ambudkar, SV Talele, TT Fu, LW Chen, ZS AF Tiwari, Amit K. Shi, Zhi Shukla, Suneet Robey, Robert W. Singh, Satyakam Kim, In-Wha Bates, Susan E. Peng, Xing-xiang Abraham, Ioana Ambudkar, Suresh V. Talele, Tanaji T. Fu, Li-wu Chen, Zhe-Sheng TI Reversal of ABCB1-and ABCG2-mediated drug resistance by sildenafil SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Tiwari, Amit K.; Shi, Zhi; Singh, Satyakam; Peng, Xing-xiang; Abraham, Ioana; Talele, Tanaji T.; Chen, Zhe-Sheng] St Johns Univ, Queens, NY USA. [Shukla, Suneet; Robey, Robert W.; Kim, In-Wha; Bates, Susan E.; Ambudkar, Suresh V.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Fu, Li-wu] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1739 DI 10.1158/1538-7445.AM2011-1739 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300087 ER PT J AU Townsend, RR Rohrs, H LeDuc, R Malone, JP Erdman-Gilmore, P Hill, DL Grubbs, CJ You, M Lubet, RA AF Townsend, Reid R. Rohrs, Henry LeDuc, Richard Malone, James P. Erdman-Gilmore, Petra Hill, Donald L. Grubbs, Clinton J. You, Ming Lubet, Ronald A. TI Proteomic credentialing in a model for chemoprevention studies of urinary bladder cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Townsend, Reid R.; Rohrs, Henry; LeDuc, Richard; Malone, James P.; Erdman-Gilmore, Petra; You, Ming] Washington Sch Med, St Louis, MO USA. [Hill, Donald L.; Grubbs, Clinton J.] UAB Chemoprevent Ctr, Birmingham, AL USA. [Lubet, Ronald A.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3700 DI 10.1158/1538-7445.AM2011-3700 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303141 ER PT J AU Tripathi, BK Lowy, DR Zelenka, PS AF Tripathi, Brajendra K. Lowy, Douglas R. Zelenka, Peggy S. TI The Cdk5 activator p39 specifically links muskelin to myosin and regulates stress fiber organization and contraction SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Tripathi, Brajendra K.; Lowy, Douglas R.] NCI, NIH, Bethesda, MD 20892 USA. [Zelenka, Peggy S.] NEI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1436 DI 10.1158/1538-7445.AM2011-1436 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304164 ER PT J AU Tripathi, V Zimonjic, DB Popescu, NC AF Tripathi, Veenu Zimonjic, Drazen B. Popescu, Nicholas C. TI DLC1 and alpha-catenin protein interaction enhances DLC1 antioncogenic activity by stabilizing adherens junctions and suppressing NF kappa B signaling SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Tripathi, Veenu; Zimonjic, Drazen B.; Popescu, Nicholas C.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4017 DI 10.1158/1538-7445.AM2011-4017 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404168 ER PT J AU Tsang, DP Lau, SS Lee, TL Wong, N Cheng, AS AF Tsang, Daisy P. Lau, Suki S. Lee, Tin L. Wong, Nathalie Cheng, Alfred S. TI EZH2-mediated H3K27 trimethylation silencing of microRNAs in hepatocellular carcinoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Tsang, Daisy P.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China. [Lau, Suki S.; Cheng, Alfred S.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China. [Lee, Tin L.] NICHHD, NIH, Bethesda, MD 20892 USA. [Wong, Nathalie] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1185 DI 10.1158/1538-7445.AM2011-1185 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404222 ER PT J AU Tsuji, PA Carlson, BA Yoo, MH Xu, XM Naranjo-Suarez, S Fomenko, D Gladyshev, VN Hatfield, DL Davis, CD AF Tsuji, Petra A. Carlson, Bradley A. Yoo, Min-Hyuk Xu, Xue-Ming Naranjo-Suarez, Salvador Fomenko, Dmitri Gladyshev, Vadim N. Hatfield, Dolph L. Davis, Cindy D. TI Sep15 knockout in mice provides protection against chemically-induced aberrant crypt formation SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Tsuji, Petra A.; Davis, Cindy D.] NCI, DCP, Bethesda, MD 20892 USA. [Carlson, Bradley A.; Yoo, Min-Hyuk; Xu, Xue-Ming; Naranjo-Suarez, Salvador; Hatfield, Dolph L.] NCI, LCP, Bethesda, MD 20892 USA. [Fomenko, Dmitri] Univ Nebraska, Lincoln, NE USA. [Gladyshev, Vadim N.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1868 DI 10.1158/1538-7445.AM2011-1868 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303183 ER PT J AU Uckun, FM Qazi, S Garner, A Ma, H Ozer, Z Pitt, J Janda, K AF Uckun, Fatih M. Qazi, Sanjive Garner, Amanda Ma, Hong Ozer, Zahide Pitt, Jason Janda, Kim TI Unfolded protein response regulator BIP/HSPA5 as a chemoresistance biomarker and molecular target in acute lymphoblastic leukemia SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Uckun, Fatih M.; Ma, Hong; Ozer, Zahide] USC Childrens Hosp Los Angeles, Los Angeles, CA USA. [Qazi, Sanjive] Gustavus Adolphus Coll, St Peter, MN 56082 USA. [Garner, Amanda; Janda, Kim] Scripps Res Inst, Worm Inst Med Res WIRM, La Jolla, CA 92037 USA. [Pitt, Jason] NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA LB-365 DI 10.1158/1538-7445.AM2011-LB-365 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303410 ER PT J AU Uppalapati, LD Ohta, N Zhang, YQ Pyle, M Becker, KG Troyer, DL Tamura, M AF Uppalapati, Lakshmi D. Ohta, Naomi Zhang, Yongqing Pyle, Marla Becker, Kevin G. Troyer, Deryl L. Tamura, Masaaki TI Identification of unique tumoricidal genes in rat umbilical cord matrix stem cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Uppalapati, Lakshmi D.; Ohta, Naomi; Pyle, Marla; Troyer, Deryl L.; Tamura, Masaaki] Kansas State Univ, Manhattan, KS 66506 USA. [Zhang, Yongqing; Becker, Kevin G.] NIA, NIH, Baltimore, MD 21224 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3355 DI 10.1158/1538-7445.AM2011-3355 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304104 ER PT J AU Vergati, M Cereda, V Intrivici, C Huen, NY Di Bari, MG Jochems, C Gulley, JL Apelian, D Schlom, J Tsang, KY AF Vergati, Matteo Cereda, Vittore Intrivici, Chiara Huen, Ngar-Yee Di Bari, Maria Giovanna Jochems, Caroline Gulley, James L. Apelian, David Schlom, Jeffrey Tsang, Kwong Y. TI Cancer vaccine immunotherapy employing Saccharomyces cerevisiae (yeast) as a vector can modulate the balance between CD4+T cells and regulatory T cells (Tregs) and enhance the specific antitumor immune response SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Vergati, Matteo; Cereda, Vittore; Intrivici, Chiara; Huen, Ngar-Yee; Di Bari, Maria Giovanna; Jochems, Caroline; Gulley, James L.; Schlom, Jeffrey; Tsang, Kwong Y.] NCI, NIH, Bethesda, MD 20892 USA. [Apelian, David] GlobeImmune, Louisville, CO USA. RI Gulley, James/K-4139-2016 OI Gulley, James/0000-0002-6569-2912 NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 758 DI 10.1158/1538-7445.AM2011-758 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303085 ER PT J AU Vistica, DT Kenney, S Scudiero, DA Reinhart, RA Selby, MH Butcher, DO Shoemaker, RH AF Vistica, David T. Kenney, Susan Scudiero, Dominic A. Reinhart, Russell A. Selby, Michael H. Butcher, Donna O. Shoemaker, Robert H. TI The proprotein convertase PCSK1 is a novel drug target in alveolar soft part sarcoma (ASPS) SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Vistica, David T.; Kenney, Susan; Scudiero, Dominic A.; Reinhart, Russell A.; Selby, Michael H.; Butcher, Donna O.; Shoemaker, Robert H.] NCI, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1621 DI 10.1158/1538-7445.AM2011-1621 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401033 ER PT J AU Wang, C Henkes, L Doughty, LB He, M Wang, DF Meyer-Almes, FJ Newman, DJ Cheng, YQ AF Wang, Cheng Henkes, Leonhard Doughty, Leah B. He, Min Wang, Difei Meyer-Almes, Franz-Josef Newman, David J. Cheng, Yi-Qiang TI Thailandepsins: Novel bacterial natural products with potent histone deacetylase inhibition activities and promising anticancer activities SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Wang, Cheng; Doughty, Leah B.; Cheng, Yi-Qiang] Univ Wisconsin, Milwaukee, WI 53201 USA. [Henkes, Leonhard; Meyer-Almes, Franz-Josef] Univ Appl Sci Darmstadt, Darmstadt, Germany. [He, Min; Newman, David J.] US NCI, Frederick, MD USA. [Wang, Difei] US NCI, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5418 DI 10.1158/1538-7445.AM2011-5418 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305282 ER PT J AU Wang, CG Zhou, J Wu, KM Tozeren, A Zhao, KJ Pestell, RG AF Wang, Chenguang Zhou, Jie Wu, Kongming Tozeren, Aydin Zhao, Keji Pestell, Richard G. TI DACH1 (Dachshund homolog 1) attenuates forkhead signaling through recruiting transcription elongation regulator 1 (TCERG1) SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Wang, Chenguang; Zhou, Jie; Wu, Kongming; Pestell, Richard G.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Tozeren, Aydin] Drexel Univ, Philadelphia, PA 19104 USA. [Zhao, Keji] NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 269 DI 10.1158/1538-7445.AM2011-269 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402201 ER PT J AU Wang, LD Bi, XL Pohl, N Cheng, YL Zhou, YX Shears, S Wang, SM Xu, XC Huang, P Chen, Z Wang, L Hong, JY Xie, H Wei, QY Meltzer, S Ding, I Okunieff, P Yang, WC AF Wang, Li-Dong Bi, Xiuli Pohl, Nicole Cheng, Yulan Zhou, Yixing Shears, Stephen Wang, Shaomeng Xu, Xiao-Chun Huang, Peng Chen, Zhong Wang, Liang Hong, Jun-Yan Xie, Heng Wei, Qingyi Meltzer, Stephen Ding, Ivan Okunieff, Paul Yang, Wancai TI A sequence variant in the phospholipase C epsilon C2 domain is associated with esophageal carcinoma and esophagitis SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Wang, Li-Dong] Xinxiang Med Univ, Xinxiang, Peoples R China. [Bi, Xiuli; Pohl, Nicole; Yang, Wancai] Univ Illinois, Chicago, IL USA. [Bi, Xiuli] Liaoning Univ, Sch Life Sci, Shenyang 110036, Peoples R China. [Cheng, Yulan; Meltzer, Stephen] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Zhou, Yixing; Shears, Stephen] NIEHS, NIH, Res Triangle Pk, NC 27709 USA. [Wang, Shaomeng] Univ Michigan, Ann Arbor, MI 48109 USA. [Xu, Xiao-Chun; Huang, Peng; Wei, Qingyi] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Chen, Zhong] Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD USA. [Wang, Liang] Mayo Clin, Coll Med, Rochester, MN USA. [Hong, Jun-Yan] Univ Med & Dent New Jersey, Piscataway, NJ 08854 USA. [Xie, Heng; Ding, Ivan] NCI, NIH, Bethesda, MD 20892 USA. [Okunieff, Paul] Univ Florida, Shands Canc Ctr, Gainesville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4704 DI 10.1158/1538-7445.AM2011-4704 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305187 ER PT J AU Wang, XY Xu, ZL Chrysoyergis, K Bienstock, R Shim, M Bensen, JT Fontham, E Smith, GJ Mohler, J Taylor, J Eling, TE AF Wang, Xingya Xu, Zongli Chrysoyergis, Kali Bienstock, Rachelle Shim, Minsub Bensen, Jeannette T. Fontham, Elizabeth Smith, Gary J. Mohler, James Taylor, Jack Eling, Thomas E. TI The dual effects of H6D polymorphism of NAG-1/GDF15 in prostate cancer carcinogenesis SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Wang, Xingya; Xu, Zongli; Chrysoyergis, Kali; Bienstock, Rachelle; Shim, Minsub; Taylor, Jack; Eling, Thomas E.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA. [Bensen, Jeannette T.] Univ N Carolina, Chapel Hill, NC USA. [Fontham, Elizabeth] LSU Hlth Sci Ctr, New Orleans, LA USA. [Smith, Gary J.] Roswell Pk Canc Inst, Bullalo, NY USA. [Mohler, James] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5541 DI 10.1158/1538-7445.AM2011-5541 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701305300 ER PT J AU Wang, Y James, M Wen, WD Lu, Y Szabo, E Lubet, RA You, M AF Wang, Yian James, Michael Wen, Weidong Lu, Yan Szabo, Eva Lubet, Ronald A. You, Ming TI Chemopreventive efficacy of pioglitazone on lung cancer in mice SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Wang, Yian; James, Michael; Wen, Weidong; Lu, Yan; You, Ming] Washington Univ, St Louis, MO USA. [Szabo, Eva; Lubet, Ronald A.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3698 DI 10.1158/1538-7445.AM2011-3698 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701303138 ER PT J AU Welzel, TM Graubard, BI Davila, JA El-Serag, HB McGlynn, KA AF Welzel, Tania M. Graubard, Barry I. Davila, Jessica A. El-Serag, Hashem B. McGlynn, Katherine A. TI Metabolic syndrome increases the risk of primary liver cancer in the United States SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Welzel, Tania M.; Graubard, Barry I.; McGlynn, Katherine A.] NCI, Bethesda, MD 20892 USA. [Davila, Jessica A.; El-Serag, Hashem B.] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 945 DI 10.1158/1538-7445.AM2011-945 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701406029 ER PT J AU Wentzensen, IM Mirabello, L Pfeiffer, RM Savage, SA AF Wentzensen, Ingrid M. Mirabello, Lisa Pfeiffer, Ruth M. Savage, Sharon A. TI Telomere length as a biomarker of cancer risk: Review and meta-analysis SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Wentzensen, Ingrid M.; Mirabello, Lisa; Pfeiffer, Ruth M.; Savage, Sharon A.] NIH, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4654 DI 10.1158/1538-7445.AM2011-4654 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701406073 ER PT J AU Wentzensen, NA Walker, J Zuna, R Smith, K Mathews, C Moxley, K Tenney, M Zhang, R Gold, M Schiffman, M AF Wentzensen, Nicolas A. Walker, Joan Zuna, Rosemary Smith, Katie Mathews, Cara Moxley, Katherine Tenney, Meaghan Zhang, Roy Gold, Michael Schiffman, Mark TI Misclassification of cervical precancer: Impact of a new colposcopy protocol on disease ascertainment and biomarker performance SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Wentzensen, Nicolas A.; Schiffman, Mark] NCI, DCEG, Bethesda, MD 20892 USA. [Walker, Joan; Zuna, Rosemary; Smith, Katie; Mathews, Cara; Moxley, Katherine; Tenney, Meaghan; Zhang, Roy] Univ Oklahoma, Oklahoma City, OK USA. [Gold, Michael] Vanderbilt Univ, Nashville, TN 37235 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3189 DI 10.1158/1538-7445.AM2011-3189 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404414 ER PT J AU Winter, SF Hunter, KW AF Winter, Scott F. Hunter, Kent W. TI Arid4b: A germline breast cancer progression modifier SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Winter, Scott F.; Hunter, Kent W.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1458 DI 10.1158/1538-7445.AM2011-1458 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301274 ER PT J AU Woditschka, S Palmieri, D Flores, NM Sledge, GW Badve, S Steeg, PS AF Woditschka, Stephan Palmieri, Diane Flores, Natasha M. Sledge, George W. Badve, Sunil Steeg, Patricia S. TI The DNA double-strand break repair genes BARD1 and RAD51 as molecular targets for brain metastases from breast cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Woditschka, Stephan] NCI, Canc Prevent Fellowship Program, Rockville, MD USA. [Palmieri, Diane; Flores, Natasha M.; Steeg, Patricia S.] NCI, Womens Canc Sect, Mol Pharmacol Lab, Ctr Canc Res, Bethesda, MD 20892 USA. [Sledge, George W.] Indiana Univ Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202 USA. [Badve, Sunil] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1478 DI 10.1158/1538-7445.AM2011-1478 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701301457 ER PT J AU Wood, LV Dahut, W Gulley, JL Madan, RA Arlen, P Parnes, HL Roberson, BD Steinberg, SM Terabe, M Berzofsky, JA AF Wood, Lauren V. Dahut, William Gulley, James L. Madan, Ravi A. Arlen, Philip Parnes, Howard L. Roberson, Brenda D. Steinberg, Seth M. Terabe, Masaki Berzofsky, Jay A. TI Therapeutic vaccination with epitope-enhanced and wild-type TARP peptides in stage DO prostate cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Wood, Lauren V.; Dahut, William; Gulley, James L.; Madan, Ravi A.; Arlen, Philip; Parnes, Howard L.; Roberson, Brenda D.; Steinberg, Seth M.; Terabe, Masaki; Berzofsky, Jay A.] NCI, Bethesda, MD 20892 USA. RI Gulley, James/K-4139-2016 OI Gulley, James/0000-0002-6569-2912 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5520 DI 10.1158/1538-7445.AM2011-5520 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701405096 ER PT J AU Wu, YZ Antony, S Lu, JM Juhasz, A Liu, H Jiang, GJ Roy, K Doroshow, JH AF Wu, Yongzhong Antony, Smitha Lu, Jiamo Juhasz, Agnes Liu, Han Jiang, Guojian Roy, Krishnendu Doroshow, James H. TI ERK activation mediated by Duox2 expression and reactive oxygen production is responsible for HIF-1 alpha accumulation and VEGF induction in IFN-gamma-treated BxPC-3 pancreatic cancer cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Wu, Yongzhong; Antony, Smitha; Lu, Jiamo; Juhasz, Agnes; Liu, Han; Jiang, Guojian] NCI, Bethesda, MD 20892 USA. [Roy, Krishnendu; Doroshow, James H.] NCI, DCTD, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2082 DI 10.1158/1538-7445.AM2011-2082 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404245 ER PT J AU Xie, Q Bradley, R Kang, L Koeman, J Worschech, A De Giorgi, V Wang, E Kefene, L Su, YL Essenburg, C Kaufman, D DeKoning, T Enter, M O'Rourke, TJ Marincola, F Vande Woude, GF AF Xie, Qian Bradley, Robert Kang, Liang Koeman, Julie Worschech, Andrea De Giorgi, Valeria Wang, Ena Kefene, Lisa Su, Yanli Essenburg, Curt Kaufman, Dafna DeKoning, Tom Enter, Mark O'Rourke, Timothy J. Marincola, Francesco Vande Woude, George F. TI Dissecting the therapeutic determinants of MET inhibition in Glioblastoma: HGF-autocrine loop predicts sensitivity to MET inhibitor SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Xie, Qian; Bradley, Robert; Kang, Liang; Koeman, Julie; Kefene, Lisa; Su, Yanli; Essenburg, Curt; Kaufman, Dafna; DeKoning, Tom; Vande Woude, George F.] Van Andel Res Inst, Grand Rapids, MI USA. [Worschech, Andrea; De Giorgi, Valeria; Wang, Ena; Marincola, Francesco] NIH, Infect Dis & Immunogenet Sect, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA. [Enter, Mark; O'Rourke, Timothy J.] Spectrum Hlth, Grand Rapids, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA LB-223 DI 10.1158/1538-7445.AM2011-LB-223 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701400304 ER PT J AU Xie, YL Camps, J Awad, KS Wangsa, D Yang, JH Yoo, N Ried, T Kwong, KF AF Xie, Yili Camps, Jordi Awad, Keytam S. Wangsa, Danny Yang, Jianhui Yoo, Nina Ried, Thomas Kwong, King F. TI MicroRNA repression of BIRC4/XIAP in lung cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Xie, Yili; Camps, Jordi; Awad, Keytam S.; Wangsa, Danny; Yang, Jianhui; Yoo, Nina; Ried, Thomas; Kwong, King F.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 135 DI 10.1158/1538-7445.AM2011-135 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404059 ER PT J AU Xin, HW Hari, DM Mullinax, JE Ambe, CM Ray, S Koizumi, T Wiegand, GW Miller, T Andersen, AJ Garfield, SH Thorgeirsson, SS Avital, I AF Xin, Hongwu Hari, Danielle M. Mullinax, John E. Ambe, Chenwi M. Ray, Satyajit Koizumi, Tomotake Wiegand, Gordon W. Miller, Tyler Andersen, Andrew J. Garfield, Susan H. Thorgeirsson, Snorri S. Avital, Itzhak TI Human solid organ cancers contain stem-like label-retaining cancer cells that undergo asymmetric cell division and have superior tumor initiating capacity SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Xin, Hongwu; Hari, Danielle M.; Mullinax, John E.; Ambe, Chenwi M.; Ray, Satyajit; Koizumi, Tomotake; Wiegand, Gordon W.; Miller, Tyler; Andersen, Andrew J.; Garfield, Susan H.; Thorgeirsson, Snorri S.; Avital, Itzhak] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 478 DI 10.1158/1538-7445.AM2011-478 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302060 ER PT J AU Yan, C Nottingham, L Allen, C Cheng, TF Pattatheyil, A Yang, XP Gius, D Dang, LN Chen, Z Van Waes, C AF Yan, Carol Nottingham, Liesl Allen, Clint Cheng, Tsu-Fan Pattatheyil, Arun Yang, Xinping Gius, David Dang, Lenny Chen, Zhong Van Waes, Carter TI Combined targeting of IKK alpha and beta effectively suppresses NF-kappa B activation, cell survival and migration in head and neck squamous cell cancers SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Yan, Carol; Nottingham, Liesl; Allen, Clint; Cheng, Tsu-Fan; Pattatheyil, Arun; Yang, Xinping; Chen, Zhong; Van Waes, Carter] NIDCD, NIH, Bethesda, MD USA. [Gius, David] NCI, NIH, Bethesda, MD 20892 USA. [Dang, Lenny] Millennium Pharmaceut Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5005 DI 10.1158/1538-7445.AM2011-5005 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402099 ER PT J AU Yang, HP Trabert, B Murphy, MA Sherman, ME Sampson, JN Brinton, LA Hartge, P Hollenbeck, A Schatzkin, A Wentzensen, N AF Yang, Hannah P. Trabert, Britton Murphy, Megan A. Sherman, Mark E. Sampson, Joshua N. Brinton, Louise A. Hartge, Patricia Hollenbeck, Albert Schatzkin, Arthur Wentzensen, Nicolas TI Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Yang, Hannah P.; Trabert, Britton; Murphy, Megan A.; Sherman, Mark E.; Sampson, Joshua N.; Brinton, Louise A.; Hartge, Patricia; Schatzkin, Arthur; Wentzensen, Nicolas] NCI, Rockville, MD USA. [Hollenbeck, Albert] AARP, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3712 DI 10.1158/1538-7445.AM2011-3712 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701406079 ER PT J AU Yang, J Kinyamu, HH Archer, TK AF Yang, Jun Kinyamu, Harriet H. Archer, Trevor K. TI Exploring LIN28 mRNA targets in breast cancer cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Yang, Jun; Kinyamu, Harriet H.; Archer, Trevor K.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3082 DI 10.1158/1538-7445.AM2011-3082 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402226 ER PT J AU Yang, M Gao, HK Sun, XL Quan, QM Mohamedali, KA Rosenblum, MG Niu, G Chen, XY AF Yang, Min Gao, Haokao Sun, Xilin Quan, Qimeng Mohamedali, Khalid A. Rosenblum, Michael G. Niu, Gang Chen, Xiaoyuan TI Multiplexed PET probes for imaging breast cancer early response to VEGF(121)/rGel treatment SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Yang, Min; Gao, Haokao; Sun, Xilin; Quan, Qimeng; Niu, Gang; Chen, Xiaoyuan] NIH, Bethesda, MD 20892 USA. [Mohamedali, Khalid A.; Rosenblum, Michael G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5273 DI 10.1158/1538-7445.AM2011-5273 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301137 ER PT J AU Yang, YA Weng, J Welsh, M Ford, HL Lonning, SM Wakefield, L AF Yang, Yu-an Weng, Jia Welsh, Michael Ford, Heide L. Lonning, Scott M. Wakefield, Lalage TI Development of predictive biomarkers for anti-TGF-beta therapy SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Yang, Yu-an; Weng, Jia; Welsh, Michael; Wakefield, Lalage] NCI, Bethesda, MD 20892 USA. [Ford, Heide L.] Univ Colorado, Sch Med, Aurora, CO USA. [Lonning, Scott M.] Genzyme Corp, Framingham, MA 01701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1090 DI 10.1158/1538-7445.AM2011-1090 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701403310 ER PT J AU Yoshikawa, N Young, MR Hegamyer, G Baker, AR Santhanam, AN Wei, Q Colburn, NH AF Yoshikawa, Noriko Young, Matthew R. Hegamyer, Glenn Baker, Alyson R. Santhanam, Arti N. Wei, Qiou Colburn, Nancy H. TI Identification of the translational targets of tumor suppressor Pdcd4 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Yoshikawa, Noriko; Young, Matthew R.; Hegamyer, Glenn; Baker, Alyson R.; Santhanam, Arti N.; Wei, Qiou; Colburn, Nancy H.] NCI, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3079 DI 10.1158/1538-7445.AM2011-3079 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402223 ER PT J AU Yoshimura, T Howard, OMZ Matsukawa, A Chen, KQ Liu, Y Wang, JM Oppenheim, JJ AF Yoshimura, Teizo Howard, O. M. Zack Matsukawa, Akihiro Chen, Keqiang Liu, Ying Wang, Ji Ming Oppenheim, Joost J. TI Monocyte chemoattractant protein-1 (MCP-1)/CCL2 produced by non-tumor cells in tumor stroma promotes lung metastasis of 4T1 murine breast cancer cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Yoshimura, Teizo; Howard, O. M. Zack; Chen, Keqiang; Liu, Ying; Wang, Ji Ming; Oppenheim, Joost J.] NCI, Frederick, MD 21701 USA. [Matsukawa, Akihiro] Okayama Univ, Okayama 7008530, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 385 DI 10.1158/1538-7445.AM2011-385 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304208 ER PT J AU Yu, HP Zhao, H Wang, LE Han, YH Wei, VC Amos, CI Rafnar, T Sulem, P Stefansson, K Landi, MT Caporaso, N Albanes, D Thun, M Mckay, JD Brennan, P Wang, YF Houlston, RS Spitz, MR Wei, QY AF Yu, Hongping Zhao, Hui Wang, Li-E Han, Younghun Wei, Chen, V Amos, Christopher I. Rafnar, Thorunn Sulem, Patrick Stefansson, Kari Landi, Maria Teresa Caporaso, Neil Albanes, Demetrius Thun, Michael McKay, James D. Brennan, Paul Wang, Yufei Houlston, Richard S. Spitz, Margaret R. Wei, Qingyi TI An analysis of single nucleotide polymorphisms of 125 DNA repair genes in the Texas genome-wide association study of lung cancer with a replication for the XRCC4 SNPs SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Yu, Hongping; Zhao, Hui; Wang, Li-E; Han, Younghun; Wei, Chen, V; Amos, Christopher I.; Spitz, Margaret R.; Wei, Qingyi] UT MD Anderson Canc Ctr, Houston, TX USA. [Rafnar, Thorunn; Sulem, Patrick; Stefansson, Kari] DeCODE Genet, Reykjavik, Iceland. [Landi, Maria Teresa] NCI, Bethesda, MD 20892 USA. [Caporaso, Neil; Albanes, Demetrius] NIH, Bethesda, MD 20892 USA. [Thun, Michael] Amer Canc Soc, Atlanta, GA 30329 USA. [McKay, James D.; Brennan, Paul] Int Agcy Res Canc, F-69372 Lyon, France. [Wang, Yufei; Houlston, Richard S.] Inst Canc Res, Sutton, Surrey, England. OI Houlston, Richard/0000-0002-5268-0242 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 889 DI 10.1158/1538-7445.AM2011-889 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701405471 ER PT J AU Yu, YL Liu, ZY Yu, YX Mendoza, A Khanna, C Merlino, G AF Yu, Yanlin Liu, Ziyang Yu, Yixin Mendoza, Arnulfo Khanna, Chand Merlino, Glenn TI Dissecting the role of PTEN/Akts in metastatic melanoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Yu, Yanlin; Liu, Ziyang; Yu, Yixin; Mendoza, Arnulfo; Khanna, Chand; Merlino, Glenn] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1446 DI 10.1158/1538-7445.AM2011-1446 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301262 ER PT J AU Zeng, HM Yu, H Lu, LG Jain, D Kidd, MS Saif, MW Chanock, SJ Hartge, P Risch, HA AF Zeng, Hongmei Yu, Herbert Lu, Lingeng Jain, Dhanpat Kidd, Mark S. Saif, M. Wasif Chanock, Stephen J. Hartge, Patricia Risch, Harvey A. TI Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Zeng, Hongmei] Peking Univ, Key Lab Carcinogenesis & Translat Res, Beijing Canc Hosp & Inst, Minist Educ,Dept Canc Epidemiol,Sch Oncol, Beijing 100871, Peoples R China. [Yu, Herbert; Lu, Lingeng; Risch, Harvey A.] Yale Univ, Dept Epidemiol & Publ Hlth, Sch Publ Hlth, New Haven, CT 06520 USA. [Yu, Herbert; Lu, Lingeng; Risch, Harvey A.] Yale Univ, Sch Med, New Haven, CT USA. [Jain, Dhanpat] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA. [Kidd, Mark S.] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA. [Saif, M. Wasif] Columbia Univ Coll Phys & Surg, Dept Med, Div Hematol Oncol, New York, NY USA. [Chanock, Stephen J.; Hartge, Patricia] NCI, Lab Translat Genom, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 4668 DI 10.1158/1538-7445.AM2011-4668 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401208 ER PT J AU Zhang, JY Thorgeirsson, SS Jessup, JM AF Zhang, Jingyu Thorgeirsson, Snorri S. Jessup, J. Milburn TI Nanog family members are essential for spherogenicity and metastasis in colorectal carcinoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Zhang, Jingyu; Thorgeirsson, Snorri S.] NCI, CCR, Bethesda, MD 20892 USA. [Jessup, J. Milburn] NCI, Canc Diag Prog, DCTD, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5206 DI 10.1158/1538-7445.AM2011-5206 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701300380 ER PT J AU Zhang, SL Pruitt, M Tran, D DuBois, W Robinson, R Mock, BA AF Zhang, Shuling Pruitt, Margaret Dena Tran DuBois, Wendy Robinson, Richard Mock, Beverly A. TI mTORC protein levels affect class switch recombination, somatic hypermutation, and antibody production SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Zhang, Shuling; Pruitt, Margaret; Dena Tran; DuBois, Wendy; Robinson, Richard; Mock, Beverly A.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 805 DI 10.1158/1538-7445.AM2011-805 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701302345 ER PT J AU Zhu, BK Khozoie, C Bility, M Blazanin, N Glick, AB Gonzalez, FJ Peters, JM AF Zhu, Bokai Khozoie, Combiz Bility, Moses Blazanin, Nicholas Glick, Adam B. Gonzalez, Frank J. Peters, Jeffrey M. TI Anti-oncogenic role of Peroxisome proliferator-activated receptor-beta/Delta (Ppar beta/Delta) involves regulation of viral Hras1 (v-Hras1)-induced senescence and endoplasmic reticulum (ER) stress in mouse primary keratinocytes SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Zhu, Bokai; Khozoie, Combiz; Bility, Moses; Blazanin, Nicholas; Glick, Adam B.; Peters, Jeffrey M.] Penn State Univ, University Pk, PA 16802 USA. [Gonzalez, Frank J.] NCI, Lab Metab, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1227 DI 10.1158/1538-7445.AM2011-1227 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701401470 ER PT J AU Zhu, ZQ Singh, V Bronte, V Feigenbaum, L Hurwitz, A AF Zhu, Ziqiang Singh, Vinod Bronte, Vincenzo Feigenbaum, Lionel Hurwitz, Arthur TI CD4+T cell help differentially influences anti-tumor immunity as a function of T cell avidity SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Zhu, Ziqiang; Singh, Vinod; Feigenbaum, Lionel; Hurwitz, Arthur] NCI, Frederick, MD 21701 USA. [Bronte, Vincenzo] Univ Padua, Padua, Italy. RI Bronte, Vincenzo/K-7902-2016 OI Bronte, Vincenzo/0000-0002-3741-5141 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 473 DI 10.1158/1538-7445.AM2011-473 PG 1 WC Oncology SC Oncology GA V43SO UT WOS:000209701301251 ER PT J AU Zielinski, RJ Lyakhov, I Moinuddin, H Chernomordik, V Garcia-Glaessner, A Ardeshirpour, Y Gandjbakhche, A Capala, J AF Zielinski, Rafal J. Lyakhov, Ilya Moinuddin, Hassan Chernomordik, Victor Garcia-Glaessner, Alejandra Ardeshirpour, Yasaman Gandjbakhche, Amir Capala, Jacek TI Affibody - NIR conjugate for optical imaging of HER2-expressing tumors SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Zielinski, Rafal J.; Garcia-Glaessner, Alejandra; Capala, Jacek] NCI, NIH, Bethesda, MD 20892 USA. [Lyakhov, Ilya] NCI, NIH, Frederick, MD 21701 USA. [Moinuddin, Hassan; Chernomordik, Victor; Ardeshirpour, Yasaman; Gandjbakhche, Amir] NICHHD, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 5298 DI 10.1158/1538-7445.AM2011-5298 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701301163 ER PT J AU Webb, SW Grillet, N Andrade, LR Xiong, W Swarthout, L Della Santina, CC Kachar, B Muller, U AF Webb, Stuart W. Grillet, Nicolas Andrade, Leonardo R. Xiong, Wei Swarthout, Lani Della Santina, Charley C. Kachar, Bechara Mueller, Ulrich TI Regulation of PCDH15 function in mechanosensory hair cells by alternative splicing of the cytoplasmic domain SO DEVELOPMENT LA English DT Article DE Hair cells; PCDH15; Deafness; Mouse ID SYNDROME TYPE 1F; INNER-EAR; USHER-SYNDROME; PLANAR POLARITY; WALTZER MICE; TIP-LINK; PROTOCADHERIN GENE; HEARING-LOSS; MUTATIONS; CADHERIN-23 AB Protocadherin 15 (PCDH15) is expressed in hair cells of the inner ear and in photoreceptors of the retina. Mutations in PCDH15 cause Usher Syndrome (deaf-blindness) and recessive deafness. In developing hair cells, PCDH15 localizes to extracellular linkages that connect the stereocilia and kinocilium into a bundle and regulate its morphogenesis. In mature hair cells, PCDH15 is a component of tip links, which gate mechanotransduction channels. PCDH15 is expressed in several isoforms differing in their cytoplasmic domains, suggesting that alternative splicing regulates PCDH15 function in hair cells. To test this model, we generated three mouse lines, each of which lacks one out of three prominent PCDH15 isoforms (CD1, CD2 and CD3). Surprisingly, mice lacking PCDH15-CD1 and PCDH15-CD3 form normal hair bundles and tip links and maintain hearing function. Tip links are also present in mice lacking PCDH15-CD2. However, PCDH15-CD2-deficient mice are deaf, lack kinociliary links and have abnormally polarized hair bundles. Planar cell polarity (PCP) proteins are distributed normally in the sensory epithelia of the mutants, suggesting that PCDH15-CD2 acts downstream of PCP components to control polarity. Despite the absence of kinociliary links, vestibular function is surprisingly intact in the PCDH15-CD2 mutants. Our findings reveal an essential role for PCDH15-CD2 in the formation of kinociliary links and hair bundle polarization, and show that several PCDH15 isoforms can function redundantly at tip links. C1 [Webb, Stuart W.; Grillet, Nicolas; Xiong, Wei; Mueller, Ulrich] Scripps Res Inst, Dorris Neurosci Ctr, La Jolla, CA 92037 USA. [Webb, Stuart W.; Grillet, Nicolas; Xiong, Wei; Mueller, Ulrich] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA. [Andrade, Leonardo R.; Kachar, Bechara] Natl Inst Deafness & Other Commun Disorders, Lab Cell Struct & Dynam, NIH, Bethesda, MD 20892 USA. [Swarthout, Lani; Della Santina, Charley C.] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg & Biomed Engn, Baltimore, MD 21287 USA. RP Webb, SW (reprint author), Scripps Res Inst, Dorris Neurosci Ctr, La Jolla, CA 92037 USA. EM swwebb@scripps.edu; kacharb@nidce.nih.gov; umueller@scripps.edu RI Andrade, Leonardo/C-9554-2011; Wang, Shirong/G-1698-2011; Xiong, Wei/A-6170-2012 OI Andrade, Leonardo/0000-0002-0004-5677; FU NIDCD [DC007704, DC005965, DC005965-S1, DC9255, DC2390, NIDCD-DIR-Z01DC000002]; Skaggs Institute for Chemical Biology; Dorris Neuroscience Center; Ruth Kirschstein Predoctoral Fellowship; CIRM FX This work was funded by NIDCD grants DC007704, DC005965, DC005965-S1 (U. M.), DC9255, DC2390 (C. D. S.) and NIDCD-DIR-Z01DC000002 (B. K.); by the Skaggs Institute for Chemical Biology (U. M.); by the Dorris Neuroscience Center (U. M.); by a Ruth Kirschstein Predoctoral Fellowship award (S. W. W.); and by a CIRM training grant (S. W. W.). Deposited in PMC for release after 12 months. NR 51 TC 43 Z9 43 U1 0 U2 10 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0950-1991 J9 DEVELOPMENT JI Development PD APR 15 PY 2011 VL 138 IS 8 BP 1607 EP 1617 DI 10.1242/dev.060061 PG 11 WC Developmental Biology SC Developmental Biology GA 738OI UT WOS:000288649400016 PM 21427143 ER PT J AU Sangeetha, M Pillai, MS Philip, L Lakatta, EG Shivakumar, K AF Sangeetha, M. Pillai, Malini S. Philip, Linda Lakatta, Edward G. Shivakumar, K. TI NF-kappa B inhibition compromises cardiac fibroblast viability under hypoxia SO EXPERIMENTAL CELL RESEARCH LA English DT Article DE Cardiac fibroblasts; Hypoxia; NF-kappa B; clAP-2; Bcl-2; Cell survival ID PROGRAMMED CELL-DEATH; SMOOTH-MUSCLE-CELLS; INDUCED APOPTOSIS; MYOCARDIAL-INFARCTION; VENTRICULAR MYOCYTES; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; ACTIVATION; SURVIVAL; PATHWAY AB Cardiac fibroblasts are reported to be relatively resistant to stress stimuli compared to cardiac myocytes and fibroblasts of non-cardiac origin. However, the mechanisms that facilitate their survival under conditions of stress remain unclear. We explored the possibility that NF-kappa B protects cardiac fibroblasts from hypoxia-induced cell death. Further, we examined the expression of the antiapoptotic clAP-2 and Bcl-2 in hypoxic cardiac fibroblasts, and their possible regulation by NF-kappa B. Phase contrast microscopy and propidium iodide staining revealed that cardiac fibroblasts are more resistant than pulmonary fibroblasts to hypoxia. Electrophoretic Mobility Shift Assay showed that hypoxia activates NF-kappa B in cardiac fibroblasts. Supershift assay indicated that the active NF-kappa B complex is a p65/p50 heterodimer. An I-kappa B-super-repressor was constructed that prevented NF-kappa B activation and compromised cell viability under hypoxic but not normoxic conditions. Similar results were obtained with Bay 11-7085, an inhibitor of NF-kappa B. Western blot analysis showed constitutive levels of Bcl-2 and hypoxic induction of clAP-2 in these cells. NF-kappa B inhibition reduced clAP-2 but not Bcl-2 levels in hypoxic cardiac fibroblasts. The results show for the first time that NF-kappa B is an important effector of survival in cardiac fibroblasts under hypoxic stress and that regulation of clAP-2 expression may contribute to its pro-survival role. (C) 2011 Elsevier Inc. All rights reserved. C1 [Sangeetha, M.; Pillai, Malini S.; Philip, Linda; Shivakumar, K.] Sree Chitra Tirunal Inst Med Sci & Technol, Div Cellular & Mol Cardiol, Trivandrum 695011, Kerala, India. [Lakatta, Edward G.] NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA. RP Shivakumar, K (reprint author), Sree Chitra Tirunal Inst Med Sci & Technol, Div Cellular & Mol Cardiol, Trivandrum 695011, Kerala, India. EM shivak@sctimst.ac.in FU NIH; National Institute on Aging; Life Science Research Board, DRDO, Government of India; CSIR, Government of India FX This work was supported in part by the Intramural Research Program of the NIH, National Institute on Aging, and in part by a research grant to K Shivakumar from the Life Science Research Board, DRDO, Government of India. Sangeetha Mohan gratefully acknowledges the Courtesy Associateship from the NIH, USA Linda Philip is recipient of a Junior Research Fellowship from the CSIR, Government of India. The authors thank Dr. Li Lin of the Laboratory of Cardiovascular Science, GRC, NIA/NIH, for providing the super-repressor used in this study, and Dr. Ranjan Sen of the Laboratory of Cellular and Molecular Biology, GRC, NIA/NIH, for critical reading of the manuscript NR 42 TC 4 Z9 4 U1 0 U2 4 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4827 EI 1090-2422 J9 EXP CELL RES JI Exp. Cell Res. PD APR 15 PY 2011 VL 317 IS 7 BP 899 EP 909 DI 10.1016/j.yexcr.2010.12.024 PG 11 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 740VN UT WOS:000288822600001 PM 21211536 ER PT J AU Zhang, X Brann, TW Zhou, M Yang, J Oguariri, RM Lidie, KB Imamichi, H Huang, DW Lempicki, RA Baseler, MW Veenstra, TD Young, HA Lane, HC Imamichi, T AF Zhang, Xing Brann, Terrence W. Zhou, Ming Yang, Jun Oguariri, Raphael M. Lidie, Kristy B. Imamichi, Hiromi Huang, Da-Wei Lempicki, Richard A. Baseler, Michael W. Veenstra, Timothy D. Young, Howard A. Lane, H. Clifford Imamichi, Tomozumi TI Cutting Edge: Ku70 Is a Novel Cytosolic DNA Sensor That Induces Type III Rather Than Type I IFN SO JOURNAL OF IMMUNOLOGY LA English DT Article ID LAMBDA; RECOGNITION; INTERFERON; CYTOKINE; VIRUS; RECOMBINATION; REPLICATION; MACROPHAGES; EXPRESSION; INFECTION AB Cytosolic foreign DNA is detected by pattern recognition receptors and mainly induces type I IFN production. We found that transfection of different types of DNA into various untreated cells induces type III IFN (IFN-lambda 1) rather than type I IFN, indicating the presence of uncharacterized DNA sensor(s). A pull-down assay using cytosolic proteins identified that Ku70 and Ku80 are the DNA-binding proteins. The knockdown studies and the reporter assay revealed that Ku70 is a novel DNA sensor inducing the IFN-lambda1 activation. The functional analysis of IFNL1 promoter revealed that positive-regulatory domain I and IFN-stimulated response element sites are predominantly involved in the DNA-mediated IFNL1 activation. A pull-down assay using nuclear proteins demonstrated that the IFN-l1 induction is associated with the activation of IFN regulatory factor-1 and -7. Thus, to our knowledge, we show for the first time that Ku70 mediates type III IFN induction by DNA. The Journal of Immunology, 2011, 186: 4541-4545. C1 [Imamichi, Tomozumi] NCI, Appl & Dev Res Directorate, Lab Human Retrovirol, Sci Applicat Int Corp Frederick Inc, Frederick, MD 21702 USA. [Zhou, Ming; Veenstra, Timothy D.] NCI, Adv Technol Program Directorate, Sci Applicat Int Corp Frederick Inc, Frederick, MD 21702 USA. [Imamichi, Hiromi; Lane, H. Clifford] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA. [Young, Howard A.] NCI, Expt Immunol Lab, Ctr Canc Res, Frederick, MD 21702 USA. RP Imamichi, T (reprint author), NCI, Appl & Dev Res Directorate, Lab Human Retrovirol, Sci Applicat Int Corp Frederick Inc, Bldg 550,Room 126,POB B, Frederick, MD 21702 USA. EM timamichi@mail.nih.gov RI Zhang, Xing/F-8230-2011; Lempicki, Richard/E-1844-2012 OI Lempicki, Richard/0000-0002-7059-409X FU National Cancer Institute, National Institutes of Health [HHSN261200800001E]; National Institute of Allergy and Infectious Disease FX This work was supported by the National Cancer Institute, National Institutes of Health (Contract HHSN261200800001E) and the National Institute of Allergy and Infectious Disease. NR 25 TC 73 Z9 81 U1 1 U2 11 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 15 PY 2011 VL 186 IS 8 BP 4541 EP 4545 DI 10.4049/jimmunol.1003389 PG 5 WC Immunology SC Immunology GA 744FY UT WOS:000289081500003 PM 21398614 ER PT J AU Metenou, S Dembele, B Konate, S Dolo, H Coulibaly, YI Diallo, AA Soumaoro, L Coulibaly, ME Coulibaly, SY Sanogo, D Doumbia, SS Traore, SF Mahanty, S Klion, A Nutman, TB AF Metenou, Simon Dembele, Benoit Konate, Siaka Dolo, Housseini Coulibaly, Yaya I. Diallo, Abdallah A. Soumaoro, Lamine Coulibaly, Michel E. Coulibaly, Siaka Y. Sanogo, Dramane Doumbia, Salif S. Traore, Sekou F. Mahanty, Siddhartha Klion, Amy Nutman, Thomas B. TI Filarial Infection Suppresses Malaria-Specific Multifunctional Th1 and Th17 Responses in Malaria and Filarial Coinfections SO JOURNAL OF IMMUNOLOGY LA English DT Article ID T-CELL RESPONSES; PLASMODIUM-FALCIPARUM MALARIA; TUMOR-NECROSIS-FACTOR; IMMUNE-RESPONSES; HELMINTH INFECTION; GAMMA-INTERFERON; MYCOBACTERIUM-TUBERCULOSIS; LYMPHATIC FILARIASIS; PROTECTIVE IMMUNITY; CYTOKINE RESPONSES AB The mechanisms underlying the modulation of both the malaria-specific immune response and the course of clinical malaria in the context of concomitant helminth infection are poorly understood. We used multiparameter flow cytometry to characterize the quality and the magnitude of malaria-specific T cell responses in filaria-infected and -uninfected individuals with concomitant asymptomatic Plasmodium falciparum malaria in Mali. In comparison with filarial-uninfected subjects, filarial infection was associated with higher ex vivo frequencies of CD4(+) cells producing IL-4, IL-10, and IL-17A (p = 0.01, p = 0.001, and p = 0.03, respectively). In response to malaria Ag stimulation, however, filarial infection was associated with lower frequencies of CD4 + T cells producing IFN-gamma, TNF-alpha, and IL-17A (p, 0.001, p = 0.04, and p = 0.04, respectively) and with higher frequencies of CD4(+)IL10(+) T cells (p = 0.0005). Importantly, filarial infection was associated with markedly lower frequencies of malaria Ag-specific Th1 (p < 0.0001), Th17 (p = 0.012), and "TNF-alpha" (p = 0.0008) cells, and a complete absence of malaria-specific multifunctional Th1 cells. Filarial infection was also associated with a marked increase in the frequency of malaria-specific adaptive regulatory T/Tr1 cells (p = 0.024), and the addition of neutralizing anti-IL-10 Ab augmented the amount of Th1-associated cytokine produced per cell. Thus, among malaria-infected individuals, concomitant filarial infection diminishes dramatically the frequencies of malaria-specific Th1 and Th17 T cells, and alters the quality and magnitude of malaria-specific T cell responses. The Journal of Immunology, 2011, 186: 4725-4733. C1 [Metenou, Simon; Mahanty, Siddhartha; Klion, Amy; Nutman, Thomas B.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA. [Dembele, Benoit; Konate, Siaka; Dolo, Housseini; Coulibaly, Yaya I.; Diallo, Abdallah A.; Soumaoro, Lamine; Coulibaly, Michel E.; Coulibaly, Siaka Y.; Sanogo, Dramane; Doumbia, Salif S.; Traore, Sekou F.] Univ Bamako, Filariasis Unit, Fac Med Pharm & Dent, Bamako, Mali. RP Metenou, S (reprint author), NIAID, Parasit Dis Lab, NIH, 4 Ctr Dr,Room B1-05, Bethesda, MD 20892 USA. EM metenous@niaid.nih.gov RI Metenou, Simon/C-1101-2013; OI Klion, Amy/0000-0002-4986-5326; Mahanty, Siddhartha/0000-0003-1068-0524 FU Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health FX This work was supported by the Intramural Research Program of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. NR 65 TC 33 Z9 33 U1 1 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 15 PY 2011 VL 186 IS 8 BP 4725 EP 4733 DI 10.4049/jimmunol.1003778 PG 9 WC Immunology SC Immunology GA 744FY UT WOS:000289081500024 PM 21411732 ER PT J AU Bray, M AF Bray, Mike TI Understanding Smallpox Vaccination SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material ID PROGRESSIVE VACCINIA; STRAIN C1 NIAID, Off Director, Div Clin Res, NIH, Bethesda, MD 20892 USA. RP Bray, M (reprint author), NIAID, Off Director, Div Clin Res, NIH, Bethesda, MD 20892 USA. EM mbray@niaid.nih.gov NR 17 TC 1 Z9 1 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD APR 15 PY 2011 VL 203 IS 8 BP 1037 EP 1039 DI 10.1093/infdis/jiq164 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 745MC UT WOS:000289168500001 PM 21450992 ER PT J AU Troxler, S Lalonde, T Wilson, JR AF Troxler, Steven Lalonde, Trent Wilson, Jeffrey R. TI Exact logistic models for nested binary data SO STATISTICS IN MEDICINE LA English DT Article DE correlated; dependent; clustering; hierarchical; multilevel; small sample ID REGRESSION MODELS AB The use of logistic models for independent binary data has relied first on asymptotic theory and later on exact distributions for small samples. However, the use of logistic models for dependent analysis based on exact analysis is not as common. Moreover, attention is usually given to one-stage clustering. In this paper, we extend the exact techniques to address hypothesis testing (estimation is not addressed) for data with second-stage and probably higher levels of clustering. The methods are demonstrated through a somewhat generic example using C++ program. Copyright (C) 2011 John Wiley & Sons, Ltd. C1 [Wilson, Jeffrey R.] Arizona State Univ, NIH, Alzheimers Res Ctr, Tempe, AZ 85287 USA. [Troxler, Steven] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA. [Lalonde, Trent] Univ No Colorado, Dept Appl Stat, Greeley, CO 80634 USA. RP Wilson, JR (reprint author), Arizona State Univ, NIH, Alzheimers Res Ctr, BAC 565, Tempe, AZ 85287 USA. EM jeffrey.wilson@asu.edu FU National Institute of Health, Arizona Alzheimer Center at the Arizona State University FX The authors thank the two referees and the editor for helping to add clarity to the issues addressed in this paper. This research was supported in part by a National Institute of Health Alzheimer's Grant in the Arizona Alzheimer Center at the Arizona State University. NR 12 TC 1 Z9 1 U1 2 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0277-6715 J9 STAT MED JI Stat. Med. PD APR 15 PY 2011 VL 30 IS 8 BP 866 EP 876 DI 10.1002/sim.4157 PG 11 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 741JH UT WOS:000288859500006 PM 21432880 ER PT J AU Chatterjee, S Lardinois, O Bhattacharjee, S Tucker, J Corbett, J Deterding, L Ehrenshaft, M Bonini, MG Mason, RP AF Chatterjee, Saurabh Lardinois, Olivier Bhattacharjee, Suchandra Tucker, Jeff Corbett, Jean Deterding, Leesa Ehrenshaft, Marilyn Bonini, Marcelo G. Mason, Ronald P. TI Oxidative stress induces protein and DNA radical formation in follicular dendritic cells of the germinal center and modulates its cell death patterns in late sepsis SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE Oxidative stress; Follicular dendritic cell; Caspase-3; Xanthine oxidase; Apoptosome; Necrosis; Plasma cell; Free radicals ID POLYMICROBIAL SEPSIS; SEPTIC SHOCK; B-CELLS; APOPTOSIS; ACTIVATION; IMMUNOSUPPRESSION; PROLIFERATION; INFLAMMATION; ANTIOXIDANTS; TRYPTOPHAN AB Profound depletion of follicular dendritic cells (FDCs) is a hallmark of sepsis-like syndrome, but the exact causes of the ensuing cell death are unknown. The cell death-driven depletion contributes to immunoparalysis and is responsible for most of the morbidity and mortality in sepsis. Here we have utilized immuno-spin trapping, a method for detection of free radical formation, to detect oxidative stress-induced protein and DNA radical adducts in FDCs isolated from the spleens of septic mice and from human tonsil-derived HK cells, a subtype of germinal center FDCs, to study their role in FDC depletion. At 24 h post-lipopolysaccharide administration, protein radical formation and oxidation were significantly elevated in vivo and in HK cells as shown by ELISA and confocal microscopy. The xanthine oxidase inhibitor allopurinol and the iron chelator desferrioxamine significantly decreased the formation of protein radicals, suggesting the role of xanthine oxidase and Fenton-like chemistry in radical formation. Protein and DNA radical formation correlated mostly with apoptotic features at 24 h and necrotic morphology of all the cell types studied at 48 h with concomitant inhibition of caspase-3. The cytotoxicity of FDCs resulted in decreased CD45R/CD138-positive plasma cell numbers, indicating a possible defect in B cell differentiation. In one such mechanism, radical formation initiated by xanthine oxidase formed protein and DNA radicals, which may lead to cell death of germinal center FDCs. Published by Elsevier Inc. C1 [Chatterjee, Saurabh; Lardinois, Olivier; Bhattacharjee, Suchandra; Corbett, Jean; Ehrenshaft, Marilyn; Bonini, Marcelo G.; Mason, Ronald P.] NIEHS, Free Rad Metab Grp, Lab Toxicol & Pharmacol, NIH, Res Triangle Pk, NC 27709 USA. [Tucker, Jeff] NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA. [Deterding, Leesa] NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA. RP Chatterjee, S (reprint author), NIEHS, Free Rad Metab Grp, Lab Toxicol & Pharmacol, NIH, POB 12233, Res Triangle Pk, NC 27709 USA. EM chatterjees2@niehs.nih.gov FU National Institutes of Health; National Institute of Environmental Health Sciences [Z01 ES050139-13] FX The authors sincerely acknowledge Tiwanda Marsh, Jeoffrey Hurlburt, and Holly Rutledge for excellent technical assistance. We also thank Dr. Carl Bortner for help in analyzing flow cytometry data and Dr. Shyamal Peddada of the Statistics Branch, NIEHS, for generous help in statistical analysis. We also sincerely thank Dr. Ann Motten and Mary Mason for help in the careful editing of the manuscript. This work was supported by the Intramural Research Program of the National Institutes of Health and the National Institute of Environmental Health Sciences (Z01 ES050139-13). NR 45 TC 13 Z9 16 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD APR 15 PY 2011 VL 50 IS 8 BP 988 EP 999 DI 10.1016/j.freeradbiomed.2010.12.037 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 740TU UT WOS:000288818100010 PM 21215311 ER PT J AU Sologuren, I Boisson-Dupuis, S Pestano, J Vincent, QB Fernandez-Perez, L Chapgier, A Cardenes, M Feinberg, J Garcia-Laorden, MI Picard, C Santiago, E Kong, XF Janniere, L Colino, E Herrera-Ramos, E Frances, A Navarrete, C Blanche, S Faria, E Remiszewski, P Cordeiro, A Freeman, A Holland, S Abarca, K Valeron-Lemaur, M Goncalo-Marques, J Silveira, L Garcia-Castellano, JM Caminero, J Perez-Arellano, JL Bustamante, J Abel, L Casanova, JL Rodriguez-Gallego, C AF Sologuren, Ithaisa Boisson-Dupuis, Stephanie Pestano, Jose Vincent, Quentin Benoit Fernandez-Perez, Leandro Chapgier, Ariane Cardenes, Maria Feinberg, Jacqueline Isabel Garcia-Laorden, M. Picard, Capucine Santiago, Esther Kong, Xiaofei Janniere, Lucile Colino, Elena Herrera-Ramos, Estefania Frances, Adela Navarrete, Carmen Blanche, Stephane Faria, Emilia Remiszewski, Pawel Cordeiro, Ana Freeman, Alexandra Holland, Steven Abarca, Katia Valeron-Lemaur, Monica Goncalo-Marques, Jose Silveira, Luisa Manuel Garcia-Castellano, Jose Caminero, Jose Luis Perez-Arellano, Jose Bustamante, Jacinta Abel, Laurent Casanova, Jean-Laurent Rodriguez-Gallego, Carlos TI Partial recessive IFN-gamma R1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds SO HUMAN MOLECULAR GENETICS LA English DT Article ID GAMMA-RECEPTOR DEFICIENCY; STEM-CELL TRANSPLANTATION; CALMETTE-GUERIN INFECTION; HUMAN STAT1 DEFICIENCY; INTERFERON-GAMMA; IFN-GAMMA; IL-12R-BETA-1 DEFICIENCY; CRYPTOSPORIDIUM-PARVUM; MEDIATED IMMUNITY; CRYSTAL-STRUCTURE AB We report a series of 14 patients from 11 kindreds with recessive partial (RP)- interferon (IFN)-gamma R1 deficiency. The I87T mutation was found in nine homozygous patients from Chile, Portugal and Poland, and the V63G mutation was found in five homozygous patients from the Canary Islands. Founder effects accounted for the recurrence of both mutations. The most recent common ancestors of the patients with the I87T and V63G mutations probably lived 1600 (875-2950) and 500 (200-1275) years ago, respectively. The two alleles confer phenotypes that are similar but differ in terms of IFN-gamma R1 levels and residual response to IFN-gamma. The patients suffered from bacillus Calmette-Guerin-osis (n = 6), environmental mycobacteriosis (n = 6) or tuberculosis (n = 1). One patient did not suffer from mycobacterial infections but had disseminated salmonellosis, which was also present in two other patients. Age at onset of the first environmental mycobacterial disease differed widely between patients, with a mean value of 11.25 +/- 9.13 years. Thirteen patients survived until the age of 14.82 +/- 11.2 years, and one patient died at the age of 7 years, 9 days after the diagnosis of long-term Mycobacterium avium infection and the initiation of antimycobacterial treatment. Up to 10 patients are currently free of infection with no prophylaxis. The clinical heterogeneity of the 14 patients was not clearly related to either IFNGR1 genotype or the resulting cellular phenotype. RP-IFN-gamma R1 deficiency is, thus, more common than initially thought and should be considered in both children and adults with mild or severe mycobacterial diseases. C1 [Sologuren, Ithaisa; Cardenes, Maria; Isabel Garcia-Laorden, M.; Santiago, Esther; Herrera-Ramos, Estefania; Rodriguez-Gallego, Carlos] Gran Canaria Dr Negrin Univ Hosp, Dept Immunol, Las Palmas Gran Canaria, Spain. [Manuel Garcia-Castellano, Jose] Gran Canaria Dr Negrin Univ Hosp, Mol Oncol Lab, Res Unit, Las Palmas Gran Canaria, Spain. [Caminero, Jose] Gran Canaria Dr Negrin Univ Hosp, Dept Resp Dis, Las Palmas Gran Canaria, Spain. [Boisson-Dupuis, Stephanie; Vincent, Quentin Benoit; Chapgier, Ariane; Feinberg, Jacqueline; Picard, Capucine; Janniere, Lucile; Bustamante, Jacinta; Abel, Laurent; Casanova, Jean-Laurent] Univ Paris 05, Lab Human Genet Infect Dis, Necker Fac, Necker Med Sch,INSERM,U980, Paris, France. [Boisson-Dupuis, Stephanie; Kong, Xiaofei; Casanova, Jean-Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, New York, NY 10021 USA. [Pestano, Jose] Univ Las Palmas Gran Canaria, Dept Biochem Mol Biol Physiol Genet & Immunol, Las Palmas Gran Canaria, Spain. [Fernandez-Perez, Leandro] Univ Las Palmas Gran Canaria, Dept Clin Sci Pharmacol Unit, Mol & Translat Endocrinol Grp, Las Palmas Gran Canaria, Spain. [Luis Perez-Arellano, Jose; Rodriguez-Gallego, Carlos] Univ Las Palmas Gran Canaria, Sch Med, Dept Med & Surg Sci, Las Palmas Gran Canaria, Spain. [Cardenes, Maria; Rodriguez-Gallego, Carlos] Canarian Inst Canc Res, San Cristobal la Laguna, Santa Cruz Tene, Spain. [Picard, Capucine] Hop Necker Enfants Malad, Study Ctr Primary Immunodeficiencies, Paris, France. [Blanche, Stephane; Casanova, Jean-Laurent] Hop Necker Enfants Malad, AP HP, Pediat Immunol & Hematol Unit, Paris, France. [Colino, Elena] Insular Materno Infantil Hosp, Dept Pediat, Infect Dis Unit, Las Palmas Gran Canaria, Spain. [Frances, Adela; Luis Perez-Arellano, Jose] Insular Materno Infantil Hosp, Dept Infect Dis, Las Palmas Gran Canaria, Spain. [Valeron-Lemaur, Monica] Insular Materno Infantil Hosp, Pediat Intens Care Unit, Las Palmas Gran Canaria, Spain. [Manuel Garcia-Castellano, Jose] Insular Materno Infantil Hosp, Dept Orthoped Surg, Las Palmas Gran Canaria, Spain. [Navarrete, Carmen] Hosp Ninos Roberto del Rio, Dept Immunol, Santiago, Chile. [Faria, Emilia] Coimbra Pediat Hosp, Coimbra, Portugal. [Cordeiro, Ana] Coimbra Pediat Hosp, Dept Med, Coimbra, Portugal. [Remiszewski, Pawel] Natl TB & Chest Dis Res Inst, Dept Lung Dis 3, Warsaw, Poland. [Freeman, Alexandra; Holland, Steven] NIH, Lab Clin Infect Dis, Bethesda, MD USA. [Abarca, Katia] Pontificia Univ Catolica Chile, Sch Med, Dept Pediat, Santiago, Chile. [Goncalo-Marques, Jose] Lisboa Norte Hosp, Santa Maria Ctr Hosp, Dept Pediat Infect Dis, Lisbon, Portugal. [Silveira, Luisa] Santo Espirito Angra Heroismo EPE Hosp, Dept Pediat, Angra Do Heroismo, Portugal. RP Rodriguez-Gallego, C (reprint author), Hosp Univ Gran Canaria Dr Negrin, Serv Inmunol, Barranco Ballena S-N, Las Palmas Gran Canaria 35010, Spain. EM jrodgal@gobiernodecanarias.org RI KONG, Xiao-Fei/G-3437-2011; Fernandez-Perez, Leandro/H-1493-2015; Pestano Brito, Jose Juan/A-9640-2017; OI Fernandez-Perez, Leandro/0000-0001-7802-465X; Pestano Brito, Jose Juan/0000-0001-6454-4785; Vincent, Quentin/0000-0001-6030-5912 FU Institute of Health Carlos III, Ministry of Health [RedRespira-ISCiii-RTIC-03/11, FIS 06/1031]; Fundacion Canaria de Investigacion y Salud (Canarian Government) [INREDCAN 05/06]; Foundation Caja Rural de Canarias-Chil y Naranjo 2004; Canarian Institute for Cancer Research [ISCiii-RTICCC-C03/10]; Proyecto Biorregion 2006; Universidad de Las Palmas de Gran Canaria FX This work was supported by grants from the Institute of Health Carlos III, Ministry of Health (RedRespira-ISCiii-RTIC-03/11, FIS 06/1031, with the funding of European Regional Development Fund-European Social Fund-FEDER-FSE); Fundacion Canaria de Investigacion y Salud (Canarian Government, INREDCAN 05/06); Research Prize of Foundation Caja Rural de Canarias-Chil y Naranjo 2004; Canarian Institute for Cancer Research (ISCiii-RTICCC-C03/10 to M. C.); Proyecto Biorregion 2006 to M. I. G.-L.; and Universidad de Las Palmas de Gran Canaria (fellowship to E.H.-R.). J.-L.C. was an International Scholar of the Howard Hughes Medical Institute. The sponsors of the study had no role in designing the study, collecting, analyzing and interpreting the data, or writing the paper. NR 55 TC 38 Z9 39 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD APR 15 PY 2011 VL 20 IS 8 BP 1509 EP 1523 DI 10.1093/hmg/ddr029 PG 15 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 740NC UT WOS:000288800500005 PM 21266457 ER PT J AU Tebbenkamp, ATN Swing, D Tessarollo, L Borchelt, DR AF Tebbenkamp, Andrew T. N. Swing, Debbie Tessarollo, Lino Borchelt, David R. TI Premature death and neurologic abnormalities in transgenic mice expressing a mutant huntingtin exon-2 fragment SO HUMAN MOLECULAR GENETICS LA English DT Article ID YAC128 MOUSE MODEL; KNOCK-IN MICE; NEURONAL INTRANUCLEAR INCLUSIONS; N-TERMINAL FRAGMENTS; MOTOR DYSFUNCTION; NUCLEAR-LOCALIZATION; NERVOUS-SYSTEM; STRIATAL CELLS; HD MUTATION; CAG REPEAT AB Huntington's disease (HD) is a fatal neurodegenerative disease characterized pathologically by aggregates composed of N-terminal fragments of the mutant form of the protein huntingtin (htt). The role of these N-terminal fragments in disease pathogenesis has been questioned based in part on studies in transgenic mice. In one important example, mice that express an N-terminal fragment of mutant htt terminating at the C-terminus of exon 2 (termed the Shortstop mouse) were reported to develop robust inclusion pathology without developing phenotypic abnormalities seen in the R6/2 or N171-82Q models of HD, which are also based on expression of mutant N-terminal htt fragments. To further explore the capacity of mutant exon-2 htt fragments to produce neurologic abnormalities (N-terminal 118 amino acids; N118), we generated transgenic mice expressing cDNA that encodes htt N118-82Q with the mouse prion promoter vector. In mice generated in this manner, we demonstrate robust inclusion pathology accompanied by early death and failure to gain weight. These phenotypes are the most robust abnormalities identified in the R6/2 and N171-82Q models. We conclude that the lack of an overt phenotype in the initial Shortstop mice cannot be completely explained by the properties of mutant htt N118 fragments. C1 [Tebbenkamp, Andrew T. N.; Borchelt, David R.] Univ Florida, McKnight Brain Inst, Dept Neurosci, SantaFe HealthCare Alzheimers Dis Res Ctr, Gainesville, FL 32610 USA. [Swing, Debbie; Tessarollo, Lino] NCI, Mouse Canc Genet Program, Neural Dev Sect, Frederick, MD 21702 USA. RP Borchelt, DR (reprint author), Univ Florida, McKnight Brain Inst, Dept Neurosci, SantaFe HealthCare Alzheimers Dis Res Ctr, 100 Newell Dr,Rm L1-100, Gainesville, FL 32610 USA. EM borchelt@mbi.ufl.edu OI Tebbenkamp, Andrew/0000-0002-9015-3427 FU Huntington's Disease Society of America; CHDI Coalition for a Cure; NIH, Center for Cancer Research, National Cancer Institute; SantaFe HealthCare Alzheimer's Disease Research Center FX This work was supported by the Huntington's Disease Society of America and the CHDI Coalition for a Cure (A.T.N.T. and D. R. B.) and the Intramural Research Program of the NIH, Center for Cancer Research, National Cancer Institute (for D. S. and L. T.). Funding to pay the Open Access publication charges for this article was provided by SantaFe HealthCare Alzheimer's Disease Research Center. NR 46 TC 12 Z9 12 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD APR 15 PY 2011 VL 20 IS 8 BP 1633 EP 1642 DI 10.1093/hmg/ddr040 PG 10 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 740NC UT WOS:000288800500015 PM 21307087 ER PT J AU Wahl, SM Redford, M Christensen, S Mack, W Cohn, J Janoff, EN Mestecky, J Jenson, HB Navazesh, M Cohen, M Reichelderfer, P Kovacs, A AF Wahl, Sharon M. Redford, Maryann Christensen, Shawna Mack, Wendy Cohn, Jon Janoff, Edward N. Mestecky, Jiri Jenson, Hal B. Navazesh, Mahvash Cohen, Mardge Reichelderfer, Patricia Kovacs, Andrea CA DATRI 009 Study Grp TI Systemic and Mucosal Differences in HIV Burden, Immune, and Therapeutic Responses SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE adaptive immunity; HIV-1; mucosa; innate immunity; IgA; SLPI ID HUMAN-IMMUNODEFICIENCY-VIRUS; LEUKOCYTE PROTEASE INHIBITOR; EPITHELIAL-CELLS; GENITAL-TRACT; TYPE-1 TRANSMISSION; IMMUNOGLOBULIN-A; HUMAN SALIVA; BREAST-MILK; INFECTION; IGA AB Background: Mucosal tissues represent major targets for HIV transmission but differ in susceptibility and reservoir function by unknown mechanisms. Methods: In a cross-sectional study, HIV RNA and infectious virus were compared between oral and genital compartments and blood in HIV-infected women, in association with clinical parameters, copathogens, and putative innate and adaptive HIV inhibitors. Results: HIV RNA was detectable in 24.5% of women from all 3 compartments, whereas 45% had RNA in only 1 or 2 sites. By comparison, infectious HIV, present in blood of the majority, was rare in mucosal sites. Innate mediators, secretory leukocyte protease inhibitor and thrombospondin, were highest in mucosae. Highly active antiretroviral therapy was associated with an 80% decreased probability of shedding. Multivariate logistic regression models revealed that mucosal HIV RNA was associated with higher plasma RNA, infectious virus, and total mucosal IgA, but not IgG. There was a 37-fold increased probability of detecting RNA in both genital and oral specimens (P = 0.008; P = 0.02, respectively) among women in highest versus lowest IgA tertiles. Conclusions: Mucosal sites exhibit distinct characteristics of infectious HIV, viral shedding, and responses to therapy, dependent upon both systemic and local factors. Of the putative innate and adaptive mucosal defense factors examined, only IgA was associated with HIV RNA shedding. However, rather than being protective, there was a striking increase in probability of detectable HIV RNA shedding in women with highest total IgA. C1 [Wahl, Sharon M.; Redford, Maryann] Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA. [Christensen, Shawna; Kovacs, Andrea] Univ So Calif, Keck Sch Med, Maternal Child & Adolescent Ctr Infect Dis & Viro, Los Angeles, CA 90033 USA. [Mack, Wendy] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Cohn, Jon] Wayne State Univ, Div Infect Dis, Detroit, MI USA. [Janoff, Edward N.] Univ Colorado, Mucosal & Vaccine Res Program Colorado MAVRC, VA Med Ctr, Denver, CO 80202 USA. [Mestecky, Jiri] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA. [Jenson, Hal B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA. [Navazesh, Mahvash] USC, Herman Ostrow Sch Dent, Div Periodontol Diagnost Sci & Dent Hyg, Los Angeles, CA USA. [Cohen, Mardge] Stroger Cook Cty Hosp, Dept Med, Chicago, IL USA. [Reichelderfer, Patricia] NICHHD, NIH, Bethesda, MD 20892 USA. RP Wahl, SM (reprint author), Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, NIH, 30 Convent Dr,MSC4352,Bldg 30,Room 320, Bethesda, MD 20892 USA. EM smwahl@dir.nidcr.nih.gov OI Jenson, Hal/0000-0002-6549-860X FU Division of AIDS Treatment Research Initiative (DATRI), NIAID, NIH, Bethesda MD [NO1-AI-15123]; Program Support Center, DHHS [282-98-0015, 21]; NIAID; NIDCR; NCI; NICHD; NIDAA; Centers for Disease Control and Prevention [U01-AI-35004, U01-AI-31834, U01-AI-34994, AI-34989, U01-HD-32632, U01-AI-34993, U01-AI-42590, NO1-DE-72621, P01-AI-28147]; NIH, NIDCR; Agency for Health Care Policy and Research FX This study was supported by the Division of AIDS Treatment Research Initiative (DATRI) program, NIAID, NIH, Bethesda MD (Contract NO1-AI-15123); the Program Support Center, DHHS (Contract 282-98-0015, Task Order Number 21); and the Women's Interagency HIV Study, funded by NIAID, NIDCR, NCI, NICHD, NIDAA, the Agency for Health Care Policy and Research, the Centers for Disease Control and Prevention (Contracts U01-AI-35004, U01-AI-31834, U01-AI-34994, AI-34989, U01-HD-32632, U01-AI-34993, U01-AI-42590, NO1-DE-72621, and P01-AI-28147), and by the Intramural Research Program of the NIH, NIDCR. NR 54 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2011 VL 56 IS 5 BP 401 EP 411 DI 10.1097/QAI.0b013e31820cdfdb PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 733DP UT WOS:000288241800010 PM 21239996 ER PT J AU Mirochnick, M Best, BM Stek, AM Capparelli, EV Hu, CC Burchett, SK Rossi, SS Hawkins, E Basar, M Smith, E Read, JS AF Mirochnick, Mark Best, Brookie M. Stek, Alice M. Capparelli, Edmund V. Hu, Chengcheng Burchett, Sandra K. Rossi, Steven S. Hawkins, Elizabeth Basar, Michael Smith, Elizabeth Read, Jennifer S. CA IMPAACT 1026s Study Team TI Atazanavir Pharmacokinetics With and Without Tenofovir During Pregnancy SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE atazanavir; HIV; mother to child transmission; pharmacokinetics; pregnancy; tenofovir ID LOPINAVIR EXPOSURE; WOMEN; RITONAVIR; SAQUINAVIR; NELFINAVIR; SAFETY; INDINAVIR; EFFICACY; ZIDOVUDINE; LAMIVUDINE AB Background: Few data are available describing atazanavir exposure during pregnancy, especially when used in combination with tenofovir, whose coadministration with atazanavir results in decreased atazanavir exposure. Design: International Maternal Pediatric Adolescent AIDS Clinical Trials 1026s is an ongoing, prospective, nonblinded study of antiretroviral pharmacokinetics in HIV-infected pregnant women that included 2 cohorts receiving atazanavir/ritonavir 300 mg/100 mg once daily, either with or without tenofovir. Methods: Intensive steady-state 24-hour pharmacokinetic profiles were performed during the third trimester and at 6-12 weeks postpartum. Atazanavir was measured by reverse-phase high-performance liquid chromatography (detection limit 0.047 mcg/mL). Pharmacokinetic targets were the estimated 10th percentile atazanavir area under the concentration versus time curve [(AUC): 29.4 mcg.hr.mL(-1)] in nonpregnant historical controls (mean AUC = 57 mcg.hr.mL(-1)) and a trough concentration of 0.15 mcg/mL, the concentration target used in therapeutic drug monitoring programs. Results: Median atazanavir AUC was reduced during the third trimester compared with postpartum for subjects not receiving tenofovir (41.9 vs. 57.9 mcg.hr.mL(-1), P = 0.02) and for subjects receiving tenofovir (28.8 vs. 39.6 mcg.hr.mL(-1), P = 0.04). During the third trimester, AUC was below the target in 33% (6 of 18) of women not receiving tenofovir and 55% (11 of 20) of women receiving tenofovir. Trough concentration was below the target in 6% (1 of 18) of women not receiving tenofovir and 15% (3 of 20) of women receiving tenofovir. The median (range) ratio of cord blood/maternal atazanavir concentration in 29-paired samples was 0.18 (0-0.45). Conclusions: Atazanavir exposure is reduced by pregnancy and by concomitant tenofovir use. A dose increase of atazanavir/ritonavir to 400 mg/100 mg may be necessary in pregnant women to ensure atazanavir exposure equivalent to that seen in nonpregnant adults. C1 [Mirochnick, Mark] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA. [Best, Brookie M.; Capparelli, Edmund V.; Rossi, Steven S.] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA. [Best, Brookie M.; Capparelli, Edmund V.; Rossi, Steven S.] Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA USA. [Stek, Alice M.] Univ So Calif, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA. [Hu, Chengcheng] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA. [Burchett, Sandra K.] Harvard Univ, Sch Med, Boston, MA USA. [Burchett, Sandra K.] Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Hawkins, Elizabeth] Social & Sci Syst, Silver Spring, MD USA. [Basar, Michael] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA. [Read, Jennifer S.] NICHD, Maternal AIDS Branch, NIH, DHHS, Bethesda, MD USA. [Smith, Elizabeth] NIAID, Bethesda, MD 20892 USA. RP Mirochnick, M (reprint author), Boston Med Ctr, 771 Albany St,Dowling 4N,Room 4111, Boston, MA 02043 USA. EM markm@bu.edu RI Hu, Chengcheng/A-8391-2017 FU National Institute of Allergy and Infectious Diseases (NIAID) [U01 AI068632]; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH) [AI068632]; Statistical and Data Analysis Center at Harvard School of Public Health under NIAID [5 U01 AI41110]; Pediatric AIDS Clinical Trials Group (PACTG); IMPAACT Group [1 U01 AI068616]; NICHD International and Domestic Pediatric and Maternal HIV Clinical Trials Network [N01-DK-9-001/HHSN267200800001C] FX Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) [U01 AI068632], the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of Mental Health (NIMH) [AI068632]. Supported by the Statistical and Data Analysis Center at Harvard School of Public Health, under NIAID cooperative agreement #5 U01 AI41110 with the Pediatric AIDS Clinical Trials Group (PACTG) and #1 U01 AI068616 with the IMPAACT Group. Support of the sites was provided by NIAID and by the NICHD International and Domestic Pediatric and Maternal HIV Clinical Trials Network (contract number N01-DK-9-001/HHSN267200800001C). NR 26 TC 44 Z9 44 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2011 VL 56 IS 5 BP 412 EP 419 DI 10.1097/QAI.0b013e31820fd093 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 733DP UT WOS:000288241800011 PM 21283017 ER PT J AU Fink, VI Shepherd, BE Cesar, C Krolewiecki, A Wehbe, F Cortes, CP Crabtree-Ramirez, B Padgett, D Shafaee, M Schechter, M Gotuzzo, E Bacon, M McGowan, C Cahn, P Masys, D AF Fink, Valeria I. Shepherd, Bryan E. Cesar, Carina Krolewiecki, Alejandro Wehbe, Firas Cortes, Claudia P. Crabtree-Ramirez, Brenda Padgett, Denis Shafaee, Maryam Schechter, Mauro Gotuzzo, Eduardo Bacon, Melanie McGowan, Catherine Cahn, Pedro Masys, Daniel CA IeDEA Program TI Cancer in HIV-Infected Persons From the Caribbean, Central and South America SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT 18th International AIDS Conference CY JUL 13-18, 2010 CL Vienna, AUSTRIA DE Caribbean; cohort studies; HIV; Latin America; neoplasms ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; AIDS-DEFINING MALIGNANCIES; NON-HODGKIN-LYMPHOMA; HUMAN-PAPILLOMAVIRUS; UNITED-STATES; COHORT; RISK; ASSOCIATION; TRENDS AB Background: HIV-infected individuals have heightened cancer risk. With the advent of highly active antiretroviral therapy (HAART), the frequency of some AIDS-defining cancers (ADC) has decreased although certain non-AIDS-defining cancers (NADC) are becoming more frequent. Cancers among HIV-infected individuals in Latin American and the Caribbean have not yet been carefully studied. Methods: Cancer cases among the Caribbean, Central and South American network for HIV Research (CCASAnet) cohort were identified reviewing clinical records and pre-existing databases. Results: There were 406 cancers reported: 331 ADC (224 Kaposi sarcomas and 98 non Hodgkin lymphomas). Most frequent NADC (n = 75) were Hodgkin lymphoma and skin cancers. Seventy-three percent of NADC and 45% of ADC were diagnosed >1 year after HIV diagnosis. Fifty-six percent of ADC occurred before HAART start. Median time from HAART start until cancer diagnosis was 2.5 years for NADC and 0.5 years for ADC (P = <0.001). Within 3372 HAART starters, 158 were diagnosed with 165 cancers (82.4% ADC); 85 cases were previous to or concomitant with HAART initiation. Incidence of cancer after HAART initiation in 8080 person-years of follow-up was 7.2 per 1000 person-years (95% confidence interval = 5.5 to 9.3) for ADC and 2.7 (95% confidence interval = 1.8 to 4.1) for NADC; incidence was higher in the first 2 months, particularly for ADC (47.6). A pre-HAART ADC was a predictor of mortality after adjusting for age, sex, and CD4 at HAART initiation. Conclusions: ADC were the most frequent cancers in this region and were often diagnosed close to HIV diagnosis and HAART start. Incidence of cancer was highest around HAART initiation. C1 [Fink, Valeria I.; Cesar, Carina; Krolewiecki, Alejandro; Cahn, Pedro] Fdn Huesped Invest Clin, Buenos Aires, DF, Argentina. [Shepherd, Bryan E.; Wehbe, Firas; McGowan, Catherine; Masys, Daniel] Vanderbilt Univ, Nashville, TN USA. [Cortes, Claudia P.] Univ Chile Fdn Arriaran, Santiago, Chile. [Crabtree-Ramirez, Brenda] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico. [Padgett, Denis] Inst Hondureno Seguro Social, Tegucigalpa, Honduras. [Padgett, Denis] Hosp Escuela Tegucigalpa, Tegucigalpa, Honduras. [Shafaee, Maryam] Cornell Univ, Weill Med Coll, GHESKIO, Port Au Prince, Haiti. [Schechter, Mauro] Univ Fed Rio de Janeiro, Projeto Praca Onze, Rio De Janeiro, Brazil. [Gotuzzo, Eduardo] Inst Med Trop Alexander von Humboldt, Lima, Peru. [Bacon, Melanie] NIAID, HJF, DAIDS, Bethesda, MD 20892 USA. RP Fink, VI (reprint author), Pasaje Peluffo 3932,C1202ABB, Buenos Aires, DF, Argentina. EM valeria.fink@huesped.org.ar OI Cortes, Claudia P./0000-0001-9101-9783; Wehbe, Firas/0000-0002-3984-9584 FU NCRR NIH HHS [UL1 RR024975, 1-UL1-RR024975]; NIAID NIH HHS [U01 AI069923, U01 AI069923-05, 1-U01-AI069923] NR 42 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2011 VL 56 IS 5 BP 467 EP 473 DI 10.1097/QAI.0b013e31820bb1c3 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 733DP UT WOS:000288241800018 PM 21239992 ER PT J AU Benton, G Kleinman, HK George, J Arnaoutova, I AF Benton, Gabriel Kleinman, Hynda K. George, Jay Arnaoutova, Irina TI Multiple uses of basement membrane-like matrix BME/Matrigel) in vitro and in vivo with cancer cells SO INTERNATIONAL JOURNAL OF CANCER LA English DT Review DE cancer cells; tumor cells; basement membrane; invasion; xenograft; 3D culture; dormancy ID BREAST-CANCER; TUMOR-CELLS; EXTRACELLULAR-MATRIX; CHEMOINVASION ASSAY; GENE-EXPRESSION; MELANOMA-CELLS; NUDE-MICE; TGF-BETA; INVASION; GROWTH AB Significant advances in our understanding of cancer cell behavior, growth, and metastasis have been facilitated by studies using a basement membrane- like extracellular matrix extract, also known as Matrigel. The basement membrane is a thin extracellular matrix that is found in normal tissues and contacts epithelial and endothelial cells, smooth muscle, fat, Schwann cells, etc. It is composed of mainly laminin- 111, collagen IV, heparan sulfate proteoglycan, entactin/ nidogen, and various growth factors ( fibroblast growth factor, transforming growth factor beta, epidermal growth factor, etc.). Most tumors of epithelial origin produce significant amounts of basement membrane matrix and interact with it particularly during metastasis. Cancer cells metastasize via degradation of the vessel basement membrane matrix to extravasate into the blood stream and colonize distant sites. This review will focus on the interaction of cancer cells and cancer stem cells with the basement membrane- like matrix and the various uses of this interaction to accelerate tumor growth in vivo and to develop in vitro assays for invasion, morphology, and dormancy. Such assays and methods have advanced our understanding of the process of cancer progression, the genes and pathways that are involved, the potential of various therapeutic agents, the effects of neighboring cells, and the role of stem cells. Mini Review C1 [Benton, Gabriel; George, Jay; Arnaoutova, Irina] Trevigen Inc, Gaithersburg, MD 20877 USA. [Kleinman, Hynda K.] NIDCR, NIH, Bethesda, MD USA. RP Benton, G (reprint author), Trevigen Inc, 8405 Helgerman Ct, Gaithersburg, MD 20877 USA. EM gbenton@trevigen.com OI Benton, Gabriel/0000-0003-4244-5764 NR 55 TC 63 Z9 67 U1 6 U2 38 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD APR 15 PY 2011 VL 128 IS 8 BP 1751 EP 1757 DI 10.1002/ijc.25781 PG 7 WC Oncology SC Oncology GA 730MM UT WOS:000288037400001 PM 21344372 ER PT J AU Crea, F Serrat, MAD Hurt, EM Thomas, SB Danesi, R Farrar, WL AF Crea, Francesco Duhagon Serrat, Maria A. Hurt, Elaine M. Thomas, Suneetha B. Danesi, Romano Farrar, William L. TI BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE docetaxel; Polycomb; prostate ID SELF-RENEWAL; CELL-LINES; STEM-CELLS; EXPRESSION; RESISTANCE; APOPTOSIS; CHEMOSENSITIVITY; CHEMORESISTANCE; CHEMOTHERAPY; MITOXANTRONE AB The BMI1 oncogene promotes prostate cancer (PC) progression. High B- cell- specific Moloney murine leukemia virus integration site 1 (BMI1) expression predicts poor prognosis in PC patients. Recent evidence suggests that BMI1 may also play a role in docetaxel chemoresistance. However, mechanisms and clinical significance of BMI1- related chemoresistance have not been investigated. For this purpose, BMI1 was silenced in 2 PC cell lines (LNCaP and DU 145). Cell proliferation and apoptosis after docetaxel treatment were measured. Guanine oxidation was assessed by in- cell western. Global gene expression analysis was performed on BMI1 silenced cells. Oncomine database was used to compare in vitro data with gene expression in PC samples. BMI1 silencing had no effect on cell proliferation but significantly enhanced docetaxel- induced antitumor activity. Gene expression analysis demonstrated that BMI1 silencing downregulates a set of antioxidant genes. Docetaxel treatment increased guanine oxidation, whereas the antioxidant N- acetyl cysteine rescued docetaxel- induced cell death. Examination of clinical datasets revealed a positive correlation of BMI1 and antioxidant gene expression. BMI1controlled antioxidant genes were predictive of poor prognosis in PC patients. In conclusion, BMI1 enhances antioxidant response, thereby allowing PC survival after docetaxel- based chemotherapy. BMI1- controlled antioxidant genes are overexpressed in aggressive PC and should be tested as predictors of chemotherapy failure. Cancer Therapy C1 [Crea, Francesco; Duhagon Serrat, Maria A.; Hurt, Elaine M.; Farrar, William L.] NCI Frederick, Canc Stem Cell Sect, Lab Canc Prevent, Ctr Canc Res, Frederick, MD 21702 USA. [Crea, Francesco] Scuola Super Sant Anna, Pisa, Italy. [Duhagon Serrat, Maria A.] UDELAR, Lab Interacc Mol, Fac Ciencias, Dept Genet,Fac Med, Montevideo, Uruguay. [Thomas, Suneetha B.] NCI Frederick, Basic Sci Program, SAIC Frederick Inc, Frederick, MD 21702 USA. [Danesi, Romano] Pisa Med Sch, Div Pharmacol, Dept Internal Med, Pisa, Italy. RP Farrar, WL (reprint author), NCI Frederick, Canc Stem Cell Sect, Lab Canc Prevent, Ctr Canc Res, Bldg 560,Room 21-81, Frederick, MD 21702 USA. EM farrar@mail.ncifcrf.gov RI Crea, Francesco /I-8383-2015; OI Crea, Francesco/0000-0002-4903-2973 FU National Institutes of Health [N01-CO-12400] FX Grant sponsor: National Institutes of Health; Grant numbers: N01-CO-12400, Intramural Research Program NR 37 TC 37 Z9 43 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD APR 15 PY 2011 VL 128 IS 8 BP 1946 EP 1954 DI 10.1002/ijc.25522 PG 9 WC Oncology SC Oncology GA 730MM UT WOS:000288037400021 PM 20568112 ER PT J AU Makhnovskii, YA Berezhkovskii, AM Bogachev, LV Zitserman, VY AF Makhnovskii, Yu. A. Berezhkovskii, A. M. Bogachev, L. V. Zitserman, V. Yu. TI Driven Diffusion in a Periodically Compartmentalized Tube: Homogeneity versus Intermittency of Particle Motion SO JOURNAL OF PHYSICAL CHEMISTRY B LA English DT Article ID CROSS-SECTION; BOUNDARY HOMOGENIZATION; TRANSPORT; ARRAYS; PORE; SURFACES; MEDIA AB We study the effect of a driving force F on drift and diffusion of a point Brownian particle in a tube formed by identical cylindrical compartments, which create periodic entropy barriers for the particle motion along the tube axis. The particle transport exhibits striking features: the effective mobility monotonically decreases with increasing F, and the effective diffusivity diverges as F-->infinity, which indicates that the entropic effects in diffusive transport are enhanced by the driving force. Our consideration is based on two different scenarios of the particle motion at small and large F, homogeneous and intermittent, respectively. The scenarios are deduced from the careful analysis of statistics of the particle transition times between neighboring openings. From this qualitative picture, the limiting small-F and large-F behaviors of the effective mobility and diffusivity are derived analytically. Brownian dynamics simulations are used to find these quantities at intermediate values of the driving force for various compartment lengths and opening radii. This work shows that the driving force may lead to qualitatively different anomalous transport features, depending on the geometry design. C1 [Makhnovskii, Yu. A.] Russian Acad Sci, AV Topchiev Petrochem Synth Inst, Moscow 119991, Russia. [Berezhkovskii, A. M.] NIH, Math & Stat Comp Lab, Div Computat Biosci, Ctr Informat Technol, Bethesda, MD 20892 USA. [Bogachev, L. V.] Univ Leeds, Dept Stat, Sch Math, Leeds LS2 9JT, W Yorkshire, England. [Zitserman, V. Yu.] Russian Acad Sci, Joint Inst High Temp, Moscow 125412, Russia. RP Makhnovskii, YA (reprint author), Russian Acad Sci, AV Topchiev Petrochem Synth Inst, Leninsky Prospect 29, Moscow 119991, Russia. EM yuam@ips.ac.ru RI Makhnovskii, Yurii/B-1223-2014 OI Makhnovskii, Yurii/0000-0002-1517-536X FU Russian Foundation for Basic Research [10-03-00393]; DFG [436 RUS 113/722]; NIH, Center for Information Technology; Leverhulme FX We are grateful to Sergio Albeverio, Igor Goychuk, Peter Hanggi, Yuri Kondratiev, Fabio Marchesoni, Peter Talkner, and Gerhard Schmidt for the helpful discussions. Yu.A.M. and V.Yu.Z. thank the Russian Foundation for Basic Research for support (Grant No. 10-03-00393). Yu.A.M. was also partially supported by DFG (Grant 436 RUS 113/722). A.M.B. was supported by the Intramural Research Program of the NIH, Center for Information Technology. L.V.B. was partially supported by a Leverhulme Research Fellowship. NR 58 TC 9 Z9 9 U1 0 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1520-6106 J9 J PHYS CHEM B JI J. Phys. Chem. B PD APR 14 PY 2011 VL 115 IS 14 BP 3992 EP 4002 DI 10.1021/jp112393q PG 11 WC Chemistry, Physical SC Chemistry GA 746BI UT WOS:000289215600028 PM 21417298 ER PT J AU Sato, N Sabzevari, H Fu, S Ju, W Petrus, MN Bamford, RN Waldmann, TA Tagaya, Y AF Sato, Noriko Sabzevari, Helen Fu, Song Ju, Wei Petrus, Michael N. Bamford, Richard N. Waldmann, Thomas A. Tagaya, Yutaka TI Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15R alpha SO BLOOD LA English DT Article ID NATURAL-KILLER; TRANSGENIC MICE; IL-15 ACTIVITY; NK CELL; INTERLEUKIN-15; IL-15/IL-15R-ALPHA; DIFFERENTIATION; PROLIFERATION; HOMEOSTASIS; CYTOKINE AB IL-15 has growth-promoting effects on select lymphoid subsets, including natural killer (NK) cells, NK T cells, intraepithelial lymphocytes (IELs), CD8 T cells, and gamma delta-T cells. Constitutive expression of murine IL-15 in IL-15-transgenic mice was reported to cause T-NK leukemia. We investigated whether IL-15 expression is sufficient for leukemic transformation using a human IL-15-transgenic (IL-15Tg) mouse model. We noted that 100% of the mice observed over a 2-year period (n > 150) developed fatal expansions of CD8 T cells with NK markers, and determined that these cells expressed IL-15 receptor alpha (IL-15R alpha). The expression of IL-15R alpha on CD8 T cells appears to be required for uncontrolled aggressive lymphoproliferation, because none of the IL-15R alpha(-/-)-IL-15Tg mice that we followed for more than 2 years developed the fatal disease despite controlled expansion of CD8 T cells. In addition, in contrast to IL-15Tg mice, in which leukemia-like CD8 T cells expressed IL-15R alpha persistently, acutely activated normal CD8 T cells only transiently expressed IL-15R alpha. Inhibition of DNA methylation enabled sustained IL-15R alpha expression induced by activation. We present a scenario for IL-15Tg mice in which CD8 T cells that acquire constitutive persistent IL-15R alpha expression are at a selective advantage and become founder cells, outgrow other lymphocytes, and lead to the establishment of a leukemia-like condition. (Blood. 2011;117(15):4032-4040) C1 [Sato, Noriko; Fu, Song; Ju, Wei; Petrus, Michael N.; Waldmann, Thomas A.; Tagaya, Yutaka] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Sabzevari, Helen] NCI, Lab Tumor Biol & Immunol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Bamford, Richard N.] Transponics, Jacobus, PA USA. RP Waldmann, TA (reprint author), NCI, Metab Branch, Ctr Canc Res, NIH, Bldg 10,Rm 4N115,9000 Rockville Pike, Bethesda, MD 20892 USA. EM tawald@mail.nih.gov; ytagaya@ihv.umaryland.edu FU Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD FX This work was supported by intramural research funds of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. NR 29 TC 12 Z9 13 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD APR 14 PY 2011 VL 117 IS 15 BP 4032 EP 4040 DI 10.1182/blood-2010-09-307504 PG 9 WC Hematology SC Hematology GA 749YF UT WOS:000289507200019 PM 21304101 ER PT J AU Findeisen, HM Pearson, KJ Gizard, F Zhao, Y Qing, H Jones, KL Cohn, D Heywood, EB de Cabo, R Bruemmer, D AF Findeisen, Hannes M. Pearson, Kevin J. Gizard, Florence Zhao, Yue Qing, Hua Jones, Karrie L. Cohn, Dianne Heywood, Elizabeth B. de Cabo, Rafael Bruemmer, Dennis TI Oxidative Stress Accumulates in Adipose Tissue during Aging and Inhibits Adipogenesis SO PLOS ONE LA English DT Article ID INSULIN SENSITIVITY; ADIPOCYTE PRECURSORS; BODY-COMPOSITION; ANATOMIC SITE; RISK-FACTORS; PPAR-GAMMA; AGE; GLUTATHIONE; OBESITY; DIFFERENTIATION AB Aging constitutes a major independent risk factor for the development of type 2 diabetes and is accompanied by insulin resistance and adipose tissue dysfunction. One of the most important factors implicitly linked to aging and age-related chronic diseases is the accumulation of oxidative stress. However, the effect of increased oxidative stress on adipose tissue biology remains elusive. In this study, we demonstrate that aging in mice results in a loss of fat mass and the accumulation of oxidative stress in adipose tissue. In vitro, increased oxidative stress through glutathione depletion inhibits preadipocyte differentiation. This inhibition of adipogenesis is at least in part the result of reduced cell proliferation and an inhibition of G(1)-> S-phase transition during the initial mitotic clonal expansion of the adipocyte differentiation process. While phosphorylation of the retinoblastoma protein (Rb) by cyclin/cdk complexes remains unaffected, oxidative stress decreases the expression of S-phase genes downstream of Rb. This silencing of S phase gene expression by increased oxidative stress is mediated through a transcriptional mechanism involving the inhibition of E2F recruitment and transactivation of its target promoters. Collectively, these data demonstrate a previously unrecognized role of oxidative stress in the regulation of adipogenesis which may contribute to age-associated adipose tissue dysfunction. C1 [Findeisen, Hannes M.; Gizard, Florence; Zhao, Yue; Qing, Hua; Jones, Karrie L.; Cohn, Dianne; Heywood, Elizabeth B.; Bruemmer, Dennis] Univ Kentucky, Coll Med, Saha Cardiovasc Res Ctr, Lexington, KY 40536 USA. [Pearson, Kevin J.; Zhao, Yue; Bruemmer, Dennis] Univ Kentucky, Coll Med, Grad Ctr Nutr Sci, Lexington, KY USA. [de Cabo, Rafael] NIA, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA. RP Findeisen, HM (reprint author), Univ Kentucky, Coll Med, Saha Cardiovasc Res Ctr, Lexington, KY 40536 USA. EM Dennis.Bruemmer@uky.edu RI de Cabo, Rafael/J-5230-2016; OI de Cabo, Rafael/0000-0002-3354-2442; , rafael/0000-0003-2830-5693 FU American Diabetes Association (ADA) [1-09-CD-02]; National Institutes of Health COBRE on Obesity and Cardiovascular Diseases [P20 RR021954]; NIA, NIH FX These studies were supported by the American Diabetes Association (ADA Award No.: 1-09-CD-02), the National Institutes of Health COBRE on Obesity and Cardiovascular Diseases (P20 RR021954) and in part by the Intramural Research Program of the NIA, NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 48 TC 41 Z9 41 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 14 PY 2011 VL 6 IS 4 AR e18532 DI 10.1371/journal.pone.0018532 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 749XQ UT WOS:000289505600008 PM 21533223 ER PT J AU Sim, BKL Narum, DL Chattopadhyay, R Ahumada, A Haynes, JD Fuhrmann, SR Wingard, JN Liang, H Moch, JK Hoffman, SL AF Sim, B. Kim Lee Narum, David L. Chattopadhyay, Rana Ahumada, Adriana Haynes, J. David Fuhrmann, Steven R. Wingard, Jennifer N. Liang, Hong Moch, J. Kathleen Hoffman, Stephen L. TI Delineation of Stage Specific Expression of Plasmodium falciparum EBA-175 by Biologically Functional Region II Monoclonal Antibodies SO PLOS ONE LA English DT Article ID ERYTHROCYTE BINDING ANTIGEN; MALARIA PARASITES; RECEPTOR-BINDING; INFECTED ERYTHROCYTES; MEROZOITE INVASION; PROTEINS; SURFACE; VACCINE; FAMILY; DOMAIN AB Background: The malaria parasite Plasmodium falciparum EBA-175 binds its receptor sialic acids on glycophorin A when invading erythrocytes. The receptor-binding region (RII) contains two cysteine-rich domains with similar cysteine motifs (F1 and F2). Functional relationships between F1 and F2 domains and characterization of EBA-175 were studied using specific monoclonal antibodies (mAbs) against these domains. Methods and Findings: Five mAbs specific for F1 or F2 were generated. Three mAbs specific for F2 potently blocked binding of EBA-175 to erythrocytes, and merozoite invasion of erythrocytes (IC(50) 10 to 100 mu g/ml IgG in growth inhibition assays). A mAb specific for F1 blocked EBA-175 binding and merozoite invasion less effectively. The difference observed between the IC(50) of F1 and F2 mAbs was not due to differing association and disassociation rates as determined by surface plasmon resonance. Four of the mAbs recognized conformation-dependent epitopes within F1 or F2. Used in combination, F1 and F2 mAbs blocked the binding of native EBA-175 to erythrocytes and inhibited parasite invasion synergistically in vitro. MAb R217, the most potent, did not recognize sporozoites, 3-day hepatocyte stage parasites, nor rings, trophozoites, gametocytes, retorts, ookinetes, and oocysts but recognized 6-day hepatocyte stage parasites, and schizonts. Even though efficient at blocking binding to erythrocytes and inhibiting invasion into erythrocytes, MAb R217 did not inhibit sporozoite invasion and development in hepatocytes in vitro. Conclusions: The role of the F1 and F2 domains in erythrocyte invasion and binding was elucidated with mAbs. These mAbs interfere with native EBA-175 binding to erythrocyte in a synergistic fashion. The stage specific expression of EBA-175 showed that the primary focus of activity was the merozoite stage. A recombinant RII protein vaccine consisting of both F1 and F2 domains that could induce synergistic activity should be optimal for induction of antibody responses that interfere with merozoite invasion of erythrocytes. C1 [Sim, B. Kim Lee; Ahumada, Adriana; Hoffman, Stephen L.] Prot Potential LLC, Rockville, MD USA. [Narum, David L.] NIAID, Lab Malaria Immunol & Vaccinol, NIH, Rockville, MD USA. [Chattopadhyay, Rana; Hoffman, Stephen L.] Sanaria Inc, Rockville, MD USA. [Haynes, J. David; Moch, J. Kathleen] US Mil Malaria Vaccine Program, Silver Spring, MD USA. [Fuhrmann, Steven R.] Intercell USA, Gaithersburg, MD USA. [Wingard, Jennifer N.] Univ Virginia, Dept Mol Physiol & Biophys, Charlottesville, VA USA. [Liang, Hong] Infect Dis Res Inst, Seattle, WA USA. RP Sim, BKL (reprint author), Prot Potential LLC, Rockville, MD USA. EM ksim@protpot.com FU Phase II National Institute of Allergy and Infectious Diseases (NIAID) Small Business Innovative Research [AI36758]; EntreMed Inc; Protein Potential; Sanaria Inc. FX This work was partially funded by a Phase II National Institute of Allergy and Infectious Diseases (NIAID) Small Business Innovative Research Grant, AI36758 supplement awarded to BKLS. The authors BKLS, DLN, SRF, JNW and HL were employees of EntreMed Inc (funder). Currently BKLS, AA and SLH are employees of Protein Potential (funder) and the role they played on this manuscript was funded by Protein Potential. As the authors BKLS, DLN, SRF, JNW and HL were employees of EntreMed Inc. and BLKS, AA and SLH are employees of Protein Potential, the funders EntreMed and Protein Potential did have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. RC and SLH are also employees of Sanaria Inc. (funder) but their role on this manuscript was funded by Protein Potential. SRF is currently an employee of Intercell but only reviewed the manuscript at this time. Intercell provided no support for this project. NR 41 TC 9 Z9 9 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 14 PY 2011 VL 6 IS 4 AR e18393 DI 10.1371/journal.pone.0018393 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 749XQ UT WOS:000289505600004 PM 21533224 ER PT J AU Tang, J Maddali, K Metifiot, M Sham, YY Vince, R Pommier, Y Wang, ZQ AF Tang, Jing Maddali, Kasthuraiah Metifiot, Mathieu Sham, Yuk Y. Vince, Robert Pommier, Yves Wang, Zhengqiang TI 3-Hydroxypyrimidine-2,4-diones as an Inhibitor Scaffold of HIV Integrase SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; DYNAMIC PHARMACOPHORE MODEL; DIKETO ACID PHARMACOPHORE; DNA STRAND TRANSFER; REVERSE-TRANSCRIPTASE; 1-<(2-HYDROXYETHOXY)METHYL>-6-(PHENYLTHIO)THYMINE HEPT; ANTI-HIV-1 ACTIVITY; RATIONAL DESIGN; DUAL INHIBITORS; RALTEGRAVIR AB Integrase (IN) represents a clinically validated target for the development of antivirals against human immunodeficiency virus (HIV). Inhibitors with a novel structure core are essential for combating resistance associated with known IN inhibitors (IN Is). We have previously disclosed a novel dual inhibitor scaffold of HIV IN and reverse transcriptase (RT). Here we report the complete structure activity relationship (SAR), molecular modeling, and resistance profile of this inhibitor type on IN inhibition. These studies support an antiviral mechanism of dual inhibition against both IN and RT and validate 3-hydroxypyrimidine-2,4-diones as an IN inhibitor scaffold. C1 [Tang, Jing; Sham, Yuk Y.; Vince, Robert; Wang, Zhengqiang] Univ Minnesota, Acad Hlth Ctr, Ctr Drug Design, Minneapolis, MN 55455 USA. [Maddali, Kasthuraiah; Metifiot, Mathieu; Pommier, Yves] NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA. RP Wang, ZQ (reprint author), Univ Minnesota, Acad Hlth Ctr, Ctr Drug Design, Minneapolis, MN 55455 USA. EM wangx472@umm.edu FU Center for Drug Design at the University of Minnesota; Center for Cancer Research; National Cancer Institute; NIH FX This research was supported by the Center for Drug Design at the University of Minnesota, the Center for Cancer Research, Intramural Program of the National Cancer Institute, and an NIH grant from IATAP (Intramural AIDS Targeted Antiviral Program). We thank Roger Ptak at Southern Research Institute for the antiviral assay and the Minnesota Supercomputing Institute for computing resources. NR 51 TC 29 Z9 32 U1 0 U2 4 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD APR 14 PY 2011 VL 54 IS 7 BP 2282 EP 2292 DI 10.1021/jm1014378 PG 11 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 746BJ UT WOS:000289215700025 PM 21381765 ER PT J AU Zhao, XC AF Zhao, Xiongce TI Self-Assembly of DNA Segments on Graphene and Carbon Nanotube Arrays in Aqueous Solution: A Molecular Simulation Study SO JOURNAL OF PHYSICAL CHEMISTRY C LA English DT Article ID BIOMEDICAL APPLICATIONS; FULLERENE DERIVATIVES; C-60 DERIVATIVES; DYNAMICS; ADSORPTION; BIOSENSORS; INSERTION; TOXICITY; DELIVERY; WATER AB Molecular dynamics simulations were performed to study the interaction of double-stranded DNA segments with the surfaces of graphene and carbon nanotube arrays in aqueous solution. Several different kinds of self-assembly phenomena were observed. First, it is found that a DNA segment can 'stand up' on the carbon surfaces with its helix axis perpendicular to the surfaces of graphene or nanotube arrays to form a forestlike structure. Second, a DNA segment can also lie on the carbon surface with its axis parallel to the surface if both of its ends can form stable structure with the carbon surfaces. In the latter case, the ending basepairs of the DNA are broken due to severe deformations. Third, it is observed that short DNA segments can concatenate to each other to form a longer DNA when they are placed in the grooves of nanotube bundles. The self-assembly observed in this study usually happens in less than 50 ns. Exploration on the molecular details and self-assembly mechanism indicates the primary driving force is the pi stacking interaction between the ending basepairs of DNA and the carbon rings. This study confirms the dominant role of hydrophobic pi stacking in the interaction between nucleotides and carbon-based nanosurfaces in aqueous environment. C1 [Zhao, Xiongce] Oak Ridge Natl Lab, Ctr Nanophase Mat Sci, Oak Ridge, TN 37831 USA. RP Zhao, XC (reprint author), NIH, Bldg 10, Bethesda, MD 20892 USA. EM xiongce.zhao@nih.gov RI sriram, dodda/F-1952-2011 FU Oak Ridge National Laboratory by the Division of Scientific User Facilities, U.S. Department of Energy; Office of Science of the U.S. Department of Energy [DE-AC02-05CH11231] FX The author thanks Peter T. Cummings for many helpful discussions. This research was conducted at the Center for Nano phase Materials Sciences, which is sponsored at Oak Ridge National Laboratory by the Division of Scientific User Facilities, U.S. Department of Energy. This research used resources of the National Energy Research Scientific Computing Center, which is supported by the Office of Science of the U.S. Department of Energy under Contract No. DE-AC02-05CH11231. NR 44 TC 45 Z9 46 U1 2 U2 54 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1932-7447 J9 J PHYS CHEM C JI J. Phys. Chem. C PD APR 14 PY 2011 VL 115 IS 14 BP 6181 EP 6189 DI 10.1021/jp110013r PG 9 WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA 746BG UT WOS:000289215400002 ER PT J AU Zhou, Z Feng, HQ Zhou, BR Ghirlando, R Hu, KF Zwolak, A Jenkins, LMM Xiao, H Tjandra, N Wu, C Bai, YW AF Zhou, Zheng Feng, Hanqiao Zhou, Bing-Rui Ghirlando, Rodolfo Hu, Kaifeng Zwolak, Adam Jenkins, Lisa M. Miller Xiao, Hua Tjandra, Nico Wu, Carl Bai, Yawen TI Structural basis for recognition of centromere histone variant CenH3 by the chaperone Scm3 SO NATURE LA English DT Article ID FISSION YEAST SCM3; SACCHAROMYCES-CEREVISIAE; SEDIMENTATION-VELOCITY; ANALYTICAL ULTRACENTRIFUGATION; PROTEIN; NMR; NUCLEOSOMES; CHROMATIN; HJURP; CSE4 AB The centromere is a unique chromosomal locus that ensures accurate segregation of chromosomes during cell division by directing the assembly of a multiprotein complex, the kinetochore(1). The centromere is marked by a conserved variant of conventional histone H3 termed CenH3 or CENP-A (ref. 2). A conserved motif of CenH3, the CATD, defined by loop 1 and helix 2 of the histone fold, is necessary and sufficient for specifying centromere functions of CenH3 (refs 3, 4). The structural basis of this specification is of particular interest. Yeast Scm3 and human HJURP are conserved non-histone proteins that interact physically with the (CenH3-H4) 2 heterotetramer and are required for the deposition of CenH3 at centromeres in vivo(5-13). Here we have elucidated the structural basis for recognition of budding yeast (Saccharomyces cerevisiae) CenH3 (called Cse4) by Scm3. We solved the structure of the Cse4-binding domain (CBD) of Scm3 in complex with Cse4 and H4 in a single chain model. An alpha-helix and an irregular loop at the conserved amino terminus and a shorter alpha-helix at the carboxy terminus of Scm3(CBD) wraps around the Cse4-H4 dimer. Four Cse4-specific residues in the N-terminal region of helix 2 are sufficient for specific recognition by conserved and functionally important residues in the N-terminal helix of Scm3 through formation of a hydrophobic cluster. Scm3(CBD) induces major conformational changes and sterically occludes DNA-binding sites in the structure of Cse4 and H4. These findings have implications for the assembly and architecture of the centromeric nucleosome. C1 [Zhou, Zheng; Feng, Hanqiao; Zhou, Bing-Rui; Xiao, Hua; Wu, Carl; Bai, Yawen] NCI, Biochem & Mol Biol Lab, Bethesda, MD 20892 USA. [Ghirlando, Rodolfo] NIDDKD, Mol Biol Lab, Bethesda, MD 20892 USA. [Hu, Kaifeng] Univ Wisconsin, Natl Magnet Resonance Facil Madison, Madison, WI 53706 USA. [Zwolak, Adam; Tjandra, Nico] NHLBI, Lab Mol Biophys, NIH, Bethesda, MD 20892 USA. [Jenkins, Lisa M. Miller] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA. RP Bai, YW (reprint author), NCI, Biochem & Mol Biol Lab, Bethesda, MD 20892 USA. EM yawen@helix.nih.gov RI Ghirlando, Rodolfo/A-8880-2009; Zhou, Bing-Rui/D-4766-2009 FU NCI; NIDDK; NHLBI FX We thank J. Ying, K. Varney, J. F. Ellena and J. Gruschus for help collecting NMR spectra, A. Bax for discussion, C. Klee and M. Lichten for comments on the manuscript, and D. Cleveland for plasmids of human CENP-A and H4 histones. This work is supported by the intramural research programs of NCI, NIDDK and NHLBI. NR 39 TC 66 Z9 68 U1 0 U2 17 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD APR 14 PY 2011 VL 472 IS 7342 BP 234 EP 237 DI 10.1038/nature09854 PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 749LR UT WOS:000289469100046 PM 21412236 ER PT J AU Huskins, WC Huckabee, CM O'Grady, NP Murray, P Kopetskie, H Zimmer, L Walker, ME Sinkowitz-Cochran, RL Jernigan, JA Samore, M Wallace, D Goldmann, DA AF Huskins, W. Charles Huckabee, Charmaine M. O'Grady, Naomi P. Murray, Patrick Kopetskie, Heather Zimmer, Louise Walker, Mary Ellen Sinkowitz-Cochran, Ronda L. Jernigan, John A. Samore, Matthew Wallace, Dennis Goldmann, Donald A. CA STAR ICU Trial Investigators TI Intervention to Reduce Transmission of Resistant Bacteria in Intensive Care SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID PREVENTING NOSOCOMIAL TRANSMISSION; STAPHYLOCOCCUS-AUREUS MRSA; ACTIVE SURVEILLANCE; NASAL CARRIAGE; GOWN-USE; ENTEROCOCCI; ACQUISITION; UNIT; IMPACT; CHLORHEXIDINE AB BACKGROUND Intensive care units (ICUs) are high-risk settings for the transmission of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE). METHODS In a cluster-randomized trial, we evaluated the effect of surveillance for MRSA and VRE colonization and of the expanded use of barrier precautions (intervention) as compared with existing practice (control) on the incidence of MRSA or VRE colonization or infection in adult ICUs. Surveillance cultures were obtained from patients in all participating ICUs; the results were reported only to ICUs assigned to the intervention. In intervention ICUs, patients who were colonized or infected with MRSA or VRE were assigned to care with contact precautions; all the other patients were assigned to care with universal gloving until their discharge or until surveillance cultures obtained at admission were reported to be negative. RESULTS During a 6-month intervention period, there were 5434 admissions to 10 intervention ICUs, and 3705 admissions to 8 control ICUs. Patients who were colonized or infected with MRSA or VRE were assigned to barrier precautions more frequently in intervention ICUs than in control ICUs (a median of 92% of ICU days with either contact precautions or universal gloving [51% with contact precautions and 43% with universal gloving] in intervention ICUs vs. a median of 38% of ICU days with contact precautions in control ICUs, P<0.001). In intervention ICUs, health care providers used clean gloves, gowns, and hand hygiene less frequently than required for contacts with patients assigned to barrier precautions; when contact precautions were specified, gloves were used for a median of 82% of contacts, gowns for 77% of contacts, and hand hygiene after 69% of contacts, and when universal gloving was specified, gloves were used for a median of 72% of contacts and hand hygiene after 62% of contacts. The mean (+/- SE) ICU-level incidence of events of colonization or infection with MRSA or VRE per 1000 patient-days at risk, adjusted for baseline incidence, did not differ significantly between the intervention and control ICUs (40.4 +/- 3.3 and 35.6 +/- 3.7 in the two groups, respectively; P = 0.35). CONCLUSIONS The intervention was not effective in reducing the transmission of MRSA or VRE, although the use of barrier precautions by providers was less than what was required. C1 [Huskins, W. Charles] Mayo Clin, Div Pediat Infect Dis, Rochester, MN 55905 USA. [Huckabee, Charmaine M.; Kopetskie, Heather; Zimmer, Louise; Wallace, Dennis] Rho Fed Syst Div, Chapel Hill, NC USA. [O'Grady, Naomi P.; Murray, Patrick] NIH, Ctr Clin, Bethesda, MD 20892 USA. [Walker, Mary Ellen] Univ Alabama, Birmingham, AL USA. [Sinkowitz-Cochran, Ronda L.; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Infect Dis, Atlanta, GA USA. [Samore, Matthew] Univ Utah, Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [Goldmann, Donald A.] Harvard Univ, Sch Med, Boston, MA USA. [Goldmann, Donald A.] Inst Healthcare Improvement, Cambridge, MA USA. RP Huskins, WC (reprint author), Mayo Clin, Div Pediat Infect Dis, 200 1st Ave SW, Rochester, MN 55905 USA. EM huskins.charles@mayo.edu OI Huskins, W. Charles/0000-0002-9989-175X FU National Institute of Allergy and Infectious Diseases [N01 AI-15440, N01 AI-15441]; National Center for Research Resources [M01-RR-00585, UL1-RR024150, M01-RR-00039]; General Clinical Research Center at Emory University; Merck; Elan Pharmaceuticals; Roche Diagnostics; Kimberly Clark; Medegen FX Supported by contracts (N01 AI-15440 and N01 AI-15441) from the National Institute of Allergy and Infectious Diseases to the Bacteriology and Mycology Study Group clinical research network and the Bacteriology and Mycology Statistical and Operations Unit data coordinating center; by institutional grants (M01-RR-00585, UL1-RR024150, and M01-RR-00039) from the National Center for Research Resources to the Mayo Clinic Center for Translational Science Activities and the General Clinical Research Center at Emory University; and by Merck, Elan Pharmaceuticals, Roche Diagnostics, and Kimberly Clark.; Dr. Huskins reports receiving consulting fees from Roche Diagnostics and serving on an advisory board for GlaxoSmithKline; and Dr. Goldmann, receiving consulting fees from Medegen and serving on an advisory board for BioNeutral Group. No other potential conflict of interest relevant to this article was reported. NR 39 TC 172 Z9 180 U1 1 U2 27 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 14 PY 2011 VL 364 IS 15 BP 1407 EP 1418 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 749LD UT WOS:000289467200005 PM 21488763 ER PT J AU Ungerleider, LG Bell, AH AF Ungerleider, Leslie G. Bell, Andrew H. TI Uncovering the visual "alphabet": Advances in our understanding of object perception SO VISION RESEARCH LA English DT Review DE Object recognition; Inferior temporal cortex; fMRI; Electrophysiology; Monkey; Vision ID INFERIOR TEMPORAL CORTEX; MONKEY INFEROTEMPORAL CORTEX; HUMAN EXTRASTRIATE CORTEX; LATERAL OCCIPITAL COMPLEX; MACAQUE CEREBRAL-CORTEX; FUSIFORM FACE AREA; LONG-TERM-MEMORY; RHESUS-MONKEY; HUMAN BRAIN; CORTICAL CONNECTIONS AB The ability to rapidly and accurately recognize visual stimuli represents a significant computational challenge. Yet, despite such complexity, the primate brain manages this task effortlessly. How it does so remains largely a mystery. The study of visual perception and object recognition was once limited to investigations of brain-damaged individuals or lesion experiments in animals. However, in the last 25 years, new methodologies, such as functional neuroimaging and advances in electrophysiological approaches, have provided scientists with the opportunity to examine this problem from new perspectives. This review highlights how some of these recent technological advances have contributed to the study of visual processing and where we now stand with respect to our understanding of neural mechanisms underlying object recognition. Published by Elsevier Ltd. C1 [Ungerleider, Leslie G.; Bell, Andrew H.] NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA. RP Ungerleider, LG (reprint author), NIMH, Lab Brain & Cognit, NIH, 10 Ctr Dr,4C104, Bethesda, MD 20892 USA. EM ungerlel@mail.nih.gov RI Ren, Huorong/C-9810-2012; OI Bell, Andrew/0000-0001-8420-4622 FU Intramural NIH HHS [Z99 MH999999] NR 177 TC 24 Z9 24 U1 2 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0042-6989 J9 VISION RES JI Vision Res. PD APR 13 PY 2011 VL 51 IS 7 SI SI BP 782 EP 799 DI 10.1016/j.visres.2010.10.002 PG 18 WC Neurosciences; Ophthalmology SC Neurosciences & Neurology; Ophthalmology GA 757CI UT WOS:000290061300012 PM 20971130 ER PT J AU Botos, I Segal, DM Davies, DR AF Botos, Istvan Segal, David M. Davies, David R. TI The Structural Biology of Toll-like Receptors SO STRUCTURE LA English DT Review ID INNATE IMMUNE-RESPONSE; GLYCOPROTEIN IB-ALPHA; LEUCINE-RICH REPEATS; CRYSTAL-STRUCTURE; TIR-DOMAIN; BACTERIAL FLAGELLIN; PATHOGEN RECOGNITION; ANTIGEN RECOGNITION; V(D)J RECOMBINATION; TLR4-MD-2 COMPLEX AB The membrane-bound Toll-like receptors (TLRs) trigger innate immune responses after recognition of a wide variety of pathogen-derived compounds. Despite the wide range of ligands recognized by TLRs, the receptors share a common structural framework in their extracellular, ligand-binding domains. These domains all adopt horseshoe-shaped structures built from leucine-rich repeat motifs. Typically, on ligand binding, two extracellular domains form an "m"-shaped dimer sandwiching the ligand molecule bringing the transmembrane and cytoplasmic domains in close proximity and triggering a downstream signaling cascade. Although the ligand-induced dimerization of these receptors has many common features, the nature of the interactions of the TLR extracellular domains with their ligands varies markedly between TLR paralogs. C1 [Botos, Istvan; Davies, David R.] NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA. [Segal, David M.] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA. RP Davies, DR (reprint author), NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA. EM david.davies@nih.gov FU National Institutes of Health (NIDDK); National Institutes of Health (NCI); NIAID FX This work was supported by the Intramural Research Program of the National Institutes of Health (NIDDK and NCI) and by a National Institutes of Health/Food and Drug Administration intramural biodefense award from NIAID. NR 82 TC 146 Z9 153 U1 4 U2 42 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0969-2126 EI 1878-4186 J9 STRUCTURE JI Structure PD APR 13 PY 2011 VL 19 IS 4 BP 447 EP 459 DI 10.1016/j.str.2011.02.004 PG 13 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 751BN UT WOS:000289592600004 PM 21481769 ER PT J AU Shiels, MS Pfeiffer, RM Hall, HI Li, JM Goedert, JJ Morton, LM Hartge, P Engels, EA AF Shiels, Meredith S. Pfeiffer, Ruth M. Hall, H. Irene Li, Jianmin Goedert, James J. Morton, Lindsay M. Hartge, Patricia Engels, Eric A. TI Proportions of Kaposi Sarcoma, Selected Non-Hodgkin Lymphomas, and Cervical Cancer in the United States Occurring in Persons With AIDS, 1980-2007 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID NERVOUS-SYSTEM LYMPHOMA; INCIDENCE PATTERNS; SURVEILLANCE DATA; HIV; TRENDS; ADULTS; RISK; RECOMMENDATIONS; ADOLESCENTS; MALIGNANCIES AB Context Given the higher risk of AIDS-defining malignancies that include Kaposi sarcoma (KS), certain non-Hodgkin lymphomas (NHLs), and cervical cancer in persons with human immunodeficiency virus (HIV) infection, the HIV epidemic has likely contributed to the overall numbers of these cancers in the United States. Objective To quantify the proportions of KS, AIDS-defining NHLs, and cervical cancer in the United States that occurred among persons with AIDS from 1980 to 2007. Design, Setting, and Participants The HIV/AIDS Cancer Match Study (19802007) linked data from 16 US HIV/AIDS and cancer registries to identify cases with and without AIDS for KS, AIDS-defining NHLs (ie, diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL], and central nervous system [CNS] lymphoma), and cervical cancer. Using linked data, we derived cancer rates for persons with and without AIDS. To estimate national counts, the rates were applied to national AIDS surveillance and US Census data. Main Outcome Measure Proportion of AIDS-defining malignancies in the United States occurring in persons with AIDS. Results In the United States, an estimated 81.6% (95% confidence interval [CI], 81.2%-81.9%) of 83 252 KS cases, 6.0% (95% CI, 5.8%-6.1%) of 351 618 DLBCL cases, 19.9% (95% CI, 18.1%-21.7%) of 17 307 BL cases, 27.1% (95% CI, 26.1%-28.1%) of 27 265 CNS lymphoma cases, and 0.42% (95% CI, 0.37%-0.47%) of 375 452 cervical cancer cases occurred among persons with AIDS during 1980-2007. The proportion of KS and AIDS-defining NHLs in persons with AIDS peaked in the early 1990s (1990-1995: KS, 90.5% [95% CI, 90.2%-90.8%]; DLBCL, 10.2% [95% CI, 9.9%-10.5%]; BL, 27.8% [95% CI, 25.0%-30.5%]; and CNS lymphoma, 48.3% [95% CI, 46.7%-49.8%]; all P < .001 [compared with 1980-1989]) and then declined (2001-2007: KS, 70.5% [95% CI, 68.1%-73.0%]; DLBCL, 4.7% [95% CI, 4.3%-5.2%]; BL, 21.5% [95% CI, 17.7%-25.4%]; and CNS lymphoma, 12.9% [95% CI, 10.5%-15.3%]; all P < .001 [compared with 1990-1995]). The proportion of cervical cancers in persons with AIDS increased over time (1980-1989: 0.11% [95% CI, 0.09%-0.13%]; 2001-2007: 0.71% [95% CI, 0.51%-0.91%]; P < .001). Conclusions In the United States, the estimated proportions of AIDS-defining malignancies that occurred among persons with AIDS were substantial, particularly for KS and some NHLs. Except for cervical cancer, the proportions of AIDS-defining malignancies occurring among persons with AIDS peaked in the mid-1990s and then declined. JAMA. 2011;305(14):1450-1459 www.jama.com C1 [Shiels, Meredith S.] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20892 USA. [Hall, H. Irene; Li, Jianmin] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Shiels, MS (reprint author), NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS 7059, Rockville, MD 20892 USA. EM shielsms@mail.nih.gov RI Morton, Lindsay/B-5234-2015 OI Morton, Lindsay/0000-0001-9767-2310 FU National Cancer Institute FX This study was funded by the Intramural Research Program of the National Cancer Institute. NR 37 TC 60 Z9 61 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 13 PY 2011 VL 305 IS 14 BP 1450 EP 1459 DI 10.1001/jama.2011.396 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 748WQ UT WOS:000289424100022 PM 21486978 ER PT J AU Marthas, ML Van Rompay, KKA Abbott, Z Earl, P Buonocore-Buzzelli, L Moss, B Rose, NF Rose, JK Kozlowski, PA Abel, K AF Marthas, Marta L. Van Rompay, Koen K. A. Abbott, Zachary Earl, Patricia Buonocore-Buzzelli, Linda Moss, Bernard Rose, Nina F. Rose, John K. Kozlowski, Pamela A. Abel, Kristina TI Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques SO VACCINE LA English DT Article DE Pediatric HIV vaccine; Mucosal immunity; SIV ID SIMIAN IMMUNODEFICIENCY VIRUS; VESICULAR STOMATITIS-VIRUS; CD4(+) T-CELLS; NEWBORN RHESUS MACAQUES; AGE-RELATED-CHANGES; LYMPHOCYTE SUBSETS; HEALTHY-CHILDREN; PROTECT INFANT; INFECTION; TRANSMISSION AB Despite antiretroviral medications, the rate of pediatric HIV-1 infections through breast-milk transmission has been staggering in developing countries. Therefore, the development of a vaccine to protect vulnerable infant populations should be actively pursued. We previously demonstrated that oral immunization of newborn macaques with vesicular stomatitis virus expressing simian immunodeficiency virus genes (VSV-SIV) followed 2 weeks later by an intramuscular boost with modified vaccinia ankara virus expressing SIV (MVA-SIV) successfully induced Sly-specific T and B cell responses in multiple lymphoid tissues, including the tonsil and intestine [13]. In the current study, we tested the oral VSV-SIV prime/systemic MVA-SIV boost vaccine for efficacy against multiple oral SIVmac251 challenges starting two weeks after the booster vaccination. The vaccine did not prevent Sly infection. However, in vaccinated infants, the level of SIV-specific plasma IgA (but not IgG) at the time of challenge was inversely correlated with peak viremia. In addition, the levels of Sly-specific IgA in saliva and plasma were inversely correlated with viral load at euthanasia. Animals with tonsils that contained higher frequencies of Sly-specific TNF-alpha- or IFN-gamma-producing CD8(+) T cells and central memory T cells at euthanasia also had lower viremia. Interestingly, a marked depletion of CD25(+)FoxP3(+)CD4(+) T cells was observed in the tonsils as well as the intestine of these animals, implying that T regulatory cells may be a major target of SIV infection in infant macaques. Overall, the data suggest that, in infant macaques orally infected with Sly, the co-induction of local antiviral cytotoxic T cells and T regulatory cells that promote the development of IgA responses may result in better control of viral replication. Thus, future vaccination efforts should be directed towards induction of IgA and mucosal T cell responses to prevent or reduce virus replication in infants. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Abel, Kristina] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA. [Marthas, Marta L.; Van Rompay, Koen K. A.; Abbott, Zachary] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA. [Earl, Patricia; Moss, Bernard] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA. [Buonocore-Buzzelli, Linda; Rose, Nina F.; Rose, John K.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA. [Kozlowski, Pamela A.] Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA USA. RP Abel, K (reprint author), Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Genet Med Bldg,Rm 2047,120 Mason Farm Rd,CB 7042, Chapel Hill, NC 27599 USA. EM abelk@med.unc.edu FU NIH/NIAID [R01 AI062518]; Louisiana Vaccine Center; Louisiana Board of Regents; National Center for Research Resources (NCRR; a component of the National Institutes of Health (NIH)) [RR00169] FX This work was supported by the NIH/NIAID grant R01 AI062518 to MM, and, in part, by the Louisiana Vaccine Center and the South Louisiana Institute for Infectious Disease Research sponsored by the Louisiana Board of Regents. The animal studies at the CNPRC were supported by grant RR00169 from the National Center for Research Resources (NCRR; a component of the National Institutes of Health (NIH)). SIVmac251 was obtained from the Analytical Core of the CNPRC. The SIV gag peptide pool was from the AIDS Research and Reference Reagent Program (Division of AIDS, NIAID, NIH). Dr. Jeff Lifson (AIDS and Cancer Virus Program, National Cancer Institute at Frederick, Frederick, MD) provided aldrithiol-2 inactivated SIVmac239 particles. We also thank the Qualitative Molecular Diagnostics Core of the AIDS Vaccine Program at SAIC Frederick/NCI for assistance with the quantitation of plasma viral RNA. In addition, we are indebted to the veterinary staff at the CNPRC, and would like to thank Yongzhi Geng and Robert L. Wilson for technical assistance in the studies, and Jeffrey Americo for preparation of the MVA viruses. The contents of this publication though are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH. NR 43 TC 20 Z9 21 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 12 PY 2011 VL 29 IS 17 BP 3124 EP 3137 DI 10.1016/j.vaccine.2011.02.051 PG 14 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 764BJ UT WOS:000290603100008 PM 21377510 ER PT J AU Talaat, KR Karron, RA Luke, CJ Thumar, B McMahon, BA Chen, GL Lamirande, EW Jin, H Coelingh, KL Kemble, G Subbarao, K AF Talaat, Kawsar R. Karron, Ruth A. Luke, Catherine J. Thumar, Bhagvanji McMahon, Bridget A. Chen, Grace L. Lamirande, Elaine W. Jin, Hong Coelingh, Kathy L. Kemble, George Subbarao, Kanta TI An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults SO VACCINE LA English DT Article DE H6N1; Avian influenza; Vaccine; Live attenuated ID A H5N1 VIRUS; HUMAN INFECTION; SOUTHERN CHINA; HONG-KONG; H9N2; RESPONSES; ANTIBODY; HUMANS; VOLUNTEERS; CHICKENS AB Background: We describe the results of an open label Phase I trial of a live attenuated H6N1 influenza virus vaccine (ClinicalTrials.gov Identifier: NCT00734175). Methods and findings: We evaluated the safety, infectivity, and immunogenicity of two doses of 10(7) TCID50 of the H6N1 Teal HK 97/AA ca vaccine, a cold-adapted and temperature sensitive live, attenuated influenza vaccine (LAIV) in healthy seronegative adults. Twenty-two participants received the first dose of the vaccine, and 18 received the second dose of vaccine 4 weeks later. The vaccine had a safety profile similar to that of other investigational LAIVs bearing avian hemagglutinin (HA) and neuraminidase (NA) genes. The vaccine was highly restricted in replication: two participants had virus detectable by rRT-PCR beyond day 1 after each dose. Antibody responses to the vaccine were also restricted: 43% of participants developed a serum antibody response as measured by any assay: 5% by hemagglutination-inhibition assay, 5% by microneutralization assay, 29% by ELISA for H6 HA-specific IgG and 24% by ELISA for H6 HA specific IgA after either 1 or 2 doses. Following the second dose, vaccine specific IgG and IgA secreting cells as measured by ELISPOT increased from a mean of 0.6 to 9.2/10(6) PBMCs and from 0.2 to 2.2/10(6) PBMCs, respectively. Conclusion: The H6N1 LAIV had a safety profile similar to that of LAIV bearing other HA and NA genes, but was highly restricted in replication in healthy seronegative adults. The H6N1 LAIV was also not as immunogenic as the seasonal LAIV. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Talaat, Kawsar R.; Karron, Ruth A.; Thumar, Bhagvanji; McMahon, Bridget A.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Baltimore, MD 21205 USA. [Luke, Catherine J.; Chen, Grace L.; Lamirande, Elaine W.; Subbarao, Kanta] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Jin, Hong; Coelingh, Kathy L.; Kemble, George] MedImmune, Mountain View, CA 94043 USA. RP Talaat, KR (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Baltimore, MD 21205 USA. EM ktalaat@jhsph.edu FU NIAID, NIH; Laboratory of Infectious Diseases, NIAID [AI-0155]; MedImmune FX We wish to thank Ruval Comendador, Jasmine Jennings and Paula Williams-Soro for expert clinical assistance, Susan DiLorenzo and Nicole Yoder for expert technical assistance. We would also like to thank Zhongying Chen, Weidong Cui, Kathy Wang, Silas Nwagwu, Alfred Pan, Lynne Fitch, Patricia Ryan, So-Ching Brazer, David Prichett, and Edith Matsuyama of MedImmune for vaccine manufacturing and testing. This research was supported by the Intramural Research Program of the NIAID, NIH. This research was performed as a Cooperative Research and Development Agreement (CRADA) (CRADA No: AI-0155) between the Laboratory of Infectious Diseases, NIAID and MedImmune. NR 32 TC 23 Z9 23 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 12 PY 2011 VL 29 IS 17 BP 3144 EP 3148 DI 10.1016/j.vaccine.2011.02.043 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 764BJ UT WOS:000290603100010 PM 21377509 ER PT J AU Brocca-Cofano, E McKinnon, K Demberg, T Venzon, D Hidajat, R Xiao, P Daltabuit-Test, M Patterson, LJ Robert-Guroff, M AF Brocca-Cofano, Egidio McKinnon, Katherine Demberg, Thorsten Venzon, David Hidajat, Rachmat Xiao, Peng Daltabuit-Test, Mara Patterson, L. Jean Robert-Guroff, Marjorie TI Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia SO VACCINE LA English DT Article DE Memory B cells; Rhesus macaque; Simian immunodeficiency virus; Vaccine; Replication-competent adenovirus; recombinant ID DEPENDENT CELLULAR CYTOTOXICITY; HELPER T-CELLS; PROTECTIVE EFFICACY; PLASMA-CELLS; SHIV89.6P CHALLENGE; ANTIGEN; NAIVE; SIVMAC251; CD27; IMMUNIZATION AB An effective HIV vaccine requires strong systemic and mucosal, cellular and humoral immunity. Numerous non-human primate studies have investigated memory T cells, but not memory B cells. Humoral immunologic memory is mediated by long-lived antibody-secreting plasma cells and differentiation of memory B cells into short-lived plasma blasts following re-exposure to immunizing antigen. Here we studied memory B cells in vaccinated rhesus macaques. PBMC were stimulated polyclonally using CD40 Ligand, IL-21 and CpG to induce B cell proliferation and differentiation into antibody secreting cells (ASCs). Flow cytometry was used for phenotyping and evaluating proliferation by CFSE dilution. B cell responses were quantified by ELISPOT. Methodology was established using PBMC of vaccinated elite-controller macaques that exhibited strong, multi-functional antibody activities. Subsequently, memory B cells elicited by two replicating Ad-recombinant prime/envelope boost regimens were retrospectively evaluated pre- and post-Sly and SHIV challenges. The vaccine regimens induced SIV and HIV Env-specific IgG and IgA memory B cells. Prior to challenge, IgA memory B cells were more numerous than IgG memory B cells, reflecting the mucosal priming immunizations. Pre- and post-challenge memory B cells were correlated with functional antibody responses including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell-mediated viral inhibition (ADCVI) and transcytosis inhibition. Post-challenge, Env-specific IgG and IgA memory B cells were correlated with reduced chronic viremia. We conclude that functional antibody responses elicited by our prime/boost regimen were effectively incorporated into the memory B cell pool where they contributed to control of viremia following re-exposure to the immunizing antigen. Published by Elsevier Ltd. C1 [Brocca-Cofano, Egidio; McKinnon, Katherine; Demberg, Thorsten; Hidajat, Rachmat; Xiao, Peng; Daltabuit-Test, Mara; Patterson, L. Jean; Robert-Guroff, Marjorie] NCI, Vaccine Branch, NIH, Bethesda, MD 20892 USA. [Venzon, David] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA. RP Robert-Guroff, M (reprint author), NCI, Vaccine Branch, NIH, 41 Medlars Dr,Bldg 41,Room D804, Bethesda, MD 20892 USA. EM guroffm@mail.nih.gov FU National Institutes of Health, National Cancer Institute FX We thank Dr. Shane Crotty for sharing reagents and helpful discussions. This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. NR 47 TC 34 Z9 34 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 12 PY 2011 VL 29 IS 17 BP 3310 EP 3319 DI 10.1016/j.vaccine.2011.02.066 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 764BJ UT WOS:000290603100032 PM 21382487 ER PT J AU Steinhagen, F Kinjo, T Bode, C Klinman, DM AF Steinhagen, Folkert Kinjo, Takeshi Bode, Christian Klinman, Dennis M. TI TLR-based immune adjuvants SO VACCINE LA English DT Review DE Toll-like receptor ligand; Vaccination; Adjuvant ID T-CELL RESPONSES; HEPATITIS-B-VACCINE; DOUBLE-STRANDED-RNA; POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID; HUMAN-PAPILLOMAVIRUS TYPE-16; RANDOMIZED CONTROLLED-TRIAL; MONOPHOSPHORYL-LIPID-A; TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTORS; ACTIVE-SPECIFIC IMMUNOTHERAPY AB This work describes the nature and strength of the immune response induced by various Toll-like receptor ligands and their ability to act as vaccine adjuvants. It reviews the various ligands capable of triggering individual TLRs, and then focuses on the efficacy and safety of those agents for which clinical results are available. Published by Elsevier Ltd. C1 [Steinhagen, Folkert; Kinjo, Takeshi; Bode, Christian; Klinman, Dennis M.] NCI, Canc & Inflammat Program, Frederick, MD 21702 USA. RP Klinman, DM (reprint author), NCI, Canc & Inflammat Program, Bldg 567,Rm 205, Frederick, MD 21702 USA. EM klinmand@mail.nih.gov FU Intramural NIH HHS [ZIA BC010852-03] NR 261 TC 148 Z9 155 U1 4 U2 52 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 12 PY 2011 VL 29 IS 17 BP 3341 EP 3355 DI 10.1016/j.vaccine.2010.08.002 PG 15 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 764BJ UT WOS:000290603100037 PM 20713100 ER PT J AU Blanco, I Lara, B De Serres, F AF Blanco, Ignacio Lara, Beatriz De Serres, Frederick TI Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema SO ORPHANET JOURNAL OF RARE DISEASES LA English DT Review ID ZZ ALPHA(1)-ANTITRYPSIN DEFICIENCY; PLASMA PROTEINASE-INHIBITORS; ALPHA-1-ANTITRYPSIN DEFICIENCY; IN-VITRO; ALPHA(1)-PROTEINASE INHIBITOR; ALPHA-1-PROTEINASE INHIBITOR; REPLACEMENT THERAPY; ANTITRYPSIN DEFICIENCY; NEUTROPHIL ELASTASE; CELL PROLIFERATION AB Up to now alpha 1-antitrypsin (AAT) augmentation therapy has been approved only for commercial use in selected adults with severe AAT deficiency-related pulmonary emphysema (i.e. PI*ZZ genotypes as well as combinations of Z, rare and null alleles expressing AAT serum concentrations <11 mu mol/L). However, the compassionate use of augmentation therapy in recent years has proven outstanding efficacy in small cohorts of patients suffering from uncommon AAT deficiency-related diseases other than pulmonary emphysema, such as fibromyalgia, systemic vasculitis, relapsing panniculitis and bronchial asthma. Moreover, a series of preclinical studies provide evidence of the efficacy of AAT augmentation therapy in several infectious diseases, diabetes mellitus and organ transplant rejection. These facts have generated an expanding number of medical applications and patents with claims for other indications of AAT besides pulmonary emphysema. The aim of the present study is to compile and analyze both clinical and histological features of the aforementioned published case studies and reports where AAT augmentation therapy was used for conditions other than pulmonary emphysema. Particularly, our research refers to ten case reports and two clinical trials on AAT augmentation therapy in patients with both AAT deficiency and, at least, one of the following diseases: fibromyalgia, vasculitis, panniculitis and bronchial asthma. In all the cases, AAT was successfully applied whereas previous maximal conventional therapies had failed. In conclusion, laboratory studies in animals and humans as well as larger clinical trials should be, thus, performed in order to determine both the strong clinical efficacy and security of AAT in the treatment of conditions other than pulmonary emphysema. C1 [Blanco, Ignacio] Biomed Res Off OIB FICYT, Oviedo 33009, Principality As, Spain. [Lara, Beatriz] Hosp Arnau Vilanova, Inst Recerca Biomed Lleida IRB, CIBERES Inst Salud Carlos III Madrid, Madrid, Spain. [De Serres, Frederick] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC 27709 USA. RP Blanco, I (reprint author), Biomed Res Off OIB FICYT, Rosal 7, Oviedo 33009, Principality As, Spain. EM ignablanco@yahoo.com NR 82 TC 28 Z9 31 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-1172 J9 ORPHANET J RARE DIS JI Orphanet J. Rare Dis. PD APR 12 PY 2011 VL 6 AR 14 DI 10.1186/1750-1172-6-14 PG 11 WC Genetics & Heredity; Medicine, Research & Experimental SC Genetics & Heredity; Research & Experimental Medicine GA 762MP UT WOS:000290483400001 PM 21486454 ER PT J AU Cellmer, T Buscaglia, M Henry, ER Hofrichter, J Eaton, WA AF Cellmer, Troy Buscaglia, Marco Henry, Eric R. Hofrichter, James Eaton, William A. TI Making connections between ultrafast protein folding kinetics and molecular dynamics simulations SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE tryptophan triplet lifetime; villin headpiece subdomain; downhill protein folding; laser temperature jump ID VILLIN HEADPIECE SUBDOMAIN; INTRAMOLECULAR CONTACT FORMATION; LASER TEMPERATURE-JUMP; LOOP FORMATION; SPEED LIMIT; FAST EVENTS; TRYPTOPHAN; PEPTIDE; MODEL; POLYPEPTIDES AB Determining the rate of forming the truly folded conformation of ultrafast folding proteins is an important issue for both experiments and simulations. The double-norleucine mutant of the 35-residue villin subdomain is the focus of recent computer simulations with atomistic molecular dynamics because it is currently the fastest folding protein. The folding kinetics of this protein have been measured in laser temperature-jump experiments using tryptophan fluorescence as a probe of overall folding. The conclusion from the simulations, however, is that the rate determined by fluorescence is significantly larger than the rate of overall folding. We have therefore employed an independent experimental method to determine the folding rate. The decay of the tryptophan triplet-state in photoselection experiments was used to monitor the change in the unfolded population for a sequence of the villin subdomain with one amino acid difference from that of the laser temperature-jump experiments, but with almost identical equilibrium properties. Folding times obtained in a two-state analysis of the results from the two methods at denaturant concentrations varying from 1.5-6.0 M guanidinium chloride are in excellent agreement, with an average difference of only 20%. Polynomial extrapolation of all the data to zero denaturant yields a folding time of 220 (+100, -70) ns at 283 K, suggesting that under these conditions the barrier between folded and unfolded states has effectively disappeared-the so-called "downhill scenario." C1 [Cellmer, Troy; Henry, Eric R.; Hofrichter, James; Eaton, William A.] NIDDKD, Lab Chem Phys, NIH, Bethesda, MD 20892 USA. [Buscaglia, Marco] Univ Milan, Dipartimento Chim Biochim & Biotecnol Med, I-20090 Segrate, Italy. RP Eaton, WA (reprint author), NIDDKD, Lab Chem Phys, NIH, Bethesda, MD 20892 USA. EM eaton@helix.nih.gov RI Henry, Eric/J-3414-2013; Buscaglia, Marco/C-2435-2008 OI Henry, Eric/0000-0002-5648-8696; Buscaglia, Marco/0000-0001-5010-0278 FU National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health FX We thank Wai-Ming Yau for peptide synthesis, Thang Chiu for preparation of Fig. 1, David Shaw for a preprint of his work, and Patrick Callis for helpful discussion. This work was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. NR 54 TC 36 Z9 36 U1 1 U2 28 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 12 PY 2011 VL 108 IS 15 BP 6103 EP 6108 DI 10.1073/pnas.1019552108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 748SZ UT WOS:000289413600039 PM 21441105 ER PT J AU Sanishvili, R Yoder, DW Pothineni, SB Rosenbaum, G Xu, SL Vogt, S Stepanova, S Makarov, OA Corcoran, S Benn, R Nagarajan, V Smith, JL Fischetti, RF AF Sanishvili, Ruslan Yoder, Derek W. Pothineni, Sudhir Babu Rosenbaum, Gerd Xu, Shenglan Vogt, Stefan Stepanova, Sergey Makarov (Oner Makapob), Oleg A. Corcoran, Stephen Benn, Richard Nagarajan, Venugopalan Smith, Janet L. Fischetti, Robert F. TI Radiation damage in protein crystals is reduced with a micron-sized X-ray beam SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE microcrystallography; synchrotron radiation ID DIFFRACTION DATA; MINI-BEAM; MACROMOLECULAR CRYSTALS; SYNCHROTRON-RADIATION; GM/CA-CAT; CRYSTALLOGRAPHY; MICRODIFFRACTION; BEAMLINES; RADDOSE AB Radiation damage is a major limitation in crystallography of biological macromolecules, even for cryocooled samples, and is particularly acute in microdiffraction. For the X-ray energies most commonly used for protein crystallography at synchrotron sources, photoelectrons are the predominant source of radiation damage. If the beam size is small relative to the photoelectron path length, then the photoelectron may escape the beam footprint, resulting in less damage in the illuminated volume. Thus, it may be possible to exploit this phenomenon to reduce radiation-induced damage during data measurement for techniques such as diffraction, spectroscopy, and imaging that use X-rays to probe both crystalline and noncrystalline biological samples. In a systematic and direct experimental demonstration of reduced radiation damage in protein crystals with small beams, damage was measured as a function of micron-sized X-ray beams of decreasing dimensions. The damage rate normalized for dose was reduced by a factor of three from the largest (15.6 mu m) to the smallest (0.84 mu m) X-ray beam used. Radiation-induced damage to protein crystals was also mapped parallel and perpendicular to the polarization direction of an incident 1-mu m X-ray beam. Damage was greatest at the beam center and decreased monotonically to zero at a distance of about 4 mu m, establishing the range of photoelectrons. The observed damage is less anisotropic than photoelectron emission probability, consistent with photoelectron trajectory simulations. These experimental results provide the basis for data collection protocols to mitigate with micron-sized X-ray beams the effects of radiation damage. C1 [Sanishvili, Ruslan; Yoder, Derek W.; Pothineni, Sudhir Babu; Xu, Shenglan; Stepanova, Sergey; Makarov (Oner Makapob), Oleg A.; Corcoran, Stephen; Benn, Richard; Nagarajan, Venugopalan; Smith, Janet L.; Fischetti, Robert F.] Argonne Natl Lab, Natl Inst Gen Med Sci, Biosci Div, Argonne, IL 60439 USA. [Sanishvili, Ruslan; Yoder, Derek W.; Pothineni, Sudhir Babu; Xu, Shenglan; Stepanova, Sergey; Makarov (Oner Makapob), Oleg A.; Corcoran, Stephen; Benn, Richard; Nagarajan, Venugopalan; Smith, Janet L.; Fischetti, Robert F.] Argonne Natl Lab, Natl Canc Inst, Biosci Div, Collaborat Access Team, Argonne, IL 60439 USA. [Rosenbaum, Gerd] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA. [Vogt, Stefan] Argonne Natl Lab, XRay Sci Div, Argonne, IL 60439 USA. [Smith, Janet L.] Univ Michigan, Life Sci Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA. RP Fischetti, RF (reprint author), Argonne Natl Lab, Natl Inst Gen Med Sci, Biosci Div, 9700 S Cass Ave, Argonne, IL 60439 USA. EM rfischetti@anl.gov RI Vogt, Stefan/B-9547-2009; Vogt, Stefan/J-7937-2013 OI Vogt, Stefan/0000-0002-8034-5513; Vogt, Stefan/0000-0002-8034-5513 FU National Institute of General Medical Sciences [Y1-GM-1104]; National Cancer Institute of the US National Institutes of Health [Y1-CO-1020]; US Department of Energy, Basic Energy Sciences, Office of Science [DE-AC02-06CH11357] FX The authors thank Colin Nave, Elspeth Garman and Liz Duke for helpful discussions. The National Institute of General Medical Sciences and National Cancer Institute Collaborative Access Team is supported by the National Institute of General Medical Sciences (Y1-GM-1104) and the National Cancer Institute (Y1-CO-1020) of the US National Institutes of Health. Use of the Advanced Photon Source was supported by the US Department of Energy, Basic Energy Sciences, Office of Science, under Contract DE-AC02-06CH11357. NR 35 TC 45 Z9 45 U1 0 U2 18 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 12 PY 2011 VL 108 IS 15 BP 6127 EP 6132 DI 10.1073/pnas.1017701108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 748SZ UT WOS:000289413600043 PM 21444772 ER PT J AU Gordon, PV Sample, C Berezhkovskii, AM Muratov, CB Shvartsman, SY AF Gordon, Peter V. Sample, Christine Berezhkovskii, Alexander M. Muratov, Cyrill B. Shvartsman, Stanislav Y. TI Local kinetics of morphogen gradients SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE robustness; tissue regulation; concentration gradient ID SONIC HEDGEHOG; POSITIONAL INFORMATION; DROSOPHILA EMBRYO; DORSAL MORPHOGEN; XENOPUS EMBRYO; PATTERN; PROTEIN; LONG; ENDOCYTOSIS; ROBUSTNESS AB Some aspects of pattern formation in developing embryos can be described by nonlinear reaction-diffusion equations. An important class of these models accounts for diffusion and degradation of a locally produced single chemical species. At long times, solutions of such models approach a steady state in which the concentration decays with distance from the source of production. We present analytical results that characterize the dynamics of this process and are in quantitative agreement with numerical solutions of the underlying nonlinear equations. The derived results provide an explicit connection between the parameters of the problem and the time needed to reach a steady state value at a given position. Our approach can be used for the quantitative analysis of tissue patterning by morphogen gradients, a subject of active research in biophysics and developmental biology. C1 [Gordon, Peter V.; Muratov, Cyrill B.] New Jersey Inst Technol, Dept Math Sci, Newark, NJ 07102 USA. [Sample, Christine; Shvartsman, Stanislav Y.] Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA. [Sample, Christine; Shvartsman, Stanislav Y.] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA. [Sample, Christine] Univ Cambridge Emmanuel Coll, Boston, MA 02115 USA. [Berezhkovskii, Alexander M.] Ctr Informat Technol, Math & Stat Comp Lab, Div Computat Biosci, NIH, Bethesda, MD 20892 USA. RP Muratov, CB (reprint author), New Jersey Inst Technol, Dept Math Sci, Newark, NJ 07102 USA. EM muratov@njit.edu; stas@princeton.edu FU United States-Israel Binational Science Foundation [2006-151]; National Institutes of Health, Center for Information Technology; National Science Foundation (NSF) [DMS-0718027, DMS-0908279, DMS-0718604]; National Institutes of Health [GM078079] FX The authors thank J. Briscoe for providing the image for Fig. 1. The work of P.V.G. was supported, in part, by the United States-Israel Binational Science Foundation Grant 2006-151. A.M.B. was supported by the Intramural Research Program of the National Institutes of Health, Center for Information Technology. C.B.M. acknowledges partial support by National Science Foundation (NSF) via Grants DMS-0718027 and DMS-0908279. S.Y.S. acknowledges partial support by NSF via Grant DMS-0718604, by National Institutes of Health via Grant GM078079, and by the NSF Career award. NR 47 TC 25 Z9 25 U1 0 U2 6 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 12 PY 2011 VL 108 IS 15 BP 6157 EP 6162 DI 10.1073/pnas.1019245108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 748SZ UT WOS:000289413600048 PM 21444770 ER PT J AU Venkova-Canova, T Chattoraj, DK AF Venkova-Canova, Tatiana Chattoraj, Dhruba K. TI Transition from a plasmid to a chromosomal mode of replication entails additional regulators SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE replication control; DNA chaperone ID VIBRIO-CHOLERAE CHROMOSOMES; ESCHERICHIA-COLI; NEGATIVE CONTROL; DNA-REPLICATION; CELL-CYCLE; INITIATOR; BINDING; RCTB; COOPERATIVITY; INACTIVATION AB Plasmid origins of replication are rare in bacterial chromosomes, except in multichromosome bacteria. The replication origin of Vibrio cholerae chromosome II (chrII) closely resembles iteron-bearing plasmid origins. Iterons are repeated initiator binding sites in plasmid origins and participate both in replication initiation and its control. The control is mediated primarily by coupling of iterons via the bound initiators ("handcuffing"), which causes steric hindrance to the origin. The control in chrII must be different, since the timing of its replication is cell cycle-specific, whereas in plasmids it is random. Here we show that chrII uses, in addition to iterons, another kind of initiator binding site, named 39-mers. The 39-mers confer stringent control by increasing handcuffing of iterons, presumably via initiator remodeling. Iterons, although potential inhibitors of replication themselves, restrain the 39-mer-mediated inhibition, possibly by direct coupling ("heterohandcuffing"). We propose that the presumptive transition of a plasmid to a chromosomal mode of control requires additional regulators to increase the stringency of control, and as will be discussed, to gain the capacity to modulate the effectiveness of the regulators at different stages of the cell cycle. C1 [Venkova-Canova, Tatiana; Chattoraj, Dhruba K.] NCI, Lab Biochem & Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP Chattoraj, DK (reprint author), NCI, Lab Biochem & Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. EM chattoraj@nih.gov FU Center for Cancer Research of the National Cancer Institute FX We are grateful to our colleagues Michael Yarmolinsky, Michael Lichten, and Yikang Rong, and one of the reviewers for suggestions to improve the manuscript. This work was supported by the Intramural Research Program, Center for Cancer Research of the National Cancer Institute. NR 30 TC 17 Z9 17 U1 1 U2 3 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 12 PY 2011 VL 108 IS 15 BP 6199 EP 6204 DI 10.1073/pnas.1013244108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 748SZ UT WOS:000289413600055 PM 21444815 ER PT J AU Joyce, MG Tran, P Zhuravleva, MA Jaw, J Colonna, M Sun, PD AF Joyce, M. Gordon Tran, Paul Zhuravleva, Marina A. Jaw, Jessica Colonna, Marco Sun, Peter D. TI Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE X-ray crystallography; BIAcore binding; NKp30 mutants; antibody epitope mapping ID KILLER-CELLS; INHIBITORY RECEPTOR; MOLECULAR-REPLACEMENT; ACTIVATING RECEPTOR; COMPLEX; DOMAINS; RECOGNITION; RESEMBLES; NKP44; NKG2D AB Natural killer (NK) cells are a group of innate immune cells that carry out continuous surveillance for the presence of virally infected or cancerous cells. The natural cytotoxicity receptor (NCR) NKp30 is critical for the elimination of a large group of tumor cell types. Although several ligands have been proposed for NKp30, the lack of a conserved structural feature among these ligands and their uncertain physiological relevance has contributed to confusion in the field and hampered a full understanding of the receptor. To gain insights into NKp30 ligand recognition, we have determined the crystal structure of the extracellular domain of human NKp30. The structure displays an I-type Ig-like fold structurally distinct from the other natural cytotoxicity receptors NKp44 and NKp46. Using cytolytic killing assays against a range of tumor cell lines and subsequent peptide epitope mapping of a NKp30 blocking antibody, we have identified a critical ligand binding region on NKp30 involving its F strand. Using different solution binding studies, we show that the N-terminal domain of B7-H6 is sufficient for NKp30 recognition. Mutations on NKp30 further confirm that residues in the vicinity of the F strand, including part of the C strand and the CD loop, affect binding to B7-H6. The structural comparison of NKp30 with CD28 family receptor and ligand complexes also supports the identified ligand binding site. This study provides insights into NKp30 ligand recognition and a framework for a potential family of unidentified ligands. C1 [Joyce, M. Gordon; Tran, Paul; Zhuravleva, Marina A.; Jaw, Jessica; Sun, Peter D.] NIAID, Struct Immunol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA. [Colonna, Marco] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA. RP Sun, PD (reprint author), NIAID, Struct Immunol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA. EM psun@nih.gov OI Colonna, Marco/0000-0001-5222-4987 FU Department of Energy, Office of Science, Office of Basic Energy Sciences [W-31-109-Eng-38]; National Institute of Allergy and Infectious Diseases FX We thank Christine Foster and Julius Chung for preliminary work at the beginning of this project. We also thank Greg Snyder and Tsan Xiao for instruction and the use of a Mosquito crystallization robot for initial high throughput crystallization screening. Use of the Advanced Photon Source was supported by the Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract W-31-109-Eng-38. This research is supported by the intramural research funding from the National Institute of Allergy and Infectious Diseases. NR 43 TC 31 Z9 35 U1 0 U2 6 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 12 PY 2011 VL 108 IS 15 BP 6223 EP 6228 DI 10.1073/pnas.1100622108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 748SZ UT WOS:000289413600059 PM 21444796 ER PT J AU Wang, WCH Juan, AH Panebra, A Liggett, SB AF Wang, Wayne C. H. Juan, Aster H. Panebra, Alfredo Liggett, Stephen B. TI MicroRNA let-7 establishes expression of beta(2)-adrenergic receptors and dynamically down-regulates agonist-promoted down-regulation SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE desensitization; airways; noncoding RNA; gene regulation ID AIRWAY SMOOTH-MUSCLE; BETA-ADRENERGIC RECEPTORS; MESSENGER-RNA; BETA-2-ADRENERGIC RECEPTOR; IN-VIVO; TARGETS; COMPLEX; PHOSPHORYLATION; TRAFFICKING; PATHWAYS AB Although beta(2)-adrenergic receptors (beta(2)AR) are expressed on most cell types, mechanisms that establish expression levels and regulate expression by chronic agonist remain unclear. The 3' UTR of ADRB2 has a conserved 8-nucleotide seed region that we hypothesized is targeted by the let-7 family of miRNAs leading to translational repression. In luciferase assays with transfected cells, luc-beta(2)WT3'UTR had decreased expression when cotransfected with let-7f, but a mutated luc-beta(2)3'UTR lacking the seed was unaffected by let-7f; a mutated let-7f also had no effect on luc-beta(2)WT3'UTR expression. ADRB2 mRNA was in greater abundance in immunoprecipitates of Ago2, a core component of the miRNA-induced silencing complex, when cells were transfected with let-7f, but not with a mutated let-7f, indicating a direct interaction with the silencing mechanism. H292 cells transfected with let-7f caused similar to 60% decrease in native beta(2)AR expression, but transfection with let-7f-specific locked nucleic acid anti-miRNA increased beta(2)AR expression by similar to twofold. We considered that an increase in let-7f leading to greater repression of translation contributes to agonist-promoted down-regulation. Paradoxically, in cells and in lungs from mice treated in vivo, an similar to 50% decrease in let-7f occurs during long-term agonist exposure, indicating a counterregulatory event. Consistent with this notion, let-7f locked nucleic acid transfection caused depressed agonist-promoted down-regulation. Thus, let-7f miRNA regulates baseline beta(2)AR expression and decreases in let-7f evoked by agonist attenuate down-regulation. This positive feedback loop has not previously been described for a G protein-coupled receptor and its miRNA. Methods to decrease let-7f expression in targeted cells may increase therapeutic responses to beta-agonist by increasing beta(2)AR expression or minimizing tachyphylaxis. C1 [Wang, Wayne C. H.; Panebra, Alfredo; Liggett, Stephen B.] Univ Maryland, Sch Med, Dept Med, Cardiopulm Genom Program, Baltimore, MD 21201 USA. [Juan, Aster H.] NIAMSD, Lab Muscle Stem Cells & Gene Regulat, NIH, Bethesda, MD 20892 USA. RP Liggett, SB (reprint author), Univ Maryland, Sch Med, Dept Med, Cardiopulm Genom Program, Baltimore, MD 21201 USA. EM sligg001@umaryland.edu RI liggett, stephen/E-7453-2012 FU National Institutes of Health [HL104119, HL045967, HL071609, HL065899] FX We thank Rachel Schillinger and Molly Malone for technical assistance, and Esther Moses for manuscript preparation. This work was funded by National Institutes of Health Grants HL104119 (to W.C.H.W.) and HL045967, HL071609, and HL065899 (to S.B.L.). NR 43 TC 23 Z9 24 U1 0 U2 0 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 12 PY 2011 VL 108 IS 15 BP 6246 EP 6251 DI 10.1073/pnas.1101439108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 748SZ UT WOS:000289413600063 PM 21447718 ER PT J AU Fenichel, EP Castillo-Chavez, C Ceddia, MG Chowell, G Parra, PAG Hickling, GJ Holloway, G Horan, R Morin, B Perrings, C Springborn, M Velazquez, L Villalobos, C AF Fenichel, Eli P. Castillo-Chavez, Carlos Ceddia, M. G. Chowell, Gerardo Parra, Paula A. Gonzalez Hickling, Graham J. Holloway, Garth Horan, Richard Morin, Benjamin Perrings, Charles Springborn, Michael Velazquez, Leticia Villalobos, Cristina TI Adaptive human behavior in epidemiological models SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE susceptible-infected-recovered model; R-0; reproductive number; bioeconomics ID INFECTIOUS-DISEASES; PANDEMIC INFLUENZA; EPIDEMICS; CHOICE; AIDS AB The science and management of infectious disease are entering a new stage. Increasingly public policy to manage epidemics focuses on motivating people, through social distancing policies, to alter their behavior to reduce contacts and reduce public disease risk. Person-to-person contacts drive human disease dynamics. People value such contacts and are willing to accept some disease risk to gain contact-related benefits. The cost-benefit trade-offs that shape contact behavior, and hence the course of epidemics, are often only implicitly incorporated in epidemiological models. This approach creates difficulty in parsing out the effects of adaptive behavior. We use an epidemiological-economic model of disease dynamics to explicitly model the trade-offs that drive person-to-person contact decisions. Results indicate that including adaptive human behavior significantly changes the predicted course of epidemics and that this inclusion has implications for parameter estimation and interpretation and for the development of social distancing policies. Acknowledging adaptive behavior requires a shift in thinking about epidemiological processes and parameters. C1 [Fenichel, Eli P.; Perrings, Charles] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA. [Fenichel, Eli P.; Perrings, Charles] Arizona State Univ, EcoSERV Grp, Tempe, AZ 85287 USA. [Castillo-Chavez, Carlos; Chowell, Gerardo; Morin, Benjamin] Arizona State Univ, Sch Human Evolut & Social Change, Tempe, AZ 85287 USA. [Ceddia, M. G.; Holloway, Garth] Univ Reading, Sch Agr Policy & Dev, Dept Food Econ & Mkt, Reading RG6 6AR, Berks, England. [Chowell, Gerardo] NIH, Div Epidemiol & Populat Studies, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Parra, Paula A. Gonzalez; Velazquez, Leticia] Univ Texas El Paso, Program Computat Sci, El Paso, TX 79968 USA. [Hickling, Graham J.] Univ Tennessee, Dept Forestry Wildlife & Fisheries, Ctr Wildlife Hlth, Knoxville, TN 37996 USA. [Hickling, Graham J.] Univ Tennessee, Natl Inst Math & Biol Synth, Knoxville, TN 37996 USA. [Horan, Richard] Michigan State Univ, Dept Agr Food & Resource Econ, E Lansing, MI 48824 USA. [Springborn, Michael] Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA. [Villalobos, Cristina] Univ Texas Pan Amer, Dept Math, Edinburg, TX 78539 USA. RP Fenichel, EP (reprint author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA. EM Eli.Fenichel@asu.edu RI Chowell, Gerardo/F-5038-2012; Castillo-Chavez, Carlos/E-1412-2014 OI Chowell, Gerardo/0000-0003-2194-2251; Castillo-Chavez, Carlos/0000-0002-1046-3901 FU National Institute for Mathematical and Biological Synthesis; National Science Foundation; United States Department of Homeland Security; US Department of Agriculture through National Science Foundation [EF-0832858]; University of Tennessee, Knoxville; US Army Research Laboratory, through the Army High Performance Computing Research Center [W911NF-07-0027]; Early History Program FX This manuscript is the result of the NIMBioS working group, in which all authors participated. E.P.F. led the working group, the modeling, and the writing. All authors, listed alphabetically following E.P.F., contributed to conception of the project, modeling, and writing. This work was conducted by the Synthesizing and Predicting Infectious Disease with Endogenous Risk work group supported by the National Institute for Mathematical and Biological Synthesis, sponsored by the National Science Foundation, United States Department of Homeland Security, and US Department of Agriculture through National Science Foundation Award EF-0832858. Additional support was from University of Tennessee, Knoxville. P.A.G.P. and L.V. were supported in part by the US Army Research Laboratory, through the Army High Performance Computing Research Center, Cooperative Agreement W911NF-07-0027. G.C. was supported in part by the Late Lessons from Early History Program. NR 33 TC 85 Z9 88 U1 0 U2 33 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 12 PY 2011 VL 108 IS 15 BP 6306 EP 6311 DI 10.1073/pnas.1011250108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 748SZ UT WOS:000289413600073 PM 21444809 ER PT J AU Mukhopadhyay, B Cinar, R Yin, S Liu, J Tam, J Godlewski, G Harvey-White, J Mordi, I Cravatt, BF Lotersztajn, S Gao, B Yuan, QP Schuebel, K Goldman, D Kunos, G AF Mukhopadhyay, Bani Cinar, Resat Yin, Shi Liu, Jie Tam, Joseph Godlewski, Grzegorz Harvey-White, Judith Mordi, Isioma Cravatt, Benjamin F. Lotersztajn, Sophie Gao, Bin Yuan, Qiaoping Schuebel, Kornel Goldman, David Kunos, George TI Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID ACID AMIDE HYDROLASE; PARTIAL-HEPATECTOMY; RAT-LIVER; 2-ARACHIDONOYL GLYCEROL; TRANSCRIPTION FACTOR; ENZYMATIC-SYNTHESIS; ENDOGENOUS LIGAND; MICE; BIOSYNTHESIS; EXPRESSION AB The mammalian liver regenerates upon tissue loss, which induces quiescent hepatocytes to enter the cell cycle and undergo limited replication under the control of multiple hormones, growth factors, and cytokines. Endocannabinoids acting via cannabinoid type 1 receptors (CB1R) promote neural progenitor cell proliferation, and in the liver they promote lipogenesis. These findings suggest the involvement of CB1R in the control of liver regeneration. Here we report that mice lacking CB1R globally or in hepatocytes only and wild-type mice treated with a CB1R antagonist have a delayed proliferative response to two-thirds partial hepatectomy (PHX). In wild-type mice, PHX leads to increased hepatic expression of CB1R and hyperactivation of the biosynthesis of the endocannabinoid anandamide in the liver via an in vivo pathway involving conjugation of arachidonic acid and ethanolamine by fatty-acid amide hydrolase. In wild-type but not CB1R-/- mice, PHX induces robust up-regulation of key cell-cycle proteins involved in mitotic progression, including cyclin-dependent kinase 1(Cdk1), cyclin B2, and their transcriptional regulator forkhead box protein M1 (FoxM1), as revealed by ultrahigh-throughput RNA sequencing and pathway analysis and confirmed by real-time PCR and Western blot analyses. Treatment of wild-type mice with anandamide induces similar changes mediated via activation of the PI3K/Akt pathway. We conclude that activation of hepatic CB1R by newly synthesized anandamide promotes liver regeneration by controlling the expression of cell-cycle regulators that drive M phase progression. C1 [Mukhopadhyay, Bani; Cinar, Resat; Liu, Jie; Tam, Joseph; Godlewski, Grzegorz; Harvey-White, Judith; Kunos, George] NIAAA, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA. [Yin, Shi; Gao, Bin] NIAAA, Lab Liver Biol, NIH, Bethesda, MD 20892 USA. [Mordi, Isioma; Yuan, Qiaoping; Schuebel, Kornel; Goldman, David] NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA. [Cravatt, Benjamin F.] Scripps Inst, La Jolla, CA 92037 USA. [Lotersztajn, Sophie] Univ Paris 12, Creteil, France. RP Kunos, G (reprint author), NIAAA, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA. EM george.kunos@nih.gov RI Goldman, David/F-9772-2010; OI Goldman, David/0000-0002-1724-5405; CINAR, RESAT/0000-0002-8597-7253 FU National Institute on Alcohol Abuse and Alcoholism FX We thank Ken Mackie for the CB1 antibodies and Beat Lutz and Giovanni Marsicano for the CB1 floxed mice used to generate LCB1-/- mice. This work was funded by the intramural program of the National Institute on Alcohol Abuse and Alcoholism. NR 51 TC 43 Z9 43 U1 1 U2 9 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 12 PY 2011 VL 108 IS 15 BP 6323 EP 6328 DI 10.1073/pnas.1017689108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 748SZ UT WOS:000289413600076 PM 21383171 ER PT J AU Abe, M Schambra, H Wassermann, EM Luckenbaugh, D Schweighofer, N Cohen, LG AF Abe, Mitsunari Schambra, Heidi Wassermann, Eric M. Luckenbaugh, Dave Schweighofer, Nicolas Cohen, Leonardo G. TI Reward Improves Long-Term Retention of a Motor Memory through Induction of Offline Memory Gains SO CURRENT BIOLOGY LA English DT Article ID MONETARY REWARD; HUMAN BRAIN; DOPAMINE TRANSMISSION; SYNAPTIC PLASTICITY; PREFRONTAL CORTEX; CONSOLIDATION; POTENTIATION; ADAPTATION; MECHANISMS; PREDICTION AB In humans, training in which good performance is rewarded or bad performance punished results in transient behavioral improvements [1-3]. The relative effects of reward and punishment on consolidation and long-term retention, critical behavioral stages for successful learning [4, 5], are not known. Here, we investigated the effects of reward and punishment on these different stages of human motor skill learning. Vie studied healthy subjects who trained on a motor task under rewarded, punished, or neutral control conditions. Performance was tested before and immediately, 6 hr, 24 hr, and 30 days after training in the absence of reward or punishment. Performance improvements immediately after training were comparable in the three groups. At 6 hr, the rewarded group maintained performance gains, whereas the other two groups experienced significant forgetting. At 24 hr, the reward group showed significant offline (post-training) improvements, whereas the other two groups did not. At 30 days, the rewarded group retained the gains identified at 24 hr, whereas the other two groups experienced significant forgetting. We conclude that training under rewarded conditions is more effective than training under punished or neutral conditions in eliciting lasting motor learning, an advantage driven by offline memory gains that persist over time. C1 [Abe, Mitsunari; Schambra, Heidi; Cohen, Leonardo G.] NIMH, Human Cort Physiol & Stroke Neurorehabil Sect, NINDS, NIH, Bethesda, MD 20892 USA. [Wassermann, Eric M.] NIMH, Behav Neurol Unit, NINDS, NIH, Bethesda, MD 20892 USA. [Luckenbaugh, Dave] NIMH, Mood & Anxiety Disorders Program, NIH, Bethesda, MD 20892 USA. [Schweighofer, Nicolas] Univ So Calif, Dept Biokinesiol & Phys Therapy, Los Angeles, CA 90089 USA. RP Cohen, LG (reprint author), NIMH, Human Cort Physiol & Stroke Neurorehabil Sect, NINDS, NIH, Bethesda, MD 20892 USA. EM cohenl@ninds.nih.gov RI Schweighofer, Nicolas/A-3675-2008; Abe, Mitsunari/F-1373-2014 OI Abe, Mitsunari/0000-0002-3913-2292 FU National Institute of Neurological Disorders and Stroke; National Science Foundation [BCS-1031899] FX This work was supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke and by National Science Foundation grant: BCS-1031899 to N.S. We thank Toyomi Abe, Nitzan Censor, Mark Hallett, Eran Dayan, Ethan Buch, John Krakauer, and Pablo Celnik for critical comments on earlier versions of this manuscript. NR 41 TC 71 Z9 71 U1 5 U2 27 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0960-9822 EI 1879-0445 J9 CURR BIOL JI Curr. Biol. PD APR 12 PY 2011 VL 21 IS 7 BP 557 EP 562 DI 10.1016/j.cub.2011.02.030 PG 6 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 752BK UT WOS:000289662600017 PM 21419628 ER PT J AU McKay, MM Ritt, DA Morrison, DK AF McKay, Melissa M. Ritt, Daniel A. Morrison, Deborah K. TI RAF Inhibitor-Induced KSR1/B-RAF Binding and Its Effects on ERK Cascade Signaling SO CURRENT BIOLOGY LA English DT Article ID KSR1 SCAFFOLD COMPLEX; B-RAF; KINASE SUPPRESSOR; ONCOGENIC RAS; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION; MECHANISM; PATHWAY; CELLS AB RAF kinase inhibitors can induce ERK cascade signaling by promoting dimerization of RAF family members in the presence of oncogenic or normally activated RAS [1-3]. This interaction is mediated by a dimer interface region in the RAF kinase domain that is conserved in members of the ERK cascade scaffold family, kinase suppressor of RAS (KSR) [4,5]. In this study, we find that most RAF inhibitors also induce the binding of KSR1 to wild-type and oncogenic B-RAF proteins, including V600E B-RAF, but promote little complex formation between KSR1 and C-RAF. The inhibitor-induced KSR1/B-RAF interaction requires direct binding of the drug to B-RAF and is dependent on conserved dimer interface residues in each protein, but, unexpectedly, is not dependent on binding of B-RAF to activated RAS. Inhibitor-induced KSR/B-RAF complex formation can occur in the cytosol and is observed in normal mouse fibroblasts, as well as a variety of human cancer cell lines. Strikingly, we find that KSR1 competes with C-RAF for inhibitor-induced binding to B-RAF and, as a result, alters the effect of the inhibitors on ERK cascade signaling. C1 [McKay, Melissa M.; Ritt, Daniel A.; Morrison, Deborah K.] NCI, Lab Cell & Dev Signaling, Ctr Canc Res, Frederick, MD 21702 USA. RP Morrison, DK (reprint author), NCI, Lab Cell & Dev Signaling, Ctr Canc Res, Frederick, MD 21702 USA. EM morrisod@mail.nih.gov FU National Cancer Institute FX We thank members of the Laboratory of Cell and Developmental Signaling for helpful discussions. This project has been funded by federal funds from the National Cancer Institute. NR 20 TC 47 Z9 48 U1 0 U2 5 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0960-9822 EI 1879-0445 J9 CURR BIOL JI Curr. Biol. PD APR 12 PY 2011 VL 21 IS 7 BP 563 EP 568 DI 10.1016/j.cub.2011.02.033 PG 6 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 752BK UT WOS:000289662600018 PM 21458265 ER PT J AU Amaratunga, C Lopera-Mesa, TM Brittain, NJ Cholera, R Arie, T Fujioka, H Keefer, JR Fairhurst, RM AF Amaratunga, Chanaki Lopera-Mesa, Tatiana M. Brittain, Nathaniel J. Cholera, Rushina Arie, Takayuki Fujioka, Hisashi Keefer, Jeffrey R. Fairhurst, Rick M. TI A Role for Fetal Hemoglobin and Maternal Immune IgG in Infant Resistance to Plasmodium falciparum Malaria SO PLOS ONE LA English DT Article ID TUMOR-NECROSIS-FACTOR; INFECTED ERYTHROCYTES; CEREBRAL MALARIA; ACQUIRED-IMMUNITY; RED-CELLS; SEQUESTRATION; SURFACE; PROTECTION; ANTIBODIES; CHILDREN AB Background: In Africa, infant susceptibility to Plasmodium falciparum malaria increases substantially as fetal hemoglobin (HbF) and maternal immune IgG disappear from circulation. During the first few months of life, however, resistance to malaria is evidenced by extremely low parasitemias, the absence of fever, and the almost complete lack of severe disease. This resistance has previously been attributed in part to poor parasite growth in HbF-containing red blood cells (RBCs). A specific role for maternal immune IgG in infant resistance to malaria has been hypothesized but not yet identified. Methods and Findings: We found that P. falciparum parasites invade and develop normally in fetal (cord blood, CB) RBCs, which contain up to 95% HbF. However, these parasitized CB RBCs are impaired in their binding to human microvascular endothelial cells (MVECs), monocytes, and nonparasitized RBCs -cytoadherence interactions that have been implicated in the development of high parasite densities and the symptoms of malaria. Abnormal display of the parasite's cytoadherence antigen P. falciparum erythrocyte membrane protein-1 (PfEMP-1) on CB RBCs accounts for these findings and is reminiscent of that on HbC and HbS RBCs. IgG purified from the plasma of immune Malian adults almost completely abolishes the adherence of parasitized CB RBCs to MVECs. Conclusions: Our data suggest a model of malaria protection in which HbF and maternal IgG act cooperatively to impair the cytoadherence of parasitized RBCs in the first few months of life. In highly malarious areas of Africa, an infant's contemporaneous expression of HbC or HbS and development of an immune IgG repertoire may effectively reconstitute the waning protective effects of HbF and maternal immune IgG, thereby extending the malaria resistance of infancy into early childhood. C1 [Amaratunga, Chanaki; Lopera-Mesa, Tatiana M.; Brittain, Nathaniel J.; Cholera, Rushina; Fairhurst, Rick M.] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA. [Arie, Takayuki] Osaka Prefecture Univ, Sch Engn, Dept Phys & Elect, Osaka, Japan. [Fujioka, Hisashi] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA. [Keefer, Jeffrey R.] Johns Hopkins Sch Med, Dept Pediat, Div Pediat Hematol, Baltimore, MD USA. RP Amaratunga, C (reprint author), NIAID, Lab Malaria & Vector Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM rfairhurst@niaid.nih.gov FU National Institutes of Health, National Institute of Allergy and Infectious Diseases FX This research was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases. The funders had no role in the study design, data collection, analysis, decision to publish or preparation of the manuscript. NR 47 TC 31 Z9 32 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 12 PY 2011 VL 6 IS 4 AR e14798 DI 10.1371/journal.pone.0014798 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 748QE UT WOS:000289404700003 PM 21532754 ER PT J AU Zou, SG Liedo, P Altamirano-Robles, L Cruz-Enriquez, J Morice, A Ingram, DK Kaub, K Papadopoulos, N Carey, JR AF Zou, Sige Liedo, Pablo Altamirano-Robles, Leopoldo Cruz-Enriquez, Janeth Morice, Amy Ingram, Donald K. Kaub, Kevin Papadopoulos, Nikos Carey, James R. TI Recording Lifetime Behavior and Movement in an Invertebrate Model SO PLOS ONE LA English DT Article ID DIETARY-RESTRICTION; DROSOPHILA; SLEEP; FLY AB Characterization of lifetime behavioral changes is essential for understanding aging and aging-related diseases. However, such studies are scarce partly due to the lack of efficient tools. Here we describe and provide proof of concept for a stereo vision system that classifies and sequentially recordsat an extremely fine scalesix different behaviors (resting, micro-movement, walking, flying, feeding and drinking) and the within-cage (3D) location of individualtephritidfruit flies by time-of-day throughout their lives. Using flies fed on two different diets, full sugar-yeast and sugar-only diets, we report for the first time their behavioral changes throughout their lives at a high resolution. We have found that the daily activity peaks at the age of 15-20 days and then gradually declines with age for flies on both diets. However, the overall daily activity is higher for flies on sugar-only diet than those on the full diet. Flies on sugar-only diet show a stronger diurnal localization pattern with higher preference to staying on the top of the cage during the period of light-off when compared to flies on the full diet. Clustering analyses of age-specific behavior patterns reveal three distinct young, middle-aged and old clusters for flies on each of the two diets. The middle-aged groups for flies on sugar-only diet consist of much younger age groups when compared to flies on full diet. This technology providesresearch opportunitiesfor using a behavioral informatics approach for understanding different ways in which behavior, movement, and aging in model organisms are mutually affecting. C1 [Zou, Sige] NIA, Lab Expt Gerontol, Baltimore, MD 21224 USA. [Liedo, Pablo] El Colegio Frontera Sur, Dept Entomol, Tapachula, Chiapas, Mexico. [Altamirano-Robles, Leopoldo; Cruz-Enriquez, Janeth] Inst Nacl Astrofis Opt & Electr, Lab Vis Comp, Puebla, Mexico. [Morice, Amy; Kaub, Kevin; Carey, James R.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA. [Ingram, Donald K.] Louisiana State Univ, Pennington Biomed Res Ctr, Nutrit Neurosci & Aging Lab, Baton Rouge, LA 70808 USA. [Papadopoulos, Nikos] Univ Thessaly, Dept Agr Crop Prod & Rural Environm, Magnisias, Greece. [Carey, James R.] Univ Calif Berkeley, Ctr Econ & Demog Aging, Berkeley, CA 94720 USA. RP Zou, SG (reprint author), NIA, Lab Expt Gerontol, Baltimore, MD 21224 USA. EM jrcarey@ucdavis.edu RI Trejo, Yesenia/D-9257-2012; Liedo, Pablo/E-9313-2010; Papadopoulos, Nikos/B-9156-2011 OI Liedo, Pablo/0000-0002-0004-1721; Papadopoulos, Nikos/0000-0003-2480-8189 FU Ellison Medical Foundation; UC MEXUS; National Institute on Aging/National Institutes of Health (NIA/NIH) [P01 AG022500-01, P01 AG08761-10] FX Research funded by the Ellison Medical Foundation, UC MEXUS and National Institute on Aging/National Institutes of Health (NIA/NIH) grants P01 AG022500-01 and P01 AG08761-10 to JRC, and the Intramural Research Program of NIA, NIH to SZ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 19 TC 16 Z9 16 U1 0 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 12 PY 2011 VL 6 IS 4 AR e18151 DI 10.1371/journal.pone.0018151 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 748QE UT WOS:000289404700007 PM 21559058 ER PT J AU Wang, DS Zhang, Z Dong, M Sun, SH Chapman, ER Jackson, MB AF Wang, Dongsheng Zhang, Zhen Dong, Min Sun, Shihu Chapman, Edwin R. Jackson, Meyer B. TI Syntaxin Requirement for Ca2+-Triggered Exocytosis in Neurons and Endocrine Cells Demonstrated with an Engineered Neurotoxin SO BIOCHEMISTRY LA English DT Article ID VOLTAGE-GATED K+; BOTULINUM NEUROTOXIN; MEMBRANE-FUSION; NEUROEXOCYTOSIS; CHANNELS; VESICLES; SNARES; C1; 1A AB Botulinum neurotoxins cleave synaptic SNAREs and block exocytosis, demonstrating that these proteins function in neurosecretion. However, the function of the SNARE syntaxin remains less clear because no neurotoxin cleaves it selectively. Starting with a botulinum neurotoxin that cleaves both syntaxin and SNAP-25, we engineered a version that retains activity against syntaxin but spares SNAP-25. These mutants block synaptic release in neurons and norepinephrine release in neuroendocrine cells, thus establishing an essential role for syntaxin in Ca2+-triggered exocytosis. These mutants can generate syntaxin-free cells as a useful experimental system for research and may lead to pharmaceuticals that target syntaxin selectively. C1 [Wang, Dongsheng; Jackson, Meyer B.] Univ Wisconsin, Dept Neurosci, Madison, WI 53706 USA. [Zhang, Zhen] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA. [Dong, Min; Sun, Shihu; Chapman, Edwin R.] Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA. RP Jackson, MB (reprint author), Univ Wisconsin, Dept Neurosci, Madison, WI 53706 USA. EM mbjackso@wisc.edu RI Zhang, Zhen/F-8561-2011 FU National Institutes of Health [NS44057]; Howard Hughes Medical Institute FX Funded by National Institutes of Health Grant NS44057 and the Howard Hughes Medical Institute. NR 24 TC 14 Z9 14 U1 0 U2 4 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD APR 12 PY 2011 VL 50 IS 14 BP 2711 EP 2713 DI 10.1021/bi200290p PG 3 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 743OW UT WOS:000289029200001 PM 21401123 ER PT J AU Gift, SK Zentner, IJ Schon, A McFadden, K Umashankara, M Rajagopal, S Contarino, M Duffy, C Courter, JR Zhang, MY Gershoni, JM Cocklin, S Dimitrov, DS Smith, AB Freire, E Chaiken, IM AF Gift, Syna Kuriakose Zentner, Isaac J. Schoen, Arne McFadden, Karyn Umashankara, M. Rajagopal, Srivats Contarino, Mark Duffy, Caitlin Courter, Joel R. Zhang, Mei-Yun Gershoni, Jonathan M. Cocklin, Simon Dimitrov, Dimiter S. Smith, Amos B., III Freire, Ernesto Chaiken, Irwin M. TI Conformational and Structural Features of HIV-1 gp120 Underlying the Dual Receptor Antagonism by Cross-Reactive Neutralizing Antibody m18 SO BIOCHEMISTRY LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; CD4 BINDING-SITE; EXTERIOR ENVELOPE GLYCOPROTEIN; POTENT NEUTRALIZATION; ENTRY INHIBITORS; CD4-BINDING SITE; MEDIATED FUSION; CD4-BOUND STATE; DISPLAY LIBRARY AB We investigated the interaction between cross-reactive HIV-1 neutralizing human monoclonal antibody m18 and HIV-I(YU-2) gp120 in an effort to understand how this antibody inhibits the entry of virus into cells. m18 binds to gp120 with high affinity (K(D) approximate to 5 nM) as measured by surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC). SPR analysis further showed that m18 inhibits interactions of gp120 with both soluble CD4 and CD4-induced antibodies that have epitopes overlapping the coreceptor binding site. This dual receptor site antagonism, which occurs with equal potency for both inhibition effects, argues that m18 is not functioning as a mimic of CD4, in spite of the presence of a putative CD4-like loop formed by HCDR3 in the antibody. Consistent with this view, m18 was found to interact with gp120 in the presence of saturating concentrations of a CD4-mimicking small molecule gp120 inhibitor, suggesting that m18 does not require unoccupied CD4 Pbe43 binding cavity residues of gp120. Thermodynamic analysis of the m18 gp120 interaction suggests that m18 stabilizes a conformation of gp120 that is unique from and less structured than the CD4-stabilized conformation. Conformational mutants of gp120 were studied for their impact on m18 interaction. Mutations known to disrupt the coreceptor binding region and to lead to complete suppression of 17b binding had minimal effects on m18 binding. This argues that energetically important epitopes for m18 binding lie outside the disrupted bridging sheet region used for 17b and coreceptor binding. In contrast, mutations in the CD4 region strongly affected m18 binding. Overall, the results obtained in this work argue that m18, rather than mimicking CD4 directly, suppresses both receptor binding site functions of HIV-1 gp120 by stabilizing a nonproductive conformation of the envelope protein. These results can be related to prior findings about the importance of conformational entrapment as a common mode of action for neutralizing CD4bs antibodies, with differences mainly in epitope utilization and the extent of gp120 structuring. C1 [Gift, Syna Kuriakose; Zentner, Isaac J.; McFadden, Karyn; Umashankara, M.; Rajagopal, Srivats; Contarino, Mark; Duffy, Caitlin; Cocklin, Simon; Chaiken, Irwin M.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA. [Gift, Syna Kuriakose; Zentner, Isaac J.; McFadden, Karyn; Chaiken, Irwin M.] Drexel Univ, Coll Med, Biochem Grad Program, Philadelphia, PA 19102 USA. [Schoen, Arne; Freire, Ernesto] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA. [Courter, Joel R.; Smith, Amos B., III] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA. [Zhang, Mei-Yun] Univ Hong Kong, Dept Microbiol, AIDS Inst, Hong Kong, Hong Kong, Peoples R China. [Gershoni, Jonathan M.] Tel Aviv Univ, IL-69978 Tel Aviv, Israel. [Dimitrov, Dimiter S.] NCI, Ctr Canc Res Nanobiol Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA. RP Chaiken, IM (reprint author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 11102 New Coll Bldg,MS 497,245N 15th St, Philadelphia, PA 19102 USA. EM ichaiken@drexelmed.edu FU National Institutes of Health (NIH) [P01 GM 56550, CHAVI U19AI067854-04]; NIH, National Cancer Institute, Center for Cancer Research FX This research was supported by National Institutes of Health (NIH) Grant P01 GM 56550 and CHAVI U19AI067854-04 and by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. NR 81 TC 4 Z9 4 U1 1 U2 12 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD APR 12 PY 2011 VL 50 IS 14 BP 2756 EP 2768 DI 10.1021/bi101160r PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 743OW UT WOS:000289029200007 PM 21351734 ER PT J AU Gift, SK McFadden, K Zentner, IJ Rajagopal, S Zhang, MY Dimitrov, DS Chaiken, IM AF Gift, Syna Kuriakose McFadden, Karyn Zentner, Isaac J. Rajagopal, Srivats Zhang, Mei-Yun Dimitrov, Dimiter S. Chaiken, Irwin M. TI Monoclonal Antibody m18 Paratope Leading to Dual Receptor Antagonism of HIV-1 gp120 SO BIOCHEMISTRY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; NEUTRALIZING ANTIBODIES; STRUCTURAL BASIS; VACCINE DESIGN; BINDING-SITE; TYPE-1 GP120; ENV BINDING; EPITOPE; CD4 AB We sought to identify sequences in the monoclonal antibody m18 complementarity determining regions (CDRs) that are responsible for its interaction with HIV-1 gpI20 and inhibition of the envelope receptor binding sites. In the accompanying paper (DOI 10.1021/bi101160r), we reported that m18 inhibits CD4 binding through a nonactivating mechanism that, at the same time, induces conformational effects leading to inhibition of the coreceptor site. Here, we sought to define the structural elements in m18 responsible for these actions. Direct binding and competition analyses using surface plasmon resonance showed that YU-2 gp120 binding is stabilized by a broad paratope of residues in the m18 CDRs. Additionally, several m18 residues were identified for which mutants retained high affinity for gpI20 but had suppressed CD4 and 17b inhibition activities. A subset of these mutants did, however, neutralize HXBc2 viral infection. The results obtained in this work demonstrate that the combined m18 paratope contains subsets of residues that are differentially important for the binding and inhibition functions of the m18 neutralizing antibody. The data also add to prior observations that high-affinity antibodies that do not inhibit monomeric gp120 receptor site interactions may still exhibit significant antiviral activity. C1 [Gift, Syna Kuriakose; McFadden, Karyn; Zentner, Isaac J.; Rajagopal, Srivats; Chaiken, Irwin M.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA. [Gift, Syna Kuriakose; Chaiken, Irwin M.] Drexel Univ, Coll Med, Biochem Grad Program, Philadelphia, PA 19102 USA. [Zhang, Mei-Yun] Univ Hong Kong, Dept Microbiol, AIDS Inst, Hong Kong, Hong Kong, Peoples R China. [Dimitrov, Dimiter S.] NCI, Ctr Canc Res Nanobiol Program, CCR, NIH, Frederick, MD 21702 USA. RP Chaiken, IM (reprint author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 11102 New Coll Bldg,MS 497,245N 15th St, Philadelphia, PA 19102 USA. EM ichaiken@drexelmed.edu FU National Institutes of Health [P01 GM 56550, CHAVI UI9AI067854-04]; NIH, National Cancer Institute, Center for Cancer Research FX This research was supported by National Institutes of Health Grants P01 GM 56550 and CHAVI UI9AI067854-04 and by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. NR 43 TC 1 Z9 1 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD APR 12 PY 2011 VL 50 IS 14 BP 2769 EP 2779 DI 10.1021/bi101161j PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 743OW UT WOS:000289029200008 PM 21417283 ER PT J AU Vunnam, N Flint, J Balbo, A Schuck, P Pedigo, S AF Vunnam, Nagamani Flint, Jon Balbo, Andrea Schuck, Peter Pedigo, Susan TI Dimeric States of Neural- and Epithelial-Cadherins are Distinguished by the Rate of Disassembly SO BIOCHEMISTRY LA English DT Article ID CELL-CELL ADHESION; N-CADHERIN; SYNAPTIC PLASTICITY; CLASSICAL CADHERINS; ANALYTICAL ULTRACENTRIFUGATION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; NERVOUS-SYSTEM; SUPERFAMILY; MOLECULES AB Epithelial- and neural-cadherins are specifically localized at synapses in neurons which can change the shape and contact surface on a time scale of seconds to months. We have focused our studies on the role of the extracellular domains of cadherins in the dynamics of synapses. The kinetics of dimer disassembly of the first two extracellular domains of E- and N-cadherin, ECAD12 and NCAD12, were studied with analytical size exclusion chromatography and sedimentation velocity. NCAD12 forms three different dimers that are distinguished by assembly conditions and kinetics of dissociation. ECAD12 dimer disassembles rapidly regardless of the calcium concentration, whereas the disassembly of NCAD12 dimers was strongly dependent on calcium concentration. In addition to the apo- and saturated-dimeric forms of NCAD12, there is a third dimeric form that is a slow exchange duller. This third dimeric form for NCAD12, formed by decalcification of the calcium-saturated dimer, was kinetically trapped in apo-conditions and did not disassemble over a period of months. Sedimentation velocity experiments showed that this dimer, upon addition of calcium, had similar weighted averages as a. calcium-saturated dimer. These studies provide evidence that the kinetics of dimer disassembly of the extracellular domains may be a major contributor to the morphological dynamics of synapses in vivo. C1 [Vunnam, Nagamani; Flint, Jon; Pedigo, Susan] Univ Mississippi, Dept Chem & Biochem, University, MS 38677 USA. [Balbo, Andrea; Schuck, Peter] NIBIB, Dynam Macromol Assembly LBPS, NIH, Bethesda, MD 20892 USA. RP Pedigo, S (reprint author), Univ Mississippi, Dept Chem & Biochem, University, MS 38677 USA. EM spedigo@olemiss.edu OI Schuck, Peter/0000-0002-8859-6966 FU National Science Foundation [MCB 0950494] FX This work was supported by Grant MCB 0950494 from the National Science Foundation. NR 73 TC 9 Z9 9 U1 0 U2 6 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD APR 12 PY 2011 VL 50 IS 14 BP 2951 EP 2961 DI 10.1021/bi2001246 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 743OW UT WOS:000289029200026 PM 21375242 ER PT J AU Edgell, DR Chalamcharla, VR Belfort, M AF Edgell, David R. Chalamcharla, Venkata R. Belfort, Marlene TI Learning to live together: mutualism between self-splicing introns and their hosts SO BMC BIOLOGY LA English DT Review ID GROUP-II INTRON; OPEN READING FRAMES; YEAST MITOCHONDRIAL-DNA; HOMING ENDONUCLEASE; TRANSFER-RNA; IN-VIVO; ENCODED ENDONUCLEASE; MESSENGER-RNA; REVERSE TRANSCRIPTASE/MATURASE; CHLAMYDOMONAS-REINHARDTII AB Group I and II introns can be considered as molecular parasites that interrupt protein-coding and structural RNA genes in all domains of life. They function as self-splicing ribozymes and thereby limit the phenotypic costs associated with disruption of a host gene while they act as mobile DNA elements to promote their spread within and between genomes. Once considered purely selfish DNA elements, they now seem, in the light of recent work on the molecular mechanisms regulating bacterial and phage group I and II intron dynamics, to show evidence of co-evolution with their hosts. These previously underappreciated relationships serve the co-evolving entities particularly well in times of environmental stress. C1 [Edgell, David R.] Univ Western Ontario, Dept Biochem, Schulich Sch Med & Dent, London, ON N6A 5C1, Canada. [Chalamcharla, Venkata R.; Belfort, Marlene] New York State Dept Hlth, Ctr Med Sci, Wadsworth Ctr, Albany, NY 12208 USA. [Chalamcharla, Venkata R.; Belfort, Marlene] SUNY Albany, Albany, NY 12208 USA. [Chalamcharla, Venkata R.] NCI, NIH, Bethesda, MD 20892 USA. RP Edgell, DR (reprint author), Univ Western Ontario, Dept Biochem, Schulich Sch Med & Dent, London, ON N6A 5C1, Canada. EM dedgell@uwo.ca; belfort@wadsworth.org OI Belfort, Marlene/0000-0002-1592-5618 FU CIHR [MOP-97780]; NIH [GM39422, GM44844] FX We thank John Dansereau for assistance with figures, and Anna Pyle and Steve Zimmerly for discussion. This work was supported by a CIHR Operating Grant (MOP-97780) to DRE, a CIHR New Investigator Salary Award to DRE, and by NIH Grants GM39422 and GM44844 to MB. NR 95 TC 23 Z9 23 U1 1 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7007 J9 BMC BIOL JI BMC Biol. PD APR 11 PY 2011 VL 9 AR 22 DI 10.1186/1741-7007-9-22 PG 9 WC Biology SC Life Sciences & Biomedicine - Other Topics GA 748QD UT WOS:000289404600001 PM 21481283 ER PT J AU Kang, SS Herz, J Kim, JV Nayak, D Stewart-Hutchinson, P Dustin, ML McGavern, DB AF Kang, Silvia S. Herz, Jasmin Kim, Jiyun V. Nayak, Debasis Stewart-Hutchinson, Phillip Dustin, Michael L. McGavern, Dorian B. TI Migration of cytotoxic lymphocytes in cell cycle permits local MHC I-dependent control of division at sites of viral infection SO JOURNAL OF EXPERIMENTAL MEDICINE LA English DT Article ID CD8(+) T-CELLS; AUTOIMMUNE ENCEPHALOMYELITIS; TOLERANCE INDUCTION; SYNAPSE FORMATION; ANTIGEN; ACTIVATION; MEMORY; EFFECTOR; NAIVE; VIVO AB After virus infection, cytotoxic T lymphocytes (CTLs) divide rapidly to eradicate the pathogen and prevent the establishment of persistence. The magnitude of an antiviral CTL response is thought to be controlled by the initiation of a cell cycle program within lymphoid tissues. However, it is presently not known whether this division program proceeds during migration or is influenced locally at sites of viral infection. We demonstrate that antiviral CTLs remain in cell cycle while transiting to infected tissues. Up to one third of virus-specific CTLs within blood were found to be in cell cycle after infection with lymphocytic choriomeningitis virus or vesicular stomatitis virus. Using two-photon microscopy, we found that effector CTL divided rapidly upon arrest in the virus-infected central nervous system as well as in meningeal blood vessels. We also observed that MHC I-dependent interactions, but not costimulation, influenced the division program by advancing effector CTL through stages of the cell cycle. These results demonstrate that CTLs are poised to divide in transit and that their numbers can be influenced locally at the site of infection through interactions with cells displaying cognate antigen. C1 [Kang, Silvia S.; Herz, Jasmin; Nayak, Debasis; McGavern, Dorian B.] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA. [Kim, Jiyun V.; Stewart-Hutchinson, Phillip; Dustin, Michael L.] NYU, Mol Pathogenesis Program, Helen L & Martin S Kimmel Ctr Biol & Med, Skirball Inst Biomol Med,Sch Med, New York, NY 10016 USA. RP McGavern, DB (reprint author), Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA. EM mcgavernd@mail.nih.gov OI McGavern, Dorian/0000-0001-9568-545X; Dustin, Michael/0000-0003-4983-6389 FU National Institutes of Health (NIH) [AI075298-01, AI055037]; Dana Foundation; New York State Spinal Cord; National Research Service Award [NS061447-01] FX This work was supported by National Institutes of Health (NIH) intramural program as well as NIH grants AI075298-01 and AI055037 (M.L Dustin), Dana Foundation Grant (M.L Dustin), and New York State Spinal Cord Injury Research Grant (J.V. Kim). S.S. Kong is presently supported by a National Research Service Award (NS061447-01). NR 42 TC 22 Z9 22 U1 0 U2 4 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA SN 0022-1007 EI 1540-9538 J9 J EXP MED JI J. Exp. Med. PD APR 11 PY 2011 VL 208 IS 4 BP 747 EP 759 DI 10.1084/jem.20101295 PG 13 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 748QF UT WOS:000289404800010 PM 21464219 ER PT J AU Keszei, M Detre, C Rietdijk, ST Munoz, P Romero, X Berger, SB Calpe, S Liao, GX Castro, W Julien, A Wu, YY Shin, DM Sancho, J Zubiaur, M Morse, HC Morel, L Engel, P Wang, NH Terhorst, C AF Keszei, Marton Detre, Cynthia Rietdijk, Svend T. Munoz, Pilar Romero, Xavier Berger, Scott B. Calpe, Silvia Liao, Gongxian Castro, Wilson Julien, Aimee Wu, Ying-Yu Shin, Dong-Mi Sancho, Jaime Zubiaur, Mercedes Morse, Herbert C., III Morel, Laurence Engel, Pablo Wang, Ninghai Terhorst, Cox TI A novel isoform of the Ly108 gene ameliorates murine lupus SO JOURNAL OF EXPERIMENTAL MEDICINE LA English DT Article ID SPLICED 3'-UNTRANSLATED REGION; B-CELL TOLERANCE; SPONTANEOUS AUTOIMMUNITY; SUSCEPTIBILITY LOCI; C57BL/6 MICE; TCR-ZETA; T-CELLS; ERYTHEMATOSUS; FAMILY; EXPRESSION AB Studies of human systemic lupus erythematosus patients and of murine congenic mouse strains associate genes in a DNA segment on chromosome 1 with a genetic predisposition for this disease. The systematic analysis of lupus-prone congenic mouse strains suggests a role for two isoforms of the Ly108 receptor in the pathogenesis of the disease. In this study, we demonstrate that Ly108 is involved in the pathogenesis of lupus-related auto-immunity in mice. More importantly, we identified a third protein isoform, Ly108-H1, which is absent in two lupus-prone congenic animals. Introduction of an Ly108-H1-expressing transgene markedly diminishes T cell-dependent autoimmunity in congenic B6.Sle1b mice. Thus, an immune response-suppressing isoform of Ly108 can regulate the pathogenesis of lupus. C1 [Keszei, Marton; Detre, Cynthia; Rietdijk, Svend T.; Romero, Xavier; Berger, Scott B.; Calpe, Silvia; Liao, Gongxian; Castro, Wilson; Julien, Aimee; Wu, Ying-Yu; Wang, Ninghai; Terhorst, Cox] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Immunol, Dept Med,Med Sch, Boston, MA 02115 USA. [Munoz, Pilar; Sancho, Jaime; Zubiaur, Mercedes] CSIC, Inst Parasitol & Biomed, Granada 18100, Spain. [Shin, Dong-Mi; Morse, Herbert C., III] NIAID, Immunopathol Lab, NIH, Rockville, MD 20852 USA. [Morel, Laurence] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA. [Engel, Pablo] Univ Barcelona, Sch Med, Dept Cellular Biol & Pathol, Immunol Unit, E-08036 Barcelona, Spain. RP Terhorst, C (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Immunol, Dept Med,Med Sch, Boston, MA 02115 USA. EM mkeszei@bidmc.harvard.edu; cterhors@bidmc.harvard.edu RI Sancho, Jaime/O-3228-2013; Keszei, Marton/F-3295-2014; Zubiaur, Mercedes/K-9390-2014; OI Sancho, Jaime/0000-0003-3852-7951; Keszei, Marton/0000-0002-1158-2179; Zubiaur, Mercedes/0000-0002-4127-3027; Morse, Herbert/0000-0002-9331-3705 FU National Institutes of Health [DK073339, AI-065687] FX This work was supported by grants from the National Institutes of Health (DK073339 and AI-065687 to C. Terhorst). NR 39 TC 29 Z9 30 U1 0 U2 5 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA SN 0022-1007 J9 J EXP MED JI J. Exp. Med. PD APR 11 PY 2011 VL 208 IS 4 BP 811 EP 822 DI 10.1084/jem.20101653 PG 12 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 748QF UT WOS:000289404800015 PM 21422172 ER PT J AU Boelte, KC Gordy, LE Joyce, S Thompson, MA Yang, L Lin, PC AF Boelte, Kimberly C. Gordy, Laura E. Joyce, Sebastian Thompson, Mary Ann Yang, Li Lin, P. Charles TI Rgs2 Mediates Pro-Angiogenic Function of Myeloid Derived Suppressor Cells in the Tumor Microenvironment via Upregulation of MCP-1 SO PLOS ONE LA English DT Article ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; MESSENGER-RNA; EXPRESSION; FAMILY; GENE; LOCALIZATION; LYMPHOCYTES; CHEMOTAXIS; ACTIVATION; CHEMOKINES AB Background: Tumor growth is intimately linked with stromal interactions. Myeloid derived suppressor cells (MDSCs) are dramatically elevated in cancer patients and tumor bearing mice. MDSCs modulate the tumor microenvironment through attenuating host immune response and increasing vascularization. Methodology/Principal Findings: In searching for molecular mediators responsible for pro-tumor functions, we found that regulator of G protein signaling-2 (Rgs2) is highly increased in tumor-derived MDSCs compared to control MDSCs. We further demonstrate that hypoxia, a common feature associated with solid tumors, upregulates the gene expression. Genetic deletion of Rgs2 in mice resulted in a significant retardation of tumor growth, and the tumors exhibit decreased vascular density and increased cell death. Interestingly, deletion of Rgs2 in MDSCs completely abolished their tumor promoting function, suggesting that Rgs2 signaling in MDSCs is responsible for the tumor promoting function. Cytokine array profiling identified that Rgs2-/- tumor MDSCs produce less MCP-1, leading to decreased angiogenesis, which could be restored with addition of recombinant MCP-1. Conclusion: Our data reveal Rgs2 as a critical regulator of the pro-angiogenic function of MDSCs in the tumor microenvironment, through regulating MCP-1 production. C1 [Boelte, Kimberly C.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37235 USA. [Gordy, Laura E.; Joyce, Sebastian] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN USA. [Thompson, Mary Ann] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA. [Yang, Li; Lin, P. Charles] NIH, Ctr Canc Res, Bethesda, MD 20892 USA. RP Boelte, KC (reprint author), Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37235 USA. EM p.lin@nih.gov FU National Institutes of Health [CA108856, NS45888, AR053718, HL054977, AI061721, AI042284, T32CA009582, T32HL069765, T32AI007611] FX This work was supported in part by grants from National Institutes of Health to PCL (CA108856, NS45888 and AR053718) and SJ (HL054977, AI061721 and AI042284) as well as training grants to KCB (T32CA009582) and LEG (T32HL069765 and T32AI007611). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 26 Z9 27 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 11 PY 2011 VL 6 IS 4 AR e18534 DI 10.1371/journal.pone.0018534 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 747XH UT WOS:000289354100019 PM 21494556 ER PT J AU Liu, SA Piatigorsky, J AF Liu, Shuang Piatigorsky, Joram TI Regulation of Mouse Small Heat Shock Protein alpha b-Crystallin Gene by Aryl Hydrocarbon Receptor SO PLOS ONE LA English DT Article ID DIOXIN-RESPONSIVE ENHANCER; LIGANDED AH RECEPTOR; DEVELOPMENTAL EXPRESSION; TRANSCRIPTION FACTORS; DNA INTERACTIONS; 2 MEMBERS; LENS; IDENTIFICATION; PROMOTER; MICE AB The stress-inducible small heat shock protein (shsp)/alpha B-crystallin gene is expressed highly in the lens and moderately in other tissues. Here we provide evidence that it is a target gene of the aryl hydrocarbon receptor (AhR) transcription factor. A sequence (-329/-323, CATGCGA) similar to the consensus xenobiotic responsive element (XRE), called here XRE-like, is present in the alpha BE2 region of alpha B-crystallin enhancer and can bind AhR in vitro and in vivo. alpha B-crystallin protein levels were reduced in retina, lens, cornea, heart, skeletal muscle and cultured muscle fibroblasts of AhR(-/-) mice; alpha B-crystallin mRNA levels were reduced in the eye, heart and skeletal muscle of AhR(-/-) mice. Increased AhR stimulated alpha B-crystallin expression in transfection experiments conducted in conjunction with the aryl hydrocarbon receptor nuclear translocator (ARNT) and decreased AhR reduced alpha B-crystallin expression. AhR effect on aB-crystallin promoter activity was cell-dependent in transfection experiments. AhR up-regulated alpha B-crystallin promoter activity in transfected HeLa, NIH3T3 and COS-7 cells in the absence of exogenously added ligand (TCDD), but had no effect on the alpha B-crystallin promoter in C(2)C(12), CV-1 or Hepa-1 cells with or without TCDD. TCDD enhanced AhR-stimulated alpha B-crystallin promoter activity in transfected alpha TN4 cells. AhR could bind to an XRE-like site in the alpha B-crystallin enhancer in vitro and in vivo. Finally, site-specific mutagenesis experiments showed that the XRE-like motif was necessary for both basal and maximal AhR-induction of alpha B-crystallin promoter activity. Our data strongly suggest that AhR is a regulator of alpha B-crystallin gene expression and provide new avenues of research for the mechanism of tissue-specific alpha B-crystallin gene regulation under normal and physiologically stressed conditions. C1 [Liu, Shuang; Piatigorsky, Joram] NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA. [Liu, Shuang] NCI, Expt Immunol Lab, NIH, Frederick, MD 21701 USA. RP Liu, SA (reprint author), NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA. EM liushuang1999@yahoo.com; joramp@nei.nih.gov FU NIH, NEI FX This research was supported by the Intramural Research Program of the NIH, NEI. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 10 Z9 10 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 11 PY 2011 VL 6 IS 4 AR e17904 DI 10.1371/journal.pone.0017904 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 747XH UT WOS:000289354100003 PM 21494593 ER PT J AU Ide, S Minami, M Uhl, GR Satoh, M Sora, I Ikeda, K AF Ide, Soichiro Minami, Masabumi Uhl, George R. Satoh, Masamichi Sora, Ichiro Ikeda, Kazutaka TI (-)-Pentazocine induces visceral chemical antinociception, but not thermal, mechanical, or somatic chemical antinociception, in mu-opioid receptor knockout mice SO MOLECULAR PAIN LA English DT Article DE Opioid receptor Knockout mice; Pentazocine; Antinociception ID MORPHINE-INDUCED ANALGESIA; POSTOPERATIVE PAIN; SEX-DIFFERENCES; KAPPA; DELTA; GENE; PENTAZOCINE; NOCICEPTION; ANTAGONIST; WITHDRAWAL AB Background: (-)-Pentazocine has been hypothesized to induce analgesia via the kappa-opioid (KOP) receptor, although the involvement of other opioid receptor subtypes in the effects of pentazocine remains unknown. In this study, we investigated the role of the mu-opioid (MOP) receptor in thermal, mechanical, and chemical antinociception induced by (-)-pentazocine using MOP receptor knockout (MOP-KO) mice. Results: (-)-Pentazocine-induced thermal antinociception, assessed by the hot-plate and tail-flick tests, was significantly reduced in heterozygous and abolished in homozygous MOP-KO mice compared with wildtype mice. The results obtained from the (-)-pentazocine-induced mechanical and somatic chemical antinociception experiments, which used the hind-paw pressure and formalin tests, were similar to the results obtained from the thermal antinociception experiments in these mice. However, (-)-pentazocine retained its ability to induce significant visceral chemical antinociception, assessed by the writhing test, in homozygous MOP-KO mice, an effect that was completely blocked by pretreatment with nor-binaltorphimine, a KOP receptor antagonist. In vitro binding and cyclic adenosine monophosphate assays showed that (-)-pentazocine possessed higher affinity for KOP and MOP receptors than for delta-opioid receptors. Conclusions: The present study demonstrated the abolition of the thermal, mechanical, and somatic chemical antinociceptive effects of (-)-pentazocine and retention of the visceral chemical antinociceptive effects of (-)-pentazocine in MOP-KO mice. These results suggest that the MOP receptor plays a pivotal role in thermal, mechanical, and somatic chemical antinociception induced by (-)-pentazocine, whereas the KOP receptor is involved in visceral chemical antinociception induced by (-)-pentazocine. C1 [Ide, Soichiro; Ikeda, Kazutaka] Tokyo Metropolitan Inst Med Sci, Res Project Addict Subst, Tokyo 1568506, Japan. [Ide, Soichiro; Minami, Masabumi] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido 0600812, Japan. [Uhl, George R.; Sora, Ichiro] Natl Inst Drug Abuse, Baltimore, MD 21224 USA. [Satoh, Masamichi] Yasuda Womens Univ, Dept Pharm, Hiroshima 7310153, Japan. [Sora, Ichiro] Tohoku Univ, Grad Sch Med, Dept Neurosci, Div Psychobiol, Sendai, Miyagi 9808574, Japan. RP Ikeda, K (reprint author), Tokyo Metropolitan Inst Med Sci, Res Project Addict Subst, Tokyo 1568506, Japan. EM ikeda-kz@igakuken.or.jp RI Ide, Soichiro/D-5472-2012; Minami, Masabumi/A-3883-2012; Ikeda, Kazutaka/I-4694-2013 OI Minami, Masabumi/0000-0002-0144-0679; Ikeda, Kazutaka/0000-0001-8342-0278 FU Japanese Ministry of Education, Culture, Sports, Science, and Technology [21600018]; Japanese Ministry of Health, Labour and Welfare; National Institutes of Health FX This study was supported by research grants from the Japanese Ministry of Education, Culture, Sports, Science, and Technology, a Grant-in-Aid for Scientific Research (C) (21600018), the Japanese Ministry of Health, Labour and Welfare, and the National Institute on Drug Abuse Intramural Research Program from the National Institutes of Health. We thank Drs. Yoko Hagino, Yukio Takamatsu, and Keiko Matsuoka for technical support and animal care. NR 37 TC 10 Z9 10 U1 0 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1744-8069 J9 MOL PAIN JI Mol. Pain PD APR 10 PY 2011 VL 7 AR 23 DI 10.1186/1744-8069-7-23 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 762AK UT WOS:000290444400001 PM 21477373 ER PT J AU Jaffe, ES AF Jaffe, Elaine S. TI Centralized Review Offers Promise for the Clinician, the Pathologist, and the Patient With Newly Diagnosed Lymphoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material C1 NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP Jaffe, ES (reprint author), NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. OI Jaffe, Elaine/0000-0003-4632-0301 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD APR 10 PY 2011 VL 29 IS 11 BP 1398 EP 1398 DI 10.1200/JCO.2010.34.2741 PG 1 WC Oncology SC Oncology GA 746VW UT WOS:000289276900017 PM 21343557 ER PT J AU Kino, T Chrousos, GP AF Kino, Tomoshige Chrousos, George P. TI Acetylation-mediated epigenetic regulation of glucocorticoid receptor activity: Circadian rhythm-associated alterations of glucocorticoid actions in target tissues SO MOLECULAR AND CELLULAR ENDOCRINOLOGY LA English DT Article; Proceedings Paper CT 14th Biennial Adrenal Cortex Conference (Adrenal 2010) CY JUN 16-18, 2010 CL San Diego, CA DE Acetylation; Circadian rhythm; Clock; Histone acetyltransferase (HAT); Histone deacetylase (HDAC); Hypothalamic-pituitary-adrenal (HPA) axis; Sirt1 ID PITUITARY-ADRENAL AXIS; ANDROGEN RECEPTOR; TRANSCRIPTIONAL ACTIVITY; MINERALOCORTICOID RECEPTOR; DNA-BINDING; CLINICAL-IMPLICATIONS; GENE-EXPRESSION; STRESS SYSTEM; MAP KINASE; P38 MAPK AB Glucocorticoids influence organ functions through the glucocorticoid receptor, a protein acetylated and deacetylated by several histone acetyltransferases and deacetylases. We reported that the circadian rhythm-related transcription factor "Clock", a key component of the biological CLOCK with inherent histone acetyltransferase activity, acetylates glucocorticoid receptor lysines within its hinge region-a "lysine cluster" containing a KXKK motif-and represses its transcriptional activity. This Clock-induced repression of the glucocorticoid receptor activity is inversely phased to the diurnally circulating glucocorticoids and may act as a local counter regulatory mechanism to the actions of these hormones. Importantly, uncoupling of the central CLOCK-regulated hypothalamic-pituitary-adrenal axis and peripheral CLOCK-mediated alterations of glucocorticoid action, such as chronic stress and frequent trans-time zone travel or night-shift work, may cause functional hypercortisolism and contribute to various pathologies. Thus, acetylation-mediated epigenetic regulation of the glucocorticoid receptor may be essential for the maintenance of proper time-integrated glucocorticoid action, significantly influencing human well-being and longevity. Published by Elsevier Ireland Ltd. C1 [Kino, Tomoshige] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Unit Mol Hormone Act, Program Reprod & Adult Endocrinol, NIH,CRC, Bethesda, MD 20892 USA. [Chrousos, George P.] Univ Athens, Sch Med, Aghia Sophia Childrens Hosp, Dept Pediat 1, GR-11527 Athens, Greece. RP Kino, T (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Unit Mol Hormone Act, Program Reprod & Adult Endocrinol, NIH,CRC, Bldg 10,Rm 1-3140,10 Ctr Dr,MSC 1109, Bethesda, MD 20892 USA. EM kinot@mail.nih.gov FU Intramural NIH HHS [ZIA HD008732-09] NR 93 TC 25 Z9 25 U1 4 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0303-7207 J9 MOL CELL ENDOCRINOL JI Mol. Cell. Endocrinol. PD APR 10 PY 2011 VL 336 IS 1-2 SI SI BP 23 EP 30 DI 10.1016/j.mce.2010.12.001 PG 8 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 748HN UT WOS:000289381400005 PM 21146585 ER PT J AU Almeida, MQ Stratakis, CA AF Almeida, Madson Q. Stratakis, Constantine A. TI How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues? SO MOLECULAR AND CELLULAR ENDOCRINOLOGY LA English DT Article; Proceedings Paper CT 14th Biennial Adrenal Cortex Conference (Adrenal 2010) CY JUN 16-18, 2010 CL San Diego, CA DE Adrenal cortex; Protein kinase A; Primary pigmented nodular adrenocortical disease; ACTH-independent macronodular adrenal hyperplasia; Adrenal tumor; Phosphodiesterase; Wnt signaling ID DEPENDENT PROTEIN-KINASE; SUBUNIT TYPE 1A; ADRENOCORTICAL DISEASE PPNAD; MCCUNE-ALBRIGHT SYNDROME; REGULATORY SUBUNIT; CARNEY COMPLEX; BETA-CATENIN; NEUROFIBROMATOSIS TYPE-1; GENETIC-HETEROGENEITY; MOLECULAR ANALYSIS AB The overwhelming majority of benign lesions of the adrenal cortex leading to Cushing syndrome are linked to one or another abnormality of the cAMP signaling pathway. A small number of both massive macronodular adrenocortical disease and cortisol-producing adenomas harbor somatic GNAS mutations. Micronodular adrenocortical hyperplasias are either pigmented (the classic form being that of primary pigmented nodular adrenocortical disease) or non-pigmented: micronodular adrenocortical hyperplasias can be seen in the context of other conditions or isolated; for example, primary pigmented nodular adrenocortical disease usually occurs in the context of Carney complex, but isolated primary pigmented nodular adrenocortical disease has also been described. Both Carney complex and isolated primary pigmented nodular adrenocortical disease are caused by germline PRKAR1A mutations; somatic mutations of this gene that regulates cAMP-dependent protein kinase are also found in cortisol-producing adenomas, and abnormalities of PKA are present in most cases of massive macronodular adrenocortical disease. Micronodular adrenocortical hyperplasias and some cortisol-producing adenomas are associated with phosphodiesterase 11A and 8B defects, coded, respectively, by the PDE11A and PDE8B genes. Mouse models of Prkar1a deficiency also show that increased cAMP signaling leads to tumors in adrenal cortex and other tissues. In this review, we summarize all recent data from ours and other laboratories, supporting the view that Wnt-signaling acts as an important mediator of tumorigenicity induced by abnormal PRKAR1A function and aberrant cAMP signaling. Published by Elsevier Ireland Ltd. C1 [Stratakis, Constantine A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, SEGEN, PDEGEN, NIH,CRC, Bethesda, MD 20892 USA. [Stratakis, Constantine A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Endocrinol Interinst Training Program, NIH, Bethesda, MD 20892 USA. RP Stratakis, CA (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, SEGEN, PDEGEN, NIH,CRC, Bldg 10,Room 1-3330,10 Ctr Dr,MSC1103, Bethesda, MD 20892 USA. EM stratakc@mail.nih.gov FU Intramural NIH HHS [ZIA HD000642-13] NR 72 TC 31 Z9 32 U1 0 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0303-7207 J9 MOL CELL ENDOCRINOL JI Mol. Cell. Endocrinol. PD APR 10 PY 2011 VL 336 IS 1-2 SI SI BP 162 EP 168 DI 10.1016/j.mce.2010.11.018 PG 7 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 748HN UT WOS:000289381400024 PM 21111774 ER PT J AU Fink-Jensen, A Schmidt, LS Dencker, D Schulein, C Wess, J Wortwein, G Woldbye, DPD AF Fink-Jensen, Anders Schmidt, Lene S. Dencker, Ditte Schulein, Christina Wess, Jurgen Wortwein, Gitta Woldbye, David P. D. TI Antipsychotic-induced catalepsy is attenuated in mice lacking the M-4 muscarinic acetylcholine receptor SO EUROPEAN JOURNAL OF PHARMACOLOGY LA English DT Article DE Muscarinic M-4 receptor; Catalepsy; Haloperidol; Risperidone; Dopamine; Scopolamine; Motoric side effects ID RAT STRIATAL NEURONS; D2 DOPAMINE; KNOCKOUT MICE; CHOLINERGIC NEURONS; MESSENGER-RNAS; EXPRESSION; D1; PROTEINS; SUBTYPE; DRUGS AB A delicate balance exists between the central dopaminergic and cholinergic neurotransmitter systems with respect to motor function. An imbalance can result in motor dysfunction as observed in Parkinson's disease patients and in patients treated with antipsychotic compounds. Cholinergic receptor antagonists can alleviate extrapyramidal symptoms in Parkinson's disease and motor side effects induced by antipsychotics. The effects of anticholinergics are mediated by muscarinic receptors of which five subtypes (M-1-M-5) exist. Muscarinic M-4 receptors are found at high concentrations in motor parts of the striatum, suggesting a role for muscarinic M-4 receptors in the motor side effects of antipsychotics, and in the alleviation of these side effects by anticholinergics. Here we investigated the potential role of the muscarinic M-4 receptor in catalepsy induced by antipsychotics (haloperidol and risperidone) as well as the anti-cataleptic effects of the non-selective anticholinergic drug scopolamine in fully backcrossed muscarinic M-4 receptor knockout mice. The drug-induced catalepsy was strongly attenuated, but not abolished, in M-4 knockout mice as compared to wild-type controls. Scopolamine further attenuated the cataleptic response in M-4 knockout mice, suggesting that non-M-4 muscarinic receptors also participate in the anti-cataleptic effects. In conclusion, these data indicate an important role for M-4 receptors in antipsychotic-induced motor side effects and suggest that M-4 receptors could be a target for future pharmacological treatment of antipsychotic-induced as well as idiopathic parkinsonism. (C) 2011 Elsevier B.V. All rights reserved. C1 [Fink-Jensen, Anders; Schmidt, Lene S.; Dencker, Ditte; Schulein, Christina; Wortwein, Gitta; Woldbye, David P. D.] Rigshosp Univ Hosp, Lab Neuropsychiat, Copenhagen, Denmark. [Fink-Jensen, Anders] Univ Hosp Copenhagen, Psychiat Ctr Copenhagen, Copenhagen, Denmark. [Wess, Jurgen] NIDDK, Mol Signaling Sect, Bioorgan Chem Lab, NIH, Bethesda, MD USA. [Wortwein, Gitta] Univ Copenhagen, Dept Publ Hlth, DK-2100 Copenhagen, Denmark. [Woldbye, David P. D.] Univ Copenhagen, Dept Neurosci & Pharmacol, DK-2100 Copenhagen, Denmark. RP Fink-Jensen, A (reprint author), Univ Copenhagen, Lab Neuropsychiat, Psychiat Ctr Copenhagen, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. EM a.fink-jensen@dadlnet.dk OI Wortwein, Gitta/0000-0001-6981-7885 FU Ivan Nielsen Foundation; 7 Lundbeck Foundation FX This work was supported by grants from the Ivan Nielsen Foundation and the 7 Lundbeck Foundation. NR 35 TC 15 Z9 16 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-2999 J9 EUR J PHARMACOL JI Eur. J. Pharmacol. PD APR 10 PY 2011 VL 656 IS 1-3 BP 39 EP 44 DI 10.1016/j.ejphar.2011.01.018 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 742IO UT WOS:000288935600007 PM 21269601 ER PT J AU Yoo, SH Park, O Henderson, LE Abdelmegeed, MA Moon, KH Song, BJ AF Yoo, Seong Ho Park, Ogyi Henderson, Lauren E. Abdelmegeed, Mohamed A. Moon, Kwan-Hoon Song, Byoung-Joon TI Lack of PPAR alpha exacerbates lipopolysaccharide-induced liver toxicity through STAT1 inflammatory signaling and increased oxidative/nitrosative stress SO TOXICOLOGY LETTERS LA English DT Article DE PPAR alpha; Lipopolysaccharide; Acute liver damage; Cytokines; STAT; Oxidative/nitrosative stress ID ACTIVATED RECEPTOR-GAMMA; OXIDATIVE STRESS; IFN-GAMMA; KAPPA-B; INJURY; LIGANDS; APOPTOSIS; TRANSCRIPTION; DYSFUNCTION; METABOLISM AB Peroxisome proliferator-activated receptor-alpha (PPAR alpha) has been implicated in a potent anti-inflammatory activity. However, no information is available on whether PPAR alpha can affect signal transducers and activator of transcription proteins (STATs) in acute liver damage. Thus, this study was aimed to investigate the in vivo role of PPAR alpha in elevating STATs as well as oxidative/nitrosative stress in a model of lipopolysaccharide (LPS)-induced acute hepatic inflammatory injury. Using age-matched Ppara-null and wild-type (WT) mice, we demonstrate that the deletion of PPAR alpha aggravates LPS-mediated liver injury through activating STAT1 and NF-KB-p65 accompanied by increased levels of pro-inflammatory cytokines. Furthermore, the activities of key anti-oxidant enzymes and mitochondrial complexes were significantly decreased while lipid peroxidation and protein nitration were elevated in LPS-exposed Ppara-null mice compared to WT. These results indicate that PPAR alpha is important in preventing LPS-induced acute liver damage by regulating STAT1 inflammatory signaling pathways and oxidative/nitrosative stress. Published by Elsevier Ireland Ltd. C1 [Yoo, Seong Ho; Henderson, Lauren E.; Abdelmegeed, Mohamed A.; Moon, Kwan-Hoon; Song, Byoung-Joon] NIAAA, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD 20892 USA. [Park, Ogyi] NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA. [Yoo, Seong Ho] Seoul Natl Univ, Coll Med, Dept Forens Med, Seoul, South Korea. [Yoo, Seong Ho] Seoul Natl Univ, Coll Med, Inst Forens Med, Seoul, South Korea. RP Song, BJ (reprint author), NIAAA, Lab Membrane Biochem & Biophys, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM bj.song@nih.gov RI Yoo, Sung Ho/J-5549-2012 FU National Institute on Alcohol Abuse and Alcoholism FX This study was supported by the Intramural Research Fund of National Institute on Alcohol Abuse and Alcoholism. NR 31 TC 10 Z9 14 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0378-4274 J9 TOXICOL LETT JI Toxicol. Lett. PD APR 10 PY 2011 VL 202 IS 1 BP 23 EP 29 DI 10.1016/j.toxlet.2011.01.013 PG 7 WC Toxicology SC Toxicology GA 742HO UT WOS:000288932400004 PM 21262334 ER PT J AU Wolfe, CL Moss, B AF Wolfe, Cindy L. Moss, Bernard TI Interaction between the G3 and L5 proteins of the vaccinia virus entry-fusion complex SO VIROLOGY LA English DT Article DE Poxvirus; Protein interactions; Multisubunit complex; Immunopurification; Mass spectrometry ID VIRION MEMBRANE-PROTEIN; SURFACE HEPARAN-SULFATE; CELL-CELL FUSION; MATURE VIRION; ESSENTIAL COMPONENT; POXVIRUS ENTRY; L1 PROTEIN; BINDS; GENE; ENCODES AB The vaccinia virus entry-fusion complex (EFC) consists of 10 to 12 proteins that are embedded in the viral membrane and individually required for fusion with the cell and entry of the core into the cytoplasm. The architecture of the EFC is unknown except for information regarding two pair-wise interactions: A28 with H2 and A16 with G9. Here we used a technique to destabilize the EFC by repressing the expression of individual components and identified a third pair-wise interaction: G3 with L5. These two proteins remained associated under several different EFC destabilization conditions and in each case were immunopurified together as demonstrated by Western blotting. Further evidence for the specific interaction of G3 and L5 was obtained by mass spectrometry. This interaction also occurred when G3 and L5 were expressed in uninfected cells, indicating that no other viral proteins were required. Thus, the present study extends our knowledge of the protein interactions important for EFC assembly and stability. Published by Elsevier Inc. C1 [Wolfe, Cindy L.; Moss, Bernard] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA. RP Moss, B (reprint author), NIAID, Viral Dis Lab, NIH, 33 North Dr, Bethesda, MD 20892 USA. EM bmoss@nih.gov FU Division of Intramural Research, NIAID, NIH FX We thank Catherine Cotter for providing cells and other members of the Laboratory of Viral Diseases for helpful discussions. The research was supported by the Division of Intramural Research, NIAID, NIH. NR 25 TC 8 Z9 12 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD APR 10 PY 2011 VL 412 IS 2 BP 278 EP 283 DI 10.1016/j.virol.2011.01.014 PG 6 WC Virology SC Virology GA 740DZ UT WOS:000288773100004 PM 21295816 ER PT J AU Singer, M Winocour, E AF Singer, Maxine Winocour, Ernest TI SV40 host-substituted variants: a new look at the monkey DNA inserts and recombinant junctions SO VIROLOGY LA English DT Article DE SV40 host-substituted variants; Microhomology-mediated end joining; Monkey genome ID SIMIAN-VIRUS 40; DEOXYRIBONUCLEIC ACID REPLICATION; VIABLE DELETION MUTANTS; DOUBLE-STRAND BREAKS; CVP8-1-P2 ECORI RES; T-ANTIGEN; VIRAL-DNA; ILLEGITIMATE RECOMBINATION; VIRUS-40-INFECTED CELLS; EVOLUTIONARY VARIANTS AB The available monkey genomic data banks were examined in order to determine the chromosomal locations of the host DNA inserts in 8 host-substituted SV40 variant DNAs. Five of the 8 variants contained more than one linked monkey DNA insert per tandem repeat unit and in all cases but one, the 19 monkey DNA inserts in the 8 variants mapped to different locations in the monkey genome. The 50 parental DNAs (32 monkey and 18 SV40 DNA segments) which spanned the crossover and flanking regions that participated in monkey/monkey and monkey/SV40 recombinations were characterized by substantial levels of microhomology of up to 8 nucleotides in length; the parental DNAs also exhibited direct and inverted repeats at or adjacent to the crossover sequences. We discuss how the host-substituted SV40 variants arose and the nature of the recombination mechanisms involved. (C) 2011 Elsevier Inc. All rights reserved. C1 [Singer, Maxine] Carnegie Inst Sci, Washington, DC 20005 USA. [Singer, Maxine] NCI, Lab Biochem & Mol Biol, Bethesda, MD 20892 USA. [Winocour, Ernest] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel. RP Singer, M (reprint author), Carnegie Inst Sci, 1530 P St NW, Washington, DC 20005 USA. EM msinger@ciw.edu; ernest.winocour@weizmann.ac.il NR 68 TC 1 Z9 1 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD APR 10 PY 2011 VL 412 IS 2 BP 325 EP 332 DI 10.1016/j.virol.2011.01.020 PG 8 WC Virology SC Virology GA 740DZ UT WOS:000288773100009 PM 21316069 ER PT J AU Qi, L Kash, JC Dugan, VG Jagger, BW Lau, YF Sheng, ZM Crouch, EC Hartshorn, KL Taubenberger, JK AF Qi, Li Kash, John C. Dugan, Vivien G. Jagger, Brett W. Lau, Yuk-Fai Sheng, Zhong-Mei Crouch, Erika C. Hartshorn, Kevan L. Taubenberger, Jeffery K. TI The ability of pandemic influenza virus hemagglutinins to induce lower respiratory pathology is associated with decreased surfactant protein D binding SO VIROLOGY LA English DT Article DE Influenza A virus; Pandemic; Hemagglutinin; Pathology; Surfactant Protein D; Mice ID A VIRUSES; IN-VIVO; MORTALITY; INFECTION; IMMUNE; CELLS; SPECIFICITY; CLEARANCE; RECEPTORS; EVOLUTION AB Pandemic influenza viral infections have been associated with viral pneumonia. Chimeric influenza viruses with the hemagglutinin segment of the 1918, 1957, 1968, or 2009 pandemic influenza viruses in the context of a seasonal H1N1 influenza genome were constructed to analyze the role of hemagglutinin (HA) in pathogenesis and cell tropism in a mouse model. We also explored whether there was an association between the ability of lung surfactant protein D (SP-D) to bind to the HA and the ability of the corresponding chimeric virus to infect bronchiolar and alveolar epithelial cells of the lower respiratory tract. Viruses expressing the hemagglutinin of pandemic viruses were associated with significant pathology in the lower respiratory tract, including acute inflammation, and showed low binding activity for SP-D. In contrast, the virus expressing the HA of a seasonal influenza strain induced only mild disease with little lung pathology in infected mice and exhibited strong in vitro binding to SP-D. Published by Elsevier Inc. C1 [Qi, Li; Kash, John C.; Dugan, Vivien G.; Jagger, Brett W.; Sheng, Zhong-Mei; Taubenberger, Jeffery K.] NIAID, Viral Pathogenesis & Evolut Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Lau, Yuk-Fai] NIAID, Emerging Resp Viruses Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Crouch, Erika C.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA. [Hartshorn, Kevan L.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Taubenberger, JK (reprint author), NIAID, Viral Pathogenesis & Evolut Sect, Infect Dis Lab, NIH, 33 N Dr,MSC 3203, Bethesda, MD 20892 USA. EM taubenbergerj@niaid.nih.gov OI Hartshorn, Kevan/0000-0002-7196-7433 FU NIH; NIAID FX We thank Christian Sauder (CBER/FDA, Bethesda) for helpful discussions. We are grateful for the help provided by the staff of the NIH Building 33 Animal Facility (NIAID/CMB). This work was supported by the Intramural Research Program of the NIH and the NIAID. NR 58 TC 38 Z9 38 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD APR 10 PY 2011 VL 412 IS 2 BP 426 EP 434 DI 10.1016/j.virol.2011.01.029 PG 9 WC Virology SC Virology GA 740DZ UT WOS:000288773100020 PM 21334038 ER PT J AU Dobbin, KK Simon, RM AF Dobbin, Kevin K. Simon, Richard M. TI Optimally splitting cases for training and testing high dimensional classifiers SO BMC MEDICAL GENOMICS LA English DT Article ID DNA MICROARRAY DATA; CLASS PREDICTION; EXPRESSION; CLASSIFICATION; CANCER; SURVIVAL AB Background: We consider the problem of designing a study to develop a predictive classifier from high dimensional data. A common study design is to split the sample into a training set and an independent test set, where the former is used to develop the classifier and the latter to evaluate its performance. In this paper we address the question of what proportion of the samples should be devoted to the training set. How does this proportion impact the mean squared error (MSE) of the prediction accuracy estimate? Results: We develop a non-parametric algorithm for determining an optimal splitting proportion that can be applied with a specific dataset and classifier algorithm. We also perform a broad simulation study for the purpose of better understanding the factors that determine the best split proportions and to evaluate commonly used splitting strategies (1/2 training or 2/3 training) under a wide variety of conditions. These methods are based on a decomposition of the MSE into three intuitive component parts. Conclusions: By applying these approaches to a number of synthetic and real microarray datasets we show that for linear classifiers the optimal proportion depends on the overall number of samples available and the degree of differential expression between the classes. The optimal proportion was found to depend on the full dataset size (n) and classification accuracy - with higher accuracy and smaller n resulting in more assigned to the training set. The commonly used strategy of allocating 2/3rd of cases for training was close to optimal for reasonable sized datasets (n >= 100) with strong signals (i.e. 85% or greater full dataset accuracy). In general, we recommend use of our nonparametric resampling approach for determing the optimal split. This approach can be applied to any dataset, using any predictor development method, to determine the best split. C1 [Dobbin, Kevin K.] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA. [Simon, Richard M.] NCI, Biometr Res Branch, NIH, Rockville, MD USA. RP Dobbin, KK (reprint author), Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA. EM dobbinke@uga.edu FU Distinguished Cancer Clinicians and Scientists Program of the Georgia Cancer Coalition FX Kevin K. Dobbin's work was partially supported by the Distinguished Cancer Clinicians and Scientists Program of the Georgia Cancer Coalition. NR 22 TC 15 Z9 15 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1755-8794 J9 BMC MED GENOMICS JI BMC Med. Genomics PD APR 8 PY 2011 VL 4 AR 31 DI 10.1186/1755-8794-4-31 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 761XW UT WOS:000290437300001 PM 21477282 ER PT J AU Parvez, MK Purcell, RH Emerson, SU AF Parvez, Mohammad K. Purcell, Robert H. Emerson, Suzanne U. TI Hepatitis E virus ORF2 protein over-expressed by baculovirus in hepatoma cells, efficiently encapsidates and transmits the viral RNA to naive cells SO VIROLOGY JOURNAL LA English DT Article ID CAPSID PROTEIN; INSECT CELLS; IN-VITRO; RECOMBINANT; PATHOGENESIS; REPLICATION; RELEASE; CULTURE; HEV AB A recombinant baculovirus(vBacORF2) that expressed the full-length ORF2 capsid protein of a genotype 1 strain of hepatitis E virus(HEV) was constructed. Transduction of S10-3 human hepatoma cells with this baculovirus led to large amounts of ORF2 protein production in similar to 50% of the cells as determined by immune fluorescence microscopy. The majority of the ORF2 protein detected by Western blot was 72 kDa, the size expected for the full-length protein. To determine if the exogenously-supplied ORF2 protein could transencapsidate viral genomes, S10-3 cell cultures that had been transfected the previous day with an HEV replicon of genotype 1 that contained the gene for green fluorescent protein(GFP), in place of that for ORF2 protein, were transduced with the vBacORF2 virus. Cell lysates were prepared 5 days later and tested for the ability to deliver the GFP gene to HepG2/C3A cells, another human hepatoma cell line. FACS analysis indicated that lysates from cell cultures receiving only the GFP replicon were incapable of introducing the replicon into the HepG2/C3A cells whereas similar to 2% of the HepG2/C3A cells that received lysate from cultures that had received both the replicon and the baculovirus produced GFP. Therefore, the baculovirus-expressed ORF2 protein was able to trans encapsidate the viral replicon and form a particle that could infect naive HepG2/C3A cells. This ex vivo RNA packaging system should be useful for studying many aspects of HEV molecular biology. C1 [Parvez, Mohammad K.; Emerson, Suzanne U.] NIAID, Mol Hepatitis Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Purcell, Robert H.] NIAID, Hepatitis Viruses Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Parvez, Mohammad K.] King Saud Univ, Coll Pharm, Dept Pharmacognosy, Riyadh, Saudi Arabia. RP Emerson, SU (reprint author), NIAID, Mol Hepatitis Sect, Infect Dis Lab, NIH, 50 South Dr, Bethesda, MD 20892 USA. EM semerson@niaid.nih.gov FU National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA FX This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA. The technical support of Kristina Faulk in flow cytometry and Danielle Burke in Western blot is acknowledged. NR 21 TC 8 Z9 11 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-422X J9 VIROL J JI Virol. J. PD APR 8 PY 2011 VL 8 AR 159 DI 10.1186/1743-422X-8-159 PG 6 WC Virology SC Virology GA 755QP UT WOS:000289951400001 PM 21477278 ER PT J AU Ghaedi, M Tuleuova, N Zern, MA Wu, J Revzin, A AF Ghaedi, Mahboobe Tuleuova, Nazgul Zern, Mark A. Wu, Jian Revzin, Alexander TI Bottom-up signaling from HGF-containing surfaces promotes hepatic differentiation of mesenchymal stem cells SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Growth factor immobilization; Extracellular matrix; Hepatic differentiation; Mesenchymal stem cells; Protein microarrays ID HEPATOCYTE GROWTH-FACTOR; LIVER EPITHELIAL-CELLS; IN-VITRO; PRINTED ARRAYS; TRANSPLANTATION; MATRIX; CULTURE; TYPE-1 AB The capacity of stem cells to differentiate into specific cell types makes them very promising in tissue regeneration and repair. However, realizing this promise requires novel methods for guiding lineage-specific differentiation of stem cells. In this study, hepatocyte growth factor (HGF), an important morphogen in liver development, was co-printed with collagen I (Col) to create arrays of protein spots on glass. Human adipose stem cells (ASCs) were cultured on top of the HGF/Col spots for 2 weeks. The effects of surface-immobilized HGF on hepatic differentiation of ASCs were analyzed using RT-PCR, ELISA and immunocytochemistry. Stimulation of stem cells with HGF from the bottom-up caused an upregulation in synthesis of alpha-fetoprotein and albumin, as determined by immunocytochemistry and ELISA. RT-PCR results showed that the mRNA levels for albumin, alpha-fetoprotein and alpha 1-antitrypsin were 10- to 20-fold higher in stem cells cultured on the HGF/Col arrays compared to stem cells on Col only spots. Our results show that surfaces containing HGF co-printed with ECM proteins may be used to differentiate mesenchymal stem cells such as ASCs into hepatocyte-like cells. These results underscore the utility of growth factor-containing culture surfaces for stem cell differentiation. (C) 2011 Elsevier Inc. All rights reserved. C1 [Ghaedi, Mahboobe; Tuleuova, Nazgul; Revzin, Alexander] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA. [Zern, Mark A.; Wu, Jian] Univ Calif Davis, Med Ctr, Dept Med, Transplant Res Program, Sacramento, CA 95817 USA. [Ghaedi, Mahboobe] NIGEB, Tehran, Iran. [Tuleuova, Nazgul] Natl Biotechnol Ctr, Astana, Kazakhstan. RP Revzin, A (reprint author), Univ Calif Davis, Dept Biomed Engn, 451 Hlth Sci,Dr 2519, Davis, CA 95616 USA. EM arevzin@ucdavis.edu FU NIH [R01DK079977] FX We thank Prof. Jan Nolta for providing stem cells used in our experiments. We gratefully acknowledge Drs. Yuyu Duan and Ji Youn Lee for technical assistance. This work was supported by an NIH grant (R01DK079977) awarded to A.R. NR 36 TC 20 Z9 21 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD APR 8 PY 2011 VL 407 IS 2 BP 295 EP 300 DI 10.1016/j.bbrc.2011.03.005 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 753DU UT WOS:000289746700005 PM 21382341 ER PT J AU Goessling, W Allen, RS Guan, X Jin, P Uchida, N Dovey, M Harris, JM Metzger, ME Bonifacino, AC Stroncek, D Stegner, J Armant, M Schlaeger, T Tisdale, JF Zon, LI Donahue, RE North, TE AF Goessling, Wolfram Allen, Robyn S. Guan, Xiao Jin, Ping Uchida, Naoya Dovey, Michael Harris, James M. Metzger, Mark E. Bonifacino, Aylin C. Stroncek, David Stegner, Joseph Armant, Myriam Schlaeger, Thorsten Tisdale, John F. Zon, Leonard I. Donahue, Robert E. North, Trista E. TI Prostaglandin E2 Enhances Human Cord Blood Stem Cell Xenotransplants and Shows Long-Term Safety in Preclinical Nonhuman Primate Transplant Models SO CELL STEM CELL LA English DT Article ID BONE-MARROW; PROGENITOR CELLS; EXPANSION; MOBILIZATION; REPOPULATION; ENGRAFTMENT; RECEPTOR; DONORS AB Hematopoietic stem cells (HSCs) are used in transplantation therapy to reconstitute the hematopoietic system. Human cord blood (hCB) transplantation has emerged as an attractive alternative treatment option when traditional HSC sources are unavailable; however, the absolute number of hCB HSCE.; transplanted is significantly lower than bone marrow or mobilized peripheral blood stem cells (MPBSCs). We previously demonstrated that dimethyl-prostaglandin E2 (dmPGE2), increased HSCs in vertebrate models. Here, we describe preclinical analyses of the therapeutic potential of dmPGE2 treatment by using human and nonhuman primate HSCs. dmPGE2 significantly increased total human hematopoietic colony formation in vitro and enhanced engraftment of unfractionated and CD34(+) hCB after xenotransplantation. In nonhuman primate autologous transplantation, dmPGE2-treated CD34(+) MPBSCs showed stable multilineage engraftment over 1 year postinfusion. Together, our analyses indicated that dmPGE2 mediates conserved responses in HSCs from human and nonhuman primates and provided sufficient preclinical information to support proceeding to an FDA-approved phase 1 clinical trial. C1 [Goessling, Wolfram; Zon, Leonard I.; North, Trista E.] Harvard Stem Cell Inst, Boston, MA 02115 USA. [Goessling, Wolfram; Zon, Leonard I.; North, Trista E.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Goessling, Wolfram] Brigham & Womens Hosp, Dana Farber Canc Inst, Gastrointestinal Canc Ctr, Div Genet, Boston, MA 02115 USA. [Goessling, Wolfram] Brigham & Womens Hosp, Dana Farber Canc Inst, Gastrointestinal Canc Ctr, Div Gastroenterol, Boston, MA 02115 USA. [Allen, Robyn S.; Metzger, Mark E.; Bonifacino, Aylin C.; Donahue, Robert E.] NHLBI, Hematol Branch, NIH, Rockville, MD 20850 USA. [Guan, Xiao; Schlaeger, Thorsten; Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Jin, Ping; Stroncek, David] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA. [Uchida, Naoya; Tisdale, John F.] NIDDK, Mol & Clin Hematol Branch, NHLBI, NIH, Bethesda, MD 20892 USA. [Dovey, Michael; Harris, James M.; North, Trista E.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA. [Stegner, Joseph; Armant, Myriam] Immune Dis Inst, Ctr Human Cell Therapy, Boston, MA 02115 USA. [Zon, Leonard I.] Howard Hughes Med Inst, Boston, MA 02115 USA. RP North, TE (reprint author), Harvard Stem Cell Inst, Boston, MA 02115 USA. EM tnorth@bidmc.harvard.edu RI Guan, Xiao/D-5656-2013; OI Goessling, Wolfram/0000-0001-9972-1569 FU Harvard Stern Cell Institute; NIH NIDDK; Howard Hughes Medical Institute; National Institutes of Health, NHLBI; NIDDK; Department of Transfusion Medicine at the NIH Clinical Center; FATE Therapeutics FX The HMS researchers thank J. Trowbridge, C. Walkley, G.O. Daley J. Ritz, L. Silberstein, G. Kao, J. Antin, R. Soiffer, K. Ballen, C. Cutler, and the members of the Center for Human Cell Therapy at Harvard Medical School, Dana-Farber Cancer Institute for helpful discussions and guidance on the clinical application of dmPGE2 and the FDA application process. We are grateful to the Carolinas Cord Blood Bank for providing us with discarded cord blood units. The NIH researchers thank K. Keyvanfar for cell-sorting assistance, Y. Tian for assisting with the processing of the microarray data, and the veterinary and animal care staff at 5 Research Court and Poolesville for maintaining the nonhuman primates used in this study. This research was supported by the Harvard Stern Cell Institute (VV.G., LIZ., T.E.N.), NIH NIDDK (W.G., LIZ., TEN.), Howard Hughes Medical Institute (LIZ.), the Intramural Research Program of the National Institutes of Health, NHLBI, and/or NIDDK (R.S.A., N.U., M.E.M., A.C.B., J.F.T., RED.), and the Department of Transfusion Medicine at the NIH Clinical Center (P.J., D.S.). T.E.N. and W.G. receive patent royalties and consulting fees from FATE Therapeutics; L.I.Z. is a scientific founder and stockholder of and receives patent royalties from FATE Therapeutics, which is currently testing the use of prostaglandin E2 to enhance the efficacy of hCB transplants in an independently conducted phase I clinical trial. NR 32 TC 124 Z9 128 U1 0 U2 10 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1934-5909 EI 1875-9777 J9 CELL STEM CELL JI Cell Stem Cell PD APR 8 PY 2011 VL 8 IS 4 BP 445 EP 458 DI 10.1016/j.stem.2011.02.003 PG 14 WC Cell & Tissue Engineering; Cell Biology SC Cell Biology GA 752QI UT WOS:000289707100016 PM 21474107 ER PT J AU Liu, YT Munro, D Layfield, D Dellinger, A Walter, J Peterson, K Rickman, CB Allingham, RR Hauser, MA AF Liu, Yutao Munro, Drew Layfield, David Dellinger, Andrew Walter, Jeffrey Peterson, Katherine Rickman, Catherine Bowes Allingham, R. Rand Hauser, Michael A. TI Serial analysis of gene expression (SAGE) in normal human trabecular meshwork SO MOLECULAR VISION LA English DT Article ID OPEN-ANGLE GLAUCOMA; GENOMIC CONVERGENCE; MICROARRAY ANALYSIS; CANDIDATE GENES; CELLS; IDENTIFICATION; DEXAMETHASONE; DISEASE; PROFILE; TRANSCRIPTOME AB Purpose: To identify the genes expressed in normal human trabecular meshwork tissue, a tissue critical to the pathogenesis of glaucoma. Methods: Total RNA was extracted from human trabecular meshwork (HTM) harvested from 3 different donors. Extracted RNA was used to synthesize individual SAGE (serial analysis of gene expression) libraries using the I-SAGE Long kit from Invitrogen. Libraries were analyzed using SAGE 2000 software to extract the 17 base pair sequence tags. The extracted sequence tags were mapped to the genome using SAGE Genie map. Results: A total of 298,834 SAGE tags were identified from all HTM libraries (96,842, 88,126, and 113,866 tags, respectively). Collectively, there were 107,325 unique tags. There were 10,329 unique tags with a minimum of 2 counts from a single library. These tags were mapped to known unique Unigene clusters. Approximately 29% of the tags (orphan tags) did not map to a known Unigene cluster. Thirteen percent of the tags mapped to at least 2 Unigene clusters. Sequence tags from many glaucoma-related genes, including myocilin, optineurin, and WD repeat domain 36, were identified. Conclusions: This is the first time SAGE analysis has been used to characterize the gene expression profile in normal HTM. SAGE analysis provides an unbiased sampling of gene expression of the target tissue. These data will provide new and valuable information to improve understanding of the biology of human aqueous outflow. C1 [Liu, Yutao; Layfield, David; Dellinger, Andrew; Walter, Jeffrey; Hauser, Michael A.] Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC USA. [Munro, Drew; Rickman, Catherine Bowes; Allingham, R. Rand; Hauser, Michael A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA. [Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA. [Peterson, Katherine] NEI, Sect Mol Struct & Funct Genom, NIH, Bethesda, MD 20892 USA. RP Hauser, MA (reprint author), 905 S LaSalle St,DUMC Box 3445, Durham, NC 27710 USA. EM mike.hauser@duke.edu FU NIH [R01EY013315, R01EY019126, R01EY015543, R01 EY019038, P30 EY005722]; Ruth and Milton Steinbach Fund; Macular Vision Research Foundation; NCRR/NIH [1 UL1 RR024128-01] FX We thank the study participants that make this work possible. We thank Dr. Graeme Wistow for displaying our SAGE data through the NEIBank genome browser. This research was supported by NIH grants R01EY013315 (M.A.H.), R01EY019126 (M.A.H.), R01EY015543 (R.R.A.), R01 EY019038 (C.B.R.), P30 EY005722 (Duke Eye Center), the Ruth and Milton Steinbach Fund (C.B.R.), and the Macular Vision Research Foundation (C.B.R.). This research was also supported in part by Duke University's CTSA grant 1 UL1 RR024128-01 from NCRR/NIH, as well as the research infrastructure of the Duke Center for Human Genetics. NR 45 TC 8 Z9 8 U1 1 U2 5 PU MOLECULAR VISION PI ATLANTA PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E, ATLANTA, GA 30322 USA SN 1090-0535 J9 MOL VIS JI Mol. Vis. PD APR 8 PY 2011 VL 17 IS 98-100 BP 885 EP 893 PG 9 WC Biochemistry & Molecular Biology; Ophthalmology SC Biochemistry & Molecular Biology; Ophthalmology GA 749AN UT WOS:000289434600002 PM 21528004 ER PT J AU Burns, KA Li, Y Arao, Y Petrovich, RM Korach, KS AF Burns, Katherine A. Li, Yin Arao, Yukitomo Petrovich, Robert M. Korach, Kenneth S. TI Selective Mutations in Estrogen Receptor alpha D-domain Alters Nuclear Translocation and Non-estrogen Response Element Gene Regulatory Mechanisms SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID DEOXYRIBONUCLEIC-ACID-BINDING; BREAST-CANCER CELLS; ER-ALPHA; HINGE REGION; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID-RECEPTOR; IN-VIVO; LYSINE METHYLATION; PLASMA-MEMBRANE; EXPORT SIGNALS AB The three main mechanisms of ER alpha action are: 1) nuclear, genomic, direct DNA binding, 2) nuclear, genomic, "tethered"-mediated, protein-protein interactions, and 3) non-nuclear, non-genomic, rapid action responses. Reports suggest the D-domain or hinge region of ER alpha plays an important role in mechanisms 1 and 2 above. Studies demonstrating the functionality of the ER alpha hinge region have resected the full D-domain; therefore, site directed mutations were made to attribute precise sequence functionality to this domain. This study focuses on the characterization and properties of three novel site directed ER alpha-D-domain mutants. The Hinge 1 (H1) ER alpha mutant has disrupted nuclear localization, can no longer perform tethered mediated responses and has lost interaction with c-Jun, but retains estrogen response element (ERE)-mediated functions as demonstrated by confocal microscopy, reporter assays, endogenous gene expression and co-immunoprecipitation. The H2 ER alpha mutant is non-nuclear, but translocates to the nucleus with estradiol (E-2) treatment and maintains ERE-mediated functionality. The H2 + NES ER alpha mutant does not maintain nuclear translocation with hormone binding, no longer activates ERE-target genes, functions in ERE-or tethered-mediated luciferase assays, but does retain the non-genomic, non-nuclear, rapid action response. These studies reveal the sequence(s) in the ER alpha hinge region that are involved in tethered-mediated actions as well as nuclear localization and attribute important functionality to this region of the receptor. In addition, the properties of these ER alpha mutants will allow future studies to further dissect and characterize the three main ER alpha mechanisms of action and determine the mechanistic role each action has in estrogen hormone regulation. C1 [Burns, Katherine A.; Li, Yin; Arao, Yukitomo; Korach, Kenneth S.] Natl Inst Environm Hlth Sci, Lab Reprod & Dev Toxicol, NIH, Res Triangle Pk, NC 27709 USA. [Petrovich, Robert M.] Natl Inst Environm Hlth Sci, Prot Express Core Facil, NIH, Res Triangle Pk, NC 27709 USA. RP Korach, KS (reprint author), 111 TW Alexander Dr, Res Triangle Pk, NC 27790 USA. EM Korach@niehs.nih.gov OI Korach, Kenneth/0000-0002-7765-418X FU National Institutes of Health [Z01ES70065, Z01ES102487-01] FX This work was supported, in whole or in part, by National Institutes of Health Grants Z01ES70065 and Z01ES102487-01. NR 56 TC 26 Z9 27 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD APR 8 PY 2011 VL 286 IS 14 DI 10.1074/jbc.M110.187773 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 744EN UT WOS:000289077500075 PM 21285458 ER PT J AU Hwang, JY Huang, WW Arnold, LA Huang, RL Attia, RR Connelly, M Wichterman, J Zhu, FY Augustinaite, I Austin, CP Inglese, J Johnson, RL Guy, RK AF Hwang, Jong Yeon Huang, Wenwei Arnold, Leggy A. Huang, Ruili Attia, Ramy R. Connelly, Michele Wichterman, Jennifer Zhu, Fangyi Augustinaite, Indre Austin, Christopher P. Inglese, James Johnson, Ronald L. Guy, R. Kiplin TI Methylsulfonylnitrobenzoates, a New Class of Irreversible Inhibitors of the Interaction of the Thyroid Hormone Receptor and Its Obligate Coactivators That Functionally Antagonizes Thyroid Hormone SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SMALL-MOLECULE INHIBITORS; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; LIGAND-BINDING; IN-VIVO; AMPHIBIAN METAMORPHOSIS; BIOLOGICAL EVALUATION; HIGH-THROUGHPUT; DRUG DISCOVERY; ION CHANNELS AB Thyroid hormone receptors (TRs) are members of the nuclear hormone receptor (NR) superfamily and regulate development, growth, and metabolism. Upon binding thyroid hormone, TR undergoes a conformational change that allows the release of corepressors and the recruitment of coactivators, which in turn regulate target gene transcription. Although a number of TR antagonists have been developed, most are analogs of the endogenous hormone that inhibit ligand binding. In a screen for inhibitors that block the association of TR beta with steroid receptor coactivator 2 (SRC2), we identified a novel methylsulfonylnitrobenzoate (MSNB)-containing series that blocks this interaction at micromolar concentrations. Here we have studied a series of MSNB analogs and characterized their structure activity relationships. MSNB members do not displace thyroid hormone T-3 but instead act by direct displacement of SRC2. MSNB series members are selective for the TR over the androgen, vitamin D, and PPAR gamma NR members, and they antagonize thyroid hormone-activated transcription action in cells. The methylsulfonylnitro group is essential for TR beta antagonism. Side-chain alkylamine substituents showed better inhibitory activity than arylamine substituents. Mass spectrum analysis suggested that MSNB inhibitors bind irreversibly to Cys-298 within the AF-2 cleft of TR beta to disrupt SRC2 association. C1 [Hwang, Jong Yeon; Attia, Ramy R.; Connelly, Michele; Zhu, Fangyi; Augustinaite, Indre; Guy, R. Kiplin] St Jude Childrens Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA. [Huang, Wenwei; Huang, Ruili; Wichterman, Jennifer; Austin, Christopher P.; Inglese, James; Johnson, Ronald L.] NHGRI, NIH Chem Genom Ctr, NIH, Bethesda, MD 20892 USA. [Arnold, Leggy A.] Univ Wisconsin, Dept Chem & Biochem, Milwaukee, WI 53211 USA. RP Guy, RK (reprint author), 262 Danny Thomas Pl,Mail Stop 1000, Memphis, TN 38105 USA. EM kip.guy@stjude.org RI Guy, Rodney/J-7107-2013 OI Guy, Rodney/0000-0002-9638-2060 FU National Institutes of Health [DK58080]; NIH Roadmap for Medical Research; National Institutes of Health NHGRI; American Lebanese Syrian Associated Charities (ALSAC); St. Jude Children's Research Hospital (SJCRH) FX This work was supported, in whole or in part, by National Institutes of Health Grant DK58080, the NIH Roadmap for Medical Research, and the National Institutes of Health NHGRI Intramural Research Program. This work was also supported by the American Lebanese Syrian Associated Charities (ALSAC) and the St. Jude Children's Research Hospital (SJCRH). NR 78 TC 19 Z9 19 U1 2 U2 9 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD APR 8 PY 2011 VL 286 IS 14 DI 10.1074/jbc.M110.200436 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 744EN UT WOS:000289077500003 PM 21321127 ER PT J AU Wu, YZ Antony, S Juhasz, A Lu, JM Ge, Y Jiang, GJ Roy, K Doroshow, JH AF Wu, Yongzhong Antony, Smitha Juhasz, Agnes Lu, Jiamo Ge, Yun Jiang, Guojian Roy, Krishnendu Doroshow, James H. TI Up-regulation and Sustained Activation of Stat1 Are Essential for Interferon-gamma (IFN-gamma)-induced Dual Oxidase 2 (Duox2) and Dual Oxidase A2 (DuoxA2) Expression in Human Pancreatic Cancer Cell Lines SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID RESPIRATORY-TRACT EPITHELIUM; FAMILY NADPH OXIDASES; IFN-GAMMA; NOX FAMILY; SER-727 PHOSPHORYLATION; TYROSINE PHOSPHATASES; DUCTAL ADENOCARCINOMA; GENE-EXPRESSION; HOST-DEFENSE; TRANSCRIPTION AB Dual oxidase 2 is a member of the NADPH oxidase (Nox) gene family that plays a critical role in the biosynthesis of thyroid hormone as well as in the inflammatory response of the upper airway mucosa and in wound healing, presumably through its ability to generate reactive oxygen species, including H2O2. The recently discovered overexpression of Duox2 in gastrointestinal malignancies, as well as our limited understanding of the regulation of Duox2 expression, led us to examine the effect of cytokines and growth factors on Duox2 in human tumor cells. We found that exposure of human pancreatic cancer cells to IFN-gamma (but not other agents) produced a profound up-regulation of the expression of Duox2, and its cognate maturation factor DuoxA2, but not other members of the Nox family. Furthermore, increased Duox2/DuoxA2 expression was closely associated with a significant increase in the production of both intracellular reactive oxygen species and extracellular H2O2. Examination of IFN-gamma-mediated signaling events demonstrated that in addition to the canonical Jak-Stat1 pathway, IFN-gamma activated the p38-MAPK pathway in pancreatic cancer cells, and both played an important role in the induction of Duox2 by IFN-gamma. Duox2 up-regulation following IFN-gamma exposure is also directly associated with the binding of Stat1 to elements of the Duox2 promoter. Our findings suggest that the pro-inflammatory cytokine IFN-gamma initiates a Duox2-mediated reactive oxygen cascade in human pancreatic cancer cells; reactive oxygen species production in this setting could contribute to the pathophysiologic characteristics of these tumors. C1 [Wu, Yongzhong; Antony, Smitha; Juhasz, Agnes; Lu, Jiamo; Ge, Yun; Jiang, Guojian; Doroshow, James H.] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Roy, Krishnendu; Doroshow, James H.] NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA. RP Doroshow, JH (reprint author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bldg 31,Rm 3A-44,31 Ctr Dr, Bethesda, MD 20892 USA. EM doroshoj@mail.nih.gov FU NCI, National Institutes of Health FX This work was supported, in whole or in part, by a NCI, National Institutes of Health, grant. NR 53 TC 24 Z9 27 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD APR 8 PY 2011 VL 286 IS 14 DI 10.1074/jbc.M110.191031 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 744EN UT WOS:000289077500039 PM 21321110 ER PT J AU Zbidi, H Jardin, I Woodard, GE Lopez, JJ Berna-Erro, A Salido, GM Rosado, JA AF Zbidi, Hanene Jardin, Isaac Woodard, Geoffrey E. Lopez, Jose J. Berna-Erro, Alejandro Salido, Gines M. Rosado, Juan A. TI STIM1 and STIM2 Are Located in the Acidic Ca2+ Stores and Associates with Orai1 upon Depletion of the Acidic Stores in Human Platelets SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID ADENINE-DINUCLEOTIDE PHOSPHATE; VACUOLAR H+-ATPASES; CALCIUM-ENTRY; TRPC CHANNELS; DIFFERENTIAL SENSITIVITY; OPERATED CHANNELS; MEMBRANE-VESICLES; MAMMALIAN-CELLS; RELEASE; PROTEIN AB Mammalian cells accumulate Ca2+ into agonist-sensitive acidic organelles, vesicles that possess a vacuolar proton-ATPase. Acidic Ca2+ stores include secretory granules and lysosome-related organelles. Current evidence clearly indicates that acidic Ca2+ stores participate in cell signaling and function, including the activation of store-operated Ca2+ entry in human platelets upon depletion of the acidic stores, although the mechanism underlying the activation of store-operated Ca2+ entry controlled by the acidic stores remains unclear. STIM1 has been presented as the endoplasmic reticulum Ca2+ sensor, but its role sensing intraluminal Ca2+ concentration in the acidic stores has not been investigated. Here we report that STIM1 and STIM2 are expressed in the lysosome-related organelles and dense granules in human platelets isolated by immunomagnetic sorting. Depletion of the acidic Ca2+ stores using the specific vacuolar proton-ATPase inhibitor, bafilomycin A1, enhanced the association between STIM1 and STIM2 as well as between these proteins and the plasma membrane channel Orai1. Depletion of the acidic Ca2+ stores also induces time-dependent co-immunoprecipitation of STIM1 with the TRPC proteins hTRPC1 and hTRPC6, as well as between Orai1 and both TRPC proteins. In addition, bafilomycin A1 enhanced the association between STIM2 and SERCA3. These findings demonstrate the location of STIM1 and STIM2 in the acidic Ca2+ stores and their association with Ca2+ channels and ATPases upon acidic stores discharge. C1 [Zbidi, Hanene; Jardin, Isaac; Berna-Erro, Alejandro; Salido, Gines M.; Rosado, Juan A.] Univ Extremadura, Cell Physiol Res Grp, Dept Physiol, Caceres 10003, Spain. [Woodard, Geoffrey E.] NIDDK, NIH, Bethesda, MD 20892 USA. [Lopez, Jose J.] INSERM, Hemostase & Dynam Cellulaire Vasc U770, F-94276 Le Kremlin Bicetre, France. RP Rosado, JA (reprint author), Univ Extremadura, Dept Physiol, Caceres 10071, Spain. EM jarosado@unex.es RI Salido, Gines/A-4292-2009; rosado, juan/H-3488-2015; Jardin, Isaac/E-8310-2016; LOPEZ, JOSE/F-4602-2016 OI Salido, Gines/0000-0002-8687-2445; rosado, juan/0000-0002-9749-2325; Jardin, Isaac/0000-0003-4575-8264; LOPEZ, JOSE/0000-0002-5234-1478 FU Ministerio de Ciencia e Innovacion [BFU2010-21043-C02-01, BES-2008-002875]; Ministerio de Asuntos Exteriores y de Cooperacion Proyecto Conjunto de Investigacion [A/023417/09]; Junta de Extremadura-Fondo Europeo de Desarrollo Regional [GR10010] FX This work was supported by Ministerio de Ciencia e Innovacion Grant BFU2010-21043-C02-01, Ministerio de Asuntos Exteriores y de Cooperacion Proyecto Conjunto de Investigacion Grant A/023417/09, and Junta de Extremadura-Fondo Europeo de Desarrollo Regional Grant GR10010.; Supported by Ministerio de Ciencia e Innovacion Fellowship BES-2008-002875. NR 64 TC 33 Z9 33 U1 0 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD APR 8 PY 2011 VL 286 IS 14 DI 10.1074/jbc.M110.190694 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 744EN UT WOS:000289077500040 PM 21321120 ER PT J AU Nikolaitchik, OA Galli, A Moore, MD Pathak, VK Hu, WS AF Nikolaitchik, Olga A. Galli, Andrea Moore, Michael D. Pathak, Vinay K. Hu, Wei-Shau TI Multiple Barriers to Recombination between Divergent HIV-1 Variants Revealed by a Dual-Marker Recombination Assay SO JOURNAL OF MOLECULAR BIOLOGY LA English DT Article DE GFP; Gag; group M; group O; reconstitution ID IMMUNODEFICIENCY-VIRUS TYPE-1; DEPENDENT DNA POLYMERASE; GENETIC-RECOMBINATION; IN-VIVO; INITIATION SIGNAL; GROUP-O; REPLICATION; INFECTION; SELECTION; IDENTIFICATION AB Recombination is a major force for generating human immunodeficiency virus type 1 (HIV-1) diversity and produces numerous recombinants circulating in the human population. We previously established a cell-based system using green fluorescent protein gene (gfp) as a reporter to study the mechanisms of HIV-1 recombination. We now report an improved system capable of detecting recombination using authentic viral sequences. Frameshift mutations were introduced into the gag gene so that parental viruses do not express full-length Gag; however, recombination can generate a progeny virus that expresses a functional Gag. We demonstrate that this Gag reconstitution assay can be used to detect recombination between two group M HIV-1 variants of the same or of different subtypes. Using both gfp and gag assays, we found that, similar to group M viruses, group O viruses also recombine frequently. When recombination between a group M virus and a group O virus was examined, we found three distinct barriers for intergroup recombination. First, similar to recombination within group M viruses, intergroup recombination is affected by the identity of the dimerization initiation signal (DIS); variants with the same DIS recombined at a higher rate than those with different DIS. Second, using the gfp recombination assay, we showed that intergroup recombination occurs much less frequently than intragroup recombination, even though the gfp target sequence is identical in all viruses. Finally, Gag reconstitution between variants from different groups is further reduced compared with green fluorescent protein, indicating that sequence divergence interferes with recombination efficiency in the gag gene. Compared with identical sequences, we estimate that recombination rates are reduced by 3-fold and by 10- to 13-fold when the target regions in gag contain 91% and 72-73% sequence identities, respectively. These results show that there are at least three distinct mechanisms preventing exchange of genetic information between divergent HIV-1 variants from different groups. Published by Elsevier Ltd. C1 [Nikolaitchik, Olga A.; Galli, Andrea; Moore, Michael D.; Pathak, Vinay K.; Hu, Wei-Shau] NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA. RP Hu, WS (reprint author), NCI, HIV Drug Resistance Program, POB B,Bldg 535,Room 336, Frederick, MD 21702 USA. EM Wei-Shau.Hu@nih.gov OI Galli, Andrea/0000-0002-4404-430X FU National Institutes of Health, National Cancer Institute, Center for Cancer Research FX We thank Hans-Georg Krausslich for group O molecular clone. This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. NR 38 TC 12 Z9 13 U1 1 U2 6 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2836 J9 J MOL BIOL JI J. Mol. Biol. PD APR 8 PY 2011 VL 407 IS 4 BP 521 EP 531 DI 10.1016/j.jmb.2011.01.052 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 742EX UT WOS:000288925200004 PM 21295586 ER PT J AU Suto, N Wise, RA Vezina, P AF Suto, Nobuyoshi Wise, Roy A. Vezina, Paul TI Dorsal as well as ventral striatal lesions affect levels of intravenous cocaine and morphine self-administration in rats SO NEUROSCIENCE LETTERS LA English DT Article DE Cocaine self-administration; Morphine self-administration; Striatum; Caudate putamen; Nucleus accumbens; Electrolytic lesion ID KAINIC ACID LESIONS; NUCLEUS-ACCUMBENS; CAUDATE-PUTAMEN; REWARD; DOPAMINE; PIMOZIDE; SEEKING; REINFORCEMENT; AMPHETAMINE; DEPENDENCE AB While the ventral striatum has long been implicated in the rewarding properties of psychomotor stimulants and opiates, little attention has been paid to the possible contribution of more dorsal regions of the striatum. We have thus examined the effects of lesions in three different striatal subregions on cocaine and morphine self-administration. Different groups of rats were trained to self-administer intravenous cocaine (1.0 mg/kg/infusion) or morphine (0.5 mg/kg/infusion) first under fixed ratio (FR) and then under progressive ratio (PR) schedules of reinforcement. Upon completion of the training, independent groups received bilateral electrolytic or sham lesions of the dorsal portion of the caudate-putamen (dCPu), the ventral portion of the caudate-putamen (vCPu) or the more ventral nucleus accumbens (NAS). Following recovery, they were tested for self-administration of cocaine (0.25, 0.5, 1.0 and 1.5 mg/kg/infusion) or morphine (0.125, 0.25, 0.5 and 0.75 mg/kg/infusion) under the PR schedule. The PR responding for each drug was significantly reduced in a dose-dependent manner following lesions of dCPu, vCPu and NAS. While the relative effectiveness of these lesions is likely to be specific to the conditions of this experiment. NAS lesions reduced self-administration of each drug to a greater extent than did dCPu or vCPu lesions. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [Suto, Nobuyoshi; Vezina, Paul] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA. [Suto, Nobuyoshi; Wise, Roy A.] NIDA, Behav Neurosci Branch, Intramural Res Program, NIH,DHHS, Baltimore, MD 21224 USA. RP Suto, N (reprint author), Univ Maryland, Sch Med, Dept Psychiat, Maryland Psychiat Res Ctr, POB 21247, Baltimore, MD 21228 USA. EM nsuto@mprc.umaryland.edu RI Wise, Roy/A-6465-2012 FU National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services [R01-DA-09397] FX Supported by grant R01-DA-09397 (PV) and funding from the Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services. We thank Dr. Stephan Steidl for critical reading of this manuscript. NR 39 TC 13 Z9 13 U1 0 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD APR 8 PY 2011 VL 493 IS 1-2 BP 29 EP 32 DI 10.1016/j.neulet.2011.02.011 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 745QN UT WOS:000289180800006 PM 21315801 ER PT J AU Niu, SQ Tan, ML Ichiye, T AF Niu, Shuqiang Tan, Ming-Liang Ichiye, Toshiko TI The large quadrupole of water molecules SO JOURNAL OF CHEMICAL PHYSICS LA English DT Article ID LIQUID WATER; POTENTIAL FUNCTIONS; MULTIPOLE MOMENTS; CONDENSED PHASES; AB-INITIO; MODEL; OCTUPOLE; SOLVATION; DYNAMICS; DENSITY AB Many quantum mechanical calculations indicate water molecules in the gas and liquid phase have much larger quadrupole moments than any of the common site models of water for computer simulations. Here, comparisons of multipoles from quantum mechanical/molecular mechanical (QM/MM) calculations at the MP2/aug-cc-pVQZ level on a B3LYP/aug-cc-pVQZ level geometry of a water-like cluster and from various site models show that the increased square planar quadrupole can be attributed to the p-orbital character perpendicular to the molecular plane of the highest occupied molecular orbital as well as a slight shift of negative charge toward the hydrogens. The common site models do not account for the p-orbital type electron density and fitting partial charges of TIP4P- or TIP5P-type models to the QM/MM dipole and quadrupole give unreasonable higher moments. Furthermore, six partial charge sites are necessary to account reasonably for the large quadrupole, and polarizable site models will not remedy the problem unless they account for the p-orbital in the gas phase since the QM calculations show it is present there too. On the other hand, multipole models by definition can use the correct multipoles and the electrostatic potential from the QM/MM multipoles is much closer than that from the site models to the potential from the QM/MM electron density. Finally, Monte Carlo simulations show that increasing the quadrupole in the soft-sticky dipole-quadrupole-octupole multipole model gives radial distribution functions that are in good agreement with experiment. (C) 2011 American Institute of Physics. [doi: 10.1063/1.3569563] C1 [Niu, Shuqiang; Tan, Ming-Liang; Ichiye, Toshiko] Georgetown Univ, Dept Chem, Washington, DC 20057 USA. [Ichiye, Toshiko] NHLBI, Lab Computat Biol, NIH, Bethesda, MD 20892 USA. RP Niu, SQ (reprint author), Georgetown Univ, Dept Chem, Washington, DC 20057 USA. EM ti9@georgetown.edu FU National Science Foundation [MCB-0544629]; William G. McGowan Foundation; National Institutes of Health, National Heart, Lung, and Blood Institute (Laboratory of Computational Biology) FX The authors are grateful to the National Science Foundation for the support of this work through Grant No. MCB-0544629. The calculations were performed on facilities provided by Georgetown University and administered by the division of Advanced Research Computing (ARC). Support was also provided by the William G. McGowan Foundation. In addition, this research was supported in part by the Intramural Research Program of the National Institutes of Health, National Heart, Lung, and Blood Institute (Laboratory of Computational Biology). T. I. also thanks Professor Sylvio Canuto for helpful discussions on his calculations and Professor Peter J. Rossky for insightful comments. NR 46 TC 22 Z9 22 U1 1 U2 19 PU AMER INST PHYSICS PI MELVILLE PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1, MELVILLE, NY 11747-4501 USA SN 0021-9606 EI 1089-7690 J9 J CHEM PHYS JI J. Chem. Phys. PD APR 7 PY 2011 VL 134 IS 13 AR 134501 DI 10.1063/1.3569563 PG 11 WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical SC Chemistry; Physics GA 746OH UT WOS:000289256100022 PM 21476758 ER PT J AU Wu, XW Brooks, BR AF Wu, Xiongwu Brooks, Bernard R. TI Toward canonical ensemble distribution from self-guided Langevin dynamics simulation SO JOURNAL OF CHEMICAL PHYSICS LA English DT Article ID PROGRAM; CHARMM AB This work derives a quantitative description of the conformational distribution in self-guided Langevin dynamics (SGLD) simulations. SGLD simulations employ guiding forces calculated from local average momentums to enhance low-frequency motion. This enhancement in low-frequency motion dramatically accelerates conformational search efficiency, but also induces certain perturbations in conformational distribution. Through the local averaging, we separate properties of molecular systems into low-frequency and high-frequency portions. The guiding force effect on the conformational distribution is quantitatively described using these low-frequency and high-frequency properties. This quantitative relation provides a way to convert between a canonical ensemble and a self-guided ensemble. Using example systems, we demonstrated how to utilize the relation to obtain canonical ensemble properties and conformational distributions from SGLD simulations. This development makes SGLD not only an efficient approach for conformational searching, but also an accurate means for conformational sampling. [doi: 10.1063/1.3574397] C1 [Wu, Xiongwu; Brooks, Bernard R.] NHLBI, Lab Computat Biol, NIH, Bethesda, MD 20892 USA. RP Wu, XW (reprint author), NHLBI, Lab Computat Biol, NIH, 5635 Fishers Lane,Room T904, Bethesda, MD 20892 USA. EM wuxw@nhlbi.nih.gov NR 11 TC 19 Z9 19 U1 0 U2 11 PU AMER INST PHYSICS PI MELVILLE PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1, MELVILLE, NY 11747-4501 USA SN 0021-9606 EI 1089-7690 J9 J CHEM PHYS JI J. Chem. Phys. PD APR 7 PY 2011 VL 134 IS 13 AR 134108 DI 10.1063/1.3574397 PG 12 WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical SC Chemistry; Physics GA 746OH UT WOS:000289256100008 PM 21476744 ER PT J AU Chiang, J Hodes, RJ AF Chiang, Jeffrey Hodes, Richard J. TI Cbl Enforces Vav1 Dependence and a Restricted Pathway of T Cell Development SO PLOS ONE LA English DT Article ID ADAPTER PROTEIN SLP-76; C-CBL; DIFFERENTIAL REQUIREMENT; TYROSINE PHOSPHORYLATION; LYMPHOCYTE DEVELOPMENT; NEGATIVE REGULATION; RECEPTOR SIGNALS; ACTIVATION; ZAP-70; FAMILY AB Extensive studies of pre-TCR- and TCR-dependent signaling have led to characterization of a pathway deemed essential for efficient T cell development, and comprised of a cascade of sequential events involving phosphorylation of Lck and ZAP-70, followed by phosphorylation of LAT and SLP-76, and subsequent additional downstream events. Of interest, however, reports from our lab as well as others have indicated that the requirements for ZAP-70, LAT, and SLP-76 are partially reversed by inactivation of c-Cbl (Cbl), an E3 ubiquitin ligase that targets multiple molecules for ubiquitination and degradation. Analysis of signaling events in these Cbl knockout models, including the recently reported analysis of SLP-76 transgenes defective in interaction with Vav1, suggested that activation of Vav1 might be a critical event in alternative pathways of T cell development. To extend the analysis of signaling requirements for thymic development, we have therefore assessed the effect of Cbl inactivation on the T cell developmental defects that occur in Vav1-deficient mice. The defects in Vav1-deficient thymic development, including a marked defect in DN3-DN4 transition, were completely reversed by Cbl inactivation, accompanied by enhanced phosphorylation of PLC-gamma 1 and ERKs in response to pre-TCR/TCR cross-linking of Vav1(-/-)Cbl(-/-)DP thymocytes. Taken together, these results suggest a substantially modified paradigm for pre-TCR/TCR signaling and T cell development. The observed consensus pathways of T cell development, including requirements for ZAP-70, LAT, SLP-76, and Vav1, appear to reflect the restriction by Cbl of an otherwise much broader set of molecular pathways capable of mediating T cell development. C1 [Chiang, Jeffrey; Hodes, Richard J.] NCI, NIH, Expt Immunol Branch, Bethesda, MD 20892 USA. [Hodes, Richard J.] NIA, NIH, Bethesda, MD 20892 USA. RP Chiang, J (reprint author), NCI, NIH, Expt Immunol Branch, Bethesda, MD 20892 USA. EM chiangj@mail.nih.gov FU National Institutes of Health (NIH), National Cancer Institute FX This research was supported by the Intramural Research Program of the National Institutes of Health (NIH), National Cancer Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 5 Z9 5 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 7 PY 2011 VL 6 IS 4 AR e18542 DI 10.1371/journal.pone.0018542 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 746IN UT WOS:000289238700022 PM 21490975 ER PT J AU Liu, ZH Naranjo, A Thiele, CJ AF Liu, Zhihui Naranjo, Arlene Thiele, Carol J. TI CASZ1b, the Short Isoform of CASZ1 Gene, Coexpresses with CASZ1a during Neurogenesis and Suppresses Neuroblastoma Cell Growth SO PLOS ONE LA English DT Article ID TUMOR-SUPPRESSOR; NERVOUS-SYSTEM; CASTOR; DROSOPHILA; EXPRESSION; DIFFERENTIATION; IDENTITY AB In Drosophila, the CASZ1 (castor) gene encodes a zinc finger transcription factor and is a neural fate-determination gene. In mammals, the CASZ1 gene encodes two major isoforms, CASZ1a with 11 zinc fingers and CASZ1b with 5 zinc fingers. CASZ1b is more evolutionally conserved since it is the only homologue found in drosophila and Xenopus. Our previous study showed that full length CASZ1 (CASZ1a) functions to suppress growth in neuroblastoma tumor. However, the function of CASZ1b isoform in mammals is unknown. In this study, realtime PCR analyses indicate that mouse CASZ1b (mCASZ1b) is dynamically expressed during neurogenesis. CASZ1b and CASZ1a co-exist in all the neuronal tissues but exhibit distinct expression patterns spatially and temporally during brain development. CASZ1b and CASZ1a expression is coordinately upregulated by the differentiation agent Retinoic Acid, as well as agents that modify the epigenome in neural crest derived neuroblastoma cell lines. In contrast CASZ1b is down regulated while CASZ1a is upregulated by agents that raise intracellular cAMP levels. CASZ1b and CASZ1a have no synergistic or antagonistic activities on the regulation of their target NGFR gene transcription. Specific restoration of CASZ1b in NB cells suppresses tumor growth in vitro and in vivo. Consistent with its function role, we find that low CASZ1b expression is significantly associated with decreased survival probability of neuroblastoma patients (p<0.02). This study indicates that although their mechanisms of regulation may be distinct, both CASZ1b and CASZ1a have largely redundant but critical roles in suppressing tumor cell growth. C1 [Liu, Zhihui; Thiele, Carol J.] NCI, Ctr Canc Res, Pediat Oncol Branch, Bethesda, MD 20892 USA. [Naranjo, Arlene] Univ Florida, Childrens Oncol Grp Stat, Gainesville, FL USA. [Naranjo, Arlene] Univ Florida, Ctr Data, Gainesville, FL USA. RP Liu, ZH (reprint author), NCI, Ctr Canc Res, Pediat Oncol Branch, Bethesda, MD 20892 USA. EM ct47a@nih.gov FU National Cancer Institute FX This work was supported by grants from National Cancer Institute intramural program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 25 TC 5 Z9 5 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 7 PY 2011 VL 6 IS 4 AR e18557 DI 10.1371/journal.pone.0018557 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 746IN UT WOS:000289238700023 PM 21490919 ER PT J AU Jun, HS Lee, YM Song, KD Mansfield, BC Chou, JY AF Jun, Hyun Sik Lee, Young Mok Song, Ki Duk Mansfield, Brian C. Chou, Janice Y. TI G-CSF improves murine G6PC3-deficient neutrophil function by modulating apoptosis and energy homeostasis SO BLOOD LA English DT Article ID COLONY-STIMULATING FACTOR; DISEASE TYPE 1B; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; ENDOPLASMIC-RETICULUM STRESS; CELL-DEATH; CONGENITAL NEUTROPENIA; GLUCOSE-TRANSPORT; HEXOSE-6-PHOSPHATE DEHYDROGENASE; GLUCOSE-6-PHOSPHATE TRANSPORTER; OXIDATIVE STRESS AB G6PC3 (or glucose-6-phosphatase-beta) deficiency underlies a congenital neutropenia syndrome in which neutrophils exhibit enhanced endoplasmic reticulum (ER) stress, increased apoptosis, impaired energy homeostasis, and impaired functionality. Here we show that murine G6pc3(-/-) neutrophils undergoing ER stress activate protein kinase-like ER kinase and phosphatidylinositol 3,4,5-trisphosphate/Akt signaling pathways, and that neutrophil apoptosis is mediated in part by the intrinsic mitochondrial pathway. In G6PC3-deficient patients, granulocyte colony-stimulating factor (G-CSF) improves neutropenia, but its impact on neutrophil apoptosis and dysfunction is unknown. We now show that G-CSF delays neutrophil apoptosis in vitro by modulating apoptotic mediators. However, G6pc3(-/-) neutrophils in culture exhibit accelerated apoptosis compared with wild-type neutrophils both in the presence or absence of G-CSF. Limiting glucose (0.6mM) accelerates apoptosis but is more pronounced for wild-type neutrophils, leading to similar survival profiles for both neutrophil populations. In vivo G-CSF therapy completely corrects neutropenia and normalizes levels of p-Akt, phosphatidylinositol 3,4,5-trisphosphate, and active caspase-3. Neutrophils from in vivo G-CSF-treated G6pc3(-/-) mice exhibit increased glucose uptake and elevated intracellular levels of G6P, lactate, and adenosine-5'-triphosphate, leading to improved functionality. Together, the results strongly suggest that G-CSF improves G6pc3(-/-) neutrophil survival by modulating apoptotic mediators and rectifies function by enhancing energy homeostasis. (Blood. 2011;117(14):3881-3892) C1 [Jun, Hyun Sik; Lee, Young Mok; Mansfield, Brian C.; Chou, Janice Y.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Cellular Differentiat, Program Dev Endocrinol & Genet, NIH, Bethesda, MD 20892 USA. [Song, Ki Duk] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Cellular & Dev Biol, Program Genom Differentiat, NIH, Bethesda, MD 20892 USA. RP Chou, JY (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Cellular Differentiat, Program Dev Endocrinol & Genet, NIH, 10 Ctr Dr,Bldg 10,Rm 9D42, Bethesda, MD 20892 USA. EM chouja@mail.nih.gov RI Jun, Hyun Sik/C-6799-2013; OI Mansfield, Brian/0000-0002-8533-2789 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health FX This work was supported by the Intramural Research Programs of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. NR 49 TC 19 Z9 19 U1 1 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD APR 7 PY 2011 VL 117 IS 14 BP 3881 EP 3892 DI 10.1182/blood-2010-08-302059 PG 12 WC Hematology SC Hematology GA 746RV UT WOS:000289265500023 PM 21292774 ER PT J AU Kelly, RJ Lopez-Chavez, A Citrin, D Janik, JE Morris, JC AF Kelly, Ronan J. Lopez-Chavez, Ariel Citrin, Deborah Janik, John E. Morris, John C. TI Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin SO MOLECULAR CANCER LA English DT Review ID PROSTATE-CANCER CELLS; CHROMOSOMAL PASSENGER COMPLEX; RIBOZYME-MEDIATED INHIBITION; ANTIAPOPTOSIS GENE SURVIVIN; NON-HODGKINS-LYMPHOMA; LUNG-CANCER; RADIORESISTANCE FACTOR; MALIGNANT-MELANOMA; NUCLEAR SURVIVIN; GASTRIC-CANCER AB Survivin (BIRC5), a member of the inhibitor of apoptosis protein (IAP) family that inhibits caspases and blocks cell death is highly expressed in cancer and is associated with a poorer clinical outcome. Functioning simultaneously during cell division and apoptosis inhibition, survivin plays a pivotal role in determining cell survival. Survivin has consistently been identified by molecular profiling analysis to be associated with higher tumor grade, more advanced disease, abbreviated survival, accelerated rates of recurrence, and chemotherapy and radiation resistance. Survivin's differential expression in cancer compared to normal tissue and its role as a nodal protein in a number of cellular pathways make it a highly flexible therapeutic target, suitable for small-molecule inhibitiors, molecular antagonists, and vaccination-based therapies. By targeting survivin it is hoped that multiple tumor signaling circuitries may be simultaneously disabled. This effect may be applicable to many tumor histologies irrespective of specific genetic makeup. To date, survivin inhibitors have shown modest activity as single agents, but it is anticipated that when given in combination with cytotoxic chemotherapy or monoclonal antibodies they may exhibit enhanced efficacy. This review discusses the complex circuitry of survivin in human cancers and highlights clinical trials involving novel agents that target this important protein. C1 [Morris, John C.] Univ Cincinnati, Dept Med, Div Hematol Oncol, Cincinnati, OH 45267 USA. [Kelly, Ronan J.; Lopez-Chavez, Ariel] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. [Citrin, Deborah] NCI, Radiat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. [Janik, John E.] NCI, Metab Branch, Ctr Canc Res, Bethesda, MD 20892 USA. RP Morris, JC (reprint author), Univ Cincinnati, Dept Med, Div Hematol Oncol, Cincinnati, OH 45267 USA. EM morri2j7@uc.edu FU NIH, National Cancer Institute, Center for Cancer Research FX This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. NR 136 TC 76 Z9 86 U1 1 U2 18 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-4598 J9 MOL CANCER JI Mol. Cancer PD APR 6 PY 2011 VL 10 AR 35 DI 10.1186/1476-4598-10-35 PG 11 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA 755OE UT WOS:000289941600001 PM 21470426 ER PT J AU Jang, H Arce, FT Mustata, M Ramachandran, S Capone, R Nussinov, R Lal, R AF Jang, Hyunbum Arce, Fernando Teran Mustata, Mirela Ramachandran, Srinivasan Capone, Ricardo Nussinov, Ruth Lal, Ratnesh TI Antimicrobial Protegrin-1 Forms Amyloid-Like Fibrils with Rapid Kinetics Suggesting a Functional Link SO BIOPHYSICAL JOURNAL LA English DT Article ID ATOMIC-FORCE MICROSCOPY; ION CHANNELS; BETA-PROTEIN; ALZHEIMERS-DISEASE; BILAYER-MEMBRANES; STRUCTURAL REQUIREMENTS; PEPTIDE PROTEGRIN-1; BROAD-SPECTRUM; CONGO RED; MECHANISM AB Protegrin-1 (PG-1) is an 18 residues long, cysteine-rich beta-sheet antimicrobial peptide (AMP). PG-1 induces strong cytotoxic activities on cell membrane and acts as a potent antibiotic agent. Earlier we reported that its cytotoxicity is mediated by its channel-forming ability. In this study, we have examined the amyloidogenic fibril formation properties of PG-1 in comparison with a well-defined amyloid, the amyloid-beta (A beta(1-42)) peptide. We have used atomic force microscopy (AFM) and thioflavin-T staining to investigate the kinetics of PG-1 fibrils growth and molecular dynamics simulations to elucidate the underlying mechanism. AFM images of PG-1 on a highly hydrophilic surface (mica) show fibrils with morphological similarities to A beta(1-42) fibrils. Real-time AFM imaging of fibril growth suggests that PG-1 fibril growth follows a relatively fast kinetics compared to the A beta(1-42) fibrils. The AFM results are in close agreement with results from thioflavin-T staining data. Furthermore, the results indicate that PG-1 forms fibrils in solution. Significantly, in contrast, we do not detect fibrillar structures of PG-1 on an anionic lipid bilayer 2-dioleoyl-sn-glycero-3-phospho-L-serine/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine; only small PG-1 oligomers can be observed. Molecular dynamics simulations are able to identify the presence of these small oligomers on the membrane bilayer. Thus, our current results show that cytotoxic AMP PG-1 is amyloidogenic and capable of forming fibrils. Overall, comparing beta-rich AMPs and amyloids such as A beta, in addition to cytotoxicity and amyloidogenicity, they share a common structural motif, and are channel forming. These combined properties support a functional relationship between amyloidogenic peptides and beta-sheet-rich cytolytic AMPs, suggesting that amyloids channels may have an antimicrobial function. C1 [Jang, Hyunbum; Nussinov, Ruth] NCI, Ctr Canc Res, Nanobiol Program, SAIC Frederick, Frederick, MD 21701 USA. [Arce, Fernando Teran; Ramachandran, Srinivasan; Capone, Ricardo; Lal, Ratnesh] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA. [Arce, Fernando Teran; Ramachandran, Srinivasan; Capone, Ricardo; Lal, Ratnesh] Univ Calif San Diego, Dept Mech & Aerosp Engn, La Jolla, CA 92093 USA. [Mustata, Mirela] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA. [Nussinov, Ruth] Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, Sackler Inst Mol Med, IL-69978 Tel Aviv, Israel. RP Nussinov, R (reprint author), NCI, Ctr Canc Res, Nanobiol Program, SAIC Frederick, Frederick, MD 21701 USA. EM ruthnu@helix.nih.gov; rlal@ucsd.edu RI Capone, Ricardo/D-1943-2010 OI Capone, Ricardo/0000-0002-7327-9837 FU National Cancer Institute, National Institutes of Health (NIH) [HHSN261200800001E]; NIH, National Cancer Institute, Center for Cancer Research; NIH [R01AG028709] FX This project was funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health (NIH), under contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. This research was supported (in part) by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. This research was supported by NIH grant No. R01AG028709 (R.L.). All simulations had been performed using the high-performance computational facilities of the Biowulf PC/Linux cluster at the National Institutes of Health, Bethesda, MD (http://biowulf.nih.gov). NR 67 TC 40 Z9 40 U1 1 U2 16 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0006-3495 EI 1542-0086 J9 BIOPHYS J JI Biophys. J. PD APR 6 PY 2011 VL 100 IS 7 BP 1775 EP 1783 DI 10.1016/j.bpj.2011.01.072 PG 9 WC Biophysics SC Biophysics GA 749TU UT WOS:000289494200023 PM 21463591 ER PT J AU Tang, JS Kiyatkin, EA AF Tang, Jeremy S. Kiyatkin, Eugene A. TI Fluctuations in central and peripheral temperatures induced by intravenous nicotine: Central and peripheral contributions SO BRAIN RESEARCH LA English DT Article DE Nicotinic receptor; Vasoconstriction; Brain hyperthermia; Peripheral sensory nerve; Nicotine pyrrolidine methiodide; Conditioning ID RAT TRIGEMINAL GANGLION; SENSORY NERVE-ENDINGS; BODY-TEMPERATURE; ACETYLCHOLINE-RECEPTORS; CEREBRAL VENTRICLES; HUMAN BRAIN; NEURONS; ADDICTION; RESPONSES; DOPAMINE AB Nicotine (NIC) is a highly addictive substance that interacts with different subtypes of nicotinic acetylcholine receptors widely distributed in the central and peripheral nervous systems. While the direct action of NIC on central neurons appears to be essential for its reinforcing properties, the role of peripheral actions of this drug remains a matter of controversy. In this study, we examined changes in locomotor activity and temperature fluctuations in the brain (nucleus accumbens and ventral tegmental area), temporal muscle, and skin induced by intravenous (iv) NIC at low human-relevant doses (10 and 30 mu g/kg) in freely moving rats. These effects were compared to those induced by social interaction, an arousing procedure that induces behavioral activation and temperature responses via pure neural mechanisms, and iv injections of a peripherally acting NIC analog, NIC pyrrolidine methiodide (NIC-PM) used at equimolar doses. We found that NIC at 30 mu g/kg induces a modest locomotor activation, rapid and strong decrease in skin temperature, and weak increases in brain and muscle temperature. While these effects were qualitatively similar to those induced by social interaction, they were much weaker and showed a tendency to increase with repeated drug administrations. In contrast, NIC-PM did not affect locomotion and induced much weaker than NIC increases in brain and muscle temperatures and decreases in skin temperature; these effects showed a tendency to be weaker with repeated drug administrations. Our data indicate that NIC's actions in the brain are essential to induce locomotor activation and brain and body hyperthermic responses. However, rapid peripheral action of NIC on sensory afferents could be an important factor in triggering its central effects, contributing to neural and physiological activation following repeated drug use. Published by Elsevier B.V. C1 [Tang, Jeremy S.; Kiyatkin, Eugene A.] Natl Inst Drug Abuse, Behav Neurosci Branch, Intramural Res Program, NIH,DHHS, Baltimore, MD 21224 USA. RP Kiyatkin, EA (reprint author), Natl Inst Drug Abuse, Behav Neurosci Branch, Intramural Res Program, NIH,DHHS, 333 Cassell Dr, Baltimore, MD 21224 USA. EM ekiyatki@intra.nida.nih.gov RI Reis, Aline/G-9573-2012 FU NIH, NIDA FX This research was supported by the Intramural Research Program of the NIH, NIDA. We wish to thank Dr. Bruce Vaupel for kindly providing us with nicotine pyrrolidine methiodide. NR 45 TC 2 Z9 2 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD APR 6 PY 2011 VL 1383 BP 141 EP 153 DI 10.1016/j.brainres.2011.01.092 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 749UF UT WOS:000289495600016 PM 21295014 ER PT J AU Li, Y Xu, SQ Mihaylova, MM Zheng, B Hou, XY Jiang, BB Park, O Luo, ZJ Lefai, E Shyy, JYJ Gao, B Wierzbicki, M Verbeuren, TJ Shaw, RJ Cohen, RA Zang, MW AF Li, Yu Xu, Shanqin Mihaylova, Maria M. Zheng, Bin Hou, Xiuyun Jiang, Bingbing Park, Ogyi Luo, Zhijun Lefai, Etienne Shyy, John Y. -J. Gao, Bin Wierzbicki, Michel Verbeuren, Tony J. Shaw, Reuben J. Cohen, Richard A. Zang, Mengwei TI AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice SO CELL METABOLISM LA English DT Article ID ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN-1; FATTY LIVER; LIPID-METABOLISM; DEFICIENT MICE; LDL RECEPTOR; EXPRESSION; CELLS; OVEREXPRESSION; TRANSCRIPTION AB AMPK has emerged as a critical mechanism for salutary effects of polyphenols on lipid metabolic disorders in type 1 and type 2 diabetes. Here we demonstrate that AMPK interacts with and directly phosphorylates sterol regulatory element binding proteins (SREBP-1c and -2). Ser372 phosphorylation of SREBP-1c by AMPK is necessary for inhibition of proteolytic processing and transcriptional activity of SREBP-1c in response to polyphenols and metformin. AMPK stimulates Ser372 phosphorylation, suppresses SREBP-1c cleavage and nuclear translocation, and represses SREBP-1c target gene expression in hepatocytes exposed to high glucose, leading to reduced lipogenesis and lipid accumulation. Hepatic activation of AMPK by the synthetic polyphenol S17834 protects against hepatic steatosis, hyperlipidemia, and accelerated atherosclerosis in diet-induced insulin-resistant LDL receptor-deficient mice in part through phosphorylation of SREBP-1c Ser372 and suppression of SREBP-1c- and -2-dependent lipogenesis. AMPK-dependent phosphorylation of SREBP may offer therapeutic strategies to combat insulin resistance, dyslipidemia, and atherosclerosis. C1 [Li, Yu; Xu, Shanqin; Hou, Xiuyun; Jiang, Bingbing; Luo, Zhijun; Cohen, Richard A.; Zang, Mengwei] Boston Univ, Sch Med, Vasc Biol Sect, Dept Med,Whitaker Cardiovasc Inst, Boston, MA 02481 USA. [Mihaylova, Maria M.; Shaw, Reuben J.] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA. [Mihaylova, Maria M.; Shaw, Reuben J.] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA. [Zheng, Bin] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA. [Park, Ogyi; Gao, Bin] NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA. [Lefai, Etienne] Univ Lyon 1, INSERM, U1060, INRA,U1235,CarMeN Lab, F-69600 Oullins, France. [Shyy, John Y. -J.] Univ Calif San Diego, Div Biomed Sci, La Jolla, CA 92093 USA. [Wierzbicki, Michel; Verbeuren, Tony J.] Inst Rech Servier, F-92150 Suresnes, France. RP Zang, MW (reprint author), Boston Univ, Sch Med, Vasc Biol Sect, Dept Med,Whitaker Cardiovasc Inst, Boston, MA 02481 USA. EM mwzang1@bu.edu RI Li, Yu/B-1071-2014; OI Zang, Mengwei/0000-0002-2502-2586; Cohen, Richard/0000-0002-1070-6408; Luo, Zhijun/0000-0003-3509-4046; li, yu/0000-0001-6910-5933 FU National Institutes of Health [RO1 DK076942, PO1 HL068758, RO1 DK080425, DK59637, R01 DK080425]; American Diabetes Association [1-08-JF-47] FX This work has been supported by the National Institutes of Health Grants RO1 DK076942 (to M.Z.), PO1 HL068758 (to R.A.C.), RO1 DK080425 (to R.J.S.), and DK59637 (Lipid, Lipoprotein, and Atherosclerosis Core of the Vanderbilt Mouse Metabolic Phenotype Center), and the American Diabetes Association Junior Faculty Award 1-08-JF-47 (to R.J.S.). M.Z. and R.A.C. are recipients of Robert Dawson Evans Junior Faculty Merit and Scholar Awards. M.Z. is also the recipient of the Wing Tat Lee Award at Boston University School of Medicine. This work was also supported by NIH R01 DK080425 (to R.J.S.). We are grateful to Dr. Benoit Viollet for kindly providing AMPK+/+ and AMPK-/- MEFs. We thank Jianxin Xie at Cell Signaling Technology for collaborating to develop the phospho-Ser372 SREBP-1c antibody. We would like to thank Dr. Vladimir R. Babaev for helping to perform FPLC analysis. We also thank Kimberly Wong and Dr. Yuxia Cao for excellent technical assistance and Karlene A. Maitland-Toolan and Robert M. Weisbrod for animal studies. We would like to thank Dr. Kenneth Walsh, Dr. Sudha B. Biddinger, Dr. Dave Pimental, and Dr. Haya Herscovitz for insightful discussion. Dr. Tony J. Verbeuren and Dr. Michel Wierzbicki are employees and Dr. Richard A. Cohen is a consultant of Servier Pharmaceutical Company. NR 34 TC 373 Z9 398 U1 9 U2 78 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1550-4131 EI 1932-7420 J9 CELL METAB JI Cell Metab. PD APR 6 PY 2011 VL 13 IS 4 BP 376 EP 388 DI 10.1016/j.cmet.2011.03.009 PG 13 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 748HM UT WOS:000289381300009 PM 21459323 ER PT J AU Gurley, SB Riquier-Brison, ADM Schnermann, J Sparks, MA Allen, AM Haase, VH Snouwaert, JN Le, TH McDonough, AA Koller, BH Coffman, TM AF Gurley, Susan B. Riquier-Brison, Anne D. M. Schnermann, Jurgen Sparks, Matthew A. Allen, Andrew M. Haase, Volker H. Snouwaert, John N. Le, Thu H. McDonough, Alicia A. Koller, Beverley H. Coffman, Thomas M. TI AT(1A) Angiotensin Receptors in the Renal Proximal Tubule Regulate Blood Pressure SO CELL METABOLISM LA English DT Article ID II RECEPTOR; SODIUM-TRANSPORT; ESSENTIAL-HYPERTENSION; MOLECULAR-MECHANISMS; CONVERTING ENZYME; IN-VIVO; KIDNEY; NEPHRON; RENIN; MICE AB Hypertension affects more than 1.5 billion people worldwide but the precise cause of elevated blood pressure (BP) cannot be determined in most affected individuals. Nonetheless, blockade of the renin-angiotensin system (RAS) lowers BP in the majority of patients with hypertension. Despite its apparent role in hypertension pathogenesis, the key cellular targets of the RAS that control BP have not been clearly identified. Here we demonstrate that RAS actions in the epithelium of the proximal tubule have a critical and nonredundant role in determining the level of BP. Abrogation of AT(1) angiotensin receptor signaling in the proximal tubule alone is sufficient to lower BP, despite intact vascular responses. Elimination of this pathway reduces proximal fluid reabsorption and alters expression of key sodium transporters, modifying pressure-natriuresis and providing substantial protection against hypertension. Thus, effectively targeting epithelial functions of the proximal tubule of the kidney should be a useful therapeutic strategy in hypertension. C1 [Gurley, Susan B.; Sparks, Matthew A.; Coffman, Thomas M.] Duke Univ, Dept Med, Div Nephrol, Durham, NC 27710 USA. [Gurley, Susan B.; Sparks, Matthew A.; Coffman, Thomas M.] VA Med Ctr, Durham, NC 27710 USA. [Riquier-Brison, Anne D. M.; McDonough, Alicia A.] Univ So Calif, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA. [Schnermann, Jurgen] NIDDK, NIH, Bethesda, MD 20892 USA. [Allen, Andrew M.] Univ Melbourne, Dept Physiol, Melbourne, Vic 3010, Australia. [Haase, Volker H.] Vanderbilt Univ, Dept Med, Div Nephrol & Hypertens, Nashville, TN 37232 USA. [Snouwaert, John N.; Koller, Beverley H.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA. [Le, Thu H.] Univ Virginia, Dept Med, Div Nephrol, Charlottesville, VA 22908 USA. [Coffman, Thomas M.] Duke NUS Grad Med Sch, Cardiovasc & Metab Disorders Res Program, Singapore 169857, Singapore. RP Coffman, TM (reprint author), Duke Univ, Dept Med, Div Nephrol, Durham, NC 27710 USA. EM tcoffman@duke.edu RI Haase, Volker Hans/A-6758-2013; OI Haase, Volker Hans/0000-0002-7051-8994; Allen, Andrew Mark/0000-0002-2183-5360; Sparks, Matthew/0000-0003-2075-2691 FU National Institutes of Health [TMC 2R01 HL056122 13, AAM DK083785]; American Heart Association [0475034N]; Veterans Affairs Research Administration; Edna and Fred L. Mandel, Jr. Foundation FX The authors gratefully acknowledge the technical support of Robert C. Griffiths and Carrie L. Mach and funding from National Institutes of Health (TMC 2R01 HL056122 13; AAM DK083785), American Heart Association (SBG Fellow-to-Faculty Award 0475034N), Veterans Affairs Research Administration, and the Edna and Fred L. Mandel, Jr. Foundation. NR 42 TC 100 Z9 101 U1 0 U2 10 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1550-4131 EI 1932-7420 J9 CELL METAB JI Cell Metab. PD APR 6 PY 2011 VL 13 IS 4 BP 469 EP 475 DI 10.1016/j.cmet.2011.03.001 PG 7 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 748HM UT WOS:000289381300017 PM 21459331 ER PT J AU Li, YQ Xue, YX He, YY Li, FQ Xue, LF Xu, CM Sacktor, TC Shaham, Y Lu, L AF Li, Yan-qin Xue, Yan-xue He, Ying-ying Li, Fang-qiong Xue, Li-fen Xu, Chun-mei Sacktor, Todd Charlton Shaham, Yavin Lu, Lin TI Inhibition of PKM xi in Nucleus Accumbens Core Abolishes Long-Term Drug Reward Memory SO JOURNAL OF NEUROSCIENCE LA English DT Article ID PROTEIN-KINASE-C; DOPAMINE D-1-FAMILY RECEPTORS; VENTRAL TEGMENTAL AREA; AMPA RECEPTORS; HEROIN SEEKING; M-ZETA; BASOLATERAL AMYGDALA; SIGNALING PATHWAY; COCAINE-SEEKING; LTP MAINTENANCE AB During abstinence, memories of drug-associated cues persist for many months, and exposure to these cues often provokes relapse to drug use. The mechanisms underlying the maintenance of these memories are unknown. A constitutively active atypical protein kinase C (PKC) isozyme, protein kinase M xi (PKM xi), is required for maintenance of spatial memory, conditioned taste aversion, and other memory forms. We used conditioned place preference (CPP) and conditioned place aversion (CPA) procedures to study the role of nucleus accumbens PKM xi in the maintenance of drug reward and aversion memories in rats. Morphine CPP training (10 mg/kg, 4 pairings) increased PKM xi levels in accumbens core but not shell. Injections of the PKM xi inhibitor xi inhibitory peptide (ZIP) into accumbens core but not shell after CPP training blocked morphine CPP expression for up to 14 d after injections. This effect was mimicked by the PKC inhibitor chelerythrine, which inhibits PKM xi, but not by the conventional and novel PKC inhibitor staurosporine, which does not effectively inhibit PKM xi. ZIP injections into accumbens core after training also blocked the expression of cocaine (10 mg/kg) and high-fat food CPP but had no effect on CPA induced by naloxone-precipitated morphine withdrawal. Accumbens core injections of Tat-GluR2(3Y), which inhibits GluR2-dependent AMPA receptor endocytosis, prevented the impairment in morphine CPP induced by local ZIP injections, indicating that the persistent effect of PKM xi is on GluR2-containing AMPA receptors. Results indicate that PKM xi activity in accumbens core is a critical cellular substrate for the maintenance of memories of relapse-provoking reward cues during prolonged abstinence periods. C1 [Li, Yan-qin; Xue, Yan-xue; He, Ying-ying; Li, Fang-qiong; Xue, Li-fen; Xu, Chun-mei; Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100191, Peoples R China. [Sacktor, Todd Charlton] Suny Downstate Med Ctr, Dept Physiol & Pharmacol, New York, NY 11203 USA. [Sacktor, Todd Charlton] Suny Downstate Med Ctr, Dept Neurol, New York, NY 11203 USA. [Shaham, Yavin] Natl Inst Drug Abuse, Intramural Res Program, NIH, Baltimore, MD 21224 USA. RP Lu, L (reprint author), Peking Univ, Natl Inst Drug Dependence, 38 Xue Yuan Rd, Beijing 100191, Peoples R China. EM linlu@bjmu.edu.cn RI shaham, yavin/G-1306-2014 FU National Basic Research Program of China [2009CB522004]; Natural Science Foundation of China [30725016]; Natural Science Foundation of Beijing Municipality [09G0762]; National Institute on Drug Abuse [National Institutes of Health (NIH), Department of Health and Human Services]; National Institutes of Health [MH057068, MH53576] FX This work was supported in part by the National Basic Research Program of China (No. 2009CB522004), the Natural Science Foundation of China (No. 30725016), Natural Science Foundation of Beijing Municipality (No. 09G0762), the Intramural Research Program of the National Institute on Drug Abuse [National Institutes of Health (NIH), Department of Health and Human Services], and National Institutes of Health Grants MH057068 and MH53576 (T.C.S.). We thank Dr. Emily Wentzell, Anna Stern, and Dr. David Epstein for helpful comments. NR 58 TC 66 Z9 67 U1 1 U2 13 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD APR 6 PY 2011 VL 31 IS 14 BP 5436 EP 5446 DI 10.1523/JNEUROSCI.5884-10.2011 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 746AO UT WOS:000289213500029 PM 21471379 ER PT J AU Ramonet, D Daher, JPL Lin, BM Stafa, K Kim, J Banerjee, R Westerlund, M Pletnikova, O Glauser, L Yang, LC Liu, Y Swing, DA Beal, MF Troncoso, JC McCaffery, JM Jenkins, NA Copeland, NG Galter, D Thomas, B Lee, MK Dawson, TM Dawson, VL Moore, DJ AF Ramonet, David Daher, Joao Paulo L. Lin, Brian M. Stafa, Klodjan Kim, Jaekwang Banerjee, Rebecca Westerlund, Marie Pletnikova, Olga Glauser, Liliane Yang, Lichuan Liu, Ying Swing, Deborah A. Beal, M. Flint Troncoso, Juan C. McCaffery, J. Michael Jenkins, Nancy A. Copeland, Neal G. Galter, Dagmar Thomas, Bobby Lee, Michael K. Dawson, Ted M. Dawson, Valina L. Moore, Darren J. TI Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2 SO PLOS ONE LA English DT Article ID FAMILIAL PARKINSONS-DISEASE; KINASE-ACTIVITY; ALPHA-SYNUCLEIN; R1441C MUTATION; BETA PROMOTER; GTP-BINDING; GENE LRRK2; BRAIN; LEUCINE-RICH-REPEAT-KINASE-2; LOCALIZATION AB Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant familial Parkinson's disease (PD) and also contribute to idiopathic PD. LRRK2 mutations represent the most common cause of PD with clinical and neurochemical features that are largely indistinguishable from idiopathic disease. Currently, transgenic mice expressing wild-type or disease-causing mutants of LRRK2 have failed to produce overt neurodegeneration, although abnormalities in nigrostriatal dopaminergic neurotransmission have been observed. Here, we describe the development and characterization of transgenic mice expressing human LRRK2 bearing the familial PD mutations, R1441C and G2019S. Our study demonstrates that expression of G2019S mutant LRRK2 induces the degeneration of nigrostriatal pathway dopaminergic neurons in an age-dependent manner. In addition, we observe autophagic and mitochondrial abnormalities in the brains of aged G2019S LRRK2 mice and markedly reduced neurite complexity of cultured dopaminergic neurons. These new LRRK2 transgenic mice will provide important tools for understanding the mechanism(s) through which familial mutations precipitate neuronal degeneration and PD. C1 [Ramonet, David; Stafa, Klodjan; Glauser, Liliane; Moore, Darren J.] Ecole Polytech Fed Lausanne, Sch Life Sci, Brain Mind Inst, Lausanne, Switzerland. [Daher, Joao Paulo L.; Lin, Brian M.; Dawson, Ted M.; Dawson, Valina L.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, NeuroRegenerat Program, Baltimore, MD USA. [Daher, Joao Paulo L.; Lin, Brian M.; Dawson, Ted M.; Dawson, Valina L.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Stem Cell Program, Baltimore, MD USA. [Daher, Joao Paulo L.; Lin, Brian M.; Dawson, Ted M.; Dawson, Valina L.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. [Daher, Joao Paulo L.] Univ Fed Fluminense, Sch Med, Dept Pathol, Niteroi, RJ, Brazil. [Kim, Jaekwang; Pletnikova, Olga; Liu, Ying; Troncoso, Juan C.; Lee, Michael K.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA. [Kim, Jaekwang; Lee, Michael K.] Univ Minnesota, Dept Neurosci, Inst Translat Neurosci, Minneapolis, MN USA. [Banerjee, Rebecca; Yang, Lichuan; Beal, M. Flint; Thomas, Bobby] Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA. [Westerlund, Marie; Galter, Dagmar] Karolinska Inst, Dept Neurosci, Stockholm, Sweden. [McCaffery, J. Michael] Johns Hopkins Univ, Integrated Imaging Ctr, Baltimore, MD USA. [McCaffery, J. Michael] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA. [Swing, Deborah A.; Jenkins, Nancy A.; Copeland, Neal G.] NCI, Mouse Canc Genet Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA. [Dawson, Ted M.; Dawson, Valina L.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA. [Dawson, Valina L.] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA. RP Ramonet, D (reprint author), Ecole Polytech Fed Lausanne, Sch Life Sci, Brain Mind Inst, Lausanne, Switzerland. EM vdawson@jhmi.edu; darren.moore@epfl.ch RI Galter, Dagmar/C-4826-2011; Lee, Michael/D-9491-2013; OI Galter, Dagmar/0000-0001-6485-6244; Lee, Michael/0000-0001-5865-9682; Dawson, Valina/0000-0002-2915-3970 FU National Parkinson Foundation; Swiss National Science Foundation [310030_127478]; Parkinson Schweiz; American Parkinson Disease Association; Ecole Polytechnique Federale de Lausanne; Swedish Research Council; National Institutes of Health [NS060885, NS062165, NS03877] FX This work was supported by the National Parkinson Foundation (D.J.M., V. L. D.); Swiss National Science Foundation (grant no. 310030_127478 to D.J.M.); Parkinson Schweiz (D.J.M.); American Parkinson Disease Association (D.J.M.); Ecole Polytechnique Federale de Lausanne (D.J.M.); Swedish Research Council (D.G.); and the National Institutes of Health (grant no. NS060885 and NS062165 to B. T., and NS03877 to T. M. D. and V. L. D.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 61 TC 139 Z9 141 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 6 PY 2011 VL 6 IS 4 AR e18568 DI 10.1371/journal.pone.0018568 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 745UM UT WOS:000289192400039 PM 21494637 ER PT J AU Subbiah, V Naing, A Brown, RE Chen, H Doyle, L LoRusso, P Benjamin, R Anderson, P Kurzrock, R AF Subbiah, Vivek Naing, Aung Brown, Robert E. Chen, Helen Doyle, Laurence LoRusso, Patricia Benjamin, Robert Anderson, Pete Kurzrock, Razelle TI Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures SO PLOS ONE LA English DT Article ID FACTOR-I RECEPTOR; MONOCLONAL-ANTIBODY; TUMORS; RESISTANCE; PATHWAYS; AKT/PKB; MTORC2; RICTOR; CELLS AB Background: Insulin-like growth factor 1 receptor (IGF1R) targeted therapies have resulted in responses in a small number of patients with advanced metastatic Ewing's sarcoma. We performed morphoproteomic profiling to better understand response/resistance mechanisms of Ewing's sarcoma to IGF1R inhibitor-based therapy. Methodology/Principal Findings: This pilot study assessed two patients with advanced Ewing's sarcoma treated with IGF1R antibody alone followed by combined IGF1R inhibitor plus mammalian target of rapamycin (mTOR) inhibitor treatment once resistance to single-agent IGF1R inhibitor developed. Immunohistochemical probes were applied to detect p-mTOR (Ser2448), p-Akt (Ser473), p-ERK1/2 (Thr202/Tyr204), nestin, and p-STAT3 (Tyr 705) in the original and recurrent tumor. The initial remarkable radiographic responses to IGF1R-antibody therapy was followed by resistance and then response to combined IGF1R plus mTOR inhibitor therapy in both patients, and then resistance to the combination regimen in one patient. In patient 1, upregulation of p-Akt and p-mTOR in the tumor that relapsed after initial response to IGF1R antibody might explain the resistance that developed, and the subsequent response to combined IGF1R plus mTOR inhibitor therapy. In patient 2, upregulation of mTOR was seen in the primary tumor, perhaps explaining the initial response to the IGF1R and mTOR inhibitor combination, while the resistant tumor that emerged showed activation of the ERK pathway as well. Conclusion/Significance: Morphoproteomic analysis revealed that the mTOR pathway was activated in these two patients with advanced Ewing's sarcoma who showed response to combined IGF1R and mTOR inhibition, and the ERK pathway in the patient in whom resistance to this combination emerged. Our pilot results suggests that morphoproteomic assessment of signaling pathway activation in Ewing's sarcoma merits further investigation as a guide to understanding response and resistance signatures. C1 [Subbiah, Vivek; Anderson, Pete] Univ Texas MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA. [Subbiah, Vivek; Naing, Aung; Kurzrock, Razelle] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA. [Brown, Robert E.] Univ Texas Houston, Sch Med, Dept Pathol & Lab Med, UT Hlth, Houston, TX 77030 USA. [Chen, Helen; Doyle, Laurence] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [LoRusso, Patricia] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA. [Benjamin, Robert] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Sarcoma Med Oncol, Houston, TX 77030 USA. RP Subbiah, V (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA. EM vsubbiah@mdanderson.org FU NCI-CTEP [R21-CA13763301A1]; National Center for Research Resources (NCRR) [RR024148]; National Institutes of Health (NIH); NIH Roadmap for Medical Research; NIH through Cancer Center [CA 016672]; [U01 CA062461-17] FX This study was funded by in part by U01 CA062461-17 (RK) and NCI-CTEP R21-CA13763301A1 (AN). This work was also supported by Grant RR024148 from the National Center for Research Resources (NCRR), National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov/. Information on Reengineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp. The University of Texas MD Anderson Cancer Center is supported in part by the NIH through Cancer Center Support Grant no. CA 016672. Presented in part as a platform presentation at the 16th Annual Meeting of the Connective Tissue Oncologic Society, November 11-13, 2010, Paris, France. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 27 TC 47 Z9 48 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 6 PY 2011 VL 6 IS 4 AR e18424 DI 10.1371/journal.pone.0018424 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 745UM UT WOS:000289192400027 PM 21494688 ER PT J AU Volkow, ND McLellan, TA Cotto, JH Karithanom, M Weiss, SRB AF Volkow, Nora D. McLellan, Thomas A. Cotto, Jessica H. Karithanom, Meena Weiss, Susan R. B. TI Characteristics of Opioid Prescriptions in 2009 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID ADOLESCENTS; DEPENDENCE; ADULTS; ABUSE C1 [Volkow, Nora D.; Cotto, Jessica H.; Karithanom, Meena; Weiss, Susan R. B.] NIDA, NIH, Bethesda, MD 20892 USA. [McLellan, Thomas A.] Univ Penn, Sch Med, Ctr Subst Abuse Solut, Philadelphia, PA 19104 USA. RP Volkow, ND (reprint author), NIDA, NIH, Bethesda, MD 20892 USA. EM nvolkow@nida.nih.gov FU Intramural NIH HHS [Z99 DA999999] NR 6 TC 110 Z9 111 U1 0 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 6 PY 2011 VL 305 IS 13 BP 1299 EP 1301 DI 10.1001/jama.2011.401 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 745JT UT WOS:000289162400016 PM 21467282 ER PT J AU Volkow, ND McLellan, TA AF Volkow, Nora D. McLellan, Thomas A. TI Curtailing Diversion and Abuse of Opioid Analgesics Without Jeopardizing Pain Treatment SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID CHRONIC NONCANCER PAIN C1 [Volkow, Nora D.] NIDA, NIH, Bethesda, MD 20892 USA. [McLellan, Thomas A.] Univ Penn, Sch Med, Ctr Subst Abuse Solut, Philadelphia, PA 19104 USA. RP Volkow, ND (reprint author), NIDA, NIH, 6001 Execut Blvd,Room 5274,MSC 9581, Bethesda, MD 20892 USA. EM nvolkow@nida.nih.gov NR 10 TC 97 Z9 98 U1 0 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 6 PY 2011 VL 305 IS 13 BP 1346 EP 1347 DI 10.1001/jama.2011.369 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 745JT UT WOS:000289162400024 PM 21467287 ER PT J AU Blair, A Marrett, L Freeman, LB AF Blair, Aaron Marrett, Loraine Freeman, Laura Beane TI Occupational cancer in developed countries SO ENVIRONMENTAL HEALTH LA English DT Article; Proceedings Paper CT Conference on Environment and Cancer CY JUN 04-05, 2009 CL Turin, ITALY ID EXPOSURE; SMOKING AB Studies of occupational exposures have made major contributions to our understanding of human carcinogenesis. About one third of the factors identified as definite or probable human carcinogens were first investigated in the workplace and these exposures exact a considerable toll on working populations. There are many additional workplace exposures that are suspect carcinogens that require further evaluation to ensure a safe work environment. Information from occupational investigations is also relevant to the general population because many occupational exposures can be found outside the workplace. Much of our understanding about occupational cancer has been obtained from studies largely composed of white men in developed countries. The movement of industry from developed to developing countries underscores the need for future investigations to include more diverse populations. C1 [Blair, Aaron; Freeman, Laura Beane] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Blair, Aaron; Marrett, Loraine] Canc Care Ontario, Occupat Canc Res Ctr, Toronto, ON, Canada. RP Blair, A (reprint author), NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. EM blaira@exchange.nih.gov RI Beane Freeman, Laura/C-4468-2015 OI Beane Freeman, Laura/0000-0003-1294-4124 NR 15 TC 6 Z9 6 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-069X J9 ENVIRON HEALTH-GLOB JI Environ. Health PD APR 5 PY 2011 VL 10 SU 1 AR S9 DI 10.1186/1476-069X-10-S1-S9 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 759II UT WOS:000290233600009 PM 21489219 ER PT J AU Melnick, RL Huff, J AF Melnick, Ronald L. Huff, James TI Lorenzo Tomatis and primary prevention of environmental cancer SO ENVIRONMENTAL HEALTH LA English DT Article; Proceedings Paper CT Conference on Environment and Cancer CY JUN 04-05, 2009 CL Turin, ITALY ID RISKS; IDENTIFICATION AB The leading 20(th) century proponent for primary prevention of environmental cancer was Dr. Lorenzo Tomatis, the former Director of the International Agency for Research on Cancer and founder of the IARC Monographs program. This paper is dedicated to the memory of Dr. Tomatis - eminent scientist, scholar, teacher, humanitarian, and public health champion - and includes many perspectives that he promoted throughout his career, with original quotations from some of his scientific writings on primary prevention of environmental cancer. Any attempt by us to simply summarize his views would only detract from the power and logic of his language. "Cancer still remains a mainly lethal disease. Primary prevention remains the most relevant approach to reduce mortality through a reduction in incidence" [1]. C1 [Melnick, Ronald L.] Ron Melnick Consulting LLC, Chapel Hill, NC 27514 USA. [Huff, James] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC 27709 USA. RP Melnick, RL (reprint author), Ron Melnick Consulting LLC, 111 Roundtree Rd, Chapel Hill, NC 27514 USA. EM ron.melnick@gmail.com NR 11 TC 4 Z9 4 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-069X J9 ENVIRON HEALTH-GLOB JI Environ. Health PD APR 5 PY 2011 VL 10 SU 1 AR S14 DI 10.1186/1476-069X-10-S1-S14 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 759II UT WOS:000290233600014 PM 21489210 ER PT J AU Tao, YG Xi, SC Shan, JG Maunakea, A Che, A Briones, V Lee, EY Geiman, T Huang, JQ Stephens, R Leighty, RM Zhao, KJ Muegge, K AF Tao, Yongguang Xi, Sichuan Shan, Jigui Maunakea, Alika Che, Anney Briones, Victorino Lee, Eunice Y. Geiman, Theresa Huang, Jiaqiang Stephens, Robert Leighty, Robert M. Zhao, Keji Muegge, Kathrin TI Lsh, chromatin remodeling family member, modulates genome-wide cytosine methylation patterns at nonrepeat sequences SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE methylated DNA immunoprecipitation; chIP-sequencing; epigenetics ID DE-NOVO METHYLATION; DNA METHYLATION; MAMMALIAN DEVELOPMENT; ARABIDOPSIS GENE; SNF2 FAMILY; HUMAN-CELLS; HETEROCHROMATIN; TRANSCRIPTION; MUTATION; ELEMENTS AB DNA methylation is critical for normal development and plays important roles in genome organization and transcriptional regulation. Although DNA methyltransferases have been identified, the factors that establish and contribute to genome-wide methylation patterns remain elusive. Here, we report a high-resolution cytosine methylation map of the murine genome modulated by Lsh, a chromatin remodeling family member that has previously been shown to regulate CpG methylation at repetitive sequences. We provide evidence that Lsh also controls genome-wide cytosine methylation at nonrepeat sequences and relate those changes to alterations in H4K4me3 modification and gene expression. Deletion of Lsh alters the allocation of cytosine methylation in chromosomal regions of 50 kb to 2 Mb and, in addition, leads to changes in the methylation profile at the 5' end of genes. Furthermore, we demonstrate that loss of Lsh promotes-as well as prevents-cytosine methylation. Our data indicate that Lsh is an epigenetic modulator that is critical for normal distribution of cytosine methylation throughout the murine genome. C1 [Tao, Yongguang; Xi, Sichuan; Briones, Victorino; Lee, Eunice Y.; Geiman, Theresa; Huang, Jiaqiang; Muegge, Kathrin] NCI, Basic Sci Program, Lab Canc Prevent, Frederick, MD 21702 USA. [Shan, Jigui; Che, Anney; Stephens, Robert] NCI, Adv Biomed Comp Ctr, Frederick, MD 21702 USA. [Leighty, Robert M.] NCI, Data Management Serv, Sci Applicat Int Corp Frederick Inc, Frederick, MD 21702 USA. [Maunakea, Alika; Zhao, Keji] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20817 USA. RP Muegge, K (reprint author), NCI, Basic Sci Program, Lab Canc Prevent, Frederick, MD 21702 USA. EM Kathrin.Muegge@nih.gov FU National Cancer Institute, National Institutes of Health [HHSN261200800001E]; National Institutes of Health, National Cancer Institute, Center for Cancer Research FX We thank Drs. Nancy Colburn, Amar Klar, and Michael Kuehn for critical comments on the manuscript. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health (Contract HHSN261200800001E) and the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. NR 37 TC 30 Z9 31 U1 0 U2 2 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 5 PY 2011 VL 108 IS 14 BP 5626 EP 5631 DI 10.1073/pnas.1017000108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 746RT UT WOS:000289265300030 PM 21427231 ER PT J AU Batorsky, R Kearney, MF Palmer, SE Maldarelli, F Rouzine, IM Coffin, JM AF Batorsky, Rebecca Kearney, Mary F. Palmer, Sarah E. Maldarelli, Frank Rouzine, Igor M. Coffin, John M. TI Estimate of effective recombination rate and average selection coefficient for HIV in chronic infection SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE modeling; clonal interference; background selection; hitchhiking; haplotype ID HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VIVO; ASEXUAL EVOLUTION; GENE-SEQUENCES; POPULATION; DYNAMICS; RESISTANCE; ADAPTATION; TYPE-1; INDIVIDUALS AB HIV adaptation to a host in chronic infection is simulated by means of a Monte-Carlo algorithm that includes the evolutionary factors of mutation, positive selection with varying strength among sites, random genetic drift, linkage, and recombination. By comparing two sensitive measures of linkage disequilibrium (LD) and the number of diverse sites measured in simulation to patient data from one-time samples of pol gene obtained by single-genome sequencing from representative untreated patients, we estimate the effective recombination rate and the average selection coefficient to be on the order of 1% per genome per generation (10(-5) per base per generation) and 0.5%, respectively. The adaptation rate is twofold higher and fourfold lower than predicted in the absence of recombination and in the limit of very frequent recombination, respectively. The level of LD and the number of diverse sites observed in data also range between the values predicted in simulation for these two limiting cases. These results demonstrate the critical importance of finite population size, linkage, and recombination in HIV evolution. C1 [Rouzine, Igor M.; Coffin, John M.] Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA. [Batorsky, Rebecca] Tufts Univ, Dept Phys & Astron, Medford, MA 02155 USA. [Kearney, Mary F.; Palmer, Sarah E.; Maldarelli, Frank] NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA. RP Rouzine, IM (reprint author), Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA. EM irouzine@tufts.edu; john.coffin@tufts.edu OI batorsky, rebecca/0000-0003-4712-6500 FU National Institutes of Health [R01AI 063926, R37CA 089441]; F. M. Kirby Foundation FX We are grateful to Nick Barton for numerous comments and to Boris Shraiman and Richard Neher for useful discussion. The work was supported by National Institutes of Health grants R01AI 063926 (to I. M. R.) and R37CA 089441 (to J.M.C.). J.M.C. was a Research Professor of the American Cancer Society with support from the F. M. Kirby Foundation. NR 51 TC 51 Z9 51 U1 3 U2 9 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 5 PY 2011 VL 108 IS 14 BP 5661 EP 5666 DI 10.1073/pnas.1102036108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 746RT UT WOS:000289265300036 PM 21436045 ER PT J AU Flatz, L Roychoudhuri, R Honda, M Filali-Mouhim, A Goulet, JP Kettaf, N Lin, M Roederer, M Haddad, EK Sekaly, RP Nabel, GJ AF Flatz, Lukas Roychoudhuri, Rahul Honda, Mitsuo Filali-Mouhim, Abdelali Goulet, Jean-Philippe Kettaf, Nadia Lin, Min Roederer, Mario Haddad, Elias K. Sekaly, Rafick P. Nabel, Gary J. TI Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE lymphocyte subsets; microarray; immune differentiation ID SIMIAN IMMUNODEFICIENCY VIRUS; RHESUS-MONKEYS; MEMORY; PROTECTION; CHALLENGE; IMMUNIZATION; REPLICATION; LYMPHOCYTES; RESPONSES; IMMUNOGENICITY AB CD8 T cells play a key role in mediating protective immunity against selected pathogens after vaccination. Understanding the mechanism of this protection is dependent upon definition of the heterogeneity and complexity of cellular immune responses generated by different vaccines. Here, we identify previously unrecognized subsets of CD8 T cells based upon analysis of gene-expression patterns within single cells and show that they are differentially induced by different vaccines. Three prime-boost vector combinations encoding HIV Env stimulated antigen-specific CD8 T-cell populations of similar magnitude, phenotype, and functionality. Remarkably, however, analysis of single-cell gene-expression profiles enabled discrimination of a majority of central memory ( CM) and effector memory ( EM) CD8 T cells elicited by the three vaccines. Subsets of T cells could be defined based on their expression of Eomes, Cxcr3, and Ccr7, or Klrk1, Klrg1, and Ccr5 in CM and EM cells, respectively. Of CM cells elicited by DNA prime-recombinant adenoviral (rAd) boost vectors, 67% were Eomes-Ccr7(+) Cxcr3(-), in contrast to only 7% and 2% stimulated by rAd5-rAd5 or rAd-LCMV, respectively. Of EM cells elicited by DNA-rAd, 74% were Klrk1(-) Klrg1(-)Ccr5(-) compared with only 26% and 20% for rAd5-rAd5 or rAd5-LCMV. Definition by single-cell gene profiling of specific CM and EM CD8 T-cell subsets that are differentially induced by different gene-based vaccines will facilitate the design and evaluation of vaccines, as well as enable our understanding of mechanisms of protective immunity. C1 [Flatz, Lukas; Roychoudhuri, Rahul; Honda, Mitsuo; Roederer, Mario; Nabel, Gary J.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Flatz, Lukas] Univ Bern, Inst Infect Dis, CH-3010 Bern, Switzerland. [Filali-Mouhim, Abdelali; Goulet, Jean-Philippe; Kettaf, Nadia; Haddad, Elias K.; Sekaly, Rafick P.] Ctr Hosp Univ Montreal, Ctr Rech, Immunol Lab, Montreal, PQ H2X 1P1, Canada. [Lin, Min] Fluidigm Corp, San Francisco, CA 94080 USA. [Haddad, Elias K.; Sekaly, Rafick P.] Vaccine & Gene Therapy Inst, Port St Lucie, FL 34987 USA. RP Nabel, GJ (reprint author), NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. EM gnabel@nih.gov RI Roychoudhuri, Rahul/A-7442-2010 OI Roychoudhuri, Rahul/0000-0002-5392-1853 FU Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Schwyzer Stiftung FX We thank Steve Perfetto, Richard Nguyen, David Ambrozak, Pratip Chattopadhyay, Enrico Lugli, Yolanda Mahnke, and Carl Hogerkorp for help and advice with cell sorting, microarray, and real time PCR; Jeff Skinner for his advice regarding hierarchical clustering of gene expression data; Derek Macallan and George Griffin, Martin Pieprzyk, Tomer Kalisky, Daniel Danila, and Nicholas Restifo for their help and advice; and Brenda Hartman for help with the figure preparation and Ati Tislerics for support in manuscript editing. This research was supported in part by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health. L. F. was supported by the Schwyzer Stiftung. NR 28 TC 61 Z9 61 U1 0 U2 11 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 5 PY 2011 VL 108 IS 14 BP 5724 EP 5729 DI 10.1073/pnas.1013084108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 746RT UT WOS:000289265300047 PM 21422297 ER PT J AU Onda, M Beers, R Xiang, LM Lee, B Weldon, JE Kreitman, RJ Pastan, I AF Onda, Masanori Beers, Richard Xiang, Laiman Lee, Byungkook Weldon, John E. Kreitman, Robert J. Pastan, Ira TI Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE protein engineering; SS1P; passive immunotherapy; target therapy/cancer therapeutics ID PHASE-I TRIAL; STAPHYLOKINASE VARIANTS; CYTOTOXIC ACTIVITY; ANTITUMOR-ACTIVITY; ANIMAL TOXICITY; ALTERED IMMUNOREACTIVITY; RFB4(DSFV)-PE38 BL22; PSEUDOMONAS EXOTOXIN; LEUKEMIA; SS1P AB Many nonhuman proteins have useful pharmacological activities, but are infrequently effective in humans because of their high immunogenicity. A recombinant immunotoxin (HA22, CAT8015, moxetumomab pasudotox) composed of an anti-CD22 antibody variable fragment fused to PE38, a 38-kDa portion of Pseudomonas exotoxin A, has produced many complete remissions in drug-resistant hairy-cell leukemia when several cycles of the agent can be given, but has much less activity when antibodies develop. We have pursued a strategy to deimmunize recombinant immunotoxins by identifying and removing B-cell epitopes. We previously reported that we could eliminate most B-cell epitopes using a combination of point mutations and deletions. Here we show the location and amino acid composition of all of the B-cell epitopes in the remaining 25-kDa portion of Pseudomonas exotoxin. Using this information, we eliminated these epitopes to produce an immunotoxin (HA22-LR-8M) that is fully cytotoxic against malignant B-cell lines, has high cytotoxic activity against cells directly isolated from patients with chronic lymphocytic leukemia, and has excellent antitumor activity in mice. HA22-LR-8M does not induce antibody formation in mice when given repeatedly by intravenous injection and does not induce a secondary antibody response when given to mice previously exposed to HA22. HA22-LR-8M also has greatly reduced antigenicity when exposed to sera from patients who have produced antibodies to HA22. The properties of HA22-LR-8M make it an excellent candidate for further clinical development. C1 [Onda, Masanori; Beers, Richard; Xiang, Laiman; Lee, Byungkook; Weldon, John E.; Kreitman, Robert J.; Pastan, Ira] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP Pastan, I (reprint author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. EM pastani@mail.nih.gov OI Weldon, John/0000-0002-6516-9064 FU National Institutes of Health, National Cancer Institute, Center for Cancer Research; MedImmune, LLC. FX We thank Dr. B. K. Sathyanaraya for making the structure drawings shown in Figs. 1 and 3. This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research, and by a Cooperative Research and Development Agreement with MedImmune, LLC. NR 31 TC 53 Z9 55 U1 0 U2 3 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 5 PY 2011 VL 108 IS 14 BP 5742 EP 5747 DI 10.1073/pnas.1102746108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 746RT UT WOS:000289265300050 PM 21436054 ER PT J AU Cullen, M Elzarrad, MK Seaman, S Zudaire, E Stevens, J Yang, MY Li, XJ Chaudhary, A Xu, LH Hilton, MB Logsdon, D Hsiao, E Stein, EV Cuttitta, F Haines, DC Nagashima, K Tessarollo, L St Croix, B AF Cullen, Mike Elzarrad, Mohammed K. Seaman, Steven Zudaire, Enrique Stevens, Janine Yang, Mi Young Li, Xiujie Chaudhary, Amit Xu, Lihong Hilton, Mary Beth Logsdon, Daniel Hsiao, Emily Stein, Erica V. Cuttitta, Frank Haines, Diana C. Nagashima, Kunio Tessarollo, Lino St Croix, Brad TI GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; GLUCOSE-TRANSPORTER GLUT-1; ANGIOGENESIS; MORPHOGENESIS; VEGF; PERMEABILITY; MICE; DIFFERENTIATION; VASCULATURE; EXPRESSION AB Every organ in the body requires blood vessels for efficient delivery of oxygen and nutrients, but independent vascular beds are highly specialized to meet the individual needs of specific organs. The vasculature of the brain is tightly sealed, with blood-brain barrier (BBB) properties developing coincident with neural vascularization. G protein-coupled receptor 124 (GPR124) (tumor endothelial marker 5, TEM5), an orphan member of the adhesion family of G protein-coupled receptors, was previously identified on the basis of its overexpression in tumor vasculature. Here, we show that global deletion or endothelial-specific deletion of GPR124 in mice results in embryonic lethality associated with abnormal angiogenesis of the forebrain and spinal cord. Expression of GPR124 was found to be required for invasion and migration of blood vessels into neuroepithelium, establishment of BBB properties, and expansion of the cerebral cortex. Thus, GPR124 is an important regulator of neurovasculature development and a potential drug target for cerebrovascular diseases. C1 [Cullen, Mike; Elzarrad, Mohammed K.; Seaman, Steven; Stevens, Janine; Yang, Mi Young; Li, Xiujie; Chaudhary, Amit; Xu, Lihong; Hilton, Mary Beth; Hsiao, Emily; Stein, Erica V.; St Croix, Brad] NCI, Tumor Angiogenesis Sect, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA. [Zudaire, Enrique; Cuttitta, Frank] NCI, Angiogenesis Core Facil, NIH, Gaithersburg, MD 20877 USA. [Hilton, Mary Beth; Logsdon, Daniel] NCI, Basic Res Program, Frederick, MD 21702 USA. [Haines, Diana C.] NCI, Vet Pathol Sect, Pathol Histotechnol Lab, Frederick, MD 21702 USA. [Nagashima, Kunio] NCI, Image Anal Lab, Adv Technol Program, Sci Applicat Int Corp, Frederick, MD 21702 USA. [Tessarollo, Lino] NCI, Neural Dev Sect, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA. RP St Croix, B (reprint author), NCI, Tumor Angiogenesis Sect, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA. EM stcroix@ncifcrf.gov RI Seaman, Steven/A-2755-2013; Cuttitta, Frank/B-4758-2016; OI Seaman, Steven/0000-0003-3349-3334; Stein, Erica/0000-0001-8778-8846 FU National Cancer Institute (NCI), National Institutes of Health; Department of Health and Social Services (DHSS); NCI [HHSN261200800001E] FX We thank Dr. Babette Weksler for the immortalized hCMEC (HCMEC/D3) cells. We thank members of the Mouse Cancer Genetics Program for helpful discussion and Dr. Neal Copeland for critical reading of the manuscript. This research was supported by the intramural research program of the National Cancer Institute (NCI), National Institutes of Health, Department of Health and Social Services (DHSS), and with federal funds from the NCI under Contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the DHSS nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. NR 38 TC 54 Z9 59 U1 3 U2 10 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 5 PY 2011 VL 108 IS 14 BP 5759 EP 5764 DI 10.1073/pnas.1017192108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 746RT UT WOS:000289265300053 PM 21421844 ER PT J AU Fernando, RN Eleuteri, B Abdelhady, S Nussenzweig, A Andang, M Ernfors, P AF Fernando, Ruani N. Eleuteri, Boris Abdelhady, Shaimaa Nussenzweig, Andre Andang, Michael Ernfors, Patrik TI Cell cycle restriction by histone H2AX limits proliferation of adult neural stem cells SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE DNA damage response; subventricular zone astrocytes; self-repair ID IN-VIVO; SONIC HEDGEHOG; PROGENITOR CELLS; MAMMALIAN BRAIN; DENTATE GYRUS; NEUROGENESIS; ZONE; MAINTENANCE; VITRO; FATE AB Adult neural stem cell proliferation is dynamic and has the potential for massive self-renewal yet undergoes limited cell division in vivo. Here, we report an epigenetic mechanism regulating proliferation and self-renewal. The recruitment of the PI3K-related kinase signaling pathway and histone H2AX phosphorylation following GABA(A) receptor activation limits subventricular zone proliferation. As a result, NSC self-renewal and niche size is dynamic and can be directly modulated in both directions pharmacologically or by genetically targeting H2AX activation. Surprisingly, changes in proliferation have long-lasting consequences on stem cell numbers, niche size, and neuronal output. These results establish a mechanism that continuously limits proliferation and demonstrates its impact on adult neurogenesis. Such homeostatic suppression of NSC proliferation may contribute to the limited self-repair capacity of the damaged brain. C1 [Fernando, Ruani N.; Eleuteri, Boris; Abdelhady, Shaimaa; Andang, Michael; Ernfors, Patrik] Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, S-17177 Stockholm, Sweden. [Nussenzweig, Andre] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA. RP Ernfors, P (reprint author), Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, S-17177 Stockholm, Sweden. EM patrik.ernfors@ki.se OI Ernfors, Patrik/0000-0002-1140-3986; Andang, Michael/0000-0002-2886-7891 FU Swedish Research Council; Swedish Cancer Foundation; Swedish Child Cancer Foundation; Swedish Brain Foundation; Bertil Hallsten Research Foundation; EU; KI Strategic Neuroscience Programme; Wallenberg Scholar Award; ERC [232675]; Knut and Alice Wallenberg Foundation (Center for Live Imaging of Cells at Karolinska Institutet); Federation of the Societies of Biochemistry and Molecular Biology; Swedish Childhood Cancer Foundation FX We thank Prof. Magdalena Gotz for sharing the GLAST-CreERT2;CAG-GFP mice and Helena Samuelsson for technical support. This work was supported by Swedish Research Council Linne Grants (Developmental Biology for Regenerative Medicine Grant), Swedish Cancer Foundation, Swedish Child Cancer Foundation, Swedish Brain Foundation, Bertil Hallsten Research Foundation, EU FP7 MOLPARK collaborative project, KI Strategic Neuroscience Programme, Wallenberg Scholar Award, ERC Advanced Grant 232675 (to P.E.), and Knut and Alice Wallenberg Foundation (Center for Live Imaging of Cells at Karolinska Institutet). R. F. was supported by the Swedish Research Council. B.E was supported by the Federation of the Societies of Biochemistry and Molecular Biology. M.A was supported by the Swedish Research Council, Swedish Cancer Foundation, and Swedish Childhood Cancer Foundation. NR 44 TC 59 Z9 62 U1 1 U2 7 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 5 PY 2011 VL 108 IS 14 BP 5837 EP 5842 DI 10.1073/pnas.1014993108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 746RT UT WOS:000289265300066 PM 21436033 ER PT J AU Phillips, D Aponte, AM Covian, R Balaban, RS AF Phillips, Darci Aponte, Angel M. Covian, Raul Balaban, Robert S. TI Intrinsic Protein Kinase Activity in Mitochondrial Oxidative Phosphorylation Complexes SO BIOCHEMISTRY LA English DT Article ID CYTOCHROME-C-OXIDASE; NUCLEOSIDE DIPHOSPHATE KINASE; PYRUVATE-DEHYDROGENASE; CREATINE-KINASE; BOUND PHOSPHOHISTIDINE; NATIVE ELECTROPHORESIS; MASS-SPECTROMETRY; ATP; AUTOPHOSPHORYLATION; MEMBRANE AB Mitochondrial protein phosphorylation is a well-recognized metabolic control mechanism, with the classical example of pyruvate dehydrogenase (PDH) regulation by specific kinases and phosphatases of bacterial origin. However, despite the growing number of reported mitochondrial phosphoproteins, the identity of the protein kinases mediating these phosphorylation events remains largely unknown. The detection of mitochondrial protein kinases is complicated by the low concentration of kinase relative to that of the target protein, the lack of specific antibodies, and contamination from associated, but nonmatrix, proteins. In this study, we use blue native gel electrophoresis (BN-PAGE) to isolate rat and porcine heart mitochondrial complexes for screening of protein kinase activity. To detect kinase activity, one-dimensional BN-PAGE gels were exposed to [gamma-(32)P]ATP and then followed by sodium dodecyl sulfate gel electrophoresis. Dozens of mitochondrial proteins were labeled with (32)P in this setting, including all five complexes of oxidative phosphorylation and several citric acid cycle enzymes. The nearly ubiquitous (32)P protein labeling demonstrates protein kinase activity within each mitochondrial protein complex. The validity of this two-dimensional BN-PAGE method was demonstrated by detecting the known PDH kinases and phosphatases within the PDH complex band using Western blots and mass spectrometry. Surprisingly, these same approaches detected only a few additional conventional protein kinases, suggesting a major role for autophosphorylation in mitochondrial proteins. Studies on purified Complex V and creatine kinase confirmed that these proteins undergo autophosphorylation and, to a lesser degree, tenacious (32)P-metabolite association. In-gel Complex IV activity was shown to be inhibited by ATP, and partially reversed by phosphatase activity, consistent with an inhibitory role for protein phosphorylation in this complex. Collectively, this study proposes that many of the mitochondrial complexes contain an autophosphorylation mechanism, which may play a functional role in the regulation of these multiprotein units. C1 [Phillips, Darci; Covian, Raul; Balaban, Robert S.] NHLBI, Cardiac Energet Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Aponte, Angel M.] NHLBI, Prote Core Facil, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. RP Balaban, RS (reprint author), NHLBI, Cardiac Energet Lab, NIH, Dept Hlth & Human Serv, 10 Ctr Dr,Room B1D416, Bethesda, MD 20892 USA. EM rsb@nih.gov FU National Institutes of Health Division of Intramural Research FX These studies were funded by the National Institutes of Health Division of Intramural Research. NR 53 TC 20 Z9 20 U1 0 U2 6 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD APR 5 PY 2011 VL 50 IS 13 BP 2515 EP 2529 DI 10.1021/bi101434x PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 742UN UT WOS:000288970800016 PM 21329348 ER PT J AU Daar, ES Tierney, C Fischl, MA Sax, PE Mollan, K Budhathoki, C Godfrey, C Jahed, NC Myers, L Katzenstein, D Farajallah, A Rooney, JF Pappa, KA Woodward, WC Patterson, K Bolivar, H Benson, CA Collier, AC AF Daar, Eric S. Tierney, Camlin Fischl, Margaret A. Sax, Paul E. Mollan, Katie Budhathoki, Chakra Godfrey, Catherine Jahed, Nasreen C. Myers, Laurie Katzenstein, David Farajallah, Awny Rooney, James F. Pappa, Keith A. Woodward, William C. Patterson, Kristine Bolivar, Hector Benson, Constance A. Collier, Ann C. CA AIDS Clinical Trials Grp Study A52 TI Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID TWICE-DAILY LOPINAVIR/RITONAVIR; ONCE-DAILY ATAZANAVIR/RITONAVIR; NAIVE HIV-1-INFECTED PATIENTS; RENAL-FUNCTION; ANTIRETROVIRAL TREATMENT; TENOFOVIR DF; THERAPY; LAMIVUDINE; ABACAVIR; EMTRICITABINE AB Background: Limited data compare once-daily options for initial therapy for HIV-1. Objective: To compare time to virologic failure; first grade-3 or -4 sign, symptom, or laboratory abnormality (safety); and change or discontinuation of regimen (tolerability) for atazanavir plus ritonavir with efavirenz-containing initial therapy for HIV-1. Design: A randomized equivalence trial accrued from September 2005 to November 2007, with median follow-up of 138 weeks. Regimens were assigned by using a central computer, stratified by screening HIV-1 RNA level less than 100 000 copies/mL or 100 000 copies/mL or greater; blinding was known only to the site pharmacist. (ClinicalTrials.gov registration number: NCT00118898) Setting: 59 AIDS Clinical Trials Group sites in the United States and Puerto Rico. Patients: Antiretroviral-naive patients. Intervention: Open-label atazanavir plus ritonavir or efavirenz, each given with with placebo-controlled abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtricitabine. Measurements: Primary outcomes were time to virologic failure, safety, and tolerability events. Secondary end points included proportion of patients with HIV-1 RNA level less than 50 copies/mL, emergence of drug resistance, changes in CD4 cell counts, calculated creatinine clearance, and lipid levels. Results: 463 eligible patients were randomly assigned to receive atazanavir plus ritonavir and 465 were assigned to receive efavirenz, both with abacavir-lamivudine; 322 (70%) and 324 (70%), respectively, completed follow-up. The respective numbers of participants in each group who received tenofovir DF-emtricitabine were 465 and 464; 342 (74%) and 343 (74%) completed follow-up. Primary efficacy was similar in the group that received atazanavir plus ritonavir and and the group that received efavirenz and did not differ according to whether abacavir-lamivudine or tenofovir DF-emtricitabine was also given. Hazard ratios for time to virologic failure were 1.13 (95% CI, 0.82 to 1.56) and 1.01 (CI, 0.70 to 1.46), respectively, although CIs did not meet prespecified criteria for equivalence. The time to safety (P = 0.048) and tolerability (P < 0.001) events was longer in persons given atazanavir plus ritonavir than in those given efavirenz with abacavir-lamivudine but not with tenofovir DF-emtricitabine. Limitations: Neither HLA-B*5701 nor resistance testing was the standard of care when A5202 enrolled patients. The third drugs, atazanavir plus ritonavir and efavirenz, were open-label; the nucleoside reverse transcriptase inhibitors were prematurely unblinded in the high viral load stratum; and 32% of patients modified or discontinued treatment with their third drug. Conclusion: Atazanavir plus ritonavir and efavirenz have similar antiviral activity when used with abacavir-lamivudine or tenofovir DF-emtricitabine. C1 Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Univ Miami, Sch Med, Miami, FL 33136 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. NIAID, Bethesda, MD 20892 USA. Social & Sci Syst, Silver Spring, MD 20910 USA. Frontier Sci & Technol Res Fdn Inc, Amherst, NY 14226 USA. Stanford Univ, Palo Alto, CA 94304 USA. Bristol Myers Squibb Co, Plainsboro, NJ USA. Gilead Sci Inc, Foster City, CA 94404 USA. GlaxoSmithKline, Res Triangle Pk, NC 27709 USA. Abbott Labs, Abbott Pk, IL 60064 USA. Univ N Carolina, Chapel Hill, NC USA. Univ Calif San Diego, San Diego, CA 92103 USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. RP Daar, ES (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, 1124 W Carson St,N-24, Torrance, CA 90502 USA. EM EDaar@LABioMed.org FU National Institutes of Health; National Institute of Allergy and Infectious Diseases [U01AI068636]; AIDS Clinical Trials Group Central Group [AI38858]; Statistical Data Management Center [AI38855, AI68634]; National Center for Research Resources FX National Institutes of Health.; By award U01AI068636 from the National Institute of Allergy and Infectious Diseases, along with the previous grant for the AIDS Clinical Trials Group Central Group (AI38858) and the Statistical Data Management Center grants (AI38855 and AI68634). The study was supported in part by the General Clinical Research Center Units, funded by the National Center for Research Resources. NR 26 TC 183 Z9 183 U1 2 U2 11 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 5 PY 2011 VL 154 IS 7 AR 445 DI 10.7326/0003-4819-154-7-201104050-00316 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 744EX UT WOS:000289078700001 PM 21320923 ER PT J AU Lauer, MS AF Lauer, Michael S. TI How Will Exercise Capacity Gain Enough Respect? SO CIRCULATION LA English DT Editorial Material DE Editorials; cardiovascular diseases; classification; exercise; mortality; risk ID RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; SUDDEN CARDIAC DEATH; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR-DISEASE; RISK; PREDICTION; OVERWEIGHT; MORTALITY C1 [Lauer, Michael S.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA. RP Lauer, MS (reprint author), 6701 Rockledge Dr,Room 8128, Bethesda, MD 20892 USA. EM lauerm@nhlbi.nih.gov RI Lauer, Michael/L-9656-2013 OI Lauer, Michael/0000-0002-9217-8177 NR 23 TC 4 Z9 4 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD APR 5 PY 2011 VL 123 IS 13 BP 1364 EP 1366 DI 10.1161/CIRCULATIONAHA.111.023218 PG 3 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 744FO UT WOS:000289080500008 PM 21422388 ER PT J AU Burke, A Zhang, R Tavora, F Li, L Fowler, D Oliveira, JB AF Burke, Allen Zhang, Richard Tavora, Fabio Li, Ling Fowler, David Oliveira, Joao Bosco TI NOVEL PKP2 MUTATIONS IN ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY AND SUDDEN ARRHYTHMIC DEATHS IN MORPHOLOGICALLY NORMAL HEARTS SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 60th Annual Scientific Session and Expo of the American-College-of-Cardiology CY APR 03-05, 2011 CL New Orleans, LA SP Amer Coll Cardiol C1 NIH, Bethesda, MD 20892 USA. Univ Maryland, Med Ctr, Baltimore, MD 21201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 5 PY 2011 VL 57 IS 14 SU 1 BP E227 EP E227 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 778HR UT WOS:000291695100228 ER PT J AU Hadnott, TN Gould, H Bondy, C AF Hadnott, Tracy N. Gould, Harley Bondy, Carolyn TI AORTIC DILATION IN THE PAROUS TURNER SYNDROME PATIENT: A CASE SERIES SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 60th Annual Scientific Session and Expo of the American-College-of-Cardiology CY APR 03-05, 2011 CL New Orleans, LA SP Amer Coll Cardiol C1 NIH, Bethesda, MD 20892 USA. Howard Hughes Med Inst, Bethesda, MD 20817 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 5 PY 2011 VL 57 IS 14 SU 1 BP E1524 EP E1524 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 778HR UT WOS:000291695101527 ER PT J AU Koh, KK Quon, M Park, Y Han, S Shin, E Chung, WJ Lee, K AF Koh, Kwang K. Quon, Michael Park, Yae Han, Seung Shin, Eak Chung, W-J Lee, Kyoung TI EFFECTS OF FENOFIBRATE THERAPY ON CIRCULATING ADIPOCYTOKINES IN PATIENTS WITH PRIMARY HYPERTRIGLYCERIDEMIA SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 60th Annual Scientific Session and Expo of the American-College-of-Cardiology CY APR 03-05, 2011 CL New Orleans, LA SP Amer Coll Cardiol C1 Gachon Univ Gil Hosp, Inchon, South Korea. NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 5 PY 2011 VL 57 IS 14 SU 1 BP E2024 EP E2024 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 778HR UT WOS:000291695102029 ER PT J AU Sims, A Frank, L Cross, R Clauss, S Dimock, D Purdy, J Jacoub, I Hazra, R Hadigan, C Sable, C AF Sims, Amy Frank, Lowell Cross, Russell Clauss, Sarah Dimock, David Purdy, Julia Jacoub, Irene Hazra, Rohan Hadigan, Colleen Sable, Craig TI ABNORMAL CARDIAC STRAIN IN CHILDREN AND YOUNG ADULTS WITH HIV ACQUIRED IN EARLY LIFE SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 60th Annual Scientific Session and Expo of the American-College-of-Cardiology CY APR 03-05, 2011 CL New Orleans, LA SP Amer Coll Cardiol C1 Childrens Natl Med Ctr, Washington, DC 20010 USA. NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 5 PY 2011 VL 57 IS 14 SU 1 BP E446 EP E446 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 778HR UT WOS:000291695100447 ER PT J AU Wang, H Lafdil, F Wang, L Yin, S Feng, DC Gao, B AF Wang, Hua Lafdil, Fouad Wang, Lei Yin, Shi Feng, Dechun Gao, Bin TI Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production SO CELL AND BIOSCIENCE LA English DT Article ID HEPATIC STELLATE CELLS; MATRIX METALLOPROTEINASES; SPECIAL EMPHASIS; GENE-EXPRESSION; ONCOSTATIN-M; RAT; MECHANISMS; ACTIVATOR; PROTEIN; IL-6 AB Background: Tissue inhibitor of metalloproteinase 1 (TIMP-1), which is thought to be produced mainly by activated hepatic stellate cells and Kupffer cells in the liver, plays a pivotal role in matrix remodeling during liver injury and repair; while the effect of TIMP-1 on hepatocellular damage remains obscure. Results: Hepatic expression of TIMP-1 mRNA and protein was up-regulated both in acute and chronic liver injury induced by carbon tetrachloride (CCl4). Compared with wild-type mice, TIMP-1 knockout mice were more susceptible to CCl4-induced acute and chronic liver injury, as shown by higher levels of serum alanine aminotransferase (ALT), greater number of apoptotic hepatocytes, and more extended necroinflammatory foci. TIMP-1 knockout mice also displayed greater degree of liver fibrosis after chronic CCl4 injection when compared with wild-type mice. In vitro treatment with TIMP-1 inhibited cycloheximide-induced cell death of primary mouse hepatocytes. Finally, up-regulation of TIMP-1 in the liver and serum after chronic CCl4 treatment was markedly diminished in hepatocyte-specific signal transducer and activator of transcription 3 (STAT3) knockout mice. In vitro treatment with interleukin-6 stimulated TIMP-1 production in primary mouse hepatocytes, but to a lesser extent in STAT3-deficient hepatocytes. Conclusions: TIMP-1 plays an important role in protecting against acute and chronic liver injury and subsequently inhibiting liver fibrosis induced by CCl4. In addition to activated stellate cells and Kupffer cells, hepatocytes are also responsible for TIMP-1 production during liver injury via a STAT3-dependent manner. C1 [Wang, Hua; Lafdil, Fouad; Wang, Lei; Yin, Shi; Feng, Dechun; Gao, Bin] NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA. [Wang, Hua] Anhui Med Univ, Affiliated Prov Hosp, Dept Oncol, Hefei 230001, Anhui, Peoples R China. [Lafdil, Fouad] Hop Henri Mondor, INSERM, U955, Lab Liver Pathophysiol, F-94010 Creteil, France. RP Gao, B (reprint author), NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA. EM bgao@mail.nih.gov RI Feng, Dechun/Q-5962-2016 FU NIAAA, NIH; Natural Science Foundation of China [30973467/H1611] FX This work was supported in part by the intramural program of NIAAA, NIH (B Gao) and in part by the Natural Science Foundation of China (H Wang, No. 30973467/H1611). NR 32 TC 12 Z9 12 U1 0 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2045-3701 J9 CELL BIOSCI JI Cell Biosci. PD APR 4 PY 2011 VL 1 AR 14 DI 10.1186/2045-3701-1-14 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 982OF UT WOS:000307054300001 PM 21711826 ER PT J AU Yu, HP Zhao, H Wang, LE Han, YH Chen, WV Amos, CI Rafnar, T Sulem, P Stefansson, K Landi, MT Caporaso, N Albanes, D Thun, M Mckay, JD Brennan, P Wang, YF Houlston, RS Spitz, MR Wei, QY AF Yu, Hongping Zhao, Hui Wang, Li-E Han, Younghun Chen, Wei V. Amos, Christopher I. Rafnar, Thorunn Sulem, Patrick Stefansson, Kari Landi, Maria Teresa Caporaso, Neil Albanes, Demetrius Thun, Michael McKay, James D. Brennan, Paul Wang, Yufei Houlston, Richard S. Spitz, Margaret R. Wei, Qingyi TI An analysis of single nucleotide polymorphisms of 125 DNA repair genes in the Texas genome-wide association study of lung cancer with a replication for the XRCC4 SNPs SO DNA REPAIR LA English DT Article DE XRCC4; Variant; Genetic susceptibility; Genome-wide association study; Replication study ID DOUBLE-STRAND; SUSCEPTIBILITY LOCUS; SEQUENCE VARIANTS; BREAK REPAIR; LIGASE IV; RISK; EPIDEMIOLOGY; RADIATION; DAMAGE; METAANALYSIS AB DNA repair genes are important for maintaining genomic stability and limiting carcinogenesis. We analyzed all single nucleotide polymorphisms (SNPs) of 125 DNA repair genes covered by the Illumina HumanHap300 (v1.1) BeadChips in a previously conducted genome-wide association study (GWAS) of 1154 lung cancer cases and 1137 controls and replicated the top-hits of XRCC4 SNPs in an independent set of 597 cases and 611 controls in Texas populations. We found that six of 20 XRCC4 SNPs were associated with a decreased risk of lung cancer with a P-value of 0.01 or lower in the discovery dataset, of which the most significant SNP was rs10040363 (P for allelic test = 4.89 x 10(-4)). Moreover, the data in this region allowed us to impute a potentially functional SNP rs2075685 (imputed P for allelic test = 1.3 x 10(-3)). A luciferase reporter assay demonstrated that the rs2075685G > T change in the XRCC4 promoter increased expression of the gene. In the replication study of rs10040363, rs1478486, rs9293329, and rs2075685, however, only rs10040363 achieved a borderline association with a decreased risk of lung cancer in a dominant model (adjusted OR = 0.80. 95% CI = 0.62-1.03 and P = 0.079). In the final combined analysis of both the Texas GWAS discovery and replication datasets, the strength of the association was increased for rs10040363 (adjusted OR = 0.77.95% CI = 0.66-0.89, P-dominant = 5 x 10(-4) and P for trend = 5 x 10(-4)) and rs1478486 (adjusted OR = 0.82, 95% CI = 0.71-0.94, P-dominant = 6 x 10(-3) and P for trend = 3.5 x 10(-3)). Finally, we conducted a meta-analysis of these XRCC4 SNPs with available data from published GWA studies of lung cancer with a total of 12,312 cases and 47,921 controls, in which none of these XRCC4 SNPs was associated with lung cancer risk. It appeared that rs2075685, although associated with increased expression of a reporter gene and lung cancer risk in the Texas populations, did not have an effect on lung cancer risk in other populations. This study underscores the importance of replication using published data in larger populations. (C) 2011 Elsevier B.V. All rights reserved. C1 [Wei, Qingyi] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Unit 1365, Houston, TX 77030 USA. [Rafnar, Thorunn; Sulem, Patrick; Stefansson, Kari] DeCODE Genet, IS-101 Reykjavik, Iceland. [Landi, Maria Teresa; Caporaso, Neil; Albanes, Demetrius] NIH, Div Canc Epidemiol, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Thun, Michael] Amer Canc Soc, Dept Epidemiol, Atlanta, GA 30329 USA. [McKay, James D.; Brennan, Paul] Int Agcy Res Canc, F-69372 Lyon, France. [Wang, Yufei; Houlston, Richard S.] Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England. RP Wei, QY (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Unit 1365, 1515 Holcombe Blvd, Houston, TX 77030 USA. EM qwei@mdanderson.org RI Yu, Hongping/F-3710-2011; Albanes, Demetrius/B-9749-2015; OI Houlston, Richard/0000-0002-5268-0242 FU National Institutes of Health [ES11740, CA131274, CA86390, CA55769, CA121197, CA 16672] FX We thank Min Zhao, Jianzhong He and Kejing Xu for their laboratory assistance, and Dakai Zhu for his technical support. This study was supported in part by National Institutes of Health grants ES11740 and CA131274 (to Q.W.), CA86390 and CA55769 (to M.R.S.), CA121197 (to C.A.), and CA 16672 (to The University of Texas M.D. Anderson Cancer Center). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. NR 44 TC 15 Z9 16 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1568-7864 J9 DNA REPAIR JI DNA Repair PD APR 3 PY 2011 VL 10 IS 4 BP 398 EP 407 DI 10.1016/j.dnarep.2011.01.005 PG 10 WC Genetics & Heredity; Toxicology SC Genetics & Heredity; Toxicology GA 751CZ UT WOS:000289596400006 PM 21296624 ER PT J AU Krijger, PHL Lee, KY Wit, N van den Berk, PCM Wu, XL Roest, HP Maas, A Ding, H Hoeijmakers, JHJ Myung, K Jacobs, H AF Krijger, Peter H. L. Lee, Kyoo-Young Wit, Niek van den Berk, Paul C. M. Wu, Xiaoli Roest, Henk P. Maas, Alex Ding, Hao Hoeijmakers, Jan H. J. Myung, Kyungjae Jacobs, Heinz TI HLTF and SHPRH are not essential for PCNA polyubiquitination, survival and somatic hypermutation: Existence of an alternative E3 ligase SO DNA REPAIR LA English DT Article DE PCNA; RAD5; HLTF; SHPRH; Somatic hypermutation; Translesion synthesis ID CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-ETA; IMMUNOGLOBULIN GENE HYPERMUTATION; POSTREPLICATION REPAIR PATHWAY; CLASS-SWITCH RECOMBINATION; SACCHAROMYCES-CEREVISIAE; TRANSLESION SYNTHESIS; UBIQUITIN LIGASE; GENOMIC INSTABILITY; DAMAGE AB DNA damage tolerance is regulated at least in part at the level of proliferating cell nuclear antigen (PCNA) ubiquitination. Monoubiquitination (PCNA-Ub) at lysine residue 164 (K164) stimulates error-prone translesion synthesis (US), Rad5-dependent polyubiquitination (PCNA-Ub(n)) stimulates error-free template switching (TS). To generate high affinity antibodies by somatic hypermutation (SHM), B cells profit from error-prone TLS polymerases. Consistent with the role of PCNA-Ub in stimulating TLS, hypermutated B cells of PCNA(K164R) mutant mice display a defect in generating selective point mutations. Two Rad5 orthologs, HLTF and SHPRH have been identified as alternative E3 ligases generating PCNA-Ub(n) in mammals. As PCNA-Ub and PCNA-Ub(n) both make use of K164, error-free PCNA-Ub(n)-dependent TS may suppress error-prone PCNA-Ub-dependent TLS. To determine a regulatory role of Shprh and Hltf in SHM, we generated Shprh/Hltf double mutant mice. Interestingly, while the formation of PCNA-Ub and PCNA-Ub(n) is prohibited in PCNA(K164R) MEFs, the formation of PCNA-Ub(n) is not abolished in Shprh/Hltf mutant MEFs. In line with these observations Shprh/Hltf double mutant B cells were not hypersensitive to DNA damage. Furthermore, SHM was normal in Shprh/Hltf mutant B cells. These data suggest the existence of an alternative E3 ligase in the generation of PCNA-Ub(n). (C) 2010 Elsevier B.V. All rights reserved. C1 [Jacobs, Heinz] Antoni van Leeuwenhoek Ziekenhuis, Netherlands Canc Inst, NKI AVL, Div Immunol, NL-1066 CX Amsterdam, Netherlands. [Lee, Kyoo-Young; Myung, Kyungjae] NHGRI, Genome Instabil Sect, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA. [Wu, Xiaoli; Ding, Hao] Univ Manitoba, Dept Biochem & Med Genet, Fac Med, Winnipeg, MB R3E 0W3, Canada. [Roest, Henk P.; Maas, Alex; Hoeijmakers, Jan H. J.] Erasmus MC, Canc Genom Ctr, Dept Cell Biol & Genet, CBG, NL-3015 GE Rotterdam, Netherlands. RP Jacobs, H (reprint author), Antoni van Leeuwenhoek Ziekenhuis, Netherlands Canc Inst, NKI AVL, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands. EM h.jacobs@nki.nl OI Krijger, Peter/0000-0003-1702-348X; Jacobs, Heinz/0000-0001-6227-9850 FU NHGRI; NIH [HG012003-09]; Korean Government [KRF-2007-357-C00092]; Netherlands Organisation for Scientific Research; Dutch Cancer Society [NWO 917.56.328, NKI-2008-4112, EUR99-2003] FX We thank Frank van Diepen and Anita Pfauth for cell sortings, the NKI-AVL mouse facility for assistance and the NKI-AVL sequence facility for sequencing. An anti-SHPRH antibody was kindly provided by Dr. Sood (NHGRI, NIH). We like to apologize everybody whose work could only be cited indirectly due to space limitations. We also thank Vanessa-Leigh van Zuylen for critically reading the manuscript. This research was supported by the intramural research program of the NHGRI, NIH (HG012003-09) to KM, by the Korea Research Foundation Grant (KRF-2007-357-C00092) funded by the Korean Government to KL, the Netherlands Organisation for Scientific Research and the Dutch Cancer Society (VIDI program NWO 917.56.328 and KWF grant NKI-2008-4112 to HJ, and EUR99-2003 to HR and JH). NR 34 TC 22 Z9 23 U1 1 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1568-7864 EI 1568-7856 J9 DNA REPAIR JI DNA Repair PD APR 3 PY 2011 VL 10 IS 4 BP 438 EP 444 DI 10.1016/j.dnarep.2010.12.008 PG 7 WC Genetics & Heredity; Toxicology SC Genetics & Heredity; Toxicology GA 751CZ UT WOS:000289596400010 PM 21269891 ER PT J AU Quinn, TC Serwadda, D AF Quinn, Thomas C. Serwadda, David TI The future of HIV/AIDS in Africa: a shared responsibility SO LANCET LA English DT Editorial Material C1 [Quinn, Thomas C.] NIAID, Bethesda, MD 20892 USA. [Quinn, Thomas C.] Johns Hopkins Univ, Ctr Global Hlth, Baltimore, MD 21205 USA. [Serwadda, David] Makerere Univ, Sch Publ Hlth, Kampala, Uganda. RP Quinn, TC (reprint author), NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM tquinn@jhmi.edu NR 2 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD APR 2 PY 2011 VL 377 IS 9772 BP 1133 EP 1134 DI 10.1016/S0140-6736(10)62183-6 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 750IH UT WOS:000289539300008 PM 21126758 ER PT J AU Gavidia, T Brune, MN McCarty, KM Pronczuk, J Etzel, R Neira, M Carpenter, DO Suk, WA Arnold, RG Ha, EH Sly, PD AF Gavidia, Tania Brune, Marie-Noel McCarty, Kathleen M. Pronczuk, Jenny Etzel, Ruth Neira, Maria Carpenter, David O. Suk, William A. Arnold, Robert G. Ha, Eun Hee Sly, Peter D. TI Children's environmental health-from knowledge to action SO LANCET LA English DT Editorial Material C1 [Gavidia, Tania; Sly, Peter D.] WHO Collaborating Ctr Res Childrens Environm Hlth, Perth, WA, Australia. [Brune, Marie-Noel; Pronczuk, Jenny; Etzel, Ruth; Neira, Maria] WHO, Dept Publ Hlth & Environm, CH-1211 Geneva, Switzerland. [McCarty, Kathleen M.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Div Environm Hlth Sci, New Haven, CT 06510 USA. [Pronczuk, Jenny] Univ Republica, Dept Toxicol, Montevideo, Uruguay. [Carpenter, David O.] SUNY Albany, Inst Hlth & Environm, Rensselaer, NY USA. [Suk, William A.] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA. [Arnold, Robert G.] Univ Arizona, Chem & Environm Engn Dept, Tucson, AZ USA. [Ha, Eun Hee] Ewha Womans Univ, Dept Prevent Med, Seoul, South Korea. [Sly, Peter D.] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld 4029, Australia. RP Sly, PD (reprint author), WHO Collaborating Ctr Res Childrens Environm Hlth, Perth, WA, Australia. EM p.sly@uq.edu.au RI Sly, Peter/F-1486-2010 OI Sly, Peter/0000-0001-6305-2201 NR 5 TC 6 Z9 6 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD APR 2 PY 2011 VL 377 IS 9772 BP 1134 EP 1136 DI 10.1016/S0140-6736(10)60929-4 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 750IH UT WOS:000289539300009 PM 20667587 ER PT J AU Gaiser, T Camps, J Meinhardt, S Wangsa, D Nguyen, QT Varma, S Dittfeld, C Kunz-Schughart, LA Kemmerling, R Becker, MR Heselmeyer-Haddad, K Ried, T AF Gaiser, Timo Camps, Jordi Meinhardt, Sandra Wangsa, Danny Quang Tri Nguyen Varma, Sudhir Dittfeld, Claudia Kunz-Schughart, Leoni A. Kemmerling, Ralf Becker, Maria R. Heselmeyer-Haddad, Kerstin Ried, Thomas TI Genome and Transcriptome Profiles of CD133-Positive Colorectal Cancer Cells SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID PLASMA-MEMBRANE PROTRUSIONS; TUMOR-INITIATING CELLS; HUMAN COLON-CANCER; STEM-CELLS; HEMATOPOIETIC STEM; EPITHELIAL-CELLS; SOLID TUMORS; CD133 EXPRESSION; DRUG-RESISTANCE; RECTAL-CANCER AB Colorectal carcinomas (CRC) might be organized hierarchically and contain a subpopulation of tumorigenic, putative cancer stem cells that are CD133 positive. We studied the biological and genetic characteristics of such cells in CRC cell lines and primary tumors. Three CRC cell lines were sorted in CD133 positive and negative fractions. The respective genetic aberration profiles were studied using array comparative genomic hybridization (aCGH) and expression profiling. Tumorigenicity for each cellular population was tested by injection into nude mice. Additionally, we compared CD133+ and CD133- cells of 12 primary colorectal tumors using laser capture microdissection and aCGH. Three of five CRC cell lines displayed both CD133+ and CD133- cells, but tumorigenicity of these subfractions did not differ significantly and aCGH revealed essentially identical genomic imbalances. However, 96 genes were differentially expressed between the two populations. Array comparative genomic hybridization analysis after laser capture microdissection of CD133+ and CD133- areas in primary colorectal tumors revealed genetic differences in 7 of 12 cases. The use of cell lines for studying genomic alterations that define cancer stem cell characteristics, therefore, seems questionable. In contrast, CD133+ cells in primary cancer samples showed a unique genomic aberration profile. In conclusion, our data suggest that CD133 positivity defines a genetically distinct cellular compartment in primary CRC, which potentially includes tumor initiating cells. (Am J Pathol 2011, 178:1478-1488; DOI: 10.1016/j.ajpath.2010.12.036) C1 [Gaiser, Timo; Camps, Jordi; Meinhardt, Sandra; Wangsa, Danny; Quang Tri Nguyen; Heselmeyer-Haddad, Kerstin; Ried, Thomas] NCI, Sect Canc Genom, NIH, Bethesda, MD 20892 USA. [Varma, Sudhir] NIAID, Bioinformat & Computat Biosci Branch, NIH, Bethesda, MD 20892 USA. [Dittfeld, Claudia; Kunz-Schughart, Leoni A.] Tech Univ Dresden, OncoRay Natl Ctr Radiat Res Oncol, Dresden, Germany. [Kemmerling, Ralf] Paracelsus Med Univ, Inst Pathol, Salzburg, Austria. [Becker, Maria R.] NCI, Dermatol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP Ried, T (reprint author), NCI, Sect Canc Genom, NIH, Bldg 50,Room 1408,50 South Dr, Bethesda, MD 20892 USA. EM riedt@mail.nih.gov RI Varma, Sudhir/N-8763-2014 OI Varma, Sudhir/0000-0002-4096-4782 FU National Institutes of Health, National Cancer Institute; Mildred Scheel Foundation; German Research Foundation (DFG) [KU 971/7-1]; Bundesministerium fuer Bildung und Forschung "Center for Innovation Competence" FX Supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. T.G. is supported by a fellowship within the post doctorate program of the Mildred Scheel Foundation. The work performed by the group of LAKS (Tumor Pathophysiology, OncoRay) was supported by the German Research Foundation (DFG) through a grant (KU 971/7-1). OncoRay is funded by the Bundesministerium fuer Bildung und Forschung in the program "Center for Innovation Competence." NR 63 TC 15 Z9 15 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD APR PY 2011 VL 178 IS 4 BP 1478 EP 1488 DI 10.1016/j.ajpath.2010.12.036 PG 11 WC Pathology SC Pathology GA 865JH UT WOS:000298306700009 PM 21435437 ER PT J AU Wang, Y Hancock, AM Bradner, J Chung, KA Quinn, JF Peskind, ER Galasko, D Jankovic, J Zabetian, CP Kim, HM Leverenz, JB Montine, TJ Ginghina, C Edwards, KL Snapinn, KW Goldstein, DS Shi, M Zhang, J AF Wang, Yu Hancock, Aneeka M. Bradner, Joshua Chung, Kathryn A. Quinn, Joseph F. Peskind, Elaine R. Galasko, Douglas Jankovic, Joseph Zabetian, Cyrus P. Kim, Hojoong M. Leverenz, James B. Montine, Thomas J. Ginghina, Carmen Edwards, Karen L. Snapinn, Katherine W. Goldstein, David S. Shi, Min Zhang, Jing TI Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID CSF AMYLOID-BETA; CONSENSUS STATEMENT; COGNITIVE DECLINE; NERVOUS-SYSTEM; PHOSPHO-TAU; LEWY BODY; DEMENTIA; BIOMARKERS; DIAGNOSIS; EXPRESSION AB Complement activation, a key component of neuroinflammation, has been reported in both Parkinson's disease (PD) and Alzheimer's disease (AD). However, it is unclear whether complement activation and neuroinflammation in general are distinctly different from each another in major neurodegenerative disorders. In the present study, cerebrospinal fluid complement 3 (C3) and factor H (FH) were measured and evaluated together with amyloid-beta(42) (A beta(42)), which in recent investigations was decreased in patients with PD, in particular those with cognitive impairment. The study included 345 participants: 126 patients with PD at various stages with or without cognitive impairment, 50 with AD, and 32 with multiple-system atrophy, and 137 healthy control individuals. In addition to changes in A beta(42) concentrations, there were clear differences in the patterns of complement profiles among neurodegenerative disorders. The C3/FH ratio demonstrated high sensitivity and specificity in differentiating patients with multiple-system atrophy from those with AD or PD and control individuals. In addition, the C3/A beta(42) and FH/A beta(42) ratios not only correlated with PD severity approximated using the Unified Parkinson's Disease Rating Scale but also with the presence of cognitive impairment or dementia in PD. Both C3 and FH correlated with the severity of impairment in AD as indicated using Mini-Mental State Examination scores. (Am J Pathol 2011, 178:1509-1516; DOI: 10.1016/j.ajpath.2011.01.006) C1 [Wang, Yu; Hancock, Aneeka M.; Bradner, Joshua; Montine, Thomas J.; Ginghina, Carmen; Shi, Min; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Peskind, Elaine R.; Leverenz, James B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [Zabetian, Cyrus P.; Kim, Hojoong M.; Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA. [Wang, Yu] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan 430074, Peoples R China. [Chung, Kathryn A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Peskind, Elaine R.; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Kim, Hojoong M.] Vet Affairs Puget Sound Hlth Care Syst, Dept Neurol, Seattle, WA USA. [Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Jankovic, Joseph] Baylor Coll Med, Parkinsons Dis Ctr, Dept Neurol, Houston, TX 77030 USA. [Jankovic, Joseph] Baylor Coll Med, Movement Disorders Clin, Dept Neurol, Houston, TX 77030 USA. [Edwards, Karen L.; Snapinn, Katherine W.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Goldstein, David S.] NINDS, Clin Neurocardiol Sect, Clin Neurosci Program, Div Intramural Res,NIH, Bethesda, MD 20892 USA. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, HMC Box 359635,325 9th Ave, Seattle, WA 98104 USA. EM zhangj@uw.edu RI Shi, Min/G-6165-2012; OI Shi, Min/0000-0002-6901-2558; Zabetian, Cyrus/0000-0002-7739-4306 FU National Institutes of Health [ES004696, NS057567, AG025327, AG033398, NS060252, NS062684, AG005136, AG008017]; Michael J. Fox Foundation; Cheng-Mei Shaw Endowment; Nancy and Buster Alvord Endowment FX Supported by grants ES004696, NS057567, AG025327, AG033398, and NS060252 (J.Z.), NS062684 (T.J.M., C.P.Z., J.B.L., and J.Z.), AG005136 (ERR. and T.J.M.), and AG008017 (K.A.C. and J.F.Q.) from the National Institutes of Health, and grants from the Michael J. Fox Foundation and the Cheng-Mei Shaw Endowment (J.Z.) and the Nancy and Buster Alvord Endowment (T.J.M.). NR 37 TC 38 Z9 41 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD APR PY 2011 VL 178 IS 4 BP 1509 EP 1516 DI 10.1016/j.ajpath.2011.01.006 PG 8 WC Pathology SC Pathology GA 865JH UT WOS:000298306700012 PM 21435440 ER PT J AU Yin, S Wang, H Park, O Wei, W Shen, JL Gao, B AF Yin, Shi Wang, Hua Park, Ogyi Wei, Wei Shen, Jilong Gao, Bin TI Enhanced Liver Regeneration in IL-10-Deficient Mice after Partial Hepatectomy via Stimulating Inflammatory Response and Activating Hepatocyte STAT3 SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID INTEGRIN-LINKED KINASE; SIGNAL TRANSDUCER; TRANSCRIPTION 3; FACTOR RECEPTOR; PROLIFERATION; CYTOKINE; MASS; INTERLEUKIN-10; HYPERTROPHY; CONTRIBUTES AB Emerging evidence suggests that proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), play a critical role in the initiation and progression of liver regeneration; however, relatively little is known about the role of anti-inflammatory cytokine IL-10 in liver regeneration after partial hepatectomy (PHx). Here, we examined the role of IL-10 in liver regeneration using a model of PHx in several strains of genetically modified mice. After PHx, expression of IL-10 mRNA in the liver and spleen was significantly elevated. Such elevation was diminished in TLR4 mutant mice. Compared with wild-type mice, IL-10(-/-) mice had higher levels of expression of proinflammatory cytokines (IL-6, TNF-alpha, and IFN-gamma) and inflamniatory markers (CCR2 and F4/80) in the liver, as well as higher serum levels of proinflammatory cytokines after PHx. The number of neutrophils and macrophages was also higher in the livers of IL-10(-/-) mice than in wild-type mice after PHx. Liver regeneration as determined by BrdU incorporation after PHx was higher in IL-10(-/-) mice than in wild-type mice, which was associated with higher levels of activation of IL-6 downstream signal STAT3 in the liver. An additional deletion of STAT3 in hepatocytes significantly reduced liver regeneration in IL-10(-/-) mice after PHx. Collectively, IL-10 plays an important role in negatively regulating liver regeneration via limiting inflammatory response and subsequently tempering hepatic STAT3 activation. (Am J Pathol 2011, 178:1614-1621; DOI: 10.1016/j.ajpath.2011.01.001) C1 [Yin, Shi; Wang, Hua; Park, Ogyi; Gao, Bin] NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA. [Yin, Shi; Shen, Jilong] Anhui Med Univ, Dept Microbiol & Parasitol, Hefei 230032, Anhui, Peoples R China. [Wang, Hua] Anhui Med Univ, Dept Oncol, Hefei 230032, Anhui, Peoples R China. [Yin, Shi; Shen, Jilong] Anhui Med Univ, Minist Educ, Prov Lab Microbiol & Parasitol, Hefei 230032, Anhui, Peoples R China. [Yin, Shi; Wei, Wei; Shen, Jilong] Anhui Med Univ, Minist Educ, Inst Clin Pharmacol, Hefei 230032, Anhui, Peoples R China. RP Gao, B (reprint author), NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA. EM jlshen@ahmu.edu.cn; bgao@mail.nih.gov FU National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health (NIH); Natural Science Foundation of China [30973467/H1611] FX Supported in part by the intramural program of National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health (NIH) (B.G.) and in part by the Natural Science Foundation of China (No. 30973467/H1611 to H.W.). NR 35 TC 17 Z9 20 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD APR PY 2011 VL 178 IS 4 BP 1614 EP 1621 DI 10.1016/j.ajpath.2011.01.001 PG 8 WC Pathology SC Pathology GA 865JH UT WOS:000298306700021 PM 21435447 ER PT J AU Pincock, LL Montello, MJ Tarosky, MJ Pierce, WF Edwards, CW AF Pincock, Laura L. Montello, Michael J. Tarosky, Matthew J. Pierce, William F. Edwards, Calvin W. TI Pharmacist readiness roles for emergency preparedness SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Editorial Material ID HURRICANE-KATRINA C1 [Pierce, William F.] US FDA, Div Biol Oncol Prod, Off New Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA. [Pincock, Laura L.] US FDA, Off Commun, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA. [Montello, Michael J.] NCI, Clin Invest Branch, Canc Therapy Evaluat Program, Div Canc Treatment & Diag, Rockville, MD USA. [Tarosky, Matthew J.] US FDA, Div Biores Monitoring, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA. [Tarosky, Matthew J.] US FDA, PHS Rapid Deployment Force 1, CDER, Planning Sect, Silver Spring, MD 20993 USA. [Edwards, Calvin W.] US FDA, Off Regulatory Affairs, Silver Spring, MD 20993 USA. RP Pierce, WF (reprint author), US FDA, Div Biol Oncol Prod, Off New Drugs, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave,Bldg 22,Room 5219, Silver Spring, MD 20993 USA. EM william.pierce@fda.hhs.gov NR 13 TC 3 Z9 3 U1 0 U2 5 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD APR 1 PY 2011 VL 68 IS 7 BP 620 EP 623 DI 10.2146/ajhp090659 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 858CF UT WOS:000297772800014 PM 21411804 ER PT J AU Hartz, SM Lin, P Edenberg, HJ Xuei, XL Rochberg, N Saccone, S Berrettini, W Nelson, E Nurnberger, J Bierut, LJ Rice, JP AF Hartz, Sarah M. Lin, Peng Edenberg, Howard J. Xuei, Xiaoling Rochberg, Nanette Saccone, Scott Berrettini, Wade Nelson, Elliot Nurnberger, John Bierut, Laura J. Rice, John P. CA NIMH Genetics Initiative Bipolar D TI Genetic association of bipolar disorder with the beta(3) nicotinic receptor subunit gene SO PSYCHIATRIC GENETICS LA English DT Article DE analyses; CHRNA3; CHRNA5; CHRNA6; genetic association nicotine; tobacco use disorder ID GENOME-WIDE ASSOCIATION; EUROPEAN-ANCESTRY; ACETYLCHOLINE-RECEPTORS; LINKAGE ANALYSES; TOBACCO SMOKING; CANDIDATE GENES; DEPENDENCE; SAMPLE; SCHIZOPHRENIA; RISK AB Objective Owing to the clinical relationship between bipolar disorder and nicotine dependence, we investigated two research questions: (i) are genetic associations with nicotine dependence different in individuals with bipolar disorder as compared with individuals without bipolar disorder, and (ii) do loci earlier associated with nicotine dependence have pleiotropic effects on these two diseases. Method Our study consisted of 916 cases with bipolar disorder and 1028 controls. On the basis of known associations with nicotine dependence, we genotyped eight single-nucleotide polymorphisms (SNPs) on chromosome 8 (three bins) in the regions of CHRNB3 and CHRNA6, and six SNPs on chromosome 15 (three bins) in the regions of CHRNA5 and CHRNA3. Results To determine whether the genetic associations with nicotine dependence are different in bipolar disorder than in the general population, we compared allele frequencies of candidate SNPs between individuals with nicotine dependence only and individuals with both nicotine dependence and bipolar disorder. There were no statistical differences between these frequencies, indicating that genetic association with nicotine dependence is similar in individuals with bipolar disorder as in the general population. In the investigation of pleiotropic effects of these SNPs on bipolar disorder, two highly correlated synonymous SNPs in CHRNB3, rs4952 and rs4953, were significantly associated with bipolar disorder (odds ratio 1.7, 95% confidence interval: 1.2-2.4, P = 0.001). This association remained significant both after adjusting for a smoking covariate and analyzing the association in nonsmokers only. Conclusion Our results suggest that (i) bipolar disorder does not modify the association between nicotine dependence and nicotinic receptor subunit genes, and (ii) variants in CHRNB3/CHRNA6 are independently associated with bipolar disorder. Psychiatr Genet 21:77-84 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins. C1 [Hartz, Sarah M.; Lin, Peng; Rochberg, Nanette; Saccone, Scott; Nelson, Elliot; Bierut, Laura J.; Rice, John P.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. NIMH, Clin Sci Lab, NIH, US Dept HHS, Bethesda, MD 20892 USA. NIMH, Unit Genet Basis Mood & Anxiety Disorders, Mood & Anxiety Disorders Program, NIH,US Dept Hlth & Human Serv, Bethesda, MD 20892 USA. Univ Calif Irvine, Dept Psychiat, Irvine, CA 92717 USA. Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Berrettini, Wade] Univ Penn, Philadelphia, PA 19104 USA. Rush Univ, Med Ctr, Dept Psychiat, Chicago, IL 60612 USA. Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA. [Edenberg, Howard J.; Xuei, Xiaoling] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA. [Nurnberger, John] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA. [NIMH Genetics Initiative Bipolar D] Howard Univ, Dept Psychiat, Washington, DC 20059 USA. RP Rice, JP (reprint author), Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. EM jrice@wustl.edu RI Meyer, Eric/C-1029-2011; Lin, P/G-7702-2014; OI Meyer, Eric/0000-0002-1998-7162; Lawson, William/0000-0002-9324-7090 FU National Cancer Institute, NIH [P50CA89392]; National Institute of Drug Abuse, NIH [5K02DA021237] FX This study was supported by the NIH grants P50CA89392 from the National Cancer Institute and 5K02DA021237 National Institute of Drug Abuse. NR 45 TC 4 Z9 4 U1 4 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0955-8829 J9 PSYCHIAT GENET JI Psychiatr. Genet. PD APR PY 2011 VL 21 IS 2 BP 77 EP 84 DI 10.1097/YPG.0b013e32834135eb PG 8 WC Genetics & Heredity; Neurosciences SC Genetics & Heredity; Neurosciences & Neurology GA 727ZK UT WOS:000287841700003 PM 21191315 ER PT J AU Daniel, CR Cross, AJ Koebnick, C Sinha, R AF Daniel, Carrie R. Cross, Amanda J. Koebnick, Corinna Sinha, Rashmi TI Trends in meat consumption in the USA SO PUBLIC HEALTH NUTRITION LA English DT Article DE Red meat; Poultry; Processed meat; US diet; Chronic disease ID CORONARY-HEART-DISEASE; COLORECTAL-CANCER RISK; BOVINE SPONGIFORM ENCEPHALOPATHY; BREAST-CANCER; RED MEAT; CARDIOVASCULAR-DISEASE; BRITISH VEGETARIANS; CARBOHYDRATE INTAKE; PROSPECTIVE COHORT; PANCREATIC-CANCER AB Objective: To characterize the trends, distribution, potential determinants and public health implications of meat consumption within the USA. Design: We examined temporal trends in meat consumption using food availability data from the FAO and US Department of Agriculture (USDA), and further evaluated the meat intake by type (red, white, processed) in the National Health and Nutrition Examination Surveys (NHANES) linked to the MyPyramid Equivalents Database (MPED). Results: Overall meat consumption has continued to rise in the USA and the rest of the developed world. Despite a shift towards higher poultry consumption, red meat still represents the largest proportion of meat consumed in the USA (58%). Twenty-two per cent of the meat consumed in the USA is processed. According to the NHANES 2003-2004, total meat intake averaged 128 g/d. The type and quantities of meat reported varied by education, race, age and gender. Conclusions: Given the plausible epidemiological evidence for red and processed meat intake in cancer and chronic disease risk, understanding the trends and determinants of meat consumption in the USA, where meat is consumed at more than three times the global average, should be particularly pertinent to researchers and other public health professionals aiming to reduce the global burden of chronic disease. C1 [Daniel, Carrie R.; Cross, Amanda J.; Sinha, Rashmi] NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv,NIH, Bethesda, MD 20892 USA. [Koebnick, Corinna] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. RP Daniel, CR (reprint author), NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv,NIH, 6120 Execut Blvd, Bethesda, MD 20892 USA. EM Carrie.Daniel@nih.hhs.gov RI Sinha, Rashmi/G-7446-2015; Koebnick, Corinna/P-4767-2016 OI Sinha, Rashmi/0000-0002-2466-7462; Koebnick, Corinna/0000-0001-8274-0309 FU NIH, National Cancer Institute FX The present study was supported by the Intramural Research Program of the NIH, National Cancer Institute. None of the authors had a financial or personal conflict of interest. C. R. D. contributed to the concept, analysis, interpretation of results and writing of the manuscript; A.J.C. contributed to the interpretation of results and writing of the manuscript; C. K. helped the analysis and interpretation of the results; R. S. contributed to the concept, interpretation of the results and writing of the manuscript; and all authors contributed to the critical review and approval of the final manuscript. The authors thank Jill Reedy and Lisa Kahle for their contributions to this manuscript. NR 78 TC 96 Z9 98 U1 18 U2 65 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 1368-9800 J9 PUBLIC HEALTH NUTR JI Public Health Nutr. PD APR PY 2011 VL 14 IS 4 BP 575 EP 583 DI 10.1017/S1368980010002077 PG 9 WC Public, Environmental & Occupational Health; Nutrition & Dietetics SC Public, Environmental & Occupational Health; Nutrition & Dietetics GA 740AH UT WOS:000288763400004 PM 21070685 ER PT J AU Garcia-Closas, M Hein, DW Silverman, D Malats, N Yeager, M Jacobs, K Doll, MA Figueroa, JD Baris, D Schwenn, M Kogevinas, M Johnson, A Chatterjee, N Moore, LE Moeller, T Real, FX Chanock, S Rothman, N AF Garcia-Closas, Montserrat Hein, David W. Silverman, Debra Malats, Nuria Yeager, Meredith Jacobs, Kevin Doll, Mark A. Figueroa, Jonine D. Baris, Dalsu Schwenn, Molly Kogevinas, Manolis Johnson, Alison Chatterjee, Nilanjan Moore, Lee E. Moeller, Timothy Real, Francisco X. Chanock, Stephen Rothman, Nathaniel TI A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background SO PHARMACOGENETICS AND GENOMICS LA English DT Article DE bladder cancer; genome-wide scan; NAT2 phenotype; single nucleotide polymorphism ID URINARY-BLADDER CANCER; HUMAN N-ACETYLTRANSFERASE-2; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-GENETICS; HUMAN HEPATOCYTES; ACETYLATION; RISK; GENOTYPE AB The arylamine N-acetyltransferase 2 (NAT2) slow acetylation phenotype is an established risk factor for urinary bladder cancer. We reported earlier on this risk association using NAT2 phenotypic categories inferred from NAT2 haplotypes based on seven single nucleotide polymorphisms (SNPs) in a study in Spain. In a subsequent genome-wide scan, we have identified a single common tag SNP (rs1495741) located in the 3' end of NAT2 that is also associated with bladder cancer risk. The aim of this report is to evaluate the agreement between the common tag SNP and the 7-SNP NAT2 inferred phenotype. The agreement between the 7-SNP NAT2 inferred phenotype and the tag SNP, rs1495741, was initially assessed in 2174 individuals from the Spanish Bladder Cancer Study (SBCS), and confirmed in a subset of individuals from the Main and Vermont component the New England Bladder Cancer Study (NEBCS). We also investigated the association of rs1495741 genotypes with NAT2 catalytic activity in cryopreserved hepatocytes from 154 individuals of European background. We observed very strong agreement between rs1495741 and the 7-SNP inferred NAT2 phenotype: sensitivity and specificity for the NAT2 slow phenotype was 99 and 95%, respectively. Our findings were replicated in an independent population from the NEBCS. Estimates for the association between NAT2 slow phenotype and bladder cancer risk in the SBCS and its interaction with cigarette smoking were comparable for the 7-SNP inferred NAT2 phenotype and rs1495741. In addition, rs1495741 genotypes were strongly related to NAT2 activity measured in hepatocytes (P < 0.0001). A novel NAT2 tag SNP (rs1495741) predicts with high accuracy the 7-SNP inferred NAT2 phenotype, and thus can be used as a sole marker in pharmacogenetic or epidemiological studies of populations of European background. These findings illustrate the utility of tag SNPs, often used in genome-wide association studies (GWAS), to identify novel phenotypic markers. Further studies are required to determine the functional implications of rs1495741 and the structure and evolution of the haplotype on which it resides. Pharmacogenetics and Genomics 21: 231-236 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins. C1 [Garcia-Closas, Montserrat; Silverman, Debra; Yeager, Meredith; Jacobs, Kevin; Figueroa, Jonine D.; Baris, Dalsu; Chatterjee, Nilanjan; Moore, Lee E.; Chanock, Stephen; Rothman, Nathaniel] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Yeager, Meredith; Jacobs, Kevin; Chanock, Stephen] NCI, Core Genotype Facil, Adv Technol Ctr, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Moeller, Timothy] Celsis Vitro Technol, Baltimore, MD USA. [Hein, David W.; Doll, Mark A.] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA. [Hein, David W.; Doll, Mark A.] Univ Louisville, Sch Med, James Graham Brown Canc Ctr, Louisville, KY 40292 USA. [Schwenn, Molly] Maine Canc Registry, Augusta, ME USA. [Johnson, Alison] Vermont Canc Registry, Burlington, VT USA. [Kogevinas, Manolis] Univ Pompeu Fabra, Ctr Res Environm Epidemiol CREAL, Barcelona, Spain. [Kogevinas, Manolis] Univ Pompeu Fabra, Hosp Mar, Municipal Inst Med Res, IMIM, Barcelona, Spain. [Kogevinas, Manolis] Univ Pompeu Fabra, CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain. [Real, Francisco X.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain. [Malats, Nuria] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain. [Garcia-Closas, Montserrat; Real, Francisco X.] Univ Cambridge, Dept Oncol, Cambridge, England. [Kogevinas, Manolis] Natl Sch Publ Hlth, Athens, Greece. RP Garcia-Closas, M (reprint author), Inst Canc Res, Epidemiol Sect, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England. EM Montse.GarciaClosas@icr.ac.uk RI Hein, David/A-9707-2008; Garcia-Closas, Montserrat /F-3871-2015; Malats, Nuria/H-7041-2015; Real Arribas, Francisco/H-5275-2015; Kogevinas, Manolis/C-3918-2017 OI Garcia-Closas, Montserrat /0000-0003-1033-2650; Malats, Nuria/0000-0003-2538-3784; Real Arribas, Francisco/0000-0001-9501-498X; FU National Institute of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics [N02-CP-11015, N02-CP-01037]; FIS/Spain [00/0745]; Fundacio Marato [TV3]; Red Tematica Investigacion Cooperativa en Cancer (RTICC) [G03/174, CA34627]; United States Public Health Service, United States National Cancer Institute, National Institutes of Health, Department of Health and Human Services [R01-CA034627] FX The SBCS and NEBCS (Maine, Vermont) were supported by Intramural Research Program of the National Institute of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics (contract numbers N02-CP-11015 for SBCS and N02-CP-01037 for NEBCS). The SBCS was also funded by grants FIS/Spain 00/0745, Fundacio Marato TV3, Red Tematica Investigacion Cooperativa en Cancer (RTICC), G03/174, and CA34627. The work on NAT2 catalytic activity in human hepatocytes was partially supported by United States Public Health Service grant R01-CA034627 from the United States National Cancer Institute, National Institutes of Health, Department of Health and Human Services. NR 18 TC 46 Z9 48 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1744-6872 J9 PHARMACOGENET GENOM JI Pharmacogenet. Genomics PD APR PY 2011 VL 21 IS 4 BP 231 EP 236 DI 10.1097/FPC.0b013e32833e1b54 PG 6 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy GA 735UH UT WOS:000288444500009 PM 20739907 ER PT J AU Yeo, L Romero, R Jodicke, C Ogge, G Lee, W Kusanovic, JP Vaisbuch, E Hassan, S AF Yeo, L. Romero, R. Jodicke, C. Ogge, G. Lee, W. Kusanovic, J. P. Vaisbuch, E. Hassan, S. TI Four-chamber view and 'swing technique' (FAST) echo: a novel and simple algorithm to visualize standard fetal echocardiographic planes SO ULTRASOUND IN OBSTETRICS & GYNECOLOGY LA English DT Article DE congenital heart disease; fetal heart; four-dimensional; OmniView; prenatal diagnosis; STIC; ultrasound ID CONGENITAL HEART-DISEASE; SPATIOTEMPORAL IMAGE CORRELATION; PRENATAL-DIAGNOSIS; 4-DIMENSIONAL ULTRASONOGRAPHY; GREAT-ARTERIES; TOMOGRAPHIC ULTRASOUND; LOW-RISK; DEFECTS; TRANSPOSITION; POPULATION AB Objective To describe a novel and simple algorithm (four-chamber view and 'swing technique' (FAST) echo) for visualization of standard diagnostic planes of fetal echocardiography from dataset volumes obtained with spatiotemporal image correlation (STIC) and applying a new display technology (OmniView). Methods We developed an algorithm to image standard fetal echocardiographic planes by drawing four dissecting lines through the longitudinal view of the ductal arch contained in a STIC volume dataset. Three of the lines are locked to provide simultaneous visualization of targeted planes, and the fourth line (unlocked) 'swings' through the ductal arch image (swing technique), providing an infinite number of cardiac planes in sequence. Each line generates the following plane(s): (a) Line 1: three-vessels and trachea view; (b) Line 2: five-chamber view and long-axis view of the aorta (obtained by rotation of the five-chamber view on the y-axis); (c) Line 3: four-chamber view; and (d) 'swing line': three-vessels and trachea view, five-chamber view and/or long-axis view of the aorta, four-chamber view and stomach. The algorithm was then tested in 50 normal hearts in fetuses at 15.3-40 weeks' gestation and visualization rates for cardiac diagnostic planes were calculated. To determine whether the algorithm could identify planes that departed from the normal images, we tested the algorithm in five cases with proven congenital heart defects. Results In normal cases, the FAST echo algorithm (three locked lines and rotation of the five-chamber view on the y-axis) was able to generate the intended planes (longitudinal view of the ductal arch, pulmonary artery, three-vessels and trachea view, five-chamber view, long-axis view of the aorta, four-chamber view) individually in 100% of cases (except for the three-vessels and trachea view, which was seen in 98% (49/50)) and simultaneously in 98% (49/50). The swing technique was able to generate the three-vessels and trachea view, five-chamber view and/or long-axis view of the aorta, four-chamber view and stomach in 100% of normal cases. In the abnormal cases, the FAST echo algorithm demonstrated the cardiac defects and displayed views that deviated from what was expected from the examination of normal hearts. The swing technique was useful for demonstrating the specific diagnosis due to visualization of an infinite number of cardiac planes in sequence. Conclusions This novel and simple algorithm can be used to visualize standard fetal echocardiographic planes in normal fetal hearts. The FAST echo algorithm may simplify examination of the fetal heart and could reduce operator dependency. Using this algorithm, inability to obtain expected views or the appearance of abnormal views in the generated planes should raise the index of suspicion for congenital heart disease. Copyright (C) 2011 ISUOG. Published by John Wiley & Sons, Ltd. C1 [Yeo, L.] Wayne State Univ, Hutzel Womens Hosp, Perinatol Res Branch, NICHD,NIH,DHHS, Detroit, MI 48201 USA. [Yeo, L.; Romero, R.; Jodicke, C.; Ogge, G.; Lee, W.; Kusanovic, J. P.; Vaisbuch, E.; Hassan, S.] NICHD, Perinatol Res Branch, NIH, DHHS, Bethesda, MD USA. [Yeo, L.; Romero, R.; Jodicke, C.; Lee, W.; Kusanovic, J. P.; Vaisbuch, E.; Hassan, S.] Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI 48201 USA. [Romero, R.] Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48201 USA. [Lee, W.] William Beaumont Hosp, Dept Obstet & Gynecol, Div Fetal Imaging, Royal Oak, MI 48072 USA. RP Yeo, L (reprint author), Wayne State Univ, Hutzel Womens Hosp, Perinatol Res Branch, NICHD,NIH,DHHS, 3990 John R,Box 4, Detroit, MI 48201 USA. EM lyeo@med.wayne.edu; prbchiefstaff@med.wayne.edu OI Vaisbuch, Edi/0000-0002-8400-9031 FU Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS FX This research was supported by the Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS. NR 73 TC 16 Z9 21 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0960-7692 J9 ULTRASOUND OBST GYN JI Ultrasound Obstet. Gynecol. PD APR PY 2011 VL 37 IS 4 BP 423 EP 431 DI 10.1002/uog.8840 PG 9 WC Acoustics; Obstetrics & Gynecology; Radiology, Nuclear Medicine & Medical Imaging SC Acoustics; Obstetrics & Gynecology; Radiology, Nuclear Medicine & Medical Imaging GA 741KB UT WOS:000288861500007 PM 20878671 ER PT J AU Xie, R Chung, JY Ylaya, K Williams, RL Guerrero, N Nakatsuka, N Badie, C Hewitt, SM AF Xie, Ran Chung, Joon-Yong Ylaya, Kris Williams, Reginald L. Guerrero, Natalie Nakatsuka, Nathan Badie, Cortessia Hewitt, Stephen M. TI Factors Influencing the Degradation of Archival Formalin-Fixed Paraffin-Embedded Tissue Sections SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Review DE Antigenicity; formalin fixed; paraffin embedded; immunohistochemistry; protein array; tissue processing ID BREAST-CANCER; GENE-EXPRESSION; FIXATION; IMMUNOHISTOCHEMISTRY; MICROARRAYS; ANTIGENICITY; PROTEIN; VALIDATION; INTENSITY; RETRIEVAL AB The loss of antigenicity in archival formalin-fixed paraffin-embedded (FFPE) tissue sections negatively affects both diagnostic histopathology and advanced molecular studies. The mechanisms underlying antigenicity loss in FFPE tissues remain unclear. The authors hypothesize that water is a crucial contributor to protein degradation and decrement of immunoreactivity in FFPE tissues. To test their hypothesis, they examined fixation time, processing time, and humidity of storage environment on protein integrity and antigenicity by immunohistochemistry, Western blotting, and protein extraction. This study revealed that inadequate tissue processing, resulting in retention of endogenous water in tissue sections, results in antigen degradation. Exposure to high humidity during storage results in significant protein degradation and reduced immunoreactivity, and the effects of storage humidity are temperature dependent. Slides stored under vacuum with desiccant do not protect against the effects of residual water from inadequate tissue processing. These results support that the presence of water, both endogenously and exogenously, plays a central role in antigenicity loss. Optimal tissue processing is essential. The parameters of optimal storage of unstained slides remain to be defined, as they are directly affected by preanalytic variables. Nevertheless, minimization of exposure to water is required for antigen preservation in FFPE tissue sections. This article contains online supplemental material at http://www.jhc.org. Please visit this article online to view these materials. (J Histochem Cytochem 59:356-365, 2011) C1 [Xie, Ran; Chung, Joon-Yong; Ylaya, Kris; Williams, Reginald L.; Guerrero, Natalie; Nakatsuka, Nathan; Badie, Cortessia; Hewitt, Stephen M.] NCI, Tissue Array Res Program, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA. RP Hewitt, SM (reprint author), Adv Technol Ctr, TARP AMPL, MSC 4605, Bethesda, MD 20892 USA. EM genejock@helix.nih.gov OI Hewitt, Stephen/0000-0001-8283-1788; Chung, Joon-Yong/0000-0001-5041-5982 FU Center for Cancer Research, National Cancer Institute, NIH FX The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. NR 26 TC 56 Z9 56 U1 2 U2 9 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0022-1554 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD APR PY 2011 VL 59 IS 4 BP 356 EP 365 DI 10.1369/0022155411398488 PG 10 WC Cell Biology SC Cell Biology GA 805CF UT WOS:000293703300001 PM 21411807 ER PT J AU Salit, RB Bishop, MR AF Salit, Rachel B. Bishop, Michael R. TI The Evolving World of Tumor Lysis Syndrome THE MUSLIMANI ET AL ARTICLE REVIEWED SO ONCOLOGY-NEW YORK LA English DT Editorial Material ID RECOMMENDATIONS; GUIDELINES; MANAGEMENT; LEUKEMIA; LYMPHOMA C1 [Salit, Rachel B.; Bishop, Michael R.] NCI, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA. RP Salit, RB (reprint author), NCI, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA. NR 8 TC 1 Z9 1 U1 0 U2 0 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD APR PY 2011 VL 25 IS 4 BP 378 EP 380 PG 2 WC Oncology SC Oncology GA 800ES UT WOS:000293343200009 PM 21618961 ER PT J AU Rao, DB Little, PB Malarkey, DE Herbert, RA Sills, RC AF Rao, Deepa B. Little, Peter B. Malarkey, David E. Herbert, Ronald A. Sills, Robert C. TI Histopathological Evaluation of the Nervous System in National Toxicology Program Rodent Studies: A Modified Approach SO TOXICOLOGIC PATHOLOGY LA English DT Article DE neuropathology; histopathology; brain; nervous system; NTP; nervous system; screening ID PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; ANIMAL-MODELS; UNITED-STATES; DEVELOPMENTAL NEUROTOXICITY; INHALATION EXPOSURE; GLUCOSE-UTILIZATION; MULTIPLE-SCLEROSIS; CARBONYL SULFIDE; ECONOMIC-IMPACT AB This article outlines the changes and underlying rationale for modifications to the histopathological evaluation of the nervous system during toxicology and carcinogenesis studies conducted by the National Toxicology Program (NTP). In the past, routine evaluation of the nervous system was mostly limited to three sections of brain, and occasionally the spinal cord and peripheral nerves. Factors such as the increasing occurrence of human neurological diseases and associated economical cost burden, the role of unidentified environmental stressors in neurodegenerative disorders, multiple therapeutic drug-induced neuropathies noted in human clinical trials, and the exponential use of environmental chemicals with unknown neurotoxic potential necessitate a more extensive evaluation of the nervous system. The NTP has modified its protocol to include examination of key anatomic subsites related to neurodegenerative diseases such as Parkinson's disease. Modifications include four additional sections of the brain. Increasing the number of brain sections permits examination of a greater number of specific anatomic subsites with unique vulnerability. In addition, the spinal cord, peripheral nerves, trigeminal ganglion, and intestinal autonomic ganglia will be evaluated as needed. It is expected that this modified approach will increase the sensitivity of detecting neurotoxicants and neurocarcinogens important in human neurologic and neurodegenerative disorders. C1 [Rao, Deepa B.; Malarkey, David E.; Herbert, Ronald A.; Sills, Robert C.] NIEHS, Natl Toxicol Program, Res Triangle Pk, NC 27709 USA. [Rao, Deepa B.] Integrated Lab Syst Inc, Res Triangle Pk, NC USA. [Little, Peter B.] Pathol Associates Inc, Charles River Labs, Durham, NC USA. RP Sills, RC (reprint author), NIEHS, Natl Toxicol Program, POB 12233,MS B3-06,111 Alexander Dr, Res Triangle Pk, NC 27709 USA. EM sills@niehs.nih.gov FU National Institutes of Health, National Institute of Environmental Health Sciences FX The authors thank fellow NTP colleagues Drs. Jean Harry, Joseph Roycroft, and Raj Chhabra, and Dr. James P. Morrison of PAI, Charles River, for their invaluable input during the development of this modified protocol, and Drs. Gordon Flake and Mark Cesta for their detailed internal review of this article. Also, the authors are deeply grateful for the comments, opinions, and advice from many toxicologic pathologists with experience and interest in neuropathology who have all generously contributed throughout the process of establishing a modified NTP approach for evaluating the nervous system. We thank Mr. David Sabio (digital imaging), Ms. Stephanie Holmgren (library information services), Ms. Beth Mahler and the National Institute of Environmental Health Sciences histopathology core laboratory, and Mr. Shean Chiou (software) for their technical expertise and assistance during the preparation of this article. This research was supported (in part) by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences. NR 79 TC 10 Z9 10 U1 0 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0192-6233 EI 1533-1601 J9 TOXICOL PATHOL JI Toxicol. Pathol. PD APR PY 2011 VL 39 IS 3 BP 463 EP 470 DI 10.1177/0192623311401044 PG 8 WC Pathology; Toxicology SC Pathology; Toxicology GA 800QX UT WOS:000293380100001 PM 21430177 ER PT J AU Hill, GD Moore, AB Kissling, GE Flagler, ND Ney, E Cline, JM Dixon, D AF Hill, Georgette D. Moore, Alicia B. Kissling, Grace E. Flagler, Norris D. Ney, Elizabeth Cline, J. Mark Dixon, Darlene TI Effects of Hormonally Active Agents on Steroid Hormone Receptor Expression and Cell Proliferation in the Myometrium of Ovariectomized Macaques SO TOXICOLOGIC PATHOLOGY LA English DT Article DE myometrium; macaques; conjugated equine estrogens (CEE); medroxyprogesterone acetate (MPA); tamoxifen (TAM); steroid receptors; Ki-67 ID CORONARY-ARTERY ATHEROSCLEROSIS; CONJUGATED EQUINE ESTROGENS; RECEIVING TAMOXIFEN THERAPY; POSTMENOPAUSAL WOMEN; BREAST-CANCER; PROGESTERONE-RECEPTOR; MEDROXYPROGESTERONE ACETATE; ENDOMETRIAL HYPERPLASIA; UTERINE LEIOMYOMATA; CYNOMOLGUS MACAQUES AB Hormone replacement therapy and selective estrogen receptor modulators have been controversial treatment options for postmenopausal women because of their potential health benefits and/or risks. In this study, we determine the effects of the hormonally active compounds, conjugated equine estrogens (CEE), medroxyprogesterone acetate (MPA), CEE + MPA, and tamoxifen (TAM) on the myometrium of ovariectomized macaques. Immunoexpression of estrogen receptor-alpha (ER alpha), progesterone receptor (PR), and Ki-67 in the myometrium is assessed. We found no significant difference in ER alpha myometrial expression in the CEE, MPA, and CEE + MPA treatment groups, but there was a significant decrease in expression in animals administered TAM versus controls. Conjugated equine estrogen-, TAM-, and CEE + MPA-treated animals had significantly increased expression of PR in myometrial cells and there was no difference in PR expression in cells from MPA-treated animals versus control animals. Myometrial cell proliferation did not significantly differ between the controls and any of the treatment groups, although normalized Ki-67 values were somewhat higher in the CEE and TAM groups. These data suggest that ERa and PR expression in the myometrium is influenced by treatment with hormonally active agents. C1 [Moore, Alicia B.; Dixon, Darlene] NIEHS, Comparat Pathobiol Grp, Cellular & Mol Pathol Branch, NTP,NIH,DHHS, Res Triangle Pk, NC 27709 USA. [Hill, Georgette D.] Integrated Syst Lab, Res Triangle Pk, NC USA. [Kissling, Grace E.] NIEHS, Biostat Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA. [Flagler, Norris D.; Ney, Elizabeth] NIEHS, Special Tech Grp, Cellular & Mol Pathol Branch, NTP,NIH,DHHS, Res Triangle Pk, NC 27709 USA. [Cline, J. Mark] Wake Forest Univ, Comparat Med Sect, Dept Pathol, Sch Med, Winston Salem, NC 27109 USA. RP Dixon, D (reprint author), NIEHS, Comparat Pathobiol Grp, Cellular & Mol Pathol Branch, NTP,NIH,DHHS, POB 12233,Bldg 101,MD B3-06,Rm B341, Res Triangle Pk, NC 27709 USA. EM dixon@niehs.nih.gov FU NIEHS [N01-ES-55548]; National Heart Lung and Blood Institute [HL490852, HL45666] FX The authors would like to thank Drs. Mark Hoenerhoff and Arun Pandiri for their critical review of this manuscript, and Ms. Beth Mahler for her expert assistance with imaging. This study was supported in part by the Intramural Research Program of the NIEHS, and Dr. Hill's work was supported by NIEHS contract #N01-ES-55548. In addition, this study was supported in part by National Heart Lung and Blood Institute grants, HL490852 and HL45666. NR 49 TC 2 Z9 2 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0192-6233 J9 TOXICOL PATHOL JI Toxicol. Pathol. PD APR PY 2011 VL 39 IS 3 BP 508 EP 515 DI 10.1177/0192623311401045 PG 8 WC Pathology; Toxicology SC Pathology; Toxicology GA 800QX UT WOS:000293380100007 PM 21411722 ER PT J AU Trinchieri, G AF Trinchieri, Giorgio TI Inflammation in Cancer: a Therapeutic Target? THE KAMP, SHACTER, AND WEITZMAN ARTICLE REVIEWED SO ONCOLOGY-NEW YORK LA English DT Editorial Material ID GENERATION; RESPONSES C1 NCI, Canc & Inflammat Program, Ctr Canc Res, NIH, Frederick, MD 21701 USA. RP Trinchieri, G (reprint author), NCI, Canc & Inflammat Program, Ctr Canc Res, NIH, Frederick, MD 21701 USA. NR 17 TC 10 Z9 10 U1 0 U2 1 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD APR PY 2011 VL 25 IS 5 BP 418 EP 420 PG 3 WC Oncology SC Oncology GA 800EU UT WOS:000293343400008 PM 21710837 ER PT J AU Stenholm, S Metter, EJ Roth, GS Ingram, DK Mattison, JA Taub, DD Ferrucci, L AF Stenholm, Sari Metter, E. Jeffrey Roth, George S. Ingram, Donald K. Mattison, Julie A. Taub, Dennis D. Ferrucci, Luigi TI Relationship between plasma ghrelin, insulin, leptin, interleukin 6, adiponectin, testosterone and longevity in the Baltimore Longitudinal Study of Aging SO AGING CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Aging; biomarkers; caloric restriction; longevity ID CALORIC RESTRICTION; OLDER MEN; DIETARY RESTRICTION; ANABOLIC HORMONES; DECLINE; FRAILTY; HUMANS; WOMEN; AGE; BIOMARKERS AB Background and aims: Caloric restriction (CR) is the most robust and reproducible intervention for slowing aging, and maintaining health and vitality in animals. Previous studies found that CR is associated with changes in specific biomarkers in monkeys that were also associated with reduced risk of mortality in healthy men. In this study we examine the association between other potential biomarkers related to CR and extended lifespan in healthy humans. Methods: Based on the Baltimore Longitudinal Study of Aging, "long-lived" participants who survived to at least 90 years of age (n=41, cases) were compared with "short-lived" participants who died between 72-76 years of age (n=31, controls) in the nested case control study. Circulating levels of ghrelin, insulin, leptin, interleukin 6, adiponectin and testosterone were measured from samples collected between the ages 58 to 70 years. Baseline differences between groups were examined with t-test or Wilcoxon test, and mixed effects general linear model was used for a logistic model to differentiate the two groups with multiple measurements on some subjects. Results: At the time of biomarkers evaluation (58-70 yrs), none of the single biomarker levels was significantly different between the two groups. However, after combining information from multiple biomarkers by adding the z-transformed values, the global score differentiated the long- and short-lived participants (p=0.05). Conclusions: In their sixties, long-lived and short-lived individuals do not differ in biomarkers that have been associated with CR in animals. However, difference between the groups was only obtained when multiple biomarker dysregulation was considered. (Aging Clin Exp Res 2011; 23: 153-158) (C)2011, Editrice Kurtis C1 [Stenholm, Sari; Metter, E. Jeffrey; Ferrucci, Luigi] NIA, Clin Res Branch, Longitudinal Studies Sect, Baltimore, MD 21225 USA. [Stenholm, Sari] Natl Inst Hlth & Welf, Turku, Finland. [Roth, George S.] GeroScience Inc, Pylesville, MD USA. [Ingram, Donald K.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Nutr Neurosci & Aging Lab, Baton Rouge, LA USA. [Mattison, Julie A.] NIA, Lab Expt Gerontol, NIA Primate Aging Studies, Baltimore, MD 21225 USA. [Taub, Dennis D.] NIA, Immunol Lab, Baltimore, MD 21225 USA. RP Ferrucci, L (reprint author), NIA, Clin Res Branch, Longitudinal Studies Sect, Harbor Hosp 5th Floor,3001 S Hanover St, Baltimore, MD 21225 USA. EM ferrucciLu@grc.nia.nih.gov RI Stenholm, Sari/G-6940-2011 FU NIH, National Institute on Aging FX This research was supported by the Intramural Research Program of the NIH, National Institute on Aging. Data for these analyses were obtained from the Baltimore Longitudinal Study of Aging, a study performed by the National Institute on Aging. NR 34 TC 6 Z9 6 U1 0 U2 1 PU EDITRICE KURTIS S R L PI MILAN PA VIA LUIGI ZOJA 30, 20153 MILAN, ITALY SN 1594-0667 J9 AGING CLIN EXP RES JI Aging Clin. Exp. Res. PD APR PY 2011 VL 23 IS 2 BP 153 EP 158 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 793FM UT WOS:000292805800012 PM 21743292 ER PT J AU Yu, M Levine, SJ AF Yu, Man Levine, Stewart J. TI Toll-like receptor 3, RIG-I-like receptors and the NLRP3 inflammasome: Key modulators of innate immune responses to double-stranded RNA viruses SO CYTOKINE & GROWTH FACTOR REVIEWS LA English DT Review DE Double-stranded viral RNA; TLR3; RIG-1; NLRP3 inflammasome; Signal transduction ID NF-KAPPA-B; HUMAN DENDRITIC CELLS; OVARIAN-CANCER CELLS; INFLUENZA-VIRUS; RHEUMATOID-ARTHRITIS; ANTIVIRAL RESPONSES; PATTERN-RECOGNITION; AIRWAY EPITHELIUM; VIRAL-INFECTION; GENE INDUCTION AB Double-stranded RNA (dsRNA), the genetic material for many RNA viruses, induces robust host immune responses via pattern recognition receptors, which include Toll-like receptor 3 (TLR3), retinoic acid-inducible gene-I-like receptors (RLRs) and the multi-protein NLRP3 inflammasome complex. The engagement of dsRNA receptors or inflammasome activation by viral dsRNA initiates complex intracellular signaling cascades that play essential roles in inflammation and innate immune responses, as well as the resultant development of adaptive immunity. This review focuses on signaling pathways mediated by TLR3, RLRs and the NLRP3 inflammasome, as well as the potential use of agonists and antagonists that target these pathways to treat disease. Published by Elsevier Ltd. C1 [Yu, Man; Levine, Stewart J.] NHLBI, Cardiovasc & Pulm Branch, NIH, Bethesda, MD 20892 USA. RP Levine, SJ (reprint author), NHLBI, Cardiovasc & Pulm Branch, NIH, 10 Ctr Dr,Room 6D16, Bethesda, MD 20892 USA. EM levines@nhlbi.nih.gov FU Division of Intramural Research, NHLBI, NIH FX This work was supported by the Division of Intramural Research, NHLBI, NIH. NR 120 TC 71 Z9 74 U1 3 U2 17 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1359-6101 J9 CYTOKINE GROWTH F R JI Cytokine Growth Factor Rev. PD APR PY 2011 VL 22 IS 2 BP 63 EP 72 DI 10.1016/j.cytogfr.2011.02.001 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 791KU UT WOS:000292664900001 PM 21466970 ER PT J AU Sedriep, S Xia, X Marotta, F Zhou, L Yadav, H Yang, H Soresi, V Catanzaro, R Zhong, K Polimeni, A Chui, DH AF Sedriep, S. Xia, X. Marotta, F. Zhou, L. Yadav, H. Yang, H. Soresi, V. Catanzaro, R. Zhong, K. Polimeni, A. Chui, D. H. TI BENEFICIAL NUTRACEUTICAL MODULATION OF CEREBRAL ERYTHROPOIETIN EXPRESSION AND OXIDATIVE STRESS: AN EXPERIMENTAL STUDY SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS LA English DT Article DE erythropoietin; brain cognitive impairment; oxidative stress; phycocyanins; prematurely senescent mice ID BLOOD-BRAIN-BARRIER; RECEPTOR EXPRESSION; NEONATAL-RATS; C-PHYCOCYANIN; IN-VITRO; ANTIOXIDANT; ISCHEMIA; DAMAGE; MICE; NEUROPROTECTION AB The main object of this study is to examine the effect of Klamin (R), a nutraceutical containing phenylethylamine, phycocyanins, mycosporine-like aminoacids and aphanizomenon flos aquae-phytochrome on the learning and memory ability, the oxidative status and cerebral erythropoietin and its receptor EPO/EPOR system in prematurely senescent (PS) mice. A total of 28 PS mice, selected according to a prior T-maze test, and 26 non-prematurely senescent mice (NPS) mice were chosen. PS animals were divided into 3 groups and followed for 4 weeks: A) normal chow diet; B) added with Klamin (R) at 20 mg/kg/day (low dose); C) added with Klamin (R) at 100mg/kg/day (high dose). A further group of NPS mice given either normal food (group D) or high dose Klamin (R) (group E) was also considered. The behavioral procedures of spatial learning ability (Morris test) showed that PS mice had significantly longer learning time as compared to their NPS counterpart (p<0.01), but this effect was prevented especially in mice supplemented with high-dose Klamin (R) (p<0.05) which improved performances in NPS mice (p<0.05). High-dose Klamin (R) supplementation restored the depleted total thiol concentration in the brain observed in PS mice while normalizing their increased malonildialdehyde level (p<0.05). Moreover, the high-dosage only caused a significant upregulation of EPO/EPOR system both in PS and in NPS animals (p<0.05). Taken together, these data suggest that this specific alga Klamath extract has considerable antioxidant and adaptogenic properties, also through a stimulatory effect of cerebral EPO/EPO system. C1 [Sedriep, S.] Biocell Unit Lab & Anal Ctr, Miyazaki, Japan. [Xia, X.] Guilin Med Univ, Affiliated Hosp, Guilin, Guangxi, Peoples R China. [Marotta, F.; Polimeni, A.] ReGenera Res Grp Aging Intervent, Milan, Italy. [Zhou, L.; Yang, H.; Zhong, K.; Chui, D. H.] Peking Univ, Neurosci Res Inst, Beijing 100871, Peoples R China. [Yadav, H.] NIDDK, NIH, Bethesda, MD USA. [Soresi, V.] Octopus Sci Assoc Bioprevent, Milan, Italy. [Catanzaro, R.] Univ Catania, Dept Internal Med, Gastroenterol Unit, I-95124 Catania, Italy. RP Marotta, F (reprint author), Piazza Firenze 12, I-20154 Milan, Italy. EM fmarchimede@libero.it NR 35 TC 12 Z9 12 U1 1 U2 2 PU BIOLIFE SAS PI SILVA MARINA (TE) PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY SN 0393-974X J9 J BIOL REG HOMEOS AG JI J. Biol. Regul. Homeost. Agents PD APR-JUN PY 2011 VL 25 IS 2 BP 187 EP 194 PG 8 WC Endocrinology & Metabolism; Immunology; Medicine, Research & Experimental; Physiology SC Endocrinology & Metabolism; Immunology; Research & Experimental Medicine; Physiology GA 793VS UT WOS:000292852600006 PM 21880207 ER PT J AU Cooper, ID AF Cooper, I. Diane TI Research: the opportunity wheel keeps turning SO JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION LA English DT Editorial Material ID MEDICAL-LIBRARY-ASSOCIATION; INFORMATION-SCIENCE; POLICY C1 [Cooper, I. Diane] NIH, Res Sect, Bethesda, MD 20892 USA. [Cooper, I. Diane] NIH, NIH Lib, Bethesda, MD 20892 USA. RP Cooper, ID (reprint author), NIH, Res Sect, Bldg 10,MSC 1150, Bethesda, MD 20892 USA. EM cooperd@mail.nih.gov RI Cooper, Diane/G-5826-2011 NR 14 TC 1 Z9 1 U1 0 U2 0 PU MEDICAL LIBRARY ASSOC PI CHICAGO PA 65 EAST WACKER PLACE, STE 1900, CHICAGO, IL 60601-7298 USA SN 1536-5050 J9 J MED LIBR ASSOC JI J. Med. Libr. Assoc. PD APR PY 2011 VL 99 IS 2 BP 107 EP 109 DI 10.3163/1536-5050.99.2.001 PG 3 WC Information Science & Library Science SC Information Science & Library Science GA 774EE UT WOS:000291363300001 PM 21464847 ER PT J AU Ripple, AM Mork, JG Knecht, LS Humphreys, BL AF Ripple, Anna M. Mork, James G. Knecht, Lou S. Humphreys, Betsy L. TI A retrospective cohort study of structured abstracts in MEDLINE, 1992-2006 SO JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION LA English DT Article ID INFORMATIVE ABSTRACTS; PROPOSAL; ARTICLES C1 [Humphreys, Betsy L.] NIH, US Dept Hlth & Human Serv, Natl Lib Med, Bethesda, MD 20894 USA. EM ripple@nlm.nih.gov; mork@nlm.nih.gov; knechtl@mail.nlm.nih.gov; betsy_humphreys@nlm.nih.gov FU Intramural NIH HHS NR 15 TC 10 Z9 10 U1 0 U2 4 PU MEDICAL LIBRARY ASSOC PI CHICAGO PA 65 EAST WACKER PLACE, STE 1900, CHICAGO, IL 60601-7298 USA SN 1536-5050 J9 J MED LIBR ASSOC JI J. Med. Libr. Assoc. PD APR PY 2011 VL 99 IS 2 BP 160 EP 163 DI 10.3163/1536-5050.99.2.009 PG 4 WC Information Science & Library Science SC Information Science & Library Science GA 774EE UT WOS:000291363300009 PM 21464855 ER PT J AU Cornell, A Bushman, B Womack, K AF Cornell, Ada Bushman, Barbara Womack, Kristina TI Analysis of journals that did not meet selection criteria for inclusion in the National Library of Medicine collection but have manuscripts in PubMed Central SO JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION LA English DT Article C1 [Cornell, Ada; Womack, Kristina] Natl Lib Med, Select & Acquisit Sect, Bethesda, MD 20894 USA. [Bushman, Barbara] Natl Lib Med, Cataloging Sect, Bethesda, MD 20894 USA. RP Cornell, A (reprint author), Natl Lib Med, Select & Acquisit Sect, 8600 Rockville Pike, Bethesda, MD 20894 USA. EM ada.cornell@inova.org; bushmanb@mail.nlm.nih.gov; womackk2@mail.nlm.nih.gov NR 5 TC 0 Z9 0 U1 0 U2 6 PU MEDICAL LIBRARY ASSOC PI CHICAGO PA 65 EAST WACKER PLACE, STE 1900, CHICAGO, IL 60601-7298 USA SN 1536-5050 J9 J MED LIBR ASSOC JI J. Med. Libr. Assoc. PD APR PY 2011 VL 99 IS 2 BP 168 EP 170 DI 10.3163/1536-5050.99.2.011 PG 3 WC Information Science & Library Science SC Information Science & Library Science GA 774EE UT WOS:000291363300011 PM 21464857 ER PT J AU Kulminski, AM Arbeev, KG Christensen, K Mayeux, R Newman, AB Province, MA Hadley, EC Rossi, W Perls, TT Elo, IT Yashin, AI AF Kulminski, Alexander M. Arbeev, Konstantin G. Christensen, Kaare Mayeux, Richard Newman, Anne B. Province, Michael A. Hadley, Evan C. Rossi, Winifred Perls, Thomas T. Elo, Irma T. Yashin, Anatoli I. TI Do gender, disability, and morbidity affect aging rate in the LLFS? Application of indices of cumulative deficits SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE Aging rates; Longevity; Cumulative indices; Long-Life Family Study ID LONG-LIFE FAMILY; LEIDEN LONGEVITY; NONAGENARIAN SIBLINGS; HEALTH DISORDERS; ELDERLY-PEOPLE; FRAILTY INDEX; FOLLOW-UP; MORTALITY; POPULATION; ACCUMULATION AB We used an approach of cumulative deficits to evaluate the rate of aging in 4954 participants of the Long-Life Family Study (LLFS) recruited in the U.S. (Boston, New York, and Pittsburg) and Denmark. We used an array of 85 health-related deficits covering major health dimensions including depression, cognition, morbidity, physical performance, and disability to construct several deficit indices (DIs) with overlapping and complementary sets of deficits to test robustness of the estimates. Our study shows that the DI robustly characterize accelerated rates of aging irrespective of specific of deficits. When a wider spectrum of health dimensions is considered these rates are better approximated by quadratic law. Exponential rates are more characteristic for more severe health dimensions. The aging rates are the same for males and females. Individuals who contracted major diseases and those who were free of them exhibited the same aging rates as characterized by the DI constructed using mild deficits. Unlike health, disability can qualitatively alter the aging patterns of the LLFS participants. We report on systemic differences in health among the LLFS centenarians residing in New York and Boston. This study highlights importance of aggregated approaches to better understand systemic mechanisms of health deterioration in long-living individuals. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [Kulminski, Alexander M.; Arbeev, Konstantin G.; Yashin, Anatoli I.] Duke Univ, Ctr Populat Hlth & Aging, Durham, NC 27708 USA. [Christensen, Kaare] Univ So Denmark, Danish Aging Res Ctr, DK-5000 Odense C, Denmark. [Mayeux, Richard] Columbia Univ, Div Hlth Sci, New York, NY 10032 USA. [Newman, Anne B.] Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Province, Michael A.] Washington Univ, Sch Med, Div Stat Genom, St Louis, MO 63108 USA. [Hadley, Evan C.; Rossi, Winifred] NIA, Bethesda, MD 20892 USA. [Perls, Thomas T.] Boston Univ, Sch Med, Div Geriatr MED Geriatr, Boston, MA 02215 USA. [Elo, Irma T.] Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA. RP Kulminski, AM (reprint author), Duke Univ, Ctr Populat Hlth & Aging, Box 90408,Trent Hall,Room 002, Durham, NC 27708 USA. EM Alexander.Kulminski@duke.edu RI Christensen, Kaare/C-2360-2009; Newman, Anne/C-6408-2013; OI Christensen, Kaare/0000-0002-5429-5292; Newman, Anne/0000-0002-0106-1150; Perls, Thomas/0000-0002-2492-4334 FU National Institute on Aging (NIA) [U01AG023746, R01AG032319] FX This work was supported by National Institute on Aging (NIA) grants U01AG023746 and R01AG032319. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIA or the National Institutes of Health. NR 46 TC 10 Z9 11 U1 1 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD APR PY 2011 VL 132 IS 4 BP 195 EP 201 DI 10.1016/j.mad.2011.03.006 PG 7 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 777NI UT WOS:000291628000008 PM 21463647 ER PT J AU Nielsen, L Mather, M AF Nielsen, Lisbeth Mather, Mara TI Emerging perspectives in social neuroscience and neuroeconomics of aging SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE LA English DT Article DE aging; life course ID AGE-RELATED DIFFERENCES; FINANCIAL RISK-TAKING; ADULT LIFE-SPAN; OLDER-ADULTS; DECISION-MAKING; EMOTION REGULATION; COGNITIVE CONTROL; INDIVIDUAL-DIFFERENCES; SELF-CONTROL; LONGITUDINAL ANALYSES AB This article introduces the special issue of 'Social Cognitive and Affective Neuroscience' on Aging Research, and offers a broad conceptual and methodological framework for considering advances in life course research in social neuroscience and neuroeconomics. The authors highlight key areas of inquiry where aging research is raising new insights about how to conceptualize and examine critical questions about the links between cognition, emotion and motivation in social and economic behavior, as well as challenges that need to be addressed when taking a life course perspective in these fields. They also point to several emerging approaches that hold the potential for addressing these challenges, through bridging approaches from laboratory and population-based science, bridging inquiry across life stages and expanding measurement of core psychological phenotypes. C1 [Nielsen, Lisbeth] NIA, Div Behav & Social Res, NIH, Bethesda, MD 20892 USA. [Mather, Mara] Univ So Calif, Davis Sch Gerontol, Los Angeles, CA USA. [Mather, Mara] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. RP Nielsen, L (reprint author), NIA, Div Behav & Social Res, NIH, 7201 Wisconsin Ave,Suite 533, Bethesda, MD 20892 USA. EM nielsenli@nia.nih.gov RI Mather, Mara/E-3232-2010 OI Mather, Mara/0000-0003-4331-6112 FU National Institute on Aging under RFAs (Neuroeconomics of Aging) [RFA-AG-06-011]; National Institute on Aging under RFAs (Neuroscience of Aging) [RFA-AG-09-006]; Social Neuroscience RFAs from the National Institute on Drug Abuse; Social Neuroscience RFAs from the National Institute on Mental Health [RFA-DA-06-004, RFA-MH-08-070] FX The National Institute on Aging has supported new research in Social Neuroscience and Neuroeconomics of Aging under two institute-sponsored RFAs (Neuroeconomics of Aging RFA-AG-06-011 and Social Neuroscience of Aging RFA-AG-09-006) as well as through participation in Social Neuroscience RFAs from the National Institute on Drug Abuse and the National Institute on Mental Health (RFA-DA-06-004 and RFA-MH-08-070). Several of the research recommendations from these previous solicitations are echoed in this article. NR 154 TC 10 Z9 11 U1 1 U2 19 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1749-5016 EI 1749-5024 J9 SOC COGN AFFECT NEUR JI Soc. Cogn. Affect. Neurosci. PD APR PY 2011 VL 6 IS 2 SI SI BP 149 EP 164 DI 10.1093/scan/nsr019 PG 16 WC Neurosciences; Psychology; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 776NT UT WOS:000291543100001 PM 21482573 ER PT J AU Oesch, NW Kothmann, WW Diamond, JS AF Oesch, Nicholas W. Kothmann, W. Wade Diamond, Jeffrey S. TI Illuminating synapses and circuitry in the retina SO CURRENT OPINION IN NEUROBIOLOGY LA English DT Article ID STARBURST AMACRINE CELLS; RABBIT RETINA; GANGLION-CELL; DIRECTIONAL SELECTIVITY; MAMMALIAN RETINA; BIPOLAR CELLS; SYNAPTIC-TRANSMISSION; ROD PHOTORECEPTOR; KAINATE RECEPTORS; NMDA RECEPTORS AB In the central nervous system, space is at a premium. This is especially true in the retina, where synapses, cells, and circuitry have evolved to maximize signal-processing capacity within a thin, optically transparent tissue. For example, at some retinal synapses, single presynaptic active zones contact multiple postsynaptic targets; some individual neurons perform completely different tasks depending on visual conditions, while others execute hundreds of circuit computations in parallel; and the retinal network adapts, at various levels, to the ever-changing visual world. Each of these features reflects efficient use of limited cellular resources to optimally encode visual information. C1 [Oesch, Nicholas W.; Kothmann, W. Wade; Diamond, Jeffrey S.] Natl Inst Neurol Disorders & Stroke, Synapt Physiol Sect, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20824 USA. RP Diamond, JS (reprint author), Natl Inst Neurol Disorders & Stroke, Synapt Physiol Sect, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20824 USA. EM diamondj@ninds.nih.gov RI Diamond, Jeffrey/C-1835-2015 OI Diamond, Jeffrey/0000-0002-1770-2629 FU NINDS FX We thank Jonathan Demb and Gabe Murphy for critically reading the manuscript. This work was supported by the NINDS Intramural Research Program. NR 50 TC 12 Z9 12 U1 1 U2 4 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0959-4388 J9 CURR OPIN NEUROBIOL JI Curr. Opin. Neurobiol. PD APR PY 2011 VL 21 IS 2 BP 238 EP 244 DI 10.1016/j.conb.2011.01.008 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 771VI UT WOS:000291188400006 PM 21349699 ER PT J AU Mayer, ML AF Mayer, Mark L. TI Structure and mechanism of glutamate receptor ion channel assembly, activation and modulation SO CURRENT OPINION IN NEUROBIOLOGY LA English DT Article ID LIGAND-BINDING DOMAIN; AMINO-TERMINAL DOMAIN; GLUR2 AMPA RECEPTOR; MOLECULAR-MECHANISM; POSITIVE MODULATORS; CRYSTAL-STRUCTURES; KAINATE RECEPTORS; CORNICHON PROTEINS; DIMER INTERFACE; NMDA RECEPTORS AB Ionotropic glutamate receptors (iGluRs) are ligand gated ion channels that mediate excitatory synaptic transmission in the brain of vertebrates. A rapidly growing body of crystal structures for isolated iGluR extracellular domains, and more recently a full length AMPA receptor, combined with data from electrophysiological experiments and MD simulations, provides a framework that makes it possible to investigate the molecular basis for assembly, gating and modulation. These unprecedented advances in structural biology are constantly challenged by novel functional properties that emerge despite decades of functional analysis, and by a growing family of auxiliary proteins that modulate iGluR activity and assembly. C1 NICHD, Lab Cellular & Mol Neurophysiol, Porter Neurosci Res Ctr, NIH,DHHS, Bethesda, MD 20892 USA. RP Mayer, ML (reprint author), NICHD, Lab Cellular & Mol Neurophysiol, Porter Neurosci Res Ctr, NIH,DHHS, Bethesda, MD 20892 USA. EM mayerm@mail.nih.gov RI Mayer, Mark/H-5500-2013 FU NICHD, NIH FX I thank Pierre Paoletti for comments on the text, Teru Nakagawa for the single particle EM maps, and Phil Biggin for the MD trajectories. Work in my lab is supported by the intramural research program of NICHD, NIH. NR 64 TC 42 Z9 42 U1 2 U2 15 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0959-4388 J9 CURR OPIN NEUROBIOL JI Curr. Opin. Neurobiol. PD APR PY 2011 VL 21 IS 2 BP 283 EP 290 DI 10.1016/j.conb.2011.02.001 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 771VI UT WOS:000291188400012 PM 21349697 ER PT J AU Roy, AK Gotimer, K Kelly, AMC Castellanos, FX Milham, MP Ernst, M AF Roy, Amy Krain Gotimer, Kristin Kelly, A. M. Clare Castellanos, F. Xavier Milham, Michael P. Ernst, Monique TI Uncovering putative neural markers of risk avoidance SO NEUROPSYCHOLOGIA LA English DT Article DE Decision-making; Precuneus; Risk; Striatum ID ANTERIOR CINGULATE CORTEX; RIGHT PREFRONTAL CORTEX; TAKING DECISION-MAKING; ANXIETY DISORDER; BRAIN IMAGES; RIGHT INSULA; REWARD; FMRI; ACTIVATION; BEHAVIOR AB Risk avoidance is a hallmark of psychopathological conditions such as anxiety disorders. Yet few studies have examined its neural basis. The present work sought to identify the neural correlates of risk avoidance. While functional MRI scans were acquired, healthy adults (N=23) played a Wheel of Fortune game during which they chose to bet or pass on each of 104 proposed gamble trials. Participants also completed the Cognitive Appraisal of Risky Events (CARE, Fromme et al., 1997), a self-report measure of "real world" risky behavior. As expected, decision-making was associated with activation, as measured by increased BOLD responses, of the striatum, insula, anterior cingulate cortex, dorsolateral prefrontal cortex, and parietal lobe. Risk avoidance during probabilistic trials (percent of trials passed) was significantly correlated with precuneus and striatal responses to trials with a certain outcome (No-Risk). Similarly, "real world" risk avoidance, as measured by the CARE, was significantly correlated with precuneus activity during No-Risk trials. Collectively, these data suggest that precuneus and striatal responses to decision-making under certainty represent putative neural markers of risk avoidance in the laboratory and in the "real world." Further, they underline the need to extend neuroimaging research on risk avoidance, and associated anxiety disorders, to posterior cortical regions. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Roy, Amy Krain] CUNY Brooklyn Coll, Dept Psychol, Brooklyn, NY 11210 USA. [Roy, Amy Krain; Gotimer, Kristin; Kelly, A. M. Clare; Castellanos, F. Xavier; Milham, Michael P.] NYU, Sch Med, Ctr Child Study, Phyllis Green & Randolph Cowen Inst Pediat Neuros, New York, NY 10016 USA. [Ernst, Monique] NIMH, Mood & Anxiety Disorders Program, NIH, US Dept HHS, Bethesda, MD 20892 USA. RP Roy, AK (reprint author), CUNY Brooklyn Coll, Dept Psychol, Brooklyn, NY 11210 USA. EM amy.roy@nyumc.org RI Roy, Amy/J-7613-2013; Milham, Michael/K-9501-2014; OI Castellanos, Francisco/0000-0001-9192-9437 FU National Institute of Mental Health [K23MH074821]; National Institute of Mental Health, NIH, DHHS FX This work was supported by the National Institute of Mental Health (grant number K23MH074821 to A.K.R.) and the Intramural Research Program of the National Institute of Mental Health, NIH, DHHS. NR 39 TC 10 Z9 11 U1 1 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD APR PY 2011 VL 49 IS 5 BP 937 EP 944 DI 10.1016/j.neuropsychologia.2011.02.038 PG 8 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 764RE UT WOS:000290649200019 PM 21354189 ER PT J AU Zopf, R Truong, S Finkbeiner, M Friedman, J Williams, MA AF Zopf, Regine Truong, Sandra Finkbeiner, Matthew Friedman, Jason Williams, Mark A. TI Viewing and feeling touch modulates hand position for reaching SO NEUROPSYCHOLOGIA LA English DT Article DE Parietal cortex; Touch; Action; Human body; Body location; Rubber hand illusion ID GRASPING VISUAL ILLUSIONS; MULTISENSORY REPRESENTATION; PERIPERSONAL SPACE; PREMOTOR CORTEX; PARIETAL CORTEX; BODY-OWNERSHIP; PERCEPTION; PROPRIOCEPTION; DISSOCIATION; INTEGRATION AB Action requires knowledge of our body location in space. Here we asked if interactions with the external world prior to a reaching action influence how visual location information is used. We investigated if the temporal synchrony between viewing and feeling touch modulates the integration of visual and proprioceptive body location information for action. We manipulated the synchrony between viewing and feeling touch in the Rubber Hand Illusion paradigm prior to participants performing a ballistic reaching task to a visually specified target. When synchronous touch was given, reaching trajectories were significantly shifted compared to asynchronous touch. The direction of this shift suggests that touch influences the encoding of hand position for action. On the basis of this data and previous findings, we propose that the brain uses correlated cues from passive touch and vision to update its own position for action and experience of self-location. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Zopf, Regine; Truong, Sandra; Finkbeiner, Matthew; Friedman, Jason; Williams, Mark A.] Macquarie Univ, Macquarie Ctr Cognit Sci, Inst Human Cognit & Brain Sci, Sydney, NSW 2109, Australia. [Truong, Sandra] NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA. RP Zopf, R (reprint author), Macquarie Univ, Macquarie Ctr Cognit Sci, Inst Human Cognt & Brain Sci, Sydney, NSW 2109, Australia. EM regine.zopf@mq.edu.au; sandra.truong@nih.gov RI Friedman, Jason/B-4690-2008; OI Friedman, Jason/0000-0001-8845-5082; Zopf, Regine/0000-0002-1375-3832; Williams, Mark/0000-0002-3897-5167 FU Australian Research Council FX We would like to thank Glenn Carruthers for fruitful discussions and Chris Baker, Dwight Kravitz and Anina Rich for their insightful comments on an earlier version of this manuscript. MF is an Australian Research Fellow and MAW is a Queen Elizabeth II Fellow, both funded by the Australian Research Council. NR 40 TC 16 Z9 17 U1 2 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD APR PY 2011 VL 49 IS 5 BP 1287 EP 1293 DI 10.1016/j.neuropsychologia.2011.02.012 PG 7 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 764RE UT WOS:000290649200054 PM 21320514 ER PT J AU Cornwell, BR Alvarez, RP Lissek, S Kaplan, R Ernst, M Grillon, C AF Cornwell, Brian R. Alvarez, Ruben P. Lissek, Shmuel Kaplan, Raphael Ernst, Monique Grillon, Christian TI Anxiety overrides the blocking effects of high perceptual load on amygdala reactivity to threat-related distractors SO NEUROPSYCHOLOGIA LA English DT Article DE Amygdala; Anxiety; Attention; Fearful faces; Perceptual load; Prefrontal cortices ID SPATIAL ATTENTION; FEARFUL FACES; DISORDERS; STARTLE; BRAIN; SHOCK AB Amygdala reactivity to threat-related distractor stimuli can be abolished in perceptually demanding contexts. Premised on the biological imperative to respond swiftly to threat, we demonstrate, however, that when participants are threatened by shock, greater amygdala responses to fearful compared to neutral distractor faces is preserved under conditions of high attentional demand. Lateral prefrontal cortices also showed selective responding to fearful distractor faces under these conditions, suggesting that threat-related distractor stimuli engaged attentional control mechanisms. We conclude that anxiety elicited by looming threat promotes neurocognitive processes that broaden attention and enhance sensitivity to potential danger cues, even when perceptual systems are taxed. Published by Elsevier Ltd. C1 [Cornwell, Brian R.; Alvarez, Ruben P.; Lissek, Shmuel; Kaplan, Raphael; Ernst, Monique; Grillon, Christian] NIMH, Mood & Anxiety Disorders Program, Bethesda, MD 20892 USA. [Cornwell, Brian R.; Alvarez, Ruben P.; Lissek, Shmuel; Kaplan, Raphael; Ernst, Monique; Grillon, Christian] NIH, Mood & Anxiety Disorders Program, Bethesda, MD 20892 USA. RP Cornwell, BR (reprint author), NIMH, Mood & Anxiety Disorders Program, 15K North Dr,MSC 2670, Bethesda, MD 20892 USA. EM cornwellb@mail.nih.gov OI Kaplan, Raphael/0000-0002-5023-1566 FU National Institute of Mental Health (NIMH) FX This research was supported by the Intramural Research Program of the National Institute of Mental Health (NIMH). We wish to thank Katye Vytal for helpful comments on an earlier draft. NR 26 TC 20 Z9 21 U1 2 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD APR PY 2011 VL 49 IS 5 BP 1363 EP 1368 DI 10.1016/j.neuropsychologia.2011.02.049 PG 6 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 764RE UT WOS:000290649200065 PM 21376745 ER PT J AU Neumann, S Gershengorn, MC AF Neumann, S. Gershengorn, M. C. TI Small molecule TSHR agonists and antagonists SO ANNALES D ENDOCRINOLOGIE LA English DT Article DE Thyroid; Thyroid cancer; Graves' disease; TSH receptor; Small molecule ligands ID THYROTROPIN RECEPTOR AB TSH activates the TSH receptor (TSHR) thereby stimulating the function of thyroid follicular cells (thyrocytes) leading to biosynthesis and secretion of thyroid hormones. Because TSHR is involved in several thyroid pathologies, there is a strong rationale for the design of small molecule "drug-like" ligands. Recombinant human TSH (rhTSH, Thyrogen (R)) has been used in the follow-up of patients with thyroid cancer to increase the sensitivity for detection of recurrence or metastasis. rhTSH is difficult to produce and must be administered by injection. A small molecule TSHR agonist could produce the same beneficial effects as rhTSH but with greater ease of oral administration. We developed a small molecule ligand that is a full agonist at TSHR. Importantly for its clinical potential, this agonist elevated serum thyroxine and stimulated thyroidal radioiodide uptake in mice after its absorption from the gastrointestinal tract following oral administration. Graves' disease (GD) is caused by persistent, unregulated stimulation of thyrocytes by thyroid-stimulating antibodies (TSAbs) that activate TSHR. We identified the first small molecule TSHR antagonists that inhibited TSH- and TSAb-stimulated signalling in primary cultures of human thyrocytes. Our results provide proof-of-principle for effectiveness of small molecule agonists and antagonists for TSHR. We suggest that these small molecule ligands are lead compounds for the development of higher potency ligands that can be used as probes of TSHR biology with therapeutic potential. Published by Elsevier Masson SAS. C1 [Neumann, S.; Gershengorn, M. C.] NIDDK, NIH, CEB, Receptor & Hormone Act Sect, Bethesda, MD 20892 USA. RP Neumann, S (reprint author), NIDDK, NIH, CEB, Receptor & Hormone Act Sect, Bldg 50,Room 4124,50 S Dr, Bethesda, MD 20892 USA. EM susannen@intra.niddk.nih.gov FU National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health FX This work was supported by the Intramural Research Programs of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. NR 10 TC 7 Z9 9 U1 0 U2 3 PU MASSON EDITEUR PI MOULINEAUX CEDEX 9 PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE SN 0003-4266 J9 ANN ENDOCRINOL-PARIS JI Ann Endocrinol. PD APR PY 2011 VL 72 IS 2 BP 74 EP 76 DI 10.1016/j.ando.2011.03.002 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 767FP UT WOS:000290841000006 PM 21511239 ER PT J AU Kazuki, Y Hoshiya, H Takiguchi, M Abe, S Iida, Y Osaki, M Katoh, M Hiratsuka, M Shirayoshi, Y Hiramatsu, K Ueno, E Kajitani, N Yoshino, T Kazuki, K Ishihara, C Takehara, S Tsuji, S Ejima, F Toyoda, A Sakaki, Y Larionov, V Kouprina, N Oshimura, M AF Kazuki, Y. Hoshiya, H. Takiguchi, M. Abe, S. Iida, Y. Osaki, M. Katoh, M. Hiratsuka, M. Shirayoshi, Y. Hiramatsu, K. Ueno, E. Kajitani, N. Yoshino, T. Kazuki, K. Ishihara, C. Takehara, S. Tsuji, S. Ejima, F. Toyoda, A. Sakaki, Y. Larionov, V. Kouprina, N. Oshimura, M. TI Refined human artificial chromosome vectors for gene therapy and animal transgenesis SO GENE THERAPY LA English DT Article DE human artificial chromosome; animal transgenesis; microcell-mediated chromosome transfer ID TRANSFORMATION-ASSOCIATED RECOMBINATION; STEM-CELLS; GENOMIC LOCI; MICE; GENERATION; CLONING; EXPRESSION; SEQUENCE; YEAST; HUMAN-CHROMOSOME-21 AB Human artificial chromosomes (HACs) have several advantages as gene therapy vectors, including stable episomal maintenance, and the ability to carry large gene inserts. We previously developed HAC vectors from the normal human chromosomes using a chromosome engineering technique. However, endogenous genes were remained in these HACs, limiting their therapeutic applications. In this study, we refined a HAC vector without endogenous genes from human chromosome 21 in homologous recombination-proficient chicken DT40 cells. The HAC was physically characterized using a transformation-associated recombination (TAR) cloning strategy followed by sequencing of TAR-bacterial artificial chromosome clones. No endogenous genes were remained in the HAC. We demonstrated that any desired gene can be cloned into the HAC using the Cre-loxP system in Chinese hamster ovary cells, or a homologous recombination system in DT40 cells. The HAC can be efficiently transferred to other type of cells including mouse ES cells via microcell-mediated chromosome transfer. The transferred HAC was stably maintained in vitro and in vivo. Furthermore, tumor cells containing a HAC carrying the suicide gene, herpes simplex virus thymidine kinase (HSV-TK), were selectively killed by ganciclovir in vitro and in vivo. Thus, this novel HAC vector may be useful not only for gene and cell therapy, but also for animal transgenesis. Gene Therapy (2011) 18, 384-393; doi:10.1038/gt.2010.147; published online 18 November 2010 C1 [Kazuki, Y.; Hoshiya, H.; Takiguchi, M.; Abe, S.; Iida, Y.; Osaki, M.; Hiramatsu, K.; Ueno, E.; Kajitani, N.; Kazuki, K.; Ishihara, C.; Takehara, S.; Tsuji, S.; Oshimura, M.] Tottori Univ, Grad Sch Med Sci, Dept Biomed Sci, Inst Regenerat Med & Biofunct, Tottori 6838503, Japan. [Kazuki, Y.; Oshimura, M.] Tottori Univ, Chromosome Engn Res Ctr, Tottori 6838503, Japan. [Katoh, M.] Tottori Univ, Div Human Genome Sci, Dept Mol & Cellular Biol, Sch Life Sci,Fac Med, Tottori 6838503, Japan. [Shirayoshi, Y.] Tottori Univ, Div Regenerat Med & Therapeut, Dept Genet Med & Regenerat Therapeut, Inst Regenerat Med & Biofunct,Grad Sch Med Sci, Tottori 6838503, Japan. [Yoshino, T.] Tottori Univ, Div Funct Genom, Res Ctr Biosci & Technol, Tottori 6838503, Japan. [Ejima, F.; Toyoda, A.; Sakaki, Y.] RIKEN, Genom Sci Ctr, Sequence Technol Team, Yokohama, Kanagawa, Japan. [Larionov, V.; Kouprina, N.] NCI, Mol Pharmacol Lab, Bethesda, MD 20892 USA. [Oshimura, M.] CREST, JST, Tokyo, Japan. RP Oshimura, M (reprint author), Tottori Univ, Grad Sch Med Sci, Dept Biomed Sci, Inst Regenerat Med & Biofunct, 86 Nishi Cho, Tottori 6838503, Japan. EM oshimura@grape.med.tottori-u.ac.jp FU JST, CREST; Ministry of Education, Culture, Sports, Science and Technology of Japan FX We thank Dr M Okabe at Osaka University for providing pCX-EGFP; Dr J Toguchida at Kyoto University for providing hiMSC; Dr M Ikeno at Keio University for providing p11-4; Dr G Felsenfeld, National Institute of Health for providing pJC5-4; the technical staffs of the Sequence Technology Team at RIKEN GSC for their assistance; Mr/Mrs Y Watanabe, Y Kai, K Kawakami and C Igawa at Tottori University for technical assistance; and Dr T Ohbayashi at Tottori University for critical discussions. This study was supported in part by JST, CREST (MO and YK), and the twenty-first Century Center of Excellence (COE) program from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MO and YK). NR 41 TC 37 Z9 37 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0969-7128 J9 GENE THER JI Gene Ther. PD APR PY 2011 VL 18 IS 4 BP 384 EP 393 DI 10.1038/gt.2010.147 PG 10 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 769YE UT WOS:000291053400008 PM 21085194 ER PT J AU Ramella-Roman, JC Nayak, A Prahl, SA AF Ramella-Roman, Jessica C. Nayak, Amritha Prahl, Scott A. TI Spectroscopic sensitive polarimeter for biomedical applications SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE Stokes vector; spectroscopic polarimeter; Mueller matrix ID TURBID MEDIA; SCATTERING; PHANTOMS; CELLS AB We present the design and calibration of a spectroscopic sensitive polarimeter. The polarimeter can measure the full Stokes vector in the wavelength range 550 to 750 nm with 1-nm resolution and consists of a fiber-based spectrophotometer, a white light emitting diode light source, two liquid crystal retarders, and one polarizer. Calibration of the system is achieved with a scheme that does not require knowledge of the polarizing elements' orientation or retardation. Six intensity spectra are required to calculate the full spectrum Stokes vector. Error in the polarimeter is less than 5%. We report the Stokes vectors for light transmitted through nonscattering polarizing elements as well as a measurement of the depolarizing properties of chicken muscle at several wavelengths. (C) 2011 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.3561907] C1 [Ramella-Roman, Jessica C.] Catholic Univ Amer, Dept Biomed Engn, Washington, DC 20064 USA. [Nayak, Amritha] NICHD NICHD, Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20817 USA. [Prahl, Scott A.] Providence St Vincent Med Ctr, Oregon Med Laser Ctr, Portland, OR 97225 USA. RP Ramella-Roman, JC (reprint author), Catholic Univ Amer, Dept Biomed Engn, 620 Michigan Ave NE, Washington, DC 20064 USA. EM ramella@cua.edu FU Applied Physics Laboratory, Johns Hopkins, Laurel, Maryland; NIH/NIDCR [1R21DE016758] FX We acknowledge and appreciate the financial support of the Applied Physics Laboratory, Johns Hopkins, Laurel, Maryland. Scott Prahl acknowledges the support of NIH/NIDCR 1R21DE016758. NR 22 TC 6 Z9 6 U1 1 U2 5 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD APR PY 2011 VL 16 IS 4 AR 047001 DI 10.1117/1.3561907 PG 7 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 769PX UT WOS:000291031400029 PM 21529091 ER PT J AU Pchelina, SN Emelyanov, AK Yakimovskii, AF Miller, DW Shabalina, IG Drozdova, AS Schwarzman, AL AF Pchelina, S. N. Emelyanov, A. K. Yakimovskii, A. F. Miller, D. W. Shabalina, I. G. Drozdova, A. S. Schwarzman, A. L. TI Reduced Content of alpha-Synuclein in Peripheral Blood Leukocytes of Patients with LRRK2-Associated Parkinson's Disease SO BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE LA English DT Article DE Parkinson's disease; alpha-synuclein; lymphocytes; leucine-rich kinase 2 ID RUSSIA AB Measurement of alpha-synuclein level in the peripheral blood was proposed as a diagnostic test for Parkinson's disease. However, the results of these studies remain contradictory, probably because the examined samples included patients with different etiology of Parkinson's disease. To verify this assumption we studied the levels of alpha-synuclein in peripheral blood leukocytes of patients with Parkinson's disease associated with mutations in the gene of leucine-rich kinase 2 (LRRK2). The mean alpha-synuclein level was significantly lower in patients with LRRK2-associated Parkinson's disease (N=8) than in patients with sporadic form of the disease (N=33; p<0.02) and in controls (N=18; p<0.05). On the other hand, we found no differences in the level of alpha-synuclein level between patients with sporadic form of the disease and controls. We hypothesize that the level of alpha-synuclein in the peripheral blood largely depends on the etiology of the disease and cannot be used as a universal diagnostic test for Parkinson's disease. C1 [Pchelina, S. N.; Emelyanov, A. K.; Drozdova, A. S.; Schwarzman, A. L.] Russian Acad Sci, BP Konstantinov Petersburg Nucl Phys Inst, Moscow 117901, Russia. [Pchelina, S. N.; Yakimovskii, A. F.; Shabalina, I. G.] St Petersburg State IP Pavlov Med Univ, Minist Hlth Care & Social Dev Russian Federat, St Petersburg, Russia. [Miller, D. W.] NIA, NIH, Bethesda, MD 20892 USA. RP Pchelina, SN (reprint author), Russian Acad Sci, BP Konstantinov Petersburg Nucl Phys Inst, Moscow 117901, Russia. EM sopche-lina@hotmail.com FU Russian Foundation for Basic Researches [09-04-00934-a]; Russian Academy of Sciences FX The study was supported by the Russian Foundation for Basic Researches (grant No. 09-04-00934-a) and Russian Academy of Sciences (Fundamental Sciences to Medicine, 2006). NR 12 TC 3 Z9 3 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0007-4888 J9 B EXP BIOL MED+ JI Bull. Exp. Biol. Med. PD APR PY 2011 VL 150 IS 6 BP 679 EP 681 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 766VF UT WOS:000290813900005 PM 22235415 ER PT J AU Ma, WJ Chen, HL Jiang, LL Song, GX Kan, HD AF Ma, Wenjuan Chen, Honglei Jiang, Lili Song, Guixiang Kan, Haidong TI Stock volatility as a risk factor for coronary heart disease death SO EUROPEAN HEART JOURNAL LA English DT Article DE Coronary heart disease; Stock volatility; Time-series analysis ID ACUTE MYOCARDIAL-INFARCTION; SUDDEN CARDIAC DEATH; TIME-SERIES; MENTAL STRESS; AIR-POLLUTION; CARDIOVASCULAR-DISEASES; ARTERY-DISEASE; DAILY MORTALITY; PUBLIC-HEALTH; GLOBAL BURDEN AB Aims The volatility of financial markets may cause substantial emotional and physical stress among investors. We hypothesize that this may have adverse effects on cardiovascular health. The Chinese stock markets were extremely volatile between 2006 and 2008. We, therefore, examined the relationship between daily change of the Shanghai Stock Exchange (SSE) Composite Index (referred as the Index) and coronary heart disease (CHD) deaths from 1 January 2006 to 31 December 2008 in Shanghai, the financial capital of China. Methods and results Daily death and stock performance data were collected from the Shanghai Center for Disease Control and Prevention and SSE, respectively. Data were analysed with over-dispersed generalized linear Poisson models, controlling for long-term and seasonal trends of CHD mortality, day of the week, Index closing value, weather conditions, and air pollution levels. We observed a U-shaped relationship between the Index change and CHD deaths: both rising and falling of the Index were associated with more deaths and the fewest deaths coincided with little or no change of the index. We also examined the absolute daily change of the Index in relation to CHD deaths: in a 1-day lag model, each 100-point change of the Index corresponded to 5.17% (95% confidence interval: 1.71, 8.63%) increase in CHD deaths. Further analysis showed that the association was stronger for out-of-hospital CHD death than for in-hospital death. Conclusion We found that CHD deaths fluctuated with daily stock changes in Shanghai, suggesting that stock volatility may adversely affect cardiovascular health. C1 [Ma, Wenjuan; Kan, Haidong] Fudan Univ, Sch Publ Hlth, Key Lab Publ Hlth Safety, Minist Educ, Shanghai 200433, Peoples R China. [Ma, Wenjuan; Kan, Haidong] Fudan Univ, Inst Global Environm Change Res, Shanghai 200433, Peoples R China. [Chen, Honglei] NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC USA. [Jiang, Lili] Natl Univ Singapore, Fac Sci, Dept Stat, Singapore 117548, Singapore. [Song, Guixiang] Shanghai Municipal Ctr Dis Control & Prevent, Shanghai, Peoples R China. RP Kan, HD (reprint author), Fudan Univ, Sch Publ Hlth, Key Lab Publ Hlth Safety, Minist Educ, Shanghai 200433, Peoples R China. EM haidongkan@gmail.com OI Chen, Honglei/0000-0003-3446-7779 FU National Basic Research Program (973 program) of China [2011CB503802]; Gong-Yi Program of China Ministry of Environmental Protection [200809109]; National Natural Science Foundation of China [30800892]; Shanghai Pu Jiang Program [09PJ1401700]; Program for New Century Excellent Talents in University [NCET-09-0314]; NIH; National Institute of Environmental Health Sciences [Z01-ES-101986] FX The study was supported by the National Basic Research Program (973 program) of China (2011CB503802), Gong-Yi Program of China Ministry of Environmental Protection (200809109), National Natural Science Foundation of China (30800892), Shanghai Pu Jiang Program (09PJ1401700), and Program for New Century Excellent Talents in University (NCET-09-0314). H. C. was supported by the Intramural Research Program of the NIH, the National Institute of Environmental Health Sciences (Z01-ES-101986). NR 35 TC 11 Z9 11 U1 1 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD APR PY 2011 VL 32 IS 8 BP 1006 EP 1011 DI 10.1093/eurheartj/ehq495 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 750XN UT WOS:000289581600022 PM 21196446 ER PT J AU Otto, M AF Otto, Michael TI Panton-Valentine leukocidin antibodies for the treatment of MRSA skin infections? SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY LA English DT Article DE drug development; MRSA; Panton-Valentine leukocidin; skin infections; Staphylococcus aureus ID RESISTANT STAPHYLOCOCCUS-AUREUS; COMMUNITY-ASSOCIATED MRSA; VIRULENCE DETERMINANTS; NECROTIZING PNEUMONIA; ALPHA-HEMOLYSIN; GENES; INFLAMMATION; EXPRESSION; SEVERITY; STRAINS AB Methicillin-resistant Staphylococcus aureus (MRSA) has recently caused epidemic outbreaks of community-associated (CA) skin infections. The infecting strains frequently contain the genes encoding the staphylococcal toxin, Panton-Valentine leukocidin (PVL). On that ground, the use of PVL-based vaccines has been proposed for the treatment of CA-MRSA infections, despite experimental and epidemiological evidence that does not support a major role of the PVL toxin in CA-MRSA skin disease. Hermos et al. show that antibodies to PVL do not protect from CA-MRSA skin infections in children, strongly suggesting that PVL-based immunization is of little benefit for this most frequent disease caused by CA-MRSA. C1 NIAID, Lab Human Bacterial Pathogenesis, NIH, Bethesda, MD 20926 USA. RP Otto, M (reprint author), NIAID, Lab Human Bacterial Pathogenesis, NIH, Bethesda, MD 20926 USA. EM motto@niaid.nih.gov OI Otto, Michael/0000-0002-2222-4115 FU National Institute of Allergy and Infectious Diseases [Z01 AI000904-06] FX Michael Otto has received funding from the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (Z01 AI000904-06). The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 37 TC 3 Z9 3 U1 1 U2 2 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1478-7210 J9 EXPERT REV ANTI-INFE JI Expert Rev. Anti-Infect. Ther. PD APR PY 2011 VL 9 IS 4 BP 389 EP 392 DI 10.1586/ERI.11.19 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 767FC UT WOS:000290839700009 PM 21504395 ER PT J AU Bode, C Zhao, G Steinhagen, F Kinjo, T Klinman, DM AF Bode, Christian Zhao, Gan Steinhagen, Folkert Kinjo, Takeshi Klinman, Dennis M. TI CpG DNA as a vaccine adjuvant SO EXPERT REVIEW OF VACCINES LA English DT Review DE adjuvant; cancer; CpG oligodeoxynucleotide; immunity; infectious disease; Toll-like receptor; vaccine ID T-CELL RESPONSES; PLASMACYTOID DENDRITIC CELLS; B SURFACE-ANTIGEN; SYSTEMIC-LUPUS-ERYTHEMATOSUS; INDUCE AUTOIMMUNE-DISEASE; NECROSIS-FACTOR-ALPHA; HIV-INFECTED ADULTS; TOLL-LIKE RECEPTORS; BACTERIAL-DNA; IN-VIVO AB Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger cells that express Toll-like receptor 9 (including human plasmacytoid dendritic cells and B cells) to mount an innate immune response characterized by the production of Th1 and proinflammatory cytokines. When used as vaccine adjuvants, CpG ODNs improve the function of professional antigen-presenting cells and boost the generation of humoral and cellular vaccine-specific immune responses. These effects are optimized by maintaining ODNs and vaccine in close proximity. The adjuvant properties of CpG ODNs are observed when administered either systemically or mucosally, and persist in immunocompromised hosts. Preclinical studies indicate that CpG ODNs improve the activity of vaccines targeting infectious diseases and cancer. Clinical trials demonstrate that CpG ODNs have a good safety profile and increase the immunogenicity of coadministered vaccines. C1 [Bode, Christian; Zhao, Gan; Steinhagen, Folkert; Kinjo, Takeshi; Klinman, Dennis M.] NCI, Canc & Inflammat Program, Frederick, MD 21702 USA. RP Klinman, DM (reprint author), NCI, Canc & Inflammat Program, Frederick, MD 21702 USA. EM klinmand@mail.nih.gov FU Intramural NIH HHS [ZIA BC010852-04] NR 143 TC 183 Z9 195 U1 7 U2 62 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1476-0584 J9 EXPERT REV VACCINES JI Expert Rev. Vaccines PD APR PY 2011 VL 10 IS 4 SI SI BP 499 EP 511 DI 10.1586/ERV.10.174 PG 13 WC Immunology SC Immunology GA 767DB UT WOS:000290834400017 PM 21506647 ER PT J AU Ahren, E AF Ahren, Eva TI The Anatomy Murders: Being the True and Spectacular History of Edinburgh's Notorious Burke and Hare and of the Man of Science Who Abetted Them in the Commission of Their Most Heinous Crimes SO JOURNAL OF THE HISTORY OF MEDICINE AND ALLIED SCIENCES LA English DT Book Review C1 [Ahren, Eva] Uppsala Univ, Uppsala, Sweden. [Ahren, Eva] NIH, Hist Off, Bethesda, MD 20892 USA. RP Ahren, E (reprint author), Uppsala Univ, Uppsala, Sweden. EM eva.ahren@idehist.uu.se NR 1 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-5045 J9 J HIST MED ALL SCI JI J. Hist. Med. Allied Sci. PD APR PY 2011 VL 66 IS 2 BP 251 EP 253 DI 10.1093/jhmas/jrq077 PG 3 WC Health Care Sciences & Services; History & Philosophy Of Science SC Health Care Sciences & Services; History & Philosophy of Science GA 764NL UT WOS:000290637100005 ER PT J AU Pekkurnaz, G Fera, A Zimmerberg-Helms, J Degiorgis, JA Bezrukov, L Blank, PS Mazar, J Reese, TS Zimmerberg, J AF Pekkurnaz, Gulcin Fera, Andrea Zimmerberg-Helms, Jessica Degiorgis, Joseph A. Bezrukov, Ludmila Blank, Paul S. Mazar, Julia Reese, Thomas S. Zimmerberg, Joshua TI Isolation and Ultrastructural Characterization of Squid Synaptic Vesicles SO BIOLOGICAL BULLETIN LA English DT Article ID ELECTRON-MICROSCOPY; PROTEINS; SYNAPTOSOMES; PURIFICATION AB Synaptic vesicles contain a variety of proteins and lipids that mediate fusion with the pre-synaptic membrane. Although the structures of many synaptic vesicle proteins are known, an overall picture of how they are organized at the vesicle surface is lacking. In this paper, we describe a better method for the isolation of squid synaptic vesicles and characterize the results. For highly pure and intact synaptic vesicles from squid optic lobe, glycerol density gradient centrifugation was the key step. Different electron microscopic methods show that vesicle membrane surfaces are largely covered with structures corresponding to surface proteins. Each vesicle contains several stalked globular structures that extend from the vesicle surface and are consistent with the V-ATPase. BLAST search of a library of squid expressed sequence tags identifies 10 V-ATPase subunits, which are expressed in the squid stellate ganglia. Negative-stain tomography demonstrates directly that vesicles flatten during the drying step of negative staining, and furthermore shows details of individual vesicles and other proteins at the vesicle surface. C1 [Pekkurnaz, Gulcin; Zimmerberg-Helms, Jessica; Bezrukov, Ludmila; Blank, Paul S.; Mazar, Julia; Zimmerberg, Joshua] NICHHD, NIH, Bethesda, MD 20892 USA. [Pekkurnaz, Gulcin; Fera, Andrea; Zimmerberg-Helms, Jessica; Degiorgis, Joseph A.; Mazar, Julia; Reese, Thomas S.; Zimmerberg, Joshua] Marine Biol Lab, Woods Hole, MA 02543 USA. [Fera, Andrea; Degiorgis, Joseph A.; Reese, Thomas S.] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA. [Degiorgis, Joseph A.] Providence Coll, Dept Biol, Providence, RI 02918 USA. RP Zimmerberg, J (reprint author), NICHHD, NIH, Bethesda, MD 20892 USA. EM joshz@mail.nih.gov FU National Center for Research Resources (NCRR), NIH [P20RR016457-10] FX We are grateful to Jane Farrington for examining fractions in the electron microscope, and Dr. Harish Pant for teaching us the optic lobe dissection and homogenization. JAD is supported by the RI-INBRE program award # P20RR016457-10 from the National Center for Research Resources (NCRR), NIH. NR 18 TC 3 Z9 3 U1 0 U2 2 PU MARINE BIOLOGICAL LABORATORY PI WOODS HOLE PA 7 MBL ST, WOODS HOLE, MA 02543 USA SN 0006-3185 EI 1939-8697 J9 BIOL BULL-US JI Biol. Bull. PD APR PY 2011 VL 220 IS 2 BP 89 EP 96 PG 8 WC Biology; Marine & Freshwater Biology SC Life Sciences & Biomedicine - Other Topics; Marine & Freshwater Biology GA 763YS UT WOS:000290596200003 PM 21551445 ER PT J AU Chan, PYS von Leupoldt, A Bradley, MM Lang, PJ Davenport, PW AF Chan, Pei-Ying S. von Leupoldt, Andreas Bradley, Margret M. Lang, Peter J. Davenport, Paul W. TI The effect of anxiety on respiratory sensory gating measured by the respiratory-related evoked potential (RREP) SO BIOLOGICAL PSYCHOLOGY LA English DT Meeting Abstract CT 17th Annual Meeting of the International-Society-for-the-Advancement-of-Respiratory-Psychophysiolog y CY SEP 26-27, 2010 CL New York, NY SP Int Soc Advancement Respiratory Psychophysiol C1 [Chan, Pei-Ying S.] Chang Gung Univ, Dept Occupat Therapy, Tao Yuan, Taiwan. [Chan, Pei-Ying S.; von Leupoldt, Andreas; Davenport, Paul W.] Univ Florida, Coll Vet Med, Dept Physiol Sci, Gainesville, FL 32610 USA. [von Leupoldt, Andreas] Univ Hamburg, Dept Psychol, Hamburg, Germany. [von Leupoldt, Andreas; Bradley, Margret M.; Lang, Peter J.] Univ Florida, NIMH, Ctr Study Emot & Attent, Gainesville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0301-0511 J9 BIOL PSYCHOL JI Biol. Psychol. PD APR PY 2011 VL 87 IS 1 BP 175 EP 176 PG 2 WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental SC Psychology; Behavioral Sciences GA 758VL UT WOS:000290195100045 ER PT J AU von Leupoldt, A Chan, PYS Bradley, MM Lang, PJ Davenport, PW AF von Leupoldt, Andreas Chan, Pei-Ying S. Bradley, Margaret M. Lang, Peter J. Davenport, Paul W. TI The impact of anxiety on the neural processing of short inspiratory occlusions SO BIOLOGICAL PSYCHOLOGY LA English DT Meeting Abstract CT 17th Annual Meeting of the International-Society-for-the-Advancement-of-Respiratory-Psychophysiolog y CY SEP 26-27, 2010 CL New York, NY SP Int Soc Advancement Respiratory Psychophysiol C1 [von Leupoldt, Andreas; Chan, Pei-Ying S.; Davenport, Paul W.] Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA. [von Leupoldt, Andreas] Univ Hamburg, Dept Psychol, Hamburg, Germany. [von Leupoldt, Andreas] Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, Hamburg, Germany. [von Leupoldt, Andreas; Bradley, Margaret M.; Lang, Peter J.] Univ Florida, NIMH, Ctr Study Emot & Attent, Gainesville, FL USA. [Chan, Pei-Ying S.] Chang Gung Univ, Dept Occupat Therapy, Tao Yuan, Taiwan. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0301-0511 J9 BIOL PSYCHOL JI Biol. Psychol. PD APR PY 2011 VL 87 IS 1 BP 175 EP 175 PG 1 WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental SC Psychology; Behavioral Sciences GA 758VL UT WOS:000290195100044 ER PT J AU Baumann, MH Williams, Z Zolkowska, D Rothman, RB AF Baumann, Michael H. Williams, Zakia Zolkowska, Dorota Rothman, Richard B. TI Serotonin (5-HT) precursor loading with 5-hydroxy-L-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Amphetamine; 5-Hydroxy-L-tryptophan; Cocaine; Drug addiction; Dopamine; Serotonin ID COCAINE-DEPENDENCE; NUCLEUS-ACCUMBENS; D-AMPHETAMINE; DOUBLE-BLIND; AGONIST-LIKE; DOPAMINE; FENFLURAMINE; L-5-HYDROXYTRYPTOPHAN; PHARMACOTHERAPY; RECEPTORS AB Background: Evidence suggests that increases in synaptic serotonin (5-HT) can reduce the stimulant properties of amphetamine-type drugs. Here we tested the hypothesis that administration of the 5-HT precursor 5-hydroxy-L-tryptophan (5-HTP), along with the peripheral decarboxylase inhibitor benserazide, would decrease locomotor effects of (+)-amphetamine. Methods: Drug treatments were administered to conscious male rats undergoing in vivo microdialysis in nucleus accumbens. During dialysis sampling, rats were housed in chambers equipped with photobeams to detect forward locomotion (i.e., ambulation) and repetitive movements (i.e., stereotypy). Extracellular concentrations of dopamine (DA) and 5-HT were measured by high-pressure liquid chromatography with electrochemical detection. Results: 5-HIP (10 & 30 mg/kg, i.p.) plus benserazide (30 mg/kg, i.p.) caused dose-related increases in 5-HT but failed to alter other parameters. (+)-Amphetamine (0.3 & 1.0 mg/kg, i.p.) produced dose-related increases in DA, ambulation and stereotypy. Combined administration of 5-HTP and (+)-amphetamine evoked large elevations in extracellular DA and 5-HT, but caused significantly less ambulation than (+)amphetamine alone (similar to 50% reduction). Conclusions: Our results confirm that 5-HIP can decrease hyperactivity produced by (+)-amphetamine, even in the presence of elevations in dialysate DA. The data suggest that 5-HTP and (+)-amphetamine may be useful to broadly enhance monoamine function in the clinical setting, while reducing undesirable effects of (+)-amphetamine. Published by Elsevier Ireland Ltd. C1 [Baumann, Michael H.; Williams, Zakia; Zolkowska, Dorota; Rothman, Richard B.] NIDA, IRP, NIH, Clin Psychopharmacol Sect, Baltimore, MD 21224 USA. RP Rothman, RB (reprint author), NIDA, IRP, NIH, Clin Psychopharmacol Sect, Suite 4500,Triad Bldg,333 Cassell Dr, Baltimore, MD 21224 USA. EM rrothman@mail.nih.gov FU National Institute on Drug Abuse (NIDA) FX Funding for this study was generously provided by the Intramural Research Program (IRP) of the National Institute on Drug Abuse (NIDA): NIDA had no further role in study design, data collection, or analysis and interpretation of the data; in writing the report; or in the decision to submit the paper for publication. NR 42 TC 11 Z9 12 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2011 VL 114 IS 2-3 BP 147 EP 152 DI 10.1016/j.drugalcdep.2010.09.015 PG 6 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 759XO UT WOS:000290283000008 PM 21071157 ER PT J AU Janssens, ACJW Ioannidis, JPA Bedrosian, S Boffetta, P Dolan, SM Dowling, N Fortier, I Freedman, AN Grimshaw, JM Gulcher, J Gwinn, M Hlatky, MA Janes, H Kraft, P Melillo, S O'Donnell, CJ Pencina, MJ Ransohoff, D Schully, SD Seminara, D Winn, DM Wright, CF van Duijn, CM Little, J Khoury, MJ AF Janssens, A. Cecile J. W. Ioannidis, John P. A. Bedrosian, Sara Boffetta, Paolo Dolan, Siobhan M. Dowling, Nicole Fortier, Isabel Freedman, Andrew N. Grimshaw, Jeremy M. Gulcher, Jeffrey Gwinn, Marta Hlatky, Mark A. Janes, Holly Kraft, Peter Melillo, Stephanie O'Donnell, Christopher J. Pencina, Michael J. Ransohoff, David Schully, Sheri D. Seminara, Daniela Winn, Deborah M. Wright, Caroline F. van Duijn, Cornelia M. Little, Julian Khoury, Muin J. TI Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration SO EUROPEAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Genetic; Risk prediction; Methodology; Guidelines; Reporting ID GENOME-WIDE ASSOCIATION; HEART-DISEASE RISK; OPERATING CHARACTERISTIC CURVE; TYPE-2 DIABETES RISK; RECLASSIFICATION MEASURES; MACULAR DEGENERATION; DIAGNOSTIC-ACCURACY; CARDIOVASCULAR RISK; CONTROLLED-TRIALS; PROSTATE-CANCER AB The rapid and continuing progress in gene discovery for complex diseases is fuelling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but they vary widely in completeness of reporting and apparent quality. Transparent reporting of the strengths and weaknesses of these studies is important to facilitate the accumulation of evidence on genetic risk prediction. A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS), building on the principles established by prior reporting guidelines. These recommendations aim to enhance the transparency, quality and completeness of study reporting, and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct or analysis. C1 [Janssens, A. Cecile J. W.; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands. [Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece. [Ioannidis, John P. A.] Fdn Res & Technol, Biomed Res Inst, Ioannina, Greece. [Ioannidis, John P. A.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Ioannidis, John P. A.] Tufts Med Ctr, Ctr Genet Epidemiol & Modeling, Inst Clin Res & Hlth Policy Studies, Boston, MA USA. [Ioannidis, John P. A.] Tufts Med Ctr, Tufts CTSI, Inst Clin Res & Hlth Policy Studies, Boston, MA USA. [Ioannidis, John P. A.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA. [Bedrosian, Sara; Dowling, Nicole; Gwinn, Marta; Melillo, Stephanie; Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Boffetta, Paolo] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA. [Boffetta, Paolo] Int Prevent Res Inst, Lyon, France. [Dolan, Siobhan M.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10467 USA. [Fortier, Isabel] Publ Populat Project Genom P3G, Montreal, PQ, Canada. [Freedman, Andrew N.; Schully, Sheri D.; Seminara, Daniela; Winn, Deborah M.] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Grimshaw, Jeremy M.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada. [Grimshaw, Jeremy M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada. [Gulcher, Jeffrey] DeCODE Genet, Reykjavik, Iceland. [Hlatky, Mark A.] Stanford Univ, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA. [Janes, Holly] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Inst, Seattle, WA 98104 USA. [Janes, Holly] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [O'Donnell, Christopher J.] NHLBI, Framingham, MA USA. [O'Donnell, Christopher J.] NHLBIs Framingham Heart Study, Framingham, MA USA. [O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. [Pencina, Michael J.] Boston Univ, Dept Biostat, Boston, MA 02215 USA. [Pencina, Michael J.] Harvard Clin Res Inst, Boston, MA USA. [Ransohoff, David] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Wright, Caroline F.] PHG Fdn, Cambridge, England. [Little, Julian] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. RP Janssens, ACJW (reprint author), Erasmus MC, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands. EM a.janssens@erasmusmc.nl RI Ioannidis, John/G-9836-2011; janssens, cecile/L-1075-2015; OI Janssens, A Cecile/0000-0002-6153-4976; Wright, Caroline/0000-0003-2958-5076 FU NCI NIH HHS [U24 CA086368, U24 CA086368-11] NR 93 TC 10 Z9 10 U1 0 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0393-2990 J9 EUR J EPIDEMIOL JI Eur. J. Epidemiol. PD APR PY 2011 VL 26 IS 4 BP 313 EP 337 DI 10.1007/s10654-011-9551-z PG 25 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 760ON UT WOS:000290333700009 PM 21424820 ER PT J AU Chernoff, N Rogers, EH Zehr, RD Gage, MI Malarkey, DE Bradfield, CA Liu, Y Schmid, JE Jaskot, RH Richards, JH Wood, CR Rosen, MB AF Chernoff, N. Rogers, E. H. Zehr, R. D. Gage, M. I. Malarkey, D. E. Bradfield, C. A. Liu, Y. Schmid, J. E. Jaskot, R. H. Richards, J. H. Wood, C. R. Rosen, M. B. TI Toxicity and recovery in the pregnant mouse after gestational exposure to the cyanobacterial toxin, cylindrospermopsin SO JOURNAL OF APPLIED TOXICOLOGY LA English DT Article DE cylindrospermopsin; cyanobacteria; toxicity; mouse; serum chemistries; gene expression ID PROTEIN-SYNTHESIS INHIBITION; ISLAND MYSTERY DISEASE; FACTOR-X DEFICIENCY; SWISS ALBINO MICE; 2 GERMAN LAKES; GENE-EXPRESSION; RACIBORSKII CYANOBACTERIA; 1ST REPORT; IN-VIVO; CYANOTOXIN CYLINDROSPERMOPSIN AB Cylindrospermopsin (CYN) is a tricyclic alkaloid toxin produced by fresh water cyanobacterial species worldwide. CYN has been responsible for both livestock and human poisoning after oral exposure. This study investigated the toxicity of CYN to pregnant mice exposed during different segments of gestation. The course of recovery and individual responses to the toxin were evaluated. Adverse effects of CYN were monitored up to 7 weeks post-dosing by clinical examination, histopathology, biochemistry and gene expression. Exposure on gestational days (GD) 8-12 induced significantly more lethality than GD13-17 exposure. Periorbital, gastrointestinal and distal tail hemorrhages were seen in both groups. Serum markers indicative of hepatic injury (alanine amino transferase, aspartate amino transferase and sorbitol dehydrogenase) were increased in both groups; markers of renal dysfunction (blood urea nitrogen and creatinine) were elevated in the GD8-12 animals. Histopathology was observed in the liver (centrilobular necrosis) and kidney (interstitial inflammation) in groups exhibiting abnormal serum markers. The expression profiles of genes involved in ribosomal biogenesis, xenobiotic and lipid metabolism, inflammatory response and oxidative stress were altered 24 h after the final dose. One week after dosing, gross, histological and serum parameters had returned to normal, although increased liver/body weight ratio and one instance of gastrointestinal bleeding was found in the GD13-17 group. Gene expression changes persisted up to 2 weeks post-dosing and returned to normal by 4 weeks. Responses of individual animals to CYN exposure indicated highly significant inter-animal variability within the treated groups. Copyright (C) 2010 John Wiley & Sons, Ltd. C1 [Chernoff, N.; Rogers, E. H.; Zehr, R. D.; Gage, M. I.; Schmid, J. E.; Jaskot, R. H.; Richards, J. H.; Wood, C. R.; Rosen, M. B.] US EPA, ORD, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA. [Malarkey, D. E.] NIEHS, Cellular & Mol Pathol Branch, Res Triangle Pk, NC 27709 USA. [Bradfield, C. A.; Liu, Y.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53711 USA. RP Chernoff, N (reprint author), US EPA, ORD, Natl Hlth & Environm Effects Res Lab, MD 67, Res Triangle Pk, NC 27711 USA. EM chernoff.neil@epa.gov FU US Environmental Protection Agency; NIH [ES012752, CA014520]; NIH, National Institute of Environmental Health Sciences FX We would like to thank Dr Carin Vanderklok, North Carolina State University School of Veterinary Medicine for assistance with the histological analyses. The information in this document has been funded by the US Environmental Protection Agency. It has been subject to review by the National Health and Environmental Effects Research Laboratory and approved for publication. Approval does not signify that the contents reflect the views of the Agency, nor does mention of trade names or commercial products constitute endorsement or recommendation for use. Drs Bradfield and Liu are supported by NIH grant numbers ES012752 and CA014520. The histological analysis was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences. NR 71 TC 12 Z9 12 U1 4 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0260-437X J9 J APPL TOXICOL JI J. Appl. Toxicol. PD APR PY 2011 VL 31 IS 3 BP 242 EP 254 DI 10.1002/jat.1586 PG 13 WC Toxicology SC Toxicology GA 759ZQ UT WOS:000290290800006 PM 20936652 ER PT J AU Lee, JH Lee, Y Ryu, H Kang, DW Lee, J Lazar, J Pearce, LV Pavlyukovets, VA Blumberg, PM Choi, S AF Lee, Jin Hee Lee, Yoonji Ryu, HyungChul Kang, Dong Wook Lee, Jeewoo Lazar, Jozsef Pearce, Larry V. Pavlyukovets, Vladimir A. Blumberg, Peter M. Choi, Sun TI Structural insights into transient receptor potential vanilloid type 1 (TRPV1) from homology modeling, flexible docking, and mutational studies SO JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN LA English DT Article DE Transient receptor potential vanilloid type 1 (TRPV1); Homology modeling; Docking; Mutation; Capsaicin; Resiniferatoxin (RTX) ID PROTEIN STRUCTURES; RESINIFERATOXIN; SENSITIVITY; ANTAGONISTS; CAPSAICIN; CHANNEL; ANALGESICS; AGONISTS AB The transient receptor potential vanilloid subtype 1 (TRPV1) is a non-selective cation channel composed of four monomers with six transmembrane helices (TM1-TM6). TRPV1 is found in the central and peripheral nervous system, and it is an important therapeutic target for pain relief. We describe here the construction of a tetrameric homology model of rat TRPV1 (rTRPV1). We experimentally evaluated by mutational analysis the contribution of residues of rTRPV1 contributing to ligand binding by the prototypical TRPV1 agonists, capsaicin and resiniferatoxin (RTX). We then performed docking analysis using our homology model. The docking results with capsaicin and RTX showed that our homology model was reliable, affording good agreement with our mutation data. Additionally, the binding mode of a simplified RTX (sRTX) ligand as predicted by the modeling agreed well with those of capsaicin and RTX, accounting for the high binding affinity of the sRTX ligand for TRPV1. Through the homology modeling, docking and mutational studies, we obtained important insights into the ligand-receptor interactions at the molecular level which should prove of value in the design of novel TRPV1 ligands. C1 [Lee, Jin Hee; Lee, Yoonji; Choi, Sun] Ewha Womans Univ, Coll Pharm, Div Life & Pharmaceut Sci, Seoul 120750, South Korea. [Lee, Jin Hee; Lee, Yoonji; Choi, Sun] Ewha Womans Univ, Natl Core Res Ctr Cell Signaling & Drug Discovery, Seoul 120750, South Korea. [Ryu, HyungChul; Kang, Dong Wook; Lee, Jeewoo] Seoul Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, Seoul 151742, South Korea. [Lazar, Jozsef; Pearce, Larry V.; Pavlyukovets, Vladimir A.; Blumberg, Peter M.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP Choi, S (reprint author), Ewha Womans Univ, Coll Pharm, Div Life & Pharmaceut Sci, Seoul 120750, South Korea. EM sunchoi@ewha.ac.kr FU Ministry of Education, Science and Technology (MEST) [R01-2007-000-20052-0]; National Research Foundation of Korea (NRF); National Core Research Center (NCRC) of MEST; NRF through the Center for Cell Signaling & Drug Discovery Research at Ewha Womans University; National Institutes of Health, Center for Cancer Research, National Cancer Institute FX This research was supported by Grants R01-2007-000-20052-0 from the Ministry of Education, Science and Technology (MEST) and National Research Foundation of Korea (NRF) (to J. Lee and S. Choi), the National Core Research Center (NCRC) program (R15-2006-020) of MEST and NRF through the Center for Cell Signaling & Drug Discovery Research at Ewha Womans University (to S. Choi), and the Intramural Research Program of the National Institutes of Health, Center for Cancer Research, National Cancer Institute (to P. M. Blumberg). NR 25 TC 36 Z9 36 U1 0 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0920-654X J9 J COMPUT AID MOL DES JI J. Comput.-Aided Mol. Des. PD APR PY 2011 VL 25 IS 4 BP 317 EP 327 DI 10.1007/s10822-011-9421-5 PG 11 WC Biochemistry & Molecular Biology; Biophysics; Computer Science, Interdisciplinary Applications SC Biochemistry & Molecular Biology; Biophysics; Computer Science GA 763QZ UT WOS:000290576100003 PM 21448716 ER PT J AU Deflorian, F Jacobson, KA AF Deflorian, Francesca Jacobson, Kenneth A. TI Comparison of three GPCR structural templates for modeling of the P2Y(12) nucleotide receptor SO JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN LA English DT Article DE G protein-coupled receptor; Nucleotides; Purines; Homology modeling; Docking; Antithrombotic drugs ID PROTEIN-COUPLED RECEPTORS; CRYSTAL-STRUCTURE; ACTIVE METABOLITE; ACTIVATION; ANTAGONISTS; RECOGNITION; RHODOPSIN; THERAPY; AGONIST; CCR5 AB The P2Y(12) receptor (P2Y(12)R) is an ADP-activated G protein-coupled receptor (GPCR) that is an important target for antithrombotic drugs. Three homology models of P2Y(12)R were compared, based on different GPCR structural templates: bovine rhodopsin (bRHO), human A(2A) adenosine receptor (A(2A)AR), and human C-X-C chemokine receptor type 4 (CXCR4). By criteria of sequence analysis (25.6% identity in transmembrane region), deviation from helicity in the second transmembrane helix (TM2), docked poses of ligands highlighting the role of key residues, accessibility of a conserved disulfide bridge that is reactive toward irreversibly-binding antagonists, and the presence of a shared disulfide bridge between the third extracellular loop (EL3) and the N-terminus, the CXCR4-based model appeared to be the most consistent with known characteristics of P2Y(12)R. The docked poses of agonist 2MeSADP and charged anthraquinone antagonist PSB-0739 in the binding pocket of P2Y(12)R-CXC agree with previously published site-directed mutagenesis studies of Arg256 and Lys280. A sulfonate at position 2 of the anthraquinone core created a strong interaction with the Lys174(EL2) side chain. The docking poses of the irreversibly-binding, active metabolite (existing as two diastereoisomers in vivo) of the clinically utilized antagonist Clopidogrel were compared. The free thiol group of the 4S diastereoisomer, but not the 4R isomer, was found in close proximity (similar to 4.7 ) to the sulfur atom of a disulfide bridge involving Cys175, suggesting greater activity in covalent binding. Therefore, ligand docking to the CXCR4-based model of the P2Y(12)R predicted poses of both reversibly and irreversibly-binding small molecules, consistent with observed pharmacology and mutagenesis studies. C1 [Deflorian, Francesca; Jacobson, Kenneth A.] NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA. RP Jacobson, KA (reprint author), NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A 19, Bethesda, MD 20892 USA. EM kajacobs@helix.nih.gov RI Jacobson, Kenneth/A-1530-2009 OI Jacobson, Kenneth/0000-0001-8104-1493 FU NIH, NIDDK FX We thank Dr. Stefano Costanzi (NIDDK) and Dr. David Erlinge (Lund University, Lund, Sweden) for helpful discussion. This research was supported by the Intramural Research Program of the NIH, NIDDK. NR 34 TC 20 Z9 20 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0920-654X J9 J COMPUT AID MOL DES JI J. Comput.-Aided Mol. Des. PD APR PY 2011 VL 25 IS 4 BP 329 EP 338 DI 10.1007/s10822-011-9423-3 PG 10 WC Biochemistry & Molecular Biology; Biophysics; Computer Science, Interdisciplinary Applications SC Biochemistry & Molecular Biology; Biophysics; Computer Science GA 763QZ UT WOS:000290576100004 PM 21461952 ER PT J AU Sabunciyan, S Mandelberg, N Rabkin, CS Yolken, R Viscidi, R AF Sabunciyan, Sarven Mandelberg, Nataniel Rabkin, Charles S. Yolken, Robert Viscidi, Raphael TI No difference in antibody titers against xenotropic MLV related virus in prostate cancer cases and cancer-free controls SO MOLECULAR AND CELLULAR PROBES LA English DT Article DE XMRV; Prostate cancer; Virus; Xenotropic murine leukemia; Virus-related virus; ELISA; Epidemiology ID TUMORS AB New ELISA assays were developed to measure immunoreactivity for XMRV. Antibody titers were measured in a cohort of prostate cancer cases and cancer free controls from the central United States. No statistically significant differences were observed in immunoreactivity between cases and controls for either the XMRV-env or the XMRV-gag antigen. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Sabunciyan, Sarven; Mandelberg, Nataniel; Yolken, Robert; Viscidi, Raphael] Johns Hopkins Univ, Dept Pediat, Stanley Div Dev Virol, Baltimore, MD 21287 USA. [Sabunciyan, Sarven] Johns Hopkins Univ, Sch Med, Ctr Epigenet, Baltimore, MD 21287 USA. [Rabkin, Charles S.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. RP Sabunciyan, S (reprint author), Johns Hopkins Univ, Dept Pediat, Stanley Div Dev Virol, 600 N Wolfe St,Blalock 1147, Baltimore, MD 21287 USA. EM ssabuncl@jhmi.edu FU Stanley Medical Research Institute FX The authors would like to thank Dr. William Switzer who kindly sent us the anti-sera necessary for assay validation. This research was funded by the Stanley Medical Research Institute. NR 7 TC 7 Z9 9 U1 0 U2 1 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0890-8508 J9 MOL CELL PROBE JI Mol. Cell. Probes PD APR-JUN PY 2011 VL 25 IS 2-3 BP 134 EP 136 DI 10.1016/j.mcp.2011.01.005 PG 3 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Cell Biology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Cell Biology GA 764DR UT WOS:000290609100011 PM 21281710 ER PT J AU Cornelis, MC Monda, KL Yu, K Paynter, N Azzato, EM Bennett, SN Berndt, SI Boerwinkle, E Chanock, S Chatterjee, N Couper, D Curhan, G Heiss, G Hu, FB Hunter, DJ Jacobs, K Jensen, MK Kraft, P Landi, MT Nettleton, JA Purdue, MP Rajaraman, P Rimm, EB Rose, LM Rothman, N Silverman, D Stolzenberg-Solomon, R Subar, A Yeager, M Chasman, DI van Dam, RM Caporaso, NE AF Cornelis, Marilyn C. Monda, Keri L. Yu, Kai Paynter, Nina Azzato, Elizabeth M. Bennett, Siiri N. Berndt, Sonja I. Boerwinkle, Eric Chanock, Stephen Chatterjee, Nilanjan Couper, David Curhan, Gary Heiss, Gerardo Hu, Frank B. Hunter, David J. Jacobs, Kevin Jensen, Majken K. Kraft, Peter Landi, Maria Teresa Nettleton, Jennifer A. Purdue, Mark P. Rajaraman, Preetha Rimm, Eric B. Rose, Lynda M. Rothman, Nathaniel Silverman, Debra Stolzenberg-Solomon, Rachael Subar, Amy Yeager, Meredith Chasman, Daniel I. van Dam, Rob M. Caporaso, Neil E. TI Genome-Wide Meta-Analysis Identifies Regions on 7p21 (AHR) and 15q24 (CYP1A2) As Determinants of Habitual Caffeine Consumption SO PLOS GENETICS LA English DT Article ID FOOD FREQUENCY QUESTIONNAIRE; ASSOCIATION; POLYMORPHISMS; RECEPTOR; REPRODUCIBILITY; ACTIVATION; VALIDITY; HEALTH; COFFEE; GENES AB We report the first genome-wide association study of habitual caffeine intake. We included 47,341 individuals of European descent based on five population-based studies within the United States. In a meta-analysis adjusted for age, sex, smoking, and eigenvectors of population variation, two loci achieved genome-wide significance: 7p21 (P = 2.4x10(-19)), near AHR, and 15q24 (P = 5.2x10(-14)), between CYP1A1 and CYP1A2. Both the AHR and CYP1A2 genes are biologically plausible candidates as CYP1A2 metabolizes caffeine and AHR regulates CYP1A2. C1 [Cornelis, Marilyn C.; Hu, Frank B.; Hunter, David J.; Jensen, Majken K.; Rimm, Eric B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Monda, Keri L.; Heiss, Gerardo] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Yu, Kai; Azzato, Elizabeth M.; Berndt, Sonja I.; Chanock, Stephen; Chatterjee, Nilanjan; Jacobs, Kevin; Landi, Maria Teresa; Purdue, Mark P.; Rajaraman, Preetha; Rothman, Nathaniel; Silverman, Debra; Stolzenberg-Solomon, Rachael; Subar, Amy; Yeager, Meredith; Caporaso, Neil E.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Curhan, Gary] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Couper, David] Univ Washington, Dept Biostat, Collaborat Studies Coordinating Ctr, Seattle, WA 98195 USA. [Boerwinkle, Eric; Nettleton, Jennifer A.] Univ Texas Hlth Sci Ctr Houston, Div Epidemiol Human Genet & Environm Sci, Houston, TX USA. [Kraft, Peter] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA 02115 USA. [van Dam, Rob M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Epidemiol & Publ Hlth, Singapore 117595, Singapore. [van Dam, Rob M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore. RP Cornelis, MC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. EM dchasman@rics.bwh.harvard.edu; ephrmvd@nus.edu.sg; caporasn@mail.nih.gov RI van Dam, Rob/F-9674-2010; Purdue, Mark/C-9228-2016 OI van Dam, Rob/0000-0002-7354-8734; Purdue, Mark/0000-0003-1177-3108 FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, R01HL087641, R01HL59367, R01HL086694, HL 043851, HL69757]; National Human Genome Research Institute [U01HG004402]; NIH [HSN268200625226C, UL1RR025005, HHSN268200782096C, HL35464, CA55075]; NCI [CA 40356, U01-CA98233, P01CA087969, P01CA055075, CA 047988]; NIH Genes, Environment, and Health Initiative (GEI) [U01HG004402, U01HG004738, U01HG004422, U01HG004729, U01HG004726, 01HG004735, U01HG004415, U01HG004436, U01HG004423, U01HG004728, AHG006033, U01HG004438]; NIH Institute, NIDCR [U01DE018993, U01DE018903]; NIH Institute, NIAAA [U10AA008401]; NIH Institute, NIDA [P01CA089392, 01DA013423]; NIH Institute, NCI [CA63464, CA54281, CA136792, Z01CP010200]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK058845, 5P01DK070756]; Division of Cancer Epidemiology and Genetics; Division of Cancer Prevention, National Cancer Institute, NIH, DHHS; Donald W. Reynolds Foundation; Fondation Leducq; Amgen; Canadian Institutes of Health Research FX ARIC is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute (NHLBI) contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research Institute contract U01HG004402; and NIH contract HSN268200625226C. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the NIH and NIH Roadmap for Medical Research. The NHS Breast Cancer GW scan was performed as part of the Cancer Genetic Markers of Susceptibility initiative of the NCI. We particularly acknowledge the contributions of R. Hoover, A. Hutchinson, K. Jacobs, and G. Thomas. The current research is supported by CA 40356 and U01-CA98233 from the NCI. The NHS/HPFS type 2 diabetes GWAS (U01HG004399) is a component of a collaborative project that includes 13 other GWAS funded as part of the Gene Environment-Association Studies (GENEVA) under the NIH Genes, Environment, and Health Initiative (GEI) (U01HG004738, U01HG004422, U01HG004402, U01HG004729, U01HG004726, 01HG004735, U01HG004415, U01HG004436, U01HG004423, U01HG004728, AHG006033) with additional support from individual NIH Institutes (NIDCR: U01DE018993, U01DE018903; NIAAA: U10AA008401; NIDA: P01CA089392, 01DA013423; NCI: CA63464, CA54281, CA136792, Z01CP010200). Assistance with genotype cleaning and general study coordination, was provided by the GENEVA Coordinating Center (U01HG004446). Assistance with data cleaning was provided by the NCBI. Genotyping was performed at the Broad Institute of MIT and Harvard, with funding support from the NIH GEI (U01HG04424), and Johns Hopkins University Center for Inherited Disease Research, with support from the NIH GEI (U01HG004438) and the NIH contract "High throughput genotyping for studying the genetic contributions to human disease" (HHSN268200782096C). Additional funding for the current research was provided by the NCI (P01CA087969, P01CA055075) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, R01DK058845). The NHS/HPFS CHD GWAS was supported by HL35464 and CA55075 from the NIH with additional support for genotyping from Merck/Rosetta Research Laboratories, North Wales, PA. The NHS/HPFS Kidney GWAS was supported by NIDDK: 5P01DK070756. PLCO was supported the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS. The WGHS is supported by HL 043851 and HL69757 from the NHLBI and CA 047988 from the NCI, the Donald W. Reynolds Foundation, and the Fondation Leducq, with collaborative scientific support and funding for genotyping provided by Amgen. MCC is a recipient of a Canadian Institutes of Health Research Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 71 Z9 73 U1 1 U2 18 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD APR PY 2011 VL 7 IS 4 AR e1002033 DI 10.1371/journal.pgen.1002033 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 755YI UT WOS:000289977000023 PM 21490707 ER PT J AU Ma, WJ Westmoreland, JW Gordenin, DA Resnick, MA AF Ma, Wenjian Westmoreland, Jim W. Gordenin, Dmitry A. Resnick, Mike A. TI Alkylation Base Damage Is Converted into Repairable Double-Strand Breaks and Complex Intermediates in G2 Cells Lacking AP Endonuclease SO PLOS GENETICS LA English DT Article ID SISTER-CHROMATID EXCHANGE; DNA METHYLATION DAMAGE; SACCHAROMYCES-CEREVISIAE; ABASIC SITES; EXCISION-REPAIR; BIOLOGICAL CONSEQUENCES; ESCHERICHIA-COLI; MAMMALIAN-CELLS; TOPOISOMERASE-I; YEAST AB DNA double-strand breaks (DSBs) are potent sources of genome instability. While there is considerable genetic and molecular information about the disposition of direct DSBs and breaks that arise during replication, relatively little is known about DSBs derived during processing of single-strand lesions, especially for the case of single-strand breaks (SSBs) with 39-blocked termini generated in vivo. Using our recently developed assay for detecting end-processing at random DSBs in budding yeast, we show that single-strand lesions produced by the alkylating agent methyl methanesulfonate (MMS) can generate DSBs in G2-arrested cells, i.e., S-phase independent. These derived DSBs were observed in apn1/2 endonuclease mutants and resulted from aborted base excision repair leading to 39 blocked single-strand breaks following the creation of abasic (AP) sites. DSB formation was reduced by additional mutations that affect processing of AP sites including ntg1, ntg2, and, unexpectedly, ogg1, or by a lack of AP sites due to deletion of the MAG1 glycosylase gene. Similar to direct DSBs, the derived DSBs were subject to MRX (Mre11, Rad50, Xrs2)-determined resection and relied upon the recombinational repair genes RAD51, RAD52, as well as on the MCD1 cohesin gene, for repair. In addition, we identified a novel DNA intermediate, detected as slow-moving chromosomal DNA (SMD) in pulsed field electrophoresis gels shortly after MMS exposure in apn1/2 cells. The SMD requires nicked AP sites, but is independent of resection/recombination processes, suggesting that it is a novel structure generated during processing of 39-blocked SSBs. Collectively, this study provides new insights into the potential consequences of alkylation base damage in vivo, including creation of novel structures as well as generation and repair of DSBs in nonreplicating cells. C1 [Ma, Wenjian; Westmoreland, Jim W.; Gordenin, Dmitry A.; Resnick, Mike A.] NIEHS, Chromosome Stabil Grp, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA. RP Ma, WJ (reprint author), NIEHS, Chromosome Stabil Grp, Mol Genet Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA. EM resnick@niehs.nih.gov RI Ma, Wenjian/C-1071-2012; OI Gordenin, Dmitry/0000-0002-8399-1836 FU NIEHS (NIH, DHHS) [1Z01ES021016] FX This work was supported by the Intramural Research Program of the NIEHS (NIH, DHHS) under project 1Z01ES021016 to MAR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 62 TC 17 Z9 17 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD APR PY 2011 VL 7 IS 4 AR e1002059 DI 10.1371/journal.pgen.1002059 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA 755YI UT WOS:000289977000005 PM 21552545 ER PT J AU Pare, G Ridker, PM Rose, L Barbalic, M Dupuis, J Dehghan, A Bis, JC Benjamin, EJ Shiffman, D Parker, AN Chasman, DI AF Pare, Guillaume Ridker, Paul M. Rose, Lynda Barbalic, Maja Dupuis, Josee Dehghan, Abbas Bis, Joshua C. Benjamin, Emelia J. Shiffman, Dov Parker, Alexander N. Chasman, Daniel I. TI Genome-Wide Association Analysis of Soluble ICAM-1 Concentration Reveals Novel Associations at the NFKBIK, PNPLA3, RELA, and SH2B3 Loci SO PLOS GENETICS LA English DT Article ID INTERCELLULAR-ADHESION MOLECULE-1; NF-KAPPA-B; TRANSCRIPTIONAL REGULATION; MYOCARDIAL-INFARCTION; CIRCULATING LEVELS; CHARGE CONSORTIUM; SEQUENCE VARIANTS; SMOKING-BEHAVIOR; GENE; DISEASE AB Soluble ICAM-1 (sICAM-1) is an endothelium-derived inflammatory marker that has been associated with diverse conditions such as myocardial infarction, diabetes, stroke, and malaria. Despite evidence for a heritable component to sICAM-1 levels, few genetic loci have been identified so far. To comprehensively address this issue, we performed a genome-wide association analysis of sICAM-1 concentration in 22,435 apparently healthy women from the Women's Genome Health Study. While our results confirm the previously reported associations at the ABO and ICAM1 loci, four novel associations were identified in the vicinity of NFKBIK (rs3136642, P = 5.4x10(-9)), PNPLA3 (rs738409, P = 5.8x10(-9)), RELA (rs1049728, P = 2.7x10(-16)), and SH2B3 (rs3184504, P = 2.9x10(-17)). Two loci, NFKBIB and RELA, are involved in NFKB signaling pathway; PNPLA3 is known for its association with fatty liver disease; and SH3B2 has been associated with a multitude of traits and disease including myocardial infarction. These associations provide insights into the genetic regulation of sICAM-1 levels and implicate these loci in the regulation of endothelial function. C1 [Pare, Guillaume; Ridker, Paul M.; Rose, Lynda; Chasman, Daniel I.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA. [Pare, Guillaume; Ridker, Paul M.; Rose, Lynda; Chasman, Daniel I.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Donald W Reynolds Ctr Cardiovasc Res, Boston, MA 02115 USA. [Pare, Guillaume] McMaster Univ, Hamilton, ON, Canada. [Barbalic, Maja] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX USA. [Barbalic, Maja] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX USA. [Dupuis, Josee; Benjamin, Emelia J.] NHLBI, Framingham, MA USA. [Dupuis, Josee; Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Framingham, MA USA. [Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Dehghan, Abbas] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands. [Dehghan, Abbas] NCHA, Leiden, Netherlands. [Bis, Joshua C.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Benjamin, Emelia J.] Boston Univ, Sch Med, Prevent Med & Epidemiol Sect, Dept Med, Boston, MA 02118 USA. [Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Shiffman, Dov] Celera, Alameda, CA USA. [Parker, Alexander N.] Amgen Inc, Cambridge, MA USA. RP Pare, G (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA. EM pareg@McMaster.ca OI Dupuis, Josee/0000-0003-2871-3603; Benjamin, Emelia/0000-0003-4076-2336; Dehghan, Abbas/0000-0001-6403-016X FU National Heart, Lung, and Blood Institute; National Cancer Institute (Bethesda, MD); Donald W. Reynolds Foundation (Las Vegas, NV); Doris Duke Charitable Foundation; Foundation Leducq (Paris, FR); Amgen FX This study was supported by grants from the National Heart, Lung, and Blood Institute and the National Cancer Institute (Bethesda, MD), the Donald W. Reynolds Foundation (Las Vegas, NV), the Doris Duke Charitable Foundation, and the Foundation Leducq (Paris, FR), with collaborative scientific and genotypic support provided by Amgen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 37 Z9 38 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD APR PY 2011 VL 7 IS 4 AR e1001374 DI 10.1371/journal.pgen.1001374 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 755YI UT WOS:000289977000022 PM 21533024 ER PT J AU Pasaniuc, B Zaitlen, N Lettre, G Chen, GK Tandon, A Kao, WHL Ruczinski, I Fornage, M Siscovick, DS Zhu, XF Larkin, E Lange, LA Cupples, LA Yang, Q Akylbekova, EL Musani, SK Divers, J Mychaleckyj, J Li, MY Papanicolaou, GJ Millikan, RC Ambrosone, CB John, EM Bernstein, L Zheng, W Hu, JJ Ziegler, RG Nyante, SJ Bandera, EV Ingles, SA Press, MF Chanock, SJ Deming, SL Rodriguez-Gil, JL Palmer, CD Buxbaum, S Ekunwe, L Hirschhorn, JN Henderson, BE Myers, S Haiman, CA Reich, D Patterson, N Wilson, JG Price, AL AF Pasaniuc, Bogdan Zaitlen, Noah Lettre, Guillaume Chen, Gary K. Tandon, Arti Kao, W. H. Linda Ruczinski, Ingo Fornage, Myriam Siscovick, David S. Zhu, Xiaofeng Larkin, Emma Lange, Leslie A. Cupples, L. Adrienne Yang, Qiong Akylbekova, Ermeg L. Musani, Solomon K. Divers, Jasmin Mychaleckyj, Joe Li, Mingyao Papanicolaou, George J. Millikan, Robert C. Ambrosone, Christine B. John, Esther M. Bernstein, Leslie Zheng, Wei Hu, Jennifer J. Ziegler, Regina G. Nyante, Sarah J. Bandera, Elisa V. Ingles, Sue A. Press, Michael F. Chanock, Stephen J. Deming, Sandra L. Rodriguez-Gil, Jorge L. Palmer, Cameron D. Buxbaum, Sarah Ekunwe, Lynette Hirschhorn, Joel N. Henderson, Brian E. Myers, Simon Haiman, Christopher A. Reich, David Patterson, Nick Wilson, James G. Price, Alkes L. TI Enhanced Statistical Tests for GWAS in Admixed Populations: Assessment using African Americans from CARe and a Breast Cancer Consortium SO PLOS GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; GENOTYPE-IMPUTATION; LINKAGE DISEQUILIBRIUM; SUSCEPTIBILITY LOCI; RACIAL-DIFFERENCES; PROSTATE-CANCER; RISK; ADMIXTURE; DISEASE; EPIDEMIOLOGY AB While genome-wide association studies (GWAS) have primarily examined populations of European ancestry, more recent studies often involve additional populations, including admixed populations such as African Americans and Latinos. In admixed populations, linkage disequilibrium (LD) exists both at a fine scale in ancestral populations and at a coarse scale (admixture-LD) due to chromosomal segments of distinct ancestry. Disease association statistics in admixed populations have previously considered SNP association (LD mapping) or admixture association (mapping by admixture-LD), but not both. Here, we introduce a new statistical framework for combining SNP and admixture association in case-control studies, as well as methods for local ancestry-aware imputation. We illustrate the gain in statistical power achieved by these methods by analyzing data of 6,209 unrelated African Americans from the CARe project genotyped on the Affymetrix 6.0 chip, in conjunction with both simulated and real phenotypes, as well as by analyzing the FGFR2 locus using breast cancer GWAS data from 5,761 African-American women. We show that, at typed SNPs, our method yields an 8% increase in statistical power for finding disease risk loci compared to the power achieved by standard methods in case-control studies. At imputed SNPs, we observe an 11% increase in statistical power for mapping disease loci when our local ancestry-aware imputation framework and the new scoring statistic are jointly employed. Finally, we show that our method increases statistical power in regions harboring the causal SNP in the case when the causal SNP is untyped and cannot be imputed. Our methods and our publicly available software are broadly applicable to GWAS in admixed populations. C1 [Pasaniuc, Bogdan; Zaitlen, Noah; Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Pasaniuc, Bogdan; Zaitlen, Noah; Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Pasaniuc, Bogdan; Zaitlen, Noah; Tandon, Arti; Palmer, Cameron D.; Hirschhorn, Joel N.; Reich, David; Patterson, Nick; Price, Alkes L.] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA USA. [Lettre, Guillaume] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. [Lettre, Guillaume] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada. [Chen, Gary K.; Ingles, Sue A.; Press, Michael F.; Henderson, Brian E.; Haiman, Christopher A.] Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90089 USA. [Tandon, Arti; Hirschhorn, Joel N.; Reich, David] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Kao, W. H. Linda] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Kao, W. H. Linda] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA. [Ruczinski, Ingo] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Sch Publ Hlth, Houston, TX USA. [Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Div Epidemiol, Sch Publ Hlth, Houston, TX USA. [Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Zhu, Xiaofeng] Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. [Larkin, Emma] Vanderbilt Univ, Dept Med, Div Allergy Pulm & Crit Care, Nashville, TN USA. [Lange, Leslie A.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA. [Cupples, L. Adrienne; Yang, Qiong] Boston Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, Boston, MA USA. [Akylbekova, Ermeg L.; Buxbaum, Sarah; Ekunwe, Lynette] Jackson State Univ, Jackson Heart Study, Jackson, MS USA. [Musani, Solomon K.; Wilson, James G.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. [Divers, Jasmin] Wake Forest Univ, Div Publ Hlth Sci, Dept Biostat Sci, Winston Salem, NC 27109 USA. [Mychaleckyj, Joe] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA. [Li, Mingyao] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Papanicolaou, George J.] NHLBI, Div Cardiovasc Sci, NIH, Bethesda, MD 20892 USA. [Millikan, Robert C.] Gillings Sch Global Publ Hlth Chapel Hill, Dept Epidemiol, Chapel Hill, NC USA. [Millikan, Robert C.; Nyante, Sarah J.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Ambrosone, Christine B.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA. [John, Esther M.] No Calif Canc Ctr, Fremont, CA USA. [John, Esther M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [John, Esther M.] Stanford Canc Ctr, Stanford, CA USA. [Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, Duarte, CA USA. [Zheng, Wei] Vanderbilt Epidemiol Ctr, Dept Med, Div Epidemiol, Nashville, TN USA. [Zheng, Wei] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA. [Hu, Jennifer J.; Rodriguez-Gil, Jorge L.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA. [Hu, Jennifer J.; Rodriguez-Gil, Jorge L.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA. [Ziegler, Regina G.] NCI, Epidemiol & Biostat Program, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Bandera, Elisa V.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA. [Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Deming, Sandra L.] Vanderbilt Epidemiol Ctr, Inst Med & Publ Hlth, Nashville, TN USA. [Palmer, Cameron D.; Hirschhorn, Joel N.] Childrens Hosp Boston, Div Genet, Boston, MA USA. [Palmer, Cameron D.; Hirschhorn, Joel N.] Childrens Hosp Boston, Div Endocrinol, Boston, MA USA. [Palmer, Cameron D.; Hirschhorn, Joel N.] Childrens Hosp Boston, Program Genom, Boston, MA USA. [Myers, Simon] Univ Oxford, Dept Stat, Oxford OX1 3TG, England. [Wilson, James G.] VA Med Ctr, Jackson, MS USA. RP Pasaniuc, B (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. EM bpasaniu@hsph.harvard.edu; aprice@hsph.harvard.edu RI Pasaniuc, Bogdan/E-9310-2012; Yang, Qiong/G-5438-2014; Bandera, Elisa/M-4169-2014; Myers, Simon/A-6792-2015; Buxbaum, Sarah/E-1970-2013; OI Bandera, Elisa/0000-0002-8789-2755; Myers, Simon/0000-0002-2585-9626; Buxbaum, Sarah/0000-0002-4886-3564; Cupples, L. Adrienne/0000-0003-0273-7965 FU NIH [RC1 GM091332-01, 5T32ES007142-27]; Department of Defense; Norris Foundation; National Heart, Lung, and Blood Institute; NHLBI [HHSN268200960009C]; Broad Institute [N01-HC-65226]; University of North Carolina at Chapel Hill [N01-HC-55015]; Baylor Medical College [N01-HC-55016]; University of Mississippi Medical Center [N01-HC-55021]; University of Minnesota [N01-HC-55019, N01-HC48048, N01-HC-95163, U01 HL053934]; Johns Hopkins University [N01-HC-55020, N01-HC-85081, N01 HC-15103, N01-HC-95162, N01-HC-95168, U01 HL053937]; University of Texas Houston [N01-HC-55017]; University of North Carolina Forsyth County [N01-HC-55018]; Cardiovascular Health Study (CHS): University of Washington [N01-HC-85079]; Wake Forest University [N01-HC-85080, N01-HC-45205, N01-HC-95165]; University of Pittsburgh [N01-HC-85082, U01 HL077813]; University of California Davis [N01-HC-85083, U01 HL053916]; University of California Irvine [N01-HC-85084, N01-HC-45134, N01-HC-95100]; New England Medical Center [N01-HC-85085, N01-HC-95167]; University of Vermont [N01-HC-85086, N01-HC-95166]; Georgetown University [N01-HC-35129]; University of Wisconsin [N01-HC-75150]; Geisinger Clinic [N01-HC-45133]; University of Washington [N01 HC-55222, U01 HL080295]; Cleveland Family Study (CFS): Case Western Reserve University [RO1 HL46380-01-16]; Cooperative Study of Sickle Cell Disease (CSSCD): University of Illinois [N01-HB-72982, N01-HB-97062]; Howard University [N01-HB-72991, N01-HB-97061]; University of Miami [N01-HB-72992, N01-HB-97064]; Duke University [N01-HB-72993]; George Washington University [N01-HB-72994]; University of Tennessee [N01-HB-72995, N01-HB-97070]; Yale University [N01-HB-72996, N01-HB-97072]; Children's Hospital-Philadelphia [N01-HB-72997, N01-HB-97056]; University of Chicago [N01-HB-72998, N01-HB-97053]; Medical College of Georgia [N01-HB-73000, N01-HB-97060]; Washington University [N01-HB-73001, N01-HB-97071]; Jewish Hospital and Medical Center of Brooklyn [N01-HB-73002]; Trustees of Health and Hospitals of the City of Boston, Inc. [N01-HB-73003]; Children's Hospital-Oakland [N01-HB-73004, N01-HB-97054]; University of Mississippi [N01-HB-73005, N01-HC-95171]; St. Luke's Hospital-New York [N01-HB-73006]; Alta Bates-Herrick Hospital [N01-HB-97051]; Columbia University [N01-HB-97058, N01-HC-95161]; St. Jude's Children's Research Hospital [N01-HB-97066]; Research Foundation - State University of New York-Albany [N01-HB-97068, N01-HB-97069]; New England Research Institute [N01-HB-97073]; Interfaith Medical Center-Brooklyn [N01-HB-97085]; Coronary Artery Risk in Young Adults (CARDIA): University of Alabama at Birmingham [N01-HC-48047]; Northwestern University [N01-HC-48049, N01-HC-95164]; Kaiser Foundation Research Institute [N01-HC-48050]; University of Alabama at Birmingham [N01-HC-95095]; Tufts-New England Medical Center [N01-HC-45204]; Harbor-UCLA Research and Education Institute [N01-HC-05187, N01-HC-95169]; Framingham Heart Study (FHS): Boston University [N01-HC-25195]; Jackson Heart Study (JHS): Jackson State University [N01-HC-95170]; Tougaloo College [N01-HC-95172]; Multi-Ethnic Study of Atherosclerosis (MESA): University of Washington [N01-HC-95159]; Regents of the University of California [N01-HC-95160]; Sleep Heart Health Study (SHHS): Johns Hopkins University [U01 HL064360]; Case Western University [U01 HL063463]; University of Arizona [U01 HL053938]; Boston University [U01 HL053941]; MedStar Research Institute [U01 HL063429]; MEC (National Institutes of Health) [R01-CA63464, R37-CA54281]; CARE (National Institute for Child Health and Development) [NO1-HD-3-3175]; WCHS (U.S. Army Medical Research and Material Command (USAMRMC)) [DAMD-17-01-0-0334]; National Institutes of Health [R01-CA100598]; Breast Cancer Research Foundation; SFBC (National Institutes of Health) [R01-CA77305]; United States Army Medical Research Program [DAMD17-96-6071]; NC-BCFR (National Institutes of Health) [U01-CA69417]; NHBS (National Institutes of Health); WFBC (National Institutes of Health); National Cancer Institute, National Institutes of Health; National Cancer Institute; Clinical and Translational Science Awards (CTSA); NCI; Florida Bankhead-Coley Cancer Research Program; NIH/NHGRI; [R01-CA100374]; [R01-CA73629]; [RFA CA-95-011]; [5K99CA126978-02]; [R01CA073629]; [10BG-04]; [U01 HG004726-01] FX This work was funded by NIH grant RC1 GM091332-01 (BP, DR, NP, JGW, ALP) and by NIH fellowship 5T32ES007142-27 (NZ), using data from NHLBI's Candidate Gene Association Resource (CARe) project and by a Department of Defense Breast Cancer Research Program Era of Hope Scholar Award to CAH and the Norris Foundation. The Candidate gene Association Resource (CARe) wishes to acknowledge the support of the National Heart, Lung, and Blood Institute and the contributions of the research institutions, study investigators, field staff, and study participants in creating this resource for biomedical research (NHLBI contract number HHSN268200960009C). The following nine parent studies have contributed parent study data, ancillary study data, and DNA samples through the Broad Institute (N01-HC-65226) to create this genotype/phenotype database for wide dissemination to the biomedical research community: Atherosclerotic Risk in Communities (ARIC): The University of North Carolina at Chapel Hill (N01-HC-55015), Baylor Medical College (N01-HC-55016), University of Mississippi Medical Center (N01-HC-55021), University of Minnesota (N01-HC-55019), Johns Hopkins University (N01-HC-55020), University of Texas Houston (N01-HC-55017), University of North Carolina Forsyth County (N01-HC-55018); Cardiovascular Health Study (CHS): University of Washington (N01-HC-85079), Wake Forest University (N01-HC-85080), Johns Hopkins University (N01-HC-85081), University of Pittsburgh (N01-HC-85082), University of California Davis (N01-HC-85083), University of California Irvine (N01-HC-85084), New England Medical Center (N01-HC-85085), University of Vermont (N01-HC-85086), Georgetown University (N01-HC-35129), Johns Hopkins University (N01 HC-15103), University of Wisconsin (N01-HC-75150), Geisinger Clinic (N01-HC-45133), University of Washington (N01 HC-55222, U01 HL080295); Cleveland Family Study (CFS): Case Western Reserve University (RO1 HL46380-01-16); Cooperative Study of Sickle Cell Disease (CSSCD): University of Illinois (N01-HB-72982, N01-HB-97062), Howard University (N01-HB-72991, N01-HB-97061), University of Miami (N01-HB-72992, N01-HB-97064), Duke University (N01-HB-72993), George Washington University (N01-HB-72994), University of Tennessee (N01-HB-72995, N01-HB-97070), Yale University (N01-HB-72996, N01-HB-97072), Children's Hospital-Philadelphia (N01-HB-72997, N01-HB-97056), University of Chicago (N01-HB-72998, N01-HB-97053), Medical College of Georgia (N01-HB-73000, N01-HB-97060), Washington University (N01-HB-73001, N01-HB-97071), Jewish Hospital and Medical Center of Brooklyn (N01-HB-73002), Trustees of Health and Hospitals of the City of Boston, Inc., (N01-HB-73003), Children's Hospital-Oakland (N01-HB-73004, N01-HB-97054), University of Mississippi (N01-HB-73005), St. Luke's Hospital-New York (N01-HB-73006), Alta Bates-Herrick Hospital (N01-HB-97051), Columbia University (N01-HB-97058), St.; Jude's Children's Research Hospital (N01-HB-97066), Research Foundation - State University of New York-Albany (N01-HB-97068, N01-HB-97069), New England Research Institute (N01-HB-97073), Interfaith Medical Center-Brooklyn (N01-HB-97085); Coronary Artery Risk in Young Adults (CARDIA): University of Alabama at Birmingham (N01-HC-48047), University of Minnesota (N01-HC48048), Northwestern University (N01-HC-48049), Kaiser Foundation Research Institute (N01-HC-48050), University of Alabama at Birmingham (N01-HC-95095), Tufts-New England Medical Center (N01-HC-45204), Wake Forest University (N01-HC-45205), Harbor-UCLA Research and Education Institute (N01-HC-05187), Univesity of California Irvine (N01-HC-45134, N01-HC-95100); Framingham Heart Study (FHS): Boston University (N01-HC-25195); Jackson Heart Study (JHS): Jackson State University (N01-HC-95170), University of Mississippi (N01-HC-95171), Tougaloo College (N01-HC-95172); Multi-Ethnic Study of Atherosclerosis (MESA): University of Washington (N01-HC-95159), Regents of the University of California (N01-HC-95160), Columbia University (N01-HC-95161), Johns Hopkins University (N01-HC-95162), University of Minnesota (N01-HC-95163), Northwestern University (N01-HC-95164), Wake Forest University (N01-HC-95165), University of Vermont (N01-HC-95166), New England Medical Center (N01-HC-95167), Johns Hopkins University (N01-HC-95168), Harbor-UCLA Research and Education Institute (N01-HC-95169); Sleep Heart Health Study (SHHS): Johns Hopkins University (U01 HL064360), Case Western University (U01 HL063463), University of California Davis (U01 HL053916), University of Arizona (U01 HL053938), University of Minnesota (relocating in 2006 to Univ Arizona) (U01 HL053934), University of Pittsburgh (U01 HL077813), Boston University (U01 HL053941), MedStar Research Institute (U01 HL063429), Johns Hopkins University (U01 HL053937). The studies that provided the Breast Cancer data were supported by the following grants: MEC (National Institutes of Health grants R01-CA63464 and R37-CA54281); CARE (National Institute for Child Health and Development grant NO1-HD-3-3175), WCHS (U.S. Army Medical Research and Material Command (USAMRMC) grant DAMD-17-01-0-0334, the National Institutes of Health grant R01-CA100598, and the Breast Cancer Research Foundation, SFBC (National Institutes of Health grant R01-CA77305 and United States Army Medical Research Program grant DAMD17-96-6071), NC-BCFR (National Institutes of Health grant U01-CA69417), CBCS (National Institutes of Health Specialized Program of Research Excellence in Breast Cancer, grant number P50-CA58223, and Center for Environmental Health and Susceptibility, National Institute of Environmental Health Sciences, National Institutes of Health, grant number P30-ES10126), PLCO (Intramural Research Program, National Cancer Institute, National Institutes of Health (, NHBS (National Institutes of Health grant R01-CA100374), WFBC (National Institutes of Health grant R01-CA73629). The Breast Cancer Family Registry (BCFR) was supported by the National Cancer Institute, National Institutes of Health under RFA CA-95-011 and through cooperative agreements with members of the Breast Cancer Family Registry and Principal Investigators. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the U. S. Government or the BCFR.; SLD is supported by a grant from the National Cancer nstitute: 5K99CA126978-02. WHLK and IR are supported by a Clinical and Translational Science Awards (CTSA) grant to the Johns Hopkins Medical Institutions. JJH and JLR-G were supported by grants funded by NCI (R01CA073629) and Florida Bankhead-Coley Cancer Research Program (10BG-04). CH, DR, NP, and AT were supported by NIH/NHGRI grant U01 HG004726-01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 65 TC 46 Z9 46 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD APR PY 2011 VL 7 IS 4 AR e1001371 DI 10.1371/journal.pgen.1001371 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA 755YI UT WOS:000289977000015 PM 21541012 ER PT J AU Smedby, KE Foo, JN Skibola, CF Darabi, H Conde, L Hjalgrim, H Kumar, V Chang, ET Rothman, N Cerhan, JR Brooks-Wilson, AR Rehnberg, E Irwan, ID Ryder, LP Brown, PN Bracci, PM Agana, L Riby, J Cozen, W Davis, S Hartge, P Morton, LM Severson, RK Wang, SS Slager, SL Fredericksen, ZS Novak, AJ Kay, NE Habermann, TM Armstrong, B Kricker, A Milliken, S Purdue, MP Vajdic, CM Boyle, P Lan, Q Zahm, SH Zhang, YW Zheng, TZ Leach, S Spinelli, JJ Smith, MT Chanock, SJ Padyukov, L Alfredsson, L Klareskog, L Glimelius, B Melbye, M Liu, ET Adami, HO Humphreys, K Liu, JJ AF Smedby, Karin E. Foo, Jia Nee Skibola, Christine F. Darabi, Hatef Conde, Lucia Hjalgrim, Henrik Kumar, Vikrant Chang, Ellen T. Rothman, Nathaniel Cerhan, James R. Brooks-Wilson, Angela R. Rehnberg, Emil Irwan, Ishak D. Ryder, Lars P. Brown, Peter N. Bracci, Paige M. Agana, Luz Riby, Jacques Cozen, Wendy Davis, Scott Hartge, Patricia Morton, Lindsay M. Severson, Richard K. Wang, Sophia S. Slager, Susan L. Fredericksen, Zachary S. Novak, Anne J. Kay, Neil E. Habermann, Thomas M. Armstrong, Bruce Kricker, Anne Milliken, Sam Purdue, Mark P. Vajdic, Claire M. Boyle, Peter Lan, Qing Zahm, Shelia H. Zhang, Yawei Zheng, Tongzhang Leach, Stephen Spinelli, John J. Smith, Martyn T. Chanock, Stephen J. Padyukov, Leonid Alfredsson, Lars Klareskog, Lars Glimelius, Bengt Melbye, Mads Liu, Edison T. Adami, Hans-Olov Humphreys, Keith Liu, Jianjun TI GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma SO PLOS GENETICS LA English DT Article ID NON-HODGKIN-LYMPHOMA; GENOME-WIDE ASSOCIATION; NECROSIS-FACTOR TNF; RHEUMATOID-ARTHRITIS; INTERLYMPH-CONSORTIUM; STATISTICAL-METHOD; RISK LOCUS; CANCER; HAPLOTYPE; HLA AB Non-Hodgkin lymphoma (NHL) represents a diverse group of hematological malignancies, of which follicular lymphoma (FL) is a prevalent subtype. A previous genome-wide association study has established a marker, rs10484561 in the human leukocyte antigen (HLA) class II region on 6p21.32 associated with increased FL risk. Here, in a three-stage genome-wide association study, starting with a genome-wide scan of 379 FL cases and 791 controls followed by validation in 1,049 cases and 5,790 controls, we identified a second independent FL-associated locus on 6p21.32, rs2647012 (OR(combined) = 0.64, P(combined)= 2x10(-21)) located 962 bp away from rs10484561 (r(2)< 0.1 in controls). After mutual adjustment, the associations at the two SNPs remained genome-wide significant (rs2647012: OR(adjusted) = 0.70, P(adjusted)= 4x10(-12); rs10484561: OR(adjusted) = 1.64, P(adjusted)= 5x10(-15)). Haplotype and coalescence analyses indicated that rs2647012 arose on an evolutionarily distinct haplotype from that of rs10484561 and tags a novel allele with an opposite (protective) effect on FL risk. Moreover, in a follow-up analysis of the top 6 FL-associated SNPs in 4,449 cases of other NHL subtypes, rs10484561 was associated with risk of diffuse large B-cell lymphoma (OR(combined) = 1.36, P(combined) = 1.4x10(-7)). Our results reveal the presence of allelic heterogeneity within the HLA class II region influencing FL susceptibility and indicate a possible shared genetic etiology with diffuse large B-cell lymphoma. These findings suggest that the HLA class II region plays a complex yet important role in NHL. C1 [Smedby, Karin E.] Karolinska Inst, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden. [Foo, Jia Nee; Kumar, Vikrant; Irwan, Ishak D.; Liu, Edison T.; Liu, Jianjun] ASTAR, Genome Inst Singapore, Singapore, Singapore. [Skibola, Christine F.; Conde, Lucia; Agana, Luz; Riby, Jacques; Smith, Martyn T.] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA. [Darabi, Hatef; Rehnberg, Emil; Adami, Hans-Olov; Humphreys, Keith] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Hjalgrim, Henrik; Melbye, Mads] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark. [Chang, Ellen T.] Canc Prevent Inst Calif, Fremont, CA USA. [Chang, Ellen T.] Stanford Univ, Div Epidemiol, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA. [Rothman, Nathaniel; Hartge, Patricia; Morton, Lindsay M.; Wang, Sophia S.; Purdue, Mark P.; Lan, Qing; Zahm, Shelia H.; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Cerhan, James R.; Slager, Susan L.; Fredericksen, Zachary S.; Novak, Anne J.; Kay, Neil E.; Habermann, Thomas M.] Mayo Clin, Coll Med, Rochester, MN USA. [Brooks-Wilson, Angela R.; Spinelli, John J.] British Columbia Canc Agcy, British Columbia Canc Res Ctr, Vancouver, BC V5Z 4E6, Canada. [Brooks-Wilson, Angela R.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC V5A 1S6, Canada. [Ryder, Lars P.] Univ Copenhagen Hosp, Dept Clin Immunol, DK-2100 Copenhagen, Denmark. [Brown, Peter N.] Univ Copenhagen Hosp, Dept Haematol, DK-2100 Copenhagen, Denmark. [Bracci, Paige M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cozen, Wendy] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Davis, Scott] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Davis, Scott] Univ Washington, Seattle, WA 98195 USA. [Severson, Richard K.] Wayne State Univ, Dept Family Med & Publ Hlth Sci, Detroit, MI USA. [Severson, Richard K.] Karmanos Canc Inst, Detroit, MI USA. [Wang, Sophia S.] Beckman Res Inst, Div Etiol, Duarte, CA USA. [Wang, Sophia S.] City Hope Natl Med Ctr, Duarte, CA USA. [Armstrong, Bruce; Kricker, Anne] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia. [Milliken, Sam] St Vincents Hosp, Dept Haematol, Sydney, NSW 2010, Australia. [Vajdic, Claire M.] Univ New S Wales, Canc Res Ctr, Prince Wales Clin Sch, Sydney, NSW, Australia. [Boyle, Peter] Int Prevent Res Inst, Lyon, France. [Zhang, Yawei; Zheng, Tongzhang] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Leach, Stephen] British Columbia Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada. [Spinelli, John J.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada. [Padyukov, Leonid; Klareskog, Lars] Karolinska Inst, Rheumatol Unit, Dept Med, Stockholm, Sweden. [Padyukov, Leonid; Klareskog, Lars] Karolinska Univ Hosp Solna, Stockholm, Sweden. [Alfredsson, Lars] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden. [Glimelius, Bengt] Karolinska Inst, Dept Pathol & Oncol, S-10401 Stockholm, Sweden. [Glimelius, Bengt] Uppsala Univ, Dept Radiol Oncol & Radiat Sci, Uppsala, Sweden. [Adami, Hans-Olov] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Smedby, KE (reprint author), Karolinska Inst, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden. EM liuj3@gis.a-star.edu.sg RI Conde, Lucia/D-9295-2011; Spinelli, John/B-6210-2013; Boyle, Peter/A-4380-2014; Tang, Macy/B-9798-2014; ryder, lars/Q-2060-2015; Purdue, Mark/C-9228-2016; Foo, Jia Nee/D-6069-2014; Brooks-Wilson, Angela/E-9399-2012; Zahm, Shelia/B-5025-2015; Morton, Lindsay/B-5234-2015; Armstrong, Bruce/K-9464-2015 OI Klareskog, Lars/0000-0001-9601-6186; Cerhan, James/0000-0002-7482-178X; Alfredsson, Lars/0000-0003-1688-6697; Padyukov, Leonid/0000-0003-2950-5670; Boyle, Peter/0000-0001-6251-0610; ryder, lars/0000-0002-4744-3496; Purdue, Mark/0000-0003-1177-3108; Foo, Jia Nee/0000-0001-9899-2308; Vajdic, Claire/0000-0002-3612-8298; Brooks-Wilson, Angela/0000-0003-1009-6408; Morton, Lindsay/0000-0001-9767-2310; Armstrong, Bruce/0000-0001-8940-7525 FU Agency for Science and Technology and Research of Singapore (A*STAR); Swedish Cancer Society [090659]; Swedish Research Council [K2008-64X-20737-01-2, 523-2006-972]; Danish Medical Research Council [FSS 09-63424]; National Cancer Institute (NCI) [CA069269-01]; Swedish Council for Working life [2008-0567]; AFA insurance company; Vinnova; NCI, National Institutes of Health (NIH) [CA122663, CA104682, CA45614, CA89745]; NIH (NCI) [N01-PC-65064, N01-PC-67008, N01-PC-67009, N01-PC-67010, N02-PC-71105, R01-CA91253, R01-CA118444, CA62006]; Public Health Service; National Health and Medical Research Council of Australia; Cancer Council NSW; University of Sydney Medical Foundation; US NIH (NCI); Canadian Cancer Society; Canadian Institutes of Health Research FX This work was funded by the Agency for Science and Technology and Research of Singapore (A*STAR), the Swedish Cancer Society (090659), the Swedish Research Council (K2008-64X-20737-01-2, 523-2006-972), and the Danish Medical Research Council (FSS 09-63424). The collection of blood samples in the founding case-control study was supported by the National Cancer Institute (NCI) (CA069269-01). Sample collection in EIRA was supported by the Swedish Council for Working life (2008-0567), the AFA insurance company, and by the Combine project founded by Vinnova. The SF1 and SF2 studies were supported by the NCI, National Institutes of Health (NIH) (CA122663, CA104682, CA45614, CA89745). The NCI-SEER study was supported by the Intramural Research Program of the NIH (NCI) and by Public Health Service contracts N01-PC-65064, N01-PC-67008, N01-PC-67009, N01-PC-67010, and N02-PC-71105. The Mayo study was supported by the NIH (NCI) (R01-CA91253, R01-CA118444). The NSW study was supported by a National Health and Medical Research Council of Australia project grant, Cancer Council NSW, a University of Sydney Medical Foundation Program Grant, and the Intramural Research Program of the US NIH (NCI). The Yale study was supported by grant CA62006 from NIH (NCI) and the Intramural Research Program of the National Institutes of Health (NCI). The BC study was funded from the Canadian Cancer Society and the Canadian Institutes of Health Research. ARB-W is a Senior Scholar of the Michael Smith Foundation for Health Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 54 Z9 56 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD APR PY 2011 VL 7 IS 4 AR e1001378 DI 10.1371/journal.pgen.1001378 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 755YI UT WOS:000289977000026 PM 21533074 ER PT J AU Stirling, PC Bloom, MS Solanki-Patil, T Smith, S Sipahimalani, P Li, ZJ Kofoed, M Ben-Aroya, S Myung, K Hieter, P AF Stirling, Peter C. Bloom, Michelle S. Solanki-Patil, Tejomayee Smith, Stephanie Sipahimalani, Payal Li, Zhijian Kofoed, Megan Ben-Aroya, Shay Myung, Kyungjae Hieter, Philip TI The Complete Spectrum of Yeast Chromosome Instability Genes Identifies Candidate CIN Cancer Genes and Functional Roles for ASTRA Complex Components SO PLOS GENETICS LA English DT Article ID SACCHAROMYCES-CEREVISIAE; INTERACTION NETWORK; GENOME INSTABILITY; STABILITY; SCREEN; TEL2; LOCALIZATION; KINASE; MTOR; CELL AB Chromosome instability (CIN) is observed in most solid tumors and is linked to somatic mutations in genome integrity maintenance genes. The spectrum of mutations that cause CIN is only partly known and it is not possible to predict a priori all pathways whose disruption might lead to CIN. To address this issue, we generated a catalogue of CIN genes and pathways by screening,2,000 reduction-of-function alleles for 90% of essential genes in Saccharomyces cerevisiae. Integrating this with published CIN phenotypes for other yeast genes generated a systematic CIN gene dataset comprised of 692 genes. Enriched gene ontology terms defined cellular CIN pathways that, together with sequence orthologs, created a list of human CIN candidate genes, which we cross-referenced to published somatic mutation databases revealing hundreds of mutated CIN candidate genes. Characterization of some poorly characterized CIN genes revealed short telomeres in mutants of the ASTRA/TTT components TTI1 and ASA1. High-throughput phenotypic profiling links ASA1 to TTT (Tel2-Tti1-Tti2) complex function and to TORC1 signaling via Tor1p stability, consistent with the role of TTT in PI3-kinase related kinase biogenesis. The comprehensive CIN gene list presented here in principle comprises all conserved eukaryotic genome integrity pathways. Deriving human CIN candidate genes from the list allows direct cross-referencing with tumor mutational data and thus candidate mutations potentially driving CIN in tumors. Overall, the CIN gene spectrum reveals new chromosome biology and will help us to understand CIN phenotypes in human disease. C1 [Stirling, Peter C.; Solanki-Patil, Tejomayee; Sipahimalani, Payal; Kofoed, Megan; Ben-Aroya, Shay; Hieter, Philip] Univ British Columbia, Michael Smith Labs, Vancouver, BC V5Z 1M9, Canada. [Bloom, Michelle S.; Smith, Stephanie; Myung, Kyungjae] NHGRI, Genome Instabil Sect, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA. [Li, Zhijian] Univ Toronto, Banting & Best Dept Med Res, Terrence Donnelly Ctr Cellular & Biomol Res, Toronto, ON, Canada. RP Stirling, PC (reprint author), Univ British Columbia, Michael Smith Labs, Vancouver, BC V5Z 1M9, Canada. EM Hieter@msl.ubc.ca FU Terry Fox Foundation [700044]; Michael Smith Foundation for Health Research (MSFHR); National Institutes of Health (NIH); Canadian Institutes for Health Research (CIHR); NHGRI, NIH; Human Frontier Science Program (HFSP); Killam trust FX PCS is a Research Fellow of the Terry Fox Foundation (Award # 700044; www.terryfox.org/) with additional support from the Michael Smith Foundation for Health Research (MSFHR; www.msfhr.org/). PH is supported by the National Institutes of Health (NIH; www.nih.gov/) and the Canadian Institutes for Health Research (CIHR; http://www.cihr-irsc.gc.ca/e/193.html). KM is supported by the intramural research program of the NHGRI, NIH. SB-A was supported by a Human Frontier Science Program (HFSP) long-term fellowship (www.hfsp.org/) and by a research grant from the Killam trust (http://www.killamtrusts.ca/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 52 Z9 52 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD APR PY 2011 VL 7 IS 4 AR e1002057 DI 10.1371/journal.pgen.1002057 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 755YI UT WOS:000289977000042 PM 21552543 ER PT J AU Zhai, GJ Teumer, A Stolk, L Perry, JRB Vandenput, L Coviello, AD Koster, A Bell, JT Bhasin, S Eriksson, J Eriksson, A Ernst, F Ferrucci, L Frayling, TM Glass, D Grundberg, E Haring, R Hedman, AK Hofman, A Kiel, DP Kroemer, HK Liu, YM Lunetta, KL Maggio, M Lorentzon, M Mangino, M Melzer, D Miljkovic, I Nica, A Penninx, BWJH Vasan, RS Rivadeneira, F Small, KS Soranzo, N Uitterlinden, AG Volzke, H Wilson, SG Xi, L Zhuang, WV Harris, TB Murabito, JM Ohlsson, C Murray, A de Jong, FH Spector, TD Wallaschofski, H AF Zhai, Guangju Teumer, Alexander Stolk, Lisette Perry, John R. B. Vandenput, Liesbeth Coviello, Andrea D. Koster, Annemarie Bell, Jordana T. Bhasin, Shalender Eriksson, Joel Eriksson, Anna Ernst, Florian Ferrucci, Luigi Frayling, Timothy M. Glass, Daniel Grundberg, Elin Haring, Robin Hedman, Asa K. Hofman, Albert Kiel, Douglas P. Kroemer, Heyo K. Liu, Yongmei Lunetta, Kathryn L. Maggio, Marcello Lorentzon, Mattias Mangino, Massimo Melzer, David Miljkovic, Iva Nica, Alexandra Penninx, Brenda W. J. H. Vasan, Ramachandran S. Rivadeneira, Fernando Small, Kerrin S. Soranzo, Nicole Uitterlinden, Andre G. Voelzke, Henry Wilson, Scott G. Xi, Li Zhuang, Wei Vivian Harris, Tamara B. Murabito, Joanne M. Ohlsson, Claes Murray, Anna de Jong, Frank H. Spector, Tim D. Wallaschofski, Henri CA MuTHER Consortium TI Eight Common Genetic Variants Associated with Serum DHEAS Levels Suggest a Key Role in Ageing Mechanisms SO PLOS GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; DEHYDROEPIANDROSTERONE-SULFATE LEVELS; POLYCYSTIC-OVARY-SYNDROME; BONE-MINERAL DENSITY; XENOBIOTIC METABOLISM; SUSCEPTIBILITY LOCI; RISK LOCI; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; ACID-METABOLISM AB Dehydroepiandrosterone sulphate (DHEAS) is the most abundant circulating steroid secreted by adrenal glands-yet its function is unknown. Its serum concentration declines significantly with increasing age, which has led to speculation that a relative DHEAS deficiency may contribute to the development of common age-related diseases or diminished longevity. We conducted a meta-analysis of genome-wide association data with 14,846 individuals and identified eight independent common SNPs associated with serum DHEAS concentrations. Genes at or near the identified loci include ZKSCAN5 (rs11761528; p = 3.15610(-36)), SULT2A1 (rs2637125; p = 2.61610(-19)), ARPC1A (rs740160; p = 1.56610(-16)), TRIM4 (rs17277546; p = 4.50610(-11)), BMF (rs7181230; p = 5.44610(-11)), HHEX (rs2497306; p = 4.64610(-9)), BCL2L11 ( rs6738028; p = 1.72610(-8)), and CYP2C9 (rs2185570; p = 2.29610(-8)). These genes are associated with type 2 diabetes, lymphoma, actin filament assembly, drug and xenobiotic metabolism, and zinc finger proteins. Several SNPs were associated with changes in gene expression levels, and the related genes are connected to biological pathways linking DHEAS with ageing. This study provides much needed insight into the function of DHEAS. C1 [Zhai, Guangju; Bell, Jordana T.; Glass, Daniel; Grundberg, Elin; Mangino, Massimo; Small, Kerrin S.; Soranzo, Nicole; Wilson, Scott G.; Spector, Tim D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England. [Teumer, Alexander; Ernst, Florian] Ernst Moritz Arndt Univ Greifswald, Interfac Inst Genet & Funct Genom, Greifswald, Germany. [Stolk, Lisette; Rivadeneira, Fernando; Uitterlinden, Andre G.; de Jong, Frank H.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands. [Stolk, Lisette; Hofman, Albert; Rivadeneira, Fernando; Uitterlinden, Andre G.] Netherlands Consortium Hlth Ageing, Rotterdam, Netherlands. [Perry, John R. B.; Frayling, Timothy M.; Melzer, David; Murray, Anna] Univ Exeter, Peninsula Med Sch, Exeter, Devon, England. [Perry, John R. B.; Bell, Jordana T.; Hedman, Asa K.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England. [Vandenput, Liesbeth; Eriksson, Joel; Eriksson, Anna; Lorentzon, Mattias; Ohlsson, Claes] Univ Gothenburg, Dept Internal Med, Inst Med, Sahlgrenska Acad, Gothenburg, Sweden. [Coviello, Andrea D.; Vasan, Ramachandran S.; Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA. [Coviello, Andrea D.; Vasan, Ramachandran S.; Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Sect Prevent Med, Boston, MA 02118 USA. [Coviello, Andrea D.; Vasan, Ramachandran S.; Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Cardiol Sect, Boston, MA 02118 USA. [Coviello, Andrea D.; Vasan, Ramachandran S.; Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA. [Koster, Annemarie; Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Bhasin, Shalender] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Claude Pepper Older Amer Independence Ctr, Boston, MA 02118 USA. [Ferrucci, Luigi] NIA, Clin Res Branch, Baltimore, MD 21224 USA. [Grundberg, Elin; Nica, Alexandra; Small, Kerrin S.; Soranzo, Nicole] Wellcome Trust Sanger Inst, Hixton, WI USA. [Haring, Robin; Wallaschofski, Henri] Ernst Moritz Arndt Univ Greifswald, Inst Clin Chem & Lab Med, Greifswald, Germany. [Hofman, Albert; Uitterlinden, Andre G.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands. [Kiel, Douglas P.] Hebrew Senior Life Inst Aging Res, Boston, MA USA. [Kiel, Douglas P.] Harvard Univ, Sch Med, Boston, MA USA. [Kroemer, Heyo K.] Ernst Moritz Arndt Univ Greifswald, Ctr Pharmacol & Expt Therapeut, Dept Pharmacol, Greifswald, Germany. [Liu, Yongmei] Wake Forest Univ Hlth Sci, Dept Epidemiol & Prevent, Winston Salem, NC USA. [Lunetta, Kathryn L.; Zhuang, Wei Vivian] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Maggio, Marcello] Univ Parma, Dept Internal Med & Biomed Sci, Sect Geriatr, I-43100 Parma, Italy. [Miljkovic, Iva] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Nica, Alexandra] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland. [Penninx, Brenda W. J. H.] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands. [Vasan, Ramachandran S.; Murabito, Joanne M.] NHLBI, Framingham Heart Study, Framingham, MA USA. [Voelzke, Henry] Ernst Moritz Arndt Univ Greifswald, Inst Community Med, Greifswald, Germany. [Wilson, Scott G.] Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia. [Wilson, Scott G.] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia. [Xi, Li] Pfizer Worldwide R&D, Mol Med Computat Biol, Groton, CT USA. RP Zhai, GJ (reprint author), Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England. EM tim.spector@kcl.ac.uk RI Koster, Annemarie/E-7438-2010; Rivadeneira, Fernando/O-5385-2015; mangino, massimo/F-5134-2011; OI Rivadeneira, Fernando/0000-0001-9435-9441; mangino, massimo/0000-0002-2167-7470; Murabito, Joanne/0000-0002-0192-7516; Lunetta, Kathryn/0000-0002-9268-810X; Miljkovic, Iva/0000-0002-3155-9777; Ramachandran, Vasan/0000-0001-7357-5970; Soranzo, Nicole/0000-0003-1095-3852; Kiel, Douglas/0000-0001-8474-0310; Melzer, David/0000-0002-0170-3838; Hedman, Asa/0000-0001-5413-204X; Vandenput, Liesbeth/0000-0002-1712-6131; Small, Kerrin/0000-0003-4566-0005 FU Wellcome Trust; Arthritis Research Campaign; European Community [HEALTH-F2-2008-201865-GEFOS, HEALTH-F4-2007-201413, QLG2-CT-2002-01254]; UK Department of Health via the National Institute for Health Research (NIHR); Biotechnology and Biological Sciences Research Council [G20234]; National Eye Institute (NEI) via an NIH/Center for Inherited Disease Research (CIDR); Federal Ministry of Education and Research [01ZZ9603, 01ZZ0103, 01ZZ0403, 03ZIK012]; Ministry of Cultural Affairs; Social Ministry of the Federal State of Mecklenburg West Pomerania; Siemens Healthcare, Erlangen, Germany; Federal State of Mecklenburg West Pomerania; Ministry of Cultural Affairs of the Federal State of Mecklenburg - West Pomerania [03IS2061A]; Siemens Healthcare Diagnostics, Eschborn; DPC Biermann GmbH, Bad Nauheim, Germany; Novo Nordisc; National Institute on Aging [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [1R01AG032098-01A1]; National Institutes of Health [HHSN268200782096C]; NIH, National Institute on Aging; Netherlands Organisation of Scientific Research NWO [175.010.2005.011, 911-03-012]; Research Institute for Diseases in the Elderly (RIDE2) [014-93-015]; Netherlands Genomics Initiative (NGI) Netherlands Consortium of Healthy Aging (NCHA) [050-060-810]; European Commision [HEALTH-F2-2008-201865, HEALTH-F2-2008-35627]; Erasmus Medical Center; Erasmus University, Rotterdam; Netherlands Organization for the Health Research and Development (ZonMw); Research Institute for Diseases in the Elderly (RIDE); Ministry of Education, Culture and Science; Ministry for Health, Welfare and Sports; European Commission [HEALTH-F2-2008-201865-GEFOS]; Municipality of Rotterdam; German Bundesministerium fuer Forschung und Technology [01 AK 803 A-H, 01 IG 07015 G]; National Institute of Aging [R21AG032598]; National Heart, Lung and Blood Institute [N01-HC-25195]; Affymetrix, Inc [N02-HL-6-4278]; Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center; NIH [R01 AR/AG 41398]; Swedish Research Council [K2010-54X-09894-19-3, 2006-3832]; Swedish Foundation for Strategic Research; ALF/LUA; Lundberg Foundation; Torsten and Ragnar Soderberg's Foundation; Petrus and Augusta Hedlunds Foundation; Vastra Gotaland Foundation; Goteborg Medical Society; Novo Nordisk foundation; Italian Ministry of Health [ICS110.1/RF97.71]; U.S. National Institute on Aging [263 MD 9164, 263 MD 821336, N.1-AG-1-1, N.1-AG-1-2111, N01-AG-5-0002]; National Institute on Aging, National Institutes of Health, Baltimore, Maryland; Sir Henry Wellcome Postdoctoral Fellowship [092447/Z/10/Z] FX TwinsUK: The study was funded by the Wellcome Trust, Arthritis Research Campaign, European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F2-2008-201865-GEFOS and Seventh Framework Programme grant 200800 Treat OA/(FP7/2007-2013), ENGAGE project grant agreement HEALTH-F4-2007-201413, and the FP-5 GenomEUtwin Project (QLG2-CT-2002-01254). The study also receives support from the UK Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London. TDS is an NIHR senior investigator. The project also received support from a Biotechnology and Biological Sciences Research Council project grant (G20234). The authors acknowledge the funding and support of the National Eye Institute (NEI) via an NIH/Center for Inherited Disease Research (CIDR) genotyping project. We thank the staff from the Genotyping Facilities at the Wellcome Trust Sanger Institute for sample preparation, quality control, and genotyping; Le Centre National de Genotypage, France, for genotyping; Duke University, NC, USA, for genotyping; and the Finnish Institute of Molecular Medicine, Finnish Genome Center, University of Helsinki. Genotyping was also done by CIDR as part of an NEI/NIH project grant.; SHIP: Computing resources have been made available by the Leibniz Supercomputing Centre of the Bavarian Academy of Sciences and Humanities (HLRB project h1231). SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg West Pomerania. Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg West Pomerania. This work is also part of the research project Greifswald Approach to Individualized Medicine (GANI_MED). The GANI_MED consortium is funded by the Federal Ministry of Education and Research and the Ministry of Cultural Affairs of the Federal State of Mecklenburg - West Pomerania (03IS2061A). The University of Greifswald is a member of the 'Center of Knowledge Interchange' program of the Siemens AG. The DHEAS reagents used were sponsored by Siemens Healthcare Diagnostics, Eschborn, formerly DPC Biermann GmbH, Bad Nauheim, Germany. Novo Nordisc provided partial grant support for the determination of serum samples and data analysis.; Health ABC: This study was supported by National Institute on Aging contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C.'' This research was supported (in part) by the Intramural Research Program of the NIH, National Institute on Aging.; RS1: The generation and management of GWAS genotype data for the Rotterdam Study is supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI) Netherlands Consortium of Healthy Aging (NCHA) project nr. 050-060-810, and funding from the European Commision (HEALTH-F2-2008-201865, GEFOS; HEALTH-F2-2008-35627, TREAT-OA). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. We thank Pascal Arp, Mila Jhamai, Dr Michael Moorhouse, Marijn Verkerk, and Sander Bervoets for their help in creating the GWAS database. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practioners and pharmacists. We would like to thank Dr. Tobias A. Knoch, Karol Estrada, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and especially the national German MediGRID and Services@MediGRID part of the German D-Grid, both funded by the German Bundesministerium fuer Forschung und Technology under grants #01 AK 803 A-H and # 01 IG 07015 G for access to their grid resources.; FHS: DHEAS-genotype genome-wide association analyses were supported by the National Institute of Aging (Genetics of Reproductive Life Period and Health Outcomes, R21AG032598; JMM, KL, DPK, WVZ). "The Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine was supported by the National Heart, Lung and Blood Institute's Framingham Heart Study Contract No. N01-HC-25195 and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). Analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. A portion of this research was conducted using the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center." DPK received support from NIH (Grant R01 AR/AG 41398).; GOOD: Financial support was received from the Swedish Research Council (K2010-54X-09894-19-3, 2006-3832), the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Soderberg's Foundation, Petrus and Augusta Hedlunds Foundation, the Vastra Gotaland Foundation, the Goteborg Medical Society, the Novo Nordisk foundation and the European Commission grant HEALTH-F2-2008-201865-GEFOS. We would like to thank Dr. Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and especially the national German MediGRID and Services@MediGRID part of the German D-Grid, both funded by the German Bundesministerium fuer Forschung und Technology under grants #01 AK 803 A-H and # 01 IG 07015 G for access to their grid resources. We would also like to thank Karol Estrada, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands for advice regarding the grid resources.; InCHIANTI: The InCHIANTI study baseline (1998-2000) was supported as a "targeted project" (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the U.S. National Institute on Aging (Contracts: 263 MD 9164 and 263 MD 821336); the InCHIANTI Followup 1 (2001-2003) was funded by the U.S. National Institute on Aging (Contracts: N.1-AG-1-1 and N.1-AG-1-2111); the InCHIANTI Follow-ups 2 and 3 studies (2004-2010) were financed by the U.S. National Institute on Aging (Contract: N01-AG-5-0002); supported in part by the Intramural research program of the National Institute on Aging, National Institutes of Health, Baltimore, Maryland. JRBP is funded by a Sir Henry Wellcome Postdoctoral Fellowship (092447/Z/10/Z). NR 61 TC 40 Z9 42 U1 0 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7404 J9 PLOS GENET JI PLoS Genet. PD APR PY 2011 VL 7 IS 4 AR e1002025 DI 10.1371/journal.pgen.1002025 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 755YI UT WOS:000289977000014 PM 21533175 ER PT J AU Brosh, RM AF Brosh, Robert M., Jr. TI Put on your thinking cap: G-quadruplexes, helicases, and telomeres SO AGING-US LA English DT Article ID GUANINE-RICH DNA; SACCHAROMYCES-CEREVISIAE; SEQUENCES; CELLS; SGS1; REPLICATION; MAINTENANCE; PROTEIN; WERNER; ROLES C1 NIA, Lab Mol Gerontol, NIH, NIH Biomed Res Ctr, Baltimore, MD 21224 USA. RP Brosh, RM (reprint author), NIA, Lab Mol Gerontol, NIH, NIH Biomed Res Ctr, Baltimore, MD 21224 USA. EM broshr@mail.nih.gov NR 31 TC 4 Z9 4 U1 1 U2 2 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1945-4589 J9 AGING-US JI Aging-US PD APR PY 2011 VL 3 IS 4 BP 332 EP 335 PG 4 WC Cell Biology SC Cell Biology GA 759HH UT WOS:000290230800002 PM 21732565 ER PT J AU Howard, VJ Kleindorfer, DO Judd, SE McClure, LA Safford, MM Rhodes, JD Cushman, M Moy, CS Soliman, EZ Kissela, BM Howard, G AF Howard, Virginia J. Kleindorfer, Dawn O. Judd, Suzanne E. McClure, Leslie A. Safford, Monika M. Rhodes, J. David Cushman, Mary Moy, Claudia S. Soliman, Elsayed Z. Kissela, Brett M. Howard, George TI Disparities in Stroke Incidence Contributing to Disparities in Stroke Mortality SO ANNALS OF NEUROLOGY LA English DT Article ID NORTHERN MANHATTAN STROKE; BLACK-WHITE DIFFERENCES; UNITED-STATES; FOLLOW-UP; RACIAL-DIFFERENCES; RISK-FACTORS; DISEASE; HYPERTENSION; COMMUNITIES; POPULATION AB Objective: While black-white and regional disparities in U. S. stroke mortality rates are well documented, the contribution of disparities in stroke incidence is unknown. We provide national estimates of stroke incidence by race and region, contrasting these to publicly available stroke mortality data. Methods: This analysis included 27,744 men and women without prevalent stroke (40.4% black), aged >= 45 years from the REasons for Geographic And Racial Differences in Stroke (REGARDS) national cohort study, enrolled 2003-2007. Incident stroke was defined as first occurrence of stroke over 4.4 years of follow-up. Age-sex-adjusted stroke mortality rates were calculated using data from the Centers for Disease Control and Prevention (CDC) Wide-Ranging Online Data for Epidemiological Research (WONDER) System. Results: There were 460 incident strokes over 113,469 person-years of follow-up. Relative to the rest of the United States, incidence rate ratios (IRRs) of stroke in the southeastern stroke belt and stroke buckle were 1.06 (95% confidence interval [CI], 0.87-1.29) and 1.19 (95% CI, 0.96-1.47), respectively. The age-sex-adjusted black/white IRR(black) was 1.51 (95% CI, 1.26-1.81), but for ages 45-54 years the IRR(black) was 4.02 (95% CI, 1.23-13.11) while for ages 85+ it was 0.86 (95% CI, 0.33-2.20). Generally, the IRRs(black) were less than the mortality rate ratios (MRRs) across age groups; however, only in ages 55-64 years and 65-74 years did the 95% CIs of IRRs(black) not include the MRR(black). The MRRs for regions were within 95% CIs for IRRs. Interpretation: National patterns of black-white and regional differences in stroke incidence are similar to those for stroke mortality; however, the magnitude of differences in incidence appear smaller. ANN NEUROL 2011; 69: 619-627 C1 [Howard, Virginia J.] Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Judd, Suzanne E.; McClure, Leslie A.; Rhodes, J. David; Howard, George] Univ Alabama, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. [Safford, Monika M.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Kleindorfer, Dawn O.; Kissela, Brett M.] Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH USA. [Cushman, Mary] Univ Vermont, Dept Med, Burlington, VT USA. [Cushman, Mary] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA. [Moy, Claudia S.] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA. [Soliman, Elsayed Z.] Wake Forest Univ, Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA. RP Howard, VJ (reprint author), Univ Alabama, Sch Publ Hlth, Dept Epidemiol, 1665 Univ Blvd, Birmingham, AL 35294 USA. EM vjhoward@uab.edu RI Soliman, Elsayed/D-8124-2011; McClure, Leslie/P-2929-2015; OI Soliman, Elsayed/0000-0001-5632-8150; Kissela, Brett/0000-0002-9773-4013 FU National Institutes of Health (National Institute of Neurological Disorders and Stroke) [U01 NS041588, NINDS R-01 NS039987, NCRR 1UL1 RR026314]; Allergan; Boehringer Ingelheim; NINDS; NIH FX This research was supported by a grant from the National Institutes of Health (National Institute of Neurological Disorders and Stroke cooperative agreement U01 NS041588) to GH.; D.R., G. H., and V.J.H. have received grant(s) from the NIH National Institute of Neurological Disorders and Stroke (NINDS) for the REGARDS Study. G. H. has grant(s) pending from the NIH-NINDS. B. K. has received funding from NIH-NINDS for the REGARDS study for travel to study meetings, effort for adjudication of stroke events, and authorship; has grant(s) pending (NINDS R-01 NS039987, NCRR 1UL1 RR026314); has consulted for Allergan; has developed educational presentations for and has been paid for travel from Allergan; and has provided expert testimony for various entities. D.O.K. has been paid travel expenses for meetings from NINDS REGARDS funding; has been paid for lectures from the Boehringer Ingelheim Speaker's Bureau; and has grant(s) pending from NINDS. M. C. has received grant(s) from the NIH and has been reimbursed travel expenses for meetings from the NIH. L. M. has received grant(s), has grant(s) pending, and has received consulting fees (as a DSMB member) from NINDS. S.J. has received grant(s) and has received support for travel to meetings from NIH-NINDS. NR 31 TC 121 Z9 121 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD APR PY 2011 VL 69 IS 4 BP 619 EP 627 DI 10.1002/ana.22385 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 758HV UT WOS:000290155800007 PM 21416498 ER PT J AU Harford, JB Otero, IV Anderson, BO Cazap, E Gradishar, WJ Gralow, JR Kane, GM Niens, LM Porter, PL Reeler, AV Rieger, PT Shockney, LD Shulman, LN Soldak, T Thomas, DB Thompson, B Winchester, DP Zelle, SG Badwe, RA AF Harford, Joe B. Otero, Isabel V. Anderson, Benjamin O. Cazap, Eduardo Gradishar, William J. Gralow, Julie R. Kane, Gabrielle M. Niens, Laurens M. Porter, Peggy L. Reeler, Anne V. Rieger, Paula T. Shockney, Lillie D. Shulman, Lawrence N. Soldak, Tanya Thomas, David B. Thompson, Beti Winchester, David P. Zelle, Sten G. Badwe, Rajendra A. TI Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative SO BREAST LA English DT Article DE Implementation science; Cost-effectiveness research; Situational analysis; Mortality-to-incidence ratio; Patient navigation; Advocacy ID REDUCE CANCER DISPARITIES; INCOME COUNTRIES; GUIDELINE IMPLEMENTATION; 5 CONTINENTS; MORTALITY; ERADICATION; ALLOCATION; POLICIES; SCIENCE; DISEASE AB International collaborations like the Breast Health Global Initiative (BHGI) can help low and middle income countries (LMCs) to establish or improve breast cancer control programs by providing evidence-based, resource-stratified guidelines for the management and control of breast cancer. The Problem Solving Working Group of the BHGI 2010 Global Summit met to develop a consensus statement on problem-solving strategies addressing breast cancer in LMCs. To better assess breast cancer burden in poorly studied populations, countries require accurate statistics regarding breast cancer incidence and mortality. To better identify health care system strengths and weaknesses, countries require reasonable indicators of true health system quality and capacity. Using qualitative and quantitative research methods, countries should formulate cancer control strategies to identify both system inefficiencies and patient barriers. Patient navigation programs linked to public advocacy efforts feed and strengthen functional early detection and treatment programs. Cost-effectiveness research and implementation science are tools that can guide and expand successful pilot programs. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Anderson, Benjamin O.] Univ Washington, Fred Hutchinson Canc Res Ctr, Breast Hlth Global Initiat, Seattle, WA 98195 USA. [Harford, Joe B.; Otero, Isabel V.] NCI, Off Int Affairs, NIH, Bethesda, MD 20892 USA. [Cazap, Eduardo] SLACOM Soc Latinoamer & Caribe Oncol Med, Buenos Aires, DF, Argentina. [Gradishar, William J.] Northwestern Univ, Feinberg Sch Med, NW Mem Hosp, Evanston, IL USA. [Gralow, Julie R.] Seattle Canc Care Alliance, Seattle, WA USA. [Anderson, Benjamin O.; Gralow, Julie R.; Kane, Gabrielle M.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Niens, Laurens M.] Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands. [Reeler, Anne V.] Axios Int, Paris, France. [Rieger, Paula T.] Oncol Nursing Soc, Pittsburgh, PA USA. [Shockney, Lillie D.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA. [Shulman, Lawrence N.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Soldak, Tanya] Resource & Policy Exchange, Delhi, NY USA. [Thomas, David B.] Amer Coll Surg, Natl Accreditat Program Breast Ctr, Chicago, IL USA. [Zelle, Sten G.] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6525 ED Nijmegen, Netherlands. [Badwe, Rajendra A.] Tata Mem Hosp, Dept Surg, Bombay 400012, Maharashtra, India. RP Anderson, BO (reprint author), Univ Washington, Fred Hutchinson Canc Res Ctr, Breast Hlth Global Initiat, Box 356410, Seattle, WA 98195 USA. EM banderso@u.washington.edu FU Breast Health Global Initiative (BHGI); Bayer Schering Pharma; Breast Cancer Research Foundation (BCRF); ASCO; UICC; ESMO; BCRF; Genetech; Amgen; Norvartis; Roche; Susan G. Komen for the CureRegistered; Fogarty International FX BOA received funding from Breast Health Global Initiative (BHGI); EC received consultancy funding from Bayer Schering Pharma, grants from the Breast Cancer Research Foundation (BCRF) and Poniard Pharmaceuticals, was on the speakers bureaus for Bayer and Bristol Meyers Squibb, and received travel expenses from ASCO, UICC, ESMO, and BCRF; DBT and PP have received funding from BHGI for travel; JRG received funding from Genetech, Amgen, Norvartis, and Roche; LMN and SGZ received funding from BHGI and Susan G. Komen for the Cure (R); BT received travel funding or other support from Fogarty International. All other authors and working group members reported no conflict of interest. NR 70 TC 17 Z9 17 U1 0 U2 8 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0960-9776 J9 BREAST JI Breast PD APR PY 2011 VL 20 SU 2 BP S20 EP S29 DI 10.1016/j.breast.2011.02.007 PG 10 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 758VB UT WOS:000290194000004 PM 21376593 ER PT J AU Yip, CH Cazap, E Anderson, BO Bright, KL Caleffi, M Cardoso, F Elzawawy, AM Harford, JB Krygier, GD Masood, S Murillo, R Muse, IM Otero, IV Passman, LJ Santini, LA da Silva, RCF Thomas, DB Torres, S Zhengs, Y Khaled, HM AF Yip, Cheng-Har Cazap, Eduardo Anderson, Benjamin O. Bright, Kristin L. Caleffi, Maira Cardoso, Fatima Elzawawy, Ahmed M. Harford, Joe B. Krygier, Gabriel D. Masood, Shahla Murillo, Raul Muse, Ignacio M. Otero, Isabel V. Passman, Leigh J. Santini, Luiz A. Ferreira da Silva, Ronaldo Correa Thomas, David B. Torres, Soledad Zhengs, Ying Khaled, Hussein M. TI Breast cancer management in middle-resource countries (MRCs): Consensus statement from the Breast Health Global Initiative SO BREAST LA English DT Article DE Breast cancer; Middle resource countries; Early detection; Treatment; Multidisciplinary services; Health care financing ID OF-AMERICAN-PATHOLOGISTS; INCOME COUNTRIES; GUIDELINE IMPLEMENTATION; QUALITY-ASSURANCE; LATIN-AMERICA; CARE; TRIAL; ALLOCATION; SOCIETY; WOMEN AB In middle resource countries (MRCs), cancer control programs are becoming a priority as the pattern of disease shifts from infectious diseases to non-communicable diseases such as breast cancer, the most common cancer among women in MRCs. The Middle Resource Scenarios Working Group of the BHGI 2010 Global Summit met to identify common issues and obstacles to breast cancer detection, diagnosis and treatment in MRCs. They concluded that breast cancer early detection programs continue to be important, should include clinical breast examination (CBE) with or without mammography, and should be coupled with active awareness programs. Mammographic screening is usually opportunistic and early detection programs are often hampered by logistical and financial problems, as well as socio-cultural barriers, despite improved public educational efforts. Although multidisciplinary services for treatment are available, geographical and economic limitations to these services can lead to an inequity in health care access. Without adequate health insurance coverage, limited personal finances can be a significant barrier to care for many patients. Despite the improved availability of services (surgery, pathology, radiology and radiotherapy), quality assurance programs remain a challenge. Better access to anticancer drugs is needed to improve outcomes, as are rehabilitation programs for survivors. Focused and sustained government health care financing in MRCs is needed to improve early detection and treatment of breast cancer. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Anderson, Benjamin O.] Univ Washington, Fred Hutchinson Canc Res Ctr, Breast Hlth Global Initiat, Seattle, WA 98195 USA. [Yip, Cheng-Har] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia. [Cazap, Eduardo] SLACOM Soc Latinoamer & Caribe Oncol Med, Buenos Aires, DF, Argentina. [Bright, Kristin L.] NYU, NYU Canc Inst, New York, NY USA. [Bright, Kristin L.] NYU, NYU Sch Med, New York, NY USA. [Caleffi, Maira] Hosp Moinhos Venta, Porto Alegre, RS, Brazil. [Cardoso, Fatima] European Sch Oncol, Milan, Italy. [Cardoso, Fatima] Champalimaud Canc Ctr, Lisbon, Portugal. [Elzawawy, Ahmed M.] ICEDOC, Port Said, Egypt. [Harford, Joe B.; Otero, Isabel V.] NCI, Off Int Affairs, NIH, Bethesda, MD 20892 USA. [Krygier, Gabriel D.] Acad Univ Clin Hosp Montevideo, Montevideo, Uruguay. [Krygier, Gabriel D.] Natl Breast Canc Program, Montevideo, Uruguay. [Masood, Shahla] Univ Florida, Coll Med, Jacksonville, FL USA. [Murillo, Raul] Inst Nacl Cancerol Colombia, Bogota, Colombia. [Muse, Ignacio M.] Natl Canc Program, Montevideo, Uruguay. [Passman, Leigh J.; Santini, Luiz A.; Ferreira da Silva, Ronaldo Correa] Inst Nacl Canc, Rio De Janeiro, Brazil. [Torres, Soledad] Clin Las Condes Breast Ctr, Santiago, Chile. [Ferreira da Silva, Ronaldo Correa; Zhengs, Ying] Shanghai Municipal Ctr Dis Control & Prevent, Shanghai, Peoples R China. [Khaled, Hussein M.] Cairo Univ, Natl Canc Inst, Cairo, Egypt. RP Anderson, BO (reprint author), Univ Washington, Fred Hutchinson Canc Res Ctr, Breast Hlth Global Initiat, Box 356410, Seattle, WA 98195 USA. EM banderso@u.washington.edu RI Yip, Cheng-Har/B-1909-2010; OI Cardoso, Fatima/0000-0002-6692-2249 FU Breast Health Global Initiative (BHGI); Bayer Sherling Pharma; Breast Cancer Research Foundation (BCRF); ASCO; UICC; ESMO; GSK; U.S. Department of Defense [W81XWH-04-1-0905]; Fred Hutchinson Cancer Research Center; Susan G. Komen for the CureRegistered [SG09-0605-01-BHGI]; U.S. Office of International Affairs, National Cancer Institute; European School of Oncology; Pan American Health Organization; Sheikh Mohammed Hussein Al-Amoudi Center of Excellence in Breast Cancer; American Society of Clinical Oncology; LIVESTRONG; U.S. Centers for Disease Control and Prevention; U.S. Office of Women's Health, Department of Health and Human Services; U.S. Office of Science Planning and Assessment, National Cancer Institute; U.S. Office of Research on Women's Health, National Institutes of Health; GE Healthcare; Sanofi-Aventis FX BOA received funding from Breast Health Global Initiative (BHGI), EC received consultancy funding from Bayer Sherling Pharma, grants from Breast Cancer Research Foundation (BCRF) and Poniard Pharmaceuticals, was on the speakers bureaus for Bayer and Bristol Meyers Squibb, and received travel expenses from ASCO, UICC, ESMO, and BCRF; CHY was on an expert panel and received research funding from GSK and was on the speakers bureaus for Sanofi-Aventis and Roche. DBT has received funding from BHGI for travel. KB received funding from U.S. Department of Defense Breast Cancer Research Program Center of Excellence (#W81XWH-04-1-0905). All other authors and working group members reported no conflict of interest.; BHGI received (2010 Global Summit) grants and contributions from Fred Hutchinson Cancer Research Center; Susan G. Komen for the Cure (R) (Grant Award SG09-0605-01-BHGI); U.S. Office of International Affairs, National Cancer Institute; European School of Oncology; Pan American Health Organization; Sheikh Mohammed Hussein Al-Amoudi Center of Excellence in Breast Cancer; American Society of Clinical Oncology; LIVESTRONG; U.S. Centers for Disease Control and Prevention; U.S. Office of Women's Health, Department of Health and Human Services; U.S. Office of Science Planning and Assessment, National Cancer Institute; U.S. Office of Research on Women's Health, National Institutes of Health and unrestricted educational grants from GE Healthcare and Sanofi-Aventis. NR 66 TC 17 Z9 18 U1 2 U2 5 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0960-9776 J9 BREAST JI Breast PD APR PY 2011 VL 20 SU 2 BP S12 EP S19 DI 10.1016/j.breast.2011.02.015 PG 8 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 758VB UT WOS:000290194000003 PM 21388811 ER PT J AU Kothapalli, NR Fugmann, SD AF Kothapalli, Naga Rama Fugmann, Sebastian D. TI Targeting of AID-mediated sequence diversification to immunoglobulin genes SO CURRENT OPINION IN IMMUNOLOGY LA English DT Review ID INDUCED CYTIDINE DEAMINASE; CLASS-SWITCH RECOMBINATION; SINGLE-STRANDED-DNA; SOMATIC HYPERMUTATION; B-CELLS; REGULATORY REGION; IG; CONVERSION; TRANSCRIPTION; ENHANCER AB Activation-induced cytidine deaminase (AID) is a key enzyme for antibody-mediated immune responses. Antibodies are encoded by the immunoglobulin genes and AID acts as a transcription-dependent DNA mutator on these genes to improve antibody affinity and effector functions. An emerging theme in field is that many transcribed genes are potential targets of AID, presenting an obvious danger to genomic integrity. Thus there are mechanisms in place to ensure that mutagenic outcomes of AID activity are specifically restricted to the immunoglobulin loci. Cis-regulatory targeting elements mediate this effect and their mode of action is probably a combination of immunoglobulin gene specific activation of AID and a perversion of faithful DNA repair towards error-prone outcomes. C1 [Kothapalli, Naga Rama; Fugmann, Sebastian D.] NIA, Mol Immunol Unit, Lab Mol Biol & Immunol, NIH,Biomed Res Ctr, Baltimore, MD 21224 USA. RP Fugmann, SD (reprint author), NIA, Mol Immunol Unit, Lab Mol Biol & Immunol, NIH,Biomed Res Ctr, 251 Bayview Blvd, Baltimore, MD 21224 USA. EM fugmanns@mail.nih.gov OI Kothapalli, Naga Rama/0000-0001-7993-8525 FU NIH, National Institute on Aging FX We thank Drs. Nina Papavasiliou and Shu Yuan Yang for helpful comments and suggestions. This work was supported entirely by the Intramural Research Program of the NIH, National Institute on Aging. NR 46 TC 11 Z9 11 U1 0 U2 1 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0952-7915 J9 CURR OPIN IMMUNOL JI Curr. Opin. Immunol. PD APR PY 2011 VL 23 IS 2 BP 184 EP 189 DI 10.1016/j.coi.2010.12.009 PG 6 WC Immunology SC Immunology GA 758VW UT WOS:000290196200006 PM 21295456 ER PT J AU Hobbs, EC Fontaine, F Yin, XF Storz, G AF Hobbs, Errett C. Fontaine, Fanette Yin, Xuefeng Storz, Gisela TI An expanding universe of small proteins SO CURRENT OPINION IN MICROBIOLOGY LA English DT Review ID CYTOCHROME B(6)F COMPLEX; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; INHIBITOR SDA; SMALL RNA; MEMBRANE; PEPTIDES; BACTERIA; TOXIN; NISIN AB Historically, small proteins (sproteins) of less than 50 amino acids, in their final processed forms or genetically encoded as such, have been understudied. However, both serendipity and more recent focused efforts have led to the identification of a number of new sproteins in both Gram-negative and Gram-positive bacteria. Increasing evidence demonstrates that sproteins participate in a wide array of cellular processes and exhibit great diversity in their mechanisms of action, yet general principles of sprotein function are emerging. This review highlights examples of sproteins that participate in cell signaling, act as antibiotics and toxins, and serve as structural proteins. We also describe roles for sproteins in detecting and altering membrane features, acting as chaperones, and regulating the functions of larger proteins. C1 [Hobbs, Errett C.; Fontaine, Fanette; Yin, Xuefeng; Storz, Gisela] NICHD, Cell Biol & Metab Program, NIH, Bethesda, MD 20892 USA. [Yin, Xuefeng] Peking Univ, Sch Basic Life Sci, Beijing 100191, Peoples R China. RP Storz, G (reprint author), NICHD, Cell Biol & Metab Program, NIH, Bldg 181,Room 101,18 Lib Dr MSC 5430, Bethesda, MD 20892 USA. EM storz@helix.nih.gov OI Storz, Gisela/0000-0001-6698-1241 FU NICHD; NIGMS FX This work was supported by the Intramural Research Program of NICHD and a fellowship from the Pharmacology Research Associate Training program of NIGMS (ECH). We thank AB Blanc-Potard, M Goulian, MR Hemm, DB Kearns, MT Laub, KS Ramamurthi, and members of the Storz lab for helpful comments and discussions. NR 43 TC 46 Z9 48 U1 0 U2 15 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1369-5274 J9 CURR OPIN MICROBIOL JI Curr. Opin. Microbiol. PD APR PY 2011 VL 14 IS 2 BP 167 EP 173 DI 10.1016/j.mib.2011.01.007 PG 7 WC Microbiology SC Microbiology GA 760YC UT WOS:000290359700009 PM 21342783 ER PT J AU Sultana, A Nakaya, N Senatorov, VV Tomarev, SI AF Sultana, Afia Nakaya, Naoki Senatorov, Vladimir V. Tomarev, Stanislav I. TI Olfactomedin 2: Expression in the Eye and Interaction with Other Olfactomedin Domain-Containing Proteins SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID OPEN-ANGLE GLAUCOMA; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; MUTATED MOUSE; MYOCILIN; GENE; CELLS; GLYCOPROTEIN; MUTATIONS; ZEBRAFISH AB PURPOSE. Olfactomedin 2 (OLFM2) belongs to the family of olfactomedin domain-containing proteins. Genetic data suggest its association with glaucoma in Japanese patients. However, its functions are still elusive. In this study, the properties of mammalian OLFM2 were investigated. METHODS. Expression of the rat and mouse Olfm2 gene was studied by using real-time PCR and in situ hybridization. Substitutions were introduced into OLFM2 by mutagenesis in vitro. Intracellular localization of OLFM2 was studied by confocal microscopy after transient transfection in HEK293 cells. Interaction of OLFM2 with olfactomedin 1 (Olfm1), olfactomedin 3 (Olfm3), myocilin, and gliomedin was studied by using co-immunoprecipitation. RESULTS. Two major human OLFM2 mRNAs encode secreted proteins with a length of 454 and 478 amino acids. OLFM2 is more closely related to OLFM1 and -3 than to any other family members. Olfm2 showed the most dynamic expression pattern compared with Olfm1 and -3 during mouse eye development and was expressed preferentially in the developing retinal ganglion cell layer. Among three OLFM2 substitutions tested (T86M, R144Q, and L420S), only L420S completely blocked secretion of the protein. OLFM2 interacted with Olfm1 and -3, but not with myocilin and gliomedin. Co-transfection of the L420S mutant with wild-type Olfm1 and -3 significantly inhibited secretion of Olfm1 and -3. CONCLUSIONS. Highly conserved OLFM2 protein may play an important role in the course of retinal and eye development. Severe mutations in one of the closely related olfactomedin domain-containing proteins (Olfm1-3) may block the secretion and probably the activity of all three family members, leading to more pronounced diseases of the retina than the knockout of individual genes. (Invest Ophthalmol Vis Sci. 2011;52:2584-2592) DOI:10.1167/iovs.10-6356 C1 [Sultana, Afia; Nakaya, Naoki; Senatorov, Vladimir V.; Tomarev, Stanislav I.] NEI, Mol Mech Glaucoma Sect, Lab Mol & Dev Biol, NIH, Bethesda, MD 20892 USA. RP Tomarev, SI (reprint author), NEI, Mol Mech Glaucoma Sect, Lab Mol & Dev Biol, NIH, 5635 Fishers Lane,Room 1124, Bethesda, MD 20892 USA. EM tomarevs@nei.nih.gov FU National Eye Institute, National Institutes of Health FX Supported by the Intramural Research Program of the National Eye Institute, National Institutes of Health. NR 45 TC 9 Z9 13 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2011 VL 52 IS 5 BP 2584 EP 2592 DI 10.1167/iovs.10-6356 PG 9 WC Ophthalmology SC Ophthalmology GA 757TQ UT WOS:000290111000011 PM 21228389 ER PT J AU Czobor, P Skolnick, P AF Czobor, Pal Skolnick, Phil TI The Secrets of a Successful Clinical Trial: Compliance, Compliance, and Compliance SO MOLECULAR INTERVENTIONS LA English DT Editorial Material ID MEDICATION; BICIFADINE; ADHERENCE; INHIBITOR; WEIGHT; MODELS; PAIN C1 [Skolnick, Phil] NIDA, Div Pharmacotherapies & Med Consequences Drug Abu, NIH, Bethesda, MD 20892 USA. [Czobor, Pal] Semmelweis Univ, Dept Psychiat & Psychotherapy, Budapest, Hungary. [Czobor, Pal] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA. RP Skolnick, P (reprint author), NIDA, Div Pharmacotherapies & Med Consequences Drug Abu, NIH, Bethesda, MD 20892 USA. EM czo-bor@psych.sote.hu; Phil.Skolnick@nih.gov NR 19 TC 16 Z9 16 U1 0 U2 0 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 1534-0384 J9 MOL INTERV JI Mol. Interv. PD APR PY 2011 VL 11 IS 2 BP 107 EP 110 DI 10.1124/mi.11.2.8 PG 4 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 758GN UT WOS:000290151400008 PM 21540470 ER PT J AU Myers, RM Stamatoyannopoulos, J Snyder, M Dunham, I Hardison, RC Bernstein, BE Gingeras, TR Kent, WJ Birney, E Wold, B Crawford, GE Bernstein, BE Epstein, CB Shoresh, N Ernst, J Mikkelsen, TS Kheradpour, P Zhang, XL Wang, L Issner, R Coyne, MJ Durham, T Ku, MC Truong, T Ward, LD Altshuler, RC Lin, MF Kellis, M Gingeras, TR Davis, CA Kapranov, P Dobin, A Zaleski, C Schlesinger, F Batut, P Chakrabortty, S Jha, S Lin, W Drenkow, J Wang, HE Bell, K Gao, H Bell, I Dumais, E Dumais, J Antonarakis, SE Ucla, C Borel, C Guigo, R Djebali, S Lagarde, J Kingswood, C Ribeca, P Sammeth, M Alioto, T Merkel, A Tilgner, H Carninci, P Hayashizaki, Y Lassmann, T Takahashi, H Abdelhamid, RF Hannon, G Fejes-Toth, K Preall, J Gordon, A Sotirova, V Reymond, A Howald, C Graison, EAY Chrast, J Ruan, YJ Ruan, XA Shahab, A Poh, WT Wei, CL Crawford, GE Furey, TS Boyle, AP Sheffield, NC Song, LY Shibata, Y Vales, T Winter, D Zhang, ZC London, D Wang, TY Birney, E Keefe, D Iyer, VR Lee, BK McDaniell, RM Liu, Z Battenhouse, A Bhinge, AA Lieb, JD Grasfeder, LL Showers, KA Giresi, PG Kim, SKC Shestak, C Myers, RM Pauli, F Reddy, TE Gertz, J Partridge, EC Jain, P Sprouse, RO Bansal, A Pusey, B Muratet, MA Varley, KE Bowling, KM Newberry, KM Nesmith, AS Dilocker, JA Parker, SL Waite, LL Thibeault, K Roberts, K Absher, DM Wold, B Mortazavi, A Williams, B Marinov, G Trout, D Pepke, S King, B McCue, K Kirilusha, A DeSalvo, G Fisher-Aylor, K Amrhein, H Vielmetter, J Sherlock, G Sidow, A Batzoglou, S Rauch, R Kundaje, A Libbrecht, M Margulies, EH Parker, SCJ Elnitski, L Green, ED Hubbard, T Harrow, J Searle, S Kokocinski, F Aken, B Frankish, A Hunt, T Despacio-Reyes, G Kay, M Mukherjee, G Bignell, A Saunders, G Boychenko, V Brent, M Van Baren, MJ Brown, RH Gerstein, M Khurana, E Balasubramanian, S Zhang, ZD Lam, H Cayting, P Robilotto, R Lu, Z Guigo, R Derrien, T Tanzer, A Knowles, DG Mariotti, M Kent, WJ Haussler, D Harte, R Diekhans, M Kellis, M Lin, M Kheradpour, P Ernst, J Reymond, A Howald, C Graison, EAY Chrast, J Valencia, A Tress, M Rodriguez, JM Snyder, M Landt, SG Raha, D Shi, MY Euskirchen, G Grubert, F Kasowski, M Lian, J Cayting, P Lacroute, P Xu, YH Monahan, H Patacsil, D Slifer, T Yang, XQ Charos, A Reed, B Wu, LF Auerbach, RK Habegger, L Hariharan, M Rozowsky, J Abyzov, A Weissman, SM Gerstein, M Struhl, K Lamarre-Vincent, N Lindahl-Allen, M Miotto, B Moqtaderi, Z Fleming, JD Newburger, P Farnham, PJ Frietze, S O'Geen, H Xu, XQ Blahnik, KR Cao, AR Iyengar, S Stamatoyannopoulos, JA Kaul, R Thurman, RE Wang, H Navas, PA Sandstrom, R Sabo, PJ Weaver, M Canfield, T Lee, K Neph, S Roach, V Reynolds, A Johnson, A Rynes, E Giste, E Vong, S Neri, J Frum, T Johnson, EM Nguyen, ED Ebersol, AK Sanchez, ME Sheffer, HH Lotakis, D Haugen, E Humbert, R Kutyavin, T Shafer, T Dekker, J Lajoie, BR Sanyal, A Kent, WJ Rosenbloom, KR Dreszer, TR Raney, BJ Barber, GP Meyer, LR Sloan, CA Malladi, VS Cline, MS Learned, K Swing, VK Zweig, AS Rhead, B Fujita, PA Roskin, K Karolchik, D Kuhn, RM Haussler, D Birney, E Dunham, I Wilder, SP Keefe, D Sobral, D Herrero, J Beal, K Lukk, M Brazma, A Vaquerizas, JM Luscombe, NM Bickel, PJ Boley, N Brown, JB Li, QH Huang, HY Gerstein, M Habegger, L Sboner, A Rozowsky, J Auerbach, RK Yip, KY Cheng, C Yan, KK Bhardwaj, N Wang, J Lochovsky, L Jee, J Gibson, T Leng, J Du, J Hardison, RC Harris, RS Song, G Miller, W Haussler, D Roskin, K Suh, B Wang, T Paten, B Noble, WS Hoffman, MM Buske, OJ Weng, ZP Dong, XJ Wang, J Xi, HL Tenenbaum, SA Doyle, F Penalva, LO Chittur, S Tullius, TD Parker, SCJ White, KP Karmakar, S Victorsen, A Jameel, N Bild, N Grossman, RL Snyder, M Landt, SG Yang, XQ Patacsil, D Slifer, T Dekker, J Lajoie, BR Sanyal, A Weng, ZP Whitfield, TW Wang, J Collins, PJ Trinklein, ND Partridge, EC Myers, RM Giddings, MC Chen, X Khatun, J Maier, C Yu, YB Gunawardena, H Risk, B Feingold, EA Lowdon, RF Dillon, LAL Good, PJ AF Myers, Richard M. Stamatoyannopoulos, John Snyder, Michael Dunham, Ian Hardison, Ross C. Bernstein, Bradley E. Gingeras, Thomas R. Kent, W. James Birney, Ewan Wold, Barbara Crawford, Gregory E. Bernstein, Bradley E. Epstein, Charles B. Shoresh, Noam Ernst, Jason Mikkelsen, Tarjei S. Kheradpour, Pouya Zhang, Xiaolan Wang, Li Issner, Robbyn Coyne, Michael J. Durham, Timothy Ku, Manching Thanh Truong Ward, Lucas D. Altshuler, Robert C. Lin, Michael F. Kellis, Manolis Gingeras, Thomas R. Davis, Carrie A. Kapranov, Philipp Dobin, Alexander Zaleski, Christopher Schlesinger, Felix Batut, Philippe Chakrabortty, Sudipto Jha, Sonali Lin, Wei Drenkow, Jorg Wang, Huaien Bell, Kim Gao, Hui Bell, Ian Dumais, Erica Dumais, Jacqueline Antonarakis, Stylianos E. Ucla, Catherine Borel, Christelle Guigo, Roderic Djebali, Sarah Lagarde, Julien Kingswood, Colin Ribeca, Paolo Sammeth, Micha Alioto, Tyler Merkel, Angelika Tilgner, Hagen Carninci, Piero Hayashizaki, Yoshihide Lassmann, Timo Takahashi, Hazuki Abdelhamid, Rehab F. Hannon, Gregory Fejes-Toth, Katalin Preall, Jonathan Gordon, Assaf Sotirova, Vihra Reymond, Alexandre Howald, Cedric Graison, Emilie Ait Yahya Chrast, Jacqueline Ruan, Yijun Ruan, Xiaoan Shahab, Atif Poh, Wan Ting Wei, Chia-Lin Crawford, Gregory E. Furey, Terrence S. Boyle, Alan P. Sheffield, Nathan C. Song, Lingyun Shibata, Yoichiro Vales, Teresa Winter, Deborah Zhang, Zhancheng London, Darin Wang, Tianyuan Birney, Ewan Keefe, Damian Iyer, Vishwanath R. Lee, Bum-Kyu McDaniell, Ryan M. Liu, Zheng Battenhouse, Anna Bhinge, Akshay A. Lieb, Jason D. Grasfeder, Linda L. Showers, Kimberly A. Giresi, Paul G. Kim, Seul K. C. Shestak, Christopher Myers, Richard M. Pauli, Florencia Reddy, Timothy E. Gertz, Jason Partridge, E. Christopher Jain, Preti Sprouse, Rebekka O. Bansal, Anita Pusey, Barbara Muratet, Michael A. Varley, Katherine E. Bowling, Kevin M. Newberry, Kimberly M. Nesmith, Amy S. Dilocker, Jason A. Parker, Stephanie L. Waite, Lindsay L. Thibeault, Krista Roberts, Kevin Absher, Devin M. Wold, Barbara Mortazavi, Ali Williams, Brian Marinov, Georgi Trout, Diane Pepke, Shirley King, Brandon McCue, Kenneth Kirilusha, Anthony DeSalvo, Gilberto Fisher-Aylor, Katherine Amrhein, Henry Vielmetter, Jost Sherlock, Gavin Sidow, Arend Batzoglou, Serafim Rauch, Rami Kundaje, Anshul Libbrecht, Max Margulies, Elliott H. Parker, Stephen C. J. Elnitski, Laura Green, Eric D. Hubbard, Tim Harrow, Jennifer Searle, Stephen Kokocinski, Felix Aken, Browen Frankish, Adam Hunt, Toby Despacio-Reyes, Gloria Kay, Mike Mukherjee, Gaurab Bignell, Alexandra Saunders, Gary Boychenko, Veronika Brent, Michael Van Baren, M. J. Brown, Randall H. Gerstein, Mark Khurana, Ekta Balasubramanian, Suganthi Zhang, Zhengdong Lam, Hugo Cayting, Philip Robilotto, Rebecca Lu, Zhi Guigo, Roderic Derrien, Thomas Tanzer, Andrea Knowles, David G. Mariotti, Marco Kent, W. James Haussler, David Harte, Rachel Diekhans, Mark Kellis, Manolis Lin, Mike Kheradpour, Pouya Ernst, Jason Reymond, Alexandre Howald, Cedric Graison, Emilie Ait Yahya Chrast, Jacqueline Valencia, Alfonso Tress, Michael Manuel Rodriguez, Jose Snyder, Michael Landt, Stephen G. Raha, Debasish Shi, Minyi Euskirchen, Ghia Grubert, Fabian Kasowski, Maya Lian, Jin Cayting, Philip Lacroute, Phil Xu, Youhan Monahan, Hannah Patacsil, Dorrelyn Slifer, Teri Yang, Xinqiong Charos, Alexandra Reed, Brian Wu, Linfeng Auerbach, Raymond K. Habegger, Lukas Hariharan, Manoj Rozowsky, Joel Abyzov, Alexej Weissman, Sherman M. Gerstein, Mark Struhl, Kevin Lamarre-Vincent, Nathan Lindahl-Allen, Marianne Miotto, Benoit Moqtaderi, Zarmik Fleming, Joseph D. Newburger, Peter Farnham, Peggy J. Frietze, Seth O'Geen, Henriette Xu, Xiaoqin Blahnik, Kim R. Cao, Alina R. Iyengar, Sushma Stamatoyannopoulos, John A. Kaul, Rajinder Thurman, Robert E. Wang, Hao Navas, Patrick A. Sandstrom, Richard Sabo, Peter J. Weaver, Molly Canfield, Theresa Lee, Kristen Neph, Shane Roach, Vaughan Reynolds, Alex Johnson, Audra Rynes, Eric Giste, Erika Vong, Shinny Neri, Jun Frum, Tristan Johnson, Ericka M. Nguyen, Eric D. Ebersol, Abigail K. Sanchez, Minerva E. Sheffer, Hadar H. Lotakis, Dimitra Haugen, Eric Humbert, Richard Kutyavin, Tanya Shafer, Tony Dekker, Job Lajoie, Bryan R. Sanyal, Amartya Kent, W. James Rosenbloom, Kate R. Dreszer, Timothy R. Raney, Brian J. Barber, Galt P. Meyer, Laurence R. Sloan, Cricket A. Malladi, Venkat S. Cline, Melissa S. Learned, Katrina Swing, Vanessa K. Zweig, Ann S. Rhead, Brooke Fujita, Pauline A. Roskin, Krishna Karolchik, Donna Kuhn, Robert M. Haussler, David Birney, Ewan Dunham, Ian Wilder, Steven P. Keefe, Damian Sobral, Daniel Herrero, Javier Beal, Kathryn Lukk, Margus Brazma, Alvis Vaquerizas, Juan M. Luscombe, Nicholas M. Bickel, Peter J. Boley, Nathan Brown, James B. Li, Qunhua Huang, Haiyan Gerstein, Mark Habegger, Lukas Sboner, Andrea Rozowsky, Joel Auerbach, Raymond K. Yip, Kevin Y. Cheng, Chao Yan, Koon-Kiu Bhardwaj, Nitin Wang, Jing Lochovsky, Lucas Jee, Justin Gibson, Theodore Leng, Jing Du, Jiang Hardison, Ross C. Harris, Robert S. Song, Giltae Miller, Webb Haussler, David Roskin, Krishna Suh, Bernard Wang, Ting Paten, Benedict Noble, William S. Hoffman, Michael M. Buske, Orion J. Weng, Zhiping Dong, Xianjun Wang, Jie Xi, Hualin Tenenbaum, Scott A. Doyle, Frank Penalva, Luiz O. Chittur, Sridar Tullius, Thomas D. Parker, Stephen C. J. White, Kevin P. Karmakar, Subhradip Victorsen, Alec Jameel, Nader Bild, Nick Grossman, Robert L. Snyder, Michael Landt, Stephen G. Yang, Xinqiong Patacsil, Dorrelyn Slifer, Teri Dekker, Job Lajoie, Bryan R. Sanyal, Amartya Weng, Zhiping Whitfield, Troy W. Wang, Jie Collins, Patrick J. Trinklein, Nathan D. Partridge, E. Christopher Myers, Richard M. Giddings, Morgan C. Chen, Xian Khatun, Jainab Maier, Chris Yu, Yanbao Gunawardena, Harsha Risk, Brian Feingold, Elise A. Lowdon, Rebecca F. Dillon, Laura A. L. Good, Peter J. CA ENCODE Project Consortium TI A User's Guide to the Encyclopedia of DNA Elements (ENCODE) SO PLOS BIOLOGY LA English DT Article ID EMBRYONIC STEM-CELLS; CHROMOSOME CONFORMATION CAPTURE; TRANSCRIPTION FACTOR-BINDING; MESSENGER-RNA SUBSETS; UCSC GENOME BROWSER; COLORECTAL-CANCER; IN-VIVO; COPY-NUMBER; RIBONUCLEOPROTEIN COMPLEXES; DEVELOPMENTAL REGULATORS AB The mission of the Encyclopedia of DNA Elements (ENCODE) Project is to enable the scientific and medical communities to interpret the human genome sequence and apply it to understand human biology and improve health. The ENCODE Consortium is integrating multiple technologies and approaches in a collective effort to discover and define the functional elements encoded in the human genome, including genes, transcripts, and transcriptional regulatory regions, together with their attendant chromatin states and DNA methylation patterns. In the process, standards to ensure high-quality data have been implemented, and novel algorithms have been developed to facilitate analysis. Data and derived results are made available through a freely accessible database. Here we provide an overview of the project and the resources it is generating and illustrate the application of ENCODE data to interpret the human genome. C1 [Pauli, Florencia; Partridge, E. Christopher; Bansal, Anita; Pusey, Barbara; Nesmith, Amy S.; Dilocker, Jason A.; Absher, Devin M.] HudsonAlpha Inst Biotechnol, Huntsville, AL USA. [Stamatoyannopoulos, John; Stamatoyannopoulos, John A.; Kaul, Rajinder; Thurman, Robert E.; Wang, Hao; Navas, Patrick A.; Sandstrom, Richard; Sabo, Peter J.; Weaver, Molly; Canfield, Theresa; Lee, Kristen; Neph, Shane; Roach, Vaughan; Reynolds, Alex; Johnson, Audra; Rynes, Eric; Giste, Erika; Vong, Shinny; Neri, Jun; Frum, Tristan; Johnson, Ericka M.; Nguyen, Eric D.; Ebersol, Abigail K.; Sanchez, Minerva E.; Sheffer, Hadar H.; Lotakis, Dimitra; Haugen, Eric; Humbert, Richard; Kutyavin, Tanya; Shafer, Tony; Noble, William S.; Hoffman, Michael M.; Buske, Orion J.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Snyder, Michael; Sherlock, Gavin; Sidow, Arend; Rauch, Rami; Cayting, Philip; Landt, Stephen G.; Shi, Minyi; Euskirchen, Ghia; Grubert, Fabian; Lacroute, Phil; Patacsil, Dorrelyn; Slifer, Teri; Yang, Xinqiong; Wu, Linfeng; Hariharan, Manoj] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA. [Dunham, Ian; Birney, Ewan; Keefe, Damian; Wilder, Steven P.; Sobral, Daniel; Herrero, Javier; Beal, Kathryn; Lukk, Margus; Brazma, Alvis; Vaquerizas, Juan M.; Luscombe, Nicholas M.] European Bioinformat Inst EBI, Cambridge, England. [Hardison, Ross C.; Harris, Robert S.; Song, Giltae; Miller, Webb] Penn State Univ, Dept Biochem & Mol Biol, Ctr Comparat Genom & Bioinformat, University Pk, PA 16802 USA. [Bernstein, Bradley E.; Epstein, Charles B.; Shoresh, Noam; Ernst, Jason; Mikkelsen, Tarjei S.; Kheradpour, Pouya; Zhang, Xiaolan; Wang, Li; Issner, Robbyn; Coyne, Michael J.; Durham, Timothy; Ku, Manching; Ward, Lucas D.; Lin, Michael F.; Kellis, Manolis; Sidow, Arend; Lin, Mike] Broad Inst MT & Harvard, Cambridge, MA USA. Howard Hughes Med Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Lian, Jin; Weissman, Sherman M.] Harvard Univ, Sch Med, Boston, MA USA. [Gingeras, Thomas R.; Davis, Carrie A.; Dobin, Alexander; Zaleski, Christopher; Schlesinger, Felix; Batut, Philippe; Chakrabortty, Sudipto; Jha, Sonali; Lin, Wei; Drenkow, Jorg; Wang, Huaien; Bell, Kim; Fejes-Toth, Katalin; Preall, Jonathan; Gordon, Assaf; Sotirova, Vihra] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA. [Haussler, David; Rosenbloom, Kate R.; Raney, Brian J.; Barber, Galt P.; Sloan, Cricket A.; Zweig, Ann S.; Rhead, Brooke; Suh, Bernard; Paten, Benedict] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA. [Wold, Barbara; Mortazavi, Ali; Kirilusha, Anthony; Reynolds, Alex; Ebersol, Abigail K.] CALTECH, Div Biol, Pasadena, CA 91125 USA. [Mortazavi, Ali] CALTECH, Beckman Inst, Pasadena, CA 91125 USA. [Crawford, Gregory E.; Boyle, Alan P.; Winter, Deborah; London, Darin] Duke Univ, Inst Genome Sci & Policy, Durham, NC USA. Duke Univ, Dept Pediat, Durham, NC 27706 USA. MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA. [Kapranov, Philipp; Bell, Ian; Dumais, Erica; Dumais, Jacqueline] Affymetrix, Santa Clara, CA USA. [Gao, Hui] Karolinska Inst, Huddinge, Sweden. [Antonarakis, Stylianos E.; Ucla, Catherine; Borel, Christelle] Univ Geneva, Geneva, Switzerland. [Guigo, Roderic; Lagarde, Julien; Kingswood, Colin; Ribeca, Paolo; Sammeth, Micha; Merkel, Angelika; Tilgner, Hagen; Tanzer, Andrea; Knowles, David G.; Mariotti, Marco] Ctr Regulacio Genom, Barcelona, Spain. [Carninci, Piero; Hayashizaki, Yoshihide; Lassmann, Timo; Takahashi, Hazuki; Abdelhamid, Rehab F.] RIKEN Yokohama Inst, Omics Sci Ctr, Kanagawa, Japan. [Hannon, Gregory] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA. [Reymond, Alexandre] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland. [Iyer, Vishwanath R.; Lee, Bum-Kyu; McDaniell, Ryan M.; Liu, Zheng; Battenhouse, Anna; Bhinge, Akshay A.] Univ Texas Austin, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, Ctr Syst & Synthet Biol, Austin, TX 78712 USA. [Lieb, Jason D.; Grasfeder, Linda L.; Showers, Kimberly A.; Giresi, Paul G.; Kim, Seul K. C.; Shestak, Christopher] Univ N Carolina, Carolina Ctr Genome Sci, Dept Biol, Chapel Hill, NC USA. [Lieb, Jason D.; Grasfeder, Linda L.; Showers, Kimberly A.; Giresi, Paul G.; Kim, Seul K. C.; Shestak, Christopher] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Pepke, Shirley] CALTECH, Ctr Adv Comp Res, Pasadena, CA 91125 USA. [Sidow, Arend; Kundaje, Anshul] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA. [Batzoglou, Serafim; Kundaje, Anshul; Libbrecht, Max] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA. [Margulies, Elliott H.; Parker, Stephen C. J.; Parker, Stephen C. J.] NHGRI, Div Intramural Res, NIH, Bethesda, MD 20892 USA. [Elnitski, Laura] NHGRI, Genome Technol Branch, NIH, Rockville, MD USA. [Green, Eric D.] NHGRI, NIH Intramural Sequencing Ctr, NIH, Bethesda, MD 20892 USA. [Hubbard, Tim; Harrow, Jennifer; Searle, Stephen; Kokocinski, Felix; Aken, Browen; Frankish, Adam; Hunt, Toby; Despacio-Reyes, Gloria; Kay, Mike; Mukherjee, Gaurab; Bignell, Alexandra; Saunders, Gary; Boychenko, Veronika] Wellcome Trust Sanger Inst, Hinxton, Cambs, England. [Boyle, Alan P.; Bhinge, Akshay A.; Frankish, Adam; Bignell, Alexandra; Khurana, Ekta; Lam, Hugo; Valencia, Alfonso; Charos, Alexandra; Rozowsky, Joel; Abyzov, Alexej; Ebersol, Abigail K.; Brown, James B.; Sboner, Andrea; Cheng, Chao; Wang, Jing; Leng, Jing] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA. [Khurana, Ekta; Lam, Hugo; Abyzov, Alexej; Sboner, Andrea; Cheng, Chao; Wang, Jing; Leng, Jing] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT USA. [Gerstein, Mark; Du, Jiang] Yale Univ, Dept Comp Sci, New Haven, CT 06520 USA. Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA. [Valencia, Alfonso; Tress, Michael; Manuel Rodriguez, Jose] Ctr Nacl Invest Oncol, Madrid, Spain. [Raha, Debasish; Kasowski, Maya; Xu, Youhan; Monahan, Hannah; Charos, Alexandra; Reed, Brian] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA. [Lian, Jin; Weissman, Sherman M.] Yale Univ, Dept Genet, New Haven, CT USA. [Newburger, Peter; Farnham, Peggy J.] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA USA. [Frietze, Seth; O'Geen, Henriette] Univ So Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA USA. [Frietze, Seth; O'Geen, Henriette; Xu, Xiaoqin; Blahnik, Kim R.; Cao, Alina R.; Iyengar, Sushma] Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA. [Sanyal, Amartya] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Program Gene Funct & Express, Worcester, MA USA. [Bickel, Peter J.; Li, Qunhua; Huang, Haiyan] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA. [Wang, Ting] Washington Univ, Dept Genet, St Louis, MO 63110 USA. [Noble, William S.] Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA. [Wang, Jie] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Program Bioinformat & Integrat Biol, Worcester, MA USA. [Xi, Hualin] Boston Univ, Bioinformat Program, Boston, MA 02215 USA. [Tenenbaum, Scott A.; Doyle, Frank; Chittur, Sridar] SUNY Albany, Coll Nanoscale Sci & Engn, Albany, NY 12222 USA. [Penalva, Luiz O.] Childrens Canc Res Inst, Dept Cellular & Struct Biol, San Antonio, TX USA. [Tullius, Thomas D.; Parker, Stephen C. J.] Boston Univ, Dept Chem, Boston, MA 02215 USA. [Tullius, Thomas D.; Parker, Stephen C. J.] Boston Univ, Program Bioinformat, Boston, MA 02215 USA. [White, Kevin P.; Karmakar, Subhradip; Victorsen, Alec; Jameel, Nader; Bild, Nick; Grossman, Robert L.] Univ Chicago, Inst Genom & Syst Biol, Chicago, IL 60637 USA. [Collins, Patrick J.; Trinklein, Nathan D.] SwitchGear Genom, Menlo Pk, CA USA. [Giddings, Morgan C.; Khatun, Jainab; Maier, Chris] Boise State Univ, Biomol Res Ctr, Boise, ID 83725 USA. [Giddings, Morgan C.; Risk, Brian] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA. [Giddings, Morgan C.; Yu, Yanbao; Gunawardena, Harsha] Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA. [Chen, Xian; Feingold, Elise A.; Lowdon, Rebecca F.; Dillon, Laura A. L.; Good, Peter J.] NHGRI, NIH, Bethesda, MD 20892 USA. RP Myers, RM (reprint author), HudsonAlpha Inst Biotechnol, Huntsville, AL USA. RI Alioto, Tyler/K-7267-2015; Hubbard, Tim/C-2567-2008; Tanzer, Andrea/L-3147-2015; Valencia, Alfonso/I-3127-2015; Hariharan, Manoj/N-2855-2015; Boyle, Alan/I-1848-2014; Hoffman, Michael/I-1924-2012; Khurana, Ekta/C-4933-2013; Yan, Koon-Kiu/A-5940-2009; Yu, Yanbao/G-3035-2010; Schlesinger, Felix/E-2143-2011; Vaquerizas, Juan/F-2676-2011; Wang, Jie/F-9747-2011; Frankish, Adam/G-6545-2011; Liu, Zheng/G-2612-2011; Sboner, Andrea/C-6487-2008; Sincan, Murat /A-3794-2010; Dong, Xianjun/B-5334-2012; Mikkelsen, Tarjei/A-1306-2007; Sherlock, Gavin/E-9110-2012; Lassmann, Timo/A-8271-2008; Tullius, Thomas/A-9685-2008; Abyzov, Alexej/M-4284-2013; Sobral, Daniel/B-4786-2014; Sammeth, Michael/C-1157-2014; Carninci, Piero/K-1568-2014; Dong, Xianjun/N-3867-2014; Antonarakis, Stylianos/N-8866-2014; Djebali, Sarah/O-9817-2014; SANYAL, AMARTYA/D-7240-2015; Brown, James/H-2971-2015; cheng, yong/I-4270-2012; Guigo, Roderic/D-1303-2010; Hardison, Ross/G-1142-2010; OI Alioto, Tyler/0000-0002-2960-5420; Hubbard, Tim/0000-0002-1767-9318; Tanzer, Andrea/0000-0003-2873-4236; Valencia, Alfonso/0000-0002-8937-6789; Hariharan, Manoj/0000-0002-1006-5372; Boyle, Alan/0000-0002-2081-1105; Marinov, Georgi/0000-0003-1822-7273; Gingeras, Thomas/0000-0001-9106-3573; Hunt, Toby/0000-0001-8377-0841; Song, Giltae/0000-0001-8796-4678; Sheffield, Nathan/0000-0001-5643-4068; Hoffman, Michael/0000-0002-4517-1562; Yu, Yanbao/0000-0003-2994-1974; Vaquerizas, Juan/0000-0002-6583-6541; Sboner, Andrea/0000-0001-6915-3070; Mikkelsen, Tarjei/0000-0002-8133-3135; Saunders, Gary/0000-0002-7468-0008; Furey, Terry/0000-0001-5546-9672; Merkel, Angelika/0000-0001-5164-6803; Ward, Lucas/0000-0002-8017-809X; Dunham, Ian/0000-0003-2525-5598; Aken, Bronwen/0000-0002-3032-4095; Grossman, Robert/0000-0003-3741-5739; Lassmann, Timo/0000-0002-0138-2691; Tullius, Thomas/0000-0003-4425-796X; Sobral, Daniel/0000-0003-3955-0117; Sammeth, Michael/0000-0002-6528-9883; Carninci, Piero/0000-0001-7202-7243; Dong, Xianjun/0000-0002-8052-9320; Antonarakis, Stylianos/0000-0001-8907-5823; Djebali, Sarah/0000-0002-0599-1267; SANYAL, AMARTYA/0000-0002-2109-4478; Guigo, Roderic/0000-0002-5738-4477; Hardison, Ross/0000-0003-4084-7516; Herrero, Javier/0000-0001-7313-717X; Haugen, Eric/0000-0001-7444-8981; Wilder, Steven/0000-0001-8049-2559; Newburger, Peter/0000-0002-8615-673X; Winter, Deborah/0000-0003-1806-673X; Birney, Ewan/0000-0001-8314-8497; Sherlock, Gavin/0000-0002-1692-4983; Rozowsky, Joel/0000-0002-3565-0762; Farnham, Peggy/0000-0003-4469-7914; Brazma, Alvis/0000-0001-5988-7409 FU National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA FX Funded by the National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. The role of the NIH Project Management Group in the preparation of this paper was limited to coordination and scientific management of the ENCODE Consortium. NR 121 TC 156 Z9 161 U1 11 U2 96 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1544-9173 J9 PLOS BIOL JI PLoS. Biol. PD APR PY 2011 VL 9 IS 4 AR e1001046 DI 10.1371/journal.pbio.1001046 PG 21 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA 755NM UT WOS:000289938900014 ER PT J AU McCormack, LA Treiman, K Rupert, D Williams-Piehota, P Nadler, E Arora, NK Lawrence, W Street, RL AF McCormack, Lauren A. Treiman, Katherine Rupert, Douglas Williams-Piehota, Pamela Nadler, Eric Arora, Neeraj K. Lawrence, William Street, Richard L., Jr. TI Measuring patient-centered communication in cancer care: A literature review and the development of a systematic approach SO SOCIAL SCIENCE & MEDICINE LA English DT Review DE Patient-centered communication; Conceptual framework; Measurement; Cancer care; Review; USA ID SELF-DETERMINATION THEORY; SHARED DECISION-MAKING; BREAST-CANCER; PHYSICIAN COMMUNICATION; PATIENTS PERSPECTIVES; STANDARDIZED PATIENTS; PATIENTS PREFERENCES; PATIENTS PERCEPTIONS; AFRICAN-AMERICAN; HUMAN CONNECTION AB Patient-centered communication (PCC) is a critical element of patient-centered care, which the Institute of Medicine (Committee on Quality of Health Care in America, 2001) promulgates as essential to improving healthcare delivery. Consequently, the US National Cancer Institute's Strategic Plan for Leading the Nation (2006) calls for assessing the delivery of PCC in cancer care. However, no comprehensive measure of PCC exists, and stakeholders continue to embrace different conceptualizations and assumptions about how to measure it. Our approach was grounded in the PCC conceptual framework presented in a recent US National Cancer Institute monograph (Epstein & Street, 2007). In this study, we developed a comprehensive inventory of domains and subdomains for PCC by reviewing relevant literature and theories, interviewing a limited number of cancer patients, and consulting experts. The resulting measurement domains are organized under the six core functions specified in the PCC conceptual framework: exchanging information, fostering healing relationships, recognizing and responding to emotions, managing uncertainty, making decisions, and enabling patient self-management. These domains represent a promising platform for operationalizing the complicated PCC construct. Although this study focused specifically on cancer care, the PCC measurements are relevant to other clinical contexts and illnesses, given that patient-centered care is a goal across all healthcare. Finally, we discuss considerations for developing PCC measures for research, quality assessment, and surveillance purposes. United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute (2006). The NCI Strategic Plan for Leading the Nation: To Eliminate the Suffering and Death Due to Cancer. NIH Publication No. 06-5773. (C) 2011 Elsevier Ltd. All rights reserved. C1 [McCormack, Lauren A.; Rupert, Douglas; Williams-Piehota, Pamela] RTI Int, Hlth Commun Program, Res Triangle Pk, NC 27709 USA. [Treiman, Katherine] RTI Int, Hlth Commun Program, Rockville, MD 20852 USA. [Nadler, Eric] Baylor Univ, Med Ctr, Charles Sammons Canc Ctr, Dallas, TX 75246 USA. [Arora, Neeraj K.] NCI, Outcomes Res Branch, ARP, DCCPS, Bethesda, MD 20892 USA. [Lawrence, William] Agcy Healthcare Res & Qual, Ctr Outcomes & Evidence, Rockville, MD 20850 USA. [Street, Richard L., Jr.] Texas A&M Univ, Dept Commun, College Stn, TX 77843 USA. RP McCormack, LA (reprint author), RTI Int, Hlth Commun Program, 3040 Cornwallis Rd, Res Triangle Pk, NC 27709 USA. EM Lmac@rti.org; Ktreiman@rti.org; drupert@rti.org; ppiehota@rti.org; Eric.Nadler@oncologytoday.com; aroran@mail.nih.gov; william.lawrence@ahrq.hhs.gov; r-street@tamu.edu NR 84 TC 63 Z9 63 U1 4 U2 33 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD APR PY 2011 VL 72 IS 7 BP 1085 EP 1095 DI 10.1016/j.socscimed.2011.01.020 PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 757DN UT WOS:000290065000011 PM 21376443 ER PT J AU Anthis, NJ Campbell, ID AF Anthis, Nicholas J. Campbell, Iain D. TI The tail of integrin activation SO TRENDS IN BIOCHEMICAL SCIENCES LA English DT Review ID BINDING-LIKE DOMAIN; STRUCTURAL BASIS; CELL-MIGRATION; CYTOPLASMIC DOMAIN; FILAMIN BINDING; TALIN HEAD; THERAPEUTIC TARGETS; CRYSTAL-STRUCTURE; FOCAL ADHESIONS; TRANSMEMBRANE AB Integrins are essential adhesion receptors found on the surfaces of all metazoan cells. As regulators of cell migration and extracellular matrix assembly, these membrane-spanning heterodimers are critical for embryonic development, tissue repair and immune responses. Signals transmitted by integrins from outside to inside the cell promote cell survival and proliferation, but integrin affinity for extracellular ligands can also be controlled by intracellular cues. This bidirectional signaling is mediated by the short cytoplasmic tails of the two integrin subunits. Recent structural and functional studies of various integrin fragments and complexes between the cytoplasmic tails and intracellular proteins, such as talin, have provided new insight into the signaling processes centered around the tails, particularly inside-out integrin activation. C1 [Campbell, Iain D.] Univ Oxford, Dept Biochem, Oxford OX1 3DR, England. [Anthis, Nicholas J.] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA. RP Campbell, ID (reprint author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3DR, England. EM iain.campbell@bioch.ox.ac.uk FU BBSRC; MRC; NIH cell migration consortium; NIH FX IDC thanks BBSRC, MRC and the NIH cell migration consortium for financial support. NJA is currently supported by an NIH post-doctoral grant. NR 85 TC 78 Z9 78 U1 4 U2 36 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0968-0004 J9 TRENDS BIOCHEM SCI JI Trends Biochem.Sci. PD APR PY 2011 VL 36 IS 4 BP 191 EP 198 DI 10.1016/j.tibs.2010.11.002 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 757XH UT WOS:000290121400003 PM 21216149 ER PT J AU Cortez, KJ Maldarelli, F AF Cortez, Karoll J. Maldarelli, Frank TI Clinical Management of HIV Drug Resistance SO VIRUSES-BASEL LA English DT Review DE HIV; drug resistance testing; clinical management ID IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE INHIBITORS; NON-B SUBTYPES; SUSTAINED VIROLOGICAL SUPPRESSION; TREATMENT-EXPERIENCED PATIENTS; RANDOMIZED CONTROLLED-TRIAL; TREATMENT-NAIVE PATIENTS; SINGLE-DOSE NEVIRAPINE; ROCHE COBAS AMPLICOR AB Combination antiretroviral therapy for HIV-1 infection has resulted in profound reductions in viremia and is associated with marked improvements in morbidity and mortality. Therapy is not curative, however, and prolonged therapy is complicated by drug toxicity and the emergence of drug resistance. Management of clinical drug resistance requires in depth evaluation, and includes extensive history, physical examination and laboratory studies. Appropriate use of resistance testing provides valuable information useful in constructing regimens for treatment-experienced individuals with viremia during therapy. This review outlines the emergence of drug resistance in vivo, and describes clinical evaluation and therapeutic options of the individual with rebound viremia during therapy. C1 [Cortez, Karoll J.; Maldarelli, Frank] NCI, HIV Drug Resistance Program, NIH, Bethesda, MD 20892 USA. RP Maldarelli, F (reprint author), NCI, HIV Drug Resistance Program, NIH, Bldg 10 Rm 5A06, Bethesda, MD 20892 USA. EM karoll.cortez@fda.hhs.gov; fmalli@mail.nih.gov NR 176 TC 28 Z9 29 U1 0 U2 3 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1999-4915 J9 VIRUSES-BASEL JI Viruses-Basel PD APR PY 2011 VL 3 IS 4 BP 347 EP 378 DI 10.3390/v3040347 PG 32 WC Virology SC Virology GA 760FE UT WOS:000290309100006 PM 21994737 ER PT J AU Reznick, JS AF Reznick, Jeffrey S. TI Reconstructing the Body: Classicism, Modernism, and the First World War SO AMERICAN HISTORICAL REVIEW LA English DT Book Review C1 [Reznick, Jeffrey S.] US Natl Lib Med, Bethesda, MD USA. RP Reznick, JS (reprint author), US Natl Lib Med, Bethesda, MD USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0002-8762 J9 AM HIST REV JI Am. Hist. Rev. PD APR PY 2011 VL 116 IS 2 BP 418 EP 419 PG 2 WC History SC History GA 751HE UT WOS:000289607300021 ER PT J AU Kim, TH Jiang, HH Lee, S Youn, YS Park, CW Byun, Y Chen, XY Lee, KC AF Kim, Tae Hyung Jiang, Hai Hua Lee, Seulki Youn, Yu Seok Park, Chan Woong Byun, Youngro Chen, Xiaoyuan Lee, Kang Choon TI Mono-PEGylated Dimeric Exendin-4 as High Receptor Binding and Long-Acting Conjugates for Type 2 Anti-Diabetes Therapeutics SO BIOCONJUGATE CHEMISTRY LA English DT Article ID GLUCAGON-LIKE PEPTIDE-1; SYNTHETIC EXENDIN-4; GLYCEMIC CONTROL; DB/DB MICE; IN-VIVO; EXENATIDE; GLUCOSE; CHAIN; INHIBITORS; RELEASE AB Dimerization is viewed as the most effective means of increasing receptor binding affinity, and both dimerization and PEGylation effectively prolong the life spans of short-lived peptides and proteins in vivo by delaying excretion via the renal route. Here, we describe the high binding affinities of two long-acting exendin-4 (Ex4) conjugates, dimerized Ex4 (Di-Ex4) and PEGylated Di-Ex-4 (PEG-Di-Ex4). Di-Ex4 and PEG-Di-Ex4 were prepared using cysteine and amine residue specific coupling reactions using Ex4-Cys, bisMal-NH(2), and activated PEG. The Ex4 conjugates produced were of high purity (>98.5%), as determined by size-exclusion chromatography and MALDI-TOF mass spectrometry. The receptor binding affinity of Di-Ex4 on RIN-m5F cells was 3.5-fold higher than that of Ex4, and the in vivo antihyperglycemic efficacy of Di-Ex4 was also greater than that of native Ex4 in type 2 diabetic db/db mice. Furthermore, Di-Ex4 and PEG-Di-Ex4 were found to have greater blood circulating t(1/2) and AUC(inf) values than native Ex4 by 2.7- and 13.7-fold, and by 4.0- and 17.3-fold, respectively. Accordingly, hypoglycemic durations were greatly increased to 15.0 and 40.1 h, respectively, at a dose of 25 nmol/kg; (native Ex4 7.3 h). The results of this study show that combined dimerization and PEGylation are effective when applied to Ex4, and suggest that PEG-Di-Ex4 has considerable potential as a type 2 anti-diabetic agent. C1 [Kim, Tae Hyung; Jiang, Hai Hua; Park, Chan Woong; Lee, Kang Choon] Sungkyunkwan Univ, Coll Pharm, Suwon 440746, South Korea. [Lee, Seulki; Chen, Xiaoyuan] NIBIB, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA. [Youn, Yu Seok] Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea. [Byun, Youngro] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea. RP Lee, KC (reprint author), Sungkyunkwan Univ, Coll Pharm, 300 Chonchon Dong, Suwon 440746, South Korea. EM kclee@skku.edu RI BYUN, YOUNG RO/D-5735-2013 NR 34 TC 19 Z9 19 U1 0 U2 26 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1043-1802 J9 BIOCONJUGATE CHEM JI Bioconjugate Chem. PD APR PY 2011 VL 22 IS 4 BP 625 EP 632 DI 10.1021/bc100404x PG 8 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA 751JM UT WOS:000289613400013 PM 21401109 ER PT J AU Zhou, Y Kim, YS Shi, JY Jacobson, O Chen, XY Liu, S AF Zhou, Yang Kim, Young-Seung Shi, Jiyun Jacobson, Orit Chen, Xiaoyuan Liu, Shuang TI Evaluation of Cu-64-Labeled Acridinium Cation: A PET Radiotracer Targeting Tumor Mitochondria SO BIOCONJUGATE CHEMISTRY LA English DT Article ID TRIPHENYLPHOSPHONIUM CATIONS; MULTIDRUG-RESISTANCE; LIPOPHILIC CATIONS; CARCINOMA-CELLS; GLIOMA-CELLS; LIVING CELLS; RHODAMINE-123; RETENTION; COMPLEXES; METABOLITE AB This report presents the synthesis and evaluation of Cu-64(DO3A-xy-ACR) (DO3A-xy-ACR = 2,6-bis(dimethylamino)-10-(4-((4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclodo-decan-1-yl)methyl)benzyl)acridin-10-ium) as a radiotracer for imaging tumors in athymic nude mice bearing U87MG glioma xenografts by PET (positron emission tomography). The biodistribution data suggested that Cu-64(DO3A-xy-ACR) was excreted mainly through the renal system with >65% of injected radioactivity being recovered from urine samples at 1 h post-injection (p.i.). The tumor uptake of Cu-64(DO3A-xy-ACR) was 1.07 +/- 0.23, 1.58 +/- 0.55, 2.71 +/- 0.66, 3.47 +/- 1.19, and 3.52 +/- 1.72%ID/g at 0.5,, 1, 2, 4, and 24 h p.i., respectively. Cu-64(DO3A-xy-ACR) had very high liver uptake (31.90 +/- 3.98, 24.95 +/- 5.64, 15.20 +/- 4.29, 14.09 +/- 6.82, and 8.18 +/- 1.27%ID/g at 0.5, 1, 2, 4, and 24 h p.i., respectively) with low tumor/liver ratios. MicroPET studies showed that the tumors were clearly visualized as early as 30 min pi in the glioma-bearing mouse administered with Cu-64(DO3A-xy-ACR). The high liver radioactivity accumulation was also seen. Cu-64(DO3A-xy-ACR) had a relatively high metabolic stability during excretion via both renal and hepatobiliary routes, but it was completely decomposed in the liver homogenate. We explored the localization mechanism of Cu(DO3A-xy-ACR) using both U87MG human glioma and the cultured primary U87MG glioma cells. The results from the cellular staining assays showed that Cu-64(DO3A-xy-ACR) is able to localize in the mitochondria of living U87MG glioma cells due to the enhanced negative mitochondrial potential as compared to normal cells. Although Cu-64(DO3A-xy-ACR) is not an ideal PET radiotracer for tumor imaging due to its high liver uptake, the results from this study strongly suggest that Cu-64-labeled acridinium cations are indeed able to localize in the energized mitochondria of tumor cells. C1 [Zhou, Yang; Kim, Young-Seung; Shi, Jiyun; Liu, Shuang] Purdue Univ, Sch Hlth Sci, W Lafayette, IN 47907 USA. [Jacobson, Orit; Chen, Xiaoyuan] NIBIB, LOMIN, NIH, Bethesda, MD USA. RP Liu, S (reprint author), Purdue Univ, Sch Hlth Sci, 550 Stadium Mall Dr, W Lafayette, IN 47907 USA. EM liu100@purdue.edu FU Purdue University; National Cancer Institute (NCI) [R01 CA115883] FX This work is supported, in part, by Purdue University and the research grant: R01 CA115883 from the National Cancer Institute (NCI). NR 33 TC 5 Z9 5 U1 1 U2 8 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1043-1802 J9 BIOCONJUGATE CHEM JI Bioconjugate Chem. PD APR PY 2011 VL 22 IS 4 BP 700 EP 708 DI 10.1021/bc100458p PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA 751JM UT WOS:000289613400021 PM 21413736 ER PT J AU Traini, R Kreitman, RJ AF Traini, Roberta Kreitman, Robert J. TI Renal Excretion of Recombinant Immunotoxins Containing Pseudomonas Exotoxin SO BIOCONJUGATE CHEMISTRY LA English DT Article ID HAIRY-CELL LEUKEMIA; RFB4(DSFV)-PE38 BL22; TRIAL; RESPONSES; RECEPTOR; TOXIN AB Recombinant immunotoxins BL22 (CAT-3888) and LMB-2, composed of Fv fragments of anti-CD22 and CD25 MAbs, respectively, have produced major responses in patients with hematologic malignancies, and are also associated with renal toxicity, particularly with BL22. Characterization of the renal excretion of recombinant immunotoxins, which have 2-4 h half-lives in plasma, has not been reported in humans. To study the renal excretion of recombinant immunotoxins, urine from patients treated with BL22 was collected and the recombinant protein visualized after trichloroacetic acid (TCA) precipitation or anion exchange chromatography. BL22 viewed by immunoblot was found in the urine of patients within 8 h after dosing as an intact protein, and progressively degraded to fragments of <20 kDa within 1 day. We studied the stability of BL22 and LMB-2 added to urine at different time points and pH. When exposed to urine ex vivo, BL22 time-dependent proteolysis was similar to that observed in treated patients. By N-terminal sequencing, proteolysis was documented at positions 348-349 and 350-351 of BL22, and 339-340 and 341-342 of LMB-2, and other proteolytic sites were observed as well. Our data suggest that BL22 is excreted into the urine in a potentially cytotoxic form, even after its plasma level declines, and may remain intact long enough to cause renal toxicity. C1 [Traini, Roberta; Kreitman, Robert J.] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP Kreitman, RJ (reprint author), NIH, Bldg 37,Room 5124B,9000 Rockville Pike, Bethesda, MD 20854 USA. EM kreitmar@mail.nih.gov FU NCI; MedImmune, LLC FX We also thank Drs. David FitzGerald and Ira Pastan for helpful suggestions and for reviewing the manuscript. This work was supported in part by the NCI, intramural program, and MedImmune, LLC. NR 15 TC 6 Z9 6 U1 0 U2 3 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1043-1802 J9 BIOCONJUGATE CHEM JI Bioconjugate Chem. PD APR PY 2011 VL 22 IS 4 BP 736 EP 740 DI 10.1021/bc1005152 PG 5 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA 751JM UT WOS:000289613400025 PM 21410247 ER PT J AU Yoon, HY Kales, SC Luo, RB Lipkowitz, S Randazzo, PA AF Yoon, Hye-Young Kales, Stephen C. Luo, Ruibai Lipkowitz, Stanley Randazzo, Paul A. TI ARAP1 association with CIN85 affects epidermal growth factor receptor endocytic trafficking SO BIOLOGY OF THE CELL LA English DT Article DE ADP-ribosylation factor GTPase-activating protein (ArfGAP); ARAP1; Cbl-interacting protein of 85 kDa (CIN85); endocytosis; epidermal growth factor receptor; membrane traffic ID ADAPTER PROTEIN; ACTIN CYTOSKELETON; SIGNALING NETWORK; TYROSINE KINASES; DOWN-REGULATION; SH3 DOMAINS; C-CBL; EGFR; DEGRADATION; UBIQUITIN AB Background information. ARAP1 is an Arf (ADP-ribosylation factor)-directed GAP (GTPase-activating protein) that inhibits the trafficking of EGFR (epidermal growth factor receptor) to the early endosome. To further understand the function of ARAP1, we sought to identify proteins that interact with ARAP1. Results. Here we report that ARAP1 associates with the CIN85 (Cbl-interacting protein of 85 kDa). Arg(86) and Arg(90) of AIRAP1 and the SH3 (Src homology 3) domains of CIN85 are necessary for the interaction. We found that a mutant of ARAP1 with reduced affinity for CIN85 does not efficiently rescue the effect of reduced ARAP1 expression on EGFR trafficking to the early endosome. Reduced expression of CIN85 has a similar effect as reduced expression of ARAP1 on traffic of the EGFR. Cbl proteins regulate the endocytic trafficking of the EGFR by mediating ubiquitination of the EGFR. Overexpression of ARAP1 reduced ubiquitination of the EGFR by Cbl and slowed Cbl-dependent degradation of the EGFR. Reduced expression of ARAP1 accelerated degradation of EGFR but did not affect the level of ubiquitination of the receptor that was detected. Conclusion. ARAP1 interaction with CIN85 regulates endocytic trafficking of the EGFR and affects ubiquitination of EGFR. We propose a model in which the ARAP1 CIN85 complex drives exit of EGF-EGFR-Cbl complex from a pre-early endosome into a pathway distinct from the early endosome/lysosome pathway. C1 [Yoon, Hye-Young; Kales, Stephen C.; Luo, Ruibai; Lipkowitz, Stanley; Randazzo, Paul A.] NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA. RP Randazzo, PA (reprint author), NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA. EM randazzp@mail.nih.gov FU National Cancer Institute; National Institutes of Health, Bethesda, MD, U.S.A. [ZIA BC 007365] FX This work was supported by the National Cancer Institute, National Institutes of Health Intramural Program (project number ZIA BC 007365), Bethesda, MD, U.S.A. NR 40 TC 7 Z9 7 U1 0 U2 4 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0248-4900 J9 BIOL CELL JI Biol. Cell PD APR PY 2011 VL 103 IS 4 BP 171 EP 184 DI 10.1042/BC20100154 PG 14 WC Cell Biology SC Cell Biology GA 755UN UT WOS:000289964200002 PM 21275903 ER PT J AU Zhou, B Zhu, YB Lin, L Cai, Q Sheng, ZH AF Zhou, Bing Zhu, Yi-Bing Lin, Lin Cai, Qian Sheng, Zu-Hang TI Snapin deficiency is associated with developmental defects of the central nervous system SO BIOSCIENCE REPORTS LA English DT Article DE apoptotic cell death; autophagy; late endocytic trafficking; lysosome; neuronal development; ubiquitin ID CELL-DEATH; PROTEIN-DEGRADATION; AUTOPHAGOSOME FORMATION; DISEASE; MICE; NEURODEGENERATION; INHIBITION; HUNTINGTIN; LYSOSOMES; TRANSPORT AB The autophagy-lysosomal pathway is an intracellular degradation process essential for maintaining neuronal homoeostasis. Defects in this pathway have been directly linked to a growing number of neurodegenerative disorders. We recently revealed that Snapin plays a critical role in co-ordinating dynein-driven retrograde transport and late encosomal-lysosomal trafficking, thus maintaining efficient autophagy-lysosomal function. Deleting snapin in neurons impairs lysosomal proteolysis and reduces the clearance of autolysosomes. The role of the autophagy-lysosomal system in neuronal development is, however, largely uncharacterized. Here, we report that snapin deficiency leads to developmental defects in the central nervous system. Embryonic snapin(-/-) mouse brain showed reduced cortical plates and intermediate zone cell density, increased apoptotic death in the cortex and third ventricle, enhanced membrane-bound LC3-II staining associated with autophagic vacuoles and an accumulation of polyubiquitinated proteins in the cortex and hippocampus. Thus our results provide in vivo evidence for the essential role of late endocytic transport and autophagy-lysosomal function in maintaining neuronal survival and development of the mammalian central nervous system. In addition, our study supports the existence of a functional interplay between the autophagy-lysosome and ubiquitin-proteasome systems in the protein quality-control process. C1 [Zhou, Bing; Zhu, Yi-Bing; Cai, Qian; Sheng, Zu-Hang] Natl Inst Neurol Disorders & Stroke, Synapt Funct Sect, NIH, Bethesda, MD 20892 USA. [Zhou, Bing; Zhu, Yi-Bing; Lin, Lin] Shanghai Jiao Tong Univ, Sch Med, Dept Neurobiol, Shanghai 200030, Peoples R China. RP Sheng, ZH (reprint author), Natl Inst Neurol Disorders & Stroke, Synapt Funct Sect, NIH, 35 Convent Dr, Bethesda, MD 20892 USA. EM shengz@ninds.nih.gov FU National Institute of Neurological Disorders and Stroke, National Institutes of Health FX This work was supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke, National Institutes of Health (to Z.-H.S.). NR 41 TC 7 Z9 7 U1 1 U2 4 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0144-8463 J9 BIOSCIENCE REP JI Biosci. Rep. PD APR PY 2011 VL 31 IS 2 BP 151 EP 158 DI 10.1042/BSR20100110 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 756IM UT WOS:000290004900009 PM 20946101 ER PT J AU Emmorey, K Xu, J Braun, A AF Emmorey, Karen Xu, Jiang Braun, Allen TI Neural responses to meaningless pseudosigns: Evidence for sign-based phonetic processing in superior temporal cortex SO BRAIN AND LANGUAGE LA English DT Article DE Sign language; Deaf signers; fMRI; Pseudowords; Phonology ID VERBAL WORKING-MEMORY; LANGUAGE; PERCEPTION; BRAIN; COMPREHENSION; FMRI AB To identify neural regions that automatically respond to linguistically structured, but meaningless manual gestures, 14 deaf native users of American Sign Language (ASL) and 14 hearing non-signers passively viewed pseudosigns (possible but non-existent ASL signs) and non-iconic ASL signs, in addition to a fixation baseline. For the contrast between pseudosigns and baseline, greater activation was observed in left posterior superior temporal sulcus (STS), but not in left inferior frontal gyrus (BA 44145), for deaf signers compared to hearing non-signers, based on VOI analyses. We hypothesize that left STS is more engaged for signers because this region becomes tuned to human body movements that conform the phonological constraints of sign language. For deaf signers, the contrast between pseudosigns and known ASL signs revealed increased activation for pseudosigns in left posterior superior temporal gyrus (STG) and in left inferior frontal cortex, but no regions were found to be more engaged for known signs than for pseudosigns. This contrast revealed no significant differences in activation for hearing non-signers. We hypothesize that left STG is involved in recognizing linguistic phonetic units within a dynamic visual or auditory signal, such that less familiar structural combinations produce increased neural activation in this region for both pseudosigns and pseudowords. (C) 2010 Elsevier Inc. All rights reserved. C1 [Emmorey, Karen] San Diego State Univ, Lab Language & Cognit Neurosci, San Diego, CA 92120 USA. [Xu, Jiang; Braun, Allen] NIH, Bethesda, MD 20892 USA. RP Emmorey, K (reprint author), San Diego State Univ, Lab Language & Cognit Neurosci, 6495 Alvarado Rd,Suite 200, San Diego, CA 92120 USA. EM kemmorey@mail.sdsu.edu FU NIH [R01 DC010997]; NIDCD FX This research was supported in part by NIH Grant R01 DC010997 (K.E.) and by the NIDCD Intramural Research Program. We would like to thank Franco Korpics for help recruiting Deaf participants, Jeannette Vincent for help with stimuli development, Helsa Borinstein for help with the gesture norming study, and all of the Deaf and hearing individuals who participated in the study. NR 28 TC 11 Z9 11 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0093-934X J9 BRAIN LANG JI Brain Lang. PD APR PY 2011 VL 117 IS 1 BP 34 EP 38 DI 10.1016/j.bandl.2010.10.003 PG 5 WC Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental SC Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology GA 752PB UT WOS:000289703500005 PM 21094525 ER PT J AU Mumford, SL Dasharathy, S Pollack, AZ Schisterman, EF AF Mumford, Sunni L. Dasharathy, Sonya Pollack, Anna Z. Schisterman, Enrique F. TI Variations in lipid levels according to menstrual cycle phase: clinical implications SO CLINICAL LIPIDOLOGY LA English DT Review DE cholesterol; estrogen; lipoprotein; menstrual cycle ID HEALTHY-YOUNG WOMEN; DENSITY-LIPOPROTEIN CHOLESTEROL; ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; POSTMENOPAUSAL WOMEN; PLASMA-LIPIDS; ORAL-CONTRACEPTIVES; SERUM-LIPOPROTEINS; CARDIOVASCULAR-DISEASE; APOLIPOPROTEIN LEVELS AB Understanding variations in lipoprotein cholesterol levels throughout the menstrual cycle is important because there may be clinical implications regarding the appropriate timing of measurement and implications on the design and interpretation of studies in women of reproductive age. Our objective was to review the evidence comparing lipoprotein cholesterol levels throughout the menstrual cycle among premenopausal women. Overall, lipoprotein cholesterol levels were observed to vary in response to changing estrogen levels. Taken together, the evidence suggests that total cholesterol and LDL-C tend to be highest during the follicular phase and to decline during the luteal phase, with HDL-C highest around ovulation. Based on these findings, the menstrual cycle phase should be taken into account when evaluating lipoprotein cholesterol levels among reproductive-aged women. Measuring cholesterol levels during menses is recommended for consistent comparisons as this phase can be more reliably identified than other phases, although women within National Cholesterol Education Program acceptable ranges, but near the boundaries when tested during menses, should undergo additional tests. C1 [Mumford, Sunni L.; Dasharathy, Sonya; Pollack, Anna Z.; Schisterman, Enrique F.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, NIH, Rockville, MD 20852 USA. RP Mumford, SL (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, NIH, 6100 Execut Blvd,7B03, Rockville, MD 20852 USA. EM mumfords@mail.nih.gov RI Pollack, Anna/F-2021-2011; OI Pollack, Anna/0000-0002-4313-3298; Schisterman, Enrique/0000-0003-3757-641X FU Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH FX This work was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 50 TC 11 Z9 13 U1 0 U2 4 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1758-4299 J9 CLIN LIPIDOL JI Clin. Lipidol. PD APR PY 2011 VL 6 IS 2 BP 225 EP 234 DI 10.2217/CLP.11.9 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 754CE UT WOS:000289828700013 PM 21743815 ER PT J AU Veenstra, TD AF Veenstra, Timothy D. TI Proteomics research in breast cancer: balancing discovery and hypothesis-driven studies SO EXPERT REVIEW OF PROTEOMICS LA English DT Editorial Material DE biomarker; discovery; liquid chromatography; mass spectrometry; validation C1 SAIC Frederick Inc, Natl Canc Inst Frederick, Adv Technol Program, Lab Prote & Analyt Technol, Frederick, MD 21702 USA. RP Veenstra, TD (reprint author), SAIC Frederick Inc, Natl Canc Inst Frederick, Adv Technol Program, Lab Prote & Analyt Technol, Frederick, MD 21702 USA. EM veenstra@ncifcrf.gov NR 8 TC 3 Z9 3 U1 0 U2 2 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1478-9450 J9 EXPERT REV PROTEOMIC JI Expert Rev. Proteomics PD APR PY 2011 VL 8 IS 2 BP 139 EP 141 DI 10.1586/EPR.11.9 PG 3 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 754SN UT WOS:000289877400001 PM 21501004 ER PT J AU Hoffert, JD Pisitkun, T Knepper, MA AF Hoffert, Jason D. Pisitkun, Trairak Knepper, Mark A. TI Phosphoproteomics of vasopressin signaling in the kidney SO EXPERT REVIEW OF PROTEOMICS LA English DT Review DE aquaporin; collecting duct; kidney; LC-MS/MS; tandem mass spectrometry; vasopressin; water transport ID RENAL COLLECTING DUCT; SCALE PHOSPHORYLATION ANALYSIS; MASS-SPECTROMETRY; QUANTITATIVE PHOSPHOPROTEOMICS; SACCHAROMYCES-CEREVISIAE; AQUAPORIN-2 ABUNDANCE; STIMULATED INCREASE; WATER PERMEABILITY; PROTEOMIC ANALYSIS; SITE LOCALIZATION AB Protein phosphorylation plays a critical role in the signaling pathways regulating water and solute transport in the distal renal tubule (i.e., renal collecting duct). A central mediator in this process is the antidiuretic peptide hormone arginine vasopressin, which regulates a number of transport proteins including water channel aquaporin-2 and urea transporters (UT-A1 and UT-A3). Within the past few years, tandem mass spectrometry-based proteomics has played a pivotal role in revealing global changes in the phosphoproteome in response to vasopressin signaling in the renal collecting duct. This type of large-scale 'shotgun' approach has resulted in an exponential increase in the number of phosphoproteins known to be regulated by vasopressin and has expanded on the established signaling mechanisms and kinase pathways regulating collecting duct physiology. This article will provide a brief background on vasopressin action, will highlight a number of recent quantitative phosphoproteomic studies in both native rat kidney and cultured collecting duct cells, and will conclude with a perspective focused on emerging trends in the field of phosphoproteomics. C1 [Hoffert, Jason D.; Pisitkun, Trairak; Knepper, Mark A.] NHLBI, Epithelial Syst Biol Lab, Bethesda, MD 20892 USA. RP Hoffert, JD (reprint author), NHLBI, Epithelial Syst Biol Lab, Bldg 10, Bethesda, MD 20892 USA. EM hoffertj@nhlbi.nih.gov OI Pisitkun, Trairak/0000-0001-6677-2271 FU Intramural NIH HHS [ZIA HL001285-24, Z01 HL001285-21, Z01 HL001285-22, Z99 HL999999, ZIA HL001285-23] NR 53 TC 7 Z9 8 U1 0 U2 6 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1478-9450 J9 EXPERT REV PROTEOMIC JI Expert Rev. Proteomics PD APR PY 2011 VL 8 IS 2 BP 157 EP 163 DI 10.1586/EPR.11.14 PG 7 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 754SN UT WOS:000289877400009 PM 21501009 ER PT J AU Theron, GB Shapiro, DE Van Dyke, R Cababasay, MP Louw, J Watts, DH Smith, E Bulterys, M Maupin, R AF Theron, Gerhard B. Shapiro, David E. Van Dyke, Russell Cababasay, Mae P. Louw, Jeanne Watts, D. Heather Smith, Elizabeth Bulterys, Marc Maupin, Robert TI Rapid intrapartum or postpartum HIV testing at a midwife obstetric unit and a district hospital in South Africa SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS LA English DT Article DE Labor; Rapid testing; Unknown HIV status ID POSTEXPOSURE PROPHYLAXIS; PREGNANT-WOMEN; TRANSMISSION; TRIAL; NEVIRAPINE; LABOR AB Objective: To compare the prepartum and postpartum feasibility and acceptance of voluntary counseling and rapid testing (VCT) among women with unknown HIV status in South Africa. Methods: Eligible women were randomized according to the calendar week of presentation to receive VCT either while in labor or after delivery. Results: Of 7238 women approached, 542 (7.5%) were eligible, 343 (63%) were enrolled, and 45 (13%) were found to be HIV infected. The proportions of eligible women who accepted VCT were 66.8% (161 of 241) in the intrapartum arm and 60.5% (182 of 301) in the postpartum arm, and the difference of 6.3% (95% CI, -1.8% to 14.5%) was not significant. The median times (44 and 45 minutes) required to conduct VCT were also similar in the 2 arms. In the intrapartum arm, all women in true labor received their test results before delivery and all those found to be HIV positive accepted prophylaxis with nevirapine before delivery. Conclusions: Rapid testing in labor wards for women with an unknown HIV status is feasible and well accepted, and allows for a more timely antiretroviral prophylaxis than postpartum testing. (C) 2010 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved. C1 [Theron, Gerhard B.] Univ Stellenbosch, Fac Hlth Sci, Dept Obstet & Gynaecol, ZA-7600 Stellenbosch, South Africa. [Theron, Gerhard B.] Tygerberg Hosp, Stellenbosch, South Africa. [Shapiro, David E.; Cababasay, Mae P.] Harvard Univ, Harvard Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA. [Van Dyke, Russell] Tulane Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70118 USA. [Louw, Jeanne] Univ Stellenbosch, Fac Hlth Sci, Dept Pediat & Child Hlth, ZA-7600 Stellenbosch, South Africa. [Watts, D. Heather] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Bethesda, MD USA. [Smith, Elizabeth] NIH, Div Aids, Bethesda, MD 20892 USA. [Bulterys, Marc] China US Ctr Dis Control & Prevent, Ctr Dis Control Global AIDS Program, Beijing, Peoples R China. [Maupin, Robert] Louisiana State Univ, Hlth Sci Ctr, Pediat AIDS Clin Trials Unit New Orleans, New Orleans, LA USA. RP Theron, GB (reprint author), Fac Hlth Sci, Dept Obstet & Gynaecol, POB 19063, ZA-7505 Tygerberg, South Africa. EM gbth@sun.ac.za FU National Institute of Allergy and Infectious Diseases [U01 AI068632]; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental Health [AI068632]; Harvard School of Public Health Statistical and Data Analysis Center, under National Institute of Allergy and Infectious Diseases [5 U01 AI41110, 1 U01 AI068616]; Child Health and Human Development [N01-DK-9-001/HHSN267200800001C] FX Support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (grant U01 AI068632), the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health (grant AI068632). The content is the sole responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was supported by the Harvard School of Public Health Statistical and Data Analysis Center, under National Institute of Allergy and Infectious Diseases cooperative agreement No. 5 U01 AI41110 with the Pediatric AIDS Clinical Trials Group and No. 1 U01 AI068616 with the IMPAACT Group. Support for the study sites was provided by the National Institute of Allergy and Infectious Diseases, the International and Domestic Pediatric and Maternal HIV Clinical Trials Network funded by Child Health and Human Development (contract No. N01-DK-9-001/HHSN267200800001C). NR 12 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0020-7292 J9 INT J GYNECOL OBSTET JI Int. J. Gynecol. Obstet. PD APR PY 2011 VL 113 IS 1 BP 44 EP 49 DI 10.1016/j.ijgo.2010.10.011 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 756KL UT WOS:000290010000009 PM 21251654 ER PT J AU Rodriguez-Garcia, M Porichis, F de Jong, OG Levi, K Diefenbach, TJ Lifson, JD Freeman, GJ Walker, BD Kaufmann, DE Kavanagh, DG AF Rodriguez-Garcia, Marta Porichis, Filippos de Jong, Olivier G. Levi, Karen Diefenbach, Thomas J. Lifson, Jeffrey D. Freeman, Gordon J. Walker, Bruce D. Kaufmann, Daniel E. Kavanagh, Daniel G. TI Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10 SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE B7-H1; B7-DC ID T-CELL-ACTIVATION; PROGRAMMED DEATH-1; DENDRITIC CELLS; DISEASE PROGRESSION; INFECTION; MONOCYTES; IMMUNITY; LIGANDS; B7-H1; B7-DC AB PD-1 plays an important role in T cell exhaustion during HIV infection. PD-1 has two ligands: PD-L1, expressed on hematopoietic and nonhematopoietic cells, and PD-L2, limited to DCs and macrophages. Little is known about PD-L1 expression and regulation in human macrophages. Previous reports have found few immediate effects of macrophage exposure to HIV, suggesting that macrophages lack PRRs for this virus. Using quantitative confocal microscopy and a multiplexed cytokine bead array, we measured induction of PD-L1, PD-L2, and innate response cytokines in human MDMs in response to chemically inactivated HIV virions. Consistent with previous reports, no cytokines were induced by HIV virion exposure. Whereas PD-L1 and PD-L2 had low baseline expression, TLR ligands (LPS and CL097) up-regulated PD-L1 but not PD-L2. Unlike what we found for cytokine expression, PD-L1 and PD-L2 were up-regulated in response to exposure with inactivated HIV virions or with replication-competent HIV. Expression of PD-L1 was differentially modulated by IL-10, which induced up-regulation of PD-L1 but not of PD-L2, and IL-10 blockade enhanced only PD-L2 expression. We discuss implications for innate recognition of HIV by macrophages and potential, different roles for PD-L1 and PD-L2 in immunity and pathogenesis. J. Leukoc. Biol. 89: 507-515; 2011. C1 [Rodriguez-Garcia, Marta; Porichis, Filippos; de Jong, Olivier G.; Levi, Karen; Diefenbach, Thomas J.; Walker, Bruce D.; Kaufmann, Daniel E.; Kavanagh, Daniel G.] MIT, Ragon Inst MGH, Charlestown, MA 02129 USA. [Rodriguez-Garcia, Marta; Porichis, Filippos; de Jong, Olivier G.; Levi, Karen; Diefenbach, Thomas J.; Walker, Bruce D.; Kaufmann, Daniel E.; Kavanagh, Daniel G.] Harvard Univ, Charlestown, MA 02129 USA. [Walker, Bruce D.] Howard Hughes Med Inst, Charlestown, MA USA. [Lifson, Jeffrey D.] SAIC Frederick Inc, AIDS & Canc Virus Program, Natl Canc Inst Frederick, Frederick, MD USA. [Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med,Dept Med Oncol, Boston, MA 02115 USA. [Kaufmann, Daniel E.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. RP Kavanagh, DG (reprint author), MIT, Ragon Inst MGH, 149 13th St, Charlestown, MA 02129 USA. EM dkavanagh@partners.org FU National Institutes of Health [1U19A1082630, A108080192, HL92565]; National Cancer Institute, National Institutes of Health [HHSN261200800001E]; [1P01AI080192-0] FX This work was supported by grant 1P01AI080192-0 and grants 1U19A1082630, A108080192, and HL92565 from the National Institutes of Health. The work was supported in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E. We thank Marcus Altfeld, Judy Chang, and Angela Meier for their comments and suggestions. NR 40 TC 43 Z9 43 U1 0 U2 6 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD APR PY 2011 VL 89 IS 4 BP 507 EP 515 DI 10.1189/jlb.0610327 PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 757OZ UT WOS:000290098900004 PM 21097698 ER PT J AU Murray, PJ Wynn, TA AF Murray, Peter J. Wynn, Thomas A. TI Obstacles and opportunities for understanding macrophage polarization SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Review DE Toll-like receptors; cytokine; chemokine; interferon ID MARROW-DERIVED MACROPHAGES; HEMATOPOIETIC STEM-CELLS; NITRIC-OXIDE SYNTHESIS; GENE-EXPRESSION; ALTERNATIVE ACTIVATION; ARGINASE-I; TYPE-2 INFLAMMATION; HELMINTH INFECTION; TUMOR PROGRESSION; DENDRITIC CELLS AB Macrophages are now routinely categorized into phenotypic subtypes based on gene expression induced in response to cytokine and pathogen-derived stimulation. In the broadest division, macrophages are described as being CAMs (M1 macrophages) or AAMs (M2 macrophages) based on their exposure to TLR and IFN signals or Th2 cytokines, respectively. Despite the prolific use of this simple classification scheme, little is known about the precise functions of effector molecules produced by AAMs, especially how representative the CAM and AAM subtypes are of tissue macrophages in homeostasis, infection, or tissue repair and how plasticity in gene expression regulates macrophage function in vivo. Furthermore, correlations between mouse and human tissue macrophages and their representative subtypes are lacking and are a major barrier to understanding human immunity. Here, we briefly summarize current features of macrophage polarization and discuss the roles of various macrophage subpopulations and macrophage-associated genes in health and disease. J. Leukoc. Biol. 89: 557-563; 2011. C1 [Murray, Peter J.] St Jude Childrens Hosp, Dept Infect Dis, Memphis, TN 38105 USA. [Murray, Peter J.] St Jude Childrens Hosp, Dept Immunol, Memphis, TN 38105 USA. [Wynn, Thomas A.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA. RP Murray, PJ (reprint author), St Jude Childrens Hosp, Dept Infect Dis, 262 Danny Thomas Pl,MS320,Room E8078, Memphis, TN 38105 USA. EM peter.murray@stjude.org RI Wynn, Thomas/C-2797-2011 NR 78 TC 176 Z9 181 U1 3 U2 50 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD APR PY 2011 VL 89 IS 4 BP 557 EP 563 DI 10.1189/jlb.0710409 PG 7 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 757OZ UT WOS:000290098900008 PM 21248152 ER PT J AU Vilar, S Karpiak, J Berk, B Costanzi, S AF Vilar, Santiago Karpiak, Joel Berk, Barkin Costanzi, Stefano TI In silico analysis of the binding of agonists and blockers to the beta(2)-adrenergic receptor SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING LA English DT Article DE G protein-coupled receptor; Agonists; Blockers; Induced Fit; Docking; Linear discriminant analysis; Molecular dynamics ID PROTEIN-COUPLED RECEPTORS; 2ND EXTRACELLULAR LOOP; STRUCTURE-BASED DISCOVERY; BETA-2-ADRENERGIC RECEPTOR; CONFORMATIONAL-CHANGES; BETA(2) ADRENOCEPTOR; MOLECULAR-DYNAMICS; HOMOLOGY MODELS; DRUG DISCOVERY; LIGAND AB Activation of G protein-coupled receptors (GPCRs) is a complex phenomenon. Here, we applied Induced Fit Docking (IFD) in tandem with linear discriminant analysis (LDA) to generate hypotheses on the conformational changes induced to the beta(2)-adrenergic receptor by agonist binding, preliminary to the sequence of events that characterize activation of the receptor. This analysis, corroborated by a follow-up molecular dynamics study, suggested that agonists induce subtle movements to the fifth transmembrane domain (TM5) of the receptor. Furthermore, molecular dynamics also highlighted a correlation between movements of TM5 and the second extracellular loop (EL2), suggesting that freedom of motion of EL2 is required for the agonist-induced TM5 displacement. Importantly, we also showed that the IFD/LDA procedure can be used as a computational means to distinguish agonists from blockers on the basis of the differential conformational changes induced to the receptor. In particular, the two most predictive models obtained are based on the RMSD induced to Ser207 and on the counterclockwise rotation induced to TM5. Published by Elsevier Inc. C1 [Vilar, Santiago; Karpiak, Joel; Berk, Barkin; Costanzi, Stefano] NIDDK, Lab Biol Modeling, NIH, DHHS, Bethesda, MD 20892 USA. RP Costanzi, S (reprint author), NIDDK, Lab Biol Modeling, NIH, DHHS, Bethesda, MD 20892 USA. EM stefanoc@mail.nih.gov RI Costanzi, Stefano/G-8990-2013; berk, barkin/P-2088-2014; OI Costanzi, Stefano/0000-0003-3183-7332; Vilar Varela, Santiago/0000-0003-2663-4370 FU NIH, NIDDK FX This research was supported by the Intramural Research Program of the NIH, NIDDK. We thank Nels Thorsteinson of Chemical Computing Group for providing the SVL script for the clustering of the docking poses. NR 59 TC 27 Z9 28 U1 2 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1093-3263 J9 J MOL GRAPH MODEL JI J. Mol. Graph. PD APR PY 2011 VL 29 IS 6 BP 809 EP 817 DI 10.1016/j.jmgm.2011.01.005 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer Science, Interdisciplinary Applications; Crystallography; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Computer Science; Crystallography; Mathematical & Computational Biology GA 755IO UT WOS:000289922900005 PM 21334234 ER PT J AU Bassig, BA Inskip, PD Burdette, L Shapiro, WR Selker, RG Fine, HA Loeffler, JS Black, PM Dubrow, R Brenner, AV AF Bassig, Bryan A. Inskip, Peter D. Burdette, Laurie Shapiro, William R. Selker, Robert G. Fine, Howard A. Loeffler, Jay S. Black, Peter M. Dubrow, Robert Brenner, Alina V. TI Selected human leukocyte antigen class II polymorphisms and risk of adult glioma SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Article DE Glioma; Brain tumors; HLA polymorphisms; DQB1; DRB1 AB Few studies have examined the relationship between human leukocyte antigen (HLA) polymorphisms and adult glioma, particularly at class II loci. We evaluated the association between selected HLA class II polymorphisms and adult glioma in a large, hospital-based case-control study, using unconditional logistic regression. DQB1*06 (OR=1.67, 95% CI=1.17-2.39) and DRB1*13 (OR=1.69, 95% CI=1.08-2.64) alleles were associated with an increased risk of glioma, while the DQB1*05 allele showed an inverse association (OR=0.63, 95% CI=0.43-0.93). These results, which were of borderline significance once controlled for the false discovery rate, suggest a potential role for the DQB1*06, DQB1*05, and DRB1*13 alleles in glioma susceptibility. (C) 2010 Published by Elsevier B.V. C1 [Inskip, Peter D.; Brenner, Alina V.] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Bassig, Bryan A.; Dubrow, Robert] Yale Univ, Sch Med, Yale Sch Publ Hlth, New Haven, CT 06510 USA. [Burdette, Laurie] NCI Frederick, Core Genotyping Facil, Adv Technol Program, SAIC Frederick Inc, Ft Detrick, MD 21702 USA. [Shapiro, William R.] St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ 85013 USA. [Selker, Robert G.] Western Penn Hosp, Div Neurosurg, Pittsburgh, PA 15224 USA. [Fine, Howard A.] NCI, Neurooncol Branch, Bethesda, MD 20892 USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Black, Peter M.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Brenner, AV (reprint author), NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,MSC 7362, Bethesda, MD 20892 USA. EM brennera@mail.nih.gov FU National Institutes of Health (National Cancer Institute, Division of Cancer Epidemiology and Genetics) FX This study was supported by Intramural Research program of the National Institutes of Health (National Cancer Institute, Division of Cancer Epidemiology and Genetics). NR 1 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD APR PY 2011 VL 233 IS 1-2 BP 185 EP 191 DI 10.1016/j.jneuroim.2010.11.005 PG 7 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 757FD UT WOS:000290070000024 PM 21195488 ER PT J AU Glaser, R York, AE Dimitrakakis, C AF Glaser, Rebecca York, Anne E. Dimitrakakis, Constantine TI Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS) SO MATURITAS LA English DT Article DE Testosterone; Implant; Health-related quality of life; Menopause; Pre-menopause ID HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; BREAST-CANCER; ANDROGEN LEVELS; SAFETY; SYMPTOMS; IMPLANTS; ESTROGEN; RISK; AGE AB Objectives: This study was designed to measure the beneficial effects of continuous testosterone therapy, delivered by subcutaneous implant, in the relief of somatic, psychological and urogenital symptoms in both pre- and post-menopausal patients, utilizing the validated Health Related Quality of Life (HRQOL), Menopause Rating Scale (MRS). Study design: 300 pre- and post-menopausal women with symptoms of relative androgen deficiency, were asked to self-administer the 11-item MRS, at baseline and 3 months after their first insertion of the subcutaneous testosterone implant. Baseline hormone measurements, menopausal status and BMI, were assessed to determine correlation with symptoms and clinical outcome. Main outcome measurements: Changes related to therapy were determined. Total MRS scores as well as psychological, somatic and urogenital subscale scores were compared prior to therapy and following testosterone implant therapy. Results: Pre-menopausal and post-menopausal females reported similar hormone deficiency symptoms. Both groups demonstrated similar improvement in total score, as well as psychological, somatic and urogenital subscale scores with testosterone therapy. Better effect was noted in women with more severe complaints. Higher doses of testosterone correlated with greater improvement in symptoms. Conclusion: Continuous testosterone alone, delivered by subcutaneous implant, was effective for the relief of hormone deficiency symptoms in both pre- and post-menopausal patients. The validated, HRQOL questionnaire, Menopause Rating Scale (MRS), proved a valuable tool in the measurement of the beneficial effects of testosterone therapy in both cohorts. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Glaser, Rebecca] Millennium Wellness Ctr, Dayton, OH 45458 USA. [Glaser, Rebecca] Wright State Univ, Boonshoft Sch Med, Dept Surg, Dayton, OH 45435 USA. [York, Anne E.] York Data Anal, Seattle, WA 98107 USA. [Dimitrakakis, Constantine] Univ Athens, Sch Med, Dept Ob Gyn 1, Athens 11528, Greece. [Dimitrakakis, Constantine] NICHD, NIH, Bethesda, MD 20892 USA. RP Glaser, R (reprint author), Millennium Wellness Ctr, 228 E Spring Valley Rd, Dayton, OH 45458 USA. EM rglaser@wohsr.com; anne.york@gmail.com; dimitrac@mail.nih.gov NR 30 TC 15 Z9 18 U1 2 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0378-5122 EI 1873-4111 J9 MATURITAS JI Maturitas PD APR PY 2011 VL 68 IS 4 BP 355 EP 361 DI 10.1016/j.maturitas.2010.12.001 PG 7 WC Geriatrics & Gerontology; Obstetrics & Gynecology SC Geriatrics & Gerontology; Obstetrics & Gynecology GA 756JP UT WOS:000290007800010 PM 21177051 ER PT J AU Yan, H Sun, LG Oppo, DW Wang, YH Liu, ZH Xie, ZQ Liu, XD Cheng, WH AF Yan, Hong Sun, Liguang Oppo, Delia W. Wang, Yuhong Liu, Zhonghui Xie, Zhouqing Liu, Xiaodong Cheng, Wenhan TI South China Sea hydrological changes and Pacific Walker Circulation variations over the last millennium SO NATURE COMMUNICATIONS LA English DT Article ID INTERTROPICAL CONVERGENCE ZONE; EL-NINO/SOUTHERN-OSCILLATION; TROPICAL PACIFIC; SURFACE TEMPERATURES; YUCATAN PENINSULA; MAYA LOWLANDS; ICE-AGE; CLIMATE; HOLOCENE; RECORD AB The relative importance of north-south migrations of the intertropical convergence zone (ITCZ) versus El Nino-Southern Oscillation and its associated Pacific Walker Circulation (PWC) variability for past hydrological change in the western tropical Pacific is unclear. Here we show that north-south ITCZ migration was not the only mechanism of tropical Pacific hydrologic variability during the last millennium, and that PWC variability profoundly influenced tropical Pacific hydrology. We present hydrological reconstructions from Cattle Pond, Dongdao Island of the South China Sea, where multi-decadal rainfall and downcore grain size variations are correlated to the Southern Oscillation Index during the instrumental era. Our downcore grain size reconstructions indicate that this site received less precipitation during relatively warm periods, AD 1000-1400 and AD 1850-2000, compared with the cool period (AD 1400-1850). Including our new reconstructions in a synthesis of tropical Pacific records results in a spatial pattern of hydrologic variability that implicates the PWC. C1 [Yan, Hong; Sun, Liguang; Xie, Zhouqing; Liu, Xiaodong; Cheng, Wenhan] Univ Sci & Technol China, Dept Earth & Space Sci, Inst Polar Environm, Hefei 230026, Anhui, Peoples R China. [Oppo, Delia W.] Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA. [Wang, Yuhong] NIH, Bethesda, MD 20892 USA. [Liu, Zhonghui] Univ Hong Kong, Dept Earth Sci, Hong Kong, Hong Kong, Peoples R China. RP Sun, LG (reprint author), Univ Sci & Technol China, Dept Earth & Space Sci, Inst Polar Environm, Hefei 230026, Anhui, Peoples R China. EM slg@ustc.edu.cn RI Liu, Zhonghui/D-3163-2009; Ma, Wentao/A-8800-2010; Yan, Hong/I-8970-2014 OI Liu, Zhonghui/0000-0002-2168-8305; FU Natural Science Foundation of China (NSFC) [40730107]; Major State Basic Research Development Program of China (973 Program) [2010CB428902]; US NSF FX This work was supported by the Natural Science Foundation of China (NSFC) (40730107) and the Major State Basic Research Development Program of China (973 Program) (No.2010CB428902). DWO acknowledges support from the US NSF. We wish to thank Chengyun Yang, Yi Liu, Nan Jia, Sanping Zhao, Xin He and Shican Qiu for their help in sampling and analyses. NR 29 TC 38 Z9 45 U1 6 U2 35 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD APR PY 2011 VL 2 AR 293 DI 10.1038/ncomms1297 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 756AN UT WOS:000289983800031 PM 21522137 ER PT J AU Millau, JF Bandele, OJ Perron, J Bastien, N Bouchard, EF Gaudreau, L Bell, DA Drouin, R AF Millau, Jean-Francois Bandele, Omari J. Perron, Josiann Bastien, Nathalie Bouchard, Eric F. Gaudreau, Luc Bell, Douglas A. Drouin, Regen TI Formation of stress-specific p53 binding patterns is influenced by chromatin but not by modulation of p53 binding affinity to response elements(dagger) SO NUCLEIC ACIDS RESEARCH LA English DT Article ID CELL-CYCLE ARREST; TRANSCRIPTION-FACTOR; APOPTOTIC FUNCTION; GENE-EXPRESSION; DNA-BINDING; TRANSACTIVATION; P21(WAF1/CIP1); ACETYLATION; ACTIVATION; INHIBITOR AB The p53 protein is crucial for adapting programs of gene expression in response to stress. Recently, we revealed that this occurs partly through the formation of stress-specific p53 binding patterns. However, the mechanisms that generate these binding patterns remain largely unknown. It is not established whether the selective binding of p53 is achieved through modulation of its binding affinity to certain response elements (REs) or via a chromatin-dependent mechanism. To shed light on this issue, we used a microsphere assay for protein-DNA binding to measure p53 binding patterns on naked DNA. In parallel, we measured p53 binding patterns within chromatin using chromatin immunoprecipitation and DNase I coupled to ligation-mediated polymerase chain reaction footprinting. Through this experimental approach, we revealed that UVB and Nutlin-3 doses, which lead to different cellular outcomes, induce similar p53 binding patterns on naked DNA. Conversely, the same treatments lead to stress-specific p53 binding patterns on chromatin. We show further that altering chromatin remodeling using an histone acetyltransferase inhibitor reduces p53 binding to REs. Altogether, our results reveal that the formation of p53 binding patterns is not due to the modulation of sequence-specific p53 binding affinity. Rather, we propose that chromatin and chromatin remodeling are required in this process. C1 [Millau, Jean-Francois; Perron, Josiann; Bastien, Nathalie; Bouchard, Eric F.; Drouin, Regen] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pediat, Div Genet, Sherbrooke, PQ J1H 5N4, Canada. [Bandele, Omari J.; Bell, Douglas A.] NIEHS, Environm Genom Grp, Mol Genet Lab, Res Triangle Pk, NC 27709 USA. [Gaudreau, Luc] Univ Sherbrooke, Fac Sci, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada. RP Drouin, R (reprint author), Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pediat, Div Genet, Sherbrooke, PQ J1H 5N4, Canada. EM regen.drouin@usherbrooke.ca FU Canada Research Chair Program; Canadian Institutes of Health Research; National Institute of Environmental Health Sciences, National Institutes of Health [ZO1-ES-100475, Z01 ES065079]; Foundation of Stars; Canadian Foundation for Innovation; Centre de Recherche Clinique Etienne-Le Bel of the CHUS FX The Canada Research Chair Program ('Genetics, Mutagenesis and Cancer' to R. D. and 'Mechanisms of Gene Transcription' to L. G.); the Canadian Institutes of Health Research (to L. G.); and the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health (ZO1-ES-100475 and Z01 ES065079 to O.J.B. and D. A. B.); Foundation of Stars, post-doctoral fellowship (to J.-F.M.); Parts of the research were carried out in facilities funded by grants from the Canadian Foundation for Innovation and from the Centre de Recherche Clinique Etienne-Le Bel of the CHUS. Funding for open access charge: Canada Research Chair Program ('Genetics, Mutagenesis and Cancer' to R. D.). NR 47 TC 7 Z9 7 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD APR PY 2011 VL 39 IS 8 BP 3053 EP 3063 DI 10.1093/nar/gkq1209 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 757AD UT WOS:000290055200012 PM 21177650 ER PT J AU Kim, KK Kim, YC Adelstein, RS Kawamoto, S AF Kim, Kee K. Kim, Yong C. Adelstein, Robert S. Kawamoto, Sachiyo TI Fox-3 and PSF interact to activate neural cell-specific alternative splicing SO NUCLEIC ACIDS RESEARCH LA English DT Article ID PRE-MESSENGER-RNA; HEAVY CHAIN-B; NONMUSCLE MYOSIN; COMPLEX-FORMATION; NERVOUS-SYSTEM; PROTEIN; EXON; EXPRESSION; CLONING; ISOFORM AB Fox-1 family (Fox) proteins, which consist of Fox-1 (A2BP1), Fox-2 (Rbm9) and Fox-3 (NeuN) in mammals, bind to the RNA element UGCAUG and regulate alternative pre-mRNA splicing. However the mechanisms for Fox-regulated splicing are largely unknown. We analyzed the expression pattern of the three Fox proteins as well as neural cell-specific alternative splicing of a cassette exon N30 of nonmuscle myosin heavy chain (NMHC) II-B in the mouse central nervous system. Histological and biochemical analyses following fluorescence-activated cell sorting demonstrate a positive correlation of N30 inclusion and Fox-3 expression. Further, we identified polypyrimidine tract binding protein-associated splicing factor (PSF) as an interacting protein with Fox-3 by affinity-chromatography. In cultured cells, enhancement of N30 inclusion by Fox-3 depends on the presence of PSF. PSF enhances N30 inclusion in a UGCAUG-dependent manner, although it does not bind directly to this element. Fox-3 is recruited to the UGCAUG element downstream of N30 in the endogenous NMHC II-B transcript in a PSF-dependent manner. This study is the first to identify PSF as a coactivator of Fox proteins and provides evidence that the Fox-3 and PSF interaction is an integral part of the mechanism by which Fox proteins regulate activation of alternative exons via a downstream intronic enhancer. C1 [Kim, Kee K.; Adelstein, Robert S.; Kawamoto, Sachiyo] NHLBI, Mol Cardiol Lab, Bethesda, MD 20892 USA. [Kim, Yong C.] NIAID, Cellular Immunol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA. RP Kawamoto, S (reprint author), NHLBI, Mol Cardiol Lab, Bethesda, MD 20892 USA. EM kawamots@mail.nih.gov RI Kim, Kee/F-8784-2011; OI Adelstein, Robert/0000-0002-8683-2144 FU Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, USA FX Funding for open access charge: Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, USA. NR 55 TC 38 Z9 40 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD APR PY 2011 VL 39 IS 8 BP 3064 EP 3078 DI 10.1093/nar/gkq1221 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 757AD UT WOS:000290055200013 PM 21177649 ER PT J AU Zhang, F Hinnebusch, AG AF Zhang, Fan Hinnebusch, Alan G. TI An upstream ORF with non-AUG start codon is translated in vivo but dispensable for translational control of GCN4 mRNA SO NUCLEIC ACIDS RESEARCH LA English DT Article ID AMINO-ACID CONTROL; EIF2-ALPHA KINASE GCN2; SACCHAROMYCES-CEREVISIAE; EUKARYOTIC TRANSLATION; MAMMALIAN-CELLS; GENE-EXPRESSION; INITIATION; PROTEIN; YEAST; REINITIATION AB Genome-wide analysis of ribosome locations in mRNAs of Saccharomyces cerevisiae has revealed the translation of upstream open reading frames that initiate with near-cognate start codons in many transcripts. Two such non-translation initiation codon (AUG)-initiated upstream open reading frames (uORFs) (nAuORFs 1 and 2) occur in GCN4 mRNA upstream of the four AUG-initiated uORFs (uORFs 1-4) that regulate GCN4 translation. We verified that nAuORF2 is translated in vivo by demonstrating beta-galactosidase production from lacZ coding sequences fused to nAuORF2, in a manner abolished by replacing its non-AUG initiation codon (AUA) start codon with the non-cognate triplet AAA, whereas translation of nAuORF1 was not detected. Importantly, replacing the near-cognate start codons of both nAuORFs with non-cognate triplets had little or no effect on the repression of GCN4 translation in non-starved cells, nor on its derepression in response to histidine limitation, nutritional shift-down or treatment with rapamycin, hydrogen peroxide or methyl methanesulfonate. Additionally, we found no evidence that initiation from the AUA codon of nAuORF2 is substantially elevated, or dependent on Gcn2, the sole eIF2 alpha kinase of yeast, in histidine-deprived cells. Thus, although nAuORF2 is translated in vivo, it appears that this event is not stimulated by eIF2 alpha phosphorylation nor significantly influences GCN4 translational induction under various starvation or stress conditions. C1 [Zhang, Fan; Hinnebusch, Alan G.] Eunice K Shriver Natl Inst Child Hlth & Human Dev, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA. RP Hinnebusch, AG (reprint author), Eunice K Shriver Natl Inst Child Hlth & Human Dev, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA. EM ahinnebusch@nih.gov FU National Institutes of Health FX The research was supported by the Intramural Research Program of the National Institutes of Health. NR 38 TC 12 Z9 12 U1 0 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD APR PY 2011 VL 39 IS 8 BP 3128 EP 3140 DI 10.1093/nar/gkq1251 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 757AD UT WOS:000290055200018 PM 21227927 ER PT J AU Prokesch, A Bogner-Strauss, JG Hackl, H Rieder, D Neuhold, C Walenta, E Krogsdam, A Scheideler, M Papak, C Wong, WC Vinson, C Eisenhaber, F Trajanoski, Z AF Prokesch, Andreas Bogner-Strauss, Juliane G. Hackl, Hubert Rieder, Dietmar Neuhold, Claudia Walenta, Evelyn Krogsdam, Anne Scheideler, Marcel Papak, Christine Wong, Wing-Cheong Vinson, Charles Eisenhaber, Frank Trajanoski, Zlatko TI Arxes: retrotransposed genes required for adipogenesis SO NUCLEIC ACIDS RESEARCH LA English DT Article ID MICROSOMAL SIGNAL PEPTIDASE; PPAR-GAMMA; HUMAN GENOME; PROCESSED PSEUDOGENES; EXPRESSION; BINDING; PROTEIN; CELLS; ADIPOCYTES; SEQUENCES AB Retrotransposed sequences arise from messenger RNAs (mRNAs) that have been reinserted into genomic DNA by reverse transcription. Usually, these sequences are embedded in dormant regions, collect missense mutations over time and constitute processed, nonfunctional pseudogenes. There are thousands of processed pseudogenes in the mouse and human genome. Here, we report evidence for two paralog genes (termed Arxes1 and Arxes2), which arose by retrotransposition of the signal peptidase Spcs3 followed by a segmental duplication event. They gained a functional promoter that we show to be transactivated by adipogenic transcription factors. We further show that the Arxes mRNAs are highly expressed in adipose tissue and strongly upregulated during adipogenesis in different cell models. Additionally, their expression is elevated by an anti-diabetic agent in vitro and in vivo. Importantly, we provide evidence that the Arxes genes are translated and that the proteins are located in the endoplasmic reticulum. Although the sequence similarity and subcellular location are reminiscent of their parental gene, our data suggest that the Arxes have developed a different function, since their expression is required for adipogenesis, whereas Spcs3 is dispensable. In summary, we report retrotransposed-duplicated genes that evolved from a parental gene to function in a tissue and adipogenesis-specific context. C1 [Prokesch, Andreas; Bogner-Strauss, Juliane G.; Neuhold, Claudia; Walenta, Evelyn; Scheideler, Marcel; Papak, Christine] Graz Univ Technol, Inst Genom & Bioinformat, A-8010 Graz, Austria. [Hackl, Hubert; Rieder, Dietmar; Krogsdam, Anne; Trajanoski, Zlatko] Innsbruck Med Univ, Div Bioinformat, Bioctr, Innsbruck, Austria. [Wong, Wing-Cheong; Eisenhaber, Frank] ASTAR, Bioinformat Inst, Singapore, Singapore. [Vinson, Charles] NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Eisenhaber, Frank] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore. [Eisenhaber, Frank] Nanyang Technol Univ, Sch Comp Engn, Singapore, Singapore. RP Prokesch, A (reprint author), Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA. EM andreas.prokesch@tugraz.at; zlatko.trajanoski@i-med.ac.at OI Bogner-Strauss, Juliane/0000-0003-2459-0124; Hackl, Hubert/0000-0003-4055-3841 FU Austrian Federal Ministry for Science and Research; Austrian Science Fund FX The GEN-AU projects BIN and GOLD from the Austrian Federal Ministry for Science and Research; SFB Project Lipotoxicity from the Austrian Science Fund. Funding for open access charge: Austrian Federal Ministry for Science and Research, GEN-AU project BIN. NR 45 TC 10 Z9 11 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 EI 1362-4962 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD APR PY 2011 VL 39 IS 8 BP 3224 EP 3239 DI 10.1093/nar/gkq1289 PG 16 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 757AD UT WOS:000290055200025 PM 21177646 ER PT J AU Baar, C d'Abbadie, M Vaisman, A Arana, ME Hofreiter, M Woodgate, R Kunkel, TA Holliger, P AF Baar, Claudia d'Abbadie, Marc Vaisman, Alexandra Arana, Mercedes E. Hofreiter, Michael Woodgate, Roger Kunkel, Thomas A. Holliger, Philipp TI Molecular breeding of polymerases for resistance to environmental inhibitors SO NUCLEIC ACIDS RESEARCH LA English DT Article ID COMPARTMENTALIZED SELF-REPLICATION; ANCIENT DNA EXTRACTION; DIRECTED-EVOLUTION; TAQ POLYMERASE; PCR INHIBITORS; CHAIN-REACTION; HUMIC-ACID; AMPLIFICATION; PURIFICATION; COMPOST AB Potent inhibitors limit the use of PCR assays in a wide spectrum of specimens. Here, we describe the engineering of polymerases with a broad resistance to complex environmental inhibitors using molecular breeding of eight different polymerase orthologues from the genus Thermus and directed evolution by CSR in the presence of inhibitors. Selecting for resistance to the inhibitory effects of Neomylodon bone powder, we isolated 2D9, a chimeric polymerase comprising sequence elements derived from DNA polymerases from Thermus aquaticus, Thermus oshimai, Thermus thermophilus and Thermus brockianus. 2D9 displayed a striking resistance to a broad spectrum of complex inhibitors of highly divergent composition including humic acid, bone dust, coprolite, peat extract, clay-rich soil, cave sediment and tar. The selected polymerase promises to have utility in PCR-based applications in a wide range of fields including palaeobiology, archaeology, conservation biology, forensic and historic medicine. C1 [Baar, Claudia; d'Abbadie, Marc; Holliger, Philipp] MRC Lab Mol Biol, Cambridge CB2 0QH, England. [Vaisman, Alexandra; Woodgate, Roger] NICHHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA. [Arana, Mercedes E.; Kunkel, Thomas A.] NIEHS, Mol Genet Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA. [Arana, Mercedes E.; Kunkel, Thomas A.] NIEHS, Struct Biol Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA. [Hofreiter, Michael] Max Planck Inst Mol Anthropol, Res Grp Mol Ecol, D-04103 Leipzig, Germany. RP Holliger, P (reprint author), MRC Lab Mol Biol, Hills Rd, Cambridge CB2 0QH, England. EM ph1@mrc-lmb.cam.ac.uk RI Vaisman, Alexandra/C-3766-2013; Hofreiter, Michael/A-3996-2017 OI Vaisman, Alexandra/0000-0002-2521-1467; Hofreiter, Michael/0000-0003-0441-4705 FU MRC (Medical Research Council) [MC_US_A024_0014]; DFG (Deutsche Forschungsgemeinschaft) [BA 3572/1-1]; MRC; Trinity College, Cambridge; NICHD (National Institute of Child Health and Human Development)/NIH; Division of Intramural Research of the NIH, NIEHS (National Institute of Environmental Health Sciences) [Z01 ES065070] FX MRC (Medical Research Council) program grant MC_US_A024_0014 (to P. H.) and DFG (Deutsche Forschungsgemeinschaft) (grant BA 3572/1-1 to C. B.); MRC studentship and a Junior Research Fellowship from Trinity College, Cambridge (to M.d'A.); NICHD (National Institute of Child Health and Human Development)/NIH Intramural Research Program (to R. W. and A. V.). The work of M. E. A. and T. A. K. was supported in part by Project Z01 ES065070 (to T. A. K.) from the Division of Intramural Research of the NIH, NIEHS (National Institute of Environmental Health Sciences). Funding for open access charge: MRC. NR 42 TC 26 Z9 26 U1 3 U2 30 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 EI 1362-4962 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD APR PY 2011 VL 39 IS 8 AR e51 DI 10.1093/nar/gkq1360 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 757AD UT WOS:000290055200003 PM 21297114 ER PT J AU Szabo, R Rasmussen, AL Moyer, AB Kosa, P Schafer, JM Molinolo, AA Gutkind, JS Bugge, TH AF Szabo, R. Rasmussen, A. L. Moyer, A. B. Kosa, P. Schafer, J. M. Molinolo, A. A. Gutkind, J. S. Bugge, T. H. TI c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase SO ONCOGENE LA English DT Article DE hepatocyte growth factor; head and neck carcinoma; mTor; protease-activated signaling; cell surface proteases ID HEPATOCYTE GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; PLASMINOGEN-ACTIVATOR; IN-VIVO; FACTOR/SCATTER FACTOR; BARRIER FUNCTION; CANCER; MICE; RAPAMYCIN; RECEPTOR AB The progression and negative outcome of a variety of human carcinomas are intimately associated with aberrant activity of the c-Met oncogene. The underlying cause of this dysregulation, however, remains a subject of discussion, as the majority of cancer patients do not present with activating mutations in c-Met receptor itself. In this study, we show that the oncogenic protease matriptase is ubiquitously co-expressed with the c-Met in human squamous cell carcinomas and amplifies migratory and proliferative responses of primary epithelial cells to the cognate ligand for c-Met, pro-hepatocyte growth factor/scatter factor (proHGF/SF), through c-Met and Gab1 signaling. Furthermore, the selective genetic ablation of c-Met from matriptase-expressing keratinocytes completely negates the oncogenic potential of matriptase. In addition, matriptase-dependent carcinoma formation could be blocked by the pharmacological inhibition of the Akt-mammalian target of Rapamycin (mTor) pathway. Our data identify matriptase as an initiator of c-Met-Akt-mTor-dependent signaling axis in tumors and reveal mTor activation as an essential component of matriptase/ c-Met-induced carcinogenesis. The study provides a specific example of how epithelial transformation can be promoted by epigenetic acquisition of the capacity to convert a widely available paracrine growth factor precursor to its signaling competent state. Oncogene (2011) 30, 2003-2016; doi:10.1038/onc.2010.586; published online 10 January 2011 C1 [Szabo, R.; Rasmussen, A. L.; Moyer, A. B.; Kosa, P.; Schafer, J. M.; Molinolo, A. A.; Gutkind, J. S.; Bugge, T. H.] NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA. RP Bugge, TH (reprint author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA. EM thomas.bugge@nih.gov RI Gutkind, J. Silvio/A-1053-2009 FU NIDCR FX We thank Dr Snorri Thorgeirsson for floxed Hgfr mice. Supported by NIDCR Intramural Research Program. We thank Dr Mary Jo Danton for critically reviewing this manuscript. NR 50 TC 36 Z9 37 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD APR PY 2011 VL 30 IS 17 BP 2003 EP 2016 DI 10.1038/onc.2010.586 PG 14 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 755YL UT WOS:000289977400004 PM 21217780 ER PT J AU Munir, S Hillyer, P Le Nouen, C Buchholz, UJ Rabin, RL Collins, PL Bukreyev, A AF Munir, Shirin Hillyer, Philippa Le Nouen, Cyril Buchholz, Ursula J. Rabin, Ronald L. Collins, Peter L. Bukreyev, Alexander TI Respiratory Syncytial Virus Interferon Antagonist NS1 Protein Suppresses and Skews the Human T Lymphocyte Response SO PLOS PATHOGENS LA English DT Article ID NF-KAPPA-B; DENDRITIC CELLS; I INTERFERON; IFN-ALPHA; NONSTRUCTURAL PROTEINS; CLONAL EXPANSION; EPITHELIAL-CELLS; ALPHA(E)BETA(7) INTEGRIN; REGULATORY FACTOR-3; PRIMARY INFECTION AB We recently demonstrated that the respiratory syncytial virus (RSV) NS1 protein, an antagonist of host type I interferon (IFN-I) production and signaling, has a suppressive effect on the maturation of human dendritic cells (DC) that was only partly dependent on released IFN-I. Here we investigated whether NS1 affects the ability of DC to activate CD8+ and CD4+ T cells. Human DC were infected with RSV deletion mutants lacking the NS1 and/or NS2 genes and assayed for the ability to activate autologous T cells in vitro, which were analyzed by multi-color flow cytometry. Deletion of the NS1, but not NS2, protein resulted in three major effects: (i) an increased activation and proliferation of CD8+ T cells that express CD103, a tissue homing integrin that directs CD8+ T cells to mucosal epithelial cells of the respiratory tract and triggers cytolytic activity; (ii) an increased activation and proliferation of Th17 cells, which have recently been shown to have anti-viral effects and also indirectly attract neutrophils; and (iii) decreased activation of IL-4-producing CD4+ T cells - which are associated with enhanced RSV disease - and reduced proliferation of total CD4+ T cells. Except for total CD4+ T cell proliferation, none of the T cell effects appeared to be due to increased IFN-I signaling. In the infected DC, deletion of the NS1 and NS2 genes strongly up-regulated the expression of cytokines and other molecules involved in DC maturation. This was partly IFN-I-independent, and thus might account for the T cell effects. Taken together, these data demonstrate that the NS1 protein suppresses proliferation and activation of two of the protective cell populations (CD103+ CD8+ T cells and Th17 cells), and promotes proliferation and activation of Th2 cells that can enhance RSV disease. C1 [Munir, Shirin; Le Nouen, Cyril; Buchholz, Ursula J.; Collins, Peter L.; Bukreyev, Alexander] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Hillyer, Philippa; Rabin, Ronald L.] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA. RP Munir, S (reprint author), NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. EM alexander.bukreyev@utmb.edu FU NIAID, NIH FX This project was funded by the NIAID, NIH, Intramural Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 89 TC 44 Z9 44 U1 3 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD APR PY 2011 VL 7 IS 4 AR e1001336 DI 10.1371/journal.ppat.1001336 PG 17 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 755ZE UT WOS:000289979900008 PM 21533073 ER PT J AU Triyatni, M Berger, EA Saunier, B AF Triyatni, Miriam Berger, Edward A. Saunier, Bertrand TI A New Model to Produce Infectious Hepatitis C Virus without the Replication Requirement SO PLOS PATHOGENS LA English DT Article ID WEST-NILE-VIRUS; PRIMARY HUMAN HEPATOCYTES; DOUBLE-STRANDED-RNA; B TYPE-I; CELL-CULTURE; ASIALOGLYCOPROTEIN RECEPTOR; KUNJIN VIRUS; EFFICIENT REPLICATION; MEDIATED ENDOCYTOSIS; STRUCTURAL PROTEINS AB Numerous constraints significantly hamper the experimental study of hepatitis C virus (HCV). Robust replication in cell culture occurs with only a few strains, and is invariably accompanied by adaptive mutations that impair in vivo infectivity/replication. This problem complicates the production and study of authentic HCV, including the most prevalent and clinically important genotype 1 (subtypes 1a and 1b). Here we describe a novel cell culture approach to generate infectious HCV virions without the HCV replication requirement and the associated cell-adaptive mutations. The system is based on our finding that the intracellular environment generated by a West-Nile virus (WNV) subgenomic replicon rendered a mammalian cell line permissive for assembly and release of infectious HCV particles, wherein the HCV RNA with correct 5' and 3' termini was produced in the cytoplasm by a plasmid-driven dual bacteriophage RNA polymerase-based transcription/amplification system. The released particles preferentially contained the HCV-based RNA compared to the WNV subgenomic RNA. Several variations of this system are described with different HCV-based RNAs: (i) HCV bicistronic particles (HCVbp) containing RNA encoding the HCV structural genes upstream of a cell-adapted subgenomic replicon, (ii) HCV reporter particles (HCVrp) containing RNA encoding the bacteriophage SP6 RNA polymerase in place of HCV nonstructural genes, and (iii) HCV wild-type particles (HCVwt) containing unmodified RNA genomes of diverse genotypes (1a, strain H77; 1b, strain Con1; 2a, strain JFH-1). Infectivity was assessed based on the signals generated by the HCV RNA molecules introduced into the cytoplasm of target cells upon virus entry, i. e. HCV RNA replication and protein production for HCVbp in Huh-7.5 cells as well as for HCVwt in HepG2-CD81 cells and human liver slices, and SP6 RNA polymerase-driven firefly luciferase for HCVrp in target cells displaying candidate HCV surface receptors. HCV infectivity was inhibited by pre-incubation of the particles with anti-HCV antibodies and by a treatment of the target cells with leukocyte interferon plus ribavirin. The production of authentic infectious HCV particles of virtually any genotype without the adaptive mutations associated with in vitro HCV replication represents a new paradigm to decipher the requirements for HCV assembly, release, and entry, amenable to analyses of wild type and genetically modified viruses of the most clinically significant HCV genotypes. C1 [Triyatni, Miriam; Berger, Edward A.; Saunier, Bertrand] NIAID, Mol Struct Sect, Viral Dis Lab, NIH, Bethesda, MD 20892 USA. [Saunier, Bertrand] Paris Descartes Univ, Fac Med, Paris, France. [Saunier, Bertrand] Inst Cochin Genet Mol, F-75014 Paris, France. [Saunier, Bertrand] INSERM, U1016, Paris, France. RP Triyatni, M (reprint author), Hoffmann La Roche Inc, 340 Kingsland St, Nutley, NJ 07110 USA. EM bertrand.saunier@inserm.fr FU NIH, NIAID FX This research was funded in part by the Intramural Program of the NIH, NIAID. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 75 TC 8 Z9 10 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD APR PY 2011 VL 7 IS 4 AR e1001333 DI 10.1371/journal.ppat.1001333 PG 19 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 755ZE UT WOS:000289979900005 PM 21533214 ER PT J AU Wurtz, RH McAlonan, K Cavanaugh, J Berman, RA AF Wurtz, Robert H. McAlonan, Kerry Cavanaugh, James Berman, Rebecca A. TI Thalamic pathways for active vision SO TRENDS IN COGNITIVE SCIENCES LA English DT Review ID MONKEY SUPERIOR COLLICULUS; SACCADIC EYE-MOVEMENTS; BRAIN-STEM TELLS; SPATIAL ATTENTION; FRONTAL-CORTEX; COROLLARY DISCHARGE; EXTRASTRIATE CORTEX; RETICULAR NUCLEUS; RECEPTIVE FIELDS; BEHAVING MONKEY AB Active vision requires the integration of information coming from the retina with that generated internally within the brain, especially by saccadic eye movements. Just as visual information reaches cortex via the lateral geniculate nucleus of the thalamus, this internal information reaches the cerebral cortex through other higher-order nuclei of the thalamus. This review summarizes recent work on four of these thalamic nuclei. The first two pathways convey internal information about up-coming saccades (a corollary discharge) and probably contribute to the neuronal mechanisms that underlie stable visual perception. The second two pathways might contribute to the neuronal mechanisms underlying visual spatial attention in cortex and in the thalamus itself. C1 [Wurtz, Robert H.; McAlonan, Kerry; Cavanaugh, James; Berman, Rebecca A.] NEI, Lab Sensorimotor Res, NIH, Bethesda, MD 20892 USA. RP Wurtz, RH (reprint author), NEI, Lab Sensorimotor Res, NIH, Bethesda, MD 20892 USA. EM bob@lsr.nei.nih.gov FU Intramural NIH HHS [ZIA EY000109-30] NR 70 TC 44 Z9 44 U1 1 U2 18 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1364-6613 J9 TRENDS COGN SCI JI TRENDS COGN. SCI. PD APR PY 2011 VL 15 IS 4 BP 177 EP 184 DI 10.1016/j.tics.2011.02.004 PG 8 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 753DY UT WOS:000289747100006 PM 21414835 ER PT J AU Colsch, B Jackson, SN Dutta, S Woods, AS AF Colsch, Benoit Jackson, Shelley N. Dutta, Sucharita Woods, Amina S. TI Molecular Microscopy of Brain Gangliosides: Illustrating their Distribution in Hippocampal Cell Layers SO ACS CHEMICAL NEUROSCIENCE LA English DT Article DE gangliosides; MALDI-imaging; molecular mapping; brain; hippocampus ID DESORPTION/IONIZATION MASS-SPECTROMETRY; CENTRAL-NERVOUS-SYSTEM; MOUSE-BRAIN; TISSUE SECTIONS; SIALIC ACIDS; MATRIX; GLYCOSPHINGOLIPIDS; CHROMATOGRAPHY; LOCALIZATION; RECOGNITION AB Gangliosides are amphiphilic molecules found in the outer layer of plasma membranes of all vertebrate cells. They play a major role in cell recognition and signaling and are involved in diseases affecting the central nervous system (CNS). We are reporting the differential distribution of ganglioside specie; in the rat brain's cerebrum, based on their ceramide associated core, and for the first time the presence of acetylation detected by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry, which was used to map and image gangliosides with detailed structural information and histological accuracy. In the hippocampus, localization of the major species GM1, GD1, O-acetylGD1, GT1, and O-acetylGT1 depends on the sphingoid base (d18:1 sphingosine or d20:1 eicosasphingosine) in the molecular layer of the dentate gyrus (ML), which is made up of three distinct layers, the inner molecular layer (IML), which contains sphingosine exclusively, and the middle molecular layer (MML) and the outer molecular layer (0 ML) where eicosasphingosine is the only sphingoid base. These results demonstrate that there is a different distribution of gangliosides in neuronal axons and dendrites depending on the ceramide core of each layer. GM3, GM2, GD3, and GD2 contain sphingosine predominantly and are mainly present in body cell layers, which are made up of the pyramidal cell layer (Py) and the granular layer of the dentate gyrus (GL), in contrast with GQ1 and the O-acetylated forms of GD1, GT1, and GQ1 gangliosides, which contain both sphingoid bases. However their distribution is based on the sialylated and acetylated oligosaccharide chains in the neuronal cell bodies. C1 [Colsch, Benoit; Jackson, Shelley N.; Woods, Amina S.] NIDA IRP, Struct Biol Unit, Cellular Neurobiol Sect, NIH, Baltimore, MD 21224 USA. [Dutta, Sucharita] Thermo Fisher Sci, San Jose, CA USA. RP Woods, AS (reprint author), NIDA IRP, Struct Biol Unit, Cellular Neurobiol Sect, NIH, Baltimore, MD 21224 USA. EM awoods@mail.nih.gov FU National Institute on Drug Abuse, NIH; Office of National Drug Control Policy (ONDCP) FX This research was supported by the Intramural Research Program of the National Institute on Drug Abuse, NIH. We thank the Office of National Drug Control Policy (ONDCP) for instrumentation funding, without which this and other projects could net have been accomplished. NR 38 TC 32 Z9 34 U1 2 U2 15 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-7193 J9 ACS CHEM NEUROSCI JI ACS Chem. Neurosci. PD APR PY 2011 VL 2 IS 4 BP 213 EP 222 DI 10.1021/cn100096h PG 10 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology GA 753HF UT WOS:000289762200005 PM 21961052 ER PT J AU Huang, KP Huang, FL AF Huang, Kuo-Ping Huang, Freesia L. TI Calcium-Sensitive Translocation of Calmodulin and Neurogranin between Soma and Dendrites of Mouse Hippocampal CA1 Neurons SO ACS CHEMICAL NEUROSCIENCE LA English DT Article DE Calmodulin; neurogranin; calcium; translocation; hippocampus; epileptic activity ID PROTEIN-KINASE-C; ACTIVE-CHEMICAL SYNAPSES; RAT-BRAIN; SYNAPTIC PLASTICITY; IN-VIVO; PHOSPHORYLATION; TRANSMISSION; SUBSTRATE; SLICES; EPILEPTOGENESIS AB Calmodulin (CaM) and neurogranin (Ng) are two abundant neuronal proteins whose interactions are implicated in the regulation of synaptic responses and plasticity. We employed the "low-calcium" model of epilepsy in hippocampal slices to investigate the mobilization of these two proteins in CA1 pyramidal neurons. Perfusion of mouse hippocampal slices with Ca(2+)-free artificial CSF (ACSF) caused a suppression of synaptic transmission and generation of epileptic activity; these responses could be reversed by normal Ca(2+)-containing ACSF. Fluorescence immunochemical staining of control hippocampal slices bathed in normal ACSF revealed that CaM and Ng were more concentrated in soma than in dendrites; especially for CaM, it was concentrated in the nucleus. Perfusion of hippocampal slices with Ca(2+)-free ACSF caused translocation of these two proteins from soma to dendrites, and this trafficking was also reversed by Ca(2+)-containing buffer. A reduction of similar to 15 and 40 nM intracellular Ca(2+), [Ca(2+)](i), caused half-maximum translocation of Ng and CaM, respectively. Hippocampal CA1 pyramidal neurons were the most responsive to this Ca(2+)-sensitive translocation as compared to those from other areas of the hippocampus. These results illustrated the unique feature of hippocampal CA1 pyramidal neurons in sequestering high concentrations of CaM and Ng in soma and releasing them to distal dendrites at reducing level of [Ca(2+)](i). C1 [Huang, Kuo-Ping; Huang, Freesia L.] NICHHD, Program Dev Neurobiol, NIH, Bethesda, MD 20892 USA. RP Huang, KP (reprint author), NICHHD, Program Dev Neurobiol, NIH, Bldg 49,Room 6A10,49 Convent Dr,MSC 4510, Bethesda, MD 20892 USA. EM huangk@mail.nih.gov FU NICHD, NIH FX This work was supported by the Intramural Program of NICHD, NIH. NR 38 TC 1 Z9 2 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-7193 J9 ACS CHEM NEUROSCI JI ACS Chem. Neurosci. PD APR PY 2011 VL 2 IS 4 BP 223 EP 230 DI 10.1021/cn200003f PG 8 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology GA 753HF UT WOS:000289762200006 ER PT J AU Xie, J Zhang, F Aronova, M Zhu, L Lin, X Quan, QM Liu, G Zhang, GF Choi, KY Kim, K Sun, XL Lee, S Sun, SH Leapman, R Chen, XY AF Xie, Jin Zhang, Fan Aronova, Maria Zhu, Lei Lin, Xin Quan, Qimeng Liu, Gang Zhang, Guofeng Choi, Ki-Young Kim, Kwangmeyung Sun, Xiaolian Lee, Seulki Sun, Shouheng Leapman, Richard Chen, Xiaoyuan TI Manipulating the Power of an Additional Phase: A Flower-like Au-Fe3O4 Optical Nanosensor for Imaging Protease Expressions In vivo SO ACS NANO LA English DT Article DE composite nanoparticles; Au-Fe3O4; matrix metalloproteinase; activatable probes; near-infrared fluorescence imaging ID IRON-OXIDE NANOPARTICLES; GOLD NANOPARTICLES; MAGNETIC NANOPARTICLES; HETEROSTRUCTURED NANOPARTICLES; FUNCTIONAL MOLECULES; PROBES; DELIVERY AB We and others have recently proposed the synthesis of composite nanoparticles that offer strongly enhanced functionality. Here we have used a flower-shaped Au-Fe3O4 nanoparticle as a template to construct an optical probe containing Cy5.5-GPLGVRG-TDOPA on the iron oxide surface and SH-PEG(5000) on the gold surface, that can be specifically activated by matrix metalloproteinases expressed in tumors. Gold nanoparticles have excellent quenching properties, but labile surface chemistry in vivo; on the other hand, iron oxide nanoparticles afford robust surface chemistry, but are suboptimal as energy receptors. By a marriage of the two, we have produced a unified structure with performance that Is unachievable with the separate components. Our results are a further demonstration that the architecture of nanoparticles can be modulated to tailor their function as molecular imaging/therapeutic agents. C1 [Xie, Jin; Zhang, Fan; Zhu, Lei; Lin, Xin; Quan, Qimeng; Liu, Gang; Lee, Seulki; Chen, Xiaoyuan] NIBIB, LOMIN, NIH, Bethesda, MD 20892 USA. [Aronova, Maria; Leapman, Richard] NIBIB, Lab Cellular Imaging & Macromol Biophys, NIH, Bethesda, MD 20892 USA. [Choi, Ki-Young; Kim, Kwangmeyung] Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 136791, South Korea. [Sun, Xiaolian; Sun, Shouheng] Brown Univ, Dept Chem, Providence, RI 02912 USA. RP Lee, S (reprint author), NIBIB, LOMIN, NIH, Bethesda, MD 20892 USA. EM Seulki.Lee@nih.gov; Shawn.Chen@nih.gov RI Xie, Jin/E-8193-2010; Zhu, Lei/P-9786-2016; CHOI, KI YOUNG/Q-7177-2016 OI Zhu, Lei/0000-0002-1820-4795; FU National Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH; National Science Foundation of China (NSFC) [81028009]; NIH [K99/R00]; National Institute of Standards and Technology (NIST) FX This work was supported by the Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH, and the International Cooperative Program of National Science Foundation of China (NSFC) (81028009). J.X. is partially supported by an NIH Pathway to Independence Grant (K99/R00). S.L. acknowledges a National Research Council Research Associateship Award funded by the National Institute of Standards and Technology (NIST) and the IRP of NIBIB, NIH. We thank Dr. H. S. Eden for proofreading the manuscript. NR 28 TC 60 Z9 62 U1 6 U2 139 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1936-0851 J9 ACS NANO JI ACS Nano PD APR PY 2011 VL 5 IS 4 BP 3043 EP 3051 DI 10.1021/nn200161v PG 9 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA 753CJ UT WOS:000289742100073 PM 21366330 ER PT J AU Burruss, S Shen, XD Baibakov, B Gao, F Semiletova, NV AF Burruss, S. Shen, X. -D. Baibakov, B. Gao, F. Semiletova, N. V. TI Soluble Donor-Like MHC Class I Proteins Induce CD4(+)CD25(+)CD8(+)FoxP3(+) Cells with Potential To Ameliorate Graft Chronic Injury. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Burruss, S.; Shen, X. -D.; Gao, F.; Semiletova, N. V.] UCLA Med Sch, Los Angeles, CA USA. [Baibakov, B.] NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 42 BP 41 EP 41 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400042 ER PT J AU Yusen, RD Hong, B Murray, SK Messersmith, E Lopez, B Brown, KL Ojo, A Odim, J Merion, RM Barr, M AF Yusen, R. D. Hong, B. Murray, S. K. Messersmith, E. Lopez, B. Brown, K. L. Ojo, A. Odim, J. Merion, R. M. Barr, M. CA RELIVE Study Grp TI Morbidity and Mortality of 369 Live Lung Donors. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Yusen, R. D.; Hong, B.; Brown, K. L.] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Murray, S. K.; Ojo, A.; Merion, R. M.] Univ Michigan, Ann Arbor, MI 48109 USA. [Lopez, B.; Barr, M.] NIAID, NIH, Bethesda, MD USA. [Odim, J.] Univ So Calif, Los Angeles, CA 90089 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 69 BP 49 EP 49 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400069 ER PT J AU Chakkera, H Dueck, A Weil, E Cook, C Swanson, C Heilman, R Reddy, K Hamawi, K Moss, A Mulligan, D Knowler, W AF Chakkera, H. Dueck, A. Weil, E. Cook, C. Swanson, C. Heilman, R. Reddy, K. Hamawi, K. Moss, A. Mulligan, D. Knowler, W. TI Pre-Transplant Risk Score Predicts Development of New Onset Diabetes Mellitus after Kidney Transplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Chakkera, H.; Dueck, A.; Cook, C.; Swanson, C.; Heilman, R.; Reddy, K.; Hamawi, K.; Moss, A.; Mulligan, D.] Mayo Clin, Phoenix, AZ USA. [Weil, E.; Knowler, W.] NIH NIDDK Phoenix, Phoenix, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 231 BP 100 EP 101 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400231 ER PT J AU Engels, EA Lin, M AF Engels, E. A. Lin, M. TI Cancer Risk in US Transplant Recipients: The Transplant Cancer Match Study SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Engels, E. A.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. [Lin, M.] US Hlth Resources & Serv Adm, Div Transplantat, Rockville, MD 20857 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 244 BP 105 EP 105 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400244 ER PT J AU Roland, M Barin, B Huprikar, S Wong, M Fox, L Diego, J Blumberg, E Simon, D Shoham, S Stock, P AF Roland, M. Barin, B. Huprikar, S. Wong, M. Fox, L. Diego, J. Blumberg, E. Simon, D. Shoham, S. Stock, P. TI HIV-Related Predictors and Outcomes in 275 Liver and/or Kidney Transplant Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Roland, M.; Stock, P.] UCSF, San Francisco, CA USA. [Fox, L.] NIAID, NIH, Bethesda, MD USA. [Diego, J.] U Miami, Miami, FL USA. [Blumberg, E.] U Penn, Philadelphia, PA USA. [Shoham, S.] Washington Hosp Ctr, Washington, DC USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 377 BP 143 EP 144 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400377 ER PT J AU Taler, SJ Gillespie, B Ibrahim, H Kew, CE Guidinger, MS Leichtman, A Kremer, W Matas, A Odim, J Merion, RM AF Taler, S. J. Gillespie, B. Ibrahim, H. Kew, C. E. Guidinger, M. S. Leichtman, A. Kremer, W. Matas, A. Odim, J. Merion, R. M. CA RELIVE Study Grp TI Predictors of End Stage Renal Disease in Live Kidney Donors at Three US Kidney Transplant Centers. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Gillespie, B.; Leichtman, A.; Merion, R. M.] Univ Michigan, Ann Arbor, MI 48109 USA. [Taler, S. J.; Kremer, W.] Mayo Clin, Rochester, MN USA. [Ibrahim, H.; Matas, A.] Univ Minnesota, Minneapolis, MN 55455 USA. [Kew, C. E.] Univ Alabama, Birmingham, AL USA. [Odim, J.] NIAID, NIH, Bethesda, MD 20892 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 419 BP 156 EP 156 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400419 ER PT J AU Roland, M Barin, B Blumberg, E Feinberg, J Fox, L Huprikar, S Wong, M Diego, J Simon, I Stock, P AF Roland, M. Barin, B. Blumberg, E. Feinberg, J. Fox, L. Huprikar, S. Wong, M. Diego, J. Simon, I. Stock, P. TI Tenofovir Is Not Associated with Renal Dysfunction Following Solid Organ Transplantation. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Feinberg, J.] U Cincinnati, Cincinnati, OH USA. [Fox, L.] NIAID, NIH, Bethesda, MD 20892 USA. [Diego, J.] U Miami, Miami, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 857 BP 285 EP 285 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401064 ER PT J AU Taler, SJ Gillespie, B Ibrahim, H Kew, CE Patel, U Leichtman, A Kremers, WK Matas, A Odim, J Merion, RM AF Taler, S. J. Gillespie, B. Ibrahim, H. Kew, C. E. Patel, U. Leichtman, A. Kremers, W. K. Matas, A. Odim, J. Merion, R. M. CA RELIVE Study Grp TI Prevalence of Pre-Donation Hypertension and Metabolic Abnormalities among Live Kidney Donors at Three US Centers: Trends over 45 Years SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Taler, S. J.; Kremers, W. K.] Mayo Clin, Rochester, MN 55905 USA. [Gillespie, B.; Leichtman, A.; Merion, R. M.] Univ Michigan, Ann Arbor, MI 48109 USA. [Ibrahim, H.; Matas, A.] Univ Minnesota, Minneapolis, MN 55455 USA. [Kew, C. E.] Univ Alabama, Birmingham, AL USA. [Odim, J.] NIAID, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 963.5 BP 316 EP 316 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401173 ER PT J AU Carpenter, M Bostom, A Hunsicker, L Ivanova, A Kasiske, B Kusek, J Levey, A Markell, M Pesavento, T Smith, S Weir, M AF Carpenter, M. Bostom, A. Hunsicker, L. Ivanova, A. Kasiske, B. Kusek, J. Levey, A. Markell, M. Pesavento, T. Smith, S. Weir, M. TI Higher Systolic Blood Pressure Is Associated with Increased Cardiovascular Risk in Patients with Hypertension in the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Carpenter, M.; Ivanova, A.] Univ N Carolina, Chapel Hill, NC USA. [Bostom, A.] Rhode Isl Hosp, Providence, RI USA. [Hunsicker, L.] Univ Iowa, Iowa City, IA USA. [Kasiske, B.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Kusek, J.] NIDDK, NIH, Bethesda, MD USA. [Levey, A.] Tufts Med Ctr, Boston, MA USA. [Markell, M.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Pesavento, T.] Ohio State Univ, Columbus, OH 43210 USA. [Smith, S.] Duke Univ, Durham, NC USA. [Weir, M.] Univ Maryland, Baltimore, MD 21201 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1178 BP 375 EP 375 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401393 ER PT J AU Putheti, P Ding, R Naqvi, R Medeiros, M Sharma, VK Liu, J Lin, G Williams, NM Bridges, ND Strom, TB Suthanthiran, M Harmon, W AF Putheti, P. Ding, R. Naqvi, R. Medeiros, M. Sharma, V. K. Liu, J. Lin, G. Williams, N. M. Bridges, N. D. Strom, T. B. Suthanthiran, M. Harmon, W. TI Gene-Expression Profiles of Peripheral Blood Cells and Urinary Cells Are Diagnostic of Acute Rejection in Renal Allograft Recipients. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Putheti, P.; Strom, T. B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Transplant Inst, Boston, MA 02215 USA. [Ding, R.; Naqvi, R.; Medeiros, M.; Sharma, V. K.; Suthanthiran, M.] Cornell Univ, Med Ctr, New York, NY 10021 USA. [Liu, J.; Lin, G.] PPD Inc, Raleigh, NC USA. [Williams, N. M.; Bridges, N. D.] NIAID, Transplantat Immunobiol Branch, Bethesda, MD 20892 USA. [Harmon, W.] Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1430 BP 446 EP 446 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401648 ER PT J AU Agurs-Collins, T Perna, F Oh, A Chriqui, JF Masse, LC AF Agurs-Collins, Tanya Perna, Frank Oh, April Chriqui, Jamie F. Masse, Louise C. TI FIVE-YEAR CHANGE IN US STATE COMPETITIVE FOOD LAWS AFFECTING MIDDLE SCHOOLS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Agurs-Collins, Tanya; Perna, Frank; Oh, April] NCI, Rockville, MD 20852 USA. [Chriqui, Jamie F.] Univ Illinois, Chicago, IL USA. [Masse, Louise C.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. EM collinsta@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S132 EP S132 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701008 ER PT J AU Beckjord, EB Rechis, R Moser, RP Hesse, BW AF Beckjord, Ellen B. Rechis, Ruth Moser, Richard P. Hesse, Bradford W. TI METHODS FOR INCREASING BROAD PARTICIPATION IN BEHAVIORAL SCIENCE: EXAMPLES OF CONSTRUCTING, FIELDING, AND HARMONIZING USE OF BEHAVIORAL MEASURES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Beckjord, Ellen B.] Univ Pittsburgh, Pittsburgh, PA USA. [Rechis, Ruth] LIVESTRONG, Austin, TX USA. [Moser, Richard P.; Hesse, Bradford W.] NCI, Bethesda, MD 20892 USA. EM ebeckjor@rand.org NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S144 EP S144 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701051 ER PT J AU Beckjord, EB Moser, RP Rutten, LJF Blake, K Hesse, BW AF Beckjord, Ellen B. Moser, Richard P. Rutten, Lila J. Finney Blake, Kelly Hesse, Bradford W. TI USING SCIENCE 2.0 TO CONSTRUCT A SURVEILLANCE TOOL: BUILDING A BETTER HEALTH INFORMATION NATIONAL TRENDS SURVEY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Beckjord, Ellen B.] Univ Pittsburgh, Pittsburgh, PA USA. [Moser, Richard P.; Blake, Kelly; Hesse, Bradford W.] NCI, Bethesda, MD 20892 USA. [Rutten, Lila J. Finney] SAIC Frederick, Frederick, MD USA. EM ebeckjor@rand.org NR 0 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S144 EP S144 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701052 ER PT J AU Bellizzi, K Breslau, E AF Bellizzi, Keith Breslau, Erica TI PREVALENCE OF CANCER SCREENING AND PHYSICIAN RECOMMENDATIONS FOR SCREENING IN OLDER ADULTS FROM MINORITY BACKGROUNDS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Bellizzi, Keith] UConn, Storrs, CT 06269 USA. [Breslau, Erica] NCI, Bethesda, MD 20892 USA. EM keith.m.bellizzi@uconn.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S239 EP S239 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701425 ER PT J AU Bergman, HE Scholl, S Moser, RP Reeve, BB Klein, WM AF Bergman, Hannah E. Scholl, Sarah Moser, Richard P. Reeve, Bryce B. Klein, William M. TI DEVELOPMENT OF A COMPREHENSIVE HEART DISEASE KNOWLEDGE QUESTIONNAIRE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Bergman, Hannah E.; Moser, Richard P.; Klein, William M.] NCI, Div Canc Control & Populat Sci, Rockville, MD 20852 USA. [Scholl, Sarah] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Reeve, Bryce B.] Univ N Carolina, Lineberger Canc Ctr, Chapel Hill, NC USA. [Reeve, Bryce B.] Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC USA. EM bergmanhe@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S89 EP S89 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700348 ER PT J AU Biesecker, BB Erby, L Woolford, S Reeve, B AF Biesecker, Barbara B. Erby, Lori Woolford, Samuel Reeve, Bryce TI DEVELOPMENT AND EVALUATION OF AN ADAPTATION SCALE: USE IN SIX STUDIES ON LIVING WITH OR BEING AT RISK FOR A GENETIC CONDITION SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Biesecker, Barbara B.] NIH, Social & Behav Res Inst, Bethesda, MD 20892 USA. [Biesecker, Barbara B.; Erby, Lori] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Woolford, Samuel] Bentley Univ, Boston, MA USA. [Reeve, Bryce] Univ N Carolina, Chapel Hill, NC USA. EM barbarab@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S22 EP S22 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700082 ER PT J AU Caccavale, LJ Nansel, T Haynie, D Laffel, L Mehta, S AF Caccavale, Laura J. Nansel, Tonja Haynie, Denise Laffel, Lori Mehta, Sanjeev TI DISORDERED EATING AMONG ADOLESCENTS WITH TYPE 1 DIABETES: RELATIONS WITH FAMILY ENVIRONMENT AND QUALITY OF LIFE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Caccavale, Laura J.; Nansel, Tonja; Haynie, Denise] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Laffel, Lori; Mehta, Sanjeev] Joslin Diabet Ctr, Boston, MA 02215 USA. EM caccavalel@mail.nih.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S206 EP S206 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701294 ER PT J AU Caccavale, LJ Farhat, T Iannotti, RJ AF Caccavale, Laura J. Farhat, Tilda Iannotti, Ronald J. TI THE EFFECT OF PARENT COMMUNICATION ON WEIGHT CONTROL BEHAVIORS IN OVERWEIGHT ADOLESCENTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Caccavale, Laura J.; Farhat, Tilda; Iannotti, Ronald J.] NICHD, NIH, Bethesda, MD USA. EM caccavalel@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S174 EP S174 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701165 ER PT J AU Chambers, D AF Chambers, David TI A DYNAMIC APPROACH TO SUSTAINABILITY OF EFFECTIVE INTERVENTIONS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Chambers, David] NIMH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S131 EP S131 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701001 ER PT J AU Czajkowski, SM Riley, W Pilkonis, PA Weinfurt, KP AF Czajkowski, Susan M. Riley, William Pilkonis, Paul A. Weinfurt, Kevin P. TI PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): USING NEW THEORY AND TECHNOLOGY TO IMPROVE MEASUREMENT OF PATIENT-REPORTED OUTCOMES IN CLINICAL RESEARCH SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Czajkowski, Susan M.; Riley, William] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA. [Pilkonis, Paul A.] Univ Pittsburgh, Sch Med, Dept Psychiat & Behav Sci, Pittsburgh, PA USA. [Weinfurt, Kevin P.] Duke Clin Res Inst, Dept Psychiat & Behav Sci, Durham, NC USA. EM czajkows@nhlbi.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S145 EP S145 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701055 ER PT J AU de Heer, DH McBride, C AF de Heer, Dirk H. McBride, Colleen TI GENOMICS-INFORMED INTERVENTIONS & GLOBAL HEALTH: WHAT DO WE KNOW? SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [de Heer, Dirk H.; McBride, Colleen] NHGRI, Social & Behav Res Branch, Silver Spring, MD 20910 USA. EM dirk.deheer@nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S55 EP S55 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700216 ER PT J AU Farhat, T Iannotti, R Caccavale, L AF Farhat, Tilda Iannotti, Ronald Caccavale, Laura TI ADOLESCENT OBESITY AND CHRONIC DISEASE-RELATED HEALTH PRACTICES: MEDIATION BY BODY IMAGE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Farhat, Tilda; Iannotti, Ronald; Caccavale, Laura] NIH, Bethesda, MD 20892 USA. EM farhatti@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S215 EP S215 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701331 ER PT J AU Ferrer, R Stipelman, B Hall, K Shmueli, D Greenberg, D Tesauro, G O'Connell, M Bergman, H Roberson, G Klein, W AF Ferrer, Rebecca Stipelman, Brooke Hall, Kara Shmueli, Dikla Greenberg, Deborah Tesauro, Gina O'Connell, Mary Bergman, Hannah Roberson, Gary Klein, William TI WHO, WHAT, AND WHERE IN THE WORLD OF FUNDING: ANALYSIS OF THE PAST FIVE YEARS OF THE NCI BEHAVIORAL RESEARCH PROGRAM RESEARCH PORTFOLIO SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Ferrer, Rebecca; Stipelman, Brooke; Hall, Kara; Shmueli, Dikla; Greenberg, Deborah; Tesauro, Gina; O'Connell, Mary; Bergman, Hannah; Roberson, Gary; Klein, William] NCI, NIH, Rockville, MD 20852 USA. EM stipelmanba@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S129 EP S129 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700507 ER PT J AU George, SM Alfano, CM Smith, AW Irwin, ML McTiernan, A Bernstein, L Ballard-Barbash, R AF George, Stephanie M. Alfano, Catherine M. Smith, Ashley W. Irwin, Melinda L. McTiernan, Anne Bernstein, Leslie Ballard-Barbash, Rachel TI SEDENTARY BEHAVIOR, HEALTH-RELATED QUALITY OF LIFE, AND SYMPTOM OUTCOMES AMONG EARLY-STAGE BREAST CANCER SURVIVORS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [George, Stephanie M.; Alfano, Catherine M.; Smith, Ashley W.; Ballard-Barbash, Rachel] NCI, Rockville, CT USA. [Irwin, Melinda L.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [McTiernan, Anne] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA. EM materess@mail.nih.gov NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S114 EP S114 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700446 ER PT J AU Glasgow, R Kaplan, R AF Glasgow, Russ Kaplan, Robert TI SUSTAINABILITY: WHAT DOES IT MEAN? SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Glasgow, Russ] NCI, DCCPS, Rockville, MD 20852 USA. [Kaplan, Robert] Univ Calif San Diego, Los Angeles, CA USA. EM russg@re-aim.net NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S130 EP S130 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700510 ER PT J AU Glasgow, R AF Glasgow, Russ TI A RE-[vertical bar#16#vertical bar]AIM PERSPECTIVE ON SUSTAINABILITY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Glasgow, Russ] NCI, DCCPS, Rockville, MD 20852 USA. EM russg@re-aim.net NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S130 EP S130 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700511 ER PT J AU Glasgow, R AF Glasgow, Russ TI THE NEED FOR PRACTICAL PATIENT CENTERED MEASURES OF HEALTH BEHAVIORS AND PSYCHOSOCIAL ISSUES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Glasgow, Russ] NCI, DCCPS, Rockville, MD 20852 USA. EM russg@re-aim.net NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S52 EP S52 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700202 ER PT J AU Hamilton, JG Wu, LS Austin, J Valdimarsdottir, H Basmajian, K Vu, A Rowley, S Isola, L Redd, W Rini, C AF Hamilton, Jada G. Wu, Lisa Austin, Jane Valdimarsdottir, Heiddis Basmajian, Katie Vu, AnnaMarie Rowley, Scott Isola, Luis Redd, William Rini, Christine TI MISERY LOVES COMPANY?: TIMING OF THE FINANCIAL CRISIS MODERATES THE ASSOCIATION BETWEEN FINANCIAL STRESS AND QUALITY OF LIFE AMONG STEM CELL TRANSPLANT SURVIVORS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hamilton, Jada G.] NCI, Canc Prevent Fellowship Program, Rockville, MD 20892 USA. [Wu, Lisa; Valdimarsdottir, Heiddis; Basmajian, Katie; Vu, AnnaMarie; Isola, Luis; Redd, William; Rini, Christine] Mt Sinai Sch Med, New York, NY USA. [Austin, Jane] William Paterson Univ, Wayne, NJ USA. [Rowley, Scott] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Rini, Christine] Univ N Carolina, Chapel Hill, NC USA. EM hamiltonjg@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S201 EP S201 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701274 ER PT J AU Han, PK Klein, WM Killam, B Lehman, T Massett, H Freedman, AN AF Han, Paul K. Klein, William M. Killam, Bill Lehman, Thomas Massett, Holly Freedman, Andrew N. TI REPRESENTING RANDOMNESS IN THE COMMUNICATION OF INDIVIDUALIZED CANCER RISK ESTIMATES: EFFECTS ON CANCER RISK PERCEPTIONS, WORRY, AND SUBJECTIVE UNCERTAINTY ABOUT RISK SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Han, Paul K.] Maine Med Ctr, Ctr Outcomes Res, Portland, ME 04101 USA. [Han, Paul K.; Klein, William M.; Massett, Holly; Freedman, Andrew N.] NCI, Bethesda, MD 20892 USA. [Killam, Bill] User Ctr Design, Ashburn, VA USA. [Lehman, Thomas] Acad Educ Dev, Washington, DC USA. EM hanp@mmc.org NR 0 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S115 EP S115 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700451 ER PT J AU Hesse, B Nelson, D Kwon, H AF Hesse, Brad Nelson, David Kwon, Harry TI STIMULATING DATA: RECOVERY ACT INVESTMENTS IN COMMUNICATING DATA EFFECTIVELY IN HEALTH AND HEALTH CARE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hesse, Brad] NCI, Hlth Commun & Informat Res Branch, Bethesda, MD 20892 USA. [Nelson, David] NCI, Canc Prevent Fellowship Program, Bethesda, MD 20892 USA. [Kwon, Harry] NCI, Off Commun & Educ, Bethesda, MD 20892 USA. EM hesseb@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S53 EP S53 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700205 ER PT J AU Hesse, B Rutten, LJ Shaikh, AR AF Hesse, Brad Rutten, Lila J. Shaikh, Abdul R. TI EMPOWERING COMMUNITIES WITH DIRECT ACCESS TO HEALTH DATA SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hesse, Brad; Rutten, Lila J.; Shaikh, Abdul R.] NCI, Hlth Commun & Informat Res Branch, Bethesda, MD 20892 USA. [Rutten, Lila J.] SAIC Frederick Inc, Clin Monitoring Res Program, Frederick, MD USA. EM hesseb@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S53 EP S53 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700207 ER PT J AU Hunt, Y Augustson, E Yaroch, A Rutten, L Moser, R AF Hunt, Yvonne Augustson, Erik Yaroch, Amy Rutten, Lila Moser, Richard TI SUN EXPOSURE, SUN PROTECTION, AND SMOKING SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hunt, Yvonne; Augustson, Erik; Moser, Richard] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Yaroch, Amy] Ctr Human Nutr, Omaha, NE USA. [Rutten, Lila] NCI, SAIC Inc, Frederick, MD 21701 USA. EM huntym@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S140 EP S140 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701039 ER PT J AU Hunt, Y Bergman, H Shmueli, D Roberson, G AF Hunt, Yvonne Bergman, Hannah Shmueli, Dikla Roberson, Gary TI TOBACCO-RELATED RESEARCH FUNDING WITHIN THE NATIONAL CANCER INSTITUTE'S BEHAVIORAL RESEARCH PROGRAM SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hunt, Yvonne; Bergman, Hannah; Shmueli, Dikla] NCI, NIH, Bethesda, MD 20892 USA. [Roberson, Gary] Williams Coll, Williamstown, MA 01267 USA. EM huntym@mail.nih.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S129 EP S129 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700508 ER PT J AU Iannotti, R Wang, J AF Iannotti, Ronald Wang, Jing TI INTERNATIONAL PATTERNS IN ADOLESCENT PHYSICAL ACTIVITY, SEDENTARY BEHAVIOR AND DIET: LATENT CLASS ANALYSES OF THE HEALTH BEHAVIOR IN SCHOOL-AGED CHILDREN SURVEY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Iannotti, Ronald; Wang, Jing] NICHHD, Prevent Res Branch, Bethesda, MD 20892 USA. EM iannottr@mail.nih.gov NR 0 TC 0 Z9 0 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S226 EP S226 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701372 ER PT J AU Kaphingst, KA Goodman, MS Cheng, MR Stafford, JD Lachance, CR AF Kaphingst, Kimberly A. Goodman, Melody S. Cheng, Meng-Ru Stafford, Jewel D. Lachance, Christina R. TI RESPONSES TO GENETIC TEST RESULTS VS. FAMILY HISTORY INFORMATION AMONG COMMUNITY HEALTH CENTER PATIENTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Kaphingst, Kimberly A.; Cheng, Meng-Ru] Washington Univ, St Louis, MO 63112 USA. [Goodman, Melody S.; Stafford, Jewel D.] SUNY Stony Brook, Stony Brook, NY 11794 USA. [Lachance, Christina R.] NHGRI, NIH, Bethesda, MD 20892 USA. EM kkaphingst@gwbmail.wustl.edu RI Goodman, Melody/F-6768-2011 OI Goodman, Melody/0000-0001-8932-624X NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S73 EP S73 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700286 ER PT J AU Kaufman, A Augustson, E AF Kaufman, Annette Augustson, Erik TI THE INFLUENCE OF SEDENTARY ACTIVITY ON THE RELATIONSHIP BETWEEN CIGARETTE SMOKING AND BODY WEIGHT: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (1999-2008) SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Kaufman, Annette; Augustson, Erik] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. EM kaufmana@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S140 EP S140 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701038 ER PT J AU Kenney, MK Wang, J Iannotti, R Yongpradit, D AF Kenney, Mary Kay Wang, Jing Iannotti, Ronald Yongpradit, Daranee TI URBAN/RURAL DIFFERENCES IN ADOLESCENT OBESITY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Kenney, Mary Kay] US Hlth Resources & Serv Adm, Rockville, MD 20857 USA. [Wang, Jing; Iannotti, Ronald; Yongpradit, Daranee] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. EM mkenney@hrsa.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S215 EP S215 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701329 ER PT J AU Kent, EE Montoya, MJ Sender, LS Morris, RA Ziogas, A Anton-Culver, H AF Kent, Erin E. Montoya, Michael J. Sender, Leonard S. Morris, Rebecca A. Ziogas, Argyrios Anton-Culver, Hoda TI A COMPARISON OF ATTITUDES TOWARD CANCER CLINICAL TRIAL PARTICIPATION BETWEEN ADOLESCENTS AND YOUNG ADULTS WITH LEUKEMIA AND LYMPHOMA AND COLLEGE STUDENTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Kent, Erin E.] NCI, Rockville, MD 20852 USA. [Kent, Erin E.; Montoya, Michael J.; Sender, Leonard S.; Ziogas, Argyrios; Anton-Culver, Hoda] Univ Calif Irvine, Irvine, CA USA. [Sender, Leonard S.; Morris, Rebecca A.] CHOC Childrens Hosp, Orange, CA USA. EM Erin.Kent@nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S5 EP S5 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700014 ER PT J AU Keogh, LA Fisher, D Schully, S Lowery, J Ahnen, D Maskiell, J Lindor, N Hopper, J Burnett, T Holter, S Gorin, SS Sinicrope, P AF Keogh, Louise A. Fisher, Douglass Schully, Sheri Lowery, Jan Ahnen, Dennis Maskiell, Judi Lindor, Noralane Hopper, John Burnett, Terrilea Holter, Spring Gorin, Sheri Sheinfeld Sinicrope, Pam TI DISCLOSING GENETIC RESEARCH RESULTS: EXPERIENCES OF THE COLON CANCER FAMILY REGISTRY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Keogh, Louise A.; Maskiell, Judi; Hopper, John] Univ Melbourne, Ctr Womens Hlth Gender & Soc, Melbourne, Vic 3010, Australia. [Fisher, Douglass] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Schully, Sheri] NIH, Bethesda, MD 20892 USA. [Lowery, Jan] Univ Colorado, Sch Publ Hlth, Aurora, CO USA. [Ahnen, Dennis] Univ Colorado, Denver, CO 80202 USA. [Lindor, Noralane; Sinicrope, Pam] Mayo Clin, Rochester, MN USA. [Burnett, Terrilea] Univ Hawaii, Honolulu, HI 96822 USA. [Holter, Spring] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. [Gorin, Sheri Sheinfeld] Columbia Univ, New York, NY USA. EM l.keogh@unimelb.edu.au NR 0 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S128 EP S128 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700501 ER PT J AU Kepka, DL Ulrich, A Coronado, G AF Kepka, Deanna L. Ulrich, Angela Coronado, Gloria TI CORRELATES OF HPV VACCINE UPTAKE AMONG RURAL LATINA MOTHERS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Kepka, Deanna L.] NCI, Div Canc Control & Populat Sci, Rockville, MD 20892 USA. [Ulrich, Angela] Univ Washington, Seattle, WA 98195 USA. [Coronado, Gloria] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. EM deanna.kepka@nih.gov NR 0 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S257 EP S257 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701496 ER PT J AU Kepka, DL Coronado, G Rodriguez, HP Thompson, B AF Kepka, Deanna L. Coronado, Gloria Rodriguez, Hector P. Thompson, Beti TI EVALUATION OF A RADIONOVELA TO PROMOTE HPV VACCINE AWARENESS AND KNOWLEDGE AMONG HISPANIC PARENTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Kepka, Deanna L.] NCI, Div Canc Control & Populat Sci, Rockville, MD 20892 USA. [Coronado, Gloria; Thompson, Beti] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Rodriguez, Hector P.] Univ Calif Los Angeles, Los Angeles, CA USA. EM deanna.kepka@nih.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S243 EP S243 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701439 ER PT J AU Klein, W Kara, H Stipelman, B Shmueli, D Kobrin, S Hunt, Y AF Klein, William Kara, Hall Stipelman, Brooke Shmueli, Dikla Kobrin, Sarah Hunt, Yvonne TI BEHAVIORAL RESEARCH AT NCI: OUR PORTFOLIO UNMASKED SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Klein, William; Kara, Hall; Stipelman, Brooke; Shmueli, Dikla; Kobrin, Sarah; Hunt, Yvonne] NCI, NIH, Rockville, MD 20852 USA. EM stipelmanba@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S129 EP S129 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700506 ER PT J AU Kobrin, S Rothman, A Meissner, H Tiro, J Hall, K Ferrer, R Shmueli, D AF Kobrin, Sarah Rothman, Alex Meissner, Helen Tiro, Jasmin Hall, Kara Ferrer, Rebecca Shmueli, Dikla TI USE OF BEHAVIORAL THEORY IN GRANT APPLICATIONS: WHAT CAN WE LEARN FROM FUNDED CANCER SCREENING INTERVENTION RESEARCH? SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Kobrin, Sarah; Hall, Kara; Ferrer, Rebecca; Shmueli, Dikla] NCI, NIH, Rockville, MD 20852 USA. [Rothman, Alex] UMN, Minneapolis, MN USA. [Tiro, Jasmin] UT SW Med Ctr, Dallas, TX USA. [Meissner, Helen] NIH, OBSSR, Bethesda, MD 20892 USA. EM kobrins@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S130 EP S130 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700509 ER PT J AU Koehly, LM Wilkinson, AV AF Koehly, Laura M. Wilkinson, Anna V. TI PROJECT RAMA: USING FAMILY HEALTH HISTORY FEEDBACK TO PROMOTE HEALTH IN MEXICAN ORIGIN FAMILIES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Koehly, Laura M.] NHGRI, Social & Behav Res Branch, NIH, Bethesda, MD 20892 USA. [Wilkinson, Anna V.] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Austin, TX USA. EM koehlyl@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S55 EP S55 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700214 ER PT J AU Leviton, LC Ory, M Dowdy, D Wilcox, S Griffin, SF Ottoson, JM Martinez, DJ Glasgow, R AF Leviton, Laura C. Ory, Marcia Dowdy, Diane Wilcox, Sara Griffin, Sarah F. Ottoson, Judith M. Martinez, Diane J. Glasgow, Russell TI IMPACT OF A PROGRAM AND ITS EVALUATION: ACTIVE FOR LIFE (R) SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Leviton, Laura C.; Martinez, Diane J.] Robert Wood Johnson Fdn, Princeton, NJ 08543 USA. [Wilcox, Sara] Univ S Carolina, Dept Exercise Sci, Columbia, SC 29208 USA. [Ory, Marcia; Dowdy, Diane] Texas A&M Univ, College Stn, TX USA. [Griffin, Sarah F.] Clemson Univ, Clemson, SC USA. [Ottoson, Judith M.] San Francisco State Univ, San Francisco, CA 94132 USA. [Glasgow, Russell] NCI, Div Canc Control & Populat Sci, Rockville, MD USA. EM llevito@rwjf.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S54 EP S54 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700209 ER PT J AU Lipsky, L Nansel, T Haynie, D Laffel, L Mehta, S AF Lipsky, Leah Nansel, Tonja Haynie, Denise Laffel, Lori Mehta, Sanjeev TI CONCORDANCE OF DIETARY INTAKE AND QUALITY BETWEEN CHILDREN WITH TYPE-1 DIABETES (T1D) AND THEIR PARENTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Lipsky, Leah; Nansel, Tonja; Haynie, Denise] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Laffel, Lori; Mehta, Sanjeev] Joslin Diabet Ctr, Boston, MA 02215 USA. EM lipskylm@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S22 EP S22 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700084 ER PT J AU Lombardero, A Parascandola, M AF Lombardero, Anayansi Parascandola, Mark TI STRATEGIES USED BY MULTINATIONAL TOBACCO COMPANIES IN EMERGING MARKETS: A CASE STUDY OF TARGETED MARKETING AND LEGISLATION INFLUENCE IN SPAIN SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Lombardero, Anayansi] Univ Montana, Missoula, MT 59812 USA. [Parascandola, Mark] NCI, Tobacco Control Res Branch, Bethesda, MD 20892 USA. EM anayansi.lombardero@umontana.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S191 EP S191 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701236 ER PT J AU Loria, C Arteaga, SS Belle, S Signore, C Riley, W AF Loria, Catherine Arteaga, S. Sonia Belle, Steven Signore, Caroline Riley, William TI EARLY ADULT REDUCTION OF WEIGHT THROUGH LIFESTYLE INTERVENTION (EARLY) TRIALS; USING INNOVATIVE TECHNOLOGIES IN RANDOMIZED CONTROLLED TRIALS TARGETING WEIGHT CONTROL AMONG YOUNG ADULTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Loria, Catherine; Arteaga, S. Sonia; Riley, William] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA. [Belle, Steven] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Signore, Caroline] Kennedy Shriver Natl Inst Child Hlth & Human Dev, Pregnancy & Perinatol Branch, Bethesda, MD USA. EM arteagass@nhlbi.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S133 EP S133 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701011 ER PT J AU McBride, C Winch, P AF McBride, Colleen Winch, Peter TI GENOMICS APPLICATIONS TO ADDRESS CHALLENGES FOR BEHAVIORAL MEDICINE IN THE US AND ABROAD SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [McBride, Colleen] NHGRI, Bethesda, MD 20892 USA. [Winch, Peter] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. EM cmcbride@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S55 EP S55 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700213 ER PT J AU McBride, C Ottman, R Figueiro, M Bryan, A Wanke, K AF McBride, Colleen Ottman, Ruth Figueiro, Mariana Bryan, Angela Wanke, Kay TI GENE-ENVIRONMENT INTERPLAY IN HEALTH BEHAVIOR: FROM MECHANISMS TO TRANSLATION SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [McBride, Colleen] NIH, Social & Behav Res Branch, Bethesda, MD 20892 USA. [Ottman, Ruth] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Figueiro, Mariana] Rensselaer Polytech Inst, Troy, NY USA. [Bryan, Angela] Univ New Mexico, Albuquerque, NM 87131 USA. [Wanke, Kay] NIH, Off Behav & Social Sci Res, Bethesda, MD 20892 USA. EM wankek@mail.nih.gov RI Ottman, Ruth/O-2371-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S3 EP S3 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700009 ER PT J AU Moser, RP Hesse, BW Shaikh, AR Courtney, P Morgan, G Auguston, E Levin, K Helba, C Garner, D Dunn, M AF Moser, Richard P. Hesse, Bradford W. Shaikh, Abdul R. Courtney, Paul Morgan, Glen Auguston, Erik Levin, Kerry Helba, Cynthia Garner, David Dunn, Marsha TI PROMOTING THE USE OF HARMONIZED MEASURES AND SHARING DATA TO CATALYZE PROGRESS IN BEHAVIORAL SCIENCE: THE NATIONAL CANCER INSTITUTE'S GRID-ENABLED MEASURES (GEM) PORTAL SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Moser, Richard P.; Hesse, Bradford W.; Shaikh, Abdul R.; Morgan, Glen; Auguston, Erik] NCI, Bethesda, MD 20892 USA. [Levin, Kerry; Helba, Cynthia; Garner, David; Dunn, Marsha] Westat Corp, Rockville, MD USA. [Courtney, Paul] SAIC Frederick, Frederick, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S145 EP S145 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701054 ER PT J AU Nansel, TR Lipsky, L Haynie, D Mehta, S Laffel, L AF Nansel, Tonja R. Lipsky, Leah Haynie, Denise Mehta, Sanjeev Laffel, Lori TI RELATIONS AMONG PARENT AND YOUTH SOCIAL COGNITIVE CONSTRUCTS AND DIETARY INTAKE IN YOUTH WITH TYPE 1 DIABETES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Nansel, Tonja R.; Lipsky, Leah; Haynie, Denise] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent Res, Bethesda, MD USA. [Mehta, Sanjeev; Laffel, Lori] Joslin Diabet Ctr, Boston, MA 02215 USA. EM nanselt@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S213 EP S213 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701322 ER PT J AU Nansel, TR Weaver, N Williams, J Willson, K Tse, J AF Nansel, Tonja R. Weaver, Nancy Williams, Janice Willson, Katherine Tse, Julia TI IMPLEMENTATION OF A KIOSK-BASED PEDIATRIC INJURY PREVENTION PROGRAM IN PRIMARY CARE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Nansel, Tonja R.; Willson, Katherine; Tse, Julia] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Weaver, Nancy] St Louis Univ, St Louis, MO 63103 USA. [Williams, Janice] Carolinas HealthCare Syst, Charlotte, NC USA. EM nanselt@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S180 EP S180 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701191 ER PT J AU Nilsen, W AF Nilsen, Wendy TI WIRELESS MONITORING AND SUPPORT FOR ENHANCING ADHERENCE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Nilsen, Wendy] NIH, Off Behav & Social Sci Res, Bethesda, MD 20892 USA. EM nilsenwj@od.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S142 EP S142 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701046 ER PT J AU Norton, WE Glanz, K Collins, CB Mittman, BS Glasgow, RE AF Norton, Wynne E. Glanz, Karen Collins, Charles B. Mittman, Brian S. Glasgow, Russell E. TI SCALING-UP EVIDENCE-BASED HEALTH PROMOTION/DISEASE PREVENTION INTERVENTIONS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Norton, Wynne E.] Univ Alabama, Birmingham, AL 35293 USA. [Glanz, Karen] Univ Penn, Philadelphia, PA 19104 USA. [Collins, Charles B.] Ctr Dis Control & Prevent, Capac Bldg Branch, Atlanta, GA USA. [Mittman, Brian S.] VA Greater Los Angeles Healthcare Syst, Ctr Implementat Practice & Res Support, Los Angeles, CA USA. [Glasgow, Russell E.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. EM wenorton@uab.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S152 EP S152 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701080 ER PT J AU O'Neill, S Zikmund-Fisher, BJ Hoffman, RM Sepucha, KR Knight, SJ Klein, WM Spring, B AF O'Neill, Suzanne Zikmund-Fisher, Brian J. Hoffman, Richard M. Sepucha, Karen R. Knight, Sara J. Klein, William M. Spring, Bonnie TI OPPORTUNITIES FOR TRANSLATIONAL RESEARCH USING THE DECISIONS STUDY: A CONVERSATION BETWEEN SBM'S DECISION MAKING SIG AND THE SOCIETY FOR MEDICAL DECISION MAKING SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [O'Neill, Suzanne] Georgetown Univ, Washington, DC 20007 USA. [Zikmund-Fisher, Brian J.] Univ Michigan, Ann Arbor, MI 48109 USA. [Hoffman, Richard M.] Univ New Mexico, Albuquerque, NM 87131 USA. [Sepucha, Karen R.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Knight, Sara J.] San Francisco VA UCSF, San Francisco, CA USA. [Klein, William M.] NCI, Bethesda, MD 20892 USA. [Spring, Bonnie] Northwestern Univ, Chicago, IL 60611 USA. EM sco4@georgetown.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S150 EP S150 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701076 ER PT J AU Oh, A Patrick, H Berrigan, D Perna, FM AF Oh, April Patrick, Heather Berrigan, David Perna, Frank M. TI ADHERENCE TO MULTIPLE HEALTH BEHAVIORS: EXAMINATION OF TOBACCO USE AND PATTERNS OF ADHERENCE IN US HISPANICS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Oh, April; Patrick, Heather; Berrigan, David; Perna, Frank M.] NCI, NIH, Rockville, MD 20852 USA. EM ohay@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S141 EP S141 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701040 ER PT J AU Oh, A Perna, FM Agurs-Collins, T Nebeling, L AF Oh, April Perna, Frank M. Agurs-Collins, Tanya Nebeling, Linda TI CLASSIFICATION OF LAWS ASSOCIATED WITH SCHOOL STUDENTS (CLASS): AN EVALUATION TOOL OF STATE PHYSICAL EDUCATION AND NUTRITION POLICY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Oh, April; Perna, Frank M.; Agurs-Collins, Tanya; Nebeling, Linda] NCI, NIH, Rockville, MD 20852 USA. EM ohay@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S133 EP S133 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701010 ER PT J AU Oh, A Erinosho, T Dunton, G Perna, FM Berrigan, D AF Oh, April Erinosho, Temitope Dunton, Genevieve Perna, Frank M. Berrigan, David TI PHYSICAL AND SOCIAL CONTEXTS OF EATING AND DRINKING EPISODES IN US ADULTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Oh, April; Perna, Frank M.; Berrigan, David] NCI, NIH, Rockville, MD 20852 USA. [Erinosho, Temitope] Univ N Carolina, Chapel Hill, NC USA. [Dunton, Genevieve] Univ So Cali, Chapel Hill, NC USA. EM ohay@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S24 EP S24 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700092 ER PT J AU Okamoto, J Johnson, CA Leventhal, A Milam, J Pentz, MA Schwartz, D Valente, TW AF Okamoto, Janet Johnson, C. Anderson Leventhal, Adam Milam, Joel Pentz, Mary Ann Schwartz, David Valente, Thomas W. TI THE CLASSROOM SOCIAL NETWORK AND DEPRESSIVE SYMPTOMS: DO NETWORK COMPOSITION AND CHARACTERISTICS INFLUENCE ADOLESCENT DEPRESSION? SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Okamoto, Janet] NCI, DCCPS, BRP, Rockville, MD 20852 USA. [Johnson, C. Anderson] Claremont Grad Univ, Claremont, CA USA. [Leventhal, Adam; Milam, Joel; Pentz, Mary Ann; Schwartz, David; Valente, Thomas W.] Univ So Calif, Los Angeles, CA USA. EM okamotojm@mail.nih.gov NR 0 TC 0 Z9 0 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S68 EP S68 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700265 ER PT J AU Patrick, H Augustson, EM AF Patrick, Heather Augustson, Erik M. TI HEALTH RISK AND HEALTH PROMOTION: DO PEOPLE PERCEIVE RISK-ENHANCING AND RISK-PROTECTIVE BEHAVIORS SIMILARLY? SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Patrick, Heather; Augustson, Erik M.] NCI, Div Canc Control & Populat Sci, Rockville, MD 20852 USA. EM patrickha@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S141 EP S141 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701041 ER PT J AU Patrick, H Nigg, CR AF Patrick, Heather Nigg, Claudio R. TI UNDERSTANDING PATTERNS IN HEALTH RISK AND HEALTH PROMOTION BEHAVIORS: PERSPECTIVES FROM NATIONALLY-REPRESENTATIVE SURVEYS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Patrick, Heather] NCI, Div Canc Control & Populat Sci, Rockville, MD 20852 USA. [Nigg, Claudio R.] Univ Hawaii, Dept Publ Hlth Sci, Honolulu, HI 96822 USA. EM patrickha@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S140 EP S140 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701037 ER PT J AU Pentz, MA Alfonzo, M Durand, C Dunton, G Meyer, A Sallis, J AF Pentz, Mary Ann Alfonzo, Mariela Durand, Casey Dunton, Genevieve Meyer, Aleta Sallis, James TI EVALUATING THE IMPACT OF SMART GROWTH PLANNING ON PHYSICAL ACTIVITY: EFFECTS OF CONTEXT SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Pentz, Mary Ann; Durand, Casey; Dunton, Genevieve] Univ So Calif, Inst Hlth Promot & Dis Prevent Res, Alhambra, CA 91803 USA. [Alfonzo, Mariela] Virginia Tech, Blacksburg, VA USA. [Meyer, Aleta] NIDA, Bethesda, MD 20892 USA. [Sallis, James] San Diego State Univ, San Diego, CA 92182 USA. EM pentz@usc.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S139 EP S139 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701033 ER PT J AU Perna, FM Oh, A Agurs-Collins, T Chriqui, J Masse, LM AF Perna, Frank M. Oh, April Agurs-Collins, Tanya Chriqui, Jamie Masse, Louise Masse TI FIVE-YEAR CHANGE IN STATE PHYSICAL EDUCATION LAWS AND CONCORDANCE WITH COMPETITIVE FOODS LAWS IN US MIDDLE SCHOOLS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Perna, Frank M.; Oh, April; Agurs-Collins, Tanya] NCI, Rockville, MD 20852 USA. [Masse, Louise Masse] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Chriqui, Jamie] Univ Illinois, Chicago, IL USA. EM pernafm@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S133 EP S133 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701009 ER PT J AU Perna, FM Oh, A Agurs-Collins, T Chriqui, JF Lee, SM Masse, LC AF Perna, Frank M. Oh, April Agurs-Collins, Tanya Chriqui, Jamie F. Lee, Sarah M. Masse, Louise C. TI POLICY AS A TOOL TO CHANGE SCHOOL NUTRITION AND PHYSICAL EDUCATION ENVIRONMENTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Perna, Frank M.; Oh, April; Agurs-Collins, Tanya] NCI, Div Canc Control & Populat Sci, Rockville, MD 20852 USA. [Chriqui, Jamie F.] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. [Masse, Louise C.] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada. [Lee, Sarah M.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. EM pernafm@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S132 EP S132 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701006 ER PT J AU Persky, S Kaphingst, KA Allen, VC Senay, I AF Persky, Susan Kaphingst, Kimberly A. Allen, Vincent C. Senay, Ibrahim TI THE EFFECT OF RACIAL DISCORDANCE WITH A VIRTUAL DOCTOR ON LUNG CANCER RISK PERCEPTION AMONG AFRICAN AMERICANS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Persky, Susan] NHGRI, Bethesda, MD 20892 USA. [Kaphingst, Kimberly A.] Washington Univ, St Louis, MO USA. [Allen, Vincent C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Senay, Ibrahim] Univ Illinois, Urbana, IL 61801 USA. EM perskys@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S81 EP S81 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700316 ER PT J AU Pilkonis, PA Choi, SW Reise, SP Stover, AM Riley, WT Cella, D AF Pilkonis, Paul A. Choi, Seung W. Reise, Steven P. Stover, Angela M. Riley, William T. Cella, David TI ITEM BANKS FOR MEASURING EMOTIONAL DISTRESS FROM THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): DEPRESSION, ANXIETY, AND ANGER SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Pilkonis, Paul A.; Stover, Angela M.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Choi, Seung W.; Cella, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Reise, Steven P.] Univ Calif Los Angeles, Los Angeles, CA USA. [Riley, William T.] NHLBI, Bethesda, MD 20892 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S145 EP S145 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701057 ER PT J AU Riley, WT Cella, D AF Riley, William T. Cella, David TI PROMIS OVERVIEW: DEVELOPMENT OF NEW TOOLS FOR MEASURING HEALTH-RELATED QUALITY OF LIFE AND RELATED OUTCOMES IN PATIENTS WITH CHRONIC DISEASES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Riley, William T.] NHLBI, Bethesda, MD 20892 USA. [Cella, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S145 EP S145 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701056 ER PT J AU Rutten, LJ Hesse, B Martinez, APO Luna, GT Kornfeld, J AF Rutten, Lila J. Hesse, Bradford Martinez, Ana Patricia Ortiz Luna, Guillermo Tortolero Kornfeld, Julie TI USE OF THE INTERNET FOR HEALTH AND CANCER INFORMATION SEEKING IN PUERTO RICO SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hesse, Bradford] NCI, Bethesda, MD 20892 USA. [Rutten, Lila J.] NCI, SAIC Inc, Frederick, MD 21701 USA. [Martinez, Ana Patricia Ortiz; Luna, Guillermo Tortolero] Univ Puerto Rico, San Juan, PR 00936 USA. [Kornfeld, Julie] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. EM finney1@mail.nih.gov NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S7 EP S7 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700023 ER PT J AU Ryan, B Theodore, M Mehta, S Butler, D Haynie, D Nansel, T Laffel, L AF Ryan, Brittany Theodore, Miranda Mehta, Sanjeev Butler, Deborah Haynie, Denise Nansel, Tonja Laffel, Lori TI DIABETES-SPECIFIC FAMILY CONFLICT, ADHERENCE AND GLYCEMIC CONTROL IN YOUTH WITH TYPE 1 DIABETES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Ryan, Brittany; Theodore, Miranda; Mehta, Sanjeev; Butler, Deborah; Laffel, Lori] Joslin Diabet Ctr, Boston, MA 02215 USA. [Haynie, Denise; Nansel, Tonja] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. EM brittany.ryan@joslin.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S92 EP S92 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700358 ER PT J AU Sanderson, S McClure, J Holm, A McBride, C AF Sanderson, Saskia McClure, Jennifer Holm, Amanda McBride, Colleen TI UNDERSTANDING EVER-SMOKERS' UPTAKE OF AND REACTIONS TO PERSONALIZED GENETIC SUSCEPTIBILITY TESTING IN THE MULTIPLEX INITIATIVE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Sanderson, Saskia] Mt Sinai Sch Med, New York, NY 10029 USA. [McClure, Jennifer] Grp Hlth Res Inst, Seattle, WA USA. [Holm, Amanda] Natl Human Genom Res Inst, Social & Behav Res Branch, Bethesda, MD USA. [McBride, Colleen] Henry Ford Hlth Syst, Detroit, MI USA. EM saskia.sanderson@mssm.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S74 EP S74 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700287 ER PT J AU Stoney, CM Blumenthal, JA Spring, B Johnston, DW Bonds, D AF Stoney, Catherine M. Blumenthal, James A. Spring, Bonnie Johnston, Derek W. Bonds, Denise TI COMPARATIVE EFFECTIVENESS RESEARCH IN CARDIOVASCULAR BEHAVIORAL MEDICINE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Stoney, Catherine M.; Bonds, Denise] NHLBI, NIH, Bethesda, MD 20892 USA. [Blumenthal, James A.] Duke Univ, Dept Psychiat, Durham, NC 27706 USA. [Spring, Bonnie] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Johnston, Derek W.] Univ Aberdeen, Aberdeen, Scotland. EM stoneyc@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S131 EP S131 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701002 ER PT J AU Tse, J Nansel, T Haynie, D Laffel, L Mehta, S AF Tse, Julia Nansel, Tonja Haynie, Denise Laffel, Lori Mehta, Sanjeev TI THE RELATIONSHIP OF DIET QUALITY AND DISORDERED EATING BEHAVIORS IN ADOLESCENTS WITH TYPE 1 DIABETES (T1D) SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Tse, Julia; Nansel, Tonja; Haynie, Denise] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Laffel, Lori; Mehta, Sanjeev] Joslin Diabet Ctr, Boston, MA 02215 USA. EM tsej2@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S60 EP S60 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700235 ER PT J AU Yaroch, AL Rutten, LJ Colon-Ramos, U Johnson-Askew, W Story, M AF Yaroch, Amy L. Rutten, Lila J. Colon-Ramos, Uriyoan Johnson-Askew, Wendy Story, Mary TI POVERTY, FOOD INSECURITY, AND OBESITY: A CONCEPTUAL FRAMEWORK FOR RESEARCH, PRACTICE, AND POLICY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Rutten, Lila J.] Natl Canc Inst Frederick, SAIC Inc, HCIRB, Bethesda, MD 20892 USA. [Yaroch, Amy L.; Rutten, Lila J.; Colon-Ramos, Uriyoan] Ctr Human Nutr, Omaha, NE USA. [Johnson-Askew, Wendy] NIH, Div Nutr Res & Coordinat, Bethesda, MD 20892 USA. [Story, Mary] Univ MN, Div Epidemiol, Sch Publ Hlth, Minneapolis, MN USA. EM finneyl@mail.nih.gov NR 0 TC 0 Z9 0 U1 2 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S99 EP S99 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700388 ER PT J AU White, LK Suway, JG Pine, DS Bar-Haim, Y Fox, NA AF White, Lauren K. Suway, Jenna G. Pine, Daniel S. Bar-Haim, Yair Fox, Nathan A. TI Cascading effects: The influence of attention bias to threat on the interpretation of ambiguous information SO BEHAVIOUR RESEARCH AND THERAPY LA English DT Article DE Anxiety; Attention bias; Attention training; Information processing; Interpretive bias ID SELECTIVE ATTENTION; COGNITIVE BIASES; ANXIETY; INDIVIDUALS; PLASTICITY; MODERATOR; CHILDREN AB Both attention bias to threat and negative interpretive bias have been implicated in the emergence and maintenance of anxiety disorders. However, relations between attention and interpretive biases remain poorly understood. The current study experimentally manipulated attention bias to threat and examined the effects of attention training on the way ambiguous information was interpreted. Results suggest that the preferential allocation of attention towards threat affects the manner in which ambiguous information is interpreted. Individuals trained to attend to threat were more likely than individuals in a placebo training group to interpret ambiguous information in a threat-related manner. These data suggest that perturbations in the initial stages of information processing associated with anxiety may lead to a cascade of subsequent processing biases. (C) 2011 Elsevier Ltd. All rights reserved. C1 [White, Lauren K.; Suway, Jenna G.; Fox, Nathan A.] Univ Maryland, Dept Human Dev, Child Dev Lab, College Pk, MD 20742 USA. [Pine, Daniel S.] NIMH, Mood & Anxiety Program, Sect Dev & Affect Neurosci, Bethesda, MD 20892 USA. [Bar-Haim, Yair] Tel Aviv Univ, Dept Psychol, Adler Ctr Res Child Dev & Psychopathol, IL-69978 Tel Aviv, Israel. RP White, LK (reprint author), Univ Maryland, Dept Human Dev, Child Dev Lab, College Pk, MD 20742 USA. EM lwhite5@umd.edu FU NIMH NIH HHS [F31 MH085424, F31 MH085424-02, 1F31MH085424] NR 26 TC 33 Z9 37 U1 1 U2 20 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7967 EI 1873-622X J9 BEHAV RES THER JI Behav. Res. Ther. PD APR PY 2011 VL 49 IS 4 BP 244 EP 251 DI 10.1016/j.brat.2011.01.004 PG 8 WC Psychology, Clinical SC Psychology GA 749HD UT WOS:000289454000004 PM 21353663 ER PT J AU Batra, J Nagle, CM O'Mara, T Higgins, M Dong, Y Tan, OL Lose, F Skeie, LM Srinivasan, S Bolton, KL Song, H Ramus, SJ Gayther, SA Pharoah, PDP Kedda, MA Spurdle, AB Clements, JA AF Batra, Jyotsna Nagle, Christina M. O'Mara, Tracy Higgins, Melanie Dong, Ying Tan, Olivia L. Lose, Felicity Skeie, Lene Marie Srinivasan, Srilakshmi Bolton, Kelly L. Song, Honglin Ramus, Susan J. Gayther, Simon A. Pharoah, Paul D. P. Kedda, Mary-Anne Spurdle, Amanda B. Clements, Judith A. TI A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival SO BMC CANCER LA English DT Article DE Kallikrein 15 single nucleotide polymorphisms; ovarian cancer; splice variants ID GENOME-WIDE ASSOCIATION; PROSTATE-CANCER; BREAST-CANCER; MESSENGER-RNA; TISSUE KALLIKREIN; EXPRESSION; GENE; SUSCEPTIBILITY; PROTEIN; VARIANTS AB Background: KLK15 over-expression is reported to be a significant predictor of reduced progression-free survival and overall survival in ovarian cancer. Our aim was to analyse the KLK15 gene for putative functional single nucleotide polymorphisms (SNPs) and assess the association of these and KLK15 HapMap tag SNPs with ovarian cancer survival. Results: In silico analysis was performed to identify KLK15 regulatory elements and to classify potentially functional SNPs in these regions. After SNP validation and identification by DNA sequencing of ovarian cancer cell lines and aggressive ovarian cancer patients, 9 SNPs were shortlisted and genotyped using the Sequenom iPLEX Mass Array platform in a cohort of Australian ovarian cancer patients (N = 319). In the Australian dataset we observed significantly worse survival for the KLK15 rs266851 SNP in a dominant model (Hazard Ratio (HR) 1.42, 95% CI 1.02-1.96). This association was observed in the same direction in two independent datasets, with a combined HR for the three studies of 1.16 (1.00-1.34). This SNP lies 15bp downstream of a novel exon and is predicted to be involved in mRNA splicing. The mutant allele is also predicted to abrogate an HSF-2 binding site. Conclusions: We provide evidence of association for the SNP rs266851 with ovarian cancer survival. Our results provide the impetus for downstream functional assays and additional independent validation studies to assess the role of KLK15 regulatory SNPs and KLK15 isoforms with alternative intracellular functional roles in ovarian cancer survival. C1 [Batra, Jyotsna; O'Mara, Tracy; Higgins, Melanie; Dong, Ying; Tan, Olivia L.; Skeie, Lene Marie; Srinivasan, Srilakshmi; Kedda, Mary-Anne; Clements, Judith A.] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4059, Australia. [Batra, Jyotsna; O'Mara, Tracy; Higgins, Melanie; Dong, Ying; Tan, Olivia L.; Skeie, Lene Marie; Srinivasan, Srilakshmi; Kedda, Mary-Anne; Clements, Judith A.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia. [Batra, Jyotsna; O'Mara, Tracy; Higgins, Melanie; Lose, Felicity; Spurdle, Amanda B.] Queensland Inst Med Res, Mol Canc Epidemiol Lab, Brisbane, Qld 4006, Australia. [Nagle, Christina M.] Queensland Inst Med Res, Gynaecol Canc Grp, Brisbane, Qld 4006, Australia. [Bolton, Kelly L.; Song, Honglin; Pharoah, Paul D. P.] Univ Cambridge, Strangeways Res Lab, Canc Res UK Dept Oncol, Cambridge, England. [Bolton, Kelly L.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. [Ramus, Susan J.; Gayther, Simon A.] UCL, Inst Womens Hlth, Dept Gynecol Oncol, London, England. RP Clements, JA (reprint author), Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4059, Australia. EM j.clements@qut.edu.au RI Song, H/C-9965-2011; Dong, Ying/C-3511-2012; Batra, Jyotsna/B-4130-2011; O'Mara, Tracy/M-7508-2016; Spurdle, Amanda/A-4978-2011; OI O'Mara, Tracy/0000-0002-5436-3232; Lose, Felicity/0000-0001-8337-3547; Ramus, Susan/0000-0003-0005-7798; Spurdle, Amanda/0000-0003-1337-7897; Clements, Judith/0000-0001-6026-1964 FU NHMRC; Institute of Health and Biomedical Innovation; Australian Postgraduate Award; IHBI; QLD; Cancer Research UK; National Health and Medical Research Council of Australia (NHMRC) [390123] FX ABS and JAC are NHMRC Senior and Principal Research Fellows respectively. CMN is supported by an NHMRC Career Development Award. JB and OLT are supported by Institute of Health and Biomedical Innovation Postdoctoral Fellowships. TOM is supported by an Australian Postgraduate Award complemented with an IHBI and QLD Government Smart State Postgraduate Awards. SEARCH is funded through a program grant from Cancer Research UK. This work was supported by funding from the National Health and Medical Research Council of Australia (NHMRC) grant 390123. NR 36 TC 17 Z9 18 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2407 J9 BMC CANCER JI BMC Cancer PD APR 1 PY 2011 VL 11 AR 119 DI 10.1186/1471-2407-11-119 PG 11 WC Oncology SC Oncology GA 752TT UT WOS:000289718100001 PM 21457553 ER PT J AU Deola, S Cavattoni, I Pusceddu, I Negri, G Kasal, A Svaldi, M Langes, M Gambato, R Morello, E Casini, M Bondanza, A Introna, M Marincola, FM Cortelazzo, S AF Deola, S. Cavattoni, I. Pusceddu, I. Negri, G. Kasal, A. Svaldi, M. Langes, M. Gambato, R. Morello, E. Casini, M. Bondanza, A. Introna, M. Marincola, F. M. Cortelazzo, S. TI B- and T-cell interactions in graft-versus-host disease SO BONE MARROW TRANSPLANTATION LA English DT Meeting Abstract CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group CY APR 03-06, 2011 CL Paris, FRANCE SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp C1 [Deola, S.; Cavattoni, I.; Pusceddu, I.; Negri, G.; Kasal, A.; Svaldi, M.; Langes, M.; Gambato, R.; Casini, M.; Cortelazzo, S.] Cent Hosp, Bolzano, Italy. [Morello, E.] Spedali Civil Brescia, I-25125 Brescia, Italy. [Bondanza, A.] Hosp San Raffaele, I-20132 Milan, Italy. [Introna, M.] United Hosp Bergamo, Bergamo, Italy. [Marincola, F. M.] NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD APR PY 2011 VL 46 SU 1 BP S327 EP S327 PG 1 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 745VC UT WOS:000289195402221 ER PT J AU Fleischhauer, K Spellman, SR Wang, T Haagenson, M Battiwalla, M Baxter-Lowe, LA Dehn, JW Gajewski, JL Hale, GA Heemskerk, MB Lee, SJ McCarthy, P Miklos, D Oudshoorn, M Pollack, MS Marino, S Reddy, V Senitzer, D Shaw, B Waller, EK Fernandez-Vina, M AF Fleischhauer, K. Spellman, S. R. Wang, T. Haagenson, M. Battiwalla, M. Baxter-Lowe, L. A. Dehn, J. W. Gajewski, J. L. Hale, G. A. Heemskerk, M. B. Lee, S. J. McCarthy, P. Miklos, D. Oudshoorn, M. Pollack, M. S. Marino, S. Reddy, V. Senitzer, D. Shaw, B. Waller, E. K. Fernandez-Vina, M. TI Non-permissive HLA-DPB1 T-cell epitope disparities are associated with non-relapse mortality after unrelated stem cell transplantation and are not dependent on HLA-DPA1 SO BONE MARROW TRANSPLANTATION LA English DT Meeting Abstract CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group CY APR 03-06, 2011 CL Paris, FRANCE SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp C1 [Fleischhauer, K.] Ist Sci San Raffaele, I-20132 Milan, Italy. [Spellman, S. R.; Haagenson, M.] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. [Wang, T.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Battiwalla, M.] NHLBI, NIH, Bethesda, MD 20892 USA. [Baxter-Lowe, L. A.] Univ Calif San Francisco, Med Ctr, San Francisco, CA 94143 USA. [Dehn, J. W.] Natl Marrow Donor Program, Minneapolis, MN USA. [Gajewski, J. L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Hale, G. A.] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA. [Heemskerk, M. B.] Dutch Transplant Fdn, Leiden, Netherlands. [Lee, S. J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [McCarthy, P.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Miklos, D.] Stanford Hosp & Clin, Stanford, CA USA. [Oudshoorn, M.] Europdonor Fdn, Leiden, Netherlands. [Pollack, M. S.] UTHSC Vet Hlth Care Syst, San Antonio, TX USA. [Marino, S.] Univ Chicago, Chicago, IL 60637 USA. [Reddy, V.] Florida Ctr Cellular Therapy, Orlando, FL USA. [Senitzer, D.] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Shaw, B.] Anthony Nolan Res Inst, London, England. [Waller, E. K.] Emory Univ Hosp, Atlanta, GA 30322 USA. [Fernandez-Vina, M.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD APR PY 2011 VL 46 SU 1 BP S74 EP S74 PG 1 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 745VC UT WOS:000289195400170 ER PT J AU Fujiwara, H Nagai, K Ochi, T An, J Shirakata, T Mineno, J Kuzushima, K Shiku, H Melenhorst, J Gostic, E Price, D Yasukawa, M AF Fujiwara, H. Nagai, K. Ochi, T. An, J. Shirakata, T. Mineno, J. Kuzushima, K. Shiku, H. Melenhorst, J. Gostic, E. Price, D. Yasukawa, M. TI Engineered T-lymphocytes using a novel anti-leukaemia antigen, aurora-A kinase-specific T-cell receptor gene transfer successfully displayed anti-leukaemia reactivity SO BONE MARROW TRANSPLANTATION LA English DT Meeting Abstract CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group CY APR 03-06, 2011 CL Paris, FRANCE SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp C1 [Fujiwara, H.; Nagai, K.; Ochi, T.; An, J.; Shirakata, T.; Yasukawa, M.] Ehime Univ, Toon, Japan. [Mineno, J.] Takara Bio Inc, Otsu, Shiga, Japan. [Kuzushima, K.] Aichi Canc Ctr, Nagoya, Aichi 464, Japan. [Shiku, H.] Mie Univ, Tsu, Mie 514, Japan. [Melenhorst, J.] NHLBI, Bethesda, MD 20892 USA. [Gostic, E.; Price, D.] Cardiff Univ, Cardiff, S Glam, Wales. RI Price, David/C-7876-2013 OI Price, David/0000-0001-9416-2737 NR 0 TC 0 Z9 0 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD APR PY 2011 VL 46 SU 1 BP S1 EP S1 PG 1 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 745VC UT WOS:000289195400002 ER PT J AU Reddy, P Toubai, T Matzinger, P Tawara, I Sun, Y Friedman, T Korngold, R AF Reddy, P. Toubai, T. Matzinger, P. Tawara, I. Sun, Y. Friedman, T. Korngold, R. TI Contribution of sex-mismatched HY antigen expression and its cross-presentation in the induction of GvHD despite the absence of epitope spreading SO BONE MARROW TRANSPLANTATION LA English DT Meeting Abstract CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group CY APR 03-06, 2011 CL Paris, FRANCE SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp C1 [Reddy, P.; Toubai, T.; Tawara, I.; Sun, Y.] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA. [Matzinger, P.] NIH, Bethesda, MD 20892 USA. [Friedman, T.; Korngold, R.] Hackensack Canc Ctr, Hackensack, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD APR PY 2011 VL 46 SU 1 BP S238 EP S238 PG 1 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 745VC UT WOS:000289195401394 ER PT J AU Switzer, G Harrington, D Haagenson, M Drexler, R Foley, A Confer, D Bishop, M Anderlini, P Rowley, S Leitman, S Anasetti, C Wingard, JR AF Switzer, G. Harrington, D. Haagenson, M. Drexler, R. Foley, A. Confer, D. Bishop, M. Anderlini, P. Rowley, S. Leitman, S. Anasetti, C. Wingard, J. R. TI Early post-donation health-related quality-of-life and recovery among adult unrelated stem cell donors: a planned subgroup analysis of a randomized trial of marrow versus PBSC donation SO BONE MARROW TRANSPLANTATION LA English DT Meeting Abstract CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group CY APR 03-06, 2011 CL Paris, FRANCE SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp C1 [Switzer, G.; Harrington, D.] Univ Pittsburgh, Pittsburgh, PA USA. [Haagenson, M.; Drexler, R.; Foley, A.; Confer, D.] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. [Wingard, J. R.] Univ Florida, Coll Med, Gainesville, FL USA. [Anderlini, P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Rowley, S.] John Theurer Canc Ctr, Hackensack, NJ USA. [Leitman, S.] NIH, Ctr Canc, Bethesda, MD 20892 USA. [Anasetti, C.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD APR PY 2011 VL 46 SU 1 BP S72 EP S73 PG 2 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 745VC UT WOS:000289195400167 ER PT J AU Bottino, MC Cerliani, JP Rojas, P Giulianelli, S Soldati, R Mondillo, C Gorostiaga, MA Pignataro, OP Calvo, JC Gutkind, JS Amornphimoltham, P Molinolo, AA Luthy, IA Lanari, C AF Cecilia Bottino, Maria Pablo Cerliani, Juan Rojas, Paola Giulianelli, Sebastian Soldati, Rocio Mondillo, Carolina Alicia Gorostiaga, Maria Pignataro, Omar P. Carlos Calvo, Juan Gutkind, J. Silvio Amornphimoltham, Panomwat Molinolo, Alfredo A. Luethy, Isabel A. Lanari, Claudia TI Classical membrane progesterone receptors in murine mammary carcinomas: agonistic effects of progestins and RU-486 mediating rapid non-genomic effects SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Membrane progesterone receptors; Mammary carcinomas; Progesterone receptor isoforms: membrane-initiated steroid signaling; Antiprogestins; Breast cancer treatment; Non-genomic effects; Progestins ID ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; EPIDERMAL-GROWTH-FACTOR; ESTROGEN-RECEPTOR; MEDROXYPROGESTERONE ACETATE; SIGNALING PATHWAYS; BINDING-SITES; IN-VITRO; METASTATIC PHENOTYPE; CYCLE PROGRESSION AB In this article, we demonstrate the expression of functional progesterone binding sites at the cell membrane in murine mammary carcinomas that are stimulated by progestins and inhibited by antiprogestins. Using confocal immunofluorescence, ligand binding and cell compartment-specific western blots, we were able to identify the presence of the classical progesterone receptors. Medroxyprogesterone acetate (MPA) and RU-486 (1 x 10(-11) and 1 x 10(-8) M) behaved as agonists activating extracellular signal-regulated kinases (ERKs) and progestin-regulated proteins, except for Cyclin D1 and Tissue factor which failed to increase with 1 x 10(-8) M RU-486, an experimental condition that allows PR to bind DNA. These results predicted a full agonist effect at low concentrations of RU-486. Accordingly, at concentrations lower than 1 x 10(-11) M, RU-486 increased cell proliferation in vitro. This effect was abolished by incubation with the ERK kinase inhibitor PD 98059 or by OH-tamoxifen. In vivo, at a daily dose of 1.2 mu g/kg body weight RU-486 increased tumor growth, whereas at 12 mg/kg induces tumor regression. Our results indicate that low concentrations of MPA and RU-486 induce similar agonistic non-genomic effects, whereas RU-486 at higher concentrations may inhibit cell proliferation by genomic-induced effects. This suggests that RU-486 should be therapeutically administered at doses high enough to guarantee its genomic inhibitory effect. C1 [Cecilia Bottino, Maria; Pablo Cerliani, Juan; Rojas, Paola; Giulianelli, Sebastian; Soldati, Rocio; Mondillo, Carolina; Alicia Gorostiaga, Maria; Lanari, Claudia] Consejo Nacl Invest Cient & Tecn CONICET, Lab Carcinogenesis Hormonal, Inst Biol & Med Expt, Buenos Aires, DF, Argentina. [Luethy, Isabel A.] Consejo Nacl Invest Cient & Tecn CONICET, Lab Hormonas & Canc, Inst Biol & Med Expt, Buenos Aires, DF, Argentina. [Pignataro, Omar P.; Carlos Calvo, Juan] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Buenos Aires, DF, Argentina. [Gutkind, J. Silvio; Amornphimoltham, Panomwat; Molinolo, Alfredo A.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA. RP Lanari, C (reprint author), Consejo Nacl Invest Cient & Tecn CONICET, Lab Carcinogenesis Hormonal, Inst Biol & Med Expt, Vuelta Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina. EM clanari@dna.uba.ar RI Gutkind, J. Silvio/A-1053-2009; OI Luthy, Isabel/0000-0001-7603-6649 FU ANPCyT [PICT 07-932, PICT 05-38302]; CONICET [PIP 5351]; Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD; UICC; Avon Foundation; Fundacion Sales FX This work was supported by Fundacion Sales, ANPCyT (PICT 07-932 and PICT 05-38302), CONICET (PIP 5351). Drs. Gutkind, Amornphimoltham and Molinolo are supported by the Intramural Research Program of the Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD. We are very grateful to Dr. Elisa Bal de Kier Joffe for providing LM3 cells, to Julieta Bolado and to Pablo Do Campo for excellent technical assistance, and to Laboratorios Craveri, Buenos Aires for providing MPA depot and to Bayer Schering Pharma AG for the ZK230211. We also wish to thank Avon Foundation for an AACR travel award to MC Bottino and the UICC for an ICRETT fellowship to MC Bottino. NR 79 TC 11 Z9 11 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD APR PY 2011 VL 126 IS 3 BP 621 EP 636 DI 10.1007/s10549-010-0971-3 PG 16 WC Oncology SC Oncology GA 735VP UT WOS:000288449000007 PM 20535544 ER PT J AU Simila, ME Valsta, LM Kontto, JP Albanes, D Virtamo, J AF Simila, Minna E. Valsta, Liisa M. Kontto, Jukka P. Albanes, Demetrius Virtamo, Jarmo TI Low-, medium- and high-glycaemic index carbohydrates and risk of type 2 diabetes in men SO BRITISH JOURNAL OF NUTRITION LA English DT Article DE Glycaemic index; Glycaemic load; Carbohydrates; Type 2 diabetes; Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study ID IMPAIRED GLUCOSE-TOLERANCE; DIETARY FIBER INTAKE; LOAD; WOMEN; MELLITUS; PREVENTION; INSULIN; DISEASE; CONSUMPTION; CANCER AB Findings on dietary glycaemic index (GI) and glycaemic load (GL) as risk factors for type 2 diabetes have been controversial. We examined the associations of dietary GI and GL and the associations of substitution of lower-GI carbohydrates for higher-GI carbohydrates with diabetes risk in a cohort of Finnish men. The cohort consisted of 25 943 male smokers aged 50-69 years. Diet was assessed, at baseline, using a validated diet history questionnaire. During a 12-year follow-up, 1098 incident diabetes cases were identified from a national register. Cox proportional hazard modelling was used to estimate the risk of diabetes, and multivariate nutrient density models were used to examine the effects of substitution of different carbohydrates. Dietary GI and GL were not associated with diabetes risk; multivariate relative risk (RR) for highest v. lowest quintile for GI was 0.87 (95% CI 0.71, 1.07) and for GL 0.88 (95% CI 0.65, 1.17). Substitution of medium-GI carbohydrates for high-GI carbohydrates was inversely associated with diabetes risk (multivariate RR for highest v. lowest quintile 0.75, 95% CI 0.59, 0.96), but substitution of low-GI carbohydrates for medium-or high-GI carbohydrates was not associated with the risk. In conclusion, dietary GI and GL were not associated with diabetes risk, and substitutions of lower-GI carbohydrates for higher-GI carbohydrates were not consistently associated with a lower diabetes risk. The associations of dietary GI and GL with diabetes risk should be interpreted by considering nutritional correlates, as foods may have different properties that affect risk. C1 [Simila, Minna E.; Valsta, Liisa M.; Kontto, Jukka P.; Virtamo, Jarmo] Natl Inst Hlth & Welf, Div Welf & Hlth Promot, FI-00271 Helsinki, Finland. [Albanes, Demetrius] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. RP Simila, ME (reprint author), Natl Inst Hlth & Welf, Div Welf & Hlth Promot, POB 30, FI-00271 Helsinki, Finland. EM minna.simila@thl.fi RI Albanes, Demetrius/B-9749-2015; OI Kontto, Jukka/0000-0003-3899-9852 FU Academy of Finland [111420]; Ministry of Agriculture and Forestry; Finnish Cultural Foundation; Kyllikki and Uolevi Lehikoinen Foundation; Juho Vainio Foundation; Yrjo Jahnsson Foundation; National Cancer Institute [N01-CN-45165, N01-RC-45035, N01-RC-37004] FX The present study was supported by the Academy of Finland (grant no. 111420), the Ministry of Agriculture and Forestry, Doctoral Programmes in Public Health, the Finnish Cultural Foundation, the Kyllikki and Uolevi Lehikoinen Foundation, the Juho Vainio Foundation and the Yrjo Jahnsson Foundation. The ATBC Study was supported by US Public Health Service contracts (N01-CN-45165, N01-RC-45035 and N01-RC-37004) from the National Cancer Institute. M. E. S., L. M. V. and J. V. contributed to the conception and design of the present study. M. E. S. and J. P. K. performed the statistical analysis. M. E. S. wrote the manuscript. All authors participated in the critical revision of the manuscript. None of the authors had any personal or financial conflict of interest. NR 33 TC 9 Z9 9 U1 1 U2 10 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0007-1145 J9 BRIT J NUTR JI Br. J. Nutr. PD APR PY 2011 VL 105 IS 8 BP 1258 EP 1264 DI 10.1017/S000711451000485X PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 739VS UT WOS:000288748700017 PM 21114892 ER PT J AU Anderson, CD Nalls, MA Biffi, A Rost, NS Greenberg, SM Singleton, AB Meschia, JF Rosand, J AF Anderson, Christopher D. Nalls, Michael A. Biffi, Alessandro Rost, Natalia S. Greenberg, Steven M. Singleton, Andrew B. Meschia, James F. Rosand, Jonathan TI The Effect of Survival Bias on Case-Control Genetic Association Studies of Highly Lethal Diseases SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE stroke; hemorrhage; myocardial infarction; genetics; epidemiology ID UNRECOGNIZED MYOCARDIAL-INFARCTION; CASE-FATALITY; STROKE INCIDENCE; GENOMEWIDE ASSOCIATION; POPULATION; EPIDEMIOLOGY; REGISTRY; RISK; PREVALENCE; ROTTERDAM AB Background-Survival bias is the phenomenon by which individuals are excluded from analysis of a trait because of mortality related to the expression of that trait. In genetic association studies, variants increasing risk for disease onset as well as risk of disease-related mortality (lethality) could be difficult to detect in genetic association case-control designs, possibly leading to underestimation of a variant's effect on disease risk. Methods and Results-We modeled cohorts for 3 diseases of high lethality (intracerebral hemorrhage, ischemic stroke, and myocardial infarction) using existing longitudinal data. Based on these models, we simulated case-control genetic association studies for genetic risk factors of varying effect sizes, lethality, and minor allele frequencies. For each disease, erosion of detected effect size was larger for case-control studies of individuals of advanced age (age >75 years) and/or variants with very high event-associated lethality (genotype relative risk for event-related death >2.0). We found that survival bias results in no more than 20% effect size erosion for cohorts with mean age <75 years, even for variants that double lethality risk. Furthermore, we found that increasing effect size erosion was accompanied by depletion of minor allele frequencies in the case population, yielding a "signature" of the presence of survival bias. Conclusions-Our simulation provides formulas to allow estimation of effect size erosion given a variant's odds ratio of disease, odds ratio of lethality, and minor allele frequencies. These formulas will add precision to power calculation and replication efforts for case-control genetic studies. Our approach requires validation using prospective data. (Circ Cardiovasc Genet. 2011;4:188-196.) C1 [Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Rosand, Jonathan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Hemorrhag Stroke Res Grp, Dept Neurol, Boston, MA 02114 USA. [Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Rosand, Jonathan] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Nalls, Michael A.; Singleton, Andrew B.] NIA, Neurogenet Lab, Intramural Res Program, Bethesda, MD 20892 USA. [Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. RP Rosand, J (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St,CPZN 6818, Boston, MA 02114 USA. EM jrosand@partners.org RI Singleton, Andrew/C-3010-2009; OI Anderson, Christopher/0000-0002-0053-2002 FU American Heart Association/Bugher Foundation Centers for Stroke Prevention Research [0775011N, 0755984T]; Deane Institute for Integrative Study of Atrial Fibrillation and Stroke; National Institute for Neurologic Disorders and Stroke [R01 NS063925, R01 NS059727, P50 NS051343, K23NS064052-01A1]; National Institute of Health, National Institute on Aging [Z01-AG000954-06:2007] FX This work was supported by funding from the American Heart Association/Bugher Foundation Centers for Stroke Prevention Research (0775011N, 0755984T), Deane Institute for Integrative Study of Atrial Fibrillation and Stroke, and the National Institute for Neurologic Disorders and Stroke (R01 NS063925, R01 NS059727, P50 NS051343, K23NS064052-01A1). This research was also supported in part by the Intramural Research Program of the National Institute of Health, National Institute on Aging, under Annual Report No. Z01-AG000954-06:2007. NR 33 TC 15 Z9 18 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD APR PY 2011 VL 4 IS 2 BP 188 EP U265 DI 10.1161/CIRCGENETICS.110.957928 PG 19 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA 752SA UT WOS:000289712700015 PM 21292865 ER PT J AU Robey, RW Ierano, C Zhan, ZR Bates, SE AF Robey, Robert W. Ierano, Caterina Zhan, Zhirong Bates, Susan E. TI The Challenge of Exploiting ABCG2 in the Clinic SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY LA English DT Review DE ABCG2/BCRP; blood-brain barrier; CNS penetration; drug resistance; gout; oral bioavailability; Q141K; single nucleotide polymorphism ID CANCER-RESISTANCE-PROTEIN; ACUTE-MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BINDING CASSETTE TRANSPORTER; TYROSINE KINASE INHIBITOR; REVERSES MULTIDRUG-RESISTANCE; MESSENGER-RNA EXPRESSION; CELL LUNG-CANCER; HIGH-AFFINITY INTERACTION; CALCIUM-CHANNEL BLOCKERS AB ABCG2, or breast cancer resistance protein (BCRP), is an ATP-binding cassette half-transporter that has been shown to transport a wide range of substrates including chemotherapeutics, antivirals, antibiotics and flavonoids. Given its wide range of substrates, much work has been dedicated to developing ABCG2 as a clinical target. But where can we intervene clinically and how can we avoid the mistakes made in past clinical trials targeting P-glycoprotein? This review will summarize the normal tissue distribution, cancer tissue expression, substrates and inhibitors of ABCG2, and highlight the challenges presented in exploiting ABCG2 in the clinic. We discuss the possibility of inhibiting ABCG2, so as to increase oral bioavailability or increase drug penetration into sanctuary sites, especially the central nervous system; and at the other end of the spectrum, the possibility of improving ABCG2 function, in the case of gout caused by a single nucleotide polymphism. Together, these aspects of ABCG2/BCRP make the protein a target of continuing interest for oncologists, biologists, and pharmacologists. C1 [Robey, Robert W.; Ierano, Caterina; Zhan, Zhirong; Bates, Susan E.] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA. RP Bates, SE (reprint author), NCI, Med Oncol Branch, NIH, 9000 Rockville Pike,Bldg 10,Rm 12N226, Bethesda, MD 20892 USA. EM sebates@helix.nih.gov RI Ierano, Caterina/K-1676-2016 OI Ierano, Caterina/0000-0003-3138-1873 FU Intramural NIH HHS [Z99 CA999999] NR 178 TC 34 Z9 35 U1 0 U2 16 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1389-2010 J9 CURR PHARM BIOTECHNO JI Curr. Pharm. Biotechnol. PD APR PY 2011 VL 12 IS 4 BP 595 EP 608 PG 14 WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA 753JZ UT WOS:000289770000013 PM 21118093 ER EF